,Unnamed: 0,Pmid,Sentences,COMPOUND,PHENOTYPE,Has Match,Cause Match,Effect Match,Verb Match,Ontology ID,Ontology term,CID,compound_name,compound_name_final,lemma_verb
0,6,35306043,Combination therapy of 10% AKBA with MTX is effective in inhibiting arthritis and circumventing hepatotoxicity produced by MTX in arthritic animals.,"['AKBA', 'MTX', 'MTX']","['arthritis', 'hepatotoxicity']",True,MTX,arthritis,inhibiting,C0003864,Arthritis,126941,Methotrexate,Methotrexate,inhibit
1,65,35093559,"Caffeine alone produces genotoxicity on this species but, when combined with diclofenac, it potentiates hepatic lipoperoxidation and the inhibition of oxidative stress enzymes, while diclofenac alone or in combination  produces a general inhibition of important enzymes.",['diclofenac'],"['hepatic lipoperoxidation', 'inhibition of oxidative stress']",True,diclofenac,inhibition of oxidative stress,produces,C0242606,Oxidative stress,3033,Diclofenac,Diclofenac,produce
2,132,35142704,De novo opioid boluses were associated with increased ICP and reduced cerebral perfusion pressure.,['opioid'],"['increased ICP', 'reduced cerebral perfusion pressure']",True,opioid,increased ICP,associated,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",opioid,associate
3,133,35142704,Ketamine bolus and infusions were not associated with increased ICP and may reduce the incidence of  cortical spreading depolarization events.,['Ketamine'],['increased ICP'],True,Ketamine,increased ICP,associated,C0302845,Increased mean corpuscular volume,3821,Ketamine,Ketamine,associate
4,152,35120712," RESULTS: Midazolam significantly inhibited tumour size and proliferative index of Ki-67 and cyclins in pancreatic ductal adenocarcinoma, which was blocked by administration of PK11195.",['Midazolam'],['pancreatic ductal adenocarcinoma'],True,Midazolam,pancreatic ductal adenocarcinoma,inhibited,C0281361,Pancreatic adenocarcinoma,4192,midazolam,midazolam,inhibit
5,154,35120712,Midazolam inhibited pancreatic ductal adenocarcinoma proliferation through downregulation of cyclins  and cyclin-dependent kinases and induced apoptosis in vitro.,['Midazolam'],"['pancreatic ductal adenocarcinoma proliferation', 'apoptosis']",True,Midazolam,pancreatic ductal adenocarcinoma proliferation,inhibited,C0281361,Pancreatic adenocarcinoma,4192,midazolam,midazolam,inhibit
6,155,35120712," CONCLUSIONS: These results suggest that midazolam inhibits pancreatic ductal adenocarcinoma proliferation and local infiltration of tumour-associated neutrophils, tumour-associated macrophages, and polymorphonuclear myeloid-derived suppressor cells, thereby inhibiting pancreatic ductal adenocarcinoma progression.",['midazolam'],"['pancreatic ductal adenocarcinoma proliferation', 'local infiltration of tumour-associated neutrophils', 'inhibiting pancreatic ductal adenocarcinoma progression']",True,midazolam,pancreatic ductal adenocarcinoma proliferation,inhibits,C0281361,Pancreatic adenocarcinoma,4192,midazolam,midazolam,inhibit
7,191,35042691,"Standard-dose lidocaine (40-60 mg) and high-dose propofol (> 1000 mg) were associated with prolonged time until death (prolonged by a median of 1 min and 3 min, respectively).",['propofol'],['death'],True,propofol,death,associated,C1546180,Age of death,4943,Propofol,Propofol,associate
8,203,35022262,"Multivariable logistic regression models were run to determine if midazolam was associated with postoperative cardiac and  pulmonary complications, delirium, and in-hospital falls.",['midazolam'],['delirium'],True,midazolam,delirium,associated,C0011206,Delirium,4192,midazolam,midazolam,associate
9,204,35022262,"Notably, the combined use of midazolam and gabapentinoids was associated with a substantial increase in the odds for respiratory failure and delirium.",['midazolam'],"['respiratory failure', 'delirium']",True,midazolam,respiratory failure,associated,C1145670,Respiratory failure,4192,midazolam,midazolam,associate
10,204,35022262,"Notably, the combined use of midazolam and gabapentinoids was associated with a substantial increase in the odds for respiratory failure and delirium.",['midazolam'],"['respiratory failure', 'delirium']",True,midazolam,delirium,associated,C0011206,Delirium,4192,midazolam,midazolam,associate
11,228,34118477,"At low glucose, sulfonylureas inhibited glucagon secretion  of islets despite the rise in α-cell [Ca2+]c that they triggered.",['sulfonylureas'],['glucagon secretion'],True,sulfonylureas,glucagon secretion,inhibited,C1295678,Decreased glucagon level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sulfonylureas,inhibit
12,255,32790843,"However, depolarization by tolbutamide, gliclazide, or 15 mM KCl increased  insulin secretion before the glucagon secretion receded.","['tolbutamide', 'gliclazide', 'KCl']","['depolarization', 'glucagon secretion']",True,tolbutamide,glucagon secretion,increased,C1295678,Decreased glucagon level,5505,tolbutamide,tolbutamide,increase
13,255,32790843,"However, depolarization by tolbutamide, gliclazide, or 15 mM KCl increased  insulin secretion before the glucagon secretion receded.","['tolbutamide', 'gliclazide', 'KCl']","['depolarization', 'glucagon secretion']",True,gliclazide,glucagon secretion,increased,C1295678,Decreased glucagon level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",gliclazide,increase
14,257,32790843," The glucagon secretion by SUR1 knockout islets was not increased by tolbutamide,  whereas 40 mM KCl was of unchanged efficiency.","['tolbutamide', 'KCl']",['glucagon secretion'],True,tolbutamide,glucagon secretion,increased,C1295678,Decreased glucagon level,5505,tolbutamide,tolbutamide,increase
15,257,32790843," The glucagon secretion by SUR1 knockout islets was not increased by tolbutamide,  whereas 40 mM KCl was of unchanged efficiency.","['tolbutamide', 'KCl']",['glucagon secretion'],True,KCl,glucagon secretion,increased,C1295678,Decreased glucagon level,4873,Potassium Chloride,Potassium Chloride,increase
16,298,35287982," CONCLUSIONS: Both the B52 and 52 combinations infrequently required repeat agitation medication; however, the B52 combination resulted in more oxygen desaturation, hypotension, physical restraint use, and longer length of stay.",['oxygen'],"['hypotension', 'longer length of stay']",True,oxygen,hypotension,resulted,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,result
17,300,35242029,"All antipsychotics caused glucose intolerance, with strongest effects by clozapine > olanzapine > risperidone > haloperidol.","['clozapine', 'olanzapine', 'risperidone', 'haloperidol']",['glucose intolerance'],True,clozapine,glucose intolerance,caused,C0271650,Abnormal glucose tolerance,135398737,Clozapine,Clozapine,cause
18,300,35242029,"All antipsychotics caused glucose intolerance, with strongest effects by clozapine > olanzapine > risperidone > haloperidol.","['clozapine', 'olanzapine', 'risperidone', 'haloperidol']",['glucose intolerance'],True,olanzapine,glucose intolerance,caused,C0271650,Abnormal glucose tolerance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",olanzapine,cause
19,300,35242029,"All antipsychotics caused glucose intolerance, with strongest effects by clozapine > olanzapine > risperidone > haloperidol.","['clozapine', 'olanzapine', 'risperidone', 'haloperidol']",['glucose intolerance'],True,risperidone,glucose intolerance,caused,C0271650,Abnormal glucose tolerance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",risperidone,cause
20,300,35242029,"All antipsychotics caused glucose intolerance, with strongest effects by clozapine > olanzapine > risperidone > haloperidol.","['clozapine', 'olanzapine', 'risperidone', 'haloperidol']",['glucose intolerance'],True,haloperidol,glucose intolerance,caused,C0271650,Abnormal glucose tolerance,3559,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,cause
21,301,35242029,"Plasma catecholamines were also increased by drug treatment, with greatest effects for norepinephrine and epinephrine caused by clozapine > risperidone > olanzapine > haloperidol.","['clozapine', 'risperidone', 'olanzapine', 'haloperidol']",['epinephrine'],True,clozapine,epinephrine,increased,C1868393,Elevated urinary epinephrine,135398737,Clozapine,Clozapine,increase
22,301,35242029,"Plasma catecholamines were also increased by drug treatment, with greatest effects for norepinephrine and epinephrine caused by clozapine > risperidone > olanzapine > haloperidol.","['clozapine', 'risperidone', 'olanzapine', 'haloperidol']",['epinephrine'],True,risperidone,epinephrine,increased,C1868393,Elevated urinary epinephrine,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",risperidone,increase
23,301,35242029,"Plasma catecholamines were also increased by drug treatment, with greatest effects for norepinephrine and epinephrine caused by clozapine > risperidone > olanzapine > haloperidol.","['clozapine', 'risperidone', 'olanzapine', 'haloperidol']",['epinephrine'],True,olanzapine,epinephrine,increased,C1868393,Elevated urinary epinephrine,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",olanzapine,increase
24,301,35242029,"Plasma catecholamines were also increased by drug treatment, with greatest effects for norepinephrine and epinephrine caused by clozapine > risperidone > olanzapine > haloperidol.","['clozapine', 'risperidone', 'olanzapine', 'haloperidol']",['epinephrine'],True,haloperidol,epinephrine,increased,C1868393,Elevated urinary epinephrine,3559,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,increase
25,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,amisulpride,acute exacerbation,produced,C0436331,Exacerbated by,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amisulpride,produce
26,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,amisulpride,mild weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amisulpride,produce
27,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,amisulpride,weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amisulpride,produce
28,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,aripiprazole,acute exacerbation,produced,C0436331,Exacerbated by,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aripiprazole,produce
29,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,aripiprazole,mild weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aripiprazole,produce
30,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,aripiprazole,weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aripiprazole,produce
31,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,brexpiprazole,acute exacerbation,produced,C0436331,Exacerbated by,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",brexpiprazole,produce
32,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,brexpiprazole,mild weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",brexpiprazole,produce
33,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,brexpiprazole,weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",brexpiprazole,produce
34,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,cariprazine,acute exacerbation,produced,C0436331,Exacerbated by,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cariprazine,produce
35,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,cariprazine,mild weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cariprazine,produce
36,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,cariprazine,weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cariprazine,produce
37,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,haloperidol,acute exacerbation,produced,C0436331,Exacerbated by,3559,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,produce
38,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,haloperidol,mild weight gain,produced,C0043094,Weight gain,3559,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,produce
39,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,haloperidol,weight gain,produced,C0043094,Weight gain,3559,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,produce
40,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,lumateperone,acute exacerbation,produced,C0436331,Exacerbated by,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lumateperone,produce
41,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,lumateperone,mild weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lumateperone,produce
42,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,lumateperone,weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lumateperone,produce
43,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,lurasidone,acute exacerbation,produced,C0436331,Exacerbated by,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lurasidone,produce
44,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,lurasidone,mild weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lurasidone,produce
45,329,35137229,"In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs.","['amisulpride', 'aripiprazole', 'brexpiprazole', 'cariprazine', 'haloperidol', 'lumateperone', 'lurasidone']","['acute exacerbation', 'mild weight gain', 'weight gain']",True,lurasidone,weight gain,produced,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lurasidone,produce
46,374,34854012,"However, haloperidol often causes extrapyramidal motor disorders such as tardive dyskinesia (TD).",['haloperidol'],"['extrapyramidal motor disorders', 'tardive dyskinesia']",True,haloperidol,extrapyramidal motor disorders,causes,C0234133,Abnormality of extrapyramidal motor function,3559,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,cause
47,374,34854012,"However, haloperidol often causes extrapyramidal motor disorders such as tardive dyskinesia (TD).",['haloperidol'],"['extrapyramidal motor disorders', 'tardive dyskinesia']",True,haloperidol,tardive dyskinesia,causes,C0686347,Tardive dyskinesia,3559,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,cause
48,413,34730624,"CE at the dose of 400 mg/kg induced ipsilateral rotations 14 days after lesion; however, chronic 30-day CE and caffeine treatments did not interfere with the animals' rotation after apomorphine or methamphetamine challenges in animals with MFB lesion, nor on monoamines levels.","['caffeine', 'methamphetamine']","['chronic 30-day CE', 'MFB lesion']",True,caffeine,chronic 30-day CE,induced,C0205191,Chronic,2519,Caffeine,Caffeine,induce
49,413,34730624,"CE at the dose of 400 mg/kg induced ipsilateral rotations 14 days after lesion; however, chronic 30-day CE and caffeine treatments did not interfere with the animals' rotation after apomorphine or methamphetamine challenges in animals with MFB lesion, nor on monoamines levels.","['caffeine', 'methamphetamine']","['chronic 30-day CE', 'MFB lesion']",True,methamphetamine,chronic 30-day CE,induced,C0205191,Chronic,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methamphetamine,induce
50,545,35295067," Conclusions: Use of propanolol was associated with reduced mortality, compared with controls, in this nationwide cohort of patients with cirrhosis and refractory ascites.",['propanolol'],"['reduced mortality', 'cirrhosis', 'refractory ascites']",True,propanolol,cirrhosis,associated,C0023890,Cirrhosis,4946,propanolol,propanolol,associate
51,545,35295067," Conclusions: Use of propanolol was associated with reduced mortality, compared with controls, in this nationwide cohort of patients with cirrhosis and refractory ascites.",['propanolol'],"['reduced mortality', 'cirrhosis', 'refractory ascites']",True,propanolol,refractory ascites,associated,C0003962,Ascites,4946,propanolol,propanolol,associate
52,552,35266887,"Propranolol treatment elevated the activity of caspase-3  and expression of bax, Wee1, GADD153 and apoptosis-inducing factor, but decreased bcl-2 which is an antiapoptotic protein.",['Propranolol'],"['expression of bax', 'decreased bcl-2']",True,Propranolol,decreased bcl-2,elevated,C0427437,Decreased mean corpuscular haemoglobin,4946,propanolol,propanolol,elevated
53,581,35188546,"Propranolol infusion did not produce any significant changes in MHR and MHRV, but significantly decreased FHR and increased FHRV.",['Propranolol'],"['decreased FHR', 'increased FHRV']",True,Propranolol,decreased FHR,produce,C0302844,Reduced erythrocyte volume,4946,propanolol,propanolol,produce
54,581,35188546,"Propranolol infusion did not produce any significant changes in MHR and MHRV, but significantly decreased FHR and increased FHRV.",['Propranolol'],"['decreased FHR', 'increased FHRV']",True,Propranolol,increased FHRV,produce,C0302845,Increased mean corpuscular volume,4946,propanolol,propanolol,produce
55,609,35154986,  Severe neutropenia in newly diagnosed hyperthyroidism is a diagnostic and therapeutic dilemma since antithyroid drugs (ATDs) cannot be started if the absolute neutrophil count (ANC) is <1 x 109/L. We report the case of a patient followed for hyperthyroidism associated with severe neutropenia treated with dexamethasone and ATD.,"['dexamethasone', 'ATD']","['neutropenia', 'hyperthyroidism', 'absolute neutrophil count', 'neutropenia']",True,dexamethasone,neutropenia,associated,C0853697,Low neutrophil count,5743,Dexamethasone,Dexamethasone,associate
56,609,35154986,  Severe neutropenia in newly diagnosed hyperthyroidism is a diagnostic and therapeutic dilemma since antithyroid drugs (ATDs) cannot be started if the absolute neutrophil count (ANC) is <1 x 109/L. We report the case of a patient followed for hyperthyroidism associated with severe neutropenia treated with dexamethasone and ATD.,"['dexamethasone', 'ATD']","['neutropenia', 'hyperthyroidism', 'absolute neutrophil count', 'neutropenia']",True,ATD,neutropenia,associated,C0853697,Low neutrophil count,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ATD,associate
57,649,35088615,  BACKGROUND: The use of atropine during dobutamine stress echocardiography (DSE) is contraindicated in persons with narrow angle glaucoma though there is limited  evidence that low doses of intravenous atropine do not cause pupillary dilation.,"['atropine', 'atropine']","['dobutamine stress', 'pupillary dilation']",True,atropine,pupillary dilation,cause,C0026961,Dilated pupil,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",atropine,cause
58,650,35088615, OBJECTIVE: The aim of this study is to investigate whether atropine when administered in persons without glaucoma during dobutamine stress echocardiography causes pupillary dilation.,['atropine'],"['glaucoma', 'dobutamine stress', 'pupillary dilation']",True,atropine,glaucoma,causes,C0017601,Glaucoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",atropine,cause
59,650,35088615, OBJECTIVE: The aim of this study is to investigate whether atropine when administered in persons without glaucoma during dobutamine stress echocardiography causes pupillary dilation.,['atropine'],"['glaucoma', 'dobutamine stress', 'pupillary dilation']",True,atropine,pupillary dilation,causes,C0026961,Dilated pupil,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",atropine,cause
60,652,35088615, CONCLUSION: Intravenous atropine in usual doses administered in DSE does not cause mydriasis in adults without glaucoma.,['atropine'],"['mydriasis', 'glaucoma']",True,atropine,mydriasis,cause,C0026961,Dilated pupil,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",atropine,cause
61,652,35088615, CONCLUSION: Intravenous atropine in usual doses administered in DSE does not cause mydriasis in adults without glaucoma.,['atropine'],"['mydriasis', 'glaucoma']",True,atropine,glaucoma,cause,C0017601,Glaucoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",atropine,cause
62,654,35088452,Carbachol inhibits chronic myeloid leukaemia K562  cell proliferation.,['Carbachol'],['chronic myeloid leukaemia'],True,Carbachol,chronic myeloid leukaemia,inhibits,C0023473,Chronic myelogenous leukemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Carbachol,inhibit
63,677,35016879,"Results: Dexamethasone induced glomerular damage, proteinuria, renal oxidative stress and upregulated the renal Wnt/β-arrestin2/β-catenin pathway and the profibrotic signals.",['Dexamethasone'],"['glomerular damage', 'proteinuria', 'renal oxidative stress', 'upregulated the renal Wnt/β-arrestin2/β-catenin pathway']",True,Dexamethasone,proteinuria,induced,C0033687,Protein in urine,5743,Dexamethasone,Dexamethasone,induce
64,677,35016879,"Results: Dexamethasone induced glomerular damage, proteinuria, renal oxidative stress and upregulated the renal Wnt/β-arrestin2/β-catenin pathway and the profibrotic signals.",['Dexamethasone'],"['glomerular damage', 'proteinuria', 'renal oxidative stress', 'upregulated the renal Wnt/β-arrestin2/β-catenin pathway']",True,Dexamethasone,renal oxidative stress,induced,C0242606,Oxidative stress,5743,Dexamethasone,Dexamethasone,induce
65,900,32841881,The in vivo experiments indicated that DMP induced iron release and oxidative stress for rat RBCs.,"['DMP', 'iron']",['oxidative stress'],True,DMP,oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DMP,induce
66,900,32841881,The in vivo experiments indicated that DMP induced iron release and oxidative stress for rat RBCs.,"['DMP', 'iron']",['oxidative stress'],True,iron,oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,induce
67,956,3691429,"Contact with the esters caused little change in the barrier properties of human skin, but caused marked increases in the permeability to water of rat skin.",['water'],"['skin', 'increases in the permeability', 'skin']",True,water,skin,caused,C0423757,Thin skin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
68,956,3691429,"Contact with the esters caused little change in the barrier properties of human skin, but caused marked increases in the permeability to water of rat skin.",['water'],"['skin', 'increases in the permeability', 'skin']",True,water,increases in the permeability,caused,C1382398,Increased capillary permeability,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
69,956,3691429,"Contact with the esters caused little change in the barrier properties of human skin, but caused marked increases in the permeability to water of rat skin.",['water'],"['skin', 'increases in the permeability', 'skin']",True,water,skin,caused,C0423757,Thin skin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
70,956,3691429,"Contact with the esters caused little change in the barrier properties of human skin, but caused marked increases in the permeability to water of rat skin.",['water'],"['skin', 'increases in the permeability', 'skin']",True,water,increases in the permeability,caused,C1382398,Increased capillary permeability,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
71,956,3691429,"Contact with the esters caused little change in the barrier properties of human skin, but caused marked increases in the permeability to water of rat skin.",['water'],"['skin', 'increases in the permeability', 'skin']",True,water,skin,caused,C0423757,Thin skin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
72,968,35182801," CONCLUSIONS: High levels of MEHP, MBzP and MBP increased the odds of depressive symptoms in the elderly, and chronic inflammation had a partial mediating effect  on the increased odds of depressive symptoms due to MEHP exposure.","['MEHP', 'MBzP', 'MEHP']","['chronic inflammation', 'increased odds of depressive symptoms']",True,MEHP,chronic inflammation,increased,C0019189,Chronic liver inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MEHP,increase
73,968,35182801," CONCLUSIONS: High levels of MEHP, MBzP and MBP increased the odds of depressive symptoms in the elderly, and chronic inflammation had a partial mediating effect  on the increased odds of depressive symptoms due to MEHP exposure.","['MEHP', 'MBzP', 'MEHP']","['chronic inflammation', 'increased odds of depressive symptoms']",True,MBzP,chronic inflammation,increased,C0019189,Chronic liver inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MBzP,increase
74,968,35182801," CONCLUSIONS: High levels of MEHP, MBzP and MBP increased the odds of depressive symptoms in the elderly, and chronic inflammation had a partial mediating effect  on the increased odds of depressive symptoms due to MEHP exposure.","['MEHP', 'MBzP', 'MEHP']","['chronic inflammation', 'increased odds of depressive symptoms']",True,MEHP,chronic inflammation,increased,C0019189,Chronic liver inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MEHP,increase
75,976,35085932,"Higher 2nd trimester mono-isobutyl phthalate (MiBP) was associated with increased IGT (Q4 v. Q1 OR: 2.07; 95% CI: 1.06, 4.07), and 2nd trimester mono-3-hydroxybutyl phthalate (MHBP) was non-monotonically associated with increased GDM (Q2 v. Q1 OR: 3.21; 95% CI: 1.54, 6.87).",['-isobutyl phthalate'],"['Higher 2nd trimester', 'increased GDM']",True,-isobutyl phthalate,increased GDM,associated,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",-isobutyl phthalate,associate
76,979,35028925,  Maternal exposure to dibutyl phthalate (DBP) may result in ovarian dysfunction in female offspring.,['dibutyl phthalate'],['ovarian dysfunction'],True,dibutyl phthalate,ovarian dysfunction,result,C0543968,Congenital stationary cone dysfunction,3026,dibutylphthalate,dibutylphthalate,result
77,984,34935432," DISCUSSION: In our cohort of pregnant women from Mexico City, exposure to phthalates and phthalate biomarkers was associated with higher blood pressure during late pregnancy, as well as with long-term changes in blood pressure trajectories.",['phthalates and phthalate'],['higher blood pressure'],True,phthalates and phthalate,higher blood pressure,associated,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phthalates and phthalate,associate
78,991,34864091,  Exposure to a combination of MWCNTs and DBP causes splenic toxicity in mice.,['MWCNTs'],['splenic toxicity'],True,MWCNTs,splenic toxicity,causes,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MWCNTs,cause
79,992,34844800,  Dibutyl phthalate induced oxidative stress and genotoxicity on adult zebrafish (Danio rerio) brain.,['Dibutyl phthalate'],"['oxidative stress', 'genotoxicity']",True,Dibutyl phthalate,oxidative stress,induced,C0242606,Oxidative stress,3026,dibutylphthalate,dibutylphthalate,induce
80,1033,34910997,Epidemiological studies have found that the exposure of DEHP and BPA could increase the susceptibility to thyroid diseases including thyroid cancer and benign thyroid nodules.,"['DEHP', 'BPA']",['benign thyroid nodules'],True,DEHP,benign thyroid nodules,increase,C0040137,Thyroid nodule,8343,Bis(2-Ethylhexyl) Phthalate,Bis(2-Ethylhexyl) Phthalate,increase
81,1033,34910997,Epidemiological studies have found that the exposure of DEHP and BPA could increase the susceptibility to thyroid diseases including thyroid cancer and benign thyroid nodules.,"['DEHP', 'BPA']",['benign thyroid nodules'],True,BPA,benign thyroid nodules,increase,C0040137,Thyroid nodule,6623,Bisphenol A,Bisphenol A,increase
82,1039,34910997," Mechanistically, BPA alone and in combination with MEHP could significantly induce the proliferation of BCPAP cells depending on HDAC6, which could modulate  H3K9ac to inhibit PTEN, activate AKT signaling pathway, and simultaneously upregulate the expression of c-MYC.","['BPA', 'MEHP']","['proliferation', 'upregulate the expression of c-MYC']",True,BPA,proliferation,induce,C4531170,Abnormal cell proliferation,6623,Bisphenol A,Bisphenol A,induce
83,1039,34910997," Mechanistically, BPA alone and in combination with MEHP could significantly induce the proliferation of BCPAP cells depending on HDAC6, which could modulate  H3K9ac to inhibit PTEN, activate AKT signaling pathway, and simultaneously upregulate the expression of c-MYC.","['BPA', 'MEHP']","['proliferation', 'upregulate the expression of c-MYC']",True,MEHP,proliferation,induce,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MEHP,induce
84,1045,34801851,"In addition, we found that DEHP inhibited paclitaxel and doxorubicin effects in breast cancer cell lines MCF-7 and MDA-MB-231 and in zebrafish and mouse tumor initiation models.","['DEHP', 'paclitaxel', 'doxorubicin']",['breast cancer'],True,DEHP,breast cancer,inhibited,C0678222,Breast cancer,8343,Bis(2-Ethylhexyl) Phthalate,Bis(2-Ethylhexyl) Phthalate,inhibit
85,1045,34801851,"In addition, we found that DEHP inhibited paclitaxel and doxorubicin effects in breast cancer cell lines MCF-7 and MDA-MB-231 and in zebrafish and mouse tumor initiation models.","['DEHP', 'paclitaxel', 'doxorubicin']",['breast cancer'],True,paclitaxel,breast cancer,inhibited,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",paclitaxel,inhibit
86,1045,34801851,"In addition, we found that DEHP inhibited paclitaxel and doxorubicin effects in breast cancer cell lines MCF-7 and MDA-MB-231 and in zebrafish and mouse tumor initiation models.","['DEHP', 'paclitaxel', 'doxorubicin']",['breast cancer'],True,doxorubicin,breast cancer,inhibited,C0678222,Breast cancer,31703,Doxorubicin,Doxorubicin,inhibit
87,1047,34781058,  Prenatal exposure to di (2-ethylhexyl) phthalate causes autism-like behavior through inducing Nischarin expression in the mouse offspring.,"['2-ethylhexyl) phthalate', 'Nischarin']",['autism-like behavior'],True,2-ethylhexyl) phthalate,autism-like behavior,causes,C0856975,Autistic behavior,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-ethylhexyl) phthalate,cause
88,1047,34781058,  Prenatal exposure to di (2-ethylhexyl) phthalate causes autism-like behavior through inducing Nischarin expression in the mouse offspring.,"['2-ethylhexyl) phthalate', 'Nischarin']",['autism-like behavior'],True,Nischarin,autism-like behavior,causes,C0856975,Autistic behavior,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Nischarin,cause
89,1062,34654571," CONCLUSIONS: In a nationally representative sample, phthalate exposures were associated with all-cause and cardiovascular mortality, with societal costs approximating $39 billion/year or more.",['phthalate'],['cardiovascular mortality'],True,phthalate,cardiovascular mortality,associated,C0243050,Cardiac anomaly,181977,phthalate,phthalate,associate
90,1070,34600010, RESULTS: Dietary exposure to DEHP at both doses induced weight gain and hepatic lipogenesis of mice by promoting the uptake of fatty acids and disrupting phospholipids and choline metabolism.,['DEHP'],"['weight gain', 'promoting the uptake of fatty acids']",True,DEHP,weight gain,induced,C0043094,Weight gain,8343,Bis(2-Ethylhexyl) Phthalate,Bis(2-Ethylhexyl) Phthalate,induce
91,1076,34537068, CONCLUSIONS: Ellagic acid considerably inhibits testicular toxicity of DEHP through reducing oxidative/nitrosative stress and inflammatory responses.,['Ellagic acid'],['oxidative/nitrosative stress'],True,Ellagic acid,oxidative/nitrosative stress,inhibits,C0242606,Oxidative stress,5281855,"6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione","6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione",inhibit
92,1080,34426190,  Ingestion of Bis(2-ethylhexyl) phthalate (DEHP) during adolescence causes depressive-like behaviors through hypoactive glutamatergic signaling in the medial prefrontal cortex.,['Bis(2-ethylhexyl) phthalate'],['depressive-like behaviors'],True,Bis(2-ethylhexyl) phthalate,depressive-like behaviors,causes,C0242606,Oxidative stress,8343,Bis(2-Ethylhexyl) Phthalate,Bis(2-Ethylhexyl) Phthalate,cause
93,1110,34186418,"Our data demonstrated that BPA alone or in combination with DEHP may induce hyperplasia of mammary glands, including the proliferation of ductal epithelial cells and an increase in the number of lobules and acinus after a 30-week exposure.",['BPA'],"['hyperplasia of mammary glands', 'proliferation of ductal epithelial cells', 'increase in the number of lobules and acinus']",True,BPA,hyperplasia of mammary glands,induce,C0266009,Mammary gland aplasia,6623,Bisphenol A,Bisphenol A,induce
94,1126,35245673,  BACKGROUND: Erythropoietic protoporphyria (EPP) is caused by deficiency of the enzyme converting protoporphyrin IX (PpIX) into heme resulting in accumulation of PpIX leading to photosensitivity and liver toxicity.,['protoporphyrin'],"['Erythropoietic protoporphyria', 'deficiency of the enzyme', 'accumulation of PpIX leading', 'photosensitivity', 'liver toxicity']",True,protoporphyrin,photosensitivity,caused,C0349506,Photosensitivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",protoporphyrin,cause
95,1126,35245673,  BACKGROUND: Erythropoietic protoporphyria (EPP) is caused by deficiency of the enzyme converting protoporphyrin IX (PpIX) into heme resulting in accumulation of PpIX leading to photosensitivity and liver toxicity.,['protoporphyrin'],"['Erythropoietic protoporphyria', 'deficiency of the enzyme', 'accumulation of PpIX leading', 'photosensitivity', 'liver toxicity']",True,protoporphyrin,liver toxicity,caused,C0349506,Photosensitivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",protoporphyrin,cause
96,1159,35054318,"Both EPP and XLP lead to the systemic accumulation of protoporphyrin IX (PPIX) in blood, erythrocytes, and tissues causing the major symptom of cutaneous photosensitivity and several other less recognized signs that need to be considered.",['protoporphyrin'],['cutaneous photosensitivity'],True,protoporphyrin,cutaneous photosensitivity,lead,C0349506,Photosensitivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",protoporphyrin,lead
97,1228,35130256, CONCLUSIONS: Treatment of asthmatic children having mild to moderate acute exacerbation with a combination of nebulized budesonide plus salbutamol resulted  in significant clinical improvement and reduction in the duration of emergency department stay compared to children on nebulized salbutamol monotherapy.,"['budesonide', 'salbutamol', 'salbutamol']","['mild to moderate acute exacerbation', 'reduction in the duration']",True,budesonide,mild to moderate acute exacerbation,resulted,C0349506,Photosensitivity,5281004,budesonide,budesonide,result
98,1311,34791942,  Sunitinib induced colitis manifesting as invasive diarrhea in a patient with renal cell carcinoma.,['Sunitinib'],"['diarrhea', 'renal cell carcinoma']",True,Sunitinib,diarrhea,induced,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Sunitinib,induce
99,1311,34791942,  Sunitinib induced colitis manifesting as invasive diarrhea in a patient with renal cell carcinoma.,['Sunitinib'],"['diarrhea', 'renal cell carcinoma']",True,Sunitinib,renal cell carcinoma,induced,C0007134,Hypernephroma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Sunitinib,induce
100,1326,34775833, CONCLUSION: Medical management with intranasal corticosteroids and saline irrigations alone leads to significant improvement in sinonasal symptomatology in a subset of AERD.,"['intranasal', 'saline']","['sinonasal symptomatology', 'AERD']",True,intranasal,AERD,leads,C0017168,Gastroesophageal reflux disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",intranasal,lead
101,1326,34775833, CONCLUSION: Medical management with intranasal corticosteroids and saline irrigations alone leads to significant improvement in sinonasal symptomatology in a subset of AERD.,"['intranasal', 'saline']","['sinonasal symptomatology', 'AERD']",True,saline,AERD,leads,C0017168,Gastroesophageal reflux disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",saline,lead
102,1342,34425485," Bcl-2-associated X/B-celllymphoma-2 (Bax/Bcl-2) ratio significantly increased in  animals receiving higher doses of BHA, and the weight of the liver significantly  increased following BHA treatment.","['BHA', 'BHA']",['weight of the liver'],True,BHA,weight of the liver,increased,C0017168,Gastroesophageal reflux disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BHA,increase
103,1342,34425485," Bcl-2-associated X/B-celllymphoma-2 (Bax/Bcl-2) ratio significantly increased in  animals receiving higher doses of BHA, and the weight of the liver significantly  increased following BHA treatment.","['BHA', 'BHA']",['weight of the liver'],True,BHA,weight of the liver,increased,C0017168,Gastroesophageal reflux disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BHA,increase
104,1342,34425485," Bcl-2-associated X/B-celllymphoma-2 (Bax/Bcl-2) ratio significantly increased in  animals receiving higher doses of BHA, and the weight of the liver significantly  increased following BHA treatment.","['BHA', 'BHA']",['weight of the liver'],True,BHA,weight of the liver,increased,C0017168,Gastroesophageal reflux disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BHA,increase
105,1346,34262020,"We found that BHA treatment completely inhibits basal and induced RIPK1 enzymatic activity in cells, monitored at the level of TNFR1 complex I under apoptotic conditions or in the cytosol under necroptosis.",['BHA'],['necroptosis'],True,BHA,necroptosis,inhibits,C0015300,Proptosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BHA,inhibit
106,1389,32458455,"Although BHT and BHA are widely in use but have  been found were associated with alteration in sleeping, induced changes in brain  serotonin and norepinephrine levels with increased cholinesterase activity.","['BHT', 'BHA', 'serotonin']",['increased cholinesterase activity'],True,BHT,increased cholinesterase activity,associated,C5209258,Reduced cholinesterase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BHT,associate
107,1389,32458455,"Although BHT and BHA are widely in use but have  been found were associated with alteration in sleeping, induced changes in brain  serotonin and norepinephrine levels with increased cholinesterase activity.","['BHT', 'BHA', 'serotonin']",['increased cholinesterase activity'],True,BHA,increased cholinesterase activity,associated,C5209258,Reduced cholinesterase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BHA,associate
108,1389,32458455,"Although BHT and BHA are widely in use but have  been found were associated with alteration in sleeping, induced changes in brain  serotonin and norepinephrine levels with increased cholinesterase activity.","['BHT', 'BHA', 'serotonin']",['increased cholinesterase activity'],True,serotonin,increased cholinesterase activity,associated,C5209258,Reduced cholinesterase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,associate
109,1406,31710847,  Butylated hydroxyanisole induces testicular dysfunction in mouse testis cells by  dysregulating calcium homeostasis and stimulating endoplasmic reticulum stress.,"['Butylated hydroxyanisole', 'calcium']","['testicular dysfunction', 'stimulating endoplasmic reticulum stress']",True,Butylated hydroxyanisole,testicular dysfunction,induces,C1843865,Vestibular dysfunction,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Butylated hydroxyanisole,induce
110,1409,31710847,"Therefore, constant BHA exposure may lead to testicular toxicity via mitochondrial dysfunction, ER stress, and abnormal calcium levels in the testis.",['BHA'],"['ER stress', 'abnormal calcium levels']",True,BHA,abnormal calcium levels,lead,C4022450,Abnormal circulating calcium concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BHA,lead
111,1426,31381342,"BHA increased the levels of pro-apoptotic proteins, such as BAX, cytochrome c, cleaved caspase 3, and cleaved caspase 9, and decreased the level of anti-apoptotic protein BCL-XL.",['BHA'],"['levels of pro-apoptotic', 'decreased the level']",True,BHA,decreased the level,increased,C4280714,Decreased level of tissue plasminogen activator,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BHA,increase
112,1444,30844416,Low nitrosamine Swedish snus as well as non-genotoxic butylated hydroxyanisole induces increased cellular proliferation in the rat forestomach epithelia.,['hydroxyanisole'],"['Low nitrosamine Swedish snus', 'increased cellular proliferation']",True,hydroxyanisole,increased cellular proliferation,induces,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydroxyanisole,induce
113,1491,34391333,"Herein, we highlight a very rare case of periungual pyogenic granulomas induced by the regularly prescribed oral retinoid acitretin during treatment for congenital palmoplantar keratoderma.",['acitretin'],"['periungual pyogenic granulomas', 'congenital palmoplantar keratoderma']",True,acitretin,congenital palmoplantar keratoderma,induced,C4551675,Palmar and plantar keratoderma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",acitretin,induce
114,1516,33761438, Increased Nrf2 levels due to hypoxia or CoCl2 were inhibited by treatment with a  HIF inhibitor.,['CoCl2'],"['Increased Nrf2 levels', 'hypoxia']",True,CoCl2,Increased Nrf2 levels,inhibited,C4073162,Elevated hemoglobin A1c,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CoCl2,inhibit
115,1561,35271498," METHODS: Unilateral ureteral obstruction (UUO) was performed to induce chronic renal inflammation and fibrosis in 84 OVX rats, which were divided into four main groups (each = 21) including sham + Vehicle (Veh.), UUO + Veh, UUO + estradiol (E2), and UUO + daidzein.",['daidzein'],"['Unilateral ureteral obstruction', 'chronic renal inflammation', 'fibrosis', 'UUO + estradiol (E2)']",True,estradiol,chronic renal inflammation,induce,C0019189,Chronic liver inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",estradiol,induce
116,1561,35271498," METHODS: Unilateral ureteral obstruction (UUO) was performed to induce chronic renal inflammation and fibrosis in 84 OVX rats, which were divided into four main groups (each = 21) including sham + Vehicle (Veh.), UUO + Veh, UUO + estradiol (E2), and UUO + daidzein.",['daidzein'],"['Unilateral ureteral obstruction', 'chronic renal inflammation', 'fibrosis', 'UUO + estradiol (E2)']",True,estradiol,fibrosis,induce,C0151650,Renal fibrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",estradiol,induce
117,1585,35070374,"DSS also greatly inhibited mitochondrial membrane potential depolarization, reactive oxygen species production, and oxidative stress.",['oxygen'],['oxidative stress'],True,oxygen,oxidative stress,inhibited,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,inhibit
118,1613,34801689,  Soy isoflavone metabolite equol inhibits cancer cell proliferation in a PAP associated domain containing 5-dependent and an estrogen receptor-independent manner.,['equol'],['cancer cell proliferation'],True,equol,cancer cell proliferation,inhibits,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",equol,inhibit
119,1625,34738035,"Interestingly, daidzein elevated the expression levels of the sodium-coupled neutral amino acid  transporter 1 (SLC38A1) and insulin-like growth factor 1 (IGF-1) genes in the placenta (P < 0.05).",['daidzein'],['insulin-like growth factor'],True,daidzein,insulin-like growth factor,elevated,C2676198,Increased serum insulin-like growth factor 1,5281708,daidzein,daidzein,elevated
120,1641,34540371," Results: In vitro, daidzein significantly inhibited 143B and U2OS osteosarcoma cell proliferation and migration, and induced cell cycle arrest.",['daidzein'],"['osteosarcoma cell proliferation', 'induced cell cycle arrest']",True,daidzein,osteosarcoma cell proliferation,inhibited,C0029463,Osteogenic sarcoma,5281708,daidzein,daidzein,inhibit
121,1707,35121802,"Both the strains were bile and acid tolerant, utilized various sugars, adhered to intestinal epithelial cells, produced exopolysaccharides and folate, were susceptible for tetracycline, erythromycin, and chloramphenicol, did not cause hemolysis, and exhibited antimicrobial and plant phenolics metabolizing activities.","['sugars', 'tetracycline', 'erythromycin', 'chloramphenicol']",['hemolysis'],True,sugars,hemolysis,cause,C0002878,Increased hemolysis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sugars,cause
122,1707,35121802,"Both the strains were bile and acid tolerant, utilized various sugars, adhered to intestinal epithelial cells, produced exopolysaccharides and folate, were susceptible for tetracycline, erythromycin, and chloramphenicol, did not cause hemolysis, and exhibited antimicrobial and plant phenolics metabolizing activities.","['sugars', 'tetracycline', 'erythromycin', 'chloramphenicol']",['hemolysis'],True,tetracycline,hemolysis,cause,C0002878,Increased hemolysis,54675776,Tetracycline,Tetracycline,cause
123,1707,35121802,"Both the strains were bile and acid tolerant, utilized various sugars, adhered to intestinal epithelial cells, produced exopolysaccharides and folate, were susceptible for tetracycline, erythromycin, and chloramphenicol, did not cause hemolysis, and exhibited antimicrobial and plant phenolics metabolizing activities.","['sugars', 'tetracycline', 'erythromycin', 'chloramphenicol']",['hemolysis'],True,erythromycin,hemolysis,cause,C0002878,Increased hemolysis,12560,Erythromycin,Erythromycin,cause
124,1707,35121802,"Both the strains were bile and acid tolerant, utilized various sugars, adhered to intestinal epithelial cells, produced exopolysaccharides and folate, were susceptible for tetracycline, erythromycin, and chloramphenicol, did not cause hemolysis, and exhibited antimicrobial and plant phenolics metabolizing activities.","['sugars', 'tetracycline', 'erythromycin', 'chloramphenicol']",['hemolysis'],True,chloramphenicol,hemolysis,cause,C0002878,Increased hemolysis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chloramphenicol,cause
125,1724,35316816," CONCLUSION: VPA produces neuroprotective effects and inhibits the glial scar formation during the recovery period of ischemic stroke via inhibition of histone deacetylase and induction of Hsp70.1B.  © 2021 S. Karger AG, Basel.",['Hsp70.1B.'],"['glial scar formation', 'ischemic stroke']",True,Hsp70.1B.,ischemic stroke,produces,C0948008,Ischemic stroke,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Hsp70.1B.,produce
126,1724,35316816," CONCLUSION: VPA produces neuroprotective effects and inhibits the glial scar formation during the recovery period of ischemic stroke via inhibition of histone deacetylase and induction of Hsp70.1B.  © 2021 S. Karger AG, Basel.",['Hsp70.1B.'],"['glial scar formation', 'ischemic stroke']",True,Hsp70.1B.,ischemic stroke,inhibits,C0948008,Ischemic stroke,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Hsp70.1B.,inhibit
127,1738,35297358,"We found that VPA induces increased levels of H3K4me2/me3 and H3K9me, which are indicative of chromatin activation.",['VPA'],['increased levels of H3K4me2/me3 and H3K9me'],True,VPA,increased levels of H3K4me2/me3 and H3K9me,induces,C4073162,Elevated hemoglobin A1c,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
128,1740,35293630,  AIM: A few studies suggested that epilepsy and antiepileptic drugs with sodium channel blocking properties were independently associated with out-of-hospital cardiac arrest (OHCA).,['sodium'],['epilepsy'],True,sodium,epilepsy,associated,C0014544,Epilepsy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium,associate
129,1752,35280824,The combination of VPA and ATRA induced autophagic flux and promoted differentiation in ATRA-sensitive and -resistant cell lines.,"['VPA', 'ATRA']",['differentiation'],True,VPA,differentiation,induced,C1859624,Defective B cell differentiation,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
130,1752,35280824,The combination of VPA and ATRA induced autophagic flux and promoted differentiation in ATRA-sensitive and -resistant cell lines.,"['VPA', 'ATRA']",['differentiation'],True,ATRA,differentiation,induced,C1859624,Defective B cell differentiation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ATRA,induce
131,1772,35251569,Sodium valproate inhibits glioma invasion and metastasis through the regulation of Smad4 expression.,['Sodium valproate'],"['glioma invasion', 'metastasis', 'regulation of Smad4 expression']",True,Sodium valproate,glioma invasion,inhibits,C0017638,Glioma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Sodium valproate,inhibit
132,1782,35235162,  INTRODUCTION: Valproic acid (VPA) toxicity commonly results in a self-limited state of CNS depression that is managed with supportive care and levocarnitine.,"['Valproic acid', 'VPA']",['depression'],True,Valproic acid,depression,results,C0011581,Depression,3121,2-propylpentanoic acid,2-propylpentanoic acid,result
133,1784,35227771,"  AIMS: Valproic acid (VPA), a commonly used antiepileptic drug, can induce testicular oxidative stress and injury.","['Valproic acid', 'VPA']","['testicular oxidative stress', 'injury']",True,Valproic acid,testicular oxidative stress,induce,C0242606,Oxidative stress,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
134,1784,35227771,"  AIMS: Valproic acid (VPA), a commonly used antiepileptic drug, can induce testicular oxidative stress and injury.","['Valproic acid', 'VPA']","['testicular oxidative stress', 'injury']",True,Valproic acid,injury,induce,C0424366,Self injury,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
135,1810,35163292,Valproate (and to a certain degree other AEDs) may induce autism spectrum disorders and attention deficit hyperactivity disorder.,['Valproate'],['deficit hyperactivity disorder'],True,Valproate,deficit hyperactivity disorder,induce,C1263846,Attention deficit,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
136,1816,35157897,"In comparison, while causing a sex-dependent increase in spatial memory,  subcutaneous injection of VPA (400 mg/kg) in infancy resulted in limited adverse  autistic features, including a decrease in males' social preference, as well as reduced avoidance memory.",['VPA'],"['infancy', 'reduced avoidance memory']",True,VPA,infancy,resulted,C1858430,Death in infancy,3121,2-propylpentanoic acid,2-propylpentanoic acid,result
137,1842,35085321,  Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19.,['valproic acid'],['less pulmonary infiltrates'],True,valproic acid,less pulmonary infiltrates,associated,C0235896,Pulmonic infiltration,3121,2-propylpentanoic acid,2-propylpentanoic acid,associate
138,1846,35078573,"Compared with those in the group of NK92 cells with VPA, the tumor volume of NOD/SCID mice was increased, and the  expressions of MICA and MICB were decreased in the group of NK92 cells with VPA and PD98059.","['VPA', 'VPA']",['tumor'],True,VPA,tumor,increased,C0027651,Neoplasm,3121,2-propylpentanoic acid,2-propylpentanoic acid,increase
139,1846,35078573,"Compared with those in the group of NK92 cells with VPA, the tumor volume of NOD/SCID mice was increased, and the  expressions of MICA and MICB were decreased in the group of NK92 cells with VPA and PD98059.","['VPA', 'VPA']",['tumor'],True,VPA,tumor,increased,C0027651,Neoplasm,3121,2-propylpentanoic acid,2-propylpentanoic acid,increase
140,1861,35052847,CoQ10 combined with VPA induced a more significant reduction in oxidative stress and improved the histopathological changes in the brain and liver compared to VPA treatment.,"['CoQ10', 'VPA', 'VPA']",['reduction in oxidative stress'],True,CoQ10,reduction in oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CoQ10,induce
141,1861,35052847,CoQ10 combined with VPA induced a more significant reduction in oxidative stress and improved the histopathological changes in the brain and liver compared to VPA treatment.,"['CoQ10', 'VPA', 'VPA']",['reduction in oxidative stress'],True,VPA,reduction in oxidative stress,induced,C0242606,Oxidative stress,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
142,1861,35052847,CoQ10 combined with VPA induced a more significant reduction in oxidative stress and improved the histopathological changes in the brain and liver compared to VPA treatment.,"['CoQ10', 'VPA', 'VPA']",['reduction in oxidative stress'],True,VPA,reduction in oxidative stress,induced,C0242606,Oxidative stress,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
143,1872,35018231,"Inhibition of HDAC2 by VPA induces apoptosis in B16F10C and B16F10R. The present study highlights the role of HDAC2, a cell cycle regulator, in the development of resistance to dual drugs in murine melanoma.",['VPA'],"['Inhibition of HDAC2', 'apoptosis', 'melanoma']",True,VPA,Inhibition of HDAC2,induces,C0424296,Disinhibition,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
144,1872,35018231,"Inhibition of HDAC2 by VPA induces apoptosis in B16F10C and B16F10R. The present study highlights the role of HDAC2, a cell cycle regulator, in the development of resistance to dual drugs in murine melanoma.",['VPA'],"['Inhibition of HDAC2', 'apoptosis', 'melanoma']",True,VPA,melanoma,induces,C0025202,Malignant melanoma,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
145,1921,35172217,"Older age, being overweight or obese, desaturation and extent of chest CT scan lesions>25% at admission (aHR: 2.2 [95% CI: 1.3-3.5]) and higher peak CRP levels and acute kidney failure (aHR: 2.0 [1.2-3.3]) during follow-up were independently associated with adverse outcomes, whereas treatment with hydrocortisone reduced the risk of mechanical ventilation or death by half (aHR: 0.5 [0.3-0.8]).",['hydrocortisone'],"['obese', 'acute kidney failure', 'mechanical ventilation or death']",True,hydrocortisone,acute kidney failure,associated,C0022660,Acute kidney failure,5754,hydrocortisone,hydrocortisone,associate
146,1987,33657393,  The phytochemical hyperforin triggers thermogenesis in adipose tissue via a Dlat-AMPK signaling axis to curb obesity.,['hyperforin'],"['thermogenesis in adipose tissue', 'obesity']",True,hyperforin,obesity,triggers,C0028754,Obesity,441298,hyperforin,hyperforin,trigger
147,2009,32624982,The value  of this extract stems from its use to treat depression and skin irritation due to its hyperforin content.,['hyperforin'],"['depression', 'skin irritation']",True,hyperforin,depression,stems,C0011581,Depression,441298,hyperforin,hyperforin,stem
148,2023,31685083,St. John's wort preparations rich in hyperforin do in fact reproducibly lead to the decrease of blood levels of medications metabolized through cytochrome P450 subtype 3A4.,['hyperforin'],['decrease of blood levels'],True,hyperforin,decrease of blood levels,lead,C4732894,Hypoprolinemia,441298,hyperforin,hyperforin,lead
149,2056,30481499,"In the present study, HF significantly inhibited the  formation of reactive oxygen species (ROS), decreased the level of lipid peroxide and enhanced the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) compared with Almal group in PC12 cells and SH-SY5Y cells.","['oxygen', 'Almal']","['decreased the level of lipid peroxide', 'enhanced the activities of superoxide dismutase (SOD) and glutathione peroxidase']",True,oxygen,enhanced the activities of superoxide dismutase,inhibited,C4703565,Abnormal superoxide dismutase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,inhibit
150,2056,30481499,"In the present study, HF significantly inhibited the  formation of reactive oxygen species (ROS), decreased the level of lipid peroxide and enhanced the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) compared with Almal group in PC12 cells and SH-SY5Y cells.","['oxygen', 'Almal']","['decreased the level of lipid peroxide', 'enhanced the activities of superoxide dismutase (SOD) and glutathione peroxidase']",True,glutathione peroxidase,enhanced the activities of superoxide dismutase,inhibited,C4703565,Abnormal superoxide dismutase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione peroxidase,inhibit
151,2056,30481499,"In the present study, HF significantly inhibited the  formation of reactive oxygen species (ROS), decreased the level of lipid peroxide and enhanced the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) compared with Almal group in PC12 cells and SH-SY5Y cells.","['oxygen', 'Almal']","['decreased the level of lipid peroxide', 'enhanced the activities of superoxide dismutase (SOD) and glutathione peroxidase']",True,Almal,enhanced the activities of superoxide dismutase,inhibited,C4703565,Abnormal superoxide dismutase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Almal,inhibit
152,2070,29599335," (6)Department of Medical Imaging, Taipei Medical University Hospital, Taipei, Taiwan, R.O.C. (7)Research Center of Translational Imaging, College of Medicine, Taipei Medical  University, Taipei, Taiwan, R.O.C.  BACKGROUND/AIM: Previous studies have indicated that hyperforin inhibits tumor growth of hepatocellular carcinoma.",['hyperforin'],['tumor growth of hepatocellular carcinoma'],True,hyperforin,tumor growth of hepatocellular carcinoma,inhibits,C2239176,Hepatocellular carcinoma,441298,hyperforin,hyperforin,inhibit
153,2089,28943862,"Therefore, the established chemistry presents a paradox for this H. perforatum oil macerate: the hyperforin responsible for the antibacterial bioactivity should degrade in the sunlight as the traditional oil is prepared; alternately, if hypericin is present in established bioactive levels, then the oil macerate should cause photosensitivity, yet none is reported.",['hyperforin'],['photosensitivity'],True,hyperforin,photosensitivity,cause,C0349506,Photosensitivity,441298,hyperforin,hyperforin,cause
154,2122,26811157,"It is important to increase consumer awareness of ""washing in"" of various compounds leading to increased risk of toxicity, as well as differences in reapplication need due to ""washing off"" caused by water, sweat and abrasion.",['water'],"['increased risk of toxicity', 'sweat']",True,water,sweat,caused,C0038990,Sweating,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
155,2190,34779371,This side effect has led to thiazides being used to treat idiopathic hypercalciuria and associated nephrolithiasis.,['thiazides'],"['idiopathic hypercalciuria', 'associated nephrolithiasis']",True,thiazides,idiopathic hypercalciuria,led,C0020438,Elevated urine calcium levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazides,lead
156,2190,34779371,This side effect has led to thiazides being used to treat idiopathic hypercalciuria and associated nephrolithiasis.,['thiazides'],"['idiopathic hypercalciuria', 'associated nephrolithiasis']",True,thiazides,associated nephrolithiasis,led,C0392525,Renal calculi,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazides,lead
157,2211,34586345,"Taxane-containing regimens were used for most patients (92 [92%]) and were associated with more severe alopecia than regimens that did not contain taxanes (median Sinclair grade, 4 [IQR, 3-5] vs 2 [IQR, 2-2.5]; P < .001).",['taxanes'],['alopecia'],True,taxanes,alopecia,associated,C0002170,Hair loss,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taxanes,associate
158,2362,28922723, These findings suggest that the cytoprotective effects of chrysin and mirtazapine on rat testes were associated with suppression of oxidative stress and apoptotic  tissue damage.,"['chrysin', 'mirtazapine']",['suppression of oxidative stress'],True,chrysin,suppression of oxidative stress,associated,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chrysin,associate
159,2362,28922723, These findings suggest that the cytoprotective effects of chrysin and mirtazapine on rat testes were associated with suppression of oxidative stress and apoptotic  tissue damage.,"['chrysin', 'mirtazapine']",['suppression of oxidative stress'],True,mirtazapine,suppression of oxidative stress,associated,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mirtazapine,associate
160,2366,35238379,"Fhypopneas, and apnea index were associated with oral appliance and atomoxetine-plus-oxybutynin efficacy (both p<0.05).",['atomoxetine-plus-oxybutynin'],['apnea index'],True,atomoxetine-plus-oxybutynin,apnea index,associated,C0003578,Apnea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",atomoxetine-plus-oxybutynin,associate
161,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,desmopressin,nocturnal enuresis,associated,C0270327,Nocturnal enuresis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",desmopressin,associate
162,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,desmopressin,urinary incontinence,associated,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",desmopressin,associate
163,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,oxybutynin,nocturnal enuresis,associated,C0270327,Nocturnal enuresis,4634,oxybutynin,oxybutynin,associate
164,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,oxybutynin,urinary incontinence,associated,C0042024,Loss of bladder control,4634,oxybutynin,oxybutynin,associate
165,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,trihexyphenidyl,nocturnal enuresis,associated,C0270327,Nocturnal enuresis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trihexyphenidyl,associate
166,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,trihexyphenidyl,urinary incontinence,associated,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trihexyphenidyl,associate
167,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,tolterodine,nocturnal enuresis,associated,C0270327,Nocturnal enuresis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tolterodine,associate
168,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,tolterodine,urinary incontinence,associated,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tolterodine,associate
169,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,imipramine,nocturnal enuresis,associated,C0270327,Nocturnal enuresis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",imipramine,associate
170,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,imipramine,urinary incontinence,associated,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",imipramine,associate
171,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,amitriptyline,nocturnal enuresis,associated,C0270327,Nocturnal enuresis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amitriptyline,associate
172,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,amitriptyline,urinary incontinence,associated,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amitriptyline,associate
173,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,ephedrine,nocturnal enuresis,associated,C0270327,Nocturnal enuresis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ephedrine,associate
174,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,ephedrine,urinary incontinence,associated,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ephedrine,associate
175,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,pseudoephedrine,nocturnal enuresis,associated,C0270327,Nocturnal enuresis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pseudoephedrine,associate
176,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,pseudoephedrine,urinary incontinence,associated,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pseudoephedrine,associate
177,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,aripiprazole,nocturnal enuresis,associated,C0270327,Nocturnal enuresis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aripiprazole,associate
178,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,aripiprazole,urinary incontinence,associated,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aripiprazole,associate
179,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,verapamil,nocturnal enuresis,associated,C0270327,Nocturnal enuresis,2520,VERAPAMIL,VERAPAMIL,associate
180,2369,35086595,"Among pharmacological treatments, desmopressin, oxybutynin, trihexyphenidyl, tolterodine, imipramine, amitriptyline, ephedrine, pseudoephedrine, aripiprazole, and verapamil were associated with complete resolution of nocturnal enuresis and urinary incontinence.","['desmopressin', 'oxybutynin', 'trihexyphenidyl', 'tolterodine', 'imipramine', 'amitriptyline', 'ephedrine', 'pseudoephedrine', 'aripiprazole', 'verapamil']","['nocturnal enuresis', 'urinary incontinence']",True,verapamil,urinary incontinence,associated,C0042024,Loss of bladder control,2520,VERAPAMIL,VERAPAMIL,associate
181,2371,35032570,"Long-term chronic administration of some polypharmacy and monotherapy therapeutic drug regimens increased the number of frailty deficits (clinical frailty index: low DBI polypharmacy (15 and 21 months), high DBI polypharmacy (15-21 months), oxycodone (15-18 months), oxybutynin (15-18 months), citalopram (15-21 months) and metoprolol monotherapy (15 months) and modified frailty phenotype assessment (over the whole duration of treatment, low DBI polypharmacy  (adjusted Risk Ratio(aRR) = 1.97, 95% confidence interval (CI) 1.43-2.72), high DBI polypharmacy (aRR = 1.88; 95% CI 1.36-2.60), oxybutynin (aRR = 1.48; 95% CI 1.01-2.16) and citalopram monotherapy (aRR = 1.96; 95% CI 1.41-2.74), p < 0.05) .","['oxycodone', 'oxybutynin', 'citalopram', 'metoprolol', 'oxybutynin', 'citalopram']",['number of frailty deficits'],True,oxycodone,number of frailty deficits,increased,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxycodone,increase
182,2371,35032570,"Long-term chronic administration of some polypharmacy and monotherapy therapeutic drug regimens increased the number of frailty deficits (clinical frailty index: low DBI polypharmacy (15 and 21 months), high DBI polypharmacy (15-21 months), oxycodone (15-18 months), oxybutynin (15-18 months), citalopram (15-21 months) and metoprolol monotherapy (15 months) and modified frailty phenotype assessment (over the whole duration of treatment, low DBI polypharmacy  (adjusted Risk Ratio(aRR) = 1.97, 95% confidence interval (CI) 1.43-2.72), high DBI polypharmacy (aRR = 1.88; 95% CI 1.36-2.60), oxybutynin (aRR = 1.48; 95% CI 1.01-2.16) and citalopram monotherapy (aRR = 1.96; 95% CI 1.41-2.74), p < 0.05) .","['oxycodone', 'oxybutynin', 'citalopram', 'metoprolol', 'oxybutynin', 'citalopram']",['number of frailty deficits'],True,oxybutynin,number of frailty deficits,increased,C0042024,Loss of bladder control,4634,oxybutynin,oxybutynin,increase
183,2371,35032570,"Long-term chronic administration of some polypharmacy and monotherapy therapeutic drug regimens increased the number of frailty deficits (clinical frailty index: low DBI polypharmacy (15 and 21 months), high DBI polypharmacy (15-21 months), oxycodone (15-18 months), oxybutynin (15-18 months), citalopram (15-21 months) and metoprolol monotherapy (15 months) and modified frailty phenotype assessment (over the whole duration of treatment, low DBI polypharmacy  (adjusted Risk Ratio(aRR) = 1.97, 95% confidence interval (CI) 1.43-2.72), high DBI polypharmacy (aRR = 1.88; 95% CI 1.36-2.60), oxybutynin (aRR = 1.48; 95% CI 1.01-2.16) and citalopram monotherapy (aRR = 1.96; 95% CI 1.41-2.74), p < 0.05) .","['oxycodone', 'oxybutynin', 'citalopram', 'metoprolol', 'oxybutynin', 'citalopram']",['number of frailty deficits'],True,citalopram,number of frailty deficits,increased,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",citalopram,increase
184,2371,35032570,"Long-term chronic administration of some polypharmacy and monotherapy therapeutic drug regimens increased the number of frailty deficits (clinical frailty index: low DBI polypharmacy (15 and 21 months), high DBI polypharmacy (15-21 months), oxycodone (15-18 months), oxybutynin (15-18 months), citalopram (15-21 months) and metoprolol monotherapy (15 months) and modified frailty phenotype assessment (over the whole duration of treatment, low DBI polypharmacy  (adjusted Risk Ratio(aRR) = 1.97, 95% confidence interval (CI) 1.43-2.72), high DBI polypharmacy (aRR = 1.88; 95% CI 1.36-2.60), oxybutynin (aRR = 1.48; 95% CI 1.01-2.16) and citalopram monotherapy (aRR = 1.96; 95% CI 1.41-2.74), p < 0.05) .","['oxycodone', 'oxybutynin', 'citalopram', 'metoprolol', 'oxybutynin', 'citalopram']",['number of frailty deficits'],True,metoprolol,number of frailty deficits,increased,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",metoprolol,increase
185,2371,35032570,"Long-term chronic administration of some polypharmacy and monotherapy therapeutic drug regimens increased the number of frailty deficits (clinical frailty index: low DBI polypharmacy (15 and 21 months), high DBI polypharmacy (15-21 months), oxycodone (15-18 months), oxybutynin (15-18 months), citalopram (15-21 months) and metoprolol monotherapy (15 months) and modified frailty phenotype assessment (over the whole duration of treatment, low DBI polypharmacy  (adjusted Risk Ratio(aRR) = 1.97, 95% confidence interval (CI) 1.43-2.72), high DBI polypharmacy (aRR = 1.88; 95% CI 1.36-2.60), oxybutynin (aRR = 1.48; 95% CI 1.01-2.16) and citalopram monotherapy (aRR = 1.96; 95% CI 1.41-2.74), p < 0.05) .","['oxycodone', 'oxybutynin', 'citalopram', 'metoprolol', 'oxybutynin', 'citalopram']",['number of frailty deficits'],True,oxybutynin,number of frailty deficits,increased,C0042024,Loss of bladder control,4634,oxybutynin,oxybutynin,increase
186,2371,35032570,"Long-term chronic administration of some polypharmacy and monotherapy therapeutic drug regimens increased the number of frailty deficits (clinical frailty index: low DBI polypharmacy (15 and 21 months), high DBI polypharmacy (15-21 months), oxycodone (15-18 months), oxybutynin (15-18 months), citalopram (15-21 months) and metoprolol monotherapy (15 months) and modified frailty phenotype assessment (over the whole duration of treatment, low DBI polypharmacy  (adjusted Risk Ratio(aRR) = 1.97, 95% confidence interval (CI) 1.43-2.72), high DBI polypharmacy (aRR = 1.88; 95% CI 1.36-2.60), oxybutynin (aRR = 1.48; 95% CI 1.01-2.16) and citalopram monotherapy (aRR = 1.96; 95% CI 1.41-2.74), p < 0.05) .","['oxycodone', 'oxybutynin', 'citalopram', 'metoprolol', 'oxybutynin', 'citalopram']",['number of frailty deficits'],True,citalopram,number of frailty deficits,increased,C0042024,Loss of bladder control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",citalopram,increase
187,2373,34991991,"Although proteinuria,  CKD and enalapril requirement increased over 5 years, almost 90% did not show changes in renal DMSA status.",['enalapril'],['proteinuria'],True,enalapril,proteinuria,increased,C0033687,Protein in urine,5388962,Enalapril,Enalapril,increase
188,2380,34742663," In the 6 mo to 1 yr prior to diagnosis, receipt of solifenacin (OR 1.34; 95% CI 1.11-1.60), darifenacin (OR 1.49; 95% CI 1.19-1.86), tolterodine (OR 1.21; 95% CI 1.02-1.45), and fesoterodine (OR 1.39; 95% CI 1.14-1.71) was associated with increased odds of incident dementia compared with receipt of mirabegron.","['solifenacin', 'darifenacin', 'tolterodine', 'fesoterodine', 'mirabegron']",['dementia'],True,solifenacin,dementia,associated,C0497327,"Dementia, progressive",154059,"[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate","[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate",associate
189,2380,34742663," In the 6 mo to 1 yr prior to diagnosis, receipt of solifenacin (OR 1.34; 95% CI 1.11-1.60), darifenacin (OR 1.49; 95% CI 1.19-1.86), tolterodine (OR 1.21; 95% CI 1.02-1.45), and fesoterodine (OR 1.39; 95% CI 1.14-1.71) was associated with increased odds of incident dementia compared with receipt of mirabegron.","['solifenacin', 'darifenacin', 'tolterodine', 'fesoterodine', 'mirabegron']",['dementia'],True,darifenacin,dementia,associated,C0497327,"Dementia, progressive",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",darifenacin,associate
190,2380,34742663," In the 6 mo to 1 yr prior to diagnosis, receipt of solifenacin (OR 1.34; 95% CI 1.11-1.60), darifenacin (OR 1.49; 95% CI 1.19-1.86), tolterodine (OR 1.21; 95% CI 1.02-1.45), and fesoterodine (OR 1.39; 95% CI 1.14-1.71) was associated with increased odds of incident dementia compared with receipt of mirabegron.","['solifenacin', 'darifenacin', 'tolterodine', 'fesoterodine', 'mirabegron']",['dementia'],True,tolterodine,dementia,associated,C0497327,"Dementia, progressive",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tolterodine,associate
191,2380,34742663," In the 6 mo to 1 yr prior to diagnosis, receipt of solifenacin (OR 1.34; 95% CI 1.11-1.60), darifenacin (OR 1.49; 95% CI 1.19-1.86), tolterodine (OR 1.21; 95% CI 1.02-1.45), and fesoterodine (OR 1.39; 95% CI 1.14-1.71) was associated with increased odds of incident dementia compared with receipt of mirabegron.","['solifenacin', 'darifenacin', 'tolterodine', 'fesoterodine', 'mirabegron']",['dementia'],True,fesoterodine,dementia,associated,C0497327,"Dementia, progressive",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fesoterodine,associate
192,2380,34742663," In the 6 mo to 1 yr prior to diagnosis, receipt of solifenacin (OR 1.34; 95% CI 1.11-1.60), darifenacin (OR 1.49; 95% CI 1.19-1.86), tolterodine (OR 1.21; 95% CI 1.02-1.45), and fesoterodine (OR 1.39; 95% CI 1.14-1.71) was associated with increased odds of incident dementia compared with receipt of mirabegron.","['solifenacin', 'darifenacin', 'tolterodine', 'fesoterodine', 'mirabegron']",['dementia'],True,mirabegron,dementia,associated,C0497327,"Dementia, progressive",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mirabegron,associate
193,2382,34742663,"Oxybutynin and trospium were  not associated with dementia, likely due to a protopathic bias.","['Oxybutynin', 'trospium']",['dementia'],True,Oxybutynin,dementia,associated,C0497327,"Dementia, progressive",4634,oxybutynin,oxybutynin,associate
194,2382,34742663,"Oxybutynin and trospium were  not associated with dementia, likely due to a protopathic bias.","['Oxybutynin', 'trospium']",['dementia'],True,trospium,dementia,associated,C0497327,"Dementia, progressive",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trospium,associate
195,2398,34213600,"Oxybutynin use was linked to functional, mental, and behavioral decline among patients with Alzheimer's disease (2 studies).",['Oxybutynin'],"[""Alzheimer's disease""]",True,Oxybutynin,Alzheimer's disease,linked,C0002395,Alzheimer disease,4634,oxybutynin,oxybutynin,link
196,2399,34213600,Solifenacin was not associated with cognitive decline (2 studies) but was linked to an increased risk of dementia among patients with diabetes (1 study).,['Solifenacin'],"['increased risk of dementia', 'diabetes']",True,Solifenacin,diabetes,associated,C0085207,Maternal diabetes,154059,"[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate","[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate",associate
197,2410,34164887,"However, while the addition of zolpidem does not  increase next-day perceived sleepiness, caution is warranted given the potential  impact on next-morning objective alertness.",['zolpidem'],['sleepiness'],True,zolpidem,sleepiness,increase,C0917799,Hypersomnia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",zolpidem,increase
198,2420,33938689,"Despite minimizing sweating, chronic use of systemic anticholinergics, in particular oxybutynin, may result in detrimental adverse effects such as dementia.",['oxybutynin'],"['detrimental adverse effects', 'dementia']",True,oxybutynin,dementia,result,C0497327,"Dementia, progressive",4634,oxybutynin,oxybutynin,result
199,2463,32691938,"A sequencing therapeutic approach to palmar hyperhidrosis increases both efficacy and safety compared with the use of oral oxybutynin chloride alone, and allows clinicians to keep lower dosage of oxybutynin chloride reducing generalized side effects and increasing the retention rate to the treatment.","['oxybutynin chloride', 'oxybutynin chloride']","['palmar hyperhidrosis', 'increasing the retention rate']",True,oxybutynin chloride,palmar hyperhidrosis,increases,C1856953,Palmar hyperhidrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxybutynin chloride,increase
200,2463,32691938,"A sequencing therapeutic approach to palmar hyperhidrosis increases both efficacy and safety compared with the use of oral oxybutynin chloride alone, and allows clinicians to keep lower dosage of oxybutynin chloride reducing generalized side effects and increasing the retention rate to the treatment.","['oxybutynin chloride', 'oxybutynin chloride']","['palmar hyperhidrosis', 'increasing the retention rate']",True,oxybutynin chloride,increasing the retention rate,increases,C1856953,Palmar hyperhidrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxybutynin chloride,increase
201,2463,32691938,"A sequencing therapeutic approach to palmar hyperhidrosis increases both efficacy and safety compared with the use of oral oxybutynin chloride alone, and allows clinicians to keep lower dosage of oxybutynin chloride reducing generalized side effects and increasing the retention rate to the treatment.","['oxybutynin chloride', 'oxybutynin chloride']","['palmar hyperhidrosis', 'increasing the retention rate']",True,oxybutynin chloride,palmar hyperhidrosis,increases,C1856953,Palmar hyperhidrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxybutynin chloride,increase
202,2463,32691938,"A sequencing therapeutic approach to palmar hyperhidrosis increases both efficacy and safety compared with the use of oral oxybutynin chloride alone, and allows clinicians to keep lower dosage of oxybutynin chloride reducing generalized side effects and increasing the retention rate to the treatment.","['oxybutynin chloride', 'oxybutynin chloride']","['palmar hyperhidrosis', 'increasing the retention rate']",True,oxybutynin chloride,increasing the retention rate,increases,C1856953,Palmar hyperhidrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxybutynin chloride,increase
203,2481,35275035,"  The non-genotoxic synthetic pyrethroid insecticide permethrin produced hepatocellular adenomas and bronchiolo-alveolar adenomas in female CD-1 mice, but not in male CD-1 mice or in female or male Wistar rats.",['permethrin'],"['hepatocellular adenomas', 'bronchiolo-alveolar adenomas']",True,permethrin,hepatocellular adenomas,produced,C0206669,Hepatic adenoma,40326,permethrin,permethrin,produce
204,2484,35275035,"Although the possibility that permethrin exposure may potentially result in enhancement of Club cell proliferation in humans cannot be completely excluded, there is sufficient information on differences in basic lung anatomy, physiology, metabolism, and biologic behavior of tumors in the general literature to conclude that humans are quantitatively less sensitive to agents that increase Club cell proliferation and lead to tumor formation in mice.",['permethrin'],"['cell proliferation', 'biologic behavior of tumors', 'increase Club', 'cell proliferation', 'tumor formation']",True,permethrin,cell proliferation,result,C4531170,Abnormal cell proliferation,40326,permethrin,permethrin,result
205,2505,35017857,"Permethrin did not cause any ultrastructural morphological changes on the lice, while 6-paradol severely damaged the head, thorax, respiratory spiracles, and abdomen of the dead lice.","['Permethrin', '6-paradol']","['damaged', 'dead lice']",True,Permethrin,damaged,cause,C3887709,Optic neuropathy,40326,permethrin,permethrin,cause
206,2505,35017857,"Permethrin did not cause any ultrastructural morphological changes on the lice, while 6-paradol severely damaged the head, thorax, respiratory spiracles, and abdomen of the dead lice.","['Permethrin', '6-paradol']","['damaged', 'dead lice']",True,6-paradol,damaged,cause,C3887709,Optic neuropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",6-paradol,cause
207,2509,34997580,"Permethrin is a frequently used synthetic pyrethroid insecticide for which longer exposure may cause toxicity in several types of tissues and the  development of metabolic diseases, including atherosclerosis, obesity and diabetes.",['Permethrin'],"['atherosclerosis', 'obesity', 'diabetes']",True,Permethrin,atherosclerosis,cause,C0004153,Narrowing and hardening of arteries,40326,permethrin,permethrin,cause
208,2509,34997580,"Permethrin is a frequently used synthetic pyrethroid insecticide for which longer exposure may cause toxicity in several types of tissues and the  development of metabolic diseases, including atherosclerosis, obesity and diabetes.",['Permethrin'],"['atherosclerosis', 'obesity', 'diabetes']",True,Permethrin,obesity,cause,C0028754,Obesity,40326,permethrin,permethrin,cause
209,2509,34997580,"Permethrin is a frequently used synthetic pyrethroid insecticide for which longer exposure may cause toxicity in several types of tissues and the  development of metabolic diseases, including atherosclerosis, obesity and diabetes.",['Permethrin'],"['atherosclerosis', 'obesity', 'diabetes']",True,Permethrin,diabetes,cause,C0085207,Maternal diabetes,40326,permethrin,permethrin,cause
210,2578,34638865,"These findings suggest that methylparaben and phenoxyethanol promote nerve elongation in hiPSC-SNs, whereas benzo[a]pyrene induces nerve degeneration.","['methylparaben', 'phenoxyethanol', 'benzo[a]pyrene']","['nerve elongation', 'nerve degeneration']",True,benzo[a]pyrene,nerve degeneration,induces,C0029124,Optic atrophy,2336,Benzo[A]Pyrene,Benzo[A]Pyrene,induce
211,2581,34358651,"Nitrite is a potential stress-inducing factor and can cause oxidative stress because excessive reactive oxygen species (ROS) formation through nitrite induction cannot be scavenged by the endogenous antioxidant system, thus leading to cell damage or death.","['Nitrite', 'oxygen']","['oxidative stress', 'cell damage', 'death']",True,oxygen,oxidative stress,cause,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,cause
212,2601,32387382,"Further, a 24-h treatment of the IHMGECs with concentrations of methylparaben, ethylparaben, phenoxyethanol and chlorphenesin close to, or at, the approved human dose induces cellular atrophy and death.","['methylparaben', 'ethylparaben', 'phenoxyethanol']","['cellular atrophy', 'death']",True,methylparaben,death,induces,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methylparaben,induce
213,2601,32387382,"Further, a 24-h treatment of the IHMGECs with concentrations of methylparaben, ethylparaben, phenoxyethanol and chlorphenesin close to, or at, the approved human dose induces cellular atrophy and death.","['methylparaben', 'ethylparaben', 'phenoxyethanol']","['cellular atrophy', 'death']",True,ethylparaben,cellular atrophy,induces,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethylparaben,induce
214,2601,32387382,"Further, a 24-h treatment of the IHMGECs with concentrations of methylparaben, ethylparaben, phenoxyethanol and chlorphenesin close to, or at, the approved human dose induces cellular atrophy and death.","['methylparaben', 'ethylparaben', 'phenoxyethanol']","['cellular atrophy', 'death']",True,ethylparaben,death,induces,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethylparaben,induce
215,2601,32387382,"Further, a 24-h treatment of the IHMGECs with concentrations of methylparaben, ethylparaben, phenoxyethanol and chlorphenesin close to, or at, the approved human dose induces cellular atrophy and death.","['methylparaben', 'ethylparaben', 'phenoxyethanol']","['cellular atrophy', 'death']",True,phenoxyethanol,cellular atrophy,induces,C1546180,Age of death,31236,2-phenoxyethanol,2-phenoxyethanol,induce
216,2601,32387382,"Further, a 24-h treatment of the IHMGECs with concentrations of methylparaben, ethylparaben, phenoxyethanol and chlorphenesin close to, or at, the approved human dose induces cellular atrophy and death.","['methylparaben', 'ethylparaben', 'phenoxyethanol']","['cellular atrophy', 'death']",True,phenoxyethanol,death,induces,C1546180,Age of death,31236,2-phenoxyethanol,2-phenoxyethanol,induce
217,2631,35264095, We have also conducted a literature review of similar cases and highlight the clinical patterns and management strategies for pregabalin induced skin rashes.,['pregabalin'],['skin rashes'],True,pregabalin,skin rashes,induced,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pregabalin,induce
218,2675,35022915,Transforming growth factor-beta (TGFβ) significantly increased in a time-dependent manner and platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) significantly increased in a time- and dose-dependent manner in phenytoin  1% and 3% in the 6- and 12-day protocols.,"['TGFβ', 'VEGF', 'phenytoin']","['growth factor', 'vascular endothelial growth factor']",True,TGFβ,vascular endothelial growth factor,increased,C4476933,Elevated vascular endothelial growth factor level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TGFβ,increase
219,2675,35022915,Transforming growth factor-beta (TGFβ) significantly increased in a time-dependent manner and platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) significantly increased in a time- and dose-dependent manner in phenytoin  1% and 3% in the 6- and 12-day protocols.,"['TGFβ', 'VEGF', 'phenytoin']","['growth factor', 'vascular endothelial growth factor']",True,phenytoin,vascular endothelial growth factor,increased,C4476933,Elevated vascular endothelial growth factor level,1775,Phenytoin,Phenytoin,increase
220,2686,34962289, EXPERIMENTAL APPROACH: Status epilepticus was induced via a unilateral microinjection of kainic acid into the amygdala in adult mice.,['kainic acid'],['Status epilepticus'],True,kainic acid,Status epilepticus,induced,C0038220,Repeated seizures without recovery between them,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",kainic acid,induce
221,2744,35305353," CONCLUSION: Tanshinone IIA, resveratrol and silibinin inhibited EV68 proliferation through inhibiting ATM and/or DNA-PK activation, and they were effective anti-EV68 candidates.","['resveratrol', 'silibinin']",['EV68 proliferation'],True,resveratrol,EV68 proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",resveratrol,inhibit
222,2744,35305353," CONCLUSION: Tanshinone IIA, resveratrol and silibinin inhibited EV68 proliferation through inhibiting ATM and/or DNA-PK activation, and they were effective anti-EV68 candidates.","['resveratrol', 'silibinin']",['EV68 proliferation'],True,silibinin,EV68 proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",silibinin,inhibit
223,2752,35294118,"A significant attenuation of alloxan induced hyperglycemia was produced by S. diversifolia extracts at 50 mg/kg (P < 0.05), 100 mg/kg (P < 0.05, < 0.01), and 150 mg/kg (P < 0.05, < 0.01, < 0.001) during 1-4 h, which was comparable to metformin (P < 0.001).",['metformin'],['hyperglycemia'],True,metformin,hyperglycemia,produced,C0020456,High blood sugar,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",metformin,produce
224,2840,35249013,2022 Mar 4. doi: 10.1159/000523905. [Epub ahead of print]  Quercetin Inhibits Glioblastoma Growth and Prolongs Survival Rate through Inhibiting Glycolytic Metabolism.,['Quercetin'],['Glioblastoma Growth and Prolongs Survival Rate'],True,Quercetin,Glioblastoma Growth and Prolongs Survival Rate,Inhibits,C1621958,Glioblastoma multiforme,5280343,quercetin,quercetin,inhibits
225,2844,35249013, RESULTS: We found that quercetin administration inhibited GBM cell proliferation  and promoted cell apoptosis in vitro.,['quercetin'],"['GBM cell proliferation', 'promoted cell apoptosis']",True,quercetin,GBM cell proliferation,inhibited,C4531170,Abnormal cell proliferation,5280343,quercetin,quercetin,inhibit
226,2847,35249013," DISCUSSION/CONCLUSION: Mechanistically, quercetin inhibited proliferation and angiogenesis, promoted cancer cell apoptosis, and finally improved locomotor activity and survival by inhibiting the glycolytic metabolism in GBM tissues, suggesting that quercetin is a potential drug for the treatment of GBM.","['quercetin', 'quercetin']","['proliferation', 'cancer cell apoptosis', 'survival', 'inhibiting the glycolytic metabolism in GBM tissues']",True,quercetin,proliferation,inhibited,C4531170,Abnormal cell proliferation,5280343,quercetin,quercetin,inhibit
227,2847,35249013," DISCUSSION/CONCLUSION: Mechanistically, quercetin inhibited proliferation and angiogenesis, promoted cancer cell apoptosis, and finally improved locomotor activity and survival by inhibiting the glycolytic metabolism in GBM tissues, suggesting that quercetin is a potential drug for the treatment of GBM.","['quercetin', 'quercetin']","['proliferation', 'cancer cell apoptosis', 'survival', 'inhibiting the glycolytic metabolism in GBM tissues']",True,quercetin,cancer cell apoptosis,inhibited,C0006826,Cancer,5280343,quercetin,quercetin,inhibit
228,2847,35249013," DISCUSSION/CONCLUSION: Mechanistically, quercetin inhibited proliferation and angiogenesis, promoted cancer cell apoptosis, and finally improved locomotor activity and survival by inhibiting the glycolytic metabolism in GBM tissues, suggesting that quercetin is a potential drug for the treatment of GBM.","['quercetin', 'quercetin']","['proliferation', 'cancer cell apoptosis', 'survival', 'inhibiting the glycolytic metabolism in GBM tissues']",True,quercetin,proliferation,inhibited,C4531170,Abnormal cell proliferation,5280343,quercetin,quercetin,inhibit
229,2847,35249013," DISCUSSION/CONCLUSION: Mechanistically, quercetin inhibited proliferation and angiogenesis, promoted cancer cell apoptosis, and finally improved locomotor activity and survival by inhibiting the glycolytic metabolism in GBM tissues, suggesting that quercetin is a potential drug for the treatment of GBM.","['quercetin', 'quercetin']","['proliferation', 'cancer cell apoptosis', 'survival', 'inhibiting the glycolytic metabolism in GBM tissues']",True,quercetin,cancer cell apoptosis,inhibited,C0006826,Cancer,5280343,quercetin,quercetin,inhibit
230,2858,35313655, Conclusions: Resveratrol and oxyresveratrol inhibit the expression of cancer stem cell markers and might target cancer stem cells in a hypoxia-associated tumor.,['oxyresveratrol'],"['cancer stem cell markers', 'cancer stem cells']",True,oxyresveratrol,cancer stem cells,inhibit,C1855752,Abnormal T cell morphology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxyresveratrol,inhibit
231,2872,35293706, Drugs such as metformin and resveratrol may inhibit high glucose-induced cancer.,"['metformin', 'resveratrol']",['cancer'],True,metformin,cancer,inhibit,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",metformin,inhibit
232,2872,35293706, Drugs such as metformin and resveratrol may inhibit high glucose-induced cancer.,"['metformin', 'resveratrol']",['cancer'],True,resveratrol,cancer,inhibit,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",resveratrol,inhibit
233,2887,35270803,"Moderate red wine consumption seems to bear the potential of being health promoting, whereas excessive alcohol consumption can induce liver cirrhosis and cancer.",['alcohol'],"['liver cirrhosis', 'cancer']",True,alcohol,liver cirrhosis,induce,C0023890,Cirrhosis,702,Ethanol,Ethanol,induce
234,2887,35270803,"Moderate red wine consumption seems to bear the potential of being health promoting, whereas excessive alcohol consumption can induce liver cirrhosis and cancer.",['alcohol'],"['liver cirrhosis', 'cancer']",True,alcohol,cancer,induce,C0006826,Cancer,702,Ethanol,Ethanol,induce
235,2934,35231462,"In the current study, in vivo and in vitro results both indicated that MeHg causes a reduction in dendritic length and branching of neurons and decreases the levels of the hippocampal neuronal synaptic protein markers SYN and PSD-95.",['MeHg'],"['reduction in dendritic length', 'branching of neurons', 'decreases the levels of the hippocampal neuronal synaptic protein markers SYN']",True,MeHg,branching of neurons,causes,C4477089,Abnormal neuron branching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MeHg,cause
236,2935,35231462,"Consistent with these findings, the Morris Water Maze results demonstrated that MeHg induces cognitive deficits in pups.",['MeHg'],['cognitive deficits'],True,MeHg,cognitive deficits,induces,C0338656,Cognitive impairment,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MeHg,induce
237,2949,35209168,"BaP induces oxidative stress through the production of reactive oxygen species (ROS), disturbances of the activity of antioxidant enzymes, and the reduction of the level of non-enzymatic  antioxidants as well as of cytokine production.",['oxygen'],"['oxidative stress', 'reduction of the level']",True,oxygen,oxidative stress,induces,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,induce
238,2986,34446191," Activities of enzymes of pentose phosphate pathway, citric acid cycle, glycolysis and gluconeogenesis were also inhibited.",['citric acid'],['gluconeogenesis'],True,citric acid,gluconeogenesis,inhibited,C3279336,Impaired gluconeogenesis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",citric acid,inhibit
239,3048,35133638, RESULTS: XC8 demonstrated clear antitussive activity and dose-dependently inhibited cough in guinea pigs induced by citric acid alone (up to 67.1%) or in combination with IFN-γ (up to 76.4%).,['citric acid'],"['antitussive activity', 'cough']",True,citric acid,cough,inhibited,C0010200,Coughing,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",citric acid,inhibit
240,3052,35096948,"On the other hand, chlortetracycline caused an increase in the ratio of the relative abundance of potential pathogenic and beneficial bacteria in the colon (P < 0.05), which could potentially have adverse effects on the intestine.",['chlortetracycline'],"['increase in the ratio of the relative abundance', 'adverse effects on the intestine']",True,chlortetracycline,increase in the ratio of the relative abundance,caused,C0010200,Coughing,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chlortetracycline,cause
241,3052,35096948,"On the other hand, chlortetracycline caused an increase in the ratio of the relative abundance of potential pathogenic and beneficial bacteria in the colon (P < 0.05), which could potentially have adverse effects on the intestine.",['chlortetracycline'],"['increase in the ratio of the relative abundance', 'adverse effects on the intestine']",True,chlortetracycline,adverse effects on the intestine,caused,C0010200,Coughing,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chlortetracycline,cause
242,3053,35096948,The addition of a high dose of MEEOs may have adverse effects on the intestine and may lead to diarrhea by increasing the level of colonic acetic acid (P < 0.05).,['acetic acid'],['diarrhea'],True,acetic acid,diarrhea,lead,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",acetic acid,lead
243,3125,34708121,Our findings revealed that IC-MeOH inhibited the proliferation of HeLa and CaSki cells.,['IC-MeOH'],['proliferation of HeLa and CaSki cells'],True,IC-MeOH,proliferation of HeLa and CaSki cells,inhibited,C1855752,Abnormal T cell morphology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",IC-MeOH,inhibit
244,3147,35162981,"The combination of both flavonoids synergistically inhibits glycosaminoglycan synthesis, modulates TFEB localization, lysosomal number, and distribution.",['flavonoids'],['glycosaminoglycan synthesis'],True,flavonoids,glycosaminoglycan synthesis,inhibits,C4025598,Urinary glycosaminoglycan excretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",flavonoids,inhibit
245,3168,35018235,  Calcitriol induces estrogen receptor α expression through direct transcriptional  regulation and epigenetic modifications in estrogen receptor-negative breast cancer cells.,['Calcitriol'],['breast cancer'],True,Calcitriol,breast cancer,induces,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Calcitriol,induce
246,3169,35018235,"Previously, we demonstrated that calcitriol, the active metabolite of vitamin D, induces ERα expression and re-establishes the response to antiestrogens in ER-negative breast cancer cells.",['calcitriol'],"['ERα expression', 'breast cancer']",True,calcitriol,ERα expression,induces,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcitriol,induce
247,3169,35018235,"Previously, we demonstrated that calcitriol, the active metabolite of vitamin D, induces ERα expression and re-establishes the response to antiestrogens in ER-negative breast cancer cells.",['calcitriol'],"['ERα expression', 'breast cancer']",True,calcitriol,breast cancer,induces,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcitriol,induce
248,3172,35018235, These results may bring forth novel mechanistic knowledge into the actions of calcitriol in ERα-negative breast cancer.,['calcitriol'],['breast cancer'],True,calcitriol,breast cancer,bring,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcitriol,bring
249,3195,34837116,"Here, we showed that biochanin A (bioA), an isoflavone present in red clover, cabbage and alfalfa, effectively inhibited hemolytic activity at a dose as low as 32 μg/mL. Further, western blot and RT-qPCR data showed that bioA reduced the production and expression of MRSA hemolysin in a dose-dependent manner.",['biochanin'],['hemolytic activity'],True,biochanin,hemolytic activity,inhibited,C4476774,Reduced hemolytic complement activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",biochanin,inhibit
250,3200,34805155,"Resistance has been associated with the activation of androgen receptors via several mechanisms, including alternative dehydroepiandrosterone biosynthetic pathways, other androgen receptor activator molecules, oncogenes, and carcinogenic signaling pathways.",['dehydroepiandrosterone'],['activation of androgen receptors'],True,dehydroepiandrosterone,activation of androgen receptors,associated,C4476774,Reduced hemolytic complement activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dehydroepiandrosterone,associate
251,3218,35232009,Vanillin  oxime treatment led to suppression of Caski cell proliferation but could not affect proliferation of (HCvEpC) cells at the tested (2 to 10 μM) concentrations.,['Vanillin'],['proliferation'],True,Vanillin,proliferation,led,C4531170,Abnormal cell proliferation,1183,vanillin,vanillin,lead
252,3220,35232009,"Vanillin oxime inhibits cervical cancer proliferation, invasive abilities, induces apoptotic signalling, and elevates ROS production.",['Vanillin oxime'],"['cervical cancer proliferation', 'ROS production']",True,Vanillin oxime,ROS production,inhibits,C4476796,Increased reactive oxygen species production,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Vanillin oxime,inhibit
253,3228,35085842,"The production of PN in the EPS and the expression of the hdtS gene were inhibited by vanillin, which served as a QS inhibitor.",['vanillin'],['expression of the hdtS gene'],True,vanillin,expression of the hdtS gene,inhibited,C4476796,Increased reactive oxygen species production,1183,vanillin,vanillin,inhibit
254,3298,35094478, Chlorophyllin caused a significant increase in the production of cellular ROS.,['Chlorophyllin'],['increase in the production of cellular ROS'],True,Chlorophyllin,increase in the production of cellular ROS,caused,C4476796,Increased reactive oxygen species production,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Chlorophyllin,cause
255,3326,35315336,doi: 10.1016/j.jinsphys.2022.104385. [Epub  ahead of print]  Calmidazolium induces a decrease in nicotine-induced currents and intracellular calcium levels after pulse application of nicotine onto insect neurosecretory cells.,['nicotine'],"['pulse', 'neurosecretory']",True,nicotine,pulse,induces,C0235472,Abnormal pulse,89594,Nicotine,Nicotine,induce
256,3327,35315336,"Here, we demonstrated that pulse application of 1 mM nicotine (300 ms pulse duration) induced inward currents which were reduced under bath application of 15 µM calmidazolium, a calmodulin inhibitor.","['nicotine', 'calmidazolium']",['pulse'],True,nicotine,pulse,induced,C0235472,Abnormal pulse,89594,Nicotine,Nicotine,induce
257,3327,35315336,"Here, we demonstrated that pulse application of 1 mM nicotine (300 ms pulse duration) induced inward currents which were reduced under bath application of 15 µM calmidazolium, a calmodulin inhibitor.","['nicotine', 'calmidazolium']",['pulse'],True,calmidazolium,pulse,induced,C0235472,Abnormal pulse,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calmidazolium,induce
258,3328,35315336,"Moreover, we found that this calmidazolium effect was associated to a strong reduction in intracellular calcium levels after pulse application of  1 mM nicotine.","['calmidazolium', 'nicotine']","['reduction in intracellular calcium levels', 'pulse']",True,calmidazolium,pulse,associated,C0235472,Abnormal pulse,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calmidazolium,associate
259,3328,35315336,"Moreover, we found that this calmidazolium effect was associated to a strong reduction in intracellular calcium levels after pulse application of  1 mM nicotine.","['calmidazolium', 'nicotine']","['reduction in intracellular calcium levels', 'pulse']",True,nicotine,pulse,associated,C0235472,Abnormal pulse,89594,Nicotine,Nicotine,associate
260,3331,35302204,  Reduced placental size and increased apoptosis are associated with prenatal nicotine exposure in rats.,['nicotine'],"['Reduced placental size', 'increased apoptosis']",True,nicotine,Reduced placental size,associated,C4022732,Abnormal placental size,89594,Nicotine,Nicotine,associate
261,3331,35302204,  Reduced placental size and increased apoptosis are associated with prenatal nicotine exposure in rats.,['nicotine'],"['Reduced placental size', 'increased apoptosis']",True,nicotine,increased apoptosis,associated,C4280724,Increased lymphocyte apoptosis,89594,Nicotine,Nicotine,associate
262,3341,35297011,"The results demonstrated that  nicotine intervention increased the density of α4β2 nAChRs and improved cognitive impairment, but this effect was blocked by AG490, and the receptors were still upregulated.",['nicotine'],['cognitive impairment'],True,nicotine,cognitive impairment,increased,C0338656,Cognitive impairment,89594,Nicotine,Nicotine,increase
263,3361,35274495,  BACKGROUND: Nicotine administration can generate severe oxidative stress and lipid peroxidation.,['Nicotine'],"['oxidative stress', 'lipid peroxidation']",True,Nicotine,oxidative stress,generate,C0242606,Oxidative stress,89594,Nicotine,Nicotine,generate
264,3457,31936188,"In conclusion, perinatal exposure to TZ within an  adequate daily intake range induced oxidative stress and neurobehavioral and hematological alterations in mice offspring.",['TZ'],['oxidative stress'],True,TZ,oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TZ,induce
265,3467,35309888,"In this study, we demonstrated that under physiological condition, neurons release few mitochondria into the extracellular  space, and the mitochondrial release increased when subjected to the challenges of acidosis, hydrogen peroxide (H2O2), N-methyl-D-aspartate (NMDA), or glutamate.","['hydrogen peroxide', 'N-methyl-D-aspartate', 'glutamate']",['acidosis'],True,hydrogen peroxide,acidosis,increased,C0001122,Acidosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydrogen peroxide,increase
266,3467,35309888,"In this study, we demonstrated that under physiological condition, neurons release few mitochondria into the extracellular  space, and the mitochondrial release increased when subjected to the challenges of acidosis, hydrogen peroxide (H2O2), N-methyl-D-aspartate (NMDA), or glutamate.","['hydrogen peroxide', 'N-methyl-D-aspartate', 'glutamate']",['acidosis'],True,N-methyl-D-aspartate,acidosis,increased,C0001122,Acidosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",N-methyl-D-aspartate,increase
267,3473,35302220," RESULTS: Ketamine applications produced memory deficits in all tests and insignificantly increased MDA levels, which were alleviated by risperidone, EP, and combination treatments.",['risperidone'],"['memory deficits', 'increased MDA levels']",True,risperidone,memory deficits,produced,C0001122,Acidosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",risperidone,produce
268,3473,35302220," RESULTS: Ketamine applications produced memory deficits in all tests and insignificantly increased MDA levels, which were alleviated by risperidone, EP, and combination treatments.",['risperidone'],"['memory deficits', 'increased MDA levels']",True,risperidone,increased MDA levels,produced,C4073162,Elevated hemoglobin A1c,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",risperidone,produce
269,3515,35239557,"N-methyl-D aspartate receptor encephalitis (NMDAR) is often associated with insomnia, then hypersomnia and sleep-related central hypoventilation.",['N-methyl-D'],"['insomnia', 'central hypoventilation']",True,N-methyl-D,insomnia,associated,C0917801,Difficulty staying or falling asleep,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",N-methyl-D,associate
270,3515,35239557,"N-methyl-D aspartate receptor encephalitis (NMDAR) is often associated with insomnia, then hypersomnia and sleep-related central hypoventilation.",['N-methyl-D'],"['insomnia', 'central hypoventilation']",True,N-methyl-D,central hypoventilation,associated,C3805839,Central hypoventilation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",N-methyl-D,associate
271,3533,35219782,"In HIP, repeated MK-801 administration led to increased respiration of SDH (p = 0.0475) only 2 h after the last application and decreased CS activity (p = 0.0160) was observed 3d after the last application.",['MK-801'],"['increased respiration of SDH', 'decreased CS activity']",True,MK-801,increased respiration of SDH,led,C1260922,Abnormal respiration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MK-801,lead
272,3533,35219782,"In HIP, repeated MK-801 administration led to increased respiration of SDH (p = 0.0475) only 2 h after the last application and decreased CS activity (p = 0.0160) was observed 3d after the last application.",['MK-801'],"['increased respiration of SDH', 'decreased CS activity']",True,MK-801,decreased CS activity,led,C0235659,Decreased movement in utero,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MK-801,lead
273,3539,35216100,"Past studies in rodent models have shown that glycine-N-methyltransferase (GNMT) knockout results in rapid steatosis, fibrosis, and hepatocellular carcinoma progression.",['glycine-N-methyltransferase'],"['fibrosis', 'hepatocellular carcinoma progression']",True,glycine-N-methyltransferase,fibrosis,results,C0151650,Renal fibrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycine-N-methyltransferase,result
274,3539,35216100,"Past studies in rodent models have shown that glycine-N-methyltransferase (GNMT) knockout results in rapid steatosis, fibrosis, and hepatocellular carcinoma progression.",['glycine-N-methyltransferase'],"['fibrosis', 'hepatocellular carcinoma progression']",True,glycine-N-methyltransferase,hepatocellular carcinoma progression,results,C2239176,Hepatocellular carcinoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycine-N-methyltransferase,result
275,3547,35203984,Methods: We present the case of a 30-year-old woman with NMDAR autoimmune encephalitis in  her 17th week of pregnancy associated with persistent hypokalemia that had no apparent cause and resisted Kalium chloride supplementation.,['Kalium chloride'],['persistent hypokalemia'],True,Kalium chloride,persistent hypokalemia,associated,C0020621,Hypokalemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Kalium chloride,associate
276,3608,35272593,"  Author information:  (1)Department of Anesthesiology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China (2)Department of Psychiatry, The Third People's Hospital of Xinhui District, Guangdong, China (3)Division of Anaesthetics, Pain Medicine & Intensive Care, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, UK (4)Department of Anesthesiology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Guangdong, China  Background: GABAergic deficits have been considered to associate with the pathophysiology of schizophrenia and hence GABA receptors subtype A (GABAARs) modulators such as commonly used volatile anesthetic sevoflurane, may have therapeutic values for schizophrenia.",['sevoflurane'],"['schizophrenia', 'schizophrenia']",True,sevoflurane,schizophrenia,associate,C0036341,Schizophrenia,5206,sevoflurane,sevoflurane,associate
277,3624,35263424," Additionally, transient stimulation of this pathway efficiently induced behavioral arousal during continuous steady-state general anesthesia with sevoflurane and reduced the depth of anesthesia during sevoflurane-induced burst  suppression.",['sevoflurane'],['transient stimulation'],True,sevoflurane,transient stimulation,induced,C0205374,Transient,5206,sevoflurane,sevoflurane,induce
278,3628,35249202," RESULTS: Both isoflurane and sevoflurane produced abnormal social behaviors at the juvenile age, with different sociality patterns in each group.","['isoflurane', 'sevoflurane']",['abnormal social behaviors'],True,isoflurane,abnormal social behaviors,produced,C4021087,Abnormal social behavior,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",isoflurane,produce
279,3628,35249202," RESULTS: Both isoflurane and sevoflurane produced abnormal social behaviors at the juvenile age, with different sociality patterns in each group.","['isoflurane', 'sevoflurane']",['abnormal social behaviors'],True,sevoflurane,abnormal social behaviors,produced,C4021087,Abnormal social behavior,5206,sevoflurane,sevoflurane,produce
280,3629,35249202,"The proteins altered by isoflurane exposure were mainly associated with epilepsy, ataxia, and brain development.",['isoflurane'],"['epilepsy', 'ataxia']",True,isoflurane,epilepsy,associated,C0014544,Epilepsy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",isoflurane,associate
281,3629,35249202,"The proteins altered by isoflurane exposure were mainly associated with epilepsy, ataxia, and brain development.",['isoflurane'],"['epilepsy', 'ataxia']",True,isoflurane,ataxia,associated,C0007758,Cerebellar ataxia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",isoflurane,associate
282,3656,35201592,Our results indicate that sevoflurane exposure produces differential effects on long-term fear memory  in neonatal and adult rats and that PSD-95 signaling may be involved in the molecular mechanism for early sevoflurane exposure-caused long-term fear memory impairment.,['sevoflurane'],['fear memory impairment'],True,sevoflurane,fear memory impairment,produces,C0233794,Memory impairment,5206,sevoflurane,sevoflurane,produce
283,3657,35196982,doi: 10.1186/s12871-022-01590-z.  miR-424 inhibits apoptosis and inflammatory responses induced by sevoflurane through TLR4/MyD88/NF-κB pathway.,['sevoflurane'],"['apoptosis', 'inflammatory responses induced']",True,sevoflurane,inflammatory responses induced,inhibits,C4022805,Abnormal inflammatory response,5206,sevoflurane,sevoflurane,inhibit
284,3660,35196982,"Sevoflurane treatment enhanced the phosphorylation of NF-κB, and up-regulated the expressions of TLR4 and MyD88 (P < 0.05), which demonstrated that sevoflurane inhibited proliferation and differentiation of neuronal cells by activating TLR4/MyD88/NF-κB signaling both in vitro and vivo.","['Sevoflurane', 'sevoflurane']","['enhanced the phosphorylation of NF-κB', 'proliferation']",True,sevoflurane,proliferation,inhibited,C4531170,Abnormal cell proliferation,5206,sevoflurane,sevoflurane,inhibit
285,3669,35174938,"In contrast, sevoflurane significantly induced the impairment of learning and memory, nerve damage, neuroinflammatory damage, and neuronal apoptosis.",['sevoflurane'],"['nerve damage', 'neuroinflammatory damage', 'neuronal apoptosis']",True,sevoflurane,nerve damage,induced,C0031117,Peripheral nerve damage,5206,sevoflurane,sevoflurane,induce
286,3684,35152870," RESULTS: Treatment with propofol and sevoflurane significantly inhibited proliferation, invasion, migration, and induced apoptosis of XWLC-05 and XWLC-05/R cells.","['propofol', 'sevoflurane']","['proliferation', 'invasion', 'induced apoptosis']",True,propofol,proliferation,inhibited,C4531170,Abnormal cell proliferation,4943,Propofol,Propofol,inhibit
287,3684,35152870," RESULTS: Treatment with propofol and sevoflurane significantly inhibited proliferation, invasion, migration, and induced apoptosis of XWLC-05 and XWLC-05/R cells.","['propofol', 'sevoflurane']","['proliferation', 'invasion', 'induced apoptosis']",True,sevoflurane,proliferation,inhibited,C4531170,Abnormal cell proliferation,5206,sevoflurane,sevoflurane,inhibit
288,3688,35127716,"Previous studies have reported that sevoflurane, a frequently used anesthetic, can induce cognitive impairment in preclinical and clinical settings.",['sevoflurane'],['cognitive impairment'],True,sevoflurane,cognitive impairment,induce,C0338656,Cognitive impairment,5206,sevoflurane,sevoflurane,induce
289,3701,35115157,"The protective mechanism is proposed to relate to anti-inflammatory properties of progesterone, which brings up important questions regarding the role of inflammation in mediating the neurobehavioural alterations  in anaesthesia-induced developmental neurotoxicity.",['progesterone'],"['inflammation', 'developmental neurotoxicity']",True,progesterone,inflammation,relate,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",progesterone,relate
290,3782,34907765,"  Dyslipidemias are lipid metabolism alterations that cause increased levels of serum lipoprotein, cholesterol, and triglycerides.",['cholesterol'],"['increased levels of serum lipoprotein', 'triglycerides']",True,cholesterol,triglycerides,cause,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholesterol,cause
291,3784,34907765,"Dyslipidemia induced with coconut saturated-fat (CSF) caused abdominal fat gain, hypercholesterolemia, hypertriglyceridemia, increased LDL levels, and atherogenesis in the aorta.",['coconut saturated-fat'],"['abdominal fat gain', 'hypercholesterolemia', 'hypertriglyceridemia', 'increased LDL levels', 'atherogenesis in the aorta']",True,coconut saturated-fat,abdominal fat gain,caused,C0000737,Stomach pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",coconut saturated-fat,cause
292,3784,34907765,"Dyslipidemia induced with coconut saturated-fat (CSF) caused abdominal fat gain, hypercholesterolemia, hypertriglyceridemia, increased LDL levels, and atherogenesis in the aorta.",['coconut saturated-fat'],"['abdominal fat gain', 'hypercholesterolemia', 'hypertriglyceridemia', 'increased LDL levels', 'atherogenesis in the aorta']",True,coconut saturated-fat,hypercholesterolemia,caused,C0020443,Hypercholesterolemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",coconut saturated-fat,cause
293,3784,34907765,"Dyslipidemia induced with coconut saturated-fat (CSF) caused abdominal fat gain, hypercholesterolemia, hypertriglyceridemia, increased LDL levels, and atherogenesis in the aorta.",['coconut saturated-fat'],"['abdominal fat gain', 'hypercholesterolemia', 'hypertriglyceridemia', 'increased LDL levels', 'atherogenesis in the aorta']",True,coconut saturated-fat,hypertriglyceridemia,caused,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",coconut saturated-fat,cause
294,3784,34907765,"Dyslipidemia induced with coconut saturated-fat (CSF) caused abdominal fat gain, hypercholesterolemia, hypertriglyceridemia, increased LDL levels, and atherogenesis in the aorta.",['coconut saturated-fat'],"['abdominal fat gain', 'hypercholesterolemia', 'hypertriglyceridemia', 'increased LDL levels', 'atherogenesis in the aorta']",True,coconut saturated-fat,increased LDL levels,caused,C0549399,Hyperbetalipoproteinemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",coconut saturated-fat,cause
295,3801,34675255,CN was also found to induce oxidative stress in CN-treated KPC-KP cells through generation of reactive oxygen species which initiated lipid peroxidation and thus damaging the bacterial cell membrane.,['oxygen'],"['oxidative stress', 'lipid peroxidation']",True,oxygen,oxidative stress,induce,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,induce
296,3807,34634738,"Moreover, BPA treatment elevated the levels of oxidative stress indexes (MDA, iNOS, and NO) and weaken antioxidases activity (SOD, GPx, and CAT) and total antioxidant capacity in chicken BF.",['BPA'],['oxidative stress'],True,BPA,oxidative stress,elevated,C0242606,Oxidative stress,6623,Bisphenol A,Bisphenol A,elevated
297,3836,30740706,"Toluene, o-xylene, m/p-xylene and ethylbenzene were significantly associated with nasal obstruction.","['Toluene', 'ethylbenzene']",['nasal obstruction'],True,Toluene,nasal obstruction,associated,C0027429,Nasal obstruction,1140,Toluene,Toluene,associate
298,3836,30740706,"Toluene, o-xylene, m/p-xylene and ethylbenzene were significantly associated with nasal obstruction.","['Toluene', 'ethylbenzene']",['nasal obstruction'],True,ethylbenzene,nasal obstruction,associated,C0027429,Nasal obstruction,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethylbenzene,associate
299,3841,29152309," CONCLUSIONS: Exposure to 2-butoxyethanol and 2-ethoxyethanol was significantly associated with reticulocytosis, necessitating the implementation of preventive measures for workers prone to occupational exposure to ethylene glycol ethers.","['2-butoxyethanol', '2-ethoxyethanol', 'ethylene glycol']",['reticulocytosis'],True,2-butoxyethanol,reticulocytosis,associated,C0206160,Increased immature red blood cells,8133,2-butoxyethanol,2-butoxyethanol,associate
300,3841,29152309," CONCLUSIONS: Exposure to 2-butoxyethanol and 2-ethoxyethanol was significantly associated with reticulocytosis, necessitating the implementation of preventive measures for workers prone to occupational exposure to ethylene glycol ethers.","['2-butoxyethanol', '2-ethoxyethanol', 'ethylene glycol']",['reticulocytosis'],True,2-ethoxyethanol,reticulocytosis,associated,C0206160,Increased immature red blood cells,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-ethoxyethanol,associate
301,3841,29152309," CONCLUSIONS: Exposure to 2-butoxyethanol and 2-ethoxyethanol was significantly associated with reticulocytosis, necessitating the implementation of preventive measures for workers prone to occupational exposure to ethylene glycol ethers.","['2-butoxyethanol', '2-ethoxyethanol', 'ethylene glycol']",['reticulocytosis'],True,ethylene glycol,reticulocytosis,associated,C0206160,Increased immature red blood cells,174,ETHYLENE GLYCOL,ETHYLENE GLYCOL,associate
302,3846,26721368,"BE and PHE increased the level of pro-apoptotic proteins (Bax, Bak) and/or reduced the concentration of anti-apoptotic proteins (Bcl-2, Bcl-xL); whereas, the effect of BE was observed mainly in the cortex and that of PHE in the hippocampus.",['PHE'],['reduced the concentration'],True,PHE,reduced the concentration,increased,C0206160,Increased immature red blood cells,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PHE,increase
303,3860,24392460,The intraperitoneal administration of butoxyethanol provokes an autoimmune response directed against own red blood cells.,['butoxyethanol'],['autoimmune response'],True,butoxyethanol,autoimmune response,provokes,C0004364,Autoimmune disorder,8133,2-butoxyethanol,2-butoxyethanol,provoke
304,3872,20560787,"Its ingestion causes rapid central nervous system depression, hypotension, and metabolic acidosis attributable to metabolism of the parent compound to butoxyacetic acid (BAA) by alcohol dehydrogenase.","['butoxyacetic acid', 'alcohol']","['rapid central nervous system depression', 'hypotension', 'metabolic acidosis']",True,butoxyacetic acid,rapid central nervous system depression,causes,C0349606,Cyst of the central nervous system,41958,2-butoxyacetic acid,2-butoxyacetic acid,cause
305,3872,20560787,"Its ingestion causes rapid central nervous system depression, hypotension, and metabolic acidosis attributable to metabolism of the parent compound to butoxyacetic acid (BAA) by alcohol dehydrogenase.","['butoxyacetic acid', 'alcohol']","['rapid central nervous system depression', 'hypotension', 'metabolic acidosis']",True,butoxyacetic acid,hypotension,causes,C0020649,Hypotension,41958,2-butoxyacetic acid,2-butoxyacetic acid,cause
306,3872,20560787,"Its ingestion causes rapid central nervous system depression, hypotension, and metabolic acidosis attributable to metabolism of the parent compound to butoxyacetic acid (BAA) by alcohol dehydrogenase.","['butoxyacetic acid', 'alcohol']","['rapid central nervous system depression', 'hypotension', 'metabolic acidosis']",True,butoxyacetic acid,metabolic acidosis,causes,C0220981,Metabolic acidosis,41958,2-butoxyacetic acid,2-butoxyacetic acid,cause
307,3872,20560787,"Its ingestion causes rapid central nervous system depression, hypotension, and metabolic acidosis attributable to metabolism of the parent compound to butoxyacetic acid (BAA) by alcohol dehydrogenase.","['butoxyacetic acid', 'alcohol']","['rapid central nervous system depression', 'hypotension', 'metabolic acidosis']",True,alcohol,rapid central nervous system depression,causes,C0349606,Cyst of the central nervous system,702,Ethanol,Ethanol,cause
308,3872,20560787,"Its ingestion causes rapid central nervous system depression, hypotension, and metabolic acidosis attributable to metabolism of the parent compound to butoxyacetic acid (BAA) by alcohol dehydrogenase.","['butoxyacetic acid', 'alcohol']","['rapid central nervous system depression', 'hypotension', 'metabolic acidosis']",True,alcohol,hypotension,causes,C0020649,Hypotension,702,Ethanol,Ethanol,cause
309,3872,20560787,"Its ingestion causes rapid central nervous system depression, hypotension, and metabolic acidosis attributable to metabolism of the parent compound to butoxyacetic acid (BAA) by alcohol dehydrogenase.","['butoxyacetic acid', 'alcohol']","['rapid central nervous system depression', 'hypotension', 'metabolic acidosis']",True,alcohol,metabolic acidosis,causes,C0220981,Metabolic acidosis,702,Ethanol,Ethanol,cause
310,3876,20153399," These findings, along with the induction of hepatic neoplastic lesions, led to our hypothesis that the induction hemangiosarcomas by 2-butoxyethanol is due to the activation of Kupffer cells, subsequent to hemolysis, that results in the induction of DNA synthesis in target cells (endothelial cells); allowing for the  selective proliferation of preneoplastic target cells and/or the promotion of new initiated cells.",['2-butoxyethanol'],"['induction of hepatic neoplastic lesions', 'induction hemangiosarcomas', 'hemolysis']",True,2-butoxyethanol,hemolysis,led,C0002878,Increased hemolysis,8133,2-butoxyethanol,2-butoxyethanol,lead
311,3900,34428673,"In the AECOPD pharmacogenetics analysis, rs56195836 (MAPK8) was significantly associated with moderate to severe exacerbation rate in subjects on fluticasone furoate with baseline blood eosinophils ≥150 cells/μl (P = 1.8 × 10-8).",['fluticasone furoate'],['blood eosinophils'],True,fluticasone furoate,blood eosinophils,associated,C0855999,Abnormal eosinophil morphology,9854489,fluticasone furoate,fluticasone furoate,associate
312,3929,33402820,  Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study.,['Corticosteroid'],['Chronic Obstructive Pulmonary Disease'],True,Corticosteroid,Chronic Obstructive Pulmonary Disease,Associated,C0024117,COPD,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Corticosteroid,associate
313,3930,33402820,"Pneumonia was strongly associated with fluticasone propionate (1.79 (1.70-1.89)) and fluticasone furoate (1.80 (1.61-2.01)) use, compared to the use of other types of ICS.","['fluticasone propionate', 'fluticasone furoate']",['Pneumonia'],True,fluticasone propionate,Pneumonia,associated,C0032285,Pneumonia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluticasone propionate,associate
314,3930,33402820,"Pneumonia was strongly associated with fluticasone propionate (1.79 (1.70-1.89)) and fluticasone furoate (1.80 (1.61-2.01)) use, compared to the use of other types of ICS.","['fluticasone propionate', 'fluticasone furoate']",['Pneumonia'],True,fluticasone furoate,Pneumonia,associated,C0032285,Pneumonia,9854489,fluticasone furoate,fluticasone furoate,associate
315,3934,33354149," CONCLUSION: Fluticasone furoate produced sustained relief of symptoms, signs, and sensory attributes with a greater reduction in eosinophil count in comparison with AH in patients with allergic rhinitis.",['Fluticasone furoate'],"['reduction in eosinophil count', 'allergic rhinitis']",True,Fluticasone furoate,reduction in eosinophil count,produced,C0853644,Abnormal eosinophil count,9854489,fluticasone furoate,fluticasone furoate,produce
316,3934,33354149," CONCLUSION: Fluticasone furoate produced sustained relief of symptoms, signs, and sensory attributes with a greater reduction in eosinophil count in comparison with AH in patients with allergic rhinitis.",['Fluticasone furoate'],"['reduction in eosinophil count', 'allergic rhinitis']",True,Fluticasone furoate,allergic rhinitis,produced,C2607914,Allergic rhinitis,9854489,fluticasone furoate,fluticasone furoate,produce
317,4007,33043805,"Oppositely, the irradiation of agomelatine caused the decrease of mutagenic potential and acute toxicity was also lower in the postirradiated mixture.",['agomelatine'],['decrease of mutagenic potential and acute toxicity'],True,agomelatine,decrease of mutagenic potential and acute toxicity,caused,C2607914,Allergic rhinitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",agomelatine,cause
318,4021,31534873,"Angioedema has specifically been associated with the use of several  antipsychotic agents, including clozapine, olanzapine, iloperidone, haloperidol,  quetiapine, paliperidone, ziprasidone, risperidone, and chlorpromazine.","['clozapine', 'olanzapine', 'iloperidone', 'haloperidol', 'quetiapine', 'paliperidone', 'ziprasidone', 'risperidone', 'chlorpromazine']",['Angioedema'],True,clozapine,Angioedema,associated,C0002994,Quincke edema,135398737,Clozapine,Clozapine,associate
319,4021,31534873,"Angioedema has specifically been associated with the use of several  antipsychotic agents, including clozapine, olanzapine, iloperidone, haloperidol,  quetiapine, paliperidone, ziprasidone, risperidone, and chlorpromazine.","['clozapine', 'olanzapine', 'iloperidone', 'haloperidol', 'quetiapine', 'paliperidone', 'ziprasidone', 'risperidone', 'chlorpromazine']",['Angioedema'],True,olanzapine,Angioedema,associated,C0002994,Quincke edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",olanzapine,associate
320,4021,31534873,"Angioedema has specifically been associated with the use of several  antipsychotic agents, including clozapine, olanzapine, iloperidone, haloperidol,  quetiapine, paliperidone, ziprasidone, risperidone, and chlorpromazine.","['clozapine', 'olanzapine', 'iloperidone', 'haloperidol', 'quetiapine', 'paliperidone', 'ziprasidone', 'risperidone', 'chlorpromazine']",['Angioedema'],True,iloperidone,Angioedema,associated,C0002994,Quincke edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iloperidone,associate
321,4021,31534873,"Angioedema has specifically been associated with the use of several  antipsychotic agents, including clozapine, olanzapine, iloperidone, haloperidol,  quetiapine, paliperidone, ziprasidone, risperidone, and chlorpromazine.","['clozapine', 'olanzapine', 'iloperidone', 'haloperidol', 'quetiapine', 'paliperidone', 'ziprasidone', 'risperidone', 'chlorpromazine']",['Angioedema'],True,haloperidol,Angioedema,associated,C0002994,Quincke edema,3559,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,associate
322,4021,31534873,"Angioedema has specifically been associated with the use of several  antipsychotic agents, including clozapine, olanzapine, iloperidone, haloperidol,  quetiapine, paliperidone, ziprasidone, risperidone, and chlorpromazine.","['clozapine', 'olanzapine', 'iloperidone', 'haloperidol', 'quetiapine', 'paliperidone', 'ziprasidone', 'risperidone', 'chlorpromazine']",['Angioedema'],True,quetiapine,Angioedema,associated,C0002994,Quincke edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",quetiapine,associate
323,4021,31534873,"Angioedema has specifically been associated with the use of several  antipsychotic agents, including clozapine, olanzapine, iloperidone, haloperidol,  quetiapine, paliperidone, ziprasidone, risperidone, and chlorpromazine.","['clozapine', 'olanzapine', 'iloperidone', 'haloperidol', 'quetiapine', 'paliperidone', 'ziprasidone', 'risperidone', 'chlorpromazine']",['Angioedema'],True,paliperidone,Angioedema,associated,C0002994,Quincke edema,115237,"3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one","3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one",associate
324,4021,31534873,"Angioedema has specifically been associated with the use of several  antipsychotic agents, including clozapine, olanzapine, iloperidone, haloperidol,  quetiapine, paliperidone, ziprasidone, risperidone, and chlorpromazine.","['clozapine', 'olanzapine', 'iloperidone', 'haloperidol', 'quetiapine', 'paliperidone', 'ziprasidone', 'risperidone', 'chlorpromazine']",['Angioedema'],True,ziprasidone,Angioedema,associated,C0002994,Quincke edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ziprasidone,associate
325,4021,31534873,"Angioedema has specifically been associated with the use of several  antipsychotic agents, including clozapine, olanzapine, iloperidone, haloperidol,  quetiapine, paliperidone, ziprasidone, risperidone, and chlorpromazine.","['clozapine', 'olanzapine', 'iloperidone', 'haloperidol', 'quetiapine', 'paliperidone', 'ziprasidone', 'risperidone', 'chlorpromazine']",['Angioedema'],True,risperidone,Angioedema,associated,C0002994,Quincke edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",risperidone,associate
326,4021,31534873,"Angioedema has specifically been associated with the use of several  antipsychotic agents, including clozapine, olanzapine, iloperidone, haloperidol,  quetiapine, paliperidone, ziprasidone, risperidone, and chlorpromazine.","['clozapine', 'olanzapine', 'iloperidone', 'haloperidol', 'quetiapine', 'paliperidone', 'ziprasidone', 'risperidone', 'chlorpromazine']",['Angioedema'],True,chlorpromazine,Angioedema,associated,C0002994,Quincke edema,2726,Chlorpromazine,Chlorpromazine,associate
327,4026,31496709,"Additionally, the use of inhaled loxapine can be associated with dysgeusia and throat irritation.",['loxapine'],"['dysgeusia', 'throat irritation']",True,loxapine,dysgeusia,associated,C0013378,Dysgeusia,3964,loxapine,loxapine,associate
328,4118,35074516, STUDY SELECTIONS: This review focused on the key trials that led to the inclusion of LAMAs in asthma guidelines.,['LAMAs'],['asthma'],True,LAMAs,asthma,led,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",LAMAs,lead
329,4122,35046733,"Overall, HD-MF/IND/GLY induced greater clinically relevant benefits even when compared to HD-FLU/SAL + TIO.",['HD-FLU/SAL'],['TIO'],True,HD-FLU/SAL,TIO,induced,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",HD-FLU/SAL,induce
330,4158,34654643,"The prevention of fentanyl-mediated bradycardia  caused no significant effect on MACISO, but increased HR, MAP and CI, and decreased SVRI when compared with isoflurane alone.","['MACISO', 'isoflurane']","['increased HR', 'decreased SVRI']",True,MACISO,increased HR,caused,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MACISO,cause
331,4158,34654643,"The prevention of fentanyl-mediated bradycardia  caused no significant effect on MACISO, but increased HR, MAP and CI, and decreased SVRI when compared with isoflurane alone.","['MACISO', 'isoflurane']","['increased HR', 'decreased SVRI']",True,MACISO,decreased SVRI,caused,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MACISO,cause
332,4158,34654643,"The prevention of fentanyl-mediated bradycardia  caused no significant effect on MACISO, but increased HR, MAP and CI, and decreased SVRI when compared with isoflurane alone.","['MACISO', 'isoflurane']","['increased HR', 'decreased SVRI']",True,isoflurane,increased HR,caused,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",isoflurane,cause
333,4158,34654643,"The prevention of fentanyl-mediated bradycardia  caused no significant effect on MACISO, but increased HR, MAP and CI, and decreased SVRI when compared with isoflurane alone.","['MACISO', 'isoflurane']","['increased HR', 'decreased SVRI']",True,isoflurane,decreased SVRI,caused,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",isoflurane,cause
334,4159,34654643," CONCLUSIONS AND CLINICAL RELEVANCE: Fentanyl caused a plasma concentration-dependent decrease in MACISO, HR and CI and an increase in SVRI.",['MACISO'],['increase in SVRI'],True,MACISO,increase in SVRI,caused,C0853225,Reduced factor II activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MACISO,cause
335,4175,34428980,"  BACKGROUND: In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose levels, resulted in significantly lower moderate/severe exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) and budesonide/formoterol fumarate (BFF).","['budesonide/glycopyrrolate/formoterol', 'glycopyrrolate/formoterol', 'budesonide/formoterol']","['chronic obstructive pulmonary disease', 'exacerbation rates']",True,budesonide/glycopyrrolate/formoterol,chronic obstructive pulmonary disease,resulted,C0024117,COPD,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",budesonide/glycopyrrolate/formoterol,result
336,4175,34428980,"  BACKGROUND: In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose levels, resulted in significantly lower moderate/severe exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) and budesonide/formoterol fumarate (BFF).","['budesonide/glycopyrrolate/formoterol', 'glycopyrrolate/formoterol', 'budesonide/formoterol']","['chronic obstructive pulmonary disease', 'exacerbation rates']",True,budesonide/glycopyrrolate/formoterol,exacerbation rates,resulted,C0024117,COPD,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",budesonide/glycopyrrolate/formoterol,result
337,4175,34428980,"  BACKGROUND: In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose levels, resulted in significantly lower moderate/severe exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) and budesonide/formoterol fumarate (BFF).","['budesonide/glycopyrrolate/formoterol', 'glycopyrrolate/formoterol', 'budesonide/formoterol']","['chronic obstructive pulmonary disease', 'exacerbation rates']",True,glycopyrrolate/formoterol,chronic obstructive pulmonary disease,resulted,C0024117,COPD,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycopyrrolate/formoterol,result
338,4175,34428980,"  BACKGROUND: In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose levels, resulted in significantly lower moderate/severe exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) and budesonide/formoterol fumarate (BFF).","['budesonide/glycopyrrolate/formoterol', 'glycopyrrolate/formoterol', 'budesonide/formoterol']","['chronic obstructive pulmonary disease', 'exacerbation rates']",True,glycopyrrolate/formoterol,exacerbation rates,resulted,C0024117,COPD,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycopyrrolate/formoterol,result
339,4175,34428980,"  BACKGROUND: In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose levels, resulted in significantly lower moderate/severe exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) and budesonide/formoterol fumarate (BFF).","['budesonide/glycopyrrolate/formoterol', 'glycopyrrolate/formoterol', 'budesonide/formoterol']","['chronic obstructive pulmonary disease', 'exacerbation rates']",True,budesonide/formoterol,chronic obstructive pulmonary disease,resulted,C0024117,COPD,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",budesonide/formoterol,result
340,4175,34428980,"  BACKGROUND: In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose levels, resulted in significantly lower moderate/severe exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) and budesonide/formoterol fumarate (BFF).","['budesonide/glycopyrrolate/formoterol', 'glycopyrrolate/formoterol', 'budesonide/formoterol']","['chronic obstructive pulmonary disease', 'exacerbation rates']",True,budesonide/formoterol,exacerbation rates,resulted,C0024117,COPD,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",budesonide/formoterol,result
341,4179,34363950,  LABA/ICS and LABA/LAMA/ICS combinations elicit beneficial effects in asthma.,['LABA/LAMA/ICS'],['asthma'],True,LABA/LAMA/ICS,asthma,elicit,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",LABA/LAMA/ICS,elicit
342,4188,34333742," RESULTS: IND/GLY/MF is associated with a higher quality of life [+ 0.25 quality-adjusted life-year (QALY)] than salmeterol/fluticasone plus tiotropium, with an incremental cost of -€3213.90.","['salmeterol/fluticasone', 'tiotropium']","['IND/GLY/MF', 'higher quality of life']",True,salmeterol/fluticasone,IND/GLY/MF,associated,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",salmeterol/fluticasone,associate
343,4217,34087418,The combination of dexmedetomidine and hypothermia results in bradycardia.,['dexmedetomidine'],['hypothermia'],True,dexmedetomidine,hypothermia,results,C0020672,Hypothermia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dexmedetomidine,result
344,4253,35292357,"However, lidocaine microinjection resulted in up-regulation levels of GFAP and Iba1 in the right-only, left-only and bilateral of VH and they were higher significantly than that of their control groups after CRS and during non-stress condition.",['lidocaine'],['microinjection'],True,lidocaine,microinjection,resulted,C0020672,Hypothermia,3676,lidocaine,lidocaine,result
345,4318,35207502,"  Administration of dexmedetomidine significantly induces sedation and anti-nociception in several nociceptive models, but clinical trials are restricted due to adverse side effects, including lethargy, hypotension, and bradycardia.",['dexmedetomidine'],"['anti-nociception', 'lethargy', 'hypotension']",True,dexmedetomidine,lethargy,induces,C0023380,Lethargy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dexmedetomidine,induce
346,4318,35207502,"  Administration of dexmedetomidine significantly induces sedation and anti-nociception in several nociceptive models, but clinical trials are restricted due to adverse side effects, including lethargy, hypotension, and bradycardia.",['dexmedetomidine'],"['anti-nociception', 'lethargy', 'hypotension']",True,dexmedetomidine,hypotension,induces,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dexmedetomidine,induce
347,4321,35207502," Besides, a high dose of dexmedetomidine (30 μg/kg) induced lessening physical ability and significantly reduced systolic pressure and heart rate.",['dexmedetomidine'],"['reduced systolic pressure', 'heart rate']",True,dexmedetomidine,reduced systolic pressure,induced,C0277885,Decreased systolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dexmedetomidine,induce
348,4321,35207502," Besides, a high dose of dexmedetomidine (30 μg/kg) induced lessening physical ability and significantly reduced systolic pressure and heart rate.",['dexmedetomidine'],"['reduced systolic pressure', 'heart rate']",True,dexmedetomidine,heart rate,induced,C0277885,Decreased systolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dexmedetomidine,induce
349,4358,35210765,"Initiation of fp-FDC-F (mean dosage furoate 99 µg; propionate 710 µg) was associated with an increased risk of pneumonia versus ef-FDC-BDP (mean beclometasone dose 395 µg), irrespective of definition (sensitive HR 1.38 95% CI 1.14-1.68; specific HR 1.31 95% CI 1.05-1.62).","['furoate', 'propionate']","['Initiation of fp-FDC-F', 'increased risk of pneumonia']",True,furoate,increased risk of pneumonia,associated,C0032285,Pneumonia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",furoate,associate
350,4359,35210765," Conclusion: In the current investigation, we found that in comparison to extrafine beclomethasone, commencing a formulation containing fluticasone is associated with an increased risk of developing pneumonia.","['beclomethasone', 'fluticasone']","['increased risk of', 'pneumonia']",True,fluticasone,pneumonia,associated,C0032285,Pneumonia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluticasone,associate
351,4376,34478483,"Extrafine HFA-BDP-F did not lead to less exacerbations than nonextrafine ICS-LABA (RR 0.61, 95% CI: 0.31 to 1.20; I2  = 0; p = 0.15).","['Extrafine', 'nonextrafine', 'ICS-LABA']",['less exacerbations'],True,Extrafine,less exacerbations,lead,C0436331,Exacerbated by,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Extrafine,lead
352,4376,34478483,"Extrafine HFA-BDP-F did not lead to less exacerbations than nonextrafine ICS-LABA (RR 0.61, 95% CI: 0.31 to 1.20; I2  = 0; p = 0.15).","['Extrafine', 'nonextrafine', 'ICS-LABA']",['less exacerbations'],True,nonextrafine,less exacerbations,lead,C0436331,Exacerbated by,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",nonextrafine,lead
353,4376,34478483,"Extrafine HFA-BDP-F did not lead to less exacerbations than nonextrafine ICS-LABA (RR 0.61, 95% CI: 0.31 to 1.20; I2  = 0; p = 0.15).","['Extrafine', 'nonextrafine', 'ICS-LABA']",['less exacerbations'],True,ICS-LABA,less exacerbations,lead,C0436331,Exacerbated by,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ICS-LABA,lead
354,4382,34267661,"Subgroup analysis based on severity of pneumonia showed that fluticasone (Peto OR, 1.75; 95% CI, 1.44-2.14) increased the risk of serious pneumonia, while budesonide and beclomethasone did not.","['fluticasone', 'budesonide', 'beclomethasone']","['pneumonia', 'pneumonia']",True,fluticasone,pneumonia,increased,C0032285,Pneumonia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluticasone,increase
355,4382,34267661,"Subgroup analysis based on severity of pneumonia showed that fluticasone (Peto OR, 1.75; 95% CI, 1.44-2.14) increased the risk of serious pneumonia, while budesonide and beclomethasone did not.","['fluticasone', 'budesonide', 'beclomethasone']","['pneumonia', 'pneumonia']",True,budesonide,pneumonia,increased,C0032285,Pneumonia,5281004,budesonide,budesonide,increase
356,4382,34267661,"Subgroup analysis based on severity of pneumonia showed that fluticasone (Peto OR, 1.75; 95% CI, 1.44-2.14) increased the risk of serious pneumonia, while budesonide and beclomethasone did not.","['fluticasone', 'budesonide', 'beclomethasone']","['pneumonia', 'pneumonia']",True,beclomethasone,pneumonia,increased,C0032285,Pneumonia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",beclomethasone,increase
357,4387,34153519,Higher exacerbation rates and poorer lung function (for fluticasone propionate) were associated with lower blood levels.,['fluticasone propionate'],"['Higher exacerbation rates', 'poorer lung function', 'lower blood levels']",True,fluticasone propionate,Higher exacerbation rates,associated,C0436331,Exacerbated by,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluticasone propionate,associate
358,4387,34153519,Higher exacerbation rates and poorer lung function (for fluticasone propionate) were associated with lower blood levels.,['fluticasone propionate'],"['Higher exacerbation rates', 'poorer lung function', 'lower blood levels']",True,fluticasone propionate,lower blood levels,associated,C0151723,Low blood Mg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluticasone propionate,associate
359,4464,30639745,"High levels of cyproconazole (10 mg/L) induced declined body weight, short snout-vent  length, slow metamorphic development and abnormal behavioral endpoints in R. nigromaculata tadpoles.",['cyproconazole'],['declined body weight'],True,cyproconazole,declined body weight,induced,C1262477,Weight loss,86132,"2-(4-chlorophenyl)-3-cyclopropyl-1-(1,2,4-triazol-1-yl)butan-2-ol","2-(4-chlorophenyl)-3-cyclopropyl-1-(1,2,4-triazol-1-yl)butan-2-ol",induce
360,4478,29995386,"Moreover, cyproconazole provoked a disruption of mitochondrial functions and induced triglyceride accumulation and the formation of fatty liver  cells as described in the AOP.",['cyproconazole'],['formation of fatty liver  cells'],True,cyproconazole,formation of fatty liver,provoked,C2711227,Steatosis,86132,"2-(4-chlorophenyl)-3-cyclopropyl-1-(1,2,4-triazol-1-yl)butan-2-ol","2-(4-chlorophenyl)-3-cyclopropyl-1-(1,2,4-triazol-1-yl)butan-2-ol",provoke
361,4479,29995386,Our study shows that cyproconazole induces steatosis in human liver cells in vitro and demonstrates the utility of systems-based approaches in the mechanistic assessment of molecular and cellular key events in an AOP.,['cyproconazole'],['steatosis'],True,cyproconazole,steatosis,induces,C2711227,Steatosis,86132,"2-(4-chlorophenyl)-3-cyclopropyl-1-(1,2,4-triazol-1-yl)butan-2-ol","2-(4-chlorophenyl)-3-cyclopropyl-1-(1,2,4-triazol-1-yl)butan-2-ol",induce
362,4483,28921992,"Increased uptake rate constants, an increase in the total internal concentration of azoxystrobin and its BTPs, in vivo assays for measuring CYP activities, and G. pulex video-tracking suggested that the 2-fold increase in bioaccumulation, and, thereby, the raised toxicity of azoxystrobin in the presence of prochloraz is not only caused by inhibited biotransformation but  even more by increased azoxystrobin uptake induced by hyperactivity.","['azoxystrobin', 'azoxystrobin', 'prochloraz', 'azoxystrobin']","['Increased uptake rate constants', 'increase in the total internal concentration', 'hyperactivity']",True,azoxystrobin,hyperactivity,caused,C0424295,Hyperactivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azoxystrobin,cause
363,4483,28921992,"Increased uptake rate constants, an increase in the total internal concentration of azoxystrobin and its BTPs, in vivo assays for measuring CYP activities, and G. pulex video-tracking suggested that the 2-fold increase in bioaccumulation, and, thereby, the raised toxicity of azoxystrobin in the presence of prochloraz is not only caused by inhibited biotransformation but  even more by increased azoxystrobin uptake induced by hyperactivity.","['azoxystrobin', 'azoxystrobin', 'prochloraz', 'azoxystrobin']","['Increased uptake rate constants', 'increase in the total internal concentration', 'hyperactivity']",True,prochloraz,hyperactivity,caused,C0424295,Hyperactivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",prochloraz,cause
364,4483,28921992,"Increased uptake rate constants, an increase in the total internal concentration of azoxystrobin and its BTPs, in vivo assays for measuring CYP activities, and G. pulex video-tracking suggested that the 2-fold increase in bioaccumulation, and, thereby, the raised toxicity of azoxystrobin in the presence of prochloraz is not only caused by inhibited biotransformation but  even more by increased azoxystrobin uptake induced by hyperactivity.","['azoxystrobin', 'azoxystrobin', 'prochloraz', 'azoxystrobin']","['Increased uptake rate constants', 'increase in the total internal concentration', 'hyperactivity']",True,azoxystrobin,hyperactivity,caused,C0424295,Hyperactivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azoxystrobin,cause
365,4487,28058446,"Changes in the expression of classic CAR/PXR target genes such as Cyp2b10 were induced by cyproconazole and phenobarbital in both genotypes, while prochloraz treatment resulted in gene expression changes indicative of additional aryl hydrocarbon receptor activation, e.g. by up-regulation of Cyp1a1 expression.","['cyproconazole', 'phenobarbital', 'prochloraz']",['gene expression changes'],True,cyproconazole,gene expression changes,induced,C0424295,Hyperactivity,86132,"2-(4-chlorophenyl)-3-cyclopropyl-1-(1,2,4-triazol-1-yl)butan-2-ol","2-(4-chlorophenyl)-3-cyclopropyl-1-(1,2,4-triazol-1-yl)butan-2-ol",induce
366,4487,28058446,"Changes in the expression of classic CAR/PXR target genes such as Cyp2b10 were induced by cyproconazole and phenobarbital in both genotypes, while prochloraz treatment resulted in gene expression changes indicative of additional aryl hydrocarbon receptor activation, e.g. by up-regulation of Cyp1a1 expression.","['cyproconazole', 'phenobarbital', 'prochloraz']",['gene expression changes'],True,phenobarbital,gene expression changes,induced,C0424295,Hyperactivity,4763,Phenobarbital,Phenobarbital,induce
367,4487,28058446,"Changes in the expression of classic CAR/PXR target genes such as Cyp2b10 were induced by cyproconazole and phenobarbital in both genotypes, while prochloraz treatment resulted in gene expression changes indicative of additional aryl hydrocarbon receptor activation, e.g. by up-regulation of Cyp1a1 expression.","['cyproconazole', 'phenobarbital', 'prochloraz']",['gene expression changes'],True,prochloraz,gene expression changes,induced,C0424295,Hyperactivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",prochloraz,induce
368,4487,28058446,"Changes in the expression of classic CAR/PXR target genes such as Cyp2b10 were induced by cyproconazole and phenobarbital in both genotypes, while prochloraz treatment resulted in gene expression changes indicative of additional aryl hydrocarbon receptor activation, e.g. by up-regulation of Cyp1a1 expression.","['cyproconazole', 'phenobarbital', 'prochloraz']",['gene expression changes'],True,prochloraz,gene expression changes,resulted,C0424295,Hyperactivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",prochloraz,result
369,4573,34170130,PCZ treatment in cells induced a morphological transition with E-cadherin decrease and vimentin and Snail increase via the oxidative stress and TGF-β/Smad pathways.,['PCZ'],"['E-cadherin decrease', 'vimentin and Snail increase via the oxidative stress']",True,PCZ,vimentin and Snail increase via the oxidative stress,induced,C0242606,Oxidative stress,468595,Posaconazole,Posaconazole,induce
370,4574,34170130,"PCZ administration in rats induced liver fibrosis through pathological changes, epithelial-mesenchymal transition, and collagen deposition.",['PCZ'],"['liver fibrosis', 'collagen deposition']",True,PCZ,liver fibrosis,induced,C0242606,Oxidative stress,468595,Posaconazole,Posaconazole,induce
371,4743,34834667,"In summary, difenoconazole exposure caused oxidative stress, reduced chlorophyll biosynthesis and functions, and then inhibited wheat plant growth and development.",['difenoconazole'],"['oxidative stress', 'reduced chlorophyll biosynthesis']",True,difenoconazole,oxidative stress,caused,C0242606,Oxidative stress,86173,difenoconazole,difenoconazole,cause
372,4768,33848738,"  Difenoconazole (DIF), a common broad-spectrum triazole fungicide, is associated with an increased risk of cardiovascular diseases.",['Difenoconazole'],['increased risk of cardiovascular diseases'],True,Difenoconazole,increased risk of cardiovascular diseases,associated,C0007222,Cardiovascular disease,86173,difenoconazole,difenoconazole,associate
373,4770,33848738,"Cardiovascular apoptosis was triggered through increased expression of p53, bcl-2, bax and caspase 9, while DIF suppressed the transcription of key genes involved in calcium signaling and cardiac muscle contraction.",['calcium'],"['Cardiovascular apoptosis', 'increased expression of p53', 'bcl-2, bax and caspase 9']",True,calcium,increased expression of p53,triggered,C1862474,Decreased facial expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,trigger
374,4814,32268158,"Myclobutanil exposure for 14 days resulted in increased liver weight, altered serum hormones, liver histopathology, and differential gene expression in liver and testis.",['Myclobutanil'],"['increased liver weight', 'altered serum hormones', 'differential gene expression in liver and testis']",True,Myclobutanil,increased liver weight,resulted,C0043094,Weight gain,6336,myclobutanil,myclobutanil,result
375,4826,30919521,"The molecular biomarkers indicated that propiconazole and myclobutanil induced lipid  peroxidation, oxidative stress, and potentially apoptosis at environmentally relevant concentrations (0.3 and 1 µg/L).","['propiconazole', 'myclobutanil']","['oxidative stress', 'apoptosis']",True,propiconazole,oxidative stress,induced,C0242606,Oxidative stress,43234,propiconazole,propiconazole,induce
376,4826,30919521,"The molecular biomarkers indicated that propiconazole and myclobutanil induced lipid  peroxidation, oxidative stress, and potentially apoptosis at environmentally relevant concentrations (0.3 and 1 µg/L).","['propiconazole', 'myclobutanil']","['oxidative stress', 'apoptosis']",True,myclobutanil,oxidative stress,induced,C0242606,Oxidative stress,6336,myclobutanil,myclobutanil,induce
377,4869,33679858,This reduced efficacy was linked to a suppression of the plant's intrinsic defense system and increased levels of DON.,['DON'],"['reduced efficacy', 'increased levels of']",True,DON,reduced efficacy,linked,C5209257,Reduced drug efficacy,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,link
378,4869,33679858,This reduced efficacy was linked to a suppression of the plant's intrinsic defense system and increased levels of DON.,['DON'],"['reduced efficacy', 'increased levels of']",True,DON,increased levels of,linked,C4073162,Elevated hemoglobin A1c,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,link
379,4875,33303200,  Embryonic exposure to prothioconazole induces oxidative stress and apoptosis in zebrafish (Danio rerio) early life stage.,['prothioconazole'],"['oxidative stress', 'apoptosis']",True,prothioconazole,oxidative stress,induces,C0242606,Oxidative stress,6451142,prothioconazole,prothioconazole,induce
380,4880,33303200,Our findings increase our understanding of the molecular mechanisms of oxidative stress and cell death caused by prothioconazole.,['prothioconazole'],"['oxidative stress', 'cell death']",True,prothioconazole,oxidative stress,increase,C0242606,Oxidative stress,6451142,prothioconazole,prothioconazole,increase
381,4890,32353726,  Stereoselective uptake and metabolism of prothioconazole caused oxidative stress  in zebrafish (Danio rerio).,['prothioconazole'],['oxidative stress'],True,prothioconazole,oxidative stress,caused,C0242606,Oxidative stress,6451142,prothioconazole,prothioconazole,cause
382,4902,31149754, RESULTS: We found that 30 days of exposure to 40 μg kg-1 of thiamethoxam significantly (P < 0.001) increased the frequency of death in worker adults by four times relative to solvent control.,['thiamethoxam'],['death'],True,thiamethoxam,death,increased,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiamethoxam,increase
383,4915,29141039,"Using this screen, isolates were identified with decreased sensitivity to the fungicide fluquinconazole when applied at field rates as a protective seed dressing: these  isolates cause significantly larger lesions on cotyledons and true leaves and increased disease severity at plant maturity.",['fluquinconazole'],"['decreased sensitivity', 'larger lesions', 'increased disease severity']",True,fluquinconazole,decreased sensitivity,cause,C3806286,Decreased sensitivity to hypoxemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluquinconazole,cause
384,4947,35204699,"The observed GA-mediated increase in melatonin was closely associated  with elevated expression levels of melatonin biosynthetic genes such as TDC3, T5H, and ASMT1; it was also associated with reduced expression levels of catabolic genes ASDAC and M2H. In a paddy field, the treatment of immature rice seeds with exogenous GA led to enhanced melatonin production in rice seeds; various transgenic rice plants downregulating a GA biosynthesis gene (GA3ox2) and a signaling gene (Gα) showed severely decreased melatonin levels, providing in vivo genetic evidence that GA has a positive effect on melatonin synthesis.","['melatonin', 'melatonin', 'M2H.', 'melatonin', 'melatonin', 'melatonin']","['elevated expression levels', 'reduced expression levels', 'GA biosynthesis gene']",True,melatonin,reduced expression levels,associated,C4531163,Reduced T cell CD40 expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,associate
385,4947,35204699,"The observed GA-mediated increase in melatonin was closely associated  with elevated expression levels of melatonin biosynthetic genes such as TDC3, T5H, and ASMT1; it was also associated with reduced expression levels of catabolic genes ASDAC and M2H. In a paddy field, the treatment of immature rice seeds with exogenous GA led to enhanced melatonin production in rice seeds; various transgenic rice plants downregulating a GA biosynthesis gene (GA3ox2) and a signaling gene (Gα) showed severely decreased melatonin levels, providing in vivo genetic evidence that GA has a positive effect on melatonin synthesis.","['melatonin', 'melatonin', 'M2H.', 'melatonin', 'melatonin', 'melatonin']","['elevated expression levels', 'reduced expression levels', 'GA biosynthesis gene']",True,melatonin,M2H.,associated,C4531163,Reduced T cell CD40 expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,associate
386,4947,35204699,"The observed GA-mediated increase in melatonin was closely associated  with elevated expression levels of melatonin biosynthetic genes such as TDC3, T5H, and ASMT1; it was also associated with reduced expression levels of catabolic genes ASDAC and M2H. In a paddy field, the treatment of immature rice seeds with exogenous GA led to enhanced melatonin production in rice seeds; various transgenic rice plants downregulating a GA biosynthesis gene (GA3ox2) and a signaling gene (Gα) showed severely decreased melatonin levels, providing in vivo genetic evidence that GA has a positive effect on melatonin synthesis.","['melatonin', 'melatonin', 'M2H.', 'melatonin', 'melatonin', 'melatonin']","['elevated expression levels', 'reduced expression levels', 'GA biosynthesis gene']",True,melatonin,reduced expression levels,associated,C4531163,Reduced T cell CD40 expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,associate
387,4947,35204699,"The observed GA-mediated increase in melatonin was closely associated  with elevated expression levels of melatonin biosynthetic genes such as TDC3, T5H, and ASMT1; it was also associated with reduced expression levels of catabolic genes ASDAC and M2H. In a paddy field, the treatment of immature rice seeds with exogenous GA led to enhanced melatonin production in rice seeds; various transgenic rice plants downregulating a GA biosynthesis gene (GA3ox2) and a signaling gene (Gα) showed severely decreased melatonin levels, providing in vivo genetic evidence that GA has a positive effect on melatonin synthesis.","['melatonin', 'melatonin', 'M2H.', 'melatonin', 'melatonin', 'melatonin']","['elevated expression levels', 'reduced expression levels', 'GA biosynthesis gene']",True,melatonin,M2H.,associated,C4531163,Reduced T cell CD40 expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,associate
388,4947,35204699,"The observed GA-mediated increase in melatonin was closely associated  with elevated expression levels of melatonin biosynthetic genes such as TDC3, T5H, and ASMT1; it was also associated with reduced expression levels of catabolic genes ASDAC and M2H. In a paddy field, the treatment of immature rice seeds with exogenous GA led to enhanced melatonin production in rice seeds; various transgenic rice plants downregulating a GA biosynthesis gene (GA3ox2) and a signaling gene (Gα) showed severely decreased melatonin levels, providing in vivo genetic evidence that GA has a positive effect on melatonin synthesis.","['melatonin', 'melatonin', 'M2H.', 'melatonin', 'melatonin', 'melatonin']","['elevated expression levels', 'reduced expression levels', 'GA biosynthesis gene']",True,melatonin,reduced expression levels,associated,C4531163,Reduced T cell CD40 expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,associate
389,4947,35204699,"The observed GA-mediated increase in melatonin was closely associated  with elevated expression levels of melatonin biosynthetic genes such as TDC3, T5H, and ASMT1; it was also associated with reduced expression levels of catabolic genes ASDAC and M2H. In a paddy field, the treatment of immature rice seeds with exogenous GA led to enhanced melatonin production in rice seeds; various transgenic rice plants downregulating a GA biosynthesis gene (GA3ox2) and a signaling gene (Gα) showed severely decreased melatonin levels, providing in vivo genetic evidence that GA has a positive effect on melatonin synthesis.","['melatonin', 'melatonin', 'M2H.', 'melatonin', 'melatonin', 'melatonin']","['elevated expression levels', 'reduced expression levels', 'GA biosynthesis gene']",True,melatonin,M2H.,associated,C4531163,Reduced T cell CD40 expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,associate
390,4947,35204699,"The observed GA-mediated increase in melatonin was closely associated  with elevated expression levels of melatonin biosynthetic genes such as TDC3, T5H, and ASMT1; it was also associated with reduced expression levels of catabolic genes ASDAC and M2H. In a paddy field, the treatment of immature rice seeds with exogenous GA led to enhanced melatonin production in rice seeds; various transgenic rice plants downregulating a GA biosynthesis gene (GA3ox2) and a signaling gene (Gα) showed severely decreased melatonin levels, providing in vivo genetic evidence that GA has a positive effect on melatonin synthesis.","['melatonin', 'melatonin', 'M2H.', 'melatonin', 'melatonin', 'melatonin']","['elevated expression levels', 'reduced expression levels', 'GA biosynthesis gene']",True,melatonin,reduced expression levels,associated,C4531163,Reduced T cell CD40 expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,associate
391,4947,35204699,"The observed GA-mediated increase in melatonin was closely associated  with elevated expression levels of melatonin biosynthetic genes such as TDC3, T5H, and ASMT1; it was also associated with reduced expression levels of catabolic genes ASDAC and M2H. In a paddy field, the treatment of immature rice seeds with exogenous GA led to enhanced melatonin production in rice seeds; various transgenic rice plants downregulating a GA biosynthesis gene (GA3ox2) and a signaling gene (Gα) showed severely decreased melatonin levels, providing in vivo genetic evidence that GA has a positive effect on melatonin synthesis.","['melatonin', 'melatonin', 'M2H.', 'melatonin', 'melatonin', 'melatonin']","['elevated expression levels', 'reduced expression levels', 'GA biosynthesis gene']",True,melatonin,M2H.,associated,C4531163,Reduced T cell CD40 expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,associate
392,4947,35204699,"The observed GA-mediated increase in melatonin was closely associated  with elevated expression levels of melatonin biosynthetic genes such as TDC3, T5H, and ASMT1; it was also associated with reduced expression levels of catabolic genes ASDAC and M2H. In a paddy field, the treatment of immature rice seeds with exogenous GA led to enhanced melatonin production in rice seeds; various transgenic rice plants downregulating a GA biosynthesis gene (GA3ox2) and a signaling gene (Gα) showed severely decreased melatonin levels, providing in vivo genetic evidence that GA has a positive effect on melatonin synthesis.","['melatonin', 'melatonin', 'M2H.', 'melatonin', 'melatonin', 'melatonin']","['elevated expression levels', 'reduced expression levels', 'GA biosynthesis gene']",True,melatonin,reduced expression levels,associated,C4531163,Reduced T cell CD40 expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,associate
393,4947,35204699,"The observed GA-mediated increase in melatonin was closely associated  with elevated expression levels of melatonin biosynthetic genes such as TDC3, T5H, and ASMT1; it was also associated with reduced expression levels of catabolic genes ASDAC and M2H. In a paddy field, the treatment of immature rice seeds with exogenous GA led to enhanced melatonin production in rice seeds; various transgenic rice plants downregulating a GA biosynthesis gene (GA3ox2) and a signaling gene (Gα) showed severely decreased melatonin levels, providing in vivo genetic evidence that GA has a positive effect on melatonin synthesis.","['melatonin', 'melatonin', 'M2H.', 'melatonin', 'melatonin', 'melatonin']","['elevated expression levels', 'reduced expression levels', 'GA biosynthesis gene']",True,melatonin,M2H.,associated,C4531163,Reduced T cell CD40 expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,associate
394,4948,35185961,Paclobutrazol treatment of WT leaves led  to limited internode growth in the stem elongation zone.,['Paclobutrazol'],"['WT', 'internode growth']",True,Paclobutrazol,WT,led,C4531163,Reduced T cell CD40 expression,73671,paclobutrazol,paclobutrazol,lead
395,4956,34915705,These results indicate that the application of paclobutrazol may result in  the emergency of triazole resistance in A. fumigatus and thus have a potential risk for the treatment of invasive aspergillosis.,"['paclobutrazol', 'triazole']",['invasive aspergillosis'],True,paclobutrazol,invasive aspergillosis,result,C0276653,Invasive pulmonary aspergillosis,73671,paclobutrazol,paclobutrazol,result
396,4956,34915705,These results indicate that the application of paclobutrazol may result in  the emergency of triazole resistance in A. fumigatus and thus have a potential risk for the treatment of invasive aspergillosis.,"['paclobutrazol', 'triazole']",['invasive aspergillosis'],True,triazole,invasive aspergillosis,result,C0276653,Invasive pulmonary aspergillosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",triazole,result
397,5037,35202779,These effects were associated with the ability of the compound to block the L-type calcium current (IC50 = 33.2 ± 7.4 μmol.l-1) and total outward potassium current (IC50 = 5.7 ± 1.5 μmol.l-1).,['calcium'],['total outward potassium current'],True,calcium,total outward potassium current,associated,C4022754,Episodic hypokalemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,associate
398,5039,35123019,"While no developmental and physiological alterations were observed, exposure to tebuconazole resulted in an increased generation of reactive oxidative species at the 0.05 and 0.5 mg L-1 concentrations and a decreased GPx activity at the 0.5 mg L-1 concentration suggesting a potential protection mechanism.",['tebuconazole'],"['increased generation of reactive oxidative species', 'decreased GPx activity']",True,tebuconazole,decreased GPx activity,resulted,C0235659,Decreased movement in utero,86102,tebuconazole,tebuconazole,result
399,5057,34763016," Specifically, exposure to tebuconazole could cause structural damage and inflammatory cell infiltration in colon tissue, activate the expression of inflammation-related genes, disrupt the expression of barrier function-related genes, and induce the colonic inflammation in mice.",['tebuconazole'],"['damage and', 'inflammatory cell infiltration in colon tissue', 'colonic inflammation']",True,tebuconazole,colonic inflammation,cause,C0019189,Chronic liver inflammation,86102,tebuconazole,tebuconazole,cause
400,5065,34681291,  Tebuconazole Fungicide Induces Lipid Accumulation and Oxidative Stress in HepG2 Cells.,['Tebuconazole Fungicide Induces'],['Oxidative Stress'],True,Tebuconazole Fungicide,Oxidative Stress,Induces,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Tebuconazole Fungicide,induce
401,5086,34015629,"Tebuconazole significantly dysregulated phase Ⅰ- and phase II-metabolizing enzymes, ATP-binding cassette (ABC) efflux transporters (Abcc2 and Abcc3) and fatty acid metabolism-related genes (Cdkn1a and Fasn), thereby directly causing liver hypertrophy and steatosis.",['Tebuconazole'],"['liver hypertrophy', 'steatosis']",True,Tebuconazole,liver hypertrophy,causing,C0020492,Bone Hypertrophy,86102,tebuconazole,tebuconazole,cause
402,5086,34015629,"Tebuconazole significantly dysregulated phase Ⅰ- and phase II-metabolizing enzymes, ATP-binding cassette (ABC) efflux transporters (Abcc2 and Abcc3) and fatty acid metabolism-related genes (Cdkn1a and Fasn), thereby directly causing liver hypertrophy and steatosis.",['Tebuconazole'],"['liver hypertrophy', 'steatosis']",True,Tebuconazole,steatosis,causing,C2711227,Steatosis,86102,tebuconazole,tebuconazole,cause
403,5091,35218879,"Zebrafish were exposed to one concentration of 5, 50, 200 or 500 ng/L fenbuconazole for 96 h. There was no effect on survival nor percentage of fish hatched, but exposure to 200 and 500 ng/L fenbuconazole resulted in malformation and hypoactivity in zebrafish.","['fenbuconazole', 'fenbuconazole']",['malformation'],True,fenbuconazole,malformation,resulted,C2711227,Steatosis,86138,fenbuconazole,fenbuconazole,result
404,5124,16542693,"Treatment of CD1  mice with 0, 20, 60, 180 or 1300 ppm fenbuconazole for up to 4 weeks caused a dose-dependent increase in liver weight that was associated with centrilobular hepatocellular hypertrophy, cytoplasmic eosinophilia and panlobular hepatocellular vacuolation, as well as an initial increase in the cell proliferation labeling index.",['fenbuconazole'],"['increase in liver weight', 'centrilobular hepatocellular hypertrophy', 'cytoplasmic eosinophilia', 'panlobular hepatocellular vacuolation', 'increase in the cell proliferation labeling index']",True,fenbuconazole,increase in liver weight,caused,C0043094,Weight gain,86138,fenbuconazole,fenbuconazole,cause
405,5164,30033008,"Ca2+ treatment by induction in Relative water content, DPPH, chlorophyll, carotenoid, indole-3-acetic acid content and the content of Ca2+ and K+ causes increase in growth in cultivar Sarigol.",['chlorophyll'],"['induction in Relative water content', 'increase in growth']",True,chlorophyll,increase in growth,causes,C0241240,Tall stature,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chlorophyll,cause
406,5166,29602133,"Results showed that penconazole induced oxidative stress in the lung demonstrated by an increase in malondialdehyde (+77%), hydrogen peroxide (+58%) and advanced oxidation protein product (+22%) levels, as compared to the controls.","['penconazole', 'hydrogen peroxide']","['oxidative stress', 'increase in malondialdehyde']",True,penconazole,oxidative stress,induced,C0242606,Oxidative stress,91693,penconazole,penconazole,induce
407,5166,29602133,"Results showed that penconazole induced oxidative stress in the lung demonstrated by an increase in malondialdehyde (+77%), hydrogen peroxide (+58%) and advanced oxidation protein product (+22%) levels, as compared to the controls.","['penconazole', 'hydrogen peroxide']","['oxidative stress', 'increase in malondialdehyde']",True,hydrogen peroxide,oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydrogen peroxide,induce
408,5170,29471168,"In addition to this, exposure to penconazole caused malformations, including pericardial edema, yolk sac edema, axial malformation, tail malformation and spinal curvature.",['penconazole'],"['malformations', 'pericardial edema', 'yolk sac edema', 'axial malformation', 'tail malformation', 'spinal curvature']",True,penconazole,malformations,caused,C0040427,Abnormality of dental shape,91693,penconazole,penconazole,cause
409,5170,29471168,"In addition to this, exposure to penconazole caused malformations, including pericardial edema, yolk sac edema, axial malformation, tail malformation and spinal curvature.",['penconazole'],"['malformations', 'pericardial edema', 'yolk sac edema', 'axial malformation', 'tail malformation', 'spinal curvature']",True,penconazole,spinal curvature,caused,C0037932,Curved spine,91693,penconazole,penconazole,cause
410,5176,27738198,Results showed that penconazole induced oxidative stress in rat cerebrum and cerebellum tissues.,['penconazole'],['oxidative stress'],True,penconazole,oxidative stress,induced,C0242606,Oxidative stress,91693,penconazole,penconazole,induce
411,5178,27738198,Penconazole also provoked histological alterations marked by pyknotic and vacuolated neurons in the cerebrum and apoptosis and edema in the cerebellum Purkinje cells' layer.,['Penconazole'],"['apoptosis', 'edema in the cerebellum Purkinje cells']",True,Penconazole,edema in the cerebellum Purkinje cells,provoked,C4316985,Cerebellar edema,91693,penconazole,penconazole,provoke
412,5233,24705896,"The microbial biomass C, basal respiration and substrate-induced respiration were inhibited, but they tended to recover at the end of the incubation when tetraconazole was applied at the recommended field rate.",['tetraconazole'],['basal respiration'],True,tetraconazole,basal respiration,inhibited,C1260922,Abnormal respiration,80277,tetraconazole,tetraconazole,inhibit
413,5247,9103974,Interaction of the azole antifungal aromatic group with Phe-233 or -235 may cause the higher  activity for (R)-tetraconazole while inactivity of the (SS)-enantiomer of SCH39304 was predicted to result from incompatibility of the hydrophilic sulfonyl moiety when located into the hydrophobic pocket of the active site.,['azole'],['hydrophobic'],True,azole,hydrophobic,cause,C1609481,Hydrophobia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azole,cause
414,5267,27908921,"Agent Orange, one toxin among many, has been linked to malignancy and the subcomponent phenoxyacetic acid has been associated with soft tissue sarcomas (STSs).",['phenoxyacetic acid'],"['malignancy', 'soft tissue sarcomas']",True,phenoxyacetic acid,soft tissue sarcomas,linked,C4551687,Soft tissue sarcomas,19188,phenoxyacetic acid,phenoxyacetic acid,link
415,5267,27908921,"Agent Orange, one toxin among many, has been linked to malignancy and the subcomponent phenoxyacetic acid has been associated with soft tissue sarcomas (STSs).",['phenoxyacetic acid'],"['malignancy', 'soft tissue sarcomas']",True,phenoxyacetic acid,soft tissue sarcomas,associated,C4551687,Soft tissue sarcomas,19188,phenoxyacetic acid,phenoxyacetic acid,associate
416,5301,1514190,  Phensuximide (PSX) is an antiepileptic agent which has been shown to induce hemorrhagic cystitis and mild nephrotoxicity following repeated administration in man or rats or when acutely administered to phenobarbital-pretreated rats.,['phenobarbital-'],"['hemorrhagic cystitis', 'mild nephrotoxicity']",True,phenobarbital-,hemorrhagic cystitis,induce,C0473311,Hemorrhagic ovarian cyst,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phenobarbital-,induce
417,5301,1514190,  Phensuximide (PSX) is an antiepileptic agent which has been shown to induce hemorrhagic cystitis and mild nephrotoxicity following repeated administration in man or rats or when acutely administered to phenobarbital-pretreated rats.,['phenobarbital-'],"['hemorrhagic cystitis', 'mild nephrotoxicity']",True,phenobarbital-,mild nephrotoxicity,induce,C0473311,Hemorrhagic ovarian cyst,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phenobarbital-,induce
418,5337,35050567,"  To realize PDE4 inhibitors with good developmental potentiality for the treatment of dementia, structure-based optimizations of lead compound FCPR03 resulted in novel aminophenylketones 9c and 9H with low nanomolar potency, which displayed comparable activity to rolipram, satisfactory bioavailability (F% = 36.92 and 42.96% respectively), and good blood-brain barrier (BBB) permeability switching from the cyclopropyl methoxy group to the cyclopropyl methylamine and the amide group to the corresponding ketone.","['rolipram', 'ketone']",['dementia'],True,rolipram,dementia,resulted,C0497327,"Dementia, progressive",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rolipram,result
419,5337,35050567,"  To realize PDE4 inhibitors with good developmental potentiality for the treatment of dementia, structure-based optimizations of lead compound FCPR03 resulted in novel aminophenylketones 9c and 9H with low nanomolar potency, which displayed comparable activity to rolipram, satisfactory bioavailability (F% = 36.92 and 42.96% respectively), and good blood-brain barrier (BBB) permeability switching from the cyclopropyl methoxy group to the cyclopropyl methylamine and the amide group to the corresponding ketone.","['rolipram', 'ketone']",['dementia'],True,ketone,dementia,resulted,C0497327,"Dementia, progressive",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ketone,result
420,5395,33926468,  A heparin-rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis.,['heparin-rosuvastatin'],"['viability', 'thrombosis']",True,heparin-rosuvastatin,thrombosis,inhibits,C4025731,Abnormal thrombosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",heparin-rosuvastatin,inhibit
421,5418,20226807,"The  embryotoxic alkoxyacetic acid metabolites ethoxyacetic acid, butoxyacetic acid and phenoxyacetic acid also caused an intracellular acidification of BALB/c-3T3 cells at concentrations that are known to inhibit ES-D3 cell differentiation.","['butoxyacetic acid', 'phenoxyacetic acid']",['ES-D3 cell differentiation'],True,butoxyacetic acid,ES-D3 cell differentiation,caused,C1859624,Defective B cell differentiation,41958,2-butoxyacetic acid,2-butoxyacetic acid,cause
422,5418,20226807,"The  embryotoxic alkoxyacetic acid metabolites ethoxyacetic acid, butoxyacetic acid and phenoxyacetic acid also caused an intracellular acidification of BALB/c-3T3 cells at concentrations that are known to inhibit ES-D3 cell differentiation.","['butoxyacetic acid', 'phenoxyacetic acid']",['ES-D3 cell differentiation'],True,phenoxyacetic acid,ES-D3 cell differentiation,caused,C1859624,Defective B cell differentiation,19188,phenoxyacetic acid,phenoxyacetic acid,cause
423,5422,16675516,"The occurrence of liver hemangiosarcomas in male mice has been linked to oxidative damage subsequent to RBC hemolysis and iron deposition and activation of macrophages (Kupffer cells) in the liver, events that exhibit a threshold in both animals and humans.",['iron'],"['liver hemangiosarcomas', 'oxidative damage', 'hemolysis', 'activation of macrophages']",True,iron,liver hemangiosarcomas,linked,C1859624,Defective B cell differentiation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,link
424,5422,16675516,"The occurrence of liver hemangiosarcomas in male mice has been linked to oxidative damage subsequent to RBC hemolysis and iron deposition and activation of macrophages (Kupffer cells) in the liver, events that exhibit a threshold in both animals and humans.",['iron'],"['liver hemangiosarcomas', 'oxidative damage', 'hemolysis', 'activation of macrophages']",True,iron,hemolysis,linked,C0002878,Increased hemolysis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,link
425,5438,15705489,"When calcium was not present in the suspending medium or when chelated by EGTA, hemolysis was increased after 2 h incubation with 1 mM or 2 mM BAA.",['BAA'],['hemolysis'],True,BAA,hemolysis,increased,C0002878,Increased hemolysis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BAA,increase
426,5445,15705489,"We speculate that: (1) BAA causes sodium and calcium to enter the cell; (2) calcium initially has a protective effect via the  calcium activated potassium channel which facilitates the loss of potassium thereby, compensating for the osmotic effect of increased cell sodium; (3) calcium subsequently may have other deleterious effects through activation of proteases and externalization of phosphatidylserine in the exterior leaflet of the membrane.","['calcium', 'potassium', 'calcium', 'phosphatidylserine']","['sodium and calcium to enter the cell', 'loss of potassium', 'increased cell sodium']",True,calcium,increased cell sodium,causes,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,cause
427,5445,15705489,"We speculate that: (1) BAA causes sodium and calcium to enter the cell; (2) calcium initially has a protective effect via the  calcium activated potassium channel which facilitates the loss of potassium thereby, compensating for the osmotic effect of increased cell sodium; (3) calcium subsequently may have other deleterious effects through activation of proteases and externalization of phosphatidylserine in the exterior leaflet of the membrane.","['calcium', 'potassium', 'calcium', 'phosphatidylserine']","['sodium and calcium to enter the cell', 'loss of potassium', 'increased cell sodium']",True,potassium,increased cell sodium,causes,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",potassium,cause
428,5445,15705489,"We speculate that: (1) BAA causes sodium and calcium to enter the cell; (2) calcium initially has a protective effect via the  calcium activated potassium channel which facilitates the loss of potassium thereby, compensating for the osmotic effect of increased cell sodium; (3) calcium subsequently may have other deleterious effects through activation of proteases and externalization of phosphatidylserine in the exterior leaflet of the membrane.","['calcium', 'potassium', 'calcium', 'phosphatidylserine']","['sodium and calcium to enter the cell', 'loss of potassium', 'increased cell sodium']",True,calcium,increased cell sodium,causes,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,cause
429,5445,15705489,"We speculate that: (1) BAA causes sodium and calcium to enter the cell; (2) calcium initially has a protective effect via the  calcium activated potassium channel which facilitates the loss of potassium thereby, compensating for the osmotic effect of increased cell sodium; (3) calcium subsequently may have other deleterious effects through activation of proteases and externalization of phosphatidylserine in the exterior leaflet of the membrane.","['calcium', 'potassium', 'calcium', 'phosphatidylserine']","['sodium and calcium to enter the cell', 'loss of potassium', 'increased cell sodium']",True,phosphatidylserine,increased cell sodium,causes,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phosphatidylserine,cause
430,5448,15672755,Ethylene glycol monobutyl ether (EGBE) causes forestomach hyperplasia and neoplasia in mice when administered chronically by inhalation.,['Ethylene glycol monobutyl ether'],"['forestomach hyperplasia', 'neoplasia']",True,Ethylene glycol monobutyl ether,forestomach hyperplasia,causes,C4025593,Increased intracellular sodium,8133,2-butoxyethanol,2-butoxyethanol,cause
431,5448,15672755,Ethylene glycol monobutyl ether (EGBE) causes forestomach hyperplasia and neoplasia in mice when administered chronically by inhalation.,['Ethylene glycol monobutyl ether'],"['forestomach hyperplasia', 'neoplasia']",True,Ethylene glycol monobutyl ether,neoplasia,causes,C0027651,Neoplasm,8133,2-butoxyethanol,2-butoxyethanol,cause
432,5455,12075109,"While the mechanism of 2-butoxyethanol-induced liver carcinogenicity has not been defined, 2-butoxyethanol has been shown to induce hemolysis in rodents via 2-butoxyacetic acid, the major metabolite of 2-butoxyethanol.","['2-butoxyethanol-induced', '2-butoxyethanol', '2-butoxyacetic acid']",['hemolysis'],True,2-butoxyacetic acid,hemolysis,induce,C0002878,Increased hemolysis,41958,2-butoxyacetic acid,2-butoxyacetic acid,induce
433,5456,12075109,"This toxic effect, coupled with the observation that continued treatment with 2-butoxyethanol results in hemosiderin deposition in the liver, has led to our hypothesis that liver carcinogenicity by 2-butoxyethnaol is mediated via oxidative stress (iron catalyzed) and Kupffer cell activation.","['2-butoxyethanol', 'iron']","['hemosiderin deposition in the liver', 'Kupffer cell activation']",True,2-butoxyethanol,Kupffer cell activation,led,C4531032,Abnormal T cell activation,8133,2-butoxyethanol,2-butoxyethanol,lead
434,5456,12075109,"This toxic effect, coupled with the observation that continued treatment with 2-butoxyethanol results in hemosiderin deposition in the liver, has led to our hypothesis that liver carcinogenicity by 2-butoxyethnaol is mediated via oxidative stress (iron catalyzed) and Kupffer cell activation.","['2-butoxyethanol', 'iron']","['hemosiderin deposition in the liver', 'Kupffer cell activation']",True,iron,Kupffer cell activation,led,C4531032,Abnormal T cell activation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,lead
435,5462,12075109,"These data support our proposal that iron, produced indirectly through hemolysis, and not 2-butoxyethanol or its metabolite  2-butoxyacetic acid, is responsible for the observed carcinogenicity of 2-butoxyethanol.","['iron', '2-butoxyethanol', '2-butoxyethanol']",['hemolysis'],True,iron,hemolysis,produced,C0002878,Increased hemolysis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,produce
436,5462,12075109,"These data support our proposal that iron, produced indirectly through hemolysis, and not 2-butoxyethanol or its metabolite  2-butoxyacetic acid, is responsible for the observed carcinogenicity of 2-butoxyethanol.","['iron', '2-butoxyethanol', '2-butoxyethanol']",['hemolysis'],True,2-butoxyethanol,hemolysis,produced,C0002878,Increased hemolysis,8133,2-butoxyethanol,2-butoxyethanol,produce
437,5467,11738267,"These studies also examined whether 2-butoxyethanol, 2-butoxy acetic acid (a major metabolite of 2-butoxyethanol) or iron (FeSO(4)) produced oxidative stress in mouse and rat hepatocytes.","['2-butoxyethanol', '2-butoxy acetic acid', 'iron']",['oxidative stress'],True,2-butoxyethanol,oxidative stress,produced,C0242606,Oxidative stress,8133,2-butoxyethanol,2-butoxyethanol,produce
438,5467,11738267,"These studies also examined whether 2-butoxyethanol, 2-butoxy acetic acid (a major metabolite of 2-butoxyethanol) or iron (FeSO(4)) produced oxidative stress in mouse and rat hepatocytes.","['2-butoxyethanol', '2-butoxy acetic acid', 'iron']",['oxidative stress'],True,2-butoxy acetic acid,oxidative stress,produced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-butoxy acetic acid,produce
439,5467,11738267,"These studies also examined whether 2-butoxyethanol, 2-butoxy acetic acid (a major metabolite of 2-butoxyethanol) or iron (FeSO(4)) produced oxidative stress in mouse and rat hepatocytes.","['2-butoxyethanol', '2-butoxy acetic acid', 'iron']",['oxidative stress'],True,iron,oxidative stress,produced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,produce
440,5473,7859828,"Ethylene glycol monobutyl ether (2-butoxyethanol, BE) causes hemolytic anemia in rats but not in  guinea pigs, and red blood cells from both guinea pigs and humans are minimally affected in vitro by the active metabolite 2-butoxyacetic acid.","['Ethylene glycol monobutyl ether', '2-butoxyethanol']",['hemolytic anemia'],True,Ethylene glycol monobutyl ether,hemolytic anemia,causes,C0002878,Increased hemolysis,8133,2-butoxyethanol,2-butoxyethanol,cause
441,5473,7859828,"Ethylene glycol monobutyl ether (2-butoxyethanol, BE) causes hemolytic anemia in rats but not in  guinea pigs, and red blood cells from both guinea pigs and humans are minimally affected in vitro by the active metabolite 2-butoxyacetic acid.","['Ethylene glycol monobutyl ether', '2-butoxyethanol']",['hemolytic anemia'],True,2-butoxyethanol,hemolytic anemia,causes,C0002878,Increased hemolysis,8133,2-butoxyethanol,2-butoxyethanol,cause
442,5480,8104009,Gavage administration of BE (250 mg kg-1) to rats resulted in increased MCV and HCT followed by haemolysis (decreased RBCs).,['Gavage administration'],"['increased MCV', 'haemolysis', 'decreased RBCs']",True,Gavage administration,increased MCV,resulted,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Gavage administration,result
443,5480,8104009,Gavage administration of BE (250 mg kg-1) to rats resulted in increased MCV and HCT followed by haemolysis (decreased RBCs).,['Gavage administration'],"['increased MCV', 'haemolysis', 'decreased RBCs']",True,Gavage administration,decreased RBCs,resulted,C0427457,Decreased red blood cell count,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Gavage administration,result
444,5483,1539158,  Early work demonstrated that a single administration of 2-butoxyethanol (BE) causes acute hemolytic anemia in rats.,['2-butoxyethanol'],['acute hemolytic anemia'],True,2-butoxyethanol,acute hemolytic anemia,causes,C0002878,Increased hemolysis,8133,2-butoxyethanol,2-butoxyethanol,cause
445,5485,2730682,"  Recent work in this laboratory indicated that 2-butoxyethanol (BE) causes acute hemolytic anemia in rats, and activation of BE to butoxyacetic acid (BAA), presumably through the intermediate 2-butoxyacetaldehyde (BAL), is a prerequisite for development of hematotoxicity.","['2-butoxyethanol', '2-butoxyacetaldehyde']","['acute hemolytic anemia', 'activation of BE to butoxyacetic acid']",True,2-butoxyethanol,acute hemolytic anemia,causes,C0002878,Increased hemolysis,8133,2-butoxyethanol,2-butoxyethanol,cause
446,5485,2730682,"  Recent work in this laboratory indicated that 2-butoxyethanol (BE) causes acute hemolytic anemia in rats, and activation of BE to butoxyacetic acid (BAA), presumably through the intermediate 2-butoxyacetaldehyde (BAL), is a prerequisite for development of hematotoxicity.","['2-butoxyethanol', '2-butoxyacetaldehyde']","['acute hemolytic anemia', 'activation of BE to butoxyacetic acid']",True,2-butoxyacetaldehyde,acute hemolytic anemia,causes,C0002878,Increased hemolysis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-butoxyacetaldehyde,cause
447,5494,4060195,"Therefore in this  series: RO(CH2)nCOOH, an increase in the value of n caused a greater reduction in embryotoxicity than did an increase in chain length of the alkyl group R.  DOI: 10.1016/0378-4274(85)90008-6  PMID: 4060195  [Indexed for MEDLINE]  ",['R.  '],"['increase in the value', 'greater reduction in embryotoxicity', 'increase in chain length']",True,R.  DOI,increase in the value,caused,C0002878,Increased hemolysis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",R.  DOI,cause
448,5494,4060195,"Therefore in this  series: RO(CH2)nCOOH, an increase in the value of n caused a greater reduction in embryotoxicity than did an increase in chain length of the alkyl group R.  DOI: 10.1016/0378-4274(85)90008-6  PMID: 4060195  [Indexed for MEDLINE]  ",['R.  '],"['increase in the value', 'greater reduction in embryotoxicity', 'increase in chain length']",True,R.  DOI,increase in chain length,caused,C1839798,Long nose,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",R.  DOI,cause
449,5568,21914487,"Corticosteroids caused a rapid, concentration-dependent inhibition of uptake of the cationic formoterol by airway smooth muscle cells, but not airway epithelial cells.",['formoterol'],['airway smooth muscle cells'],True,formoterol,airway smooth muscle cells,caused,C1855752,Abnormal T cell morphology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",formoterol,cause
450,5571,20154483,"Given that a higher grade of gut  GVHD was associated with a higher blood level of 17BMP, BDP absorption might be associated with gut mucosal injury.",['BDP'],"['higher grade of gut  GVHD', 'higher blood level', 'mucosal injury']",True,BDP,higher blood level,associated,C1522135,Hypermagnesemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BDP,associate
451,5572,19561649,  Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials.,['beclomethasone dipropionate'],['allogeneic hematopoietic cell transplantation'],True,beclomethasone dipropionate,allogeneic hematopoietic cell transplantation,results,C4039246,History of bone marrow transplant,21700,beclomethasone dipropionate,beclomethasone dipropionate,result
452,5598,9756205," RESULTS: Eosinophil viability was prolonged by interleukin (IL)-5 in a concentration-dependent manner; in contrast, dexamethasone inhibited the IL-5 effect.",['dexamethasone'],['Eosinophil viability'],True,dexamethasone,Eosinophil viability,inhibited,C0014457,High blood eosinophil count,5743,Dexamethasone,Dexamethasone,inhibit
453,5606,7604948,"Pretreatment with fluticasone propionate significantly inhibits the increase in mast cell numbers in the nasal  mucosa of rats chronically exposed to toluene di-isocyanate (TDI), and suppresses TDI-induced mast cell degranulation.","['fluticasone propionate', 'toluene di-isocyanate']","['increase in mast cell numbers', 'mast cell degranulation']",True,fluticasone propionate,increase in mast cell numbers,inhibits,C4021960,Increased T cell count,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluticasone propionate,inhibit
454,5606,7604948,"Pretreatment with fluticasone propionate significantly inhibits the increase in mast cell numbers in the nasal  mucosa of rats chronically exposed to toluene di-isocyanate (TDI), and suppresses TDI-induced mast cell degranulation.","['fluticasone propionate', 'toluene di-isocyanate']","['increase in mast cell numbers', 'mast cell degranulation']",True,toluene di-isocyanate,increase in mast cell numbers,inhibits,C4021960,Increased T cell count,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",toluene di-isocyanate,inhibit
455,5624,34302410,"The commercially available anti-diabetic drugs in the market include metformin, sulphonyl urea, meglitinides, miglitol, acarbose, biguanides, and thiazolidinediones cause side effects like hypoglycaemia, dizziness, liver cell injury, digestive discomfort, neurological defects, etc.","['metformin', 'sulphonyl', 'miglitol', 'acarbose', 'biguanides', 'thiazolidinediones']","['hypoglycaemia', 'dizziness', 'liver cell injury', 'digestive discomfort', 'neurological defects']",True,thiazolidinediones,hypoglycaemia,cause,C0020615,Hypoglycaemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazolidinediones,cause
456,5624,34302410,"The commercially available anti-diabetic drugs in the market include metformin, sulphonyl urea, meglitinides, miglitol, acarbose, biguanides, and thiazolidinediones cause side effects like hypoglycaemia, dizziness, liver cell injury, digestive discomfort, neurological defects, etc.","['metformin', 'sulphonyl', 'miglitol', 'acarbose', 'biguanides', 'thiazolidinediones']","['hypoglycaemia', 'dizziness', 'liver cell injury', 'digestive discomfort', 'neurological defects']",True,thiazolidinediones,dizziness,cause,C0012833,Dizziness,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazolidinediones,cause
457,5624,34302410,"The commercially available anti-diabetic drugs in the market include metformin, sulphonyl urea, meglitinides, miglitol, acarbose, biguanides, and thiazolidinediones cause side effects like hypoglycaemia, dizziness, liver cell injury, digestive discomfort, neurological defects, etc.","['metformin', 'sulphonyl', 'miglitol', 'acarbose', 'biguanides', 'thiazolidinediones']","['hypoglycaemia', 'dizziness', 'liver cell injury', 'digestive discomfort', 'neurological defects']",True,thiazolidinediones,neurological defects,cause,C0497552,Neurologic abnormalities,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazolidinediones,cause
458,5682,28683829," RESULTS: Although frequent episodes of subclinical hypoglycemia (≤4.44 mmo/L) during CGM were observed on Day 1 in the both groups (35% of patients in the control group and 31% in the miglitol group), glucose fluctuations were decreased and the minimum glucose level was increased with substantial reduction in the episodes of subclinical hypoglycemia to 7.7% in the miglitol group on Day 2.","['miglitol', 'miglitol']","['subclinical hypoglycemia', 'subclinical hypoglycemia']",True,miglitol,subclinical hypoglycemia,increased,C0020615,Hypoglycaemia,441314,MIGLITOL,MIGLITOL,increase
459,5693,28097882,"Antidiabetic agents: Of agents approved prior to 2008, metformin has not been associated with  measurable harm in patients with diabetes in terms of mortality and CV events (and has a trend of benefit).",['metformin'],"['diabetes', 'mortality']",True,metformin,diabetes,associated,C0085207,Maternal diabetes,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",metformin,associate
460,5704,27640062,"In most trials the participants with CT needed less insulin, whereas insulin requirements increased or remained stable in participants with IM.We did  not perform a meta-analysis for hypoglycaemic events because the included studies used different definitions.. In most trials the insulin-sulphonylurea combination resulted in a higher number of mild episodes of hypoglycaemia, compared to the IM group (range: 2.2 to 6.1 episodes per participant in CT versus 2.0 to 2.6 episodes per participant in IM; low-quality evidence).","['insulin', 'insulin-sulphonylurea']",['hypoglycaemia'],True,insulin,hypoglycaemia,resulted,C0020615,Hypoglycaemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",insulin,result
461,5704,27640062,"In most trials the participants with CT needed less insulin, whereas insulin requirements increased or remained stable in participants with IM.We did  not perform a meta-analysis for hypoglycaemic events because the included studies used different definitions.. In most trials the insulin-sulphonylurea combination resulted in a higher number of mild episodes of hypoglycaemia, compared to the IM group (range: 2.2 to 6.1 episodes per participant in CT versus 2.0 to 2.6 episodes per participant in IM; low-quality evidence).","['insulin', 'insulin-sulphonylurea']",['hypoglycaemia'],True,insulin-sulphonylurea,hypoglycaemia,resulted,C0020615,Hypoglycaemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",insulin-sulphonylurea,result
462,5705,27640062, The trials that reported hypoglycaemic episodes in the other combinations found comparable numbers of mild to moderate hypoglycaemic events (low-quality evidence).The addition of sulphonylureas resulted in an additional weight gain of 0.4 kg to 1.9 kg versus -0.8 kg to 2.1 kg in the IM group (220 participants; 7 trials; low-quality evidence).,['sulphonylureas'],"['numbers of mild to moderate hypoglycaemic events', 'weight gain']",True,sulphonylureas,weight gain,resulted,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sulphonylureas,result
463,5726,34952136,  Rifampin and ritonavir increase oral availability and elacridar enhances overall  exposure and brain accumulation of the NTRK inhibitor larotrectinib.,"['ritonavir', 'elacridar']",['brain accumulation of the NTRK inhibitor larotrectinib'],True,ritonavir,brain accumulation of the NTRK inhibitor larotrectinib,increase,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ritonavir,increase
464,5726,34952136,  Rifampin and ritonavir increase oral availability and elacridar enhances overall  exposure and brain accumulation of the NTRK inhibitor larotrectinib.,"['ritonavir', 'elacridar']",['brain accumulation of the NTRK inhibitor larotrectinib'],True,elacridar,brain accumulation of the NTRK inhibitor larotrectinib,increase,C0043094,Weight gain,119373,Elacridar,Elacridar,increase
465,5745,32078103,"Therefore, elacridar inhibited P-gp  without affecting CYP3A. The absorption of oral verapamil, diltiazem and tacrolimus was not influenced by elacridar pre-treatment, and the increase in the AUC0-t of fexofenadine was approximately 3-fold when co-administered with each substrate; the minimal effect of elacridar was attributable to the limited contribution of P-gp but not to their self-inhibition against the transporter.","['elacridar', 'verapamil', 'diltiazem', 'tacrolimus', 'elacridar', 'fexofenadine', 'elacridar']",['increase in the AUC0-t'],True,elacridar,increase in the AUC0-t,inhibited,C0043094,Weight gain,119373,Elacridar,Elacridar,inhibit
466,5745,32078103,"Therefore, elacridar inhibited P-gp  without affecting CYP3A. The absorption of oral verapamil, diltiazem and tacrolimus was not influenced by elacridar pre-treatment, and the increase in the AUC0-t of fexofenadine was approximately 3-fold when co-administered with each substrate; the minimal effect of elacridar was attributable to the limited contribution of P-gp but not to their self-inhibition against the transporter.","['elacridar', 'verapamil', 'diltiazem', 'tacrolimus', 'elacridar', 'fexofenadine', 'elacridar']",['increase in the AUC0-t'],True,verapamil,increase in the AUC0-t,inhibited,C0043094,Weight gain,2520,VERAPAMIL,VERAPAMIL,inhibit
467,5745,32078103,"Therefore, elacridar inhibited P-gp  without affecting CYP3A. The absorption of oral verapamil, diltiazem and tacrolimus was not influenced by elacridar pre-treatment, and the increase in the AUC0-t of fexofenadine was approximately 3-fold when co-administered with each substrate; the minimal effect of elacridar was attributable to the limited contribution of P-gp but not to their self-inhibition against the transporter.","['elacridar', 'verapamil', 'diltiazem', 'tacrolimus', 'elacridar', 'fexofenadine', 'elacridar']",['increase in the AUC0-t'],True,diltiazem,increase in the AUC0-t,inhibited,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",diltiazem,inhibit
468,5745,32078103,"Therefore, elacridar inhibited P-gp  without affecting CYP3A. The absorption of oral verapamil, diltiazem and tacrolimus was not influenced by elacridar pre-treatment, and the increase in the AUC0-t of fexofenadine was approximately 3-fold when co-administered with each substrate; the minimal effect of elacridar was attributable to the limited contribution of P-gp but not to their self-inhibition against the transporter.","['elacridar', 'verapamil', 'diltiazem', 'tacrolimus', 'elacridar', 'fexofenadine', 'elacridar']",['increase in the AUC0-t'],True,tacrolimus,increase in the AUC0-t,inhibited,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tacrolimus,inhibit
469,5745,32078103,"Therefore, elacridar inhibited P-gp  without affecting CYP3A. The absorption of oral verapamil, diltiazem and tacrolimus was not influenced by elacridar pre-treatment, and the increase in the AUC0-t of fexofenadine was approximately 3-fold when co-administered with each substrate; the minimal effect of elacridar was attributable to the limited contribution of P-gp but not to their self-inhibition against the transporter.","['elacridar', 'verapamil', 'diltiazem', 'tacrolimus', 'elacridar', 'fexofenadine', 'elacridar']",['increase in the AUC0-t'],True,elacridar,increase in the AUC0-t,inhibited,C0043094,Weight gain,119373,Elacridar,Elacridar,inhibit
470,5745,32078103,"Therefore, elacridar inhibited P-gp  without affecting CYP3A. The absorption of oral verapamil, diltiazem and tacrolimus was not influenced by elacridar pre-treatment, and the increase in the AUC0-t of fexofenadine was approximately 3-fold when co-administered with each substrate; the minimal effect of elacridar was attributable to the limited contribution of P-gp but not to their self-inhibition against the transporter.","['elacridar', 'verapamil', 'diltiazem', 'tacrolimus', 'elacridar', 'fexofenadine', 'elacridar']",['increase in the AUC0-t'],True,fexofenadine,increase in the AUC0-t,inhibited,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fexofenadine,inhibit
471,5745,32078103,"Therefore, elacridar inhibited P-gp  without affecting CYP3A. The absorption of oral verapamil, diltiazem and tacrolimus was not influenced by elacridar pre-treatment, and the increase in the AUC0-t of fexofenadine was approximately 3-fold when co-administered with each substrate; the minimal effect of elacridar was attributable to the limited contribution of P-gp but not to their self-inhibition against the transporter.","['elacridar', 'verapamil', 'diltiazem', 'tacrolimus', 'elacridar', 'fexofenadine', 'elacridar']",['increase in the AUC0-t'],True,elacridar,increase in the AUC0-t,inhibited,C0043094,Weight gain,119373,Elacridar,Elacridar,inhibit
472,5787,29674491,Inhibition of Bcrp and Pgp in WT mice using the dual  Pgp/Bcrp inhibitor elacridar increased the ketamine-induced dLORR compared with vehicle-treated mice.,['elacridar'],['Inhibition of Bcrp and Pgp'],True,elacridar,Inhibition of Bcrp and Pgp,increased,C0424296,Disinhibition,119373,Elacridar,Elacridar,increase
473,5800,29175983,"In WT mice, the addition  of elacridar (at systemic plasma concentrations of ≥200 ng/mL) resulted in an increased brain concentration of erlotinib, without affecting erlotinib plasma concentration.","['elacridar', 'erlotinib', 'erlotinib']",['increased brain concentration'],True,elacridar,increased brain concentration,resulted,C5139336,Increased HDL2b concentration,119373,Elacridar,Elacridar,result
474,5800,29175983,"In WT mice, the addition  of elacridar (at systemic plasma concentrations of ≥200 ng/mL) resulted in an increased brain concentration of erlotinib, without affecting erlotinib plasma concentration.","['elacridar', 'erlotinib', 'erlotinib']",['increased brain concentration'],True,erlotinib,increased brain concentration,resulted,C5139336,Increased HDL2b concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",erlotinib,result
475,5800,29175983,"In WT mice, the addition  of elacridar (at systemic plasma concentrations of ≥200 ng/mL) resulted in an increased brain concentration of erlotinib, without affecting erlotinib plasma concentration.","['elacridar', 'erlotinib', 'erlotinib']",['increased brain concentration'],True,erlotinib,increased brain concentration,resulted,C5139336,Increased HDL2b concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",erlotinib,result
476,5835,26883271,"Pharmacokinetic analysis demonstrates that dasatinib delivery into the normal brain, but not into the tumor core, is significantly increased in ABC KO mice compared with ABC WT mice.",['dasatinib'],['tumor'],True,dasatinib,tumor,increased,C0027651,Neoplasm,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dasatinib,increase
477,5872,33045228,"Higher baseline paraben and phthalate exposures were associated with reduced weight loss, suggesting obesogenic properties.","['paraben', 'phthalate']",['reduced weight loss'],True,paraben,reduced weight loss,associated,C1262477,Weight loss,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",paraben,associate
478,5872,33045228,"Higher baseline paraben and phthalate exposures were associated with reduced weight loss, suggesting obesogenic properties.","['paraben', 'phthalate']",['reduced weight loss'],True,phthalate,reduced weight loss,associated,C1262477,Weight loss,181977,phthalate,phthalate,associate
479,5873,33014082,"Being female, non-Hispanic White, and non-Hispanic Black were associated with decreasing triglyceride levels in the presence of methylparaben, ethylparaben, and propylparaben, and age, BMI, and being male were associated with increasing circulating triglycerides.","['methylparaben', 'ethylparaben', 'propylparaben']","['decreasing triglyceride levels in the presence', 'increasing circulating triglycerides']",True,methylparaben,increasing circulating triglycerides,associated,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methylparaben,associate
480,5873,33014082,"Being female, non-Hispanic White, and non-Hispanic Black were associated with decreasing triglyceride levels in the presence of methylparaben, ethylparaben, and propylparaben, and age, BMI, and being male were associated with increasing circulating triglycerides.","['methylparaben', 'ethylparaben', 'propylparaben']","['decreasing triglyceride levels in the presence', 'increasing circulating triglycerides']",True,ethylparaben,increasing circulating triglycerides,associated,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethylparaben,associate
481,5873,33014082,"Being female, non-Hispanic White, and non-Hispanic Black were associated with decreasing triglyceride levels in the presence of methylparaben, ethylparaben, and propylparaben, and age, BMI, and being male were associated with increasing circulating triglycerides.","['methylparaben', 'ethylparaben', 'propylparaben']","['decreasing triglyceride levels in the presence', 'increasing circulating triglycerides']",True,propylparaben,increasing circulating triglycerides,associated,C0813230,Increased plasma Tg levels,7175,propyl 4-hydroxybenzoate,propyl 4-hydroxybenzoate,associate
482,5874,33014082," Conclusion: Despite the potential detrimental effects of parabens on triglycerides, our results suggest that urinary excretions of methylparaben, ethylparaben, and propylparaben are associated with lower concentrations of circulating triglycerides in certain populations.","['methylparaben', 'ethylparaben', 'propylparaben']","['triglycerides', 'urinary excretions', 'triglycerides']",True,methylparaben,urinary excretions,associated,C0392178,Lipiduria,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methylparaben,associate
483,5874,33014082," Conclusion: Despite the potential detrimental effects of parabens on triglycerides, our results suggest that urinary excretions of methylparaben, ethylparaben, and propylparaben are associated with lower concentrations of circulating triglycerides in certain populations.","['methylparaben', 'ethylparaben', 'propylparaben']","['triglycerides', 'urinary excretions', 'triglycerides']",True,methylparaben,triglycerides,associated,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methylparaben,associate
484,5874,33014082," Conclusion: Despite the potential detrimental effects of parabens on triglycerides, our results suggest that urinary excretions of methylparaben, ethylparaben, and propylparaben are associated with lower concentrations of circulating triglycerides in certain populations.","['methylparaben', 'ethylparaben', 'propylparaben']","['triglycerides', 'urinary excretions', 'triglycerides']",True,ethylparaben,urinary excretions,associated,C0392178,Lipiduria,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethylparaben,associate
485,5874,33014082," Conclusion: Despite the potential detrimental effects of parabens on triglycerides, our results suggest that urinary excretions of methylparaben, ethylparaben, and propylparaben are associated with lower concentrations of circulating triglycerides in certain populations.","['methylparaben', 'ethylparaben', 'propylparaben']","['triglycerides', 'urinary excretions', 'triglycerides']",True,ethylparaben,triglycerides,associated,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethylparaben,associate
486,5874,33014082," Conclusion: Despite the potential detrimental effects of parabens on triglycerides, our results suggest that urinary excretions of methylparaben, ethylparaben, and propylparaben are associated with lower concentrations of circulating triglycerides in certain populations.","['methylparaben', 'ethylparaben', 'propylparaben']","['triglycerides', 'urinary excretions', 'triglycerides']",True,propylparaben,urinary excretions,associated,C0392178,Lipiduria,7175,propyl 4-hydroxybenzoate,propyl 4-hydroxybenzoate,associate
487,5874,33014082," Conclusion: Despite the potential detrimental effects of parabens on triglycerides, our results suggest that urinary excretions of methylparaben, ethylparaben, and propylparaben are associated with lower concentrations of circulating triglycerides in certain populations.","['methylparaben', 'ethylparaben', 'propylparaben']","['triglycerides', 'urinary excretions', 'triglycerides']",True,propylparaben,triglycerides,associated,C0813230,Increased plasma Tg levels,7175,propyl 4-hydroxybenzoate,propyl 4-hydroxybenzoate,associate
488,5888,32585503,"2,4-dichlorophenol concentrations was associated  with lower BMD and a higher prevalence of osteopenia + osteoporosis in men.","['2,4-dichlorophenol']","['osteopenia', 'osteoporosis']",True,"2,4-dichlorophenol",osteopenia,associated,C0029453,Osteopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","2,4-dichlorophenol",associate
489,5888,32585503,"2,4-dichlorophenol concentrations was associated  with lower BMD and a higher prevalence of osteopenia + osteoporosis in men.","['2,4-dichlorophenol']","['osteopenia', 'osteoporosis']",True,"2,4-dichlorophenol",osteoporosis,associated,C0029456,Osteoporosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","2,4-dichlorophenol",associate
490,5893,32279061," CONCLUSION: Our study showed that PCP use was associated with a short-term increase in the urinary concentration of ethylparaben, butylparaben and propylparaben, but not methylparaben.","['ethylparaben', 'butylparaben', 'propylparaben', 'methylparaben']",['increase in the urinary concentration'],True,ethylparaben,increase in the urinary concentration,associated,C4023688,Increased urinary copper concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethylparaben,associate
491,5893,32279061," CONCLUSION: Our study showed that PCP use was associated with a short-term increase in the urinary concentration of ethylparaben, butylparaben and propylparaben, but not methylparaben.","['ethylparaben', 'butylparaben', 'propylparaben', 'methylparaben']",['increase in the urinary concentration'],True,butylparaben,increase in the urinary concentration,associated,C4023688,Increased urinary copper concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",butylparaben,associate
492,5893,32279061," CONCLUSION: Our study showed that PCP use was associated with a short-term increase in the urinary concentration of ethylparaben, butylparaben and propylparaben, but not methylparaben.","['ethylparaben', 'butylparaben', 'propylparaben', 'methylparaben']",['increase in the urinary concentration'],True,propylparaben,increase in the urinary concentration,associated,C4023688,Increased urinary copper concentration,7175,propyl 4-hydroxybenzoate,propyl 4-hydroxybenzoate,associate
493,5893,32279061," CONCLUSION: Our study showed that PCP use was associated with a short-term increase in the urinary concentration of ethylparaben, butylparaben and propylparaben, but not methylparaben.","['ethylparaben', 'butylparaben', 'propylparaben', 'methylparaben']",['increase in the urinary concentration'],True,methylparaben,increase in the urinary concentration,associated,C4023688,Increased urinary copper concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methylparaben,associate
494,5897,32169736,Our results suggested that prenatal triclosan and parabens exposure might be associated with head circumference at birth.,"['triclosan', 'parabens']",['head circumference at birth'],True,triclosan,head circumference at birth,associated,C4551563,Abnormally small skull,5564,"5-chloro-2-(2,4-dichlorophenoxy)phenol","5-chloro-2-(2,4-dichlorophenoxy)phenol",associate
495,5897,32169736,Our results suggested that prenatal triclosan and parabens exposure might be associated with head circumference at birth.,"['triclosan', 'parabens']",['head circumference at birth'],True,parabens,head circumference at birth,associated,C4551563,Abnormally small skull,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",parabens,associate
496,5967,28302371,"Increased urinary lysine and NMMA were associated with a lower risk of CKD (0.73 [0.50-0.90] and 0.66 [0.53-0.83], respectively) in the univariate model.",['NMMA'],['Increased urinary lysine'],True,NMMA,Increased urinary lysine,associated,C1846351,Increased urinary potassium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",NMMA,associate
497,6035,25961284," Insulin sensitivity was assessed in the fed state and after ipv glucagon infusion in the presence of GSH-E. We founf that DBcAMP and glucagon produce a decrease of insulin sensitivity, in a dose-dependent manner.","['glucagon', 'DBcAMP']",['decrease of insulin sensitivity'],True,DBcAMP,decrease of insulin sensitivity,produce,C1864570,Insulin insensitivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DBcAMP,produce
498,6044,21086190,Diabetic nephropathy rats were induced by intraperitoneal injection of STZ.,['STZ'],['Diabetic nephropathy rats'],True,STZ,Diabetic nephropathy rats,induced,C0022658,Kidney disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",STZ,induce
499,6080,34953397,"Subsequent administration of fentanyl in rats pretreated with vehicle produced negative effects on breathing, including decreases in frequency, tidal volume and therefore minute ventilation.",['fentanyl'],['breathing'],True,fentanyl,breathing,produced,C3203358,Hypoventilation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fentanyl,produce
500,6081,34953397,"Fentanyl elicited markedly different responses in rats that were pretreated with L-NAME, and conclusively, the negative effects of fentanyl were augmented by the NOS inhibitor.",['L-NAME'],['fentanyl'],True,L-NAME,fentanyl,elicited,C3203358,Hypoventilation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",L-NAME,elicit
501,6083,34904852, RESULTS: L-NAME led to a significant increase in blood pressure.,['L-NAME'],['increase in blood pressure'],True,L-NAME,increase in blood pressure,led,C0497247,Increased BP,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",L-NAME,lead
502,6093,34884571,Daily L-NAME administration caused a rapid rise in blood pressure.,['L-NAME'],['rise in blood pressure'],True,L-NAME,rise in blood pressure,caused,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",L-NAME,cause
503,6106,34799318,"In isolated rat aortic ring preparations previously vasoconstricted by phenylephrine and High K+, it also resulted in dose dependent vasodilation (0.01-10 mg/kg).In the presence of L-NAME, the relaxation curve of Ga.Cr was partially inhibited showing involvement of Nitric oxide (NO) mediated pathway.","['phenylephrine', 'L-NAME', 'Cr']","['High K+', 'vasodilation']",True,phenylephrine,High K+,resulted,C0151632,High ESR,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phenylephrine,result
504,6106,34799318,"In isolated rat aortic ring preparations previously vasoconstricted by phenylephrine and High K+, it also resulted in dose dependent vasodilation (0.01-10 mg/kg).In the presence of L-NAME, the relaxation curve of Ga.Cr was partially inhibited showing involvement of Nitric oxide (NO) mediated pathway.","['phenylephrine', 'L-NAME', 'Cr']","['High K+', 'vasodilation']",True,L-NAME,High K+,resulted,C0151632,High ESR,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",L-NAME,result
505,6106,34799318,"In isolated rat aortic ring preparations previously vasoconstricted by phenylephrine and High K+, it also resulted in dose dependent vasodilation (0.01-10 mg/kg).In the presence of L-NAME, the relaxation curve of Ga.Cr was partially inhibited showing involvement of Nitric oxide (NO) mediated pathway.","['phenylephrine', 'L-NAME', 'Cr']","['High K+', 'vasodilation']",True,Cr,High K+,resulted,C0151632,High ESR,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Cr,result
506,6126,34739536,R568 increased the secretion of cholecystokinin in the intestinal tissues and serum but had no effect on the secretion of glucagon like peptide-1.,['cholecystokinin'],"['secretion', 'secretion of glucagon like peptide-1']",True,cholecystokinin,secretion,increased,C0235857,Decreased lacrimation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholecystokinin,increase
507,6213,34177048,"L-NAME application led to longer duration of corneal insensitivity, increase in corneal lesions and decrease in tear volume.",['L-NAME'],"['increase in corneal lesions', 'decrease in tear volume']",True,L-NAME,decrease in tear volume,led,C4476780,Reduced amygdala volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",L-NAME,lead
508,6244,33957565,Subcutaneous (s.c.) injection of phlorizin inhibited visceral hypersensitivity and colonic hyperpermeability induced by LPS in a dose-dependent manner.,['phlorizin'],"['Subcutaneous (s.c.) injection', 'visceral hypersensitivity', 'colonic hyperpermeability']",True,phlorizin,colonic hyperpermeability,inhibited,C4703391,Choroidal vascular hyperpermeability,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phlorizin,inhibit
509,6263,33826116, AIM: This study investigated the effect of methanol extract of Adansonia digitata fruit (MEADF) pulp on NG-nitro-L-arginine methyl ester (L-NAME) induced hypertension in rats.,"['methanol', 'L-NAME']",['hypertension'],True,methanol,hypertension,induced,C0020538,Systemic hypertension,887,Methanol,Methanol,induce
510,6263,33826116, AIM: This study investigated the effect of methanol extract of Adansonia digitata fruit (MEADF) pulp on NG-nitro-L-arginine methyl ester (L-NAME) induced hypertension in rats.,"['methanol', 'L-NAME']",['hypertension'],True,L-NAME,hypertension,induced,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",L-NAME,induce
511,6266,33826116," CONCLUSION: This study therefore demonstrates that MEADF possesses an in vivo ACE inhibitory activity, hypotensive potential and the ability to avert further degeneration of biochemical and physiological upsets associated with L-NAME induced hypertension.",['L-NAME'],"['inhibitory activity', 'hypertension']",True,L-NAME,hypertension,associated,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",L-NAME,associate
512,6286,25585231,"  Sulforaphane and its methylcarbonyl analogs inhibit the LPS-stimulated inflammatory response in human monocytes through modulating cytokine production,  suppressing chemotactic migration and phagocytosis in a NF-κB- and MAPK-dependent manner.",['Sulforaphane'],"['inflammatory response', 'cytokine production', 'phagocytosis']",True,Sulforaphane,inflammatory response,inhibit,C4022805,Abnormal inflammatory response,5350,1-Isothiocyanato-4-(Methylsulfinyl)Butane,1-Isothiocyanato-4-(Methylsulfinyl)Butane,inhibit
513,6286,25585231,"  Sulforaphane and its methylcarbonyl analogs inhibit the LPS-stimulated inflammatory response in human monocytes through modulating cytokine production,  suppressing chemotactic migration and phagocytosis in a NF-κB- and MAPK-dependent manner.",['Sulforaphane'],"['inflammatory response', 'cytokine production', 'phagocytosis']",True,Sulforaphane,phagocytosis,inhibit,C5139054,Abnormal phagocytosis,5350,1-Isothiocyanato-4-(Methylsulfinyl)Butane,1-Isothiocyanato-4-(Methylsulfinyl)Butane,inhibit
514,6338,33263644,"Our results suggested that oseltamivir and zanamivir are effective in reducing body temperature, while oseltamivir led to better clinical improvement regarding influenza-like symptoms in patients with COPD.","['oseltamivir', 'zanamivir', 'oseltamivir']",['COPD'],True,oseltamivir,COPD,led,C0024117,COPD,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oseltamivir,lead
515,6340,33200130,"In vivo , treatment with Oseltamivir results in infection control and host survival in peritonitis and pneumonia models of sepsis.",['Oseltamivir'],"['host survival', 'peritonitis', 'pneumonia models', 'sepsis']",True,Oseltamivir,host survival,results,C0024117,COPD,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Oseltamivir,result
516,6340,33200130,"In vivo , treatment with Oseltamivir results in infection control and host survival in peritonitis and pneumonia models of sepsis.",['Oseltamivir'],"['host survival', 'peritonitis', 'pneumonia models', 'sepsis']",True,Oseltamivir,peritonitis,results,C0031154,Peritonitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Oseltamivir,result
517,6340,33200130,"In vivo , treatment with Oseltamivir results in infection control and host survival in peritonitis and pneumonia models of sepsis.",['Oseltamivir'],"['host survival', 'peritonitis', 'pneumonia models', 'sepsis']",True,Oseltamivir,pneumonia models,results,C0032285,Pneumonia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Oseltamivir,result
518,6340,33200130,"In vivo , treatment with Oseltamivir results in infection control and host survival in peritonitis and pneumonia models of sepsis.",['Oseltamivir'],"['host survival', 'peritonitis', 'pneumonia models', 'sepsis']",True,Oseltamivir,sepsis,results,C0036690,Infection in blood stream,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Oseltamivir,result
519,6346,32853849," Passage with zanamivir induced an E119G substitution in NA, whereas passage with  oseltamivir induced R292K and E119V substitutions that simulated that seen in oseltamivir -treated HPAI H7N9 cases, indicating that the high frequency of resistant strains in the HPAI H7N9 isolates is related to NAIs use.",['oseltamivir'],['induced R292K and E119V substitutions'],True,oseltamivir,induced R292K and E119V substitutions,induced,C0036690,Infection in blood stream,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oseltamivir,induce
520,6377,35273413,"After exclusion of common infectious, autoimmune, and neoplastic causes, she was finally diagnosed with scrub typhus associated with an abducens nerve palsy, which responded to doxycycline therapy.",['doxycycline'],['nerve palsy'],True,doxycycline,nerve palsy,associated,C4551519,Abducens palsy,54671203,"(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide","(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide",associate
521,6392,35237605,Doxycycline induces concentration-dependent anti-proliferation in both breast cancer cell lines.,['Doxycycline'],['breast cancer'],True,Doxycycline,breast cancer,induces,C0678222,Breast cancer,54671203,"(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide","(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide",induce
522,6444,35174094,"  The BRAF inhibitor vemurafenib, approved for treating patients with BRAF V600E-mutant and unresectable or metastatic melanomas, rapidly induces cutaneous  adverse events, including hyperkeratotic skin lesions and cutaneous squamous cell carcinomas (cSCC).",['vemurafenib'],"['BRAF V600E-mutant', 'hyperkeratotic skin lesions', 'cutaneous squamous cell carcinomas']",True,vemurafenib,cutaneous squamous cell carcinomas,induces,C0007137,Squamous cell carcinoma,42611257,"N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide","N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide",induce
523,6445,35174094,"To determine, how vemurafenib would provoke these adverse events, we utilized long-term in vitro skin equivalents (SEs) comprising epidermal keratinocytes and dermal fibroblasts in their physiological environment.",['vemurafenib'],['adverse events'],True,vemurafenib,adverse events,provoke,C0007137,Squamous cell carcinoma,42611257,"N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide","N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide",provoke
524,6503,19925785," Formoterol elicited a significant decrease in total cell number, neutrophil and macrophage counts in bronchoalveolar lavage fluid, whereas ipratropium bromide reduced neutrophil numbers.","['Formoterol', 'ipratropium bromide']","['decrease in total cell number', 'bronchoalveolar lavage fluid', 'reduced neutrophil numbers']",True,Formoterol,decrease in total cell number,elicited,C2931322,Decrease in T cell count,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Formoterol,elicit
525,6503,19925785," Formoterol elicited a significant decrease in total cell number, neutrophil and macrophage counts in bronchoalveolar lavage fluid, whereas ipratropium bromide reduced neutrophil numbers.","['Formoterol', 'ipratropium bromide']","['decrease in total cell number', 'bronchoalveolar lavage fluid', 'reduced neutrophil numbers']",True,Formoterol,reduced neutrophil numbers,elicited,C0580316,Abnormal neutrophil cell number,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Formoterol,elicit
526,6503,19925785," Formoterol elicited a significant decrease in total cell number, neutrophil and macrophage counts in bronchoalveolar lavage fluid, whereas ipratropium bromide reduced neutrophil numbers.","['Formoterol', 'ipratropium bromide']","['decrease in total cell number', 'bronchoalveolar lavage fluid', 'reduced neutrophil numbers']",True,ipratropium bromide,decrease in total cell number,elicited,C2931322,Decrease in T cell count,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ipratropium bromide,elicit
527,6503,19925785," Formoterol elicited a significant decrease in total cell number, neutrophil and macrophage counts in bronchoalveolar lavage fluid, whereas ipratropium bromide reduced neutrophil numbers.","['Formoterol', 'ipratropium bromide']","['decrease in total cell number', 'bronchoalveolar lavage fluid', 'reduced neutrophil numbers']",True,ipratropium bromide,reduced neutrophil numbers,elicited,C0580316,Abnormal neutrophil cell number,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ipratropium bromide,elicit
528,6505,19925785,"Although only formoterol induced a decrease protein concentration in bronchoalveolar lavage fluid, both compounds inhibited the pulmonary edema by reducing wet-to-dry weight ratio which returned to values similar to those recorded in the sham group.",['formoterol'],"['decrease protein concentration in bronchoalveolar lavage fluid', 'pulmonary edema']",True,formoterol,pulmonary edema,inhibited,C0034063,Wet lung,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",formoterol,inhibit
529,6571,35165326,doi: 10.1038/s41598-022-06416-z.  Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy.,['rifaximin'],['minimal hepatic encephalopathy'],True,rifaximin,minimal hepatic encephalopathy,associated,C0019151,Hepatic encephalopathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rifaximin,associate
530,6594,34946536,"Penicillin may produce a wide range of neurological  dysfunctions, including encephalopathy, behavioral changes, myoclonus or seizures.",['Penicillin'],"['neurological  dysfunctions', 'myoclonus', 'seizures']",True,Penicillin,myoclonus,produce,C0027066,Myoclonic jerks,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Penicillin,produce
531,6594,34946536,"Penicillin may produce a wide range of neurological  dysfunctions, including encephalopathy, behavioral changes, myoclonus or seizures.",['Penicillin'],"['neurological  dysfunctions', 'myoclonus', 'seizures']",True,Penicillin,seizures,produce,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Penicillin,produce
532,6629,34504135,"Overall, while rifaximin alone appeared  to induce no significant effect on the neurometabolic profile of BDL rats, its association with the probiotic resulted in more attenuated neurometabolic alterations in BDL rats followed longitudinally (i.e. a smaller increase in Gln and milder decrease in Glu and Cr levels).","['rifaximin', 'Cr']","['neurometabolic alterations', 'increase in Gln and']",True,rifaximin,neurometabolic alterations,resulted,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rifaximin,result
533,6696,33777678,It was reported that CAR agonist TCPOBOP induces hepatomegaly but the underlying mechanism remains largely unknown.,['TCPOBOP'],['hepatomegaly'],True,TCPOBOP,hepatomegaly,induces,C0019209,Enlarged liver,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TCPOBOP,induce
534,6752,35295143,"  Nitrapyrin, a nitrification inhibitor, produces liver tumors in B6C3F1 mice.",['Nitrapyrin'],['liver tumors'],True,Nitrapyrin,liver tumors,produces,C0023903,Liver tumor,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Nitrapyrin,produce
535,6776,35143593,"Treatment with the carbonic anhydrase inhibitor, acetazolamide, caused wild type luminal pH to become more acidic, and increased both Vibrio abundance and intestinal inflammation.","['acetazolamide', 'Vibrio']","['wild type luminal pH', 'intestinal inflammation']",True,acetazolamide,intestinal inflammation,caused,C1535950,Gastrointestinal inflammation,1986,Acetazolamide,Acetazolamide,cause
536,6776,35143593,"Treatment with the carbonic anhydrase inhibitor, acetazolamide, caused wild type luminal pH to become more acidic, and increased both Vibrio abundance and intestinal inflammation.","['acetazolamide', 'Vibrio']","['wild type luminal pH', 'intestinal inflammation']",True,Vibrio,intestinal inflammation,caused,C1535950,Gastrointestinal inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Vibrio,cause
537,6776,35143593,"Treatment with the carbonic anhydrase inhibitor, acetazolamide, caused wild type luminal pH to become more acidic, and increased both Vibrio abundance and intestinal inflammation.","['acetazolamide', 'Vibrio']","['wild type luminal pH', 'intestinal inflammation']",True,Vibrio,intestinal inflammation,increased,C1535950,Gastrointestinal inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Vibrio,increase
538,6804,34861924,"On day 18, the serum calcium increased to 3.3 mmol/L. It was associated with hypertriglyceridemia at 2.6 mmol/L. Bilateral nephrocalcinosis was detected on renal ultrasound.",['calcium'],"['hypertriglyceridemia', 'Bilateral nephrocalcinosis']",True,calcium,hypertriglyceridemia,increased,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,increase
539,6804,34861924,"On day 18, the serum calcium increased to 3.3 mmol/L. It was associated with hypertriglyceridemia at 2.6 mmol/L. Bilateral nephrocalcinosis was detected on renal ultrasound.",['calcium'],"['hypertriglyceridemia', 'Bilateral nephrocalcinosis']",True,calcium,Bilateral nephrocalcinosis,increased,C0027709,Too much calcium deposited in kidneys,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,increase
540,6819,34710770,"Perampanel was associated with low incidence of insomnia, and lacosamide with low incidence of daytime sleepiness adverse events.",['lacosamide'],"['insomnia', 'low incidence of daytime sleepiness adverse events']",True,lacosamide,insomnia,associated,C0917801,Difficulty staying or falling asleep,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lacosamide,associate
541,6829,34671100, CONCLUSIONS: First-line treatment of neonatal seizures with phenobarbital is associated with a lower rate of treatment failure than levetiracetam.,"['phenobarbital', 'levetiracetam']","['neonatal seizures', 'failure']",True,phenobarbital,neonatal seizures,associated,C0036572,Seizure,4763,Phenobarbital,Phenobarbital,associate
542,6829,34671100, CONCLUSIONS: First-line treatment of neonatal seizures with phenobarbital is associated with a lower rate of treatment failure than levetiracetam.,"['phenobarbital', 'levetiracetam']","['neonatal seizures', 'failure']",True,phenobarbital,failure,associated,C0036572,Seizure,4763,Phenobarbital,Phenobarbital,associate
543,6829,34671100, CONCLUSIONS: First-line treatment of neonatal seizures with phenobarbital is associated with a lower rate of treatment failure than levetiracetam.,"['phenobarbital', 'levetiracetam']","['neonatal seizures', 'failure']",True,levetiracetam,neonatal seizures,associated,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",levetiracetam,associate
544,6829,34671100, CONCLUSIONS: First-line treatment of neonatal seizures with phenobarbital is associated with a lower rate of treatment failure than levetiracetam.,"['phenobarbital', 'levetiracetam']","['neonatal seizures', 'failure']",True,levetiracetam,failure,associated,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",levetiracetam,associate
545,6871,34921803,"95% confidence interval, 1.98-4.03) and extended cycle regimens (hazard ratio, 3.49; 95% confidence interval, 1.28-9.53) and norgestrel in monophasic regimens (hazard ratio, 1.91; 95% confidence interval, 1.19-3.06), all combined with ethinyl estradiol, was associated with a higher breast cancer risk when compared with never oral contraceptive use.","['norgestrel', 'ethinyl estradiol']",['higher breast cancer'],True,norgestrel,higher breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",norgestrel,associate
546,6871,34921803,"95% confidence interval, 1.98-4.03) and extended cycle regimens (hazard ratio, 3.49; 95% confidence interval, 1.28-9.53) and norgestrel in monophasic regimens (hazard ratio, 1.91; 95% confidence interval, 1.19-3.06), all combined with ethinyl estradiol, was associated with a higher breast cancer risk when compared with never oral contraceptive use.","['norgestrel', 'ethinyl estradiol']",['higher breast cancer'],True,ethinyl estradiol,higher breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethinyl estradiol,associate
547,6924,31935385,"Among those who  accessed care, some progestins (i.e., levonorgestrel, Hazard Ratio (HR) = 1.46, and norelgestromin, HR = 1.93) were associated with an increased rate of depression diagnosis but not antidepressant use; norethindrone (HR = 0.21) was associated with a decreased rate of depression diagnosis.","['levonorgestrel', 'norethindrone']","['depression', 'decreased rate', 'depression']",True,levonorgestrel,depression,associated,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",levonorgestrel,associate
548,6924,31935385,"Among those who  accessed care, some progestins (i.e., levonorgestrel, Hazard Ratio (HR) = 1.46, and norelgestromin, HR = 1.93) were associated with an increased rate of depression diagnosis but not antidepressant use; norethindrone (HR = 0.21) was associated with a decreased rate of depression diagnosis.","['levonorgestrel', 'norethindrone']","['depression', 'decreased rate', 'depression']",True,levonorgestrel,decreased rate,associated,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",levonorgestrel,associate
549,6924,31935385,"Among those who  accessed care, some progestins (i.e., levonorgestrel, Hazard Ratio (HR) = 1.46, and norelgestromin, HR = 1.93) were associated with an increased rate of depression diagnosis but not antidepressant use; norethindrone (HR = 0.21) was associated with a decreased rate of depression diagnosis.","['levonorgestrel', 'norethindrone']","['depression', 'decreased rate', 'depression']",True,levonorgestrel,depression,associated,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",levonorgestrel,associate
550,6924,31935385,"Among those who  accessed care, some progestins (i.e., levonorgestrel, Hazard Ratio (HR) = 1.46, and norelgestromin, HR = 1.93) were associated with an increased rate of depression diagnosis but not antidepressant use; norethindrone (HR = 0.21) was associated with a decreased rate of depression diagnosis.","['levonorgestrel', 'norethindrone']","['depression', 'decreased rate', 'depression']",True,norethindrone,depression,associated,C0011581,Depression,6230,Norethindrone,Norethindrone,associate
551,6924,31935385,"Among those who  accessed care, some progestins (i.e., levonorgestrel, Hazard Ratio (HR) = 1.46, and norelgestromin, HR = 1.93) were associated with an increased rate of depression diagnosis but not antidepressant use; norethindrone (HR = 0.21) was associated with a decreased rate of depression diagnosis.","['levonorgestrel', 'norethindrone']","['depression', 'decreased rate', 'depression']",True,norethindrone,decreased rate,associated,C0011581,Depression,6230,Norethindrone,Norethindrone,associate
552,6924,31935385,"Among those who  accessed care, some progestins (i.e., levonorgestrel, Hazard Ratio (HR) = 1.46, and norelgestromin, HR = 1.93) were associated with an increased rate of depression diagnosis but not antidepressant use; norethindrone (HR = 0.21) was associated with a decreased rate of depression diagnosis.","['levonorgestrel', 'norethindrone']","['depression', 'decreased rate', 'depression']",True,norethindrone,depression,associated,C0011581,Depression,6230,Norethindrone,Norethindrone,associate
553,7002,33148062,The co-exposure with drospirenone and ethinylestradiol results in potentiation of genotoxicity which may pose a threat of cancer development in  women taking these drugs for long periods.,"['drospirenone', 'ethinylestradiol']",['cancer'],True,drospirenone,cancer,results,C0006826,Cancer,68873,Drospirenone,Drospirenone,result
554,7002,33148062,The co-exposure with drospirenone and ethinylestradiol results in potentiation of genotoxicity which may pose a threat of cancer development in  women taking these drugs for long periods.,"['drospirenone', 'ethinylestradiol']",['cancer'],True,ethinylestradiol,cancer,results,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethinylestradiol,result
555,7015,32668346,"CLO caused a decrease of spontaneous muscle contraction and increase of heart rate, as well as transcriptional induction of pepck1, fkbp5, sult2st3 and vitellogenin (vtg1) at 24 and/or 48 h post fertilization (hpf).","['CLO', 'vitellogenin']","['decrease of spontaneous muscle contraction', 'increase of heart rate']",True,CLO,increase of heart rate,caused,C0039231,Heart racing,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CLO,cause
556,7015,32668346,"CLO caused a decrease of spontaneous muscle contraction and increase of heart rate, as well as transcriptional induction of pepck1, fkbp5, sult2st3 and vitellogenin (vtg1) at 24 and/or 48 h post fertilization (hpf).","['CLO', 'vitellogenin']","['decrease of spontaneous muscle contraction', 'increase of heart rate']",True,vitellogenin,increase of heart rate,caused,C0039231,Heart racing,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",vitellogenin,cause
557,7042,31916574,"The study showed that use of OCs containing DSG, CPA  and DRSP for 3-6 months was associated with a higher increase of sex hormone-binding globulin (SHBG), compared with products containing LNG (P < 0.001).","['DSG', 'CPA', 'DRSP']",['increase of sex hormone-binding globulin'],True,DSG,increase of sex hormone-binding globulin,associated,C4531027,Abnormal sex hormone-binding globulin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DSG,associate
558,7042,31916574,"The study showed that use of OCs containing DSG, CPA  and DRSP for 3-6 months was associated with a higher increase of sex hormone-binding globulin (SHBG), compared with products containing LNG (P < 0.001).","['DSG', 'CPA', 'DRSP']",['increase of sex hormone-binding globulin'],True,CPA,increase of sex hormone-binding globulin,associated,C4531027,Abnormal sex hormone-binding globulin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CPA,associate
559,7042,31916574,"The study showed that use of OCs containing DSG, CPA  and DRSP for 3-6 months was associated with a higher increase of sex hormone-binding globulin (SHBG), compared with products containing LNG (P < 0.001).","['DSG', 'CPA', 'DRSP']",['increase of sex hormone-binding globulin'],True,DRSP,increase of sex hormone-binding globulin,associated,C4531027,Abnormal sex hormone-binding globulin level,68873,Drospirenone,Drospirenone,associate
560,7044,31916574,"Our results showed that the use of OCs containing DRSP for 6 months was associated with more  improvement in acne, compared with products containing LNG (P = 0.007).",['DRSP'],['acne'],True,DRSP,acne,associated,C0702166,Acne,68873,Drospirenone,Drospirenone,associate
561,7056,31706240,  Chronic simultaneous exposure of common carp (Cyprinus carpio) from embryonic to  juvenile stage to drospirenone and gestodene at low ng/L level caused intersex.,"['drospirenone', 'gestodene']",['intersex'],True,drospirenone,intersex,caused,C0266362,Ambiguous external genitalia,68873,Drospirenone,Drospirenone,cause
562,7056,31706240,  Chronic simultaneous exposure of common carp (Cyprinus carpio) from embryonic to  juvenile stage to drospirenone and gestodene at low ng/L level caused intersex.,"['drospirenone', 'gestodene']",['intersex'],True,gestodene,intersex,caused,C0266362,Ambiguous external genitalia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",gestodene,cause
563,7088,35241735,"Additionally, four-week sunitinib treatment increased miR-96-5p and decreased PTEN only in tumors from a sunitinib-resistant patient-derived xenograft model.",['sunitinib'],['tumors'],True,sunitinib,tumors,increased,C0022665,Renal neoplasia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sunitinib,increase
564,7111,35157045,doi: 10.1093/hmg/ddac042. [Epub ahead of print]  Sunitinib inhibits STAT3 phosphorylation in cardiac muscle and prevents cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy.,['Sunitinib'],"['phosphorylation in cardiac muscle', 'cardiomyopathy in the', 'Duchenne muscular dystrophy']",True,Sunitinib,cardiomyopathy in the,inhibits,C0878544,Disease of the heart muscle,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Sunitinib,inhibit
565,7111,35157045,doi: 10.1093/hmg/ddac042. [Epub ahead of print]  Sunitinib inhibits STAT3 phosphorylation in cardiac muscle and prevents cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy.,['Sunitinib'],"['phosphorylation in cardiac muscle', 'cardiomyopathy in the', 'Duchenne muscular dystrophy']",True,Sunitinib,Duchenne muscular dystrophy,inhibits,C0026850,Muscular dystrophy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Sunitinib,inhibit
566,7116,35155225,"The results demonstrated that crizotinib and sunitinib caused cytotoxicity in HepG2 cells and chronic liver injury in mice, which were associated with oxidative stress, apoptosis and/or necrosis.","['crizotinib', 'sunitinib']","['cytotoxicity', 'chronic liver injury', 'oxidative stress', 'apoptosis', 'necrosis']",True,crizotinib,oxidative stress,caused,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",crizotinib,cause
567,7116,35155225,"The results demonstrated that crizotinib and sunitinib caused cytotoxicity in HepG2 cells and chronic liver injury in mice, which were associated with oxidative stress, apoptosis and/or necrosis.","['crizotinib', 'sunitinib']","['cytotoxicity', 'chronic liver injury', 'oxidative stress', 'apoptosis', 'necrosis']",True,crizotinib,necrosis,caused,C0151798,Hepatic necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",crizotinib,cause
568,7116,35155225,"The results demonstrated that crizotinib and sunitinib caused cytotoxicity in HepG2 cells and chronic liver injury in mice, which were associated with oxidative stress, apoptosis and/or necrosis.","['crizotinib', 'sunitinib']","['cytotoxicity', 'chronic liver injury', 'oxidative stress', 'apoptosis', 'necrosis']",True,sunitinib,oxidative stress,caused,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sunitinib,cause
569,7116,35155225,"The results demonstrated that crizotinib and sunitinib caused cytotoxicity in HepG2 cells and chronic liver injury in mice, which were associated with oxidative stress, apoptosis and/or necrosis.","['crizotinib', 'sunitinib']","['cytotoxicity', 'chronic liver injury', 'oxidative stress', 'apoptosis', 'necrosis']",True,sunitinib,necrosis,caused,C0151798,Hepatic necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sunitinib,cause
570,7117,35155225,Crizotinib- and sunitinib-induced oxidative stress was accompanied by increasing reactive oxygen species and malondialdehyde  levels and decreasing the activity of superoxide dismutase and glutathione peroxidase.,['oxygen'],"['oxidative stress', 'decreasing the activity of superoxide dismutase and glutathione peroxidase']",True,oxygen,decreasing the activity of superoxide dismutase and glutathione peroxidase,increasing,C0151798,Hepatic necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,increase
571,7143,35116623, Results: Curcumin plus sunitinib inhibited the proliferation of sunitinib-resistant ccRCC cells (P<0.05).,"['Curcumin', 'sunitinib']",['proliferation'],True,Curcumin,proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Curcumin,inhibit
572,7143,35116623, Results: Curcumin plus sunitinib inhibited the proliferation of sunitinib-resistant ccRCC cells (P<0.05).,"['Curcumin', 'sunitinib']",['proliferation'],True,sunitinib,proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sunitinib,inhibit
573,7152,35066605,doi: 10.1007/s00262-022-03146-z. [Epub ahead of print]  The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC.,['sunitinib'],['resistance of HER2 positive'],True,sunitinib,resistance of HER2 positive,induces,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sunitinib,induce
574,7154,35066605,"Moreover, sunitinib induced downregulation of HER2 on the target cells' surface, changed the morphology and increased adherence of the  target cells.",['sunitinib'],['increased adherence of the  target cells'],True,sunitinib,increased adherence of the  target cells,induced,C1855752,Abnormal T cell morphology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sunitinib,induce
575,7169,35033866,  Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.,"['cabozantinib', 'nivolumab']",['renal cell carcinoma'],True,cabozantinib,renal cell carcinoma,associated,C0007134,Hypernephroma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cabozantinib,associate
576,7169,35033866,  Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.,"['cabozantinib', 'nivolumab']",['renal cell carcinoma'],True,nivolumab,renal cell carcinoma,associated,C0007134,Hypernephroma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",nivolumab,associate
577,7253,11473844,"Therefore, we designed this study to examine whether cibenzoline may produce changes in vasorelaxation in response  to a selective ATP-sensitive K(+) channel opener, levcromakalim, in the isolated  rat carotid artery.","['cibenzoline', 'levcromakalim']","['vasorelaxation', 'carotid artery']",True,cibenzoline,carotid artery,produce,C0007282,Carotid artery stenosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cibenzoline,produce
578,7253,11473844,"Therefore, we designed this study to examine whether cibenzoline may produce changes in vasorelaxation in response  to a selective ATP-sensitive K(+) channel opener, levcromakalim, in the isolated  rat carotid artery.","['cibenzoline', 'levcromakalim']","['vasorelaxation', 'carotid artery']",True,levcromakalim,carotid artery,produce,C0007282,Carotid artery stenosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",levcromakalim,produce
579,7271,31526816,"However, WZ3146 did not inhibit degranulation of MCs by thapsigargin or ionomycin, which increase calcium concentration in cytosol.","['thapsigargin', 'ionomycin']",['increase calcium concentration'],True,thapsigargin,increase calcium concentration,inhibit,C4022450,Abnormal circulating calcium concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thapsigargin,inhibit
580,7271,31526816,"However, WZ3146 did not inhibit degranulation of MCs by thapsigargin or ionomycin, which increase calcium concentration in cytosol.","['thapsigargin', 'ionomycin']",['increase calcium concentration'],True,ionomycin,increase calcium concentration,inhibit,C4022450,Abnormal circulating calcium concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ionomycin,inhibit
581,7275,28192098,"We demonstrated that APL cell treatment with combinations of differentiation inductor RA, HDACi Belinostat and HMTi DZNep caused a depletion of leukemia cell  growth and viability, initiated apoptosis and exaggerated RA induced granulocytic differentiation.","['RA', 'RA']","['differentiation', 'depletion of leukemia cell', 'viability', 'apoptosis', 'granulocytic differentiation']",True,RA,differentiation,caused,C1859624,Defective B cell differentiation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",RA,cause
582,7275,28192098,"We demonstrated that APL cell treatment with combinations of differentiation inductor RA, HDACi Belinostat and HMTi DZNep caused a depletion of leukemia cell  growth and viability, initiated apoptosis and exaggerated RA induced granulocytic differentiation.","['RA', 'RA']","['differentiation', 'depletion of leukemia cell', 'viability', 'apoptosis', 'granulocytic differentiation']",True,RA,differentiation,caused,C1859624,Defective B cell differentiation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",RA,cause
583,7307,34658899,"We show that deletion of M4 in the GluN1, GluN2A, or GluN3A subunit, despite retained receptor assembly and cell surface expression, results in nonfunctional membrane receptors.",['M4'],['cell surface expression'],True,M4,cell surface expression,results,C4531025,Abnormal MHC II surface expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",M4,result
584,7314,34465588,Increasing levels of 17-hydroxypregnenolone were inversely associated with endometrial cancer risk [0.40 (0.18-0.91); 0.03] and positively associated with ovarian cancer risk [3.11 (1.39-6.93); 0.01].,['17-hydroxypregnenolone'],"['Increasing levels', 'ovarian cancer']",True,17-hydroxypregnenolone,Increasing levels,associated,C4531025,Abnormal MHC II surface expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",17-hydroxypregnenolone,associate
585,7314,34465588,Increasing levels of 17-hydroxypregnenolone were inversely associated with endometrial cancer risk [0.40 (0.18-0.91); 0.03] and positively associated with ovarian cancer risk [3.11 (1.39-6.93); 0.01].,['17-hydroxypregnenolone'],"['Increasing levels', 'ovarian cancer']",True,17-hydroxypregnenolone,ovarian cancer,associated,C1140680,Ovarian cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",17-hydroxypregnenolone,associate
586,7342,34015388,Progress in neurosteroid research has led to the successful translation of allopregnanolone into an approved therapy for postpartum depression.,['allopregnanolone'],['depression'],True,allopregnanolone,depression,led,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",allopregnanolone,lead
587,7356,33851518,"Rifampicin treatment increased ALP activity and mRNA level of bone biomarker genes (ALP, MGP, OPN and  OPG).",['Rifampicin'],['ALP activity'],True,Rifampicin,ALP activity,increased,C4025328,Abnormality of alkaline phosphatase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Rifampicin,increase
588,7363,33827983," RESULTS: High concentrations of pregnenolone and progesterone were not associated with colorectal cancer [quintile(Q)5 versus Q1: pregnenolone HR, 0.71, 95% CI, 0.40-1.25; progesterone HR, 1.25; 95% CI, 0.71-2.22].","['pregnenolone', 'progesterone', 'pregnenolone']",['cancer'],True,pregnenolone,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pregnenolone,associate
589,7363,33827983," RESULTS: High concentrations of pregnenolone and progesterone were not associated with colorectal cancer [quintile(Q)5 versus Q1: pregnenolone HR, 0.71, 95% CI, 0.40-1.25; progesterone HR, 1.25; 95% CI, 0.71-2.22].","['pregnenolone', 'progesterone', 'pregnenolone']",['cancer'],True,progesterone,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",progesterone,associate
590,7363,33827983," RESULTS: High concentrations of pregnenolone and progesterone were not associated with colorectal cancer [quintile(Q)5 versus Q1: pregnenolone HR, 0.71, 95% CI, 0.40-1.25; progesterone HR, 1.25; 95% CI, 0.71-2.22].","['pregnenolone', 'progesterone', 'pregnenolone']",['cancer'],True,pregnenolone,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pregnenolone,associate
591,7478,35053371,"A number of neurologic diseases are associated with dysfunction of the hSERT, and several  medications for their treatment are hSERT blockers, including citalopram, fluoxetine, and paroxetine.","['citalopram', 'fluoxetine', 'paroxetine']",['dysfunction of the hSERT'],True,citalopram,dysfunction of the hSERT,associated,C0543968,Congenital stationary cone dysfunction,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",citalopram,associate
592,7478,35053371,"A number of neurologic diseases are associated with dysfunction of the hSERT, and several  medications for their treatment are hSERT blockers, including citalopram, fluoxetine, and paroxetine.","['citalopram', 'fluoxetine', 'paroxetine']",['dysfunction of the hSERT'],True,fluoxetine,dysfunction of the hSERT,associated,C0543968,Congenital stationary cone dysfunction,3386,Fluoxetine,Fluoxetine,associate
593,7478,35053371,"A number of neurologic diseases are associated with dysfunction of the hSERT, and several  medications for their treatment are hSERT blockers, including citalopram, fluoxetine, and paroxetine.","['citalopram', 'fluoxetine', 'paroxetine']",['dysfunction of the hSERT'],True,paroxetine,dysfunction of the hSERT,associated,C0543968,Congenital stationary cone dysfunction,43815,"(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine","(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine",associate
594,7492,35042170,"Depression was induced in rats by social isolation (SI) for 12 weeks,  AlCL3 (70 mg/kg/day, i.p.) was used to induce AD which was administered either in SI or normal control (NC) grouped rats starting at 8th week till the end of the experiment, fluoxetine (10 mg/kg/day, p.o) treatment also was started at 8th week.",['fluoxetine'],['Depression'],True,fluoxetine,Depression,induced,C0011581,Depression,3386,Fluoxetine,Fluoxetine,induce
595,7505,35011254,Zinc  supplementation (10 mg/kg) slightly increases the effectiveness of FLU (5 mg/kg)  in the TST.,['FLU'],['Zinc  supplementation'],True,FLU,Zinc  supplementation,increases,C0040457,Supernumary teeth,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",FLU,increase
596,7544,32305016,"The results indicated that (1) the average diclofenac and clofibric acid removal efficiency in the 3DE-BAF firstly increased, attained the  peak of 79.40 ± 6.74% and 69.50 ± 6.26% at 0.35 A, and then decreased to 71.82 ± 4.90% and 55.92 ± 5.17% at 0.40 A, respectively; (2) the concentration of the diclofenac and clofibric acid in 3DE-BAF gradually decreased with the increase of reactor height; (3) the current intensity and space position affected the microbial structure at the different level; (4) at the optimum current intensity, Thiothrix, Flavobacteriaceae, Halothiobacillaceae, Hydrogenophaga, and Comamonadaceae accounted for the main bacterial community for removal diclofenac  and clofibric acid in the 3DE-BAF.","['diclofenac', 'clofibric acid', 'diclofenac', 'clofibric acid', 'Halothiobacillaceae', 'clofibric acid']",['increase of reactor height'],True,diclofenac,increase of reactor height,increased,C1839798,Long nose,3033,Diclofenac,Diclofenac,increase
597,7544,32305016,"The results indicated that (1) the average diclofenac and clofibric acid removal efficiency in the 3DE-BAF firstly increased, attained the  peak of 79.40 ± 6.74% and 69.50 ± 6.26% at 0.35 A, and then decreased to 71.82 ± 4.90% and 55.92 ± 5.17% at 0.40 A, respectively; (2) the concentration of the diclofenac and clofibric acid in 3DE-BAF gradually decreased with the increase of reactor height; (3) the current intensity and space position affected the microbial structure at the different level; (4) at the optimum current intensity, Thiothrix, Flavobacteriaceae, Halothiobacillaceae, Hydrogenophaga, and Comamonadaceae accounted for the main bacterial community for removal diclofenac  and clofibric acid in the 3DE-BAF.","['diclofenac', 'clofibric acid', 'diclofenac', 'clofibric acid', 'Halothiobacillaceae', 'clofibric acid']",['increase of reactor height'],True,clofibric acid,increase of reactor height,increased,C1839798,Long nose,2797,Clofibric Acid,Clofibric Acid,increase
598,7544,32305016,"The results indicated that (1) the average diclofenac and clofibric acid removal efficiency in the 3DE-BAF firstly increased, attained the  peak of 79.40 ± 6.74% and 69.50 ± 6.26% at 0.35 A, and then decreased to 71.82 ± 4.90% and 55.92 ± 5.17% at 0.40 A, respectively; (2) the concentration of the diclofenac and clofibric acid in 3DE-BAF gradually decreased with the increase of reactor height; (3) the current intensity and space position affected the microbial structure at the different level; (4) at the optimum current intensity, Thiothrix, Flavobacteriaceae, Halothiobacillaceae, Hydrogenophaga, and Comamonadaceae accounted for the main bacterial community for removal diclofenac  and clofibric acid in the 3DE-BAF.","['diclofenac', 'clofibric acid', 'diclofenac', 'clofibric acid', 'Halothiobacillaceae', 'clofibric acid']",['increase of reactor height'],True,diclofenac,increase of reactor height,increased,C1839798,Long nose,3033,Diclofenac,Diclofenac,increase
599,7544,32305016,"The results indicated that (1) the average diclofenac and clofibric acid removal efficiency in the 3DE-BAF firstly increased, attained the  peak of 79.40 ± 6.74% and 69.50 ± 6.26% at 0.35 A, and then decreased to 71.82 ± 4.90% and 55.92 ± 5.17% at 0.40 A, respectively; (2) the concentration of the diclofenac and clofibric acid in 3DE-BAF gradually decreased with the increase of reactor height; (3) the current intensity and space position affected the microbial structure at the different level; (4) at the optimum current intensity, Thiothrix, Flavobacteriaceae, Halothiobacillaceae, Hydrogenophaga, and Comamonadaceae accounted for the main bacterial community for removal diclofenac  and clofibric acid in the 3DE-BAF.","['diclofenac', 'clofibric acid', 'diclofenac', 'clofibric acid', 'Halothiobacillaceae', 'clofibric acid']",['increase of reactor height'],True,clofibric acid,increase of reactor height,increased,C1839798,Long nose,2797,Clofibric Acid,Clofibric Acid,increase
600,7544,32305016,"The results indicated that (1) the average diclofenac and clofibric acid removal efficiency in the 3DE-BAF firstly increased, attained the  peak of 79.40 ± 6.74% and 69.50 ± 6.26% at 0.35 A, and then decreased to 71.82 ± 4.90% and 55.92 ± 5.17% at 0.40 A, respectively; (2) the concentration of the diclofenac and clofibric acid in 3DE-BAF gradually decreased with the increase of reactor height; (3) the current intensity and space position affected the microbial structure at the different level; (4) at the optimum current intensity, Thiothrix, Flavobacteriaceae, Halothiobacillaceae, Hydrogenophaga, and Comamonadaceae accounted for the main bacterial community for removal diclofenac  and clofibric acid in the 3DE-BAF.","['diclofenac', 'clofibric acid', 'diclofenac', 'clofibric acid', 'Halothiobacillaceae', 'clofibric acid']",['increase of reactor height'],True,Halothiobacillaceae,increase of reactor height,increased,C1839798,Long nose,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Halothiobacillaceae,increase
601,7544,32305016,"The results indicated that (1) the average diclofenac and clofibric acid removal efficiency in the 3DE-BAF firstly increased, attained the  peak of 79.40 ± 6.74% and 69.50 ± 6.26% at 0.35 A, and then decreased to 71.82 ± 4.90% and 55.92 ± 5.17% at 0.40 A, respectively; (2) the concentration of the diclofenac and clofibric acid in 3DE-BAF gradually decreased with the increase of reactor height; (3) the current intensity and space position affected the microbial structure at the different level; (4) at the optimum current intensity, Thiothrix, Flavobacteriaceae, Halothiobacillaceae, Hydrogenophaga, and Comamonadaceae accounted for the main bacterial community for removal diclofenac  and clofibric acid in the 3DE-BAF.","['diclofenac', 'clofibric acid', 'diclofenac', 'clofibric acid', 'Halothiobacillaceae', 'clofibric acid']",['increase of reactor height'],True,clofibric acid,increase of reactor height,increased,C1839798,Long nose,2797,Clofibric Acid,Clofibric Acid,increase
602,7549,32240865,"PCIB significantly reduced the IAA content in 'Commander', while DMTU significantly increased the IAA content in 'Crossfire III' and effectively relieved the inhibition of root elongation.","['PCIB', 'IAA', 'DMTU', 'IAA']",['inhibition of root elongation'],True,DMTU,inhibition of root elongation,increased,C1839798,Long nose,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DMTU,increase
603,7549,32240865,"PCIB significantly reduced the IAA content in 'Commander', while DMTU significantly increased the IAA content in 'Crossfire III' and effectively relieved the inhibition of root elongation.","['PCIB', 'IAA', 'DMTU', 'IAA']",['inhibition of root elongation'],True,IAA,inhibition of root elongation,increased,C1839798,Long nose,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",IAA,increase
604,7554,31710167,"Epidemiological findings have demonstrated that exposure to fluoride induced neurodevelopmental toxicity,  developmental neurotoxicity, and motor disorders.",['fluoride'],['neurodevelopmental toxicity'],True,fluoride,neurodevelopmental toxicity,induced,C4022737,Neurodevelopmental abnormality,28179,fluoride,fluoride,induce
605,7589,29095960,  Prenatal PPARα activation by clofibrate increases subcutaneous fat browning in male C57BL/6J mice fed a high-fat diet during adulthood.,['clofibrate'],['subcutaneous fat browning'],True,clofibrate,subcutaneous fat browning,increases,C1857657,Reduced fat tissue below the skin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",clofibrate,increase
606,7657,35059317," Finally, xenograft OC tumors were generated in nude mice, which were then treated with intraperitoneal DDP or phosphate-buffered saline (PBS) injections to investigate if Gli2 affected DDP resistance in OC in vivo.","['intraperitoneal DDP', 'phosphate-buffered saline']",['tumors'],True,intraperitoneal DDP,tumors,generated,C0022665,Renal neoplasia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",intraperitoneal DDP,generate
607,7657,35059317," Finally, xenograft OC tumors were generated in nude mice, which were then treated with intraperitoneal DDP or phosphate-buffered saline (PBS) injections to investigate if Gli2 affected DDP resistance in OC in vivo.","['intraperitoneal DDP', 'phosphate-buffered saline']",['tumors'],True,phosphate-buffered saline,tumors,generated,C0022665,Renal neoplasia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phosphate-buffered saline,generate
608,7764,34793912,"Meanwhile, five other common pesticides including chlorpyrifos-methyl, prochloraz, chlorfenapyr, chlorpyrifos, and chlorothalonil could significantly inhibit the region-selective hydroxylation of CBZ, and consequently remarkably increased CBZ exposure in vivo.","['chlorpyrifos-methyl', 'prochloraz', 'chlorfenapyr', 'chlorpyrifos', 'chlorothalonil', 'CBZ']",['increased CBZ exposure'],True,chlorpyrifos-methyl,increased CBZ exposure,inhibit,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chlorpyrifos-methyl,inhibit
609,7764,34793912,"Meanwhile, five other common pesticides including chlorpyrifos-methyl, prochloraz, chlorfenapyr, chlorpyrifos, and chlorothalonil could significantly inhibit the region-selective hydroxylation of CBZ, and consequently remarkably increased CBZ exposure in vivo.","['chlorpyrifos-methyl', 'prochloraz', 'chlorfenapyr', 'chlorpyrifos', 'chlorothalonil', 'CBZ']",['increased CBZ exposure'],True,prochloraz,increased CBZ exposure,inhibit,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",prochloraz,inhibit
610,7764,34793912,"Meanwhile, five other common pesticides including chlorpyrifos-methyl, prochloraz, chlorfenapyr, chlorpyrifos, and chlorothalonil could significantly inhibit the region-selective hydroxylation of CBZ, and consequently remarkably increased CBZ exposure in vivo.","['chlorpyrifos-methyl', 'prochloraz', 'chlorfenapyr', 'chlorpyrifos', 'chlorothalonil', 'CBZ']",['increased CBZ exposure'],True,chlorfenapyr,increased CBZ exposure,inhibit,C0302845,Increased mean corpuscular volume,91778,4-bromo-2-(4-chlorophenyl)-1-(ethoxymethyl)-5-(trifluoromethyl)pyrrole-3-carbonitrile,4-bromo-2-(4-chlorophenyl)-1-(ethoxymethyl)-5-(trifluoromethyl)pyrrole-3-carbonitrile,inhibit
611,7764,34793912,"Meanwhile, five other common pesticides including chlorpyrifos-methyl, prochloraz, chlorfenapyr, chlorpyrifos, and chlorothalonil could significantly inhibit the region-selective hydroxylation of CBZ, and consequently remarkably increased CBZ exposure in vivo.","['chlorpyrifos-methyl', 'prochloraz', 'chlorfenapyr', 'chlorpyrifos', 'chlorothalonil', 'CBZ']",['increased CBZ exposure'],True,chlorpyrifos,increased CBZ exposure,inhibit,C0302845,Increased mean corpuscular volume,2730,Chlorpyrifos,Chlorpyrifos,inhibit
612,7764,34793912,"Meanwhile, five other common pesticides including chlorpyrifos-methyl, prochloraz, chlorfenapyr, chlorpyrifos, and chlorothalonil could significantly inhibit the region-selective hydroxylation of CBZ, and consequently remarkably increased CBZ exposure in vivo.","['chlorpyrifos-methyl', 'prochloraz', 'chlorfenapyr', 'chlorpyrifos', 'chlorothalonil', 'CBZ']",['increased CBZ exposure'],True,chlorothalonil,increased CBZ exposure,inhibit,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chlorothalonil,inhibit
613,7764,34793912,"Meanwhile, five other common pesticides including chlorpyrifos-methyl, prochloraz, chlorfenapyr, chlorpyrifos, and chlorothalonil could significantly inhibit the region-selective hydroxylation of CBZ, and consequently remarkably increased CBZ exposure in vivo.","['chlorpyrifos-methyl', 'prochloraz', 'chlorfenapyr', 'chlorpyrifos', 'chlorothalonil', 'CBZ']",['increased CBZ exposure'],True,CBZ,increased CBZ exposure,inhibit,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CBZ,inhibit
614,7809,35242099,"However, compared with aspirin monotherapy, cilostazol was associated with significantly higher rates of headache (RR: 1.77; 95% CI: 1.41-2.20) and dizziness (RR: 1.28; 95% CI: 1.08-1.52).","['aspirin', 'cilostazol']","['higher rates of headache', 'dizziness']",True,aspirin,higher rates of headache,associated,C0018681,Headaches,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aspirin,associate
615,7809,35242099,"However, compared with aspirin monotherapy, cilostazol was associated with significantly higher rates of headache (RR: 1.77; 95% CI: 1.41-2.20) and dizziness (RR: 1.28; 95% CI: 1.08-1.52).","['aspirin', 'cilostazol']","['higher rates of headache', 'dizziness']",True,aspirin,dizziness,associated,C0012833,Dizziness,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aspirin,associate
616,7809,35242099,"However, compared with aspirin monotherapy, cilostazol was associated with significantly higher rates of headache (RR: 1.77; 95% CI: 1.41-2.20) and dizziness (RR: 1.28; 95% CI: 1.08-1.52).","['aspirin', 'cilostazol']","['higher rates of headache', 'dizziness']",True,cilostazol,higher rates of headache,associated,C0018681,Headaches,2754,Cilostazol,Cilostazol,associate
617,7809,35242099,"However, compared with aspirin monotherapy, cilostazol was associated with significantly higher rates of headache (RR: 1.77; 95% CI: 1.41-2.20) and dizziness (RR: 1.28; 95% CI: 1.08-1.52).","['aspirin', 'cilostazol']","['higher rates of headache', 'dizziness']",True,cilostazol,dizziness,associated,C0012833,Dizziness,2754,Cilostazol,Cilostazol,associate
618,7810,35242099,"However, the use of cilostazol monotherapy is associated with several adverse life outcomes such as headaches and dizziness.",['cilostazol'],['dizziness'],True,cilostazol,dizziness,associated,C0012833,Dizziness,2754,Cilostazol,Cilostazol,associate
619,7832,34997200,"PAD causes leg pain, impaired health-related quality of life, immobility, tissue loss and a high risk of major adverse events, including myocardial infarction, stroke, revascularization, amputation and death.",['PAD'],"['leg pain', 'immobility', 'myocardial infarction', 'stroke', 'revascularization', 'amputation', 'death']",True,PAD,leg pain,causes,C0023222,Leg pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PAD,cause
620,7832,34997200,"PAD causes leg pain, impaired health-related quality of life, immobility, tissue loss and a high risk of major adverse events, including myocardial infarction, stroke, revascularization, amputation and death.",['PAD'],"['leg pain', 'immobility', 'myocardial infarction', 'stroke', 'revascularization', 'amputation', 'death']",True,PAD,immobility,causes,C0023222,Leg pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PAD,cause
621,7832,34997200,"PAD causes leg pain, impaired health-related quality of life, immobility, tissue loss and a high risk of major adverse events, including myocardial infarction, stroke, revascularization, amputation and death.",['PAD'],"['leg pain', 'immobility', 'myocardial infarction', 'stroke', 'revascularization', 'amputation', 'death']",True,PAD,myocardial infarction,causes,C0027051,Heart attack,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PAD,cause
622,7832,34997200,"PAD causes leg pain, impaired health-related quality of life, immobility, tissue loss and a high risk of major adverse events, including myocardial infarction, stroke, revascularization, amputation and death.",['PAD'],"['leg pain', 'immobility', 'myocardial infarction', 'stroke', 'revascularization', 'amputation', 'death']",True,PAD,stroke,causes,C0027051,Heart attack,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PAD,cause
623,7832,34997200,"PAD causes leg pain, impaired health-related quality of life, immobility, tissue loss and a high risk of major adverse events, including myocardial infarction, stroke, revascularization, amputation and death.",['PAD'],"['leg pain', 'immobility', 'myocardial infarction', 'stroke', 'revascularization', 'amputation', 'death']",True,PAD,death,causes,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PAD,cause
624,7849,34740185," CONCLUSIONS: APT is associated with improved outcomes in aSAH without an increased risk of bleeding events, particularly in patients who underwent surgical aneurysm repair and those treated with cilostazol.",['cilostazol'],"['aSAH', 'increased risk of bleeding events']",True,cilostazol,aSAH,associated,C0018817,Atrial septum defect,2754,Cilostazol,Cilostazol,associate
625,7946,33948351,"In contrast, Cilostazol inhibited CIIR-induced cell motility, proliferation, and the ability to form tumor spheres.",['Cilostazol'],"['cell motility', 'proliferation']",True,Cilostazol,proliferation,inhibited,C4531170,Abnormal cell proliferation,2754,Cilostazol,Cilostazol,inhibit
626,7976,34478028,"IV milrinone infusion was independently associated with a lower likelihood of 6-month functional disability (adjusted odds ratio [aOR] = 0.28, 95% confidence interval [CI] = 0.10-0.77]) and vasospasm-related brain infarction (aOR = 0.19, 95% CI 0.04-0.94).",['milrinone'],"['vasospasm-related', 'brain infarction']",True,milrinone,vasospasm-related,associated,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",milrinone,associate
627,7976,34478028,"IV milrinone infusion was independently associated with a lower likelihood of 6-month functional disability (adjusted odds ratio [aOR] = 0.28, 95% confidence interval [CI] = 0.10-0.77]) and vasospasm-related brain infarction (aOR = 0.19, 95% CI 0.04-0.94).",['milrinone'],"['vasospasm-related', 'brain infarction']",True,milrinone,brain infarction,associated,C0877326,Bone infarction,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",milrinone,associate
628,7977,34478028,"IV milrinone was associated with a higher incidence of polyuria (IV milrinone patients had creatinine clearance of 191 [153-238] ml/min-1) and hyponatremia or  hypokalemia, whereas arrhythmia, myocardial ischemia, and thrombocytopenia were infrequent.",['milrinone'],"['IV milrinone', 'higher incidence of polyuria', 'creatinine clearance', 'hyponatremia', 'arrhythmia', 'myocardial ischemia', 'thrombocytopenia']",True,milrinone,creatinine clearance,associated,C0853068,Decreased glomerular filtration rate,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",milrinone,associate
629,7977,34478028,"IV milrinone was associated with a higher incidence of polyuria (IV milrinone patients had creatinine clearance of 191 [153-238] ml/min-1) and hyponatremia or  hypokalemia, whereas arrhythmia, myocardial ischemia, and thrombocytopenia were infrequent.",['milrinone'],"['IV milrinone', 'higher incidence of polyuria', 'creatinine clearance', 'hyponatremia', 'arrhythmia', 'myocardial ischemia', 'thrombocytopenia']",True,milrinone,hyponatremia,associated,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",milrinone,associate
630,7977,34478028,"IV milrinone was associated with a higher incidence of polyuria (IV milrinone patients had creatinine clearance of 191 [153-238] ml/min-1) and hyponatremia or  hypokalemia, whereas arrhythmia, myocardial ischemia, and thrombocytopenia were infrequent.",['milrinone'],"['IV milrinone', 'higher incidence of polyuria', 'creatinine clearance', 'hyponatremia', 'arrhythmia', 'myocardial ischemia', 'thrombocytopenia']",True,milrinone,arrhythmia,associated,C0003811,Cardiac arrhythmia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",milrinone,associate
631,7977,34478028,"IV milrinone was associated with a higher incidence of polyuria (IV milrinone patients had creatinine clearance of 191 [153-238] ml/min-1) and hyponatremia or  hypokalemia, whereas arrhythmia, myocardial ischemia, and thrombocytopenia were infrequent.",['milrinone'],"['IV milrinone', 'higher incidence of polyuria', 'creatinine clearance', 'hyponatremia', 'arrhythmia', 'myocardial ischemia', 'thrombocytopenia']",True,milrinone,thrombocytopenia,associated,C0040034,Thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",milrinone,associate
632,7978,34478028," CONCLUSIONS: Despite its premature discontinuation in 29% of patients as a result of its poor tolerance, IV milrinone was associated with a lower rate of endovascular angioplasty and a positive impact on long-term neurological and radiological outcomes.",['IV milrinone'],['premature'],True,IV milrinone,premature,associated,C0151526,Shortened gestation time,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",IV milrinone,associate
633,8070,32504661,"We found that amlexanox significantly inhibited the production of pro-inflammatory mediators, both in vitro and in vivo, while increased interleukin-10 level in LPS-activated macrophages.",['amlexanox'],"['production of pro-inflammatory mediators', 'increased interleukin-10 level']",True,amlexanox,increased interleukin-10 level,inhibited,C4280771,Increased serum interleukin-6,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amlexanox,inhibit
634,8075,32353509,"Milrinone caused myocardial injuries characterized by myocardial degeneration/necrosis, cell infiltration and hemorrhage 24 h after drug administration.",['Milrinone'],"['myocardial injuries', 'myocardial degeneration/necrosis', 'cell infiltration', 'hemorrhage']",True,Milrinone,myocardial degeneration/necrosis,caused,C1442837,Myocardial necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Milrinone,cause
635,8075,32353509,"Milrinone caused myocardial injuries characterized by myocardial degeneration/necrosis, cell infiltration and hemorrhage 24 h after drug administration.",['Milrinone'],"['myocardial injuries', 'myocardial degeneration/necrosis', 'cell infiltration', 'hemorrhage']",True,Milrinone,hemorrhage,caused,C0029163,Oral bleeding,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Milrinone,cause
636,8076,32353509,"Cardiac functional analysis revealed that milrinone dose-dependently increased the maximum upstroke velocity of the left ventricular pressure and heart rate, and decreased the QA interval and systemic blood pressure 1-4 h post-dosing, being associated with pharmacological  action of the drug.",['milrinone'],"['heart rate', 'decreased the QA interval']",True,milrinone,heart rate,increased,C0029163,Oral bleeding,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",milrinone,increase
637,8116,31793373, CONCLUSION: The present study showed that the use of epinephrine and dobutamine was associated with significantly increased in-hospital mortality in patients with septic shock.,['epinephrine'],"['dobutamine', 'mortality', 'septic shock']",True,epinephrine,septic shock,associated,C0036974,Shock,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",epinephrine,associate
638,8121,31503048, CONCLUSIONS: The use of milrinone for induced hypotension led to less intraoperative blood loss and higher urine output than the use of sodium nitroprusside or nitroglycerine in elderly patients undergoing spine surgery.,"['milrinone', 'sodium nitroprusside', 'nitroglycerine']","['induced hypotension', 'less intraoperative blood loss', 'higher urine output']",True,milrinone,induced hypotension,led,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",milrinone,lead
639,8121,31503048, CONCLUSIONS: The use of milrinone for induced hypotension led to less intraoperative blood loss and higher urine output than the use of sodium nitroprusside or nitroglycerine in elderly patients undergoing spine surgery.,"['milrinone', 'sodium nitroprusside', 'nitroglycerine']","['induced hypotension', 'less intraoperative blood loss', 'higher urine output']",True,milrinone,higher urine output,led,C3693260,Abnormal urine output,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",milrinone,lead
640,8121,31503048, CONCLUSIONS: The use of milrinone for induced hypotension led to less intraoperative blood loss and higher urine output than the use of sodium nitroprusside or nitroglycerine in elderly patients undergoing spine surgery.,"['milrinone', 'sodium nitroprusside', 'nitroglycerine']","['induced hypotension', 'less intraoperative blood loss', 'higher urine output']",True,sodium nitroprusside,induced hypotension,led,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium nitroprusside,lead
641,8121,31503048, CONCLUSIONS: The use of milrinone for induced hypotension led to less intraoperative blood loss and higher urine output than the use of sodium nitroprusside or nitroglycerine in elderly patients undergoing spine surgery.,"['milrinone', 'sodium nitroprusside', 'nitroglycerine']","['induced hypotension', 'less intraoperative blood loss', 'higher urine output']",True,sodium nitroprusside,higher urine output,led,C3693260,Abnormal urine output,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium nitroprusside,lead
642,8121,31503048, CONCLUSIONS: The use of milrinone for induced hypotension led to less intraoperative blood loss and higher urine output than the use of sodium nitroprusside or nitroglycerine in elderly patients undergoing spine surgery.,"['milrinone', 'sodium nitroprusside', 'nitroglycerine']","['induced hypotension', 'less intraoperative blood loss', 'higher urine output']",True,nitroglycerine,induced hypotension,led,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",nitroglycerine,lead
643,8121,31503048, CONCLUSIONS: The use of milrinone for induced hypotension led to less intraoperative blood loss and higher urine output than the use of sodium nitroprusside or nitroglycerine in elderly patients undergoing spine surgery.,"['milrinone', 'sodium nitroprusside', 'nitroglycerine']","['induced hypotension', 'less intraoperative blood loss', 'higher urine output']",True,nitroglycerine,higher urine output,led,C3693260,Abnormal urine output,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",nitroglycerine,lead
644,8126,35219730,Ulcerative colitis in male BALB/c mice was induced using Dextran sulphate sodium (3 %w/v) for 3 cycles  with 7 days recovery period in-between.,['Dextran sulphate sodium'],['Ulcerative colitis'],True,Dextran sulphate sodium,Ulcerative colitis,induced,C0009324,Ulcerative colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Dextran sulphate sodium,induce
645,8136,32186196,"Here, we developed a novel model to induce cisplatin nephrotoxicity in adult zebrafish and demonstrated that intraperitoneal injection of cisplatin caused a decline in kidney proximal tubular function based on fluorescein-labeled dextran uptake and  alkaline phosphatase staining.","['cisplatin', 'dextran']","['cisplatin nephrotoxicity', 'decline in kidney proximal tubular function']",True,cisplatin,decline in kidney proximal tubular function,caused,C0009324,Ulcerative colitis,5702198,azane;dichloroplatinum,azane;dichloroplatinum,cause
646,8136,32186196,"Here, we developed a novel model to induce cisplatin nephrotoxicity in adult zebrafish and demonstrated that intraperitoneal injection of cisplatin caused a decline in kidney proximal tubular function based on fluorescein-labeled dextran uptake and  alkaline phosphatase staining.","['cisplatin', 'dextran']","['cisplatin nephrotoxicity', 'decline in kidney proximal tubular function']",True,dextran,decline in kidney proximal tubular function,caused,C0009324,Ulcerative colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dextran,cause
647,8158,29327278,Subcutaneous administration of ethanol in postnatal 4-day-old mice induced an over-activation of caspase-3 and PARP-1 followed by a massive neurodegeneration in the developing cerebellum.,['ethanol'],"['Subcutaneous administration', 'massive neurodegeneration']",True,ethanol,massive neurodegeneration,induced,C0027746,Neurodegeneration,702,Ethanol,Ethanol,induce
648,8164,29051731,We have previously shown that lymphocytes from Alzheimer's disease (AD) patients have increased susceptibility  to hydrogen peroxide (H2O2)-induced death that depends on dementia severity.,['hydrogen peroxide'],['dementia'],True,hydrogen peroxide,death,increased,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydrogen peroxide,increase
649,8164,29051731,We have previously shown that lymphocytes from Alzheimer's disease (AD) patients have increased susceptibility  to hydrogen peroxide (H2O2)-induced death that depends on dementia severity.,['hydrogen peroxide'],['dementia'],True,hydrogen peroxide,dementia,increased,C0497327,"Dementia, progressive",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydrogen peroxide,increase
650,8204,25790525,"  Dönmez M, Uysal B, Poyrazoğlu Y, Öztas YE, Türker T, Kaldirim Ü, Korkmaz A.  BACKGROUND/AIM: Acetaminophen (APAP) overdose results in severe liver damage that may develop into acute liver failure.",['Acetaminophen'],"['severe liver damage', 'acute liver failure']",True,Acetaminophen,acute liver failure,results,C0162557,Acute liver failure,1983,Acetaminophen,Acetaminophen,result
651,8222,25238491," However, its activation in damaged cells can lead to adenosine triphosphate depletion and death.",['adenosine triphosphate depletion'],"['activation in', 'death']",True,adenosine triphosphate depletion,death,lead,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",adenosine triphosphate depletion,lead
652,8223,25111857,"Ex vivo Aβ(1-42) treatment significantly induced oxidative stress and mitochondrial  dysfunction in synaptosomes of the saline group, while synaptosomes of 3-AB and NA groups showed significant decreases in lipid peroxidation, reactive oxygen species production and protein oxidation.",['oxygen'],"['oxidative stress', 'decreases in lipid peroxidation']",True,oxygen,oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,induce
653,8226,24802330,"TNF-α induces caspase-8 activation leading to ROS production, PARP-1 activation, and ADP-ribose production.",['ADP-ribose production'],['ROS production'],True,ADP-ribose production,ROS production,induces,C4476796,Increased reactive oxygen species production,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ADP-ribose production,induce
654,8262,32522601, These findings suggest that both 2% isoflurane and 3% sevoflurane significantly inhibited EBI by suppressing post-SAH apoptosis and brain inflammation possibly via the SphK1-related pathway.,"['isoflurane', 'sevoflurane']",['brain inflammation'],True,isoflurane,brain inflammation,inhibited,C0014038,Encephalitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",isoflurane,inhibit
655,8262,32522601, These findings suggest that both 2% isoflurane and 3% sevoflurane significantly inhibited EBI by suppressing post-SAH apoptosis and brain inflammation possibly via the SphK1-related pathway.,"['isoflurane', 'sevoflurane']",['brain inflammation'],True,sevoflurane,brain inflammation,inhibited,C0014038,Encephalitis,5206,sevoflurane,sevoflurane,inhibit
656,8289,26537220,"Here, we show that in isolated rat chemoreceptor clusters, type I cell depolarization induced by hypoxia, hypercapnia, or high K(+) caused delayed intracellular Ca(2+) elevations (Δ[Ca(2+)]i) in nearby type II cells that were inhibited by the P2Y2R blocker suramin, or by the nucleoside hydrolase apyrase.",['suramin'],"['hypoxia', 'hypercapnia', 'delayed intracellular Ca(2']",True,suramin,hypercapnia,caused,C0020440,Hypercapnia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",suramin,cause
657,8333,34784594, CONCLUSIONS: Treatment of hyperkalaemic metabolic acidosis in transplant patients on tacrolimus with low-dose fludrocortisone resulted in rapid correction of hyperkalaemia and acidosis without significant effects on blood pressure or serum sodium.,"['tacrolimus', 'fludrocortisone', 'sodium']","['hyperkalaemia', 'acidosis']",True,tacrolimus,acidosis,resulted,C0001122,Acidosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tacrolimus,result
658,8333,34784594, CONCLUSIONS: Treatment of hyperkalaemic metabolic acidosis in transplant patients on tacrolimus with low-dose fludrocortisone resulted in rapid correction of hyperkalaemia and acidosis without significant effects on blood pressure or serum sodium.,"['tacrolimus', 'fludrocortisone', 'sodium']","['hyperkalaemia', 'acidosis']",True,fludrocortisone,acidosis,resulted,C0001122,Acidosis,31378,Fludrocortisone,Fludrocortisone,result
659,8333,34784594, CONCLUSIONS: Treatment of hyperkalaemic metabolic acidosis in transplant patients on tacrolimus with low-dose fludrocortisone resulted in rapid correction of hyperkalaemia and acidosis without significant effects on blood pressure or serum sodium.,"['tacrolimus', 'fludrocortisone', 'sodium']","['hyperkalaemia', 'acidosis']",True,sodium,acidosis,resulted,C0001122,Acidosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium,result
660,8343,34660134,  Primary adrenal insufficiency leads to the decreased production of cortisol and aldosterone.,['aldosterone'],"['Primary adrenal insufficiency', 'decreased production of cortisol']",True,aldosterone,decreased production of cortisol,leads,C1836623,Low blood cortisol level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aldosterone,lead
661,8344,34660134,"Correction of hyponatremia, treatment with hydrocortisone and fludrocortisone, and water restriction in the management  of this patient resulted in full clinical recovery.","['hydrocortisone', 'fludrocortisone', 'water']",['hyponatremia'],True,hydrocortisone,hyponatremia,resulted,C0020625,Hyponatremia,5754,hydrocortisone,hydrocortisone,result
662,8344,34660134,"Correction of hyponatremia, treatment with hydrocortisone and fludrocortisone, and water restriction in the management  of this patient resulted in full clinical recovery.","['hydrocortisone', 'fludrocortisone', 'water']",['hyponatremia'],True,fludrocortisone,hyponatremia,resulted,C0020625,Hyponatremia,31378,Fludrocortisone,Fludrocortisone,result
663,8344,34660134,"Correction of hyponatremia, treatment with hydrocortisone and fludrocortisone, and water restriction in the management  of this patient resulted in full clinical recovery.","['hydrocortisone', 'fludrocortisone', 'water']",['hyponatremia'],True,water,hyponatremia,resulted,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,result
664,8346,34645113,"Consequently,fludrocortisone was initiated with a presumptive diagnosis of HH While correction of hyponatremia, fludrocortisone treatment led to hypertension and discontinued in a short time.","['fludrocortisone', 'fludrocortisone']","['hyponatremia', 'hypertension']",True,fludrocortisone,hypertension,led,C0020538,Systemic hypertension,31378,Fludrocortisone,Fludrocortisone,lead
665,8356,34415991,The most common variant (40%) was p.T185I. CONCLUSIONS: Fludrocortisone treatment is associated with a rapid catch-up growth and control of electrolyte imbalances in ASD.,['Fludrocortisone'],['electrolyte imbalances'],True,Fludrocortisone,electrolyte imbalances,associated,C0020538,Systemic hypertension,31378,Fludrocortisone,Fludrocortisone,associate
666,8369,34107482,Incomplete dRTA (idRTA) is defined as impaired urinary acidification that does not lead to overt metabolic acidosis and therefore can be diagnosed if patients fail to adequately  acidify urine after an ammonium chloride (NH4Cl) challenge or furosemide and fludrocortisone test.,"['ammonium chloride', 'furosemide', 'fludrocortisone']","['Incomplete dRTA', 'overt metabolic acidosis']",True,ammonium chloride,overt metabolic acidosis,lead,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ammonium chloride,lead
667,8369,34107482,Incomplete dRTA (idRTA) is defined as impaired urinary acidification that does not lead to overt metabolic acidosis and therefore can be diagnosed if patients fail to adequately  acidify urine after an ammonium chloride (NH4Cl) challenge or furosemide and fludrocortisone test.,"['ammonium chloride', 'furosemide', 'fludrocortisone']","['Incomplete dRTA', 'overt metabolic acidosis']",True,furosemide,overt metabolic acidosis,lead,C0020538,Systemic hypertension,3440,Furosemide,Furosemide,lead
668,8369,34107482,Incomplete dRTA (idRTA) is defined as impaired urinary acidification that does not lead to overt metabolic acidosis and therefore can be diagnosed if patients fail to adequately  acidify urine after an ammonium chloride (NH4Cl) challenge or furosemide and fludrocortisone test.,"['ammonium chloride', 'furosemide', 'fludrocortisone']","['Incomplete dRTA', 'overt metabolic acidosis']",True,fludrocortisone,overt metabolic acidosis,lead,C0020538,Systemic hypertension,31378,Fludrocortisone,Fludrocortisone,lead
669,8388,32734004,"Hyponatremia <120mEq/L or a rapid decline in serum sodium can result in neurological manifestations, ranging  from confusion to coma and seizure.",['sodium'],"['Hyponatremia', 'neurological manifestations', 'coma', 'seizure']",True,sodium,Hyponatremia,result,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium,result
670,8388,32734004,"Hyponatremia <120mEq/L or a rapid decline in serum sodium can result in neurological manifestations, ranging  from confusion to coma and seizure.",['sodium'],"['Hyponatremia', 'neurological manifestations', 'coma', 'seizure']",True,sodium,coma,result,C0009421,Coma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium,result
671,8388,32734004,"Hyponatremia <120mEq/L or a rapid decline in serum sodium can result in neurological manifestations, ranging  from confusion to coma and seizure.",['sodium'],"['Hyponatremia', 'neurological manifestations', 'coma', 'seizure']",True,sodium,seizure,result,C0009421,Coma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium,result
672,8403,33664032,"It is essential to remember that cotrimoxazole, a commonly used antibiotic, can induce a potentially fatal hyperkalaemia especially in patients with known hypoadrenalism.",['cotrimoxazole'],['known hypoadrenalism'],True,cotrimoxazole,known hypoadrenalism,induce,C0001623,Hypoadrenalism,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cotrimoxazole,induce
673,8440,33155789,  Does fludrocortisone treatment cause hypomagnesemia in children with primary adrenal insufficiency?,['fludrocortisone'],"['hypomagnesemia', 'primary adrenal insufficiency']",True,fludrocortisone,hypomagnesemia,cause,C0151723,Low blood Mg levels,31378,Fludrocortisone,Fludrocortisone,cause
674,8440,33155789,  Does fludrocortisone treatment cause hypomagnesemia in children with primary adrenal insufficiency?,['fludrocortisone'],"['hypomagnesemia', 'primary adrenal insufficiency']",True,fludrocortisone,primary adrenal insufficiency,cause,C0001403,Primary adrenocortical failure,31378,Fludrocortisone,Fludrocortisone,cause
675,8441,33155789,"  Author information:  (1)Department of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey (2)Department of Pediatric Endocrinology, Faculty of Medicine, Pamukkale University, Denizli, Turkey (3)Department of Pediatric Endocrinology, Faculty of Medicine, İzmir Kâtip Çelebi University, İzmir, Turkey (4)Department of Pediatric Endocrinology, Faculty of Medicine, Aydın Adnan Menderes University, Aydın, Turkey  Background/aim: Aldosterone is a mineralocorticoid that secreted from adrenal glands and a known factor to increase magnesium excretion by direct and indirect  effects on renal tubular cells.","['Aldosterone', 'magnesium']",['renal tubular cells'],True,magnesium,renal tubular cells,increase,C1858395,Renal tubular cell atrophy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",magnesium,increase
676,8448,33036650,"Although not a problem with aquaporin protein expression or production, gradient washout causes a different type of secondary nephrogenic diabetes insipidus because the absence of a medullary gradient impairs water reabsorption.",['water'],['nephrogenic diabetes insipidus'],True,water,nephrogenic diabetes insipidus,causes,C0162283,Nephrogenic diabetes insipidus,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
677,8458,32994263,"We report here a case of a 46, XY patient with normal male genitalia associated with hypertension not related to fludrocortisone in which genetic study showed that a homozygous mutation in the CYP21A2 also carries the heterozygous missense variant of unclear pathogenicity in the POR gene.",['fludrocortisone'],"['hypertension', 'homozygous mutation in the CYP21A2', 'heterozygous missense variant']",True,fludrocortisone,hypertension,associated,C0020538,Systemic hypertension,31378,Fludrocortisone,Fludrocortisone,associate
678,8458,32994263,"We report here a case of a 46, XY patient with normal male genitalia associated with hypertension not related to fludrocortisone in which genetic study showed that a homozygous mutation in the CYP21A2 also carries the heterozygous missense variant of unclear pathogenicity in the POR gene.",['fludrocortisone'],"['hypertension', 'homozygous mutation in the CYP21A2', 'heterozygous missense variant']",True,fludrocortisone,homozygous mutation in the CYP21A2,associated,C0020538,Systemic hypertension,31378,Fludrocortisone,Fludrocortisone,associate
679,8468,32809961,  Background Aldosterone deficiency (hypoaldosteronism) or aldosterone resistance (pseudohypoaldosteronism) both result in defective aldosterone activity.,['aldosterone'],"['Aldosterone deficiency', 'aldosterone resistance (pseudohypoaldosteronism)']",True,aldosterone,aldosterone resistance (pseudohypoaldosteronism),result,C0033805,Pseudohypoaldosteronism,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aldosterone,result
680,8471,32784048,"In multivariate analysis, the intake of conventional hydrocortisone (HC) instead of synthetic glucocorticoids was independently associated with a higher bone mineral density (BMD) at the hip region in both sexes.",['glucocorticoids'],['higher bone mineral density'],True,hydrocortisone,higher bone mineral density,associated,C4021657,Abnormality of bone mineral density,5754,hydrocortisone,hydrocortisone,associate
681,8471,32784048,"In multivariate analysis, the intake of conventional hydrocortisone (HC) instead of synthetic glucocorticoids was independently associated with a higher bone mineral density (BMD) at the hip region in both sexes.",['glucocorticoids'],['higher bone mineral density'],True,glucocorticoids,higher bone mineral density,associated,C4021657,Abnormality of bone mineral density,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,associate
682,8472,32784048," Interestingly, higher sodium levels were associated with a lower BMD independent  of renin levels and fludrocortisone dosage.",['fludrocortisone'],['higher sodium levels'],True,fludrocortisone,higher sodium levels,associated,C0020488,High blood sodium levels,31378,Fludrocortisone,Fludrocortisone,associate
683,8491,35000806,"However, eplerenone use was associated to lower cardiovascular mortality (HR 0.55; 95% CI 0.35-0.85; p= 0.008) and lower all-cause mortality (HR 0.67; 95% CI 0.47-0.95; p= 0.027).",['eplerenone'],"['lower cardiovascular mortality', 'mortality']",True,eplerenone,lower cardiovascular mortality,associated,C0243050,Cardiac anomaly,443872,Eplerenone,Eplerenone,associate
684,8492,35000806," CONCLUSIONS: In this observational, real-world, propensity-score matched study of patients with HFrEF, eplerenone was associated to lower cardiovascular mortality  and lower all-cause mortality than spironolactone.","['eplerenone', 'spironolactone']","['lower cardiovascular mortality', 'mortality']",True,eplerenone,lower cardiovascular mortality,associated,C0243050,Cardiac anomaly,443872,Eplerenone,Eplerenone,associate
685,8492,35000806," CONCLUSIONS: In this observational, real-world, propensity-score matched study of patients with HFrEF, eplerenone was associated to lower cardiovascular mortality  and lower all-cause mortality than spironolactone.","['eplerenone', 'spironolactone']","['lower cardiovascular mortality', 'mortality']",True,spironolactone,lower cardiovascular mortality,associated,C0243050,Cardiac anomaly,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",spironolactone,associate
686,8532,34386059,Eplerenone could inhibit aldosterone-induced cell proliferation  and collagen deposition.,['Eplerenone'],['cell proliferation'],True,Eplerenone,cell proliferation,inhibit,C4531170,Abnormal cell proliferation,443872,Eplerenone,Eplerenone,inhibit
687,8534,34386059," Conclusions: Aldosterone perfusion can induce proliferation of mouse kidney cells in vivo, and eplerenone can inhibit this change, but aldosterone stimulates HK2 cells and mDCT in vitro without causing their proliferation.","['Aldosterone perfusion', 'eplerenone', 'aldosterone']",['proliferation'],True,Aldosterone perfusion,proliferation,induce,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Aldosterone perfusion,induce
688,8534,34386059," Conclusions: Aldosterone perfusion can induce proliferation of mouse kidney cells in vivo, and eplerenone can inhibit this change, but aldosterone stimulates HK2 cells and mDCT in vitro without causing their proliferation.","['Aldosterone perfusion', 'eplerenone', 'aldosterone']",['proliferation'],True,eplerenone,proliferation,induce,C4531170,Abnormal cell proliferation,443872,Eplerenone,Eplerenone,induce
689,8534,34386059," Conclusions: Aldosterone perfusion can induce proliferation of mouse kidney cells in vivo, and eplerenone can inhibit this change, but aldosterone stimulates HK2 cells and mDCT in vitro without causing their proliferation.","['Aldosterone perfusion', 'eplerenone', 'aldosterone']",['proliferation'],True,aldosterone,proliferation,induce,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aldosterone,induce
690,8538,34351585," RESULTS: While blood pressure and kidney function were similar in the placebo and eplerenone treatment group during the study period, distinct differences in RAAS  regulation occurred: eplerenone treatment resulted in an increase in plasma renin activity, Ang I and aldosterone concentrations, indicating global RAAS activation.","['eplerenone', 'eplerenone', 'aldosterone']","['blood pressure', 'kidney function', 'increase in plasma renin activity']",True,eplerenone,increase in plasma renin activity,resulted,C1845206,Decreased circulating renin level,443872,Eplerenone,Eplerenone,result
691,8544,34325504,  Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor.,['Aldosterone'],['Increasing Intracellular Oxidative Stress'],True,Aldosterone,Increasing Intracellular Oxidative Stress,Inhibits,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Aldosterone,inhibits
692,8547,34325504,"Furthermore, aldosterone significantly increased intracellular reactive oxygen species (ROS) levels in myotubes, and treatment with N-acetyl cysteine, a potent biological thiol antioxidant, reversed the decrease of myotube area, myotube area per myotube, nucleus number per myotube, and fusion index due to aldosterone through decreasing oxidative stress.","['aldosterone', 'oxygen', 'N-acetyl cysteine', 'aldosterone']","['decrease of myotube area', 'myotube area per myotube', 'oxidative stress']",True,aldosterone,oxidative stress,increased,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aldosterone,increase
693,8547,34325504,"Furthermore, aldosterone significantly increased intracellular reactive oxygen species (ROS) levels in myotubes, and treatment with N-acetyl cysteine, a potent biological thiol antioxidant, reversed the decrease of myotube area, myotube area per myotube, nucleus number per myotube, and fusion index due to aldosterone through decreasing oxidative stress.","['aldosterone', 'oxygen', 'N-acetyl cysteine', 'aldosterone']","['decrease of myotube area', 'myotube area per myotube', 'oxidative stress']",True,oxygen,oxidative stress,increased,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,increase
694,8547,34325504,"Furthermore, aldosterone significantly increased intracellular reactive oxygen species (ROS) levels in myotubes, and treatment with N-acetyl cysteine, a potent biological thiol antioxidant, reversed the decrease of myotube area, myotube area per myotube, nucleus number per myotube, and fusion index due to aldosterone through decreasing oxidative stress.","['aldosterone', 'oxygen', 'N-acetyl cysteine', 'aldosterone']","['decrease of myotube area', 'myotube area per myotube', 'oxidative stress']",True,N-acetyl cysteine,oxidative stress,increased,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",N-acetyl cysteine,increase
695,8547,34325504,"Furthermore, aldosterone significantly increased intracellular reactive oxygen species (ROS) levels in myotubes, and treatment with N-acetyl cysteine, a potent biological thiol antioxidant, reversed the decrease of myotube area, myotube area per myotube, nucleus number per myotube, and fusion index due to aldosterone through decreasing oxidative stress.","['aldosterone', 'oxygen', 'N-acetyl cysteine', 'aldosterone']","['decrease of myotube area', 'myotube area per myotube', 'oxidative stress']",True,aldosterone,oxidative stress,increased,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aldosterone,increase
696,8571,34200377,  High levels of aldosterone (Aldo) trigger oxidative stress and vascular dysfunction independent of effects on blood pressure.,['aldosterone'],"['oxidative stress', 'vascular dysfunction']",True,aldosterone,oxidative stress,trigger,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aldosterone,trigger
697,8571,34200377,  High levels of aldosterone (Aldo) trigger oxidative stress and vascular dysfunction independent of effects on blood pressure.,['aldosterone'],"['oxidative stress', 'vascular dysfunction']",True,aldosterone,vascular dysfunction,trigger,C0543968,Congenital stationary cone dysfunction,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aldosterone,trigger
698,8606,33904521,"  OBJECTIVES: In human studies and genetically altered mouse studies, variants in the striatin gene (STRN) are associated with increased blood pressure (BP) and aldosterone on a liberal salt diet.",['aldosterone'],['increased blood pressure'],True,aldosterone,increased blood pressure,associated,C0497247,Increased BP,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aldosterone,associate
699,8612,33893561,"Hyponatremia, but  not hypernatremia was associated with adverse outcome for all outcome endpoints in the placebo group but not in the eplerenone group (interaction p value < 0.05  for all).",['eplerenone'],"['Hyponatremia', 'hypernatremia']",True,eplerenone,hypernatremia,associated,C0020488,High blood sodium levels,443872,Eplerenone,Eplerenone,associate
700,8614,33893561,Development of new-onset hyponatremia following eplerenone initiation did not diminish the beneficial eplerenone treatment effect.,['eplerenone'],['hyponatremia'],True,eplerenone,hyponatremia,diminish,C0020625,Hyponatremia,443872,Eplerenone,Eplerenone,diminish
701,8636,33663739,  BACKGROUND: Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF).,['spironolactone'],"['heart failure', 'preserved ejection fraction', 'lower risk of heart failure hospitalization', 'increased risk of worsening renal function']",True,spironolactone,heart failure,associated,C0018802,Heart failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",spironolactone,associate
702,8636,33663739,  BACKGROUND: Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF).,['spironolactone'],"['heart failure', 'preserved ejection fraction', 'lower risk of heart failure hospitalization', 'increased risk of worsening renal function']",True,spironolactone,preserved ejection fraction,associated,C4022792,Reduced ejection fraction,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",spironolactone,associate
703,8650,33747183,"However, administering a high dose of magnolol did not lead to any improvement in the clinical and pathological features of the psoriasis severity Taken together, these results demonstrated that downregulation of IL-23 may contribute to barrier function improvement in a  psoriatic skin model.",['magnolol'],"['psoriasis', 'downregulation of IL-23']",True,magnolol,psoriasis,lead,C0033860,Psoriasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",magnolol,lead
704,8650,33747183,"However, administering a high dose of magnolol did not lead to any improvement in the clinical and pathological features of the psoriasis severity Taken together, these results demonstrated that downregulation of IL-23 may contribute to barrier function improvement in a  psoriatic skin model.",['magnolol'],"['psoriasis', 'downregulation of IL-23']",True,magnolol,downregulation of IL-23,lead,C0033860,Psoriasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",magnolol,lead
705,8707,17186796,"Of note, pruritus at the application site was diminished in subjects treated with desoximetasone and tacrolimus together compared with tacrolimus alone (P=.04).","['desoximetasone', 'tacrolimus', 'tacrolimus']",['pruritus'],True,desoximetasone,pruritus,diminished,C0033774,Skin itching,5311067,Desoximetasone,Desoximetasone,diminish
706,8707,17186796,"Of note, pruritus at the application site was diminished in subjects treated with desoximetasone and tacrolimus together compared with tacrolimus alone (P=.04).","['desoximetasone', 'tacrolimus', 'tacrolimus']",['pruritus'],True,tacrolimus,pruritus,diminished,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tacrolimus,diminish
707,8707,17186796,"Of note, pruritus at the application site was diminished in subjects treated with desoximetasone and tacrolimus together compared with tacrolimus alone (P=.04).","['desoximetasone', 'tacrolimus', 'tacrolimus']",['pruritus'],True,tacrolimus,pruritus,diminished,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tacrolimus,diminish
708,8712,16298558,"Dexamethasone,  prednisolone, deflazacort and the RU compounds all inhibited OPG production by a  maximum of approximately 70-80%, whereas AL438-F1 and ZK 216348 inhibited OPG production by a maximum of only 40-50% at 1 microM. All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.","['Dexamethasone', 'prednisolone', 'ZK', 'glucocorticoids', 'deflazacort', 'prednisolone']",['poor stimulators of RANKL gene expression'],True,Dexamethasone,poor stimulators of RANKL gene expression,inhibited,C0033774,Skin itching,5743,Dexamethasone,Dexamethasone,inhibit
709,8712,16298558,"Dexamethasone,  prednisolone, deflazacort and the RU compounds all inhibited OPG production by a  maximum of approximately 70-80%, whereas AL438-F1 and ZK 216348 inhibited OPG production by a maximum of only 40-50% at 1 microM. All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.","['Dexamethasone', 'prednisolone', 'ZK', 'glucocorticoids', 'deflazacort', 'prednisolone']",['poor stimulators of RANKL gene expression'],True,prednisolone,poor stimulators of RANKL gene expression,inhibited,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",prednisolone,inhibit
710,8712,16298558,"Dexamethasone,  prednisolone, deflazacort and the RU compounds all inhibited OPG production by a  maximum of approximately 70-80%, whereas AL438-F1 and ZK 216348 inhibited OPG production by a maximum of only 40-50% at 1 microM. All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.","['Dexamethasone', 'prednisolone', 'ZK', 'glucocorticoids', 'deflazacort', 'prednisolone']",['poor stimulators of RANKL gene expression'],True,ZK,poor stimulators of RANKL gene expression,inhibited,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ZK,inhibit
711,8712,16298558,"Dexamethasone,  prednisolone, deflazacort and the RU compounds all inhibited OPG production by a  maximum of approximately 70-80%, whereas AL438-F1 and ZK 216348 inhibited OPG production by a maximum of only 40-50% at 1 microM. All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.","['Dexamethasone', 'prednisolone', 'ZK', 'glucocorticoids', 'deflazacort', 'prednisolone']",['poor stimulators of RANKL gene expression'],True,glucocorticoids,poor stimulators of RANKL gene expression,inhibited,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,inhibit
712,8712,16298558,"Dexamethasone,  prednisolone, deflazacort and the RU compounds all inhibited OPG production by a  maximum of approximately 70-80%, whereas AL438-F1 and ZK 216348 inhibited OPG production by a maximum of only 40-50% at 1 microM. All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.","['Dexamethasone', 'prednisolone', 'ZK', 'glucocorticoids', 'deflazacort', 'prednisolone']",['poor stimulators of RANKL gene expression'],True,deflazacort,poor stimulators of RANKL gene expression,inhibited,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",deflazacort,inhibit
713,8712,16298558,"Dexamethasone,  prednisolone, deflazacort and the RU compounds all inhibited OPG production by a  maximum of approximately 70-80%, whereas AL438-F1 and ZK 216348 inhibited OPG production by a maximum of only 40-50% at 1 microM. All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.","['Dexamethasone', 'prednisolone', 'ZK', 'glucocorticoids', 'deflazacort', 'prednisolone']",['poor stimulators of RANKL gene expression'],True,prednisolone,poor stimulators of RANKL gene expression,inhibited,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",prednisolone,inhibit
714,8712,16298558,"Dexamethasone,  prednisolone, deflazacort and the RU compounds all inhibited OPG production by a  maximum of approximately 70-80%, whereas AL438-F1 and ZK 216348 inhibited OPG production by a maximum of only 40-50% at 1 microM. All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.","['Dexamethasone', 'prednisolone', 'ZK', 'glucocorticoids', 'deflazacort', 'prednisolone']",['poor stimulators of RANKL gene expression'],True,ZK,poor stimulators of RANKL gene expression,inhibited,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ZK,inhibit
715,8712,16298558,"Dexamethasone,  prednisolone, deflazacort and the RU compounds all inhibited OPG production by a  maximum of approximately 70-80%, whereas AL438-F1 and ZK 216348 inhibited OPG production by a maximum of only 40-50% at 1 microM. All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.","['Dexamethasone', 'prednisolone', 'ZK', 'glucocorticoids', 'deflazacort', 'prednisolone']",['poor stimulators of RANKL gene expression'],True,glucocorticoids,poor stimulators of RANKL gene expression,inhibited,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,inhibit
716,8712,16298558,"Dexamethasone,  prednisolone, deflazacort and the RU compounds all inhibited OPG production by a  maximum of approximately 70-80%, whereas AL438-F1 and ZK 216348 inhibited OPG production by a maximum of only 40-50% at 1 microM. All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.","['Dexamethasone', 'prednisolone', 'ZK', 'glucocorticoids', 'deflazacort', 'prednisolone']",['poor stimulators of RANKL gene expression'],True,deflazacort,poor stimulators of RANKL gene expression,inhibited,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",deflazacort,inhibit
717,8712,16298558,"Dexamethasone,  prednisolone, deflazacort and the RU compounds all inhibited OPG production by a  maximum of approximately 70-80%, whereas AL438-F1 and ZK 216348 inhibited OPG production by a maximum of only 40-50% at 1 microM. All of the dissociated glucocorticoids and deflazacort were poor stimulators of RANKL gene expression stimulating by only approximately 1-3-fold compared to 7-fold by prednisolone.","['Dexamethasone', 'prednisolone', 'ZK', 'glucocorticoids', 'deflazacort', 'prednisolone']",['poor stimulators of RANKL gene expression'],True,prednisolone,poor stimulators of RANKL gene expression,inhibited,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",prednisolone,inhibit
718,8717,12499651,"When the reporter plasmid was inoculated into mouse abdominal skin using a gene gun, followed by orally administration of glucocorticoids, RU24858 induced significantly higher reporter enzyme activity than prednisolone.","['glucocorticoids', 'prednisolone']","['abdominal skin', 'higher reporter enzyme activity']",True,glucocorticoids,abdominal skin,induced,C0000737,Stomach pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,induce
719,8717,12499651,"When the reporter plasmid was inoculated into mouse abdominal skin using a gene gun, followed by orally administration of glucocorticoids, RU24858 induced significantly higher reporter enzyme activity than prednisolone.","['glucocorticoids', 'prednisolone']","['abdominal skin', 'higher reporter enzyme activity']",True,prednisolone,abdominal skin,induced,C0000737,Stomach pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",prednisolone,induce
720,8727,9476258,Calcipotriol and desoximetasone also inhibited cell growth in fibroblast cultures whereas proliferation and DNA synthesis were strongly stimulated by 1 ng/ml EGF.,"['Calcipotriol', 'desoximetasone', 'EGF']","['cell growth', 'proliferation', 'DNA synthesis']",True,Calcipotriol,proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Calcipotriol,inhibit
721,8727,9476258,Calcipotriol and desoximetasone also inhibited cell growth in fibroblast cultures whereas proliferation and DNA synthesis were strongly stimulated by 1 ng/ml EGF.,"['Calcipotriol', 'desoximetasone', 'EGF']","['cell growth', 'proliferation', 'DNA synthesis']",True,desoximetasone,proliferation,inhibited,C4531170,Abnormal cell proliferation,5311067,Desoximetasone,Desoximetasone,inhibit
722,8727,9476258,Calcipotriol and desoximetasone also inhibited cell growth in fibroblast cultures whereas proliferation and DNA synthesis were strongly stimulated by 1 ng/ml EGF.,"['Calcipotriol', 'desoximetasone', 'EGF']","['cell growth', 'proliferation', 'DNA synthesis']",True,EGF,proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",EGF,inhibit
723,8743,3527074,  This study was undertaken to determine whether the commonly used treatment of psoriasis with potent topical glucocorticoids results in hypercortisolism and whether metabolic changes might provide a means for monitoring pharmacologic effects of excessive systemic absorption of glucocorticoids.,"['glucocorticoids', 'glucocorticoids']",['psoriasis'],True,glucocorticoids,psoriasis,results,C0033860,Psoriasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,result
724,8743,3527074,  This study was undertaken to determine whether the commonly used treatment of psoriasis with potent topical glucocorticoids results in hypercortisolism and whether metabolic changes might provide a means for monitoring pharmacologic effects of excessive systemic absorption of glucocorticoids.,"['glucocorticoids', 'glucocorticoids']",['psoriasis'],True,glucocorticoids,psoriasis,results,C0033860,Psoriasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,result
725,8759,7047591,We have studied changes in carbohydrate metabolism induced by topical glucocorticoids in a psoriatic patient who had developed Cushing's syndrome from topical desoximetasone (Topicort).,"['glucocorticoids', 'desoximetasone']","[""Cushing's syndrome""]",True,glucocorticoids,Cushing's syndrome,induced,C0010481,Cushing syndrome,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,induce
726,8759,7047591,We have studied changes in carbohydrate metabolism induced by topical glucocorticoids in a psoriatic patient who had developed Cushing's syndrome from topical desoximetasone (Topicort).,"['glucocorticoids', 'desoximetasone']","[""Cushing's syndrome""]",True,desoximetasone,Cushing's syndrome,induced,C0010481,Cushing syndrome,5311067,Desoximetasone,Desoximetasone,induce
727,8760,7047591,"The  results indicated that (1) fasting hyperglycemia and increased insulin-glucose ratios could be induced within 24 hours of administration of topical glucocorticoids, (2) insulin resistance accompanied abnormal carbohydrate tolerance, and (3) fluctuations in circulating leukocytes paralleled the changes  in carbohydrate metabolism.",['glucocorticoids'],"['hyperglycemia', 'increased insulin-glucose ratios', 'insulin resistance']",True,glucocorticoids,hyperglycemia,induced,C0020456,High blood sugar,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,induce
728,8760,7047591,"The  results indicated that (1) fasting hyperglycemia and increased insulin-glucose ratios could be induced within 24 hours of administration of topical glucocorticoids, (2) insulin resistance accompanied abnormal carbohydrate tolerance, and (3) fluctuations in circulating leukocytes paralleled the changes  in carbohydrate metabolism.",['glucocorticoids'],"['hyperglycemia', 'increased insulin-glucose ratios', 'insulin resistance']",True,glucocorticoids,insulin resistance,induced,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,induce
729,8773,35307019, RESULTS: Both hair cortisol and cortisone levels were negatively associated with  CD4 count but not with HIV viral load.,['cortisone'],['Both hair cortisol'],True,cortisone,Both hair cortisol,associated,C0021655,Insulin resistance,222786,Cortisone,Cortisone,associate
730,8815,34811866,"  BACKGROUND: Long-term glucocorticoids (HairGC) measured in scalp hair have been associated with body mass index (BMI), waist circumference (WC), and waist-hip-ratio (WHR) in several cross-sectional studies.",['glucocorticoids'],"['body mass index', 'waist circumference', 'waist-hip-ratio']",True,glucocorticoids,waist-hip-ratio,associated,C4703554,Increased waist to hip ratio,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,associate
731,8846,34509065,Job stress was associated with increased cortisol and cortisone.,['cortisone'],['increased cortisol'],True,cortisone,increased cortisol,associated,C4025651,Hypercortisolism,222786,Cortisone,Cortisone,associate
732,8855,34464733,"Inhibition of 11β-HSD by glycyrrhetinic acid metabolites, bioactive components of licorice, causes sodium retention and potassium loss, with hypertension characterized by low renin and aldosterone.",['aldosterone'],"['sodium retention and potassium loss', 'hypertension']",True,aldosterone,hypertension,causes,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aldosterone,cause
733,8898,35277389,"Multivariate logistic regression analyses in the ARD group revealed that older age (OR=0.98, 95% CI 0.96 to 1.0, p=0.024), vasculitis diagnosis (OR=0.24, 95% CI 0.11 to 0.53, p<0.001), prednisone ≥5 mg/day (OR=0.46, 95% CI 0.27 to 0.77, p=0.003), MMF (OR=0.30, 95% CI 0.15 to 0.61, p<0.001) and biologics (OR=0.27, 95% CI 0.16 to 0.46, p<0.001) were associated with reduced anti-S1/S2 IgG positivity.",['prednisone ≥5'],['vasculitis diagnosis'],True,prednisone,vasculitis diagnosis,associated,C0020538,Systemic hypertension,5865,Prednisone,Prednisone,associate
734,8917,35243137, eCollection 2022 Mar.  Multiple evanescent white dot syndrome-like reaction associated with ipilimumab and nivolumab immune checkpoint inhibitor therapy for metastasis of choroidal melanoma.,"['ipilimumab', 'nivolumab']",['metastasis of choroidal melanoma'],True,ipilimumab,metastasis of choroidal melanoma,associated,C0346388,Choroidal melanoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ipilimumab,associate
735,8917,35243137, eCollection 2022 Mar.  Multiple evanescent white dot syndrome-like reaction associated with ipilimumab and nivolumab immune checkpoint inhibitor therapy for metastasis of choroidal melanoma.,"['ipilimumab', 'nivolumab']",['metastasis of choroidal melanoma'],True,nivolumab,metastasis of choroidal melanoma,associated,C0346388,Choroidal melanoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",nivolumab,associate
736,8938,35225034,Whether treatment with glucocorticoids caused reactivation of coccidioidomycosis is discussed in this case series.,['glucocorticoids'],['reactivation of coccidioidomycosis'],True,glucocorticoids,reactivation of coccidioidomycosis,caused,C0009186,Coccidioidomycosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucocorticoids,cause
737,9010,28856166,The addition of canagliflozin daily resulted in ketoacidosis and hospitalization within 1 week.,['canagliflozin'],['ketoacidosis'],True,canagliflozin,ketoacidosis,resulted,C0220982,Ketoacidosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",canagliflozin,result
738,9022,33411427,"Use of triptans, NSAIDs, antiemetics, dihydroergotamine, CGRP antagonists, and lasmiditan is associated with improved pain and function.","['dihydroergotamine', 'lasmiditan']",['pain'],True,lasmiditan,pain,associated,C0030193,Pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lasmiditan,associate
739,9032,31009120,"The Mg2+ and memantine concentrations achieved after systemic administration may not effectively inhibit activation of the trigeminocervical complex, perhaps providing an explanation for the relatively poor efficacy of these NMDA receptor open-channel blockers for headache treatment in clinical studies.",['memantine'],"['activation of the trigeminocervical complex', 'headache']",True,memantine,headache,inhibit,C0018681,Headaches,4054,"3,5-dimethyladamantan-1-amine","3,5-dimethyladamantan-1-amine",inhibit
740,9073,23992516," Among persons with less than 10 headache days per month, frequency of NSAID use was associated with dose-dependent reductions in risk of CM onset.",['NSAID'],"['headache', 'reductions in risk of CM']",True,NSAID,headache,associated,C0018681,Headaches,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",NSAID,associate
741,9077,23877022,"Moreover, lamotrigine led to complete remission of his headache without homonymous hemianopsia.",['lamotrigine'],['headache'],True,lamotrigine,headache,led,C0018681,Headaches,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lamotrigine,lead
742,9085,22306360,"The 2 cases of dyspnea, induced by 2.5mg and 7.5mg of zolmitriptan, respectively, were associated with cardiovascular symptoms and were left untreated.",['zolmitriptan'],['dyspnea'],True,zolmitriptan,dyspnea,associated,C0013404,Dyspnea,60857,"(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one","(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one",associate
743,9129,33287162,"Over four weeks, in this population of patients with  Clozapine induced constipation, Prucalopride 2 mg significantly improved the bowel movement and it was safe.","['Clozapine', 'Prucalopride 2 mg']",['constipation'],True,Clozapine,constipation,induced,C0009806,Constipation,135398737,Clozapine,Clozapine,induce
744,9129,33287162,"Over four weeks, in this population of patients with  Clozapine induced constipation, Prucalopride 2 mg significantly improved the bowel movement and it was safe.","['Clozapine', 'Prucalopride 2 mg']",['constipation'],True,Prucalopride 2 mg,constipation,induced,C0009806,Constipation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Prucalopride 2 mg,induce
745,9131,33080085,"  BACKGROUND AND AIM: Prucalopride, a high-affinity 5-hydroxytryptamine 4 receptor  agonist, promotes esophageal peristalsis, while phosphodiesterase type 5 inhibitor sildenafil inhibits esophageal peristalsis.",['sildenafil'],"['esophageal peristalsis', 'phosphodiesterase']",True,sildenafil,phosphodiesterase,inhibits,C0009806,Constipation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sildenafil,inhibit
746,9210,26805884,"  Oxaliplatin, a chemotherapeutic drug for colorectal cancer, induces severe peripheral neuropathy.",['Oxaliplatin'],"['cancer', 'severe peripheral neuropathy']",True,Oxaliplatin,cancer,induces,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Oxaliplatin,induce
747,9210,26805884,"  Oxaliplatin, a chemotherapeutic drug for colorectal cancer, induces severe peripheral neuropathy.",['Oxaliplatin'],"['cancer', 'severe peripheral neuropathy']",True,Oxaliplatin,severe peripheral neuropathy,induces,C0031117,Peripheral nerve damage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Oxaliplatin,induce
748,9218,25481535,"  BACKGROUND: Oxaliplatin, an important chemotherapy drug for advanced colorectal cancer, often induces peripheral neuropathy, especially cold allodynia.",['Oxaliplatin'],"['peripheral neuropathy', 'allodynia']",True,Oxaliplatin,peripheral neuropathy,induces,C0031117,Peripheral nerve damage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Oxaliplatin,induce
749,9218,25481535,"  BACKGROUND: Oxaliplatin, an important chemotherapy drug for advanced colorectal cancer, often induces peripheral neuropathy, especially cold allodynia.",['Oxaliplatin'],"['peripheral neuropathy', 'allodynia']",True,Oxaliplatin,allodynia,induces,C0458247,Allodynia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Oxaliplatin,induce
750,9239,16288851,"Ketamine (3-40 mg/kg) produced ataxia, stereotypes and diminished exploratory activity in mice, and reduced prepulse inhibition of acoustic startle response, lowered accuracy in fixed consecutive number and in delayed non-matching-to-sample tasks in rats.",['Ketamine'],"['ataxia', 'diminished exploratory activity', 'reduced prepulse inhibition of acoustic startle response', 'lowered accuracy', 'delayed non-matching-to-sample tasks']",True,Ketamine,ataxia,produced,C0007758,Cerebellar ataxia,3821,Ketamine,Ketamine,produce
751,9280,9928884,"The chemotherapeutic agent, cisplatin, caused a dose-dependent increase in the number of animals exhibiting vomiting and retching behaviours with ED50 values of 6.43+/-1 and 7.9+/-1.2 mg/kg, respectively.",['cisplatin'],"['vomiting', 'retching behaviours']",True,cisplatin,vomiting,caused,C0042963,Throwing up,5702198,azane;dichloroplatinum,azane;dichloroplatinum,cause
752,9280,9928884,"The chemotherapeutic agent, cisplatin, caused a dose-dependent increase in the number of animals exhibiting vomiting and retching behaviours with ED50 values of 6.43+/-1 and 7.9+/-1.2 mg/kg, respectively.",['cisplatin'],"['vomiting', 'retching behaviours']",True,cisplatin,retching behaviours,caused,C0033774,Skin itching,5702198,azane;dichloroplatinum,azane;dichloroplatinum,cause
753,9283,9928884,"As with other established experimental animal emesis models,  the present data indicate that cisplatin causes emesis by activating 5-HT3 receptors indirectly via release of 5-HT.",['cisplatin'],['emesis'],True,cisplatin,emesis,causes,C0042963,Throwing up,5702198,azane;dichloroplatinum,azane;dichloroplatinum,cause
754,9288,9838105,"  Author information:  (1)Department of Anatomy SL49, Tulane University School of Medicine/Medical Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA.pfranke@mailhost.tcs.tulane.edu  Previous studies from this laboratory have demonstrated that acute administration of morphine induces the immediate-early genes (IEGs) c-Fos and JunB in the rat caudate putamen (CPu).",['morphine'],['acute administration'],True,morphine,acute administration,induces,C0042963,Throwing up,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",morphine,induce
755,9318,7503254,"In control animals, pretreatment with naltrexone increased the hemorrhage was initiated volume required to achieve hypotension in hypoxic but not normoxic conditions.",['naltrexone'],"['hemorrhage', 'hypotension in hypoxic']",True,naltrexone,hemorrhage,increased,C0029163,Oral bleeding,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",naltrexone,increase
756,9318,7503254,"In control animals, pretreatment with naltrexone increased the hemorrhage was initiated volume required to achieve hypotension in hypoxic but not normoxic conditions.",['naltrexone'],"['hemorrhage', 'hypotension in hypoxic']",True,naltrexone,hypotension in hypoxic,increased,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",naltrexone,increase
757,9338,7796848,Our  results show that cisplatin treatment resulted in a dramatic loss of CGRP neurons in the dorsal horn of the spinal cord and a corresponding increase in the animals' threshold for pain.,['cisplatin'],"['spinal cord', 'pain']",True,cisplatin,spinal cord,resulted,C0266510,Absent spinal cord,5702198,azane;dichloroplatinum,azane;dichloroplatinum,result
758,9338,7796848,Our  results show that cisplatin treatment resulted in a dramatic loss of CGRP neurons in the dorsal horn of the spinal cord and a corresponding increase in the animals' threshold for pain.,['cisplatin'],"['spinal cord', 'pain']",True,cisplatin,pain,resulted,C0030193,Pain,5702198,azane;dichloroplatinum,azane;dichloroplatinum,result
759,9344,7965707,"  The phenylisopropylamine hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) produced dose-related increases in plasma concentrations of prolactin, adrenocorticotropic hormone (ACTH) and corticosterone but not growth hormone in rats.",['adrenocorticotropic hormone'],"['prolactin', 'corticosterone']",True,adrenocorticotropic hormone,prolactin,produced,C0033375,Pituitary prolactin cell adenoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",adrenocorticotropic hormone,produce
760,9385,35000482, A recent pharmacoepidemiology study reported that ondansetron may be associated with an increased risk for acute kidney injury (AKI).,['ondansetron'],['increased risk for acute kidney injury'],True,ondansetron,increased risk for acute kidney injury,associated,C2609414,Acute kidney injury,4595,Ondansetron,Ondansetron,associate
761,9386,35000482,"Ondansetron was associated with a 5.48% decrease (CI -6.17--4.79) in death within 90 days of ICU-admission, which was independent of AKI status; an effect not seen with other anti-emetics.",['Ondansetron'],['death'],True,Ondansetron,death,associated,C1546180,Age of death,4595,Ondansetron,Ondansetron,associate
762,9395,34954302,"[3H]GR65630 binding also increased in the ipsilateral entopeduncular nucleus and thalamus of 6-OHDA-lesioned rats with severe AIMs (75  % and 88 %, P < 0.05).",['6-OHDA-lesioned'],['thalamus'],True,6-OHDA-lesioned,thalamus,increased,C4021243,Abnormality of thalamus morphology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",6-OHDA-lesioned,increase
763,9399,34907523,"Standard general anaesthesia is induced and 30 min before emergence 0.2 μg/kg total body weight sufentanil IV, 1 g of paracetamol IV and 4 mg of ondansetron IV (post-operative nausea and vomiting, PONV, prophylaxis) will be administered.","['sufentanil', 'paracetamol', 'ondansetron']","['vomiting', 'PONV']",True,sufentanil,vomiting,induced,C0042963,Throwing up,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sufentanil,induce
764,9399,34907523,"Standard general anaesthesia is induced and 30 min before emergence 0.2 μg/kg total body weight sufentanil IV, 1 g of paracetamol IV and 4 mg of ondansetron IV (post-operative nausea and vomiting, PONV, prophylaxis) will be administered.","['sufentanil', 'paracetamol', 'ondansetron']","['vomiting', 'PONV']",True,paracetamol,vomiting,induced,C0042963,Throwing up,1983,Acetaminophen,Acetaminophen,induce
765,9399,34907523,"Standard general anaesthesia is induced and 30 min before emergence 0.2 μg/kg total body weight sufentanil IV, 1 g of paracetamol IV and 4 mg of ondansetron IV (post-operative nausea and vomiting, PONV, prophylaxis) will be administered.","['sufentanil', 'paracetamol', 'ondansetron']","['vomiting', 'PONV']",True,ondansetron,vomiting,induced,C0042963,Throwing up,4595,Ondansetron,Ondansetron,induce
766,9405,34836765,"Also, ondansetron is associated with a lower incidence of hypotension necessitating vasopressor treatment, and nausea and vomiting with no effects on the incidence of bradycardia.",['ondansetron'],"['lower incidence of hypotension', 'nausea', 'vomiting']",True,ondansetron,nausea,associated,C0027497,Nausea,4595,Ondansetron,Ondansetron,associate
767,9405,34836765,"Also, ondansetron is associated with a lower incidence of hypotension necessitating vasopressor treatment, and nausea and vomiting with no effects on the incidence of bradycardia.",['ondansetron'],"['lower incidence of hypotension', 'nausea', 'vomiting']",True,ondansetron,vomiting,associated,C0042963,Throwing up,4595,Ondansetron,Ondansetron,associate
768,9427,34758763, CONCLUSION: Oral administration of a single dose of ondansetron in children with  AGE did not cause high-risk QTc prolongation or fatal arrhythmia.,['ondansetron'],['arrhythmia'],True,ondansetron,arrhythmia,cause,C0003811,Cardiac arrhythmia,4595,Ondansetron,Ondansetron,cause
769,9434,34678470,"  Systemic administration of morphine increases serotonin (5-HT) in the spinal dorsal horn (SDH), which attenuates the analgesic effects of morphine on neuropathic pain through spinal 5-HT3 receptors.","['morphine', 'serotonin', 'morphine']",['neuropathic pain'],True,morphine,neuropathic pain,increases,C0003892,Charcot arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",morphine,increase
770,9434,34678470,"  Systemic administration of morphine increases serotonin (5-HT) in the spinal dorsal horn (SDH), which attenuates the analgesic effects of morphine on neuropathic pain through spinal 5-HT3 receptors.","['morphine', 'serotonin', 'morphine']",['neuropathic pain'],True,serotonin,neuropathic pain,increases,C0003892,Charcot arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,increase
771,9434,34678470,"  Systemic administration of morphine increases serotonin (5-HT) in the spinal dorsal horn (SDH), which attenuates the analgesic effects of morphine on neuropathic pain through spinal 5-HT3 receptors.","['morphine', 'serotonin', 'morphine']",['neuropathic pain'],True,morphine,neuropathic pain,increases,C0003892,Charcot arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",morphine,increase
772,9464,34423897,  SLCO1B1 *15 allele is associated with methotrexate-induced nausea in pediatric patients with inflammatory bowel disease.,['methotrexate-induced'],['inflammatory bowel disease'],True,methotrexate-induced,inflammatory bowel disease,associated,C0021390,Inflammatory bowel disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methotrexate-induced,associate
773,9477,34389195," CONCLUSION: Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge.",['ondansetron'],"['gastroenteritis', 'reduction in index ED', 'vomiting', 'diarrhea']",True,ondansetron,gastroenteritis,associated,C3808828,Recurrent gastroenteritis,4595,Ondansetron,Ondansetron,associate
774,9477,34389195," CONCLUSION: Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge.",['ondansetron'],"['gastroenteritis', 'reduction in index ED', 'vomiting', 'diarrhea']",True,ondansetron,vomiting,associated,C0042963,Throwing up,4595,Ondansetron,Ondansetron,associate
775,9477,34389195," CONCLUSION: Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge.",['ondansetron'],"['gastroenteritis', 'reduction in index ED', 'vomiting', 'diarrhea']",True,ondansetron,diarrhea,associated,C0011991,Diarrhoea,4595,Ondansetron,Ondansetron,associate
776,9481,34318567,These results suggested that CDDP administration generated some state of stress in goats via the similar physiological mechanisms as emesis-caused stress in emetic species.,['CDDP'],['stress'],True,CDDP,stress,generated,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CDDP,generate
777,9537,33467149,We propose that the modulatory effect of lorcaserin on the 'affective' aspects of nicotine cessation may be linked to the positive changes caused by the compound in hippocampal neurogenesis during nicotine withdrawal.,"['lorcaserin', 'nicotine']",['hippocampal neurogenesis'],True,lorcaserin,hippocampal neurogenesis,linked,C4476591,Dysgenesis of the hippocampus,11658860,Lorcaserin,Lorcaserin,link
778,9537,33467149,We propose that the modulatory effect of lorcaserin on the 'affective' aspects of nicotine cessation may be linked to the positive changes caused by the compound in hippocampal neurogenesis during nicotine withdrawal.,"['lorcaserin', 'nicotine']",['hippocampal neurogenesis'],True,nicotine,hippocampal neurogenesis,linked,C4476591,Dysgenesis of the hippocampus,89594,Nicotine,Nicotine,link
779,9576,32222404," Further evidence supporting a role of the 5-HT2C receptor as an important regulator of impulsive-compulsive behaviours, the selective antagonist SB-242084  produced the opposing effects to lorcaserin, i.e promoting both impulsive and compulsive behaviours.",['lorcaserin'],['promoting both impulsive and compulsive behaviours'],True,lorcaserin,promoting both impulsive and compulsive behaviours,produced,C0021125,Impulsive,11658860,Lorcaserin,Lorcaserin,produce
780,9591,31987863,"administration, intrathecal (i.t.) administration of lorcaserin alone induced antinociceptive TFR behavior, an effect that was not prevented by the opioid receptor antagonist naloxone.","['lorcaserin', 'naloxone']",['TFR behavior'],True,lorcaserin,TFR behavior,induced,C0424323,Violent behavior,11658860,Lorcaserin,Lorcaserin,induce
781,9591,31987863,"administration, intrathecal (i.t.) administration of lorcaserin alone induced antinociceptive TFR behavior, an effect that was not prevented by the opioid receptor antagonist naloxone.","['lorcaserin', 'naloxone']",['TFR behavior'],True,naloxone,TFR behavior,induced,C0424323,Violent behavior,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",naloxone,induce
782,9594,31880085,"Researchers have speculated that risperidone induces obesity by modulating central signals; however, the precise central mechanisms involved remain to be fully elucidated.",['risperidone'],['obesity'],True,risperidone,obesity,induces,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",risperidone,induce
783,9603,31774584,  RATIONALE: Impulsive aggressive behavior is associated with reduced central function of serotonin (5-HT).,['serotonin'],"['Impulsive aggressive behavior', 'reduced central function']",True,serotonin,Impulsive aggressive behavior,associated,C0001807,Aggression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,associate
784,9603,31774584,  RATIONALE: Impulsive aggressive behavior is associated with reduced central function of serotonin (5-HT).,['serotonin'],"['Impulsive aggressive behavior', 'reduced central function']",True,serotonin,reduced central function,associated,C1849242,Abnormality of B cell physiology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,associate
785,9642,31019729, Results: This analysis shows that lorcaserin was associated with improved weight  loss relative to placebo regardless of age.,['lorcaserin'],['improved weight  loss'],True,lorcaserin,improved weight  loss,associated,C1849242,Abnormality of B cell physiology,11658860,Lorcaserin,Lorcaserin,associate
786,9658,34989857,"The susceptibility of Gram-negative bacteria to aminoglycoside antibiotics, particularly gentamicin, has previously been linked to both the production of ROS and the rate of antibiotic uptake that is mediated by the PMF, although the relative contributions of ROS and PMF to aminoglycoside toxicity has remained poorly understood.","['aminoglycoside', 'gentamicin', 'aminoglycoside']",['production of ROS'],True,aminoglycoside,production of ROS,linked,C4476796,Increased reactive oxygen species production,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aminoglycoside,link
787,9658,34989857,"The susceptibility of Gram-negative bacteria to aminoglycoside antibiotics, particularly gentamicin, has previously been linked to both the production of ROS and the rate of antibiotic uptake that is mediated by the PMF, although the relative contributions of ROS and PMF to aminoglycoside toxicity has remained poorly understood.","['aminoglycoside', 'gentamicin', 'aminoglycoside']",['production of ROS'],True,gentamicin,production of ROS,linked,C4476796,Increased reactive oxygen species production,3467,Gentamicin,Gentamicin,link
788,9658,34989857,"The susceptibility of Gram-negative bacteria to aminoglycoside antibiotics, particularly gentamicin, has previously been linked to both the production of ROS and the rate of antibiotic uptake that is mediated by the PMF, although the relative contributions of ROS and PMF to aminoglycoside toxicity has remained poorly understood.","['aminoglycoside', 'gentamicin', 'aminoglycoside']",['production of ROS'],True,aminoglycoside,production of ROS,linked,C4476796,Increased reactive oxygen species production,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aminoglycoside,link
789,9672,34236558,"These effects resulted in a rise in swelling and a decrease in the content, the potential, and mitochondrial respiration in 3 and 2,4-dinitrophenol-uncoupled states.","['2,4-dinitrophenol-']","['rise in swelling', 'decrease in the content']",True,"2,4-dinitrophenol-",rise in swelling,resulted,C0239598,Swollen finger,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","2,4-dinitrophenol-",result
790,9720,32078021,"The main symptoms associated with 2,4-DNP intoxication, including hyperthermia, tachycardia, decreased blood pressure, and acute renal failure, motivated a worldwide warning, issued by the Interpol Anti-Doping Unit in 2015, reinforcing its hazard.","['2,4-DNP']","['tachycardia', 'decreased blood pressure', 'acute renal failure']",True,"2,4-DNP",tachycardia,associated,C0039231,Heart racing,1493,"2,4-dinitrophenol","2,4-dinitrophenol",associate
791,9757,29225323,"Mancozeb also induces  a premalignant status in mouse granulosa cells (GCs) cultured in vitro, as indicated by decreased p53 expression and tenuous oxidative stress.",['Mancozeb'],"['decreased p53 expression', 'oxidative stress']",True,Mancozeb,decreased p53 expression,induces,C1862474,Decreased facial expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Mancozeb,induce
792,9757,29225323,"Mancozeb also induces  a premalignant status in mouse granulosa cells (GCs) cultured in vitro, as indicated by decreased p53 expression and tenuous oxidative stress.",['Mancozeb'],"['decreased p53 expression', 'oxidative stress']",True,Mancozeb,oxidative stress,induces,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Mancozeb,induce
793,9759,29225323,"In conclusion, mancozeb induced dose-dependent toxicity against GCs in vitro, including ultrastructural signs of cell degeneration compatible with apoptosis, likely due to the toxic breakdown product ethylenethiourea.","['mancozeb', 'ethylenethiourea']","['cell degeneration', 'apoptosis']",True,mancozeb,cell degeneration,induced,C0151514,Atrophic skin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mancozeb,induce
794,9759,29225323,"In conclusion, mancozeb induced dose-dependent toxicity against GCs in vitro, including ultrastructural signs of cell degeneration compatible with apoptosis, likely due to the toxic breakdown product ethylenethiourea.","['mancozeb', 'ethylenethiourea']","['cell degeneration', 'apoptosis']",True,ethylenethiourea,cell degeneration,induced,C0151514,Atrophic skin,2723650,imidazolidine-2-thione,imidazolidine-2-thione,induce
795,9763,26714745,"  AIMS: We recently reported the death-inducing activity of a small-molecule compound, C1, which triggered reactive oxygen species (ROS)-dependent autophagy-associated apoptosis in a variety of human cancer cell lines.",['oxygen'],"['apoptosis', 'cancer']",True,oxygen,cancer,triggered,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,trigger
796,9782,24502213,The mineralization of ETU in the absence of hydrogen peroxide has led to the conclusion that ETU transformation products are susceptible to photolysis by UV light.,"['ETU', 'hydrogen peroxide', 'photolysis']",['mineralization of'],True,ETU,mineralization of,led,C1857074,Absent sternal ossification,2723650,imidazolidine-2-thione,imidazolidine-2-thione,lead
797,9782,24502213,The mineralization of ETU in the absence of hydrogen peroxide has led to the conclusion that ETU transformation products are susceptible to photolysis by UV light.,"['ETU', 'hydrogen peroxide', 'photolysis']",['mineralization of'],True,hydrogen peroxide,mineralization of,led,C1857074,Absent sternal ossification,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydrogen peroxide,lead
798,9782,24502213,The mineralization of ETU in the absence of hydrogen peroxide has led to the conclusion that ETU transformation products are susceptible to photolysis by UV light.,"['ETU', 'hydrogen peroxide', 'photolysis']",['mineralization of'],True,photolysis,mineralization of,led,C1857074,Absent sternal ossification,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",photolysis,lead
799,9786,23207758, CONCLUSION: The fetal exposure to ethylenethiourea caused hepatic damage characterized by severe extramedullary hematopoiesis.,['ethylenethiourea'],"['hepatic damage', 'extramedullary hematopoiesis']",True,ethylenethiourea,extramedullary hematopoiesis,caused,C2613439,Extramedullary hematopoiesis,2723650,imidazolidine-2-thione,imidazolidine-2-thione,cause
800,9803,33494474,"EVOO phenols induced vasodilation of mesenteric arteries in a dose-dependent manner, and this effect was reduced by pre-incubation with Paxillin, Verapamil, Ryanodine, 2-APB, U73122, and Pertussis  Toxin.","['Verapamil', 'Ryanodine', 'Pertussis']","['vasodilation of mesenteric arteries', 'Paxillin']",True,Verapamil,vasodilation of mesenteric arteries,induced,C4476552,Dilatation of mesenteric artery,2520,VERAPAMIL,VERAPAMIL,induce
801,9803,33494474,"EVOO phenols induced vasodilation of mesenteric arteries in a dose-dependent manner, and this effect was reduced by pre-incubation with Paxillin, Verapamil, Ryanodine, 2-APB, U73122, and Pertussis  Toxin.","['Verapamil', 'Ryanodine', 'Pertussis']","['vasodilation of mesenteric arteries', 'Paxillin']",True,Ryanodine,vasodilation of mesenteric arteries,induced,C4476552,Dilatation of mesenteric artery,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Ryanodine,induce
802,9803,33494474,"EVOO phenols induced vasodilation of mesenteric arteries in a dose-dependent manner, and this effect was reduced by pre-incubation with Paxillin, Verapamil, Ryanodine, 2-APB, U73122, and Pertussis  Toxin.","['Verapamil', 'Ryanodine', 'Pertussis']","['vasodilation of mesenteric arteries', 'Paxillin']",True,Pertussis,vasodilation of mesenteric arteries,induced,C4476552,Dilatation of mesenteric artery,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Pertussis,induce
803,9813,25066613,Primary afferent nerve stimulation (300 nM capsaicin) caused a venular dilatation by releasing calcitonin gene-related peptide.,"['capsaicin', 'calcitonin']","['Primary afferent nerve stimulation', 'venular dilatation']",True,capsaicin,venular dilatation,caused,C3278923,Dilated ventricles,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",capsaicin,cause
804,9813,25066613,Primary afferent nerve stimulation (300 nM capsaicin) caused a venular dilatation by releasing calcitonin gene-related peptide.,"['capsaicin', 'calcitonin']","['Primary afferent nerve stimulation', 'venular dilatation']",True,calcitonin,venular dilatation,caused,C3278923,Dilated ventricles,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcitonin,cause
805,9921,33772077,"In GSHee-pretreated rats, fentanyl elicited a more prolonged analgesia, relatively minor changes in ABG chemistry and Alveolar-arterial gradient, and a substantially milder depression of ventilation.",['fentanyl'],['depression'],True,fentanyl,depression,elicited,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fentanyl,elicit
806,9955,22733624,Cytotoxicity of wedelolactone was partially inhibited by N-acetylcysteine and glutathione ethyl ester in breast cancer MDA-MB-231 and MDA-MB-468 cells while the inhibitory effect of catalase was observed only in the former cell line.,"['wedelolactone', 'N-acetylcysteine', 'glutathione', 'catalase']",['breast cancer'],True,wedelolactone,breast cancer,inhibited,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",wedelolactone,inhibit
807,9955,22733624,Cytotoxicity of wedelolactone was partially inhibited by N-acetylcysteine and glutathione ethyl ester in breast cancer MDA-MB-231 and MDA-MB-468 cells while the inhibitory effect of catalase was observed only in the former cell line.,"['wedelolactone', 'N-acetylcysteine', 'glutathione', 'catalase']",['breast cancer'],True,N-acetylcysteine,breast cancer,inhibited,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",N-acetylcysteine,inhibit
808,9955,22733624,Cytotoxicity of wedelolactone was partially inhibited by N-acetylcysteine and glutathione ethyl ester in breast cancer MDA-MB-231 and MDA-MB-468 cells while the inhibitory effect of catalase was observed only in the former cell line.,"['wedelolactone', 'N-acetylcysteine', 'glutathione', 'catalase']",['breast cancer'],True,glutathione,breast cancer,inhibited,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione,inhibit
809,9955,22733624,Cytotoxicity of wedelolactone was partially inhibited by N-acetylcysteine and glutathione ethyl ester in breast cancer MDA-MB-231 and MDA-MB-468 cells while the inhibitory effect of catalase was observed only in the former cell line.,"['wedelolactone', 'N-acetylcysteine', 'glutathione', 'catalase']",['breast cancer'],True,catalase,breast cancer,inhibited,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",catalase,inhibit
810,9959,21810555,"Fonofos exposure was associated with a monotonic increase in prostate cancer risk among men with CT/TT genotypes for rs1983132 [odds ratios (95% confidence intervals) for low and high use compared with no use were 1.65 (0.91, 3.01) and 3.25 (1.78, 5.92), respectively], whereas  fonofos was not associated with prostate cancer risk among men with the CC genotype.",['Fonofos'],"['increase in prostate cancer', 'prostate cancer']",True,Fonofos,increase in prostate cancer,associated,C0376358,Prostatic cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Fonofos,associate
811,9959,21810555,"Fonofos exposure was associated with a monotonic increase in prostate cancer risk among men with CT/TT genotypes for rs1983132 [odds ratios (95% confidence intervals) for low and high use compared with no use were 1.65 (0.91, 3.01) and 3.25 (1.78, 5.92), respectively], whereas  fonofos was not associated with prostate cancer risk among men with the CC genotype.",['Fonofos'],"['increase in prostate cancer', 'prostate cancer']",True,Fonofos,prostate cancer,associated,C0376358,Prostatic cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Fonofos,associate
812,9973,20194814, CONCLUSIONS: Our results demonstrate that gliotoxin and patulin increase the allergic immune response in mice by modulating the Th1/Th2 balance via direct effects on IL-12 secretion in DCs and by inducing oxidative stress.,"['gliotoxin', 'patulin']","['IL-12 secretion', 'oxidative stress']",True,gliotoxin,oxidative stress,increase,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",gliotoxin,increase
813,9973,20194814, CONCLUSIONS: Our results demonstrate that gliotoxin and patulin increase the allergic immune response in mice by modulating the Th1/Th2 balance via direct effects on IL-12 secretion in DCs and by inducing oxidative stress.,"['gliotoxin', 'patulin']","['IL-12 secretion', 'oxidative stress']",True,patulin,oxidative stress,increase,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",patulin,increase
814,10005,17804861,These results indicate that low concentrations of domoic acid cause apoptotic neuronal cell death mediated by oxidative stress.,['domoic acid'],"['apoptotic neuronal cell death', 'oxidative stress']",True,domoic acid,oxidative stress,cause,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",domoic acid,cause
815,10102,35150295,[Epub ahead of print]  Anhidrosis associated with long-term use of hydroxyurea in a patient with myeloproliferative neoplasm.,['hydroxyurea'],['myeloproliferative neoplasm'],True,hydroxyurea,myeloproliferative neoplasm,associated,C0027022,Myeloproliferative disorder,3657,hydroxyurea,hydroxyurea,associate
816,10105,35142007,"After adjustment for covariates and additional SCD severity markers in multivariate analyses, hydroxyurea use during conception and pregnancy, but not during conception only, was associated with an increase in the odds ratio (OR) of miscarriage or stillbirth (OR 2.21, 95% confidence interval [CI] 1.40-3.47).",['hydroxyurea'],"['miscarriage', 'stillbirth']",True,hydroxyurea,miscarriage,associated,C0000786,Miscarriage,3657,hydroxyurea,hydroxyurea,associate
817,10105,35142007,"After adjustment for covariates and additional SCD severity markers in multivariate analyses, hydroxyurea use during conception and pregnancy, but not during conception only, was associated with an increase in the odds ratio (OR) of miscarriage or stillbirth (OR 2.21, 95% confidence interval [CI] 1.40-3.47).",['hydroxyurea'],"['miscarriage', 'stillbirth']",True,hydroxyurea,stillbirth,associated,C0595939,Stillborn,3657,hydroxyurea,hydroxyurea,associate
818,10131,35018106,"In previous cases, a number of chemotherapeutic agents such as azathioprine, bleomycin sulfate, cyclophosphamide, hydroxyurea and methotrexate were usually linked to melanonychia.","['azathioprine', 'bleomycin sulfate', 'cyclophosphamide', 'hydroxyurea', 'methotrexate']",['melanonychia'],True,azathioprine,melanonychia,linked,C1142305,Melanonychia,2265,Azathioprine,Azathioprine,link
819,10131,35018106,"In previous cases, a number of chemotherapeutic agents such as azathioprine, bleomycin sulfate, cyclophosphamide, hydroxyurea and methotrexate were usually linked to melanonychia.","['azathioprine', 'bleomycin sulfate', 'cyclophosphamide', 'hydroxyurea', 'methotrexate']",['melanonychia'],True,bleomycin sulfate,melanonychia,linked,C1142305,Melanonychia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bleomycin sulfate,link
820,10131,35018106,"In previous cases, a number of chemotherapeutic agents such as azathioprine, bleomycin sulfate, cyclophosphamide, hydroxyurea and methotrexate were usually linked to melanonychia.","['azathioprine', 'bleomycin sulfate', 'cyclophosphamide', 'hydroxyurea', 'methotrexate']",['melanonychia'],True,cyclophosphamide,melanonychia,linked,C1142305,Melanonychia,2907,Cyclophosphamide,Cyclophosphamide,link
821,10131,35018106,"In previous cases, a number of chemotherapeutic agents such as azathioprine, bleomycin sulfate, cyclophosphamide, hydroxyurea and methotrexate were usually linked to melanonychia.","['azathioprine', 'bleomycin sulfate', 'cyclophosphamide', 'hydroxyurea', 'methotrexate']",['melanonychia'],True,hydroxyurea,melanonychia,linked,C1142305,Melanonychia,3657,hydroxyurea,hydroxyurea,link
822,10131,35018106,"In previous cases, a number of chemotherapeutic agents such as azathioprine, bleomycin sulfate, cyclophosphamide, hydroxyurea and methotrexate were usually linked to melanonychia.","['azathioprine', 'bleomycin sulfate', 'cyclophosphamide', 'hydroxyurea', 'methotrexate']",['melanonychia'],True,methotrexate,melanonychia,linked,C1142305,Melanonychia,126941,Methotrexate,Methotrexate,link
823,10158,34961963,The latter case was associated with chronic hydroxyurea therapy for an underlying myeloproliferative disorder.,['hydroxyurea'],['myeloproliferative disorder'],True,hydroxyurea,myeloproliferative disorder,associated,C0027022,Myeloproliferative disorder,3657,hydroxyurea,hydroxyurea,associate
824,10207,35241544,"Multivariate analysis revealed that low GNRI (p=0.014), hypothyroidism (model 1 p=0.021, model 2 p=0.013), and advanced age (p=0.026) were independently associated with the discontinuation of lenvatinib.",['lenvatinib'],"['GNRI', 'hypothyroidism']",True,lenvatinib,hypothyroidism,associated,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lenvatinib,associate
825,10212,35239781,"Oral roflumilast causes gastrointestinal side effects, especially vomiting, which could be reduced by administering roflumilast via off-label routes.","['roflumilast', 'roflumilast']",['gastrointestinal side effects'],True,roflumilast,gastrointestinal side effects,causes,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",roflumilast,cause
826,10212,35239781,"Oral roflumilast causes gastrointestinal side effects, especially vomiting, which could be reduced by administering roflumilast via off-label routes.","['roflumilast', 'roflumilast']",['gastrointestinal side effects'],True,roflumilast,gastrointestinal side effects,causes,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",roflumilast,cause
827,10235,35191376,"  Low doses of the organic insecticide spinosad trigger lysosomal defects, elevated ROS, lipid dysregulation, and neurodegeneration in flies.",['spinosad'],"['lysosomal defects', 'elevated ROS,', 'lipid dysregulation', 'neurodegeneration']",True,spinosad,neurodegeneration,trigger,C0027746,Neurodegeneration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",spinosad,trigger
828,10275,23453071,"We found that 2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chloroph enyl) pyridine-3-carboxamide (BRN-250) significantly inhibited human umbilical vascular endothelial cells (HUVECs) proliferation, migration, tube formation, and microvessel growth in a concentration range of 10-100 nM. Furthermore, BRN-250 inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.","['2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chloroph enyl', 'VEGF']","['proliferation', 'microvessel growth', 'activation of its downstream AKT pathway']",True,2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chloroph,proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chloroph,inhibit
829,10306,33956338,"Lamotrigine, levetiracetam and fenfluramine are associated with improvements in some cognitive domains, although it is unclear whether these effects are directly attributable to the medications or are a result of improvements in seizures.","['Lamotrigine', 'levetiracetam', 'fenfluramine']",['seizures'],True,Lamotrigine,seizures,associated,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Lamotrigine,associate
830,10306,33956338,"Lamotrigine, levetiracetam and fenfluramine are associated with improvements in some cognitive domains, although it is unclear whether these effects are directly attributable to the medications or are a result of improvements in seizures.","['Lamotrigine', 'levetiracetam', 'fenfluramine']",['seizures'],True,levetiracetam,seizures,associated,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",levetiracetam,associate
831,10306,33956338,"Lamotrigine, levetiracetam and fenfluramine are associated with improvements in some cognitive domains, although it is unclear whether these effects are directly attributable to the medications or are a result of improvements in seizures.","['Lamotrigine', 'levetiracetam', 'fenfluramine']",['seizures'],True,fenfluramine,seizures,associated,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fenfluramine,associate
832,10348,32190378,"Sodium valproate causes a time-dependent, drug-induced proximal myopathy.",['Sodium valproate'],['proximal myopathy'],True,Sodium valproate,proximal myopathy,causes,C0026848,Myopathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Sodium valproate,cause
833,10353,32048251," RESULTS: After 3 days of treatment, VGB in doses up to 500 mg/kg increased PTZ-induced seizure threshold, whereas after 7 days VGB (at the dose of 125 mg/kg) inhibited clonic seizures in experimental mice.","['VGB', 'VGB']",['clonic seizures'],True,VGB,clonic seizures,inhibited,C0270846,drop seizures,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",VGB,inhibit
834,10353,32048251," RESULTS: After 3 days of treatment, VGB in doses up to 500 mg/kg increased PTZ-induced seizure threshold, whereas after 7 days VGB (at the dose of 125 mg/kg) inhibited clonic seizures in experimental mice.","['VGB', 'VGB']",['clonic seizures'],True,VGB,clonic seizures,inhibited,C0270846,drop seizures,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",VGB,inhibit
835,10360,31797451,"Neuropathic pain was induced by  administration of vincristine (50 µg/kg, i.p.) for 10 days in rats.",['vincristine'],['Neuropathic pain'],True,vincristine,Neuropathic pain,induced,C0003892,Charcot arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",vincristine,induce
836,10381,31440726,"In contrast, compounds  targeting either GABA receptors (clobazam, clonazepam, phenobarbital) or GABA-uptake proteins (tiagabine) produced dose-dependent efficacy against convulsive seizures.","['clobazam', 'clonazepam', 'phenobarbital', 'tiagabine']",['convulsive seizures'],True,clobazam,convulsive seizures,produced,C0877017,Generalized tonic-clonic seizures with focal onset,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",clobazam,produce
837,10381,31440726,"In contrast, compounds  targeting either GABA receptors (clobazam, clonazepam, phenobarbital) or GABA-uptake proteins (tiagabine) produced dose-dependent efficacy against convulsive seizures.","['clobazam', 'clonazepam', 'phenobarbital', 'tiagabine']",['convulsive seizures'],True,clonazepam,convulsive seizures,produced,C0877017,Generalized tonic-clonic seizures with focal onset,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",clonazepam,produce
838,10381,31440726,"In contrast, compounds  targeting either GABA receptors (clobazam, clonazepam, phenobarbital) or GABA-uptake proteins (tiagabine) produced dose-dependent efficacy against convulsive seizures.","['clobazam', 'clonazepam', 'phenobarbital', 'tiagabine']",['convulsive seizures'],True,phenobarbital,convulsive seizures,produced,C0877017,Generalized tonic-clonic seizures with focal onset,4763,Phenobarbital,Phenobarbital,produce
839,10381,31440726,"In contrast, compounds  targeting either GABA receptors (clobazam, clonazepam, phenobarbital) or GABA-uptake proteins (tiagabine) produced dose-dependent efficacy against convulsive seizures.","['clobazam', 'clonazepam', 'phenobarbital', 'tiagabine']",['convulsive seizures'],True,tiagabine,convulsive seizures,produced,C0877017,Generalized tonic-clonic seizures with focal onset,60648,"(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid","(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid",produce
840,10382,31386986,"Accordingly, ethosuximide increases remission occurrence in children with childhood absence epilepsy in comparison to valproic  acid.","['ethosuximide', 'valproic']",['childhood absence'],True,ethosuximide,childhood absence,increases,C0877017,Generalized tonic-clonic seizures with focal onset,3291,"3-ethyl-3-methylpyrrolidine-2,5-dione","3-ethyl-3-methylpyrrolidine-2,5-dione",increase
841,10382,31386986,"Accordingly, ethosuximide increases remission occurrence in children with childhood absence epilepsy in comparison to valproic  acid.","['ethosuximide', 'valproic']",['childhood absence'],True,valproic,childhood absence,increases,C0877017,Generalized tonic-clonic seizures with focal onset,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",valproic,increase
842,10403,30862509,"  Developmental exposure to organophosphates (OPs), at doses that do not cause cholinergic crisis, induces profound and lasting alterations in different neurotransmitter systems, which contribute to several behavioral outcomes.",['organophosphates'],['cholinergic crisis'],True,organophosphates,cholinergic crisis,induces,C0877017,Generalized tonic-clonic seizures with focal onset,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",organophosphates,induce
843,10508,16332129,"In darkness, NaSA alone or in combination  with atrazine caused plant death, whereas atrazine alone had little effect.","['atrazine', 'atrazine']",['plant death'],True,atrazine,plant death,caused,C1546180,Age of death,2256,"6-chloro-4-N-ethyl-2-N-propan-2-yl-1,3,5-triazine-2,4-diamine","6-chloro-4-N-ethyl-2-N-propan-2-yl-1,3,5-triazine-2,4-diamine",cause
844,10508,16332129,"In darkness, NaSA alone or in combination  with atrazine caused plant death, whereas atrazine alone had little effect.","['atrazine', 'atrazine']",['plant death'],True,atrazine,plant death,caused,C1546180,Age of death,2256,"6-chloro-4-N-ethyl-2-N-propan-2-yl-1,3,5-triazine-2,4-diamine","6-chloro-4-N-ethyl-2-N-propan-2-yl-1,3,5-triazine-2,4-diamine",cause
845,10521,35292896,"In conclusion, lead, mercury and arsenic were associated with ALT elevation in adults, and the associations were mainly observed in women.","['mercury', 'arsenic']",['ALT elevation'],True,mercury,ALT elevation,associated,C0151905,Elevated serum ALT,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mercury,associate
846,10521,35292896,"In conclusion, lead, mercury and arsenic were associated with ALT elevation in adults, and the associations were mainly observed in women.","['mercury', 'arsenic']",['ALT elevation'],True,arsenic,ALT elevation,associated,C0151905,Elevated serum ALT,5359596,arsenic,arsenic,associate
847,10554,33991841,"Compared to the lowest quartile, the highest quartile of daily excretion of all urinary arsenic metabolites was associated with lower BMI, waist circumference, and obesity except for dimethylarsinic acid in unadjusted and adjusted analyses.",['dimethylarsinic acid'],['obesity'],True,dimethylarsinic acid,obesity,associated,C0028754,Obesity,2513,dimethylarsinic acid,dimethylarsinic acid,associate
848,10557,33916749,"Each 10% increase in the proportion of urinary dimethylarsinic acid (DMA%)  was associated with an odds ratio (OR) of 0.59 (95% confidence interval (CI): 0.28-1.26) for prediabetes, 0.46 (0.22-0.94) for diabetes, and 0.51 (0.26-0.99) for prediabetes and diabetes combined.",['dimethylarsinic acid'],['diabetes'],True,dimethylarsinic acid,diabetes,associated,C0085207,Maternal diabetes,2513,dimethylarsinic acid,dimethylarsinic acid,associate
849,10595,33434570," Our results showed that inorganic arsenic-both As2O3 and Na2HAsO4 significantly induced the expression of Nrf2 protein and mRNA, enhanced the transcription activity of Nrf2, and induced the expression of downstream target genes.","['As2O3', 'Na2HAsO4']","['expression of Nrf2 protein', 'induced the expression of downstream target genes']",True,As2O3,expression of Nrf2 protein,induced,C4022653,Abnormal muscle fiber protein expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",As2O3,induce
850,10595,33434570," Our results showed that inorganic arsenic-both As2O3 and Na2HAsO4 significantly induced the expression of Nrf2 protein and mRNA, enhanced the transcription activity of Nrf2, and induced the expression of downstream target genes.","['As2O3', 'Na2HAsO4']","['expression of Nrf2 protein', 'induced the expression of downstream target genes']",True,Na2HAsO4,expression of Nrf2 protein,induced,C4022653,Abnormal muscle fiber protein expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Na2HAsO4,induce
851,10620,32890875,"Dimethylarsinic acid (DMAV) is a methylated metabolite of arsenicals found in most mammals, and long-term exposure to DMAV can lead to bladder cancer  in rats.","['Dimethylarsinic acid', 'DMAV', 'DMAV']",['bladder cancer'],True,Dimethylarsinic acid,bladder cancer,lead,C0006826,Cancer,2513,dimethylarsinic acid,dimethylarsinic acid,lead
852,10620,32890875,"Dimethylarsinic acid (DMAV) is a methylated metabolite of arsenicals found in most mammals, and long-term exposure to DMAV can lead to bladder cancer  in rats.","['Dimethylarsinic acid', 'DMAV', 'DMAV']",['bladder cancer'],True,DMAV,bladder cancer,lead,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DMAV,lead
853,10620,32890875,"Dimethylarsinic acid (DMAV) is a methylated metabolite of arsenicals found in most mammals, and long-term exposure to DMAV can lead to bladder cancer  in rats.","['Dimethylarsinic acid', 'DMAV', 'DMAV']",['bladder cancer'],True,DMAV,bladder cancer,lead,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DMAV,lead
854,10623,32871521,"Moreover, the CF treatment increased As translocation from roots to shoots by reducing soil available sulfur and phytochelatins (PCs) biosynthesis and vacuolar sequestration in rice roots compared with the IF treatment.",['phytochelatins'],['vacuolar sequestration'],True,phytochelatins,vacuolar sequestration,increased,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phytochelatins,increase
855,10627,32816635,"Primaphos, fenitrothion, malathion and deltamethrin pesticides were associated with a blood pressure increase.","['Primaphos', 'fenitrothion', 'malathion', 'deltamethrin']",['blood pressure increase'],True,fenitrothion,blood pressure increase,associated,C0497247,Increased BP,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fenitrothion,associate
856,10627,32816635,"Primaphos, fenitrothion, malathion and deltamethrin pesticides were associated with a blood pressure increase.","['Primaphos', 'fenitrothion', 'malathion', 'deltamethrin']",['blood pressure increase'],True,malathion,blood pressure increase,associated,C0497247,Increased BP,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",malathion,associate
857,10627,32816635,"Primaphos, fenitrothion, malathion and deltamethrin pesticides were associated with a blood pressure increase.","['Primaphos', 'fenitrothion', 'malathion', 'deltamethrin']",['blood pressure increase'],True,deltamethrin,blood pressure increase,associated,C0497247,Increased BP,40585,Deltamethrin,Deltamethrin,associate
858,10628,32816635," Environmental contamination by tetrachlorodibenzo-p-dioxin was associated with CVD with risk of 1.09 to 2.78 and organochlorine, 1.19 to 4.54; heavy metals, arsenic, trimethylarsine and dimethylarsinic acid with atherosclerosis and systemic arterial hypertension.","['arsenic, trimethylarsine', 'dimethylarsinic acid']","['CVD', 'atherosclerosis', 'systemic arterial hypertension']",True,"arsenic, trimethylarsine",atherosclerosis,associated,C0004153,Narrowing and hardening of arteries,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","arsenic, trimethylarsine",associate
859,10628,32816635," Environmental contamination by tetrachlorodibenzo-p-dioxin was associated with CVD with risk of 1.09 to 2.78 and organochlorine, 1.19 to 4.54; heavy metals, arsenic, trimethylarsine and dimethylarsinic acid with atherosclerosis and systemic arterial hypertension.","['arsenic, trimethylarsine', 'dimethylarsinic acid']","['CVD', 'atherosclerosis', 'systemic arterial hypertension']",True,"arsenic, trimethylarsine",systemic arterial hypertension,associated,C0004153,Narrowing and hardening of arteries,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","arsenic, trimethylarsine",associate
860,10628,32816635," Environmental contamination by tetrachlorodibenzo-p-dioxin was associated with CVD with risk of 1.09 to 2.78 and organochlorine, 1.19 to 4.54; heavy metals, arsenic, trimethylarsine and dimethylarsinic acid with atherosclerosis and systemic arterial hypertension.","['arsenic, trimethylarsine', 'dimethylarsinic acid']","['CVD', 'atherosclerosis', 'systemic arterial hypertension']",True,dimethylarsinic acid,atherosclerosis,associated,C0004153,Narrowing and hardening of arteries,2513,dimethylarsinic acid,dimethylarsinic acid,associate
861,10628,32816635," Environmental contamination by tetrachlorodibenzo-p-dioxin was associated with CVD with risk of 1.09 to 2.78 and organochlorine, 1.19 to 4.54; heavy metals, arsenic, trimethylarsine and dimethylarsinic acid with atherosclerosis and systemic arterial hypertension.","['arsenic, trimethylarsine', 'dimethylarsinic acid']","['CVD', 'atherosclerosis', 'systemic arterial hypertension']",True,dimethylarsinic acid,systemic arterial hypertension,associated,C0004153,Narrowing and hardening of arteries,2513,dimethylarsinic acid,dimethylarsinic acid,associate
862,10677,9420527,"Miscarriage was not associated with chemical activities overall but was increased in combination with reported use of thiocarbamates, carbaryl, and unclassified pesticides on the farm.","['thiocarbamates', 'carbaryl']",['Miscarriage'],True,thiocarbamates,Miscarriage,associated,C0000786,Miscarriage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiocarbamates,associate
863,10677,9420527,"Miscarriage was not associated with chemical activities overall but was increased in combination with reported use of thiocarbamates, carbaryl, and unclassified pesticides on the farm.","['thiocarbamates', 'carbaryl']",['Miscarriage'],True,carbaryl,Miscarriage,associated,C0000786,Miscarriage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carbaryl,associate
864,10788,3952729,"A single, dermal dose of DEF or TOCP also caused an initial decrease in plasma BuChE activity with maximum depression of enzymatic activity observed 1 to 7 days after administration.","['DEF', 'TOCP']","['decrease in plasma BuChE activity', 'depression']",True,DEF,decrease in plasma BuChE activity,caused,C1845206,Decreased circulating renin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DEF,cause
865,10788,3952729,"A single, dermal dose of DEF or TOCP also caused an initial decrease in plasma BuChE activity with maximum depression of enzymatic activity observed 1 to 7 days after administration.","['DEF', 'TOCP']","['decrease in plasma BuChE activity', 'depression']",True,DEF,depression,caused,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DEF,cause
866,10788,3952729,"A single, dermal dose of DEF or TOCP also caused an initial decrease in plasma BuChE activity with maximum depression of enzymatic activity observed 1 to 7 days after administration.","['DEF', 'TOCP']","['decrease in plasma BuChE activity', 'depression']",True,TOCP,decrease in plasma BuChE activity,caused,C1845206,Decreased circulating renin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TOCP,cause
867,10788,3952729,"A single, dermal dose of DEF or TOCP also caused an initial decrease in plasma BuChE activity with maximum depression of enzymatic activity observed 1 to 7 days after administration.","['DEF', 'TOCP']","['decrease in plasma BuChE activity', 'depression']",True,TOCP,depression,caused,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TOCP,cause
868,10790,3952729,"While parathion produced acute cholinergic  effects, it did not cause delayed neurotoxicity.",['parathion'],"['acute cholinergic  effects', 'delayed neurotoxicity']",True,parathion,acute cholinergic  effects,produced,C0011581,Depression,991,diethoxy-(4-nitrophenoxy)-sulfanylidene-lambda5-phosphane,diethoxy-(4-nitrophenoxy)-sulfanylidene-lambda5-phosphane,produce
869,10790,3952729,"While parathion produced acute cholinergic  effects, it did not cause delayed neurotoxicity.",['parathion'],"['acute cholinergic  effects', 'delayed neurotoxicity']",True,parathion,acute cholinergic  effects,cause,C0011581,Depression,991,diethoxy-(4-nitrophenoxy)-sulfanylidene-lambda5-phosphane,diethoxy-(4-nitrophenoxy)-sulfanylidene-lambda5-phosphane,cause
870,10805,7077681,In CD-1 mice neither TOCP nor cyanophenphos induced any of the usually recognized clinical symptoms of neuropathy when administered daily by gavage at 262 or 31.25 mg/kg .,['TOCP'],['neuropathy'],True,TOCP,neuropathy,induced,C0442874,Neuropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TOCP,induce
871,10845,30457871,"In particular, applied to punctured leaves of host and nonhost plants, the three new compounds and lentisone caused severe necrosis, with lentiquinone A being the most active among the new metabolites.","['lentisone', 'lentiquinone']",['severe necrosis'],True,lentiquinone,necrosis,caused,C0151798,Hepatic necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lentiquinone,cause
872,10904,27086176,"Hypertension caused an increase in the levels of endocannabinoids [anandamide (AEA), 2-arachidonoyl-glycerol (2-AG) and N-arachidonoyl-dopamine (NADA)] and CB1 receptor and the activities of FAAH and monoacylglycerol lipase (MAGL).","['2-arachidonoyl-glycerol', 'N-arachidonoyl-dopamine']","['Hypertension', 'increase in the levels of endocannabinoids [anandamide (AEA)']",True,2-arachidonoyl-glycerol,Hypertension,caused,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-arachidonoyl-glycerol,cause
873,10904,27086176,"Hypertension caused an increase in the levels of endocannabinoids [anandamide (AEA), 2-arachidonoyl-glycerol (2-AG) and N-arachidonoyl-dopamine (NADA)] and CB1 receptor and the activities of FAAH and monoacylglycerol lipase (MAGL).","['2-arachidonoyl-glycerol', 'N-arachidonoyl-dopamine']","['Hypertension', 'increase in the levels of endocannabinoids [anandamide (AEA)']",True,N-arachidonoyl-dopamine,Hypertension,caused,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",N-arachidonoyl-dopamine,cause
874,11033,34700294,"In addition, naproxen administration resulted in a significant increase in mean corpuscular volume (MCV) and had a preventive effect on the reduction of systolic blood pressure in  COVID-19 patients.",['naproxen'],"['increase in mean corpuscular volume', 'reduction of systolic blood pressure']",True,naproxen,increase in mean corpuscular volume,resulted,C0302845,Increased mean corpuscular volume,156391,naproxen,naproxen,result
875,11033,34700294,"In addition, naproxen administration resulted in a significant increase in mean corpuscular volume (MCV) and had a preventive effect on the reduction of systolic blood pressure in  COVID-19 patients.",['naproxen'],"['increase in mean corpuscular volume', 'reduction of systolic blood pressure']",True,naproxen,reduction of systolic blood pressure,resulted,C0277885,Decreased systolic blood pressure,156391,naproxen,naproxen,result
876,11057,34626216,"Colitis was induced by  injection of 2,4,6-trinitrobenzene sulfonic acid (TNBS) into the large intestine.","['2,4,6-trinitrobenzene sulfonic acid']",['Colitis'],True,"2,4,6-trinitrobenzene sulfonic acid",Colitis,induced,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","2,4,6-trinitrobenzene sulfonic acid",induce
877,11080,33734697,We investigated whether depression increased the  susceptibility to PD and whether this resulted from neuroinflammation mediated by purinergic ligand-gated ion channel 7 receptor (P2X7R) of microglia in mice.,['ligand-gated'],"['depression increased', 'neuroinflammation mediated']",True,ligand-gated,depression,increased,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ligand-gated,increase
878,11080,33734697,We investigated whether depression increased the  susceptibility to PD and whether this resulted from neuroinflammation mediated by purinergic ligand-gated ion channel 7 receptor (P2X7R) of microglia in mice.,['ligand-gated'],"['depression increased', 'neuroinflammation mediated']",True,ligand-gated,neuroinflammation mediated,increased,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ligand-gated,increase
879,11080,33734697,We investigated whether depression increased the  susceptibility to PD and whether this resulted from neuroinflammation mediated by purinergic ligand-gated ion channel 7 receptor (P2X7R) of microglia in mice.,['ligand-gated'],"['depression increased', 'neuroinflammation mediated']",True,ligand-gated,neuroinflammation mediated,resulted,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ligand-gated,result
880,11091,33548307,"After acylation with phenolic acids, the 1,1-diphenyl-2-picryl hydrazine clearance of pectin changed from 7.68% (Na-Pe) to 6.88% (Ph-Pe), 40.80% (Dh-Pe), and 90.30% (Ga-Pe), whereas its inhibition ratio of pectin increased from 3.11% (Na-Pe) to 35.02% (Ph-Pe), 66.36% (Dh-Pe), and 77.89% (Ga-Pe).","['phenolic acids', 'pectin', 'pectin']",['inhibition ratio'],True,pectin,inhibition ratio,increased,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pectin,increase
881,11162,34345835,"Mrp4 has been shown to be upregulated during oxidative stress, and it is  well-established that APAP overdose causes oxidative stress due to depletion of glutathione.","['APAP', 'glutathione']","['upregulated', 'overdose', 'oxidative stress']",True,APAP,oxidative stress,causes,C0242606,Oxidative stress,1983,Acetaminophen,Acetaminophen,cause
882,11162,34345835,"Mrp4 has been shown to be upregulated during oxidative stress, and it is  well-established that APAP overdose causes oxidative stress due to depletion of glutathione.","['APAP', 'glutathione']","['upregulated', 'overdose', 'oxidative stress']",True,glutathione,oxidative stress,causes,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione,cause
883,11166,31399506,"The loss of Bcrp resulted in  a 1.8- to 3.2-fold increase of diclofenac acyl glucuronide (DCF-AG) plasma concentrations in KO animals compared with WT mice, while the biliary excretion of DCF-AG increased 1.4-fold in WT versus KO mice.","['diclofenac acyl', 'glucuronide']",['biliary excretion'],True,diclofenac acyl,biliary excretion,resulted,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",diclofenac acyl,result
884,11166,31399506,"The loss of Bcrp resulted in  a 1.8- to 3.2-fold increase of diclofenac acyl glucuronide (DCF-AG) plasma concentrations in KO animals compared with WT mice, while the biliary excretion of DCF-AG increased 1.4-fold in WT versus KO mice.","['diclofenac acyl', 'glucuronide']",['biliary excretion'],True,glucuronide,biliary excretion,resulted,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glucuronide,result
885,11172,17123753,"dnes@liv.ac.uk  Oral administration of the non-steroidal anti-inflammatory drug diclofenac (DCF)  is associated with a high incidence of adverse drug reactions, some of which are  thought to be mediated by the immune system.",['diclofenac'],['high incidence of adverse drug reactions'],True,diclofenac,high incidence of adverse drug reactions,associated,C0041755,Adverse drug response,3033,Diclofenac,Diclofenac,associate
886,11257,24085261," RESULTS: Inhibition of CYP3A4 by ketoconazole increased midostaurin exposure more than tenfold, and induction of CYP3A4 by rifampicin decreased midostaurin exposure by more than tenfold.","['ketoconazole', 'midostaurin', 'CYP3A4', 'midostaurin']",['Inhibition of CYP3A4'],True,ketoconazole,Inhibition of CYP3A4,increased,C0424296,Disinhibition,456201,"1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone","1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone",increase
887,11257,24085261," RESULTS: Inhibition of CYP3A4 by ketoconazole increased midostaurin exposure more than tenfold, and induction of CYP3A4 by rifampicin decreased midostaurin exposure by more than tenfold.","['ketoconazole', 'midostaurin', 'CYP3A4', 'midostaurin']",['Inhibition of CYP3A4'],True,midostaurin,Inhibition of CYP3A4,increased,C0424296,Disinhibition,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",midostaurin,increase
888,11257,24085261," RESULTS: Inhibition of CYP3A4 by ketoconazole increased midostaurin exposure more than tenfold, and induction of CYP3A4 by rifampicin decreased midostaurin exposure by more than tenfold.","['ketoconazole', 'midostaurin', 'CYP3A4', 'midostaurin']",['Inhibition of CYP3A4'],True,CYP3A4,Inhibition of CYP3A4,increased,C0424296,Disinhibition,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CYP3A4,increase
889,11257,24085261," RESULTS: Inhibition of CYP3A4 by ketoconazole increased midostaurin exposure more than tenfold, and induction of CYP3A4 by rifampicin decreased midostaurin exposure by more than tenfold.","['ketoconazole', 'midostaurin', 'CYP3A4', 'midostaurin']",['Inhibition of CYP3A4'],True,midostaurin,Inhibition of CYP3A4,increased,C0424296,Disinhibition,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",midostaurin,increase
890,11300,12695342,"Pretreatment with ketoconazole increased  orally dosed MDZ maximum plasma concentration (C(max)), time of the maximum concentration, area under the plasma concentration-time curve from zero to infinity (AUC(0- infinity)), and elimination half-life (t(1/2)) to 3.2-, 1.7-, 7.7-, 2-fold, and decreased MDZ apparent oral clearance about 8-fold in Tg-CYP3A4 mice.","['ketoconazole', 'MDZ']",['decreased MDZ'],True,ketoconazole,decreased MDZ,increased,C0302844,Reduced erythrocyte volume,456201,"1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone","1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone",increase
891,11300,12695342,"Pretreatment with ketoconazole increased  orally dosed MDZ maximum plasma concentration (C(max)), time of the maximum concentration, area under the plasma concentration-time curve from zero to infinity (AUC(0- infinity)), and elimination half-life (t(1/2)) to 3.2-, 1.7-, 7.7-, 2-fold, and decreased MDZ apparent oral clearance about 8-fold in Tg-CYP3A4 mice.","['ketoconazole', 'MDZ']",['decreased MDZ'],True,MDZ,decreased MDZ,increased,C0302844,Reduced erythrocyte volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MDZ,increase
892,11317,34682373,First-trimester mono-n-butyl phthalate (MBP) and MEP along with the sum of di-(2-ethylhexyl) phthalate metabolites (∑DEHP) were each associated with increased systolic blood pressure across pregnancy.,['di-(2-ethylhexyl) phthalate metabolites'],['increased systolic blood pressure'],True,di-(2-ethylhexyl) phthalate metabolites,increased systolic blood pressure,associated,C0277885,Decreased systolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",di-(2-ethylhexyl) phthalate metabolites,associate
893,11318,34682373,"In conclusion, several phthalate metabolite concentrations were significantly associated with PIH and greater increases in systolic blood pressure across pregnancy.",['phthalate'],['greater increases in systolic blood pressure'],True,phthalate,greater increases in systolic blood pressure,associated,C0277885,Decreased systolic blood pressure,181977,phthalate,phthalate,associate
894,11327,32867766," RESULTS: In the multivariable logistic regression model, 2,5-dichlorophenol (2,5-DCP) (OR (95% CI): 1.25 (1.11, 1.40)), monoethyl phthalate (MEP) (OR (95% CI): 1.28 (1.04, 1.58)), and mono-isobutyl phthalate (MiBP) (OR (95% CI): 1.42 (1.07, 1.89)) were found to be positively associated with obesity, while methylparaben (MeP) (OR (95% CI): 0.80 (0.68, 0.94)) was negatively associated with obesity.","['monoethyl phthalate', 'mono-isobutyl phthalate', 'methylparaben']","['obesity', 'obesity']",True,methylparaben,obesity,associated,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methylparaben,associate
895,11329,32866875,"Our pooled results showed that spontaneous pregnancy loss was associated with higher urinary levels of monobutyl phthalate (MBP) (OR: 1.34, 95% CI: 1.04-1.72), mono(2-ethylhexyl) phthalate (MEHP) (OR: 1.57, 95% CI: 1.29-1.90), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) (OR: 1.59, 95% CI: 1.23-2.07) and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) (OR: 1.47, 95% CI: 1.15-1.89).","['monobutyl phthalate', 'mono(2-ethylhexyl) phthalate', 'mono(2-ethyl-5-hydroxyhexyl) phthalate', 'mono(2-ethyl-5-oxohexyl) phthalate']","['pregnancy loss', 'higher urinary levels']",True,monobutyl phthalate,pregnancy loss,associated,C0028754,Obesity,8575,Mono-n-butyl phthalate,Mono-n-butyl phthalate,associate
896,11337,31726561,The sum of di-(2-ethylhexyl) phthalate metabolites (ΣDEHPm) and ethyl paraben (EtP) were associated with increased serum adiponectin levels.,"['di-(2-ethylhexyl) phthalate metabolites', 'ethyl paraben']",['increased serum adiponectin levels'],True,di-(2-ethylhexyl) phthalate metabolites,increased serum adiponectin levels,associated,C4073128,Increased adiponectin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",di-(2-ethylhexyl) phthalate metabolites,associate
897,11337,31726561,The sum of di-(2-ethylhexyl) phthalate metabolites (ΣDEHPm) and ethyl paraben (EtP) were associated with increased serum adiponectin levels.,"['di-(2-ethylhexyl) phthalate metabolites', 'ethyl paraben']",['increased serum adiponectin levels'],True,ethyl paraben,increased serum adiponectin levels,associated,C4073128,Increased adiponectin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethyl paraben,associate
898,11360,30226539,"This study suggests that metabolites of phthalate such as MEHHP, MECPP, MEOHP and Σ4MEHP may increase the intron 1 methylation level to elevate ADAM33 gene expression and have a protective effect on reducing the risk of breast cancer.",['phthalate'],"['methylation', 'elevate ADAM33 gene expression', 'breast cancer']",True,phthalate,breast cancer,increase,C0678222,Breast cancer,181977,phthalate,phthalate,increase
899,11375,28274229,  Exposure to phthalates and bisphenol A are associated with atopic dermatitis symptoms in children: a time-series analysis.,['bisphenol'],['atopic dermatitis'],True,bisphenol,atopic dermatitis,associated,C0011615,"Atopic dermatitis, chronic",6623,Bisphenol A,Bisphenol A,associate
900,11377,28274229,"Manifestation of AD symptoms was associated with an increase in urinary levels of MnBP (adjusted odds ratio, aOR = 2.85, 95% CI: 1.12-7.26 per 1 μg/L of MnBP) and BPAG (aOR = 1.79, 95% CI: 0.91-3.52 per 1 μg/L BPAG) on the same day.",['BPAG'],['increase in urinary levels'],True,BPAG,increase in urinary levels,associated,C5139105,Increased urinary zinc level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BPAG,associate
901,11381,27588698,Exposure to di-2-ethylhexyl phthalate (DEHP) in floor dust was associated with parental-reported rhino-conjunctivitis.,['di-2-ethylhexyl phthalate'],['rhino-conjunctivitis'],True,di-2-ethylhexyl phthalate,rhino-conjunctivitis,associated,C0009763,Conjunctivitis,8343,Bis(2-Ethylhexyl) Phthalate,Bis(2-Ethylhexyl) Phthalate,associate
902,11391,27428989,MBzP was associated with repeated coughing and MEHP was associated with itching.,"['MBzP', 'MEHP']",['itching'],True,MBzP,itching,associated,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MBzP,associate
903,11391,27428989,MBzP was associated with repeated coughing and MEHP was associated with itching.,"['MBzP', 'MEHP']",['itching'],True,MEHP,itching,associated,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MEHP,associate
904,11391,27428989,MBzP was associated with repeated coughing and MEHP was associated with itching.,"['MBzP', 'MEHP']",['itching'],True,MEHP,itching,associated,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MEHP,associate
905,11412,34425642," METHODS: We used the Health Outcomes and Measures of the Environment (HOME) Study to examine whether bisphenol A (BPA), polybrominated diphenyl ethers (PBDEs), per- and polyfluoroalkyl substances (PFAS), and phthalates are associated with blood pressure, glucose, and lipids in 388 pregnant women.","['bisphenol A', 'BPA', 'polybrominated diphenyl', 'polyfluoroalkyl substances']",['blood pressure'],True,bisphenol A,blood pressure,associated,C0020649,Hypotension,6623,Bisphenol A,Bisphenol A,associate
906,11412,34425642," METHODS: We used the Health Outcomes and Measures of the Environment (HOME) Study to examine whether bisphenol A (BPA), polybrominated diphenyl ethers (PBDEs), per- and polyfluoroalkyl substances (PFAS), and phthalates are associated with blood pressure, glucose, and lipids in 388 pregnant women.","['bisphenol A', 'BPA', 'polybrominated diphenyl', 'polyfluoroalkyl substances']",['blood pressure'],True,polybrominated diphenyl,blood pressure,associated,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",polybrominated diphenyl,associate
907,11412,34425642," METHODS: We used the Health Outcomes and Measures of the Environment (HOME) Study to examine whether bisphenol A (BPA), polybrominated diphenyl ethers (PBDEs), per- and polyfluoroalkyl substances (PFAS), and phthalates are associated with blood pressure, glucose, and lipids in 388 pregnant women.","['bisphenol A', 'BPA', 'polybrominated diphenyl', 'polyfluoroalkyl substances']",['blood pressure'],True,polyfluoroalkyl substances,blood pressure,associated,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",polyfluoroalkyl substances,associate
908,11413,34425642,"Mono-n-butyl phthalate (MBP) (β = -7.9 mg/dL, 95% CI -12.9, -3.0) and monobenzyl phthalate (MBzP) (β = -6.3 mg/dL, 95% CI -10.6, -2.0) were both associated with significant decreases in cholesterol in linear regression, but only MBzP was identified as an important contributor in the BKMR model.",['monobenzyl phthalate'],['decreases in cholesterol'],True,monobenzyl phthalate,decreases in cholesterol,associated,C0151691,Decreased HDL cholesterol concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",monobenzyl phthalate,associate
909,11422,33850448,"Endometriosis causes detrimental effects on the granulosa cells, and phthalate interferes with the biological and reproductive function of endometrial cells at a molecular level.",['phthalate'],['Endometriosis'],True,phthalate,Endometriosis,causes,C0014175,Endometriosis,181977,phthalate,phthalate,cause
910,11424,33850448,"Several in vitro studies have demonstrated that phthalate caused inflammation, invasion, change in cytokines, increased oxidative stress, viability, resistance to hydrogen peroxide, and proliferation of endometrial cells.",['phthalate'],"['inflammation', 'invasion', 'increased oxidative stress', 'viability', 'resistance to hydrogen peroxide', 'proliferation of endometrial cells']",True,phthalate,inflammation,caused,C3875321,Skin inflammation,181977,phthalate,phthalate,cause
911,11424,33850448,"Several in vitro studies have demonstrated that phthalate caused inflammation, invasion, change in cytokines, increased oxidative stress, viability, resistance to hydrogen peroxide, and proliferation of endometrial cells.",['phthalate'],"['inflammation', 'invasion', 'increased oxidative stress', 'viability', 'resistance to hydrogen peroxide', 'proliferation of endometrial cells']",True,phthalate,increased oxidative stress,caused,C0242606,Oxidative stress,181977,phthalate,phthalate,cause
912,11428,33516688,"A doubling of urinary monoethyl phthalate (MEP) concentration was associated with a -0.49% (95%CI: -0.95%, -0.02%) smaller head circumference, although seven other phthalate metabolites were null.",['monoethyl phthalate'],['smaller head circumference'],True,monoethyl phthalate,smaller head circumference,associated,C4551563,Abnormally small skull,75318,Mono-ethyl phthalate,Mono-ethyl phthalate,associate
913,11431,33429469, CONCLUSION: BPA exposure might be associated with DOR and infertility.,['BPA'],['infertility'],True,BPA,infertility,associated,C0021359,Infertility,6623,Bisphenol A,Bisphenol A,associate
914,11433,33422710,"Cu (IRR: 0.90, 95%CI: 0.82;0.98), perfluoroundecanoate (PFUnDA, IRR: 0.92, 95%CI: 0.84;0.99) and organochlorine compounds (OCs) were associated with lower risk of externalizing behaviour problems, however the associations with OCs were mainly seen among women with insufficient weight gain  during pregnancy.","['Cu', 'perfluoroundecanoate']","['lower risk of externalizing behaviour problems', 'insufficient weight gain']",True,Cu,insufficient weight gain  ,associated,C0043094,Weight gain,23978,copper,copper,associate
915,11433,33422710,"Cu (IRR: 0.90, 95%CI: 0.82;0.98), perfluoroundecanoate (PFUnDA, IRR: 0.92, 95%CI: 0.84;0.99) and organochlorine compounds (OCs) were associated with lower risk of externalizing behaviour problems, however the associations with OCs were mainly seen among women with insufficient weight gain  during pregnancy.","['Cu', 'perfluoroundecanoate']","['lower risk of externalizing behaviour problems', 'insufficient weight gain']",True,perfluoroundecanoate,insufficient weight gain  ,associated,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",perfluoroundecanoate,associate
916,11450,32679391,"Among girls, decreased hyperactivity was associated with two DEHP metabolites, mono(2-ethyl-5-oxohexyl) phthalate (MR = 0.83, 95%CI 0.71-0.98) and  mono(2-ethyl-5-hydroxyhexyl) phthalate (MR = 0.85, 95%CI 0.72-0.99).",['mono(2-ethyl-5-oxohexyl) phthalate'],['decreased hyperactivity'],True,mono(2-ethyl-5-oxohexyl) phthalate,decreased hyperactivity,associated,C0424295,Hyperactivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mono(2-ethyl-5-oxohexyl) phthalate,associate
917,11452,32679391,DEHP phthalate metabolites were associated with decreased hyperactivity and impulsivity among girls on CPRS scores.,['DEHP phthalate metabolites'],"['decreased hyperactivity', 'impulsivity']",True,DEHP phthalate metabolites,decreased hyperactivity,associated,C0424295,Hyperactivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DEHP phthalate metabolites,associate
918,11452,32679391,DEHP phthalate metabolites were associated with decreased hyperactivity and impulsivity among girls on CPRS scores.,['DEHP phthalate metabolites'],"['decreased hyperactivity', 'impulsivity']",True,DEHP phthalate metabolites,impulsivity,associated,C0021125,Impulsive,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DEHP phthalate metabolites,associate
919,11459,32505048,"When stratified by gender, higher urinary levels of MEOHP, MBP, MEP, and MMP were associated with general obesity in males, whereas MBP and MMP levels were eminently correlated with general obesity in females.",['MBP'],"['higher urinary levels of MEOHP', 'general obesity', 'obesity']",True,MBP,general obesity,associated,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MBP,associate
920,11459,32505048,"When stratified by gender, higher urinary levels of MEOHP, MBP, MEP, and MMP were associated with general obesity in males, whereas MBP and MMP levels were eminently correlated with general obesity in females.",['MBP'],"['higher urinary levels of MEOHP', 'general obesity', 'obesity']",True,MBP,obesity,associated,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MBP,associate
921,11471,33804363,"The urinary phthalate metabolite mono-benzyl phthalate (MBzP) and mono-2-isobutyl phthalate (MiBP) were negatively associated with breast cancer (OR = 0.73, 95% CI: 0.60-0.90; OR = 0.75, 95% CI: 0.58-0.98, respectively).","['mono-benzyl phthalate', '-isobutyl phthalate']",['breast cancer'],True,mono-benzyl phthalate,breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mono-benzyl phthalate,associate
922,11472,33804363," CONCLUSION: Phthalate metabolites MBzP and MiBP were passively associated with breast cancer, whereas no associations were found between BPA, MEP, MEHHP, MEHP,  MEOHP, MCPP, and MBP and breast cancer.","['MBzP', 'BPA', 'MEHP']","['breast cancer', 'breast cancer']",True,MBzP,breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MBzP,associate
923,11472,33804363," CONCLUSION: Phthalate metabolites MBzP and MiBP were passively associated with breast cancer, whereas no associations were found between BPA, MEP, MEHHP, MEHP,  MEOHP, MCPP, and MBP and breast cancer.","['MBzP', 'BPA', 'MEHP']","['breast cancer', 'breast cancer']",True,MBzP,breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MBzP,associate
924,11472,33804363," CONCLUSION: Phthalate metabolites MBzP and MiBP were passively associated with breast cancer, whereas no associations were found between BPA, MEP, MEHHP, MEHP,  MEOHP, MCPP, and MBP and breast cancer.","['MBzP', 'BPA', 'MEHP']","['breast cancer', 'breast cancer']",True,BPA,breast cancer,associated,C0678222,Breast cancer,6623,Bisphenol A,Bisphenol A,associate
925,11472,33804363," CONCLUSION: Phthalate metabolites MBzP and MiBP were passively associated with breast cancer, whereas no associations were found between BPA, MEP, MEHHP, MEHP,  MEOHP, MCPP, and MBP and breast cancer.","['MBzP', 'BPA', 'MEHP']","['breast cancer', 'breast cancer']",True,BPA,breast cancer,associated,C0678222,Breast cancer,6623,Bisphenol A,Bisphenol A,associate
926,11472,33804363," CONCLUSION: Phthalate metabolites MBzP and MiBP were passively associated with breast cancer, whereas no associations were found between BPA, MEP, MEHHP, MEHP,  MEOHP, MCPP, and MBP and breast cancer.","['MBzP', 'BPA', 'MEHP']","['breast cancer', 'breast cancer']",True,MEHP,breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MEHP,associate
927,11472,33804363," CONCLUSION: Phthalate metabolites MBzP and MiBP were passively associated with breast cancer, whereas no associations were found between BPA, MEP, MEHHP, MEHP,  MEOHP, MCPP, and MBP and breast cancer.","['MBzP', 'BPA', 'MEHP']","['breast cancer', 'breast cancer']",True,MEHP,breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MEHP,associate
928,11474,32763629,"In sex-stratified analyses, boys' phthalate index was adversely associated with all outcomes (e.g., boys' ever asthma: adjusted odds ratio per one quintile increase in WQS phthalate index (AOR): 1.42; 95% confidence interval (CI): 1.08, 1.85, with mono-ethyl phthalate  (MEP) weighted highest).",['mono-ethyl phthalate'],['asthma'],True,mono-ethyl phthalate,asthma,associated,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mono-ethyl phthalate,associate
929,11475,31678884,Phthalic acid ester (PAE) has been associated with symptoms of attention deficit hyperactivity disorder (ADHD) in cross-sectional studies.,['Phthalic acid ester'],['deficit hyperactivity disorder'],True,Phthalic acid,deficit hyperactivity disorder,associated,C1263846,Attention deficit,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Phthalic acid,associate
930,11477,31419700,"Furthermore, factors significantly associated with phthalate metabolite levels included the use of plastic food packages (DEHP metabolites), physical exercise (MEOHP), the frequency of fast food consumption (MBP), and the frequency of skin care cosmetics and color cosmetics use (MEP).",['phthalate'],['physical exercise'],True,phthalate,physical exercise,associated,C1263846,Attention deficit,181977,phthalate,phthalate,associate
931,11478,31368075,"Out of  10 metabolites, only mono-benzyl phthalate (MBzP) was positively associated with  the prevalence of self-reported asthma in children, after adjusting for a range of potential confounders (odds ratio 1.54; 95% confidence interval 1.05-2.27).",['mono-benzyl phthalate'],['asthma'],True,mono-benzyl phthalate,asthma,associated,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mono-benzyl phthalate,associate
932,11480,31368075,"While no other phthalates showed a positive relationship with current asthma in males, mono-(carboxynonyl) phthalate (MCNP) and mono-(3-carboxylpropyl) phthalate (MCPP) were inversely associated with spirometrically defined asthma in adult females.",['phthalate'],"['asthma', 'asthma']",True,phthalate,asthma,associated,C0004096,Asthma,181977,phthalate,phthalate,associate
933,11480,31368075,"While no other phthalates showed a positive relationship with current asthma in males, mono-(carboxynonyl) phthalate (MCNP) and mono-(3-carboxylpropyl) phthalate (MCPP) were inversely associated with spirometrically defined asthma in adult females.",['phthalate'],"['asthma', 'asthma']",True,phthalate,asthma,associated,C0004096,Asthma,181977,phthalate,phthalate,associate
934,11483,30704894,"Recent studies suggest that phthalate exposure is associated with elevated glucose levels in pregnant women, with implications for  higher birth weight in the offspring.",['phthalate'],"['elevated glucose levels', 'higher birth weight']",True,phthalate,higher birth weight,associated,C0024032,Low birth weight,181977,phthalate,phthalate,associate
935,11490,29860692,"In boys, a 1-ng/mL increase in monobenzyl phthalate (MBzP) concentration was associated with a 0.027-cm decrease in the skinfold measurement (95% confidence interval [CI], - 0.053 to 0.001), whereas a 1-ng/mL increase in mono-ethyl-phthalate (MEP) concentration was associated with a 0.016-mm Hg decrease in systolic blood pressure (95% CI, - 0.031 to 0.001).","['monobenzyl phthalate', 'mono-ethyl-phthalate']",['decrease in systolic blood pressure'],True,monobenzyl phthalate,decrease in systolic blood pressure,associated,C0277885,Decreased systolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",monobenzyl phthalate,associate
936,11490,29860692,"In boys, a 1-ng/mL increase in monobenzyl phthalate (MBzP) concentration was associated with a 0.027-cm decrease in the skinfold measurement (95% confidence interval [CI], - 0.053 to 0.001), whereas a 1-ng/mL increase in mono-ethyl-phthalate (MEP) concentration was associated with a 0.016-mm Hg decrease in systolic blood pressure (95% CI, - 0.031 to 0.001).","['monobenzyl phthalate', 'mono-ethyl-phthalate']",['decrease in systolic blood pressure'],True,mono-ethyl-phthalate,decrease in systolic blood pressure,associated,C0277885,Decreased systolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mono-ethyl-phthalate,associate
937,11490,29860692,"In boys, a 1-ng/mL increase in monobenzyl phthalate (MBzP) concentration was associated with a 0.027-cm decrease in the skinfold measurement (95% confidence interval [CI], - 0.053 to 0.001), whereas a 1-ng/mL increase in mono-ethyl-phthalate (MEP) concentration was associated with a 0.016-mm Hg decrease in systolic blood pressure (95% CI, - 0.031 to 0.001).","['monobenzyl phthalate', 'mono-ethyl-phthalate']",['decrease in systolic blood pressure'],True,mono-ethyl-phthalate,decrease in systolic blood pressure,associated,C0277885,Decreased systolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mono-ethyl-phthalate,associate
938,11492,29751433,"Our results demonstrate that in children with allergic diseases, a per log unit increase in the urinary phthalate metabolite mono-ethyl  phthalate (MEP) concentration at age 9 was associated with a decreasing forced expiratory volume in 1 sec (FEV1) (β=-25.22; 95% CI: -47.53 to -2.91 per log ml/ln-μg/g cr) and forced vital capacity (FVC) (β=-32.3; 95% CI: -63.51 to -1.09  per log ml/ln-μg/g cr).",['mono-ethyl  phthalate'],"['decreasing forced expiratory volume', 'forced vital capacity']",True,mono-ethyl  phthalate,decreasing forced expiratory volume,associated,C5139291,Decreased post-bronchodilator forced expiratory volume in one second,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mono-ethyl  phthalate,associate
939,11496,28576446," RESULTS: After adjustment for potential confounders, maternal ∑MEHP level was associated with decreased levels of progesterone in girls (β = -0.309 p = 0.001).",['progesterone'],['decreased levels of'],True,progesterone,decreased levels of,associated,C4280714,Decreased level of tissue plasminogen activator,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",progesterone,associate
940,11504,27475039, CONCLUSIONS: Urinary levels of phthalate metabolites were not associated with increased cardiovascular disease mortality.,['phthalate metabolites'],['increased cardiovascular disease mortality'],True,phthalate metabolites,increased cardiovascular disease mortality,associated,C0007222,Cardiovascular disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phthalate metabolites,associate
941,11527,23710608," RESULTS: Serum BPA was positively associated with mammographic breast density after adjusting for age, body mass index, and other potentially confounding factors.",['BPA'],"['breast', 'body mass index']",True,BPA,breast,associated,C0266009,Mammary gland aplasia,6623,Bisphenol A,Bisphenol A,associate
942,11527,23710608," RESULTS: Serum BPA was positively associated with mammographic breast density after adjusting for age, body mass index, and other potentially confounding factors.",['BPA'],"['breast', 'body mass index']",True,BPA,body mass index,associated,C0266009,Mammary gland aplasia,6623,Bisphenol A,Bisphenol A,associate
943,11582,16075285, RESULTS: Intraplantar administration of formalin (2.5%) to CD-1 mice produced a biphasic period of pain.,['formalin'],['pain'],True,formalin,pain,produced,C0030193,Pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",formalin,produce
944,11589,16025420," CONCLUSION: In psychiatric patients treated with haloperidol for the long-term, the severity of TD and parkinsonism is associated with an increased ratio HP+/H.  This is explained by the neurotoxicity of HP+ according to the pyridinium hypothesis.","['haloperidol', 'pyridinium']","['parkinsonism', 'neurotoxicity']",True,haloperidol,parkinsonism,associated,C0242422,Parkinsonian disease,3559,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,associate
945,11589,16025420," CONCLUSION: In psychiatric patients treated with haloperidol for the long-term, the severity of TD and parkinsonism is associated with an increased ratio HP+/H.  This is explained by the neurotoxicity of HP+ according to the pyridinium hypothesis.","['haloperidol', 'pyridinium']","['parkinsonism', 'neurotoxicity']",True,pyridinium,parkinsonism,associated,C0242422,Parkinsonian disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pyridinium,associate
946,11626,11779040,Atypical antipsychotics such as clozapine and rispiridone are associated with a lower incidence of extrapyramidal side effects and tardive dyskinesia.,"['clozapine', 'rispiridone']","['lower incidence of extrapyramidal side effects', 'tardive dyskinesia']",True,clozapine,tardive dyskinesia,associated,C0686347,Tardive dyskinesia,135398737,Clozapine,Clozapine,associate
947,11732,7583212,"  Haloperidol and reduced haloperidol-induced exacerbation of the dystonia produced by the kappa opioid U50,488H in guinea-pigs is associated with inhibition of sigma binding sites: behavioural and autoradiographical studies.","['U50,488H']","['reduced haloperidol-induced exacerbation of the', 'dystonia']",True,Haloperidol,dystonia,associated,C0013421,Dystonic movements,3559,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one,associate
948,11732,7583212,"  Haloperidol and reduced haloperidol-induced exacerbation of the dystonia produced by the kappa opioid U50,488H in guinea-pigs is associated with inhibition of sigma binding sites: behavioural and autoradiographical studies.","['U50,488H']","['reduced haloperidol-induced exacerbation of the', 'dystonia']",True,"U50,488H",reduced haloperidol-induced exacerbation of the,associated,C0013421,Dystonic movements,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","U50,488H",associate
949,11732,7583212,"  Haloperidol and reduced haloperidol-induced exacerbation of the dystonia produced by the kappa opioid U50,488H in guinea-pigs is associated with inhibition of sigma binding sites: behavioural and autoradiographical studies.","['U50,488H']","['reduced haloperidol-induced exacerbation of the', 'dystonia']",True,"U50,488H",dystonia,associated,C0013421,Dystonic movements,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","U50,488H",associate
950,11739,7583212,"The results indicate that the exacerbation by sigma ligands of the dystonia produced by U50,488H was associated with the degree of inhibition of [3H]-3-PPP binding.","['U50,488H']",['dystonia'],True,"U50,488H",dystonia,associated,C0013421,Dystonic movements,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","U50,488H",associate
951,11776,21131461,Applications of 5 g of 4% lidocaine resulted in higher serum concentration of both lidocaine and MEGX.,"['lidocaine', 'MEGX']",['higher serum concentration'],True,lidocaine,higher serum concentration,resulted,C4732832,Abnormal serum bicarbonate concentration,3676,lidocaine,lidocaine,result
952,11776,21131461,Applications of 5 g of 4% lidocaine resulted in higher serum concentration of both lidocaine and MEGX.,"['lidocaine', 'MEGX']",['higher serum concentration'],True,MEGX,higher serum concentration,resulted,C4732832,Abnormal serum bicarbonate concentration,24415,monoethylglycinexylidide,monoethylglycinexylidide,result
953,11780,19595327,The acute inflammatory response was increased in the Dopexamine group while a decreased pHi and MEGX formation and increased serum lactate levels were measured.,['Dopexamine'],"['acute inflammatory response', 'decreased pHi', 'increased serum lactate levels']",True,Dopexamine,acute inflammatory response,increased,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Dopexamine,increase
954,11780,19595327,The acute inflammatory response was increased in the Dopexamine group while a decreased pHi and MEGX formation and increased serum lactate levels were measured.,['Dopexamine'],"['acute inflammatory response', 'decreased pHi', 'increased serum lactate levels']",True,Dopexamine,decreased pHi,increased,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Dopexamine,increase
955,11780,19595327,The acute inflammatory response was increased in the Dopexamine group while a decreased pHi and MEGX formation and increased serum lactate levels were measured.,['Dopexamine'],"['acute inflammatory response', 'decreased pHi', 'increased serum lactate levels']",True,Dopexamine,increased serum lactate levels,increased,C1836440,Increased blood lactate,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Dopexamine,increase
956,11860,12546613,"Multivariate stepwise logistic analysis showed that AST/ALT ratio, platelet count (PLT), MEGX values, and prothrombin activity were independently associated with the presence of cirrhosis.",['MEGX values'],"['platelet count', 'prothrombin activity']",True,MEGX values,prothrombin activity,associated,C0853225,Reduced factor II activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MEGX values,associate
957,11875,1591467,"However, both experimental conditions increased plasma concentrations of MEGX and GX and increased the ratio of the area under their plasma concentration curves to the dose of lidocaine received.",['lidocaine'],['increased the ratio of the area'],True,lidocaine,increased the ratio of the area,increased,C4022846,Increased T3/T4 ratio,3676,lidocaine,lidocaine,increase
958,11900,34748005," Objective: To determine whether caffeinated-beverage intake and plasma caffeine and paraxanthine are associated with cardiometabolic complications in pregnancy (ie, gestational diabetes [GDM], preeclampsia, and gestational hypertension [GH]).","['caffeine', 'paraxanthine']","['cardiometabolic complications', 'preeclampsia', 'gestational hypertension']",True,caffeine,cardiometabolic complications,associated,C4022846,Increased T3/T4 ratio,2519,Caffeine,Caffeine,associate
959,11900,34748005," Objective: To determine whether caffeinated-beverage intake and plasma caffeine and paraxanthine are associated with cardiometabolic complications in pregnancy (ie, gestational diabetes [GDM], preeclampsia, and gestational hypertension [GH]).","['caffeine', 'paraxanthine']","['cardiometabolic complications', 'preeclampsia', 'gestational hypertension']",True,caffeine,preeclampsia,associated,C0032914,Preeclampsia,2519,Caffeine,Caffeine,associate
960,11900,34748005," Objective: To determine whether caffeinated-beverage intake and plasma caffeine and paraxanthine are associated with cardiometabolic complications in pregnancy (ie, gestational diabetes [GDM], preeclampsia, and gestational hypertension [GH]).","['caffeine', 'paraxanthine']","['cardiometabolic complications', 'preeclampsia', 'gestational hypertension']",True,caffeine,gestational hypertension,associated,C0020538,Systemic hypertension,2519,Caffeine,Caffeine,associate
961,11900,34748005," Objective: To determine whether caffeinated-beverage intake and plasma caffeine and paraxanthine are associated with cardiometabolic complications in pregnancy (ie, gestational diabetes [GDM], preeclampsia, and gestational hypertension [GH]).","['caffeine', 'paraxanthine']","['cardiometabolic complications', 'preeclampsia', 'gestational hypertension']",True,paraxanthine,cardiometabolic complications,associated,C0020538,Systemic hypertension,4687,paraxanthine,paraxanthine,associate
962,11900,34748005," Objective: To determine whether caffeinated-beverage intake and plasma caffeine and paraxanthine are associated with cardiometabolic complications in pregnancy (ie, gestational diabetes [GDM], preeclampsia, and gestational hypertension [GH]).","['caffeine', 'paraxanthine']","['cardiometabolic complications', 'preeclampsia', 'gestational hypertension']",True,paraxanthine,preeclampsia,associated,C0032914,Preeclampsia,4687,paraxanthine,paraxanthine,associate
963,11900,34748005," Objective: To determine whether caffeinated-beverage intake and plasma caffeine and paraxanthine are associated with cardiometabolic complications in pregnancy (ie, gestational diabetes [GDM], preeclampsia, and gestational hypertension [GH]).","['caffeine', 'paraxanthine']","['cardiometabolic complications', 'preeclampsia', 'gestational hypertension']",True,paraxanthine,gestational hypertension,associated,C0020538,Systemic hypertension,4687,paraxanthine,paraxanthine,associate
964,11906,34644210,"Among subjects without current asthma, each log10-unit increment in paraxanthine level was associated with a 0.83% increment in percent  predicted (%pred) FEV1 and a 1.27% increment in %pred FVC, while each log10-unit  in theophylline was associated with a 1.24% increment in %pred FVC.","['paraxanthine', 'theophylline']",['asthma'],True,paraxanthine,asthma,associated,C0004096,Asthma,4687,paraxanthine,paraxanthine,associate
965,11906,34644210,"Among subjects without current asthma, each log10-unit increment in paraxanthine level was associated with a 0.83% increment in percent  predicted (%pred) FEV1 and a 1.27% increment in %pred FVC, while each log10-unit  in theophylline was associated with a 1.24% increment in %pred FVC.","['paraxanthine', 'theophylline']",['asthma'],True,theophylline,asthma,associated,C0004096,Asthma,2153,theophylline,theophylline,associate
966,11911,34602096, Low serum potassium levels (2.9 and 3.5 mM) on days 1 and 2 may have been caused  by the caffeine overdose in the current case.,['caffeine'],['Low serum potassium levels'],True,caffeine,Low serum potassium levels,caused,C0020461,Elevated serum potassium levels,2519,Caffeine,Caffeine,cause
967,11927,33072431,"From these studies, we deduced that caffeine intake during pregnancy between 50 mg and <150 mg/day was associated with increased risk of overweight and obesity by excess fat deposition or increased weight, and elevated BMI per International Obesity Task Force (IOTF) criteria using a reference population.",['caffeine'],"['increased risk of overweight and obesity', 'increased weight']",True,caffeine,increased weight,associated,C0043094,Weight gain,2519,Caffeine,Caffeine,associate
968,11970,28875060,"In a double-blind, placebo-controlled study, theacrine increased energy, concentration, and mood, while reducing fatigue.",['theacrine'],"['mood', 'reducing fatigue']",True,theacrine,mood,increased,C0085633,Emotional instability,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",theacrine,increase
969,11970,28875060,"In a double-blind, placebo-controlled study, theacrine increased energy, concentration, and mood, while reducing fatigue.",['theacrine'],"['mood', 'reducing fatigue']",True,theacrine,reducing fatigue,increased,C0085633,Emotional instability,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",theacrine,increase
970,11992,34927187,"  Uric acid (UA) and melamine (MM) crystallization in humans is associated with adverse medical conditions, including the germination of kidney stones, because of their low solubility.",['melamine'],['germination of kidney stones'],True,melamine,germination of kidney stones,associated,C0392525,Renal calculi,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melamine,associate
971,12037,34400461," METHODS AND ANALYSIS: Veterans Affairs (VA) PTXRx is a pragmatic, randomised, placebo-controlled multicentre VA Cooperative Study to test the hypothesis that PTX, when added to usual care, leads to a reduction in the time to ESRD or death  in patients with type 2 diabetes with DKD when compared with usual care plus placebo.",['DKD'],"['ESRD', 'death']",True,DKD,death,leads,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DKD,lead
972,12096,35153479, Conclusion: Combination low-dose theophylline and prednisone was associated with  a significant increase in the annual moderate-severe exacerbation rate in participants with a blood eosinophil count ≥300 cells/µL compared to placebo.,"['theophylline', 'prednisone']",['blood eosinophil'],True,theophylline,blood eosinophil count,associated,C0014457,High blood eosinophil count,2153,theophylline,theophylline,associate
973,12096,35153479, Conclusion: Combination low-dose theophylline and prednisone was associated with  a significant increase in the annual moderate-severe exacerbation rate in participants with a blood eosinophil count ≥300 cells/µL compared to placebo.,"['theophylline', 'prednisone']",['blood eosinophil'],True,prednisone,blood eosinophil count,associated,C0014457,High blood eosinophil count,5865,Prednisone,Prednisone,associate
974,12132,34849728,"Most of the benefit of theophylline is derived from reduction of syncope due to asystolic atrioventricular (AV) block (hazard ratio of 0.13; 95% CI, 0.03-0.58; P = 0.008).",['theophylline'],['reduction of syncope'],True,theophylline,reduction of syncope,derived,C0039070,Syncope,2153,theophylline,theophylline,derive
975,12184,35101395," CONCLUSION: Within a low-to-middle range, exposure to the BTEXs mixture may be associated with shorter telomere length in the general nonsmoking population.",['BTEXs'],['shorter telomere length'],True,BTEXs,shorter telomere length,associated,C4531138,Short telomere length,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BTEXs,associate
976,12197,34906634,"  PURPOSE: The aim of this study was to check if self-reported smoking is still associated with back pain above and beyond its association with cotinine, to test the hypothesis that the association of self-reported cigarette smoking with back  pain is due to residual confounding.",['cotinine'],['pain'],True,cotinine,pain,associated,C0030193,Pain,854019,cotinine,cotinine,associate
977,12205,34769882,"Cotinine, creatinine, methylmalonic acid, and the methylenetetrahydrofolate reductase genotype (MTHFR) T allele were positively associated with tHcy among the smokers, but not among the snus users.",['Cotinine'],['methylenetetrahydrofolate reductase genotype'],True,Cotinine,methylenetetrahydrofolate reductase genotype,associated,C0030193,Pain,854019,cotinine,cotinine,associate
978,12209,34732802,"In the unadjusted model, the P value for trend shows that urinary caffeine metabolites 137X and AAMU were significantly associated with low-frequency PTA, and that 17X, 137X, AAMU were significantly associated with high-frequency PTA, but when the model was adjusted for sex, age, education level, firearm noise exposure, occupational noise exposure, recreational noise exposure, serum cotinine, body mass index, diabetes, hypertension, these were no  longer statistically significant.",['cotinine'],"['body mass index, diabetes', 'hypertension']",True,cotinine,"body mass index, diabetes",associated,C0085207,Maternal diabetes,854019,cotinine,cotinine,associate
979,12209,34732802,"In the unadjusted model, the P value for trend shows that urinary caffeine metabolites 137X and AAMU were significantly associated with low-frequency PTA, and that 17X, 137X, AAMU were significantly associated with high-frequency PTA, but when the model was adjusted for sex, age, education level, firearm noise exposure, occupational noise exposure, recreational noise exposure, serum cotinine, body mass index, diabetes, hypertension, these were no  longer statistically significant.",['cotinine'],"['body mass index, diabetes', 'hypertension']",True,cotinine,hypertension,associated,C0020538,Systemic hypertension,854019,cotinine,cotinine,associate
980,12264,33412282,"Urinary 3-&4-Methylhippuric acid (3-&4-MHA, OR: 5.78, 95% CI: 3.50, 9.54), rac 2-Aminothiazoline-4-carboxylic acid (ATCA, OR: 2.90, 95% CI: 1.69, 4.99) and N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine (DHBMA, OR: 2.76, 95% CI: 1.73, 4.43) which may derive from m/p-xylene, cyanide and 1,3-butadiene exposure, respectively, could significantly and maximally increase the odds of asthma.","['N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine', 'cyanide']",['asthma'],True,"N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine",asthma,increase,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine",increase
981,12264,33412282,"Urinary 3-&4-Methylhippuric acid (3-&4-MHA, OR: 5.78, 95% CI: 3.50, 9.54), rac 2-Aminothiazoline-4-carboxylic acid (ATCA, OR: 2.90, 95% CI: 1.69, 4.99) and N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine (DHBMA, OR: 2.76, 95% CI: 1.73, 4.43) which may derive from m/p-xylene, cyanide and 1,3-butadiene exposure, respectively, could significantly and maximally increase the odds of asthma.","['N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine', 'cyanide']",['asthma'],True,cyanide,asthma,increase,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cyanide,increase
982,12267,32899527,"Five metabolites (cotinine, creatinine riboside, N-acetylneuraminic acid, proline and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene) and five metabolite groups (total 3-hydroxycotinine, total cotinine, total nicotine, total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (sum of concentrations of the metabolite and its glucuronides), and total nicotine equivalent (sum of total 3-hydroxycotinine, total cotinine and total nicotine)) were associated with higher lung cancer risk, while three others (folate, methionine and tryptophan) were associated with lower lung cancer risk.","['N-acetylneuraminic acid', 'proline', 'nicotine', 'nicotine', 'nicotine']","['creatinine riboside', 'higher lung cancer', 'lower lung cancer']",True,N-acetylneuraminic acid,higher lung cancer,associated,C0242379,Lung cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",N-acetylneuraminic acid,associate
983,12267,32899527,"Five metabolites (cotinine, creatinine riboside, N-acetylneuraminic acid, proline and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene) and five metabolite groups (total 3-hydroxycotinine, total cotinine, total nicotine, total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (sum of concentrations of the metabolite and its glucuronides), and total nicotine equivalent (sum of total 3-hydroxycotinine, total cotinine and total nicotine)) were associated with higher lung cancer risk, while three others (folate, methionine and tryptophan) were associated with lower lung cancer risk.","['N-acetylneuraminic acid', 'proline', 'nicotine', 'nicotine', 'nicotine']","['creatinine riboside', 'higher lung cancer', 'lower lung cancer']",True,N-acetylneuraminic acid,lower lung cancer,associated,C0242379,Lung cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",N-acetylneuraminic acid,associate
984,12267,32899527,"Five metabolites (cotinine, creatinine riboside, N-acetylneuraminic acid, proline and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene) and five metabolite groups (total 3-hydroxycotinine, total cotinine, total nicotine, total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (sum of concentrations of the metabolite and its glucuronides), and total nicotine equivalent (sum of total 3-hydroxycotinine, total cotinine and total nicotine)) were associated with higher lung cancer risk, while three others (folate, methionine and tryptophan) were associated with lower lung cancer risk.","['N-acetylneuraminic acid', 'proline', 'nicotine', 'nicotine', 'nicotine']","['creatinine riboside', 'higher lung cancer', 'lower lung cancer']",True,proline,higher lung cancer,associated,C0242379,Lung cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",proline,associate
985,12267,32899527,"Five metabolites (cotinine, creatinine riboside, N-acetylneuraminic acid, proline and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene) and five metabolite groups (total 3-hydroxycotinine, total cotinine, total nicotine, total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (sum of concentrations of the metabolite and its glucuronides), and total nicotine equivalent (sum of total 3-hydroxycotinine, total cotinine and total nicotine)) were associated with higher lung cancer risk, while three others (folate, methionine and tryptophan) were associated with lower lung cancer risk.","['N-acetylneuraminic acid', 'proline', 'nicotine', 'nicotine', 'nicotine']","['creatinine riboside', 'higher lung cancer', 'lower lung cancer']",True,proline,lower lung cancer,associated,C0242379,Lung cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",proline,associate
986,12267,32899527,"Five metabolites (cotinine, creatinine riboside, N-acetylneuraminic acid, proline and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene) and five metabolite groups (total 3-hydroxycotinine, total cotinine, total nicotine, total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (sum of concentrations of the metabolite and its glucuronides), and total nicotine equivalent (sum of total 3-hydroxycotinine, total cotinine and total nicotine)) were associated with higher lung cancer risk, while three others (folate, methionine and tryptophan) were associated with lower lung cancer risk.","['N-acetylneuraminic acid', 'proline', 'nicotine', 'nicotine', 'nicotine']","['creatinine riboside', 'higher lung cancer', 'lower lung cancer']",True,nicotine,higher lung cancer,associated,C0242379,Lung cancer,89594,Nicotine,Nicotine,associate
987,12267,32899527,"Five metabolites (cotinine, creatinine riboside, N-acetylneuraminic acid, proline and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene) and five metabolite groups (total 3-hydroxycotinine, total cotinine, total nicotine, total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (sum of concentrations of the metabolite and its glucuronides), and total nicotine equivalent (sum of total 3-hydroxycotinine, total cotinine and total nicotine)) were associated with higher lung cancer risk, while three others (folate, methionine and tryptophan) were associated with lower lung cancer risk.","['N-acetylneuraminic acid', 'proline', 'nicotine', 'nicotine', 'nicotine']","['creatinine riboside', 'higher lung cancer', 'lower lung cancer']",True,nicotine,lower lung cancer,associated,C0242379,Lung cancer,89594,Nicotine,Nicotine,associate
988,12267,32899527,"Five metabolites (cotinine, creatinine riboside, N-acetylneuraminic acid, proline and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene) and five metabolite groups (total 3-hydroxycotinine, total cotinine, total nicotine, total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (sum of concentrations of the metabolite and its glucuronides), and total nicotine equivalent (sum of total 3-hydroxycotinine, total cotinine and total nicotine)) were associated with higher lung cancer risk, while three others (folate, methionine and tryptophan) were associated with lower lung cancer risk.","['N-acetylneuraminic acid', 'proline', 'nicotine', 'nicotine', 'nicotine']","['creatinine riboside', 'higher lung cancer', 'lower lung cancer']",True,nicotine,higher lung cancer,associated,C0242379,Lung cancer,89594,Nicotine,Nicotine,associate
989,12267,32899527,"Five metabolites (cotinine, creatinine riboside, N-acetylneuraminic acid, proline and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene) and five metabolite groups (total 3-hydroxycotinine, total cotinine, total nicotine, total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (sum of concentrations of the metabolite and its glucuronides), and total nicotine equivalent (sum of total 3-hydroxycotinine, total cotinine and total nicotine)) were associated with higher lung cancer risk, while three others (folate, methionine and tryptophan) were associated with lower lung cancer risk.","['N-acetylneuraminic acid', 'proline', 'nicotine', 'nicotine', 'nicotine']","['creatinine riboside', 'higher lung cancer', 'lower lung cancer']",True,nicotine,lower lung cancer,associated,C0242379,Lung cancer,89594,Nicotine,Nicotine,associate
990,12267,32899527,"Five metabolites (cotinine, creatinine riboside, N-acetylneuraminic acid, proline and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene) and five metabolite groups (total 3-hydroxycotinine, total cotinine, total nicotine, total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (sum of concentrations of the metabolite and its glucuronides), and total nicotine equivalent (sum of total 3-hydroxycotinine, total cotinine and total nicotine)) were associated with higher lung cancer risk, while three others (folate, methionine and tryptophan) were associated with lower lung cancer risk.","['N-acetylneuraminic acid', 'proline', 'nicotine', 'nicotine', 'nicotine']","['creatinine riboside', 'higher lung cancer', 'lower lung cancer']",True,nicotine,higher lung cancer,associated,C0242379,Lung cancer,89594,Nicotine,Nicotine,associate
991,12267,32899527,"Five metabolites (cotinine, creatinine riboside, N-acetylneuraminic acid, proline and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene) and five metabolite groups (total 3-hydroxycotinine, total cotinine, total nicotine, total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (sum of concentrations of the metabolite and its glucuronides), and total nicotine equivalent (sum of total 3-hydroxycotinine, total cotinine and total nicotine)) were associated with higher lung cancer risk, while three others (folate, methionine and tryptophan) were associated with lower lung cancer risk.","['N-acetylneuraminic acid', 'proline', 'nicotine', 'nicotine', 'nicotine']","['creatinine riboside', 'higher lung cancer', 'lower lung cancer']",True,nicotine,lower lung cancer,associated,C0242379,Lung cancer,89594,Nicotine,Nicotine,associate
992,12275,31678612,"Cotinine (0.1 to 1 mM) induced the highest cell proliferation compared to the others, including nicotine, in three bladder cancer cell lines (RT4, T24 and UMUC3 cells).","['Cotinine', 'nicotine']",['cancer'],True,Cotinine,cancer,induced,C0006826,Cancer,854019,cotinine,cotinine,induce
993,12275,31678612,"Cotinine (0.1 to 1 mM) induced the highest cell proliferation compared to the others, including nicotine, in three bladder cancer cell lines (RT4, T24 and UMUC3 cells).","['Cotinine', 'nicotine']",['cancer'],True,nicotine,cancer,induced,C0006826,Cancer,89594,Nicotine,Nicotine,induce
994,12277,31678612,"In an in vivo study, cotinine (13, 40 and 120 ppm) in drinking water also induced cell proliferation and simple hyperplasia in urinary bladder and renal pelvis urothelium of rats, but to a lesser degree compared to nicotine (40 ppm).","['cotinine', 'nicotine']","['cell proliferation', 'hyperplasia in urinary bladder', 'renal pelvis urothelium']",True,cotinine,cell proliferation,induced,C4531170,Abnormal cell proliferation,854019,cotinine,cotinine,induce
995,12277,31678612,"In an in vivo study, cotinine (13, 40 and 120 ppm) in drinking water also induced cell proliferation and simple hyperplasia in urinary bladder and renal pelvis urothelium of rats, but to a lesser degree compared to nicotine (40 ppm).","['cotinine', 'nicotine']","['cell proliferation', 'hyperplasia in urinary bladder', 'renal pelvis urothelium']",True,cotinine,hyperplasia in urinary bladder,induced,C4021531,Hypertrophy of the urinary bladder,854019,cotinine,cotinine,induce
996,12277,31678612,"In an in vivo study, cotinine (13, 40 and 120 ppm) in drinking water also induced cell proliferation and simple hyperplasia in urinary bladder and renal pelvis urothelium of rats, but to a lesser degree compared to nicotine (40 ppm).","['cotinine', 'nicotine']","['cell proliferation', 'hyperplasia in urinary bladder', 'renal pelvis urothelium']",True,nicotine,cell proliferation,induced,C4531170,Abnormal cell proliferation,89594,Nicotine,Nicotine,induce
997,12277,31678612,"In an in vivo study, cotinine (13, 40 and 120 ppm) in drinking water also induced cell proliferation and simple hyperplasia in urinary bladder and renal pelvis urothelium of rats, but to a lesser degree compared to nicotine (40 ppm).","['cotinine', 'nicotine']","['cell proliferation', 'hyperplasia in urinary bladder', 'renal pelvis urothelium']",True,nicotine,hyperplasia in urinary bladder,induced,C4021531,Hypertrophy of the urinary bladder,89594,Nicotine,Nicotine,induce
998,12300,29158210,"In conclusion, pregnancy-induced increases in nicotine metabolism start by 12 weeks gestation and continue as pregnancy progresses most likely due to induction of CYP2A6 and UGT2B10, resulting in potential reductions in the effectiveness of nicotine replacement therapies and an increase in metabolism of other CYP2A6 and UGT2B10 substrates during pregnancy.","['nicotine', 'nicotine']",['increase in metabolism'],True,nicotine,increase in metabolism,resulting,C5139220,Abnormal metabolism,89594,Nicotine,Nicotine,result
999,12319,35288978," RESULTS: In MAP, compared to ≤100mg/d, caffeine intake >100mg/d was associated with a significantly higher HR(95%CI) of all-cause[1.35(1.03,1.76)] and Alzheimer's[1.41(1.07,1.85)] dementia.",['caffeine'],['dementia'],True,caffeine,dementia,associated,C0497327,"Dementia, progressive",2519,Caffeine,Caffeine,associate
1000,12321,35285887,"  The impact of drug-foods (tobacco and cane sugar, cocoa and caffeine) and the consequences of their production on the health of both public and planet are wide ranging and increasing from obesity to pressure on water supply.","['caffeine', 'water']",['obesity'],True,water,obesity,increasing,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,increase
1001,12322,35285102,"  Caffeine has a significant effect on cerebrovascular systems, and the dual action of caffeine on both neural and vascular responses leads to concerns for the interpretation of blood oxygenation level-dependent (BOLD) functional MRI (fMRI).",['caffeine'],['blood oxygenation'],True,caffeine,blood oxygenation,leads,C0700292,Low blood oxygen level,2519,Caffeine,Caffeine,lead
1002,12381,30442421,  Oxidative nucleophilic substitution selectively produces cambinol derivatives with antiproliferative activity on bladder cancer cell lines.,['cambinol'],['cancer'],True,cambinol,cancer,produces,C0006826,Cancer,3246390,Cambinol,Cambinol,produce
1003,12394,23339189,"In an orthotopic  xenograft model, knockdown of SIRT1 resulted in 50% fewer animals developing tumors and cambinol treatment resulted in an overall lower tumor burden.",['cambinol'],['tumors'],True,cambinol,tumors,resulted,C0022665,Renal neoplasia,3246390,Cambinol,Cambinol,result
1004,12452,30158316,"Here, we discovered that ritanserin induced apoptotic cell death of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells via a  serotonin-independent mechanism.",['ritanserin'],"['apoptotic cell death', 'cancer', 'small cell lung cancer']",True,ritanserin,cancer,induced,C0006826,Cancer,5074,Ritanserin,Ritanserin,induce
1005,12452,30158316,"Here, we discovered that ritanserin induced apoptotic cell death of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells via a  serotonin-independent mechanism.",['ritanserin'],"['apoptotic cell death', 'cancer', 'small cell lung cancer']",True,ritanserin,small cell lung cancer,induced,C0149925,Small cell lung carcinoma,5074,Ritanserin,Ritanserin,induce
1006,12459,29118192,"  Endocannabinoids, such as 2-arachidonoyl glycerol (2-AG) and anandamide, can elicit long-term depression of both excitatory and inhibitory synapses.","['2-arachidonoyl glycerol', 'anandamide']",['depression'],True,2-arachidonoyl glycerol,depression,elicit,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-arachidonoyl glycerol,elicit
1007,12459,29118192,"  Endocannabinoids, such as 2-arachidonoyl glycerol (2-AG) and anandamide, can elicit long-term depression of both excitatory and inhibitory synapses.","['2-arachidonoyl glycerol', 'anandamide']",['depression'],True,anandamide,depression,elicit,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",anandamide,elicit
1008,12462,28890736,"This 25B-NBOMe-induced rhabdomyolysis was inhibited by the 5-HT2A receptor antagonists ritanserin and aripirazole, but not  by the 5-HT1A + 5-HT1B receptor antagonist propranolol and the 5-HT3 receptor antagonist granisetron, indicating 5-HT2A-dependent rhabdomyolysis.","['ritanserin', 'aripirazole', 'granisetron']",['rhabdomyolysis'],True,ritanserin,rhabdomyolysis,inhibited,C0035410,Breakdown of skeletal muscle,5074,Ritanserin,Ritanserin,inhibit
1009,12462,28890736,"This 25B-NBOMe-induced rhabdomyolysis was inhibited by the 5-HT2A receptor antagonists ritanserin and aripirazole, but not  by the 5-HT1A + 5-HT1B receptor antagonist propranolol and the 5-HT3 receptor antagonist granisetron, indicating 5-HT2A-dependent rhabdomyolysis.","['ritanserin', 'aripirazole', 'granisetron']",['rhabdomyolysis'],True,aripirazole,rhabdomyolysis,inhibited,C0035410,Breakdown of skeletal muscle,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aripirazole,inhibit
1010,12462,28890736,"This 25B-NBOMe-induced rhabdomyolysis was inhibited by the 5-HT2A receptor antagonists ritanserin and aripirazole, but not  by the 5-HT1A + 5-HT1B receptor antagonist propranolol and the 5-HT3 receptor antagonist granisetron, indicating 5-HT2A-dependent rhabdomyolysis.","['ritanserin', 'aripirazole', 'granisetron']",['rhabdomyolysis'],True,granisetron,rhabdomyolysis,inhibited,C0035410,Breakdown of skeletal muscle,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",granisetron,inhibit
1011,12464,28647281,  We previously demonstrated that nicotine elicited kinetic tremor by elevating the neural activity of the inferior olive via α7 nicotinic acetylcholine (nACh) receptors.,"['nicotine', 'nicotinic acetylcholine']",['tremor'],True,nicotine,tremor,elicited,C0040822,Tremors,89594,Nicotine,Nicotine,elicit
1012,12493,25382136,"Recent reports have suggested that perinatal exposure to selective serotonin reuptake inhibitors (SSRIs) resulted in cortical  network miswiring, abnormal social behavior, callosal myelin malformation, as well as oligodendrocyte (OL) pathology in rats.",['serotonin'],"['abnormal social behavior', 'callosal myelin malformation']",True,serotonin,abnormal social behavior,resulted,C4021087,Abnormal social behavior,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,result
1013,12570,34357964,"The research resulted in a conclusion that applications of ergot in gynecology and obstetrics in the 19th century were limited to controlling excessive uterine bleeding and irregular spasms, treatment of fibrous tumors of the uterus, and prevention of miscarriage, abortion, and amenorrhoea.",['ergot'],"['excessive uterine bleeding', 'irregular spasms', 'treatment of fibrous tumors of the uterus', 'miscarriage', 'abortion', 'amenorrhoea']",True,ergot,miscarriage,resulted,C0000786,Miscarriage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ergot,result
1014,12577,34128998,"Use of triptans, nonsteroidal anti-inflammatory drugs, acetaminophen, dihydroergotamine, calcitonin gene-related peptide antagonists, lasmiditan, and some nonpharmacologic treatments was associated with improved pain and function.","['acetaminophen', 'dihydroergotamine', 'calcitonin', 'lasmiditan']",['pain'],True,acetaminophen,pain,associated,C0030193,Pain,1983,Acetaminophen,Acetaminophen,associate
1015,12577,34128998,"Use of triptans, nonsteroidal anti-inflammatory drugs, acetaminophen, dihydroergotamine, calcitonin gene-related peptide antagonists, lasmiditan, and some nonpharmacologic treatments was associated with improved pain and function.","['acetaminophen', 'dihydroergotamine', 'calcitonin', 'lasmiditan']",['pain'],True,dihydroergotamine,pain,associated,C0030193,Pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dihydroergotamine,associate
1016,12577,34128998,"Use of triptans, nonsteroidal anti-inflammatory drugs, acetaminophen, dihydroergotamine, calcitonin gene-related peptide antagonists, lasmiditan, and some nonpharmacologic treatments was associated with improved pain and function.","['acetaminophen', 'dihydroergotamine', 'calcitonin', 'lasmiditan']",['pain'],True,calcitonin,pain,associated,C0030193,Pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcitonin,associate
1017,12577,34128998,"Use of triptans, nonsteroidal anti-inflammatory drugs, acetaminophen, dihydroergotamine, calcitonin gene-related peptide antagonists, lasmiditan, and some nonpharmacologic treatments was associated with improved pain and function.","['acetaminophen', 'dihydroergotamine', 'calcitonin', 'lasmiditan']",['pain'],True,lasmiditan,pain,associated,C0030193,Pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lasmiditan,associate
1018,12595,31792093,"Ergotamine ingestion (n = 16) resulted in abdominal pain (16%), vomiting (12.5%), numbness (12.5%), nausea (6.3%), diarrhea (6.3%), and vertigo (6.3%).",['Ergotamine'],"['abdominal pain', 'vomiting', 'numbness', 'nausea', 'diarrhea']",True,Ergotamine,abdominal pain,resulted,C0000737,Stomach pain,8223,ERGOTAMINE,ERGOTAMINE,result
1019,12595,31792093,"Ergotamine ingestion (n = 16) resulted in abdominal pain (16%), vomiting (12.5%), numbness (12.5%), nausea (6.3%), diarrhea (6.3%), and vertigo (6.3%).",['Ergotamine'],"['abdominal pain', 'vomiting', 'numbness', 'nausea', 'diarrhea']",True,Ergotamine,vomiting,resulted,C0042963,Throwing up,8223,ERGOTAMINE,ERGOTAMINE,result
1020,12595,31792093,"Ergotamine ingestion (n = 16) resulted in abdominal pain (16%), vomiting (12.5%), numbness (12.5%), nausea (6.3%), diarrhea (6.3%), and vertigo (6.3%).",['Ergotamine'],"['abdominal pain', 'vomiting', 'numbness', 'nausea', 'diarrhea']",True,Ergotamine,nausea,resulted,C0027497,Nausea,8223,ERGOTAMINE,ERGOTAMINE,result
1021,12595,31792093,"Ergotamine ingestion (n = 16) resulted in abdominal pain (16%), vomiting (12.5%), numbness (12.5%), nausea (6.3%), diarrhea (6.3%), and vertigo (6.3%).",['Ergotamine'],"['abdominal pain', 'vomiting', 'numbness', 'nausea', 'diarrhea']",True,Ergotamine,diarrhea,resulted,C0011991,Diarrhoea,8223,ERGOTAMINE,ERGOTAMINE,result
1022,12600,31575844,The authors consider that ergotamine might have triggered tongue ischemia in this case.,['ergotamine'],['tongue ischemia'],True,ergotamine,tongue ischemia,triggered,C0011991,Diarrhoea,8223,ERGOTAMINE,ERGOTAMINE,trigger
1023,12604,31248334,"Conclusions and clinical relevance: A single oral dose of 300 mg/kg bromide in lambs with neurological signs of PRGT resulted in reduced composite gait scores and reduced  RMS voltages, indicating a significant improvement in clinical signs of ataxia, movement disorder and muscle tremor associated with the neurotoxic effects of lolitrem B.  DOI: 10.1080/00480169.2019.1637300  PMID: 31248334  [Indexed for MEDLINE]  ","['bromide', 'PRGT']","['reduced composite gait scores', 'ataxia']",True,bromide,ataxia,resulted,C0007758,Cerebellar ataxia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bromide,result
1024,12608,30763439,"Increasing concentrations of serotonin resulted in negligible responses in uterine preparations, whereas umbilical artery preparations were responsive (P < 0.05) to serotonin.","['serotonin', 'serotonin']",['umbilical artery'],True,serotonin,umbilical artery,resulted,C1384670,2 vessel cord,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,result
1025,12608,30763439,"Increasing concentrations of serotonin resulted in negligible responses in uterine preparations, whereas umbilical artery preparations were responsive (P < 0.05) to serotonin.","['serotonin', 'serotonin']",['umbilical artery'],True,serotonin,umbilical artery,resulted,C1384670,2 vessel cord,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,result
1026,12640,31213753,"The headache intensity two hours after ingestion of the study medication increased more frequently with sumatriptan, while other adverse events were rare in both groups.",['sumatriptan'],['headache intensity'],True,sumatriptan,headache intensity,increased,C0018681,Headaches,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sumatriptan,increase
1027,12644,35274935,"In particular, the fluoroquinolone molecules produced singlet oxygen (1O2) to kill cancer cells, and this was triggered by UCNPs when irradiation was performed with a 980 nm laser.","['fluoroquinolone', 'singlet', 'oxygen']","['kill', 'cancer']",True,fluoroquinolone,cancer,produced,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluoroquinolone,produce
1028,12644,35274935,"In particular, the fluoroquinolone molecules produced singlet oxygen (1O2) to kill cancer cells, and this was triggered by UCNPs when irradiation was performed with a 980 nm laser.","['fluoroquinolone', 'singlet', 'oxygen']","['kill', 'cancer']",True,singlet,cancer,produced,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",singlet,produce
1029,12644,35274935,"In particular, the fluoroquinolone molecules produced singlet oxygen (1O2) to kill cancer cells, and this was triggered by UCNPs when irradiation was performed with a 980 nm laser.","['fluoroquinolone', 'singlet', 'oxygen']","['kill', 'cancer']",True,oxygen,cancer,produced,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,produce
1030,12690,29277118,"  OBJECTIVE: In this study, PEGylated rosin derivatives (PRDs) namely D1 and D2 were synthesized and evaluated for their application to produce sustained-release antibacterial films containing sparfloxacin for periodontitis.",['sparfloxacin'],['periodontitis'],True,sparfloxacin,periodontitis,produce,C0031099,Periodontitis,60464,Sparfloxacin,Sparfloxacin,produce
1031,12693,29277118, CONCLUSION: Results revealed that PRDs can be used successfully to produce sustained-release antibacterial films containing sparfloxacin for the treatment of periodontitis.,['sparfloxacin'],['periodontitis'],True,sparfloxacin,periodontitis,produce,C0031099,Periodontitis,60464,Sparfloxacin,Sparfloxacin,produce
1032,12696,29196029,"  The aim of the present work was to evaluate the effects of photo-activated toxicity induced after administration of two known melanin-binding phototoxic compounds, sparfloxacin (SPX) and 8-methoxypsoralen (8-MOP), followed or not by UVA/Vis exposure, in pigmented rats (Long Evans: LE) and albino rats (Sprague Dawley: SD).","['sparfloxacin', '8-methoxypsoralen']",['melanin-binding'],True,sparfloxacin,melanin-binding,induced,C0031099,Periodontitis,60464,Sparfloxacin,Sparfloxacin,induce
1033,12703,27297489,"However, GyrB-E540D caused low-level resistance to early-generation quinolones, including  ofloxacin, levofloxacin, and ciprofloxacin (2- to 4-fold increases in MICs and 1.5- to 2.0-fold increases in IC50s).","['ofloxacin', 'levofloxacin', 'ciprofloxacin']",['low-level resistance to early-generation quinolones'],True,ofloxacin,low-level resistance to early-generation quinolones,caused,C0031099,Periodontitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ofloxacin,cause
1034,12703,27297489,"However, GyrB-E540D caused low-level resistance to early-generation quinolones, including  ofloxacin, levofloxacin, and ciprofloxacin (2- to 4-fold increases in MICs and 1.5- to 2.0-fold increases in IC50s).","['ofloxacin', 'levofloxacin', 'ciprofloxacin']",['low-level resistance to early-generation quinolones'],True,levofloxacin,low-level resistance to early-generation quinolones,caused,C0031099,Periodontitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",levofloxacin,cause
1035,12703,27297489,"However, GyrB-E540D caused low-level resistance to early-generation quinolones, including  ofloxacin, levofloxacin, and ciprofloxacin (2- to 4-fold increases in MICs and 1.5- to 2.0-fold increases in IC50s).","['ofloxacin', 'levofloxacin', 'ciprofloxacin']",['low-level resistance to early-generation quinolones'],True,ciprofloxacin,low-level resistance to early-generation quinolones,caused,C0031099,Periodontitis,2764,Ciprofloxacin,Ciprofloxacin,cause
1036,12704,27199950,"Several compounds increased the bacterial susceptibility toward nalidixic acid, chloramphenicol and sparfloxacin and were further pharmacomodulated to obtain a better activity against the AcrAB producing bacteria.","['nalidixic acid', 'chloramphenicol', 'sparfloxacin']",['bacterial susceptibility'],True,nalidixic acid,bacterial susceptibility,increased,C0031099,Periodontitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",nalidixic acid,increase
1037,12704,27199950,"Several compounds increased the bacterial susceptibility toward nalidixic acid, chloramphenicol and sparfloxacin and were further pharmacomodulated to obtain a better activity against the AcrAB producing bacteria.","['nalidixic acid', 'chloramphenicol', 'sparfloxacin']",['bacterial susceptibility'],True,chloramphenicol,bacterial susceptibility,increased,C0031099,Periodontitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chloramphenicol,increase
1038,12704,27199950,"Several compounds increased the bacterial susceptibility toward nalidixic acid, chloramphenicol and sparfloxacin and were further pharmacomodulated to obtain a better activity against the AcrAB producing bacteria.","['nalidixic acid', 'chloramphenicol', 'sparfloxacin']",['bacterial susceptibility'],True,sparfloxacin,bacterial susceptibility,increased,C0031099,Periodontitis,60464,Sparfloxacin,Sparfloxacin,increase
1039,12746,34327026,One hypothesis suggests antibody-dependent pathways which cause thrombocytopenia upon subsequent reexposure to eptifibatide.,['eptifibatide'],['thrombocytopenia'],True,eptifibatide,thrombocytopenia,cause,C0040034,Thrombocytopenia,448812,Eptifibatide,Eptifibatide,cause
1040,12768,32807436," CONCLUSIONS: The use of eptifibatide post procedure was associated with low risk  of symptomatic intracranial hemorrhage, including in patients treated with rtPA.",['eptifibatide'],['intracranial hemorrhage'],True,eptifibatide,intracranial hemorrhage,associated,C0151699,Intracranial hemorrhage,448812,Eptifibatide,Eptifibatide,associate
1041,12771,34805930," Conclusion: Both eptifibatide and tirofiban can effectively inhibit platelets, but the effect of etifeptide is better than that of tirofiban in preventing intracranial microhemorrhage and asymptomatic cerebral infarction.","['eptifibatide', 'tirofiban', 'tirofiban']",['intracranial microhemorrhage'],True,eptifibatide,intracranial microhemorrhage,inhibit,C0151699,Intracranial hemorrhage,448812,Eptifibatide,Eptifibatide,inhibit
1042,12771,34805930," Conclusion: Both eptifibatide and tirofiban can effectively inhibit platelets, but the effect of etifeptide is better than that of tirofiban in preventing intracranial microhemorrhage and asymptomatic cerebral infarction.","['eptifibatide', 'tirofiban', 'tirofiban']",['intracranial microhemorrhage'],True,tirofiban,intracranial microhemorrhage,inhibit,C0151699,Intracranial hemorrhage,60947,(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid,(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid,inhibit
1043,12771,34805930," Conclusion: Both eptifibatide and tirofiban can effectively inhibit platelets, but the effect of etifeptide is better than that of tirofiban in preventing intracranial microhemorrhage and asymptomatic cerebral infarction.","['eptifibatide', 'tirofiban', 'tirofiban']",['intracranial microhemorrhage'],True,tirofiban,intracranial microhemorrhage,inhibit,C0151699,Intracranial hemorrhage,60947,(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid,(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid,inhibit
1044,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,abciximab,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",abciximab,cause
1045,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,carbamazepine,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carbamazepine,cause
1046,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,ceftriaxone,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ceftriaxone,cause
1047,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,eptifibatide,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,448812,Eptifibatide,Eptifibatide,cause
1048,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,heparin,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",heparin,cause
1049,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,ibuprofen,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,3672,Ibuprofen,Ibuprofen,cause
1050,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,mirtazapine,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mirtazapine,cause
1051,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,oxaliplatin,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxaliplatin,cause
1052,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,penicillin,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",penicillin,cause
1053,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,quinine,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",quinine,cause
1054,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,quinidine,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",quinidine,cause
1055,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,rifampicin,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rifampicin,cause
1056,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,suramin,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",suramin,cause
1057,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,tirofiban,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,60947,(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid,(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid,cause
1058,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,trimethoprim-sulfamethoxazole,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trimethoprim-sulfamethoxazole,cause
1059,12778,32668640,"Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin.","['abciximab', 'carbamazepine', 'ceftriaxone', 'eptifibatide', 'heparin', 'ibuprofen', 'mirtazapine', 'oxaliplatin', 'penicillin', 'quinine', 'quinidine', 'rifampicin', 'suramin', 'tirofiban', 'trimethoprim-sulfamethoxazole', 'vancomycin']",['immune-mediated thrombocytopenia'],True,vancomycin,immune-mediated thrombocytopenia,cause,C0242584,Immune thrombocytopenia,14969,"(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid","(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid",cause
1060,12793,31877725,"Consistent  with their different binding epitopes, a combination of TFV-1 and AP2 did not induce FcγRIIa-mediated activation of the ITAM-Syk-PLCγ2 pathway and platelet aggregation, in contrast to the clinical antithrombotics, abciximab, eptifibatide, and disintegrin TFV-3.","['abciximab', 'eptifibatide', 'disintegrin']",['platelet aggregation'],True,abciximab,platelet aggregation,induce,C0541767,Abnormal platelet aggregation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",abciximab,induce
1061,12793,31877725,"Consistent  with their different binding epitopes, a combination of TFV-1 and AP2 did not induce FcγRIIa-mediated activation of the ITAM-Syk-PLCγ2 pathway and platelet aggregation, in contrast to the clinical antithrombotics, abciximab, eptifibatide, and disintegrin TFV-3.","['abciximab', 'eptifibatide', 'disintegrin']",['platelet aggregation'],True,eptifibatide,platelet aggregation,induce,C0541767,Abnormal platelet aggregation,448812,Eptifibatide,Eptifibatide,induce
1062,12793,31877725,"Consistent  with their different binding epitopes, a combination of TFV-1 and AP2 did not induce FcγRIIa-mediated activation of the ITAM-Syk-PLCγ2 pathway and platelet aggregation, in contrast to the clinical antithrombotics, abciximab, eptifibatide, and disintegrin TFV-3.","['abciximab', 'eptifibatide', 'disintegrin']",['platelet aggregation'],True,disintegrin,platelet aggregation,induce,C0541767,Abnormal platelet aggregation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",disintegrin,induce
1063,12802,31766977,"Eptifibatide bolus plus clopidogrel, but not CTIC, significantly inhibited platelet aggregation induced by thrombin-receptor activating peptide.","['Eptifibatide bolus', 'clopidogrel']",['platelet aggregation'],True,Eptifibatide bolus,platelet aggregation,inhibited,C0541767,Abnormal platelet aggregation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Eptifibatide bolus,inhibit
1064,12802,31766977,"Eptifibatide bolus plus clopidogrel, but not CTIC, significantly inhibited platelet aggregation induced by thrombin-receptor activating peptide.","['Eptifibatide bolus', 'clopidogrel']",['platelet aggregation'],True,clopidogrel,platelet aggregation,inhibited,C0541767,Abnormal platelet aggregation,60606,"methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate","methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate",inhibit
1065,12816,31197974,The dosage of eptifibatide recommended on the label for whites can effectively inhibit platelet aggregation.,['eptifibatide'],['platelet aggregation'],True,eptifibatide,platelet aggregation,inhibit,C0541767,Abnormal platelet aggregation,448812,Eptifibatide,Eptifibatide,inhibit
1066,12819,31175488,"LPS causes hemolysis, schistocyte formation, and red cell membrane weakening in rats.",['LPS'],"['hemolysis', 'schistocyte formation', 'red cell membrane weakening']",True,LPS,hemolysis,causes,C0002878,Increased hemolysis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",LPS,cause
1067,12819,31175488,"LPS causes hemolysis, schistocyte formation, and red cell membrane weakening in rats.",['LPS'],"['hemolysis', 'schistocyte formation', 'red cell membrane weakening']",True,LPS,schistocyte formation,causes,C0002878,Increased hemolysis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",LPS,cause
1068,12854,34109517,  Acute ethanol intoxication increases the risk of sepsis and aggravates the symptoms of sepsis and lung injury.,['ethanol'],"['sepsis', 'aggravates the symptoms of sepsis', 'lung injury']",True,ethanol,sepsis,increases,C0036690,Infection in blood stream,702,Ethanol,Ethanol,increase
1069,12854,34109517,  Acute ethanol intoxication increases the risk of sepsis and aggravates the symptoms of sepsis and lung injury.,['ethanol'],"['sepsis', 'aggravates the symptoms of sepsis', 'lung injury']",True,ethanol,aggravates the symptoms of sepsis,increases,C0036690,Infection in blood stream,702,Ethanol,Ethanol,increase
1070,12855,34109517,"Therefore, this study aimed to explore whether sphingosine kinase 1 (SphK1)/sphingosine-1-phosphate (S1P)/S1P receptor 1 (S1PR1) signaling pathway functions in lung injury caused by acute ethanol intoxication-enhanced sepsis, as well as its underlying mechanism.",['ethanol'],['sepsis'],True,ethanol,sepsis,caused,C0036690,Infection in blood stream,702,Ethanol,Ethanol,cause
1071,12858,34109517,PF-543 alleviated lung injury caused by sepsis in acute ethanol intoxication rats by suppressing the SphK1/S1P/S1PR1 signaling pathway.,['ethanol'],"['lung injury', 'sepsis', 'suppressing the SphK1/S1P/S1PR1 signaling pathway']",True,ethanol,sepsis,caused,C0036690,Infection in blood stream,702,Ethanol,Ethanol,cause
1072,12903,29439513,"In animal models, the severely hemorrhagic toxicity of D. acutus and A. halys venom was almost fully inhibited after administration of varespladib.",['varespladib'],['hemorrhagic'],True,varespladib,hemorrhagic,inhibited,C1458140,Abnormal bleeding,155815,Varespladib,Varespladib,inhibit
1073,12910,25820137,"Treatment with either  indomethacin (to inhibit cyclooxygenase-dependent eicosanoid production) or varespladib (which inhibited eicosanoid production) triggered acute hypertension  in Mmp2(-/-) mice, revealing their reliance on eicosanoids for blood pressure homeostasis.","['indomethacin', 'varespladib']","['acute hypertension  ', 'blood pressure homeostasis']",True,indomethacin,acute hypertension  ,triggered,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",indomethacin,trigger
1074,12910,25820137,"Treatment with either  indomethacin (to inhibit cyclooxygenase-dependent eicosanoid production) or varespladib (which inhibited eicosanoid production) triggered acute hypertension  in Mmp2(-/-) mice, revealing their reliance on eicosanoids for blood pressure homeostasis.","['indomethacin', 'varespladib']","['acute hypertension  ', 'blood pressure homeostasis']",True,varespladib,acute hypertension  ,triggered,C0020538,Systemic hypertension,155815,Varespladib,Varespladib,trigger
1075,12918,23349189,"  OBJECTIVE: Several secreted phospholipases A2 (sPLA2s), including group IIA, III, V, and X, have been linked to the development of atherosclerosis, which led to the clinical testing of A-002 (varespladib), a broad sPLA2 inhibitor for the treatment of coronary artery disease.",['A-002'],"['atherosclerosis', 'coronary artery disease']",True,A-002,atherosclerosis,linked,C0004153,Narrowing and hardening of arteries,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",A-002,link
1076,12918,23349189,"  OBJECTIVE: Several secreted phospholipases A2 (sPLA2s), including group IIA, III, V, and X, have been linked to the development of atherosclerosis, which led to the clinical testing of A-002 (varespladib), a broad sPLA2 inhibitor for the treatment of coronary artery disease.",['A-002'],"['atherosclerosis', 'coronary artery disease']",True,A-002,coronary artery disease,linked,C1956346,Coronary disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",A-002,link
1077,12918,23349189,"  OBJECTIVE: Several secreted phospholipases A2 (sPLA2s), including group IIA, III, V, and X, have been linked to the development of atherosclerosis, which led to the clinical testing of A-002 (varespladib), a broad sPLA2 inhibitor for the treatment of coronary artery disease.",['A-002'],"['atherosclerosis', 'coronary artery disease']",True,A-002,coronary artery disease,led,C1956346,Coronary disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",A-002,lead
1078,12934,21081550,"Varespladib  methyl treatment resulted in statistically significant dose-dependent reductions  that were different from placebo in sPLA(2) concentration, low-density lipoprotein (LDL) cholesterol, and non-high-density lipoprotein (HDL) cholesterol.","['Varespladib', 'LDL', 'cholesterol', 'HDL']",['low-density lipoprotein'],True,Varespladib,low-density lipoprotein,resulted,C1956346,Coronary disease,155815,Varespladib,Varespladib,result
1079,12967,15467263,"Combined intraductal injection of sodium taurocholate (5 mg/rat) and porcine pancreatic sPLA2-IB (300 microg/rat) caused severe hemorrhagic necrotizing pancreatitis resulting in high mortality, along with rapid increases  of catalytic PLA2 and lipase activities in plasma and ascites and with gradual increases of plasma amylase and aspartate aminotransferase levels over 9 h after  the pancreatitis.",['sodium taurocholate'],"['severe hemorrhagic necrotizing pancreatitis', 'high mortality', 'ascites', 'increases of plasma amylase and aspartate aminotransferase levels', 'pancreatitis']",True,sodium taurocholate,ascites,caused,C0003962,Ascites,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium taurocholate,cause
1080,12967,15467263,"Combined intraductal injection of sodium taurocholate (5 mg/rat) and porcine pancreatic sPLA2-IB (300 microg/rat) caused severe hemorrhagic necrotizing pancreatitis resulting in high mortality, along with rapid increases  of catalytic PLA2 and lipase activities in plasma and ascites and with gradual increases of plasma amylase and aspartate aminotransferase levels over 9 h after  the pancreatitis.",['sodium taurocholate'],"['severe hemorrhagic necrotizing pancreatitis', 'high mortality', 'ascites', 'increases of plasma amylase and aspartate aminotransferase levels', 'pancreatitis']",True,sodium taurocholate,increases of plasma amylase and aspartate aminotransferase levels,caused,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium taurocholate,cause
1081,12967,15467263,"Combined intraductal injection of sodium taurocholate (5 mg/rat) and porcine pancreatic sPLA2-IB (300 microg/rat) caused severe hemorrhagic necrotizing pancreatitis resulting in high mortality, along with rapid increases  of catalytic PLA2 and lipase activities in plasma and ascites and with gradual increases of plasma amylase and aspartate aminotransferase levels over 9 h after  the pancreatitis.",['sodium taurocholate'],"['severe hemorrhagic necrotizing pancreatitis', 'high mortality', 'ascites', 'increases of plasma amylase and aspartate aminotransferase levels', 'pancreatitis']",True,sodium taurocholate,pancreatitis,caused,C0030305,Pancreatitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium taurocholate,cause
1082,13000,30443714,"In addition, dicoumarol inhibited also the Mrp1-mediated export of GSSG during menadione-induced oxidative stress and the export of the GSH-bimane-conjugate (GS-B) that had been generated in the cells after exposure to monochlorobimane.","['dicoumarol', 'GSSG', 'monochlorobimane']",['oxidative stress'],True,dicoumarol,oxidative stress,inhibited,C0242606,Oxidative stress,54676038,Dicumarol,Dicumarol,inhibit
1083,13000,30443714,"In addition, dicoumarol inhibited also the Mrp1-mediated export of GSSG during menadione-induced oxidative stress and the export of the GSH-bimane-conjugate (GS-B) that had been generated in the cells after exposure to monochlorobimane.","['dicoumarol', 'GSSG', 'monochlorobimane']",['oxidative stress'],True,GSSG,oxidative stress,inhibited,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",GSSG,inhibit
1084,13000,30443714,"In addition, dicoumarol inhibited also the Mrp1-mediated export of GSSG during menadione-induced oxidative stress and the export of the GSH-bimane-conjugate (GS-B) that had been generated in the cells after exposure to monochlorobimane.","['dicoumarol', 'GSSG', 'monochlorobimane']",['oxidative stress'],True,monochlorobimane,oxidative stress,inhibited,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",monochlorobimane,inhibit
1085,13028,26971361," CONCLUSIONS: The presence of a high thrombotic or haemorrhagic risk and the failure of previous dicoumarin therapy lead to choosing a new oral anticoagulant  in patients with non-valvular atrial fibrillation, while kidney failure, cognitive impairment, good control with dicoumarins, and a low bleeding risk predispose to selecting a classic dicoumarin anticoagulant.",['dicoumarins'],"['failure of previous dicoumarin therapy', 'kidney failure']",True,dicoumarins,kidney failure,lead,C0022660,Acute kidney failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dicoumarins,lead
1086,13030,26969764,"In detail, miltirone induced direct mitochondrial damage, including significant decrease of mitochondrial ROS, MMP, mass and increase of intracellular ROS and Ca(2+).",['miltirone'],"['decrease of mitochondrial ROS', 'increase of intracellular ROS and Ca(2']",True,miltirone,decrease of mitochondrial ROS,induced,C0887941,Mitochondrial inheritance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",miltirone,induce
1087,13030,26969764,"In detail, miltirone induced direct mitochondrial damage, including significant decrease of mitochondrial ROS, MMP, mass and increase of intracellular ROS and Ca(2+).",['miltirone'],"['decrease of mitochondrial ROS', 'increase of intracellular ROS and Ca(2']",True,miltirone,increase of intracellular ROS,induced,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",miltirone,induce
1088,13034,26838129,"Additionally, changes in global  stability due to polymorphisms and ligand binding are linked to the dynamics of the dimer interface, whereas the low activity and affinity for FAD in p.P187S is  caused by increased fluctuations at the FAD binding site.","['FAD', 'FAD']","['ligand binding', 'increased fluctuations']",True,FAD,increased fluctuations,linked,C0231241,Fluctuating,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",FAD,link
1089,13034,26838129,"Additionally, changes in global  stability due to polymorphisms and ligand binding are linked to the dynamics of the dimer interface, whereas the low activity and affinity for FAD in p.P187S is  caused by increased fluctuations at the FAD binding site.","['FAD', 'FAD']","['ligand binding', 'increased fluctuations']",True,FAD,increased fluctuations,linked,C0231241,Fluctuating,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",FAD,link
1090,13034,26838129,"Additionally, changes in global  stability due to polymorphisms and ligand binding are linked to the dynamics of the dimer interface, whereas the low activity and affinity for FAD in p.P187S is  caused by increased fluctuations at the FAD binding site.","['FAD', 'FAD']","['ligand binding', 'increased fluctuations']",True,FAD,increased fluctuations,caused,C0231241,Fluctuating,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",FAD,cause
1091,13038,26602448,"Combining ß-lapachone with XRCC1 knockdown or methoxyamine (MeOX), an apyrimidinic/apurinic (AP)-modifying agent,  led to NQO1-dependent synergistic killing in PDA, NSCLC, breast and head and neck cancers.",['methoxyamine'],"['apyrimidinic/apurinic', 'breast']",True,methoxyamine,breast,led,C0266009,Mammary gland aplasia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methoxyamine,lead
1092,13048,25638376,"Aristolochic acid causes aristolochic acid nephropathy (AAN), and Balkan endemic nephropathy (BEN), as well as associated urothelial malignancies.","['Aristolochic acid', 'aristolochic acid']","['nephropathy', 'associated urothelial malignancies']",True,Aristolochic acid,nephropathy,causes,C0022658,Kidney disease,2236,"8-methoxy-6-nitronaphtho[2,1-g][1,3]benzodioxole-5-carboxylic acid","8-methoxy-6-nitronaphtho[2,1-g][1,3]benzodioxole-5-carboxylic acid",cause
1093,13048,25638376,"Aristolochic acid causes aristolochic acid nephropathy (AAN), and Balkan endemic nephropathy (BEN), as well as associated urothelial malignancies.","['Aristolochic acid', 'aristolochic acid']","['nephropathy', 'associated urothelial malignancies']",True,aristolochic acid,nephropathy,causes,C0022658,Kidney disease,2236,"8-methoxy-6-nitronaphtho[2,1-g][1,3]benzodioxole-5-carboxylic acid","8-methoxy-6-nitronaphtho[2,1-g][1,3]benzodioxole-5-carboxylic acid",cause
1094,13055,25566548,"We  found that the cytotoxicity of aziridinyl-unsubstituted quinones (n = 12) in mice splenocytes with a low amount of NQO1, 4 nmol × mg(-1) × min(-1), was caused mainly by the oxidative stress.",['aziridinyl-unsubstituted quinones'],['oxidative stress'],True,aziridinyl-unsubstituted quinones,oxidative stress,caused,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aziridinyl-unsubstituted quinones,cause
1095,13066,25051199,"ANE-induced cytotoxicity was inhibited by catalase and enhanced by dicoumarol, suggesting that AN components may contribute to the pathogenesis of OSF and oral cancer via  induction of aberrant differentiation, cytotoxicity, COX-2 expression, and PGE2/PGF2α production.",['dicoumarol'],"['pathogenesis', 'cancer', 'cytotoxicity', 'PGE2/PGF2α production']",True,dicoumarol,PGE2/PGF2α production,inhibited,C4703505,Increased tear production,54676038,Dicumarol,Dicumarol,inhibit
1096,13068,25051199,Addition of PBL into BQ and curcumin consumption could inhibit the ANE-induced inflammatory response.,"['BQ', 'curcumin']",['inflammatory response'],True,BQ,inflammatory response,inhibit,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BQ,inhibit
1097,13068,25051199,Addition of PBL into BQ and curcumin consumption could inhibit the ANE-induced inflammatory response.,"['BQ', 'curcumin']",['inflammatory response'],True,curcumin,inflammatory response,inhibit,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",curcumin,inhibit
1098,13072,24955606,"Taken together, these data indicate that carmustine induced platelet  apoptosis, suggesting the possible pathogenesis of thrombocytopenia in patients treated with carmustine.",['carmustine'],['thrombocytopenia'],True,carmustine,thrombocytopenia,induced,C0040034,Thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carmustine,induce
1099,13077,24466103,"ATO did not induce surface expression of P-selectin and PAC-1 binding, whereas, obviously reduced collagen, ADP, and thrombin induced platelet aggregation.",['ATO'],['reduced collagen'],True,ATO,reduced collagen,induce,C4021054,Reduced muscle collagen VI,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ATO,induce
1100,13095,22509579,"Rotenone (an inhibitor of complex I in the mitochondria electron transport chain) decreased the DBP induced ROS production, and dicumarol (an inhibitor of the redox enzyme system in the plasma membrane) stimulated the DBP induced ROS production.","['Rotenone', 'dicumarol']","['ROS production', 'ROS production']",True,dicumarol,ROS production,induced,C4476796,Increased reactive oxygen species production,54676038,Dicumarol,Dicumarol,induce
1101,13095,22509579,"Rotenone (an inhibitor of complex I in the mitochondria electron transport chain) decreased the DBP induced ROS production, and dicumarol (an inhibitor of the redox enzyme system in the plasma membrane) stimulated the DBP induced ROS production.","['Rotenone', 'dicumarol']","['ROS production', 'ROS production']",True,dicumarol,ROS production,induced,C4476796,Increased reactive oxygen species production,54676038,Dicumarol,Dicumarol,induce
1102,13170,32780517,"Moreover, isoproterenol induced a rise in plasma angiotensin-converting enzyme activity (ACE) by 49%, dyslipidaemia, and increased thiobarbituric acid-reactive substances (TBARS) by 117% associated with decrease in the activity of superoxide dismutase (SOD) and glutathione peroxidase (GPx) by 46% and 58%, respectively in  myocardium.","['isoproterenol', 'glutathione peroxidase']","['rise in plasma angiotensin-converting enzyme activity', 'dyslipidaemia', 'increased thiobarbituric acid-reactive substances (TBARS)']",True,isoproterenol,dyslipidaemia,induced,C0242339,Dyslipidemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",isoproterenol,induce
1103,13170,32780517,"Moreover, isoproterenol induced a rise in plasma angiotensin-converting enzyme activity (ACE) by 49%, dyslipidaemia, and increased thiobarbituric acid-reactive substances (TBARS) by 117% associated with decrease in the activity of superoxide dismutase (SOD) and glutathione peroxidase (GPx) by 46% and 58%, respectively in  myocardium.","['isoproterenol', 'glutathione peroxidase']","['rise in plasma angiotensin-converting enzyme activity', 'dyslipidaemia', 'increased thiobarbituric acid-reactive substances (TBARS)']",True,glutathione peroxidase,dyslipidaemia,induced,C0242339,Dyslipidemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione peroxidase,induce
1104,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,spironolactone,hyponatremia,resulted,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",spironolactone,result
1105,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,spironolactone,potassium,resulted,C1846348,Renal potassium wasting,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",spironolactone,result
1106,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,spironolactone,hyperkalemia,resulted,C0020461,Elevated serum potassium levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",spironolactone,result
1107,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,furosemide,hyponatremia,resulted,C0020625,Hyponatremia,3440,Furosemide,Furosemide,result
1108,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,furosemide,potassium,resulted,C1846348,Renal potassium wasting,3440,Furosemide,Furosemide,result
1109,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,furosemide,hyperkalemia,resulted,C0020461,Elevated serum potassium levels,3440,Furosemide,Furosemide,result
1110,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,enoxaparin,hyponatremia,resulted,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enoxaparin,result
1111,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,enoxaparin,potassium,resulted,C1846348,Renal potassium wasting,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enoxaparin,result
1112,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,enoxaparin,hyperkalemia,resulted,C0020461,Elevated serum potassium levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enoxaparin,result
1113,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,enoxaparin,potassium,resulted,C1846348,Renal potassium wasting,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enoxaparin,result
1114,13172,32564759,The combination of spironolactone and furosemide resulted in hyponatremia while the combination of enoxaparin and potassium resulted in hyperkalemia.,"['spironolactone', 'furosemide', 'enoxaparin']","['hyponatremia', 'potassium', 'hyperkalemia']",True,enoxaparin,hyperkalemia,resulted,C0020461,Elevated serum potassium levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enoxaparin,result
1115,13182,32471279," Pretreatment with warfarin given at a dose of 90 or 180 µg/kg/dose increased the  international normalized ratio and reduced morphological signs of pancreatic damage such as pancreatic edema, vacuolization of acinar cells, necrosis and the  number of hemorrhages.",['warfarin'],"['reduced morphological signs', 'pancreatic damage', 'pancreatic edema', 'vacuolization of acinar cells', 'necrosis']",True,warfarin,pancreatic edema,increased,C0013604,Edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",warfarin,increase
1116,13182,32471279," Pretreatment with warfarin given at a dose of 90 or 180 µg/kg/dose increased the  international normalized ratio and reduced morphological signs of pancreatic damage such as pancreatic edema, vacuolization of acinar cells, necrosis and the  number of hemorrhages.",['warfarin'],"['reduced morphological signs', 'pancreatic damage', 'pancreatic edema', 'vacuolization of acinar cells', 'necrosis']",True,warfarin,necrosis,increased,C0151798,Hepatic necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",warfarin,increase
1117,13184,32471279,"In addition, this dose of warfarin resulted in deaths in some animals.",['warfarin'],['deaths'],True,warfarin,deaths,resulted,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",warfarin,result
1118,13196,31848263,"  -An 83-year-old woman with a history of hypertension, diabetes and paroxysmal atrial fibrillation anticoagulated with acenocoumarol was brought to the emergency department due to dyspnoea.","['fibrillation', 'acenocoumarol']","['hypertension', 'diabetes']",True,fibrillation,hypertension,brought,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fibrillation,bring
1119,13196,31848263,"  -An 83-year-old woman with a history of hypertension, diabetes and paroxysmal atrial fibrillation anticoagulated with acenocoumarol was brought to the emergency department due to dyspnoea.","['fibrillation', 'acenocoumarol']","['hypertension', 'diabetes']",True,fibrillation,diabetes,brought,C0085207,Maternal diabetes,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fibrillation,bring
1120,13196,31848263,"  -An 83-year-old woman with a history of hypertension, diabetes and paroxysmal atrial fibrillation anticoagulated with acenocoumarol was brought to the emergency department due to dyspnoea.","['fibrillation', 'acenocoumarol']","['hypertension', 'diabetes']",True,acenocoumarol,hypertension,brought,C0020538,Systemic hypertension,54676537,ACENOCOUMAROL,ACENOCOUMAROL,bring
1121,13196,31848263,"  -An 83-year-old woman with a history of hypertension, diabetes and paroxysmal atrial fibrillation anticoagulated with acenocoumarol was brought to the emergency department due to dyspnoea.","['fibrillation', 'acenocoumarol']","['hypertension', 'diabetes']",True,acenocoumarol,diabetes,brought,C0085207,Maternal diabetes,54676537,ACENOCOUMAROL,ACENOCOUMAROL,bring
1122,13220,35291602," Conclusion: Administration of bortezomib 50μg/kg for four days in progressive atherosclerosis model rats can inhibit VCAM-1 expression, although it does not affect ICAM-1 expression and cannot inhibit atherosclerotic lesion formation.",['bortezomib'],['atherosclerotic lesion formation'],True,bortezomib,atherosclerotic lesion formation,inhibit,C4703473,Atherosclerotic lesion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bortezomib,inhibit
1123,13238,35277211,Renal involvement is one of the factors associated with vitamin D deficiency/insufficiency in patients with vasculitis.,['vitamin D'],['vasculitis'],True,vitamin D,vasculitis,associated,C0042384,Vasculitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",vitamin D,associate
1124,13260,35254755," CONCLUSION: In real-world clinical practice, for patients with moderate-to-severe plaque psoriasis who had residual plaques following &ge;24 weeks of ixekizumab monotherapy, adjunctive treatment with Cal/BD foam was associated with notable and sustained improvements in disease control.",['ixekizumab'],"['plaque psoriasis', 'plaques']",True,ixekizumab,plaques,associated,C0333463,Braindruse,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ixekizumab,associate
1125,13270,35236423," (#)Contributed equally  BACKGROUND: The prevalence of vitamin D deficiency is increasing globally and is  associated with an increased risk of metabolic syndrome, autoimmune disease, and  cardiovascular disease.",['vitamin D'],"['increased risk of metabolic syndrome', 'autoimmune disease']",True,vitamin D,autoimmune disease,increasing,C0004364,Autoimmune disorder,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",vitamin D,increase
1126,13293,35211544,"Treatment with 1,25(OH)2D3 resulted in decreased secretion for some pro-inflammatory cytokines in clinical animals, including IL-1β, IL-6, and IFN-γ.","['1,25(OH)2D3']",['decreased secretion'],True,"1,25(OH)2D3",decreased secretion,resulted,C0235857,Decreased lacrimation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","1,25(OH)2D3",result
1127,13330,35177066,A cohort analysis showed that serum calcidiol at hospital admission was associated with outcomes.,['calcidiol'],['hospital admission'],True,calcidiol,hospital admission,associated,C0235857,Decreased lacrimation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcidiol,associate
1128,13366,35227526,"  Chronic Kidney Disease (CKD) is associated with a strong impact on phosphocalcic  homeostasis, due to the chronic reduction in glomerular filtration rate (GFR) (phosphate excretion decrease), the inhibition of calcitriol synthesis and dietary restrictions.","['phosphate', 'calcitriol']","['Chronic Kidney Disease', 'reduction in glomerular filtration']",True,phosphate,Chronic Kidney Disease,associated,C1561643,Loss of renal function,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phosphate,associate
1129,13366,35227526,"  Chronic Kidney Disease (CKD) is associated with a strong impact on phosphocalcic  homeostasis, due to the chronic reduction in glomerular filtration rate (GFR) (phosphate excretion decrease), the inhibition of calcitriol synthesis and dietary restrictions.","['phosphate', 'calcitriol']","['Chronic Kidney Disease', 'reduction in glomerular filtration']",True,phosphate,reduction in glomerular filtration,associated,C0854050,Abnormal glomerular filtration rate,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phosphate,associate
1130,13366,35227526,"  Chronic Kidney Disease (CKD) is associated with a strong impact on phosphocalcic  homeostasis, due to the chronic reduction in glomerular filtration rate (GFR) (phosphate excretion decrease), the inhibition of calcitriol synthesis and dietary restrictions.","['phosphate', 'calcitriol']","['Chronic Kidney Disease', 'reduction in glomerular filtration']",True,calcitriol,Chronic Kidney Disease,associated,C1561643,Loss of renal function,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcitriol,associate
1131,13366,35227526,"  Chronic Kidney Disease (CKD) is associated with a strong impact on phosphocalcic  homeostasis, due to the chronic reduction in glomerular filtration rate (GFR) (phosphate excretion decrease), the inhibition of calcitriol synthesis and dietary restrictions.","['phosphate', 'calcitriol']","['Chronic Kidney Disease', 'reduction in glomerular filtration']",True,calcitriol,reduction in glomerular filtration,associated,C0854050,Abnormal glomerular filtration rate,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcitriol,associate
1132,13373,35185345,"Nevertheless, sarcoidosis can be associated with small-vessel, medium-vessel, and large vessel vasculitis, although it is frequently difficult to differentiate between the co-existence of a pure vasculitis and sarcoidosis and sarcoid vasculitis.",['medium-vessel'],"['sarcoidosis', 'vessel vasculitis', 'sarcoidosis', 'sarcoid vasculitis']",True,medium-vessel,vessel vasculitis,associated,C4023113,Small vessel vasculitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",medium-vessel,associate
1133,13405,35103802,"These reduce the phosphate back resorption in the proximal tubules of the kidneys, thereby causing hypophosphatemia and lead to an absolute or relatively low calcitriol serum concentration.",['calcitriol'],"['phosphate back resorption in the proximal tubules of the kidneys', 'hypophosphatemia']",True,calcitriol,hypophosphatemia,causing,C0085682,Low blood phosphate level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcitriol,cause
1134,13416,35079976,"doi: 10.1007/s40618-022-01746-1. [Epub ahead of print]  A decrease in serum 1,25(OH)2D after elective hip replacement and during bone healing is associated with changes in serum iron and plasma FGF23.",['iron'],"['decrease in serum 1,25(OH)2D', 'elective hip replacement']",True,iron,"decrease in serum 1,25(OH)2D",associated,C4021093,Decreased serum complement C9,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,associate
1135,13428,35065185,Cisplatin exposure also resulted in enhanced reaction time to the thermal stimulus and decreased muscle ability.,['Cisplatin'],['decreased muscle ability'],True,Cisplatin,decreased muscle ability,resulted,C1858120,Low muscle tone,5702198,azane;dichloroplatinum,azane;dichloroplatinum,result
1136,13435,35057465,"Notably, calcitriol signaling induces secretion of antibacterial activity in vitro and in vivo, and low circulating levels of calcifediol are associated with diverse indications characterized by impaired antibacterial immunity such as dental caries and urinary tract infections.",['calcitriol'],"['secretion of antibacterial activity', 'low circulating levels of calcifediol', 'dental caries', 'urinary tract infections']",True,calcitriol,urinary tract infections,induces,C0262655,Urinary infection,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcitriol,induce
1137,13448,35033017," Moreover, LAD, LVDd, LVDs, IVST and LVMI in B allele of Bsm I increased significantly.","['LVDs', 'Bsm']","['LVDd', 'IVST', 'LVMI']",True,LVDs,LVMI,increased,C0027051,Heart attack,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",LVDs,increase
1138,13448,35033017," Moreover, LAD, LVDd, LVDs, IVST and LVMI in B allele of Bsm I increased significantly.","['LVDs', 'Bsm']","['LVDd', 'IVST', 'LVMI']",True,Bsm,LVMI,increased,C0027051,Heart attack,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Bsm,increase
1139,13489,34974811,"In conclusion, RA inhibits HeLa proliferation and induces apoptosis and autophagy via suppressing HPV18E6/E7, PD-L1 and VDR, and VD3 showed reinforced effects of RA on HeLa cells.","['RA', 'RA']","['HeLa proliferation', 'apoptosis']",True,RA,HeLa proliferation,inhibits,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",RA,inhibit
1140,13489,34974811,"In conclusion, RA inhibits HeLa proliferation and induces apoptosis and autophagy via suppressing HPV18E6/E7, PD-L1 and VDR, and VD3 showed reinforced effects of RA on HeLa cells.","['RA', 'RA']","['HeLa proliferation', 'apoptosis']",True,RA,HeLa proliferation,inhibits,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",RA,inhibit
1141,13520,34950983,"Meanwhile, overexpression of kojR resulted in the decreased expression of Aokap1, suggesting that disruption of Aokap1 increased kojic acid production by affecting the expression of kojA, kojR  and kojT. The discovery of Aokap1 provides a new target for genetic modification  of the growth and kojic acid production in A. oryzae.","['kojic acid', 'kojic acid']",['decreased expression'],True,kojic acid,decreased expression,resulted,C1862474,Decreased facial expression,3840,Kojic Acid,Kojic Acid,result
1142,13520,34950983,"Meanwhile, overexpression of kojR resulted in the decreased expression of Aokap1, suggesting that disruption of Aokap1 increased kojic acid production by affecting the expression of kojA, kojR  and kojT. The discovery of Aokap1 provides a new target for genetic modification  of the growth and kojic acid production in A. oryzae.","['kojic acid', 'kojic acid']",['decreased expression'],True,kojic acid,decreased expression,resulted,C1862474,Decreased facial expression,3840,Kojic Acid,Kojic Acid,result
1143,13543,34255249,"Intracerebroventricular injection (i.c.v) of Aβ1-42 (5 μL/5 min/mouse) into wild-type adult mice induced AD-like pathological changes in the mouse hippocampus by increasing oxidative stress and neuroinflammation, affecting memory and cognitive functions.",['Intracerebroventricular injection'],['increasing oxidative stress'],True,Intracerebroventricular injection,increasing oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Intracerebroventricular injection,induce
1144,13555,33992354,"Furthermore, the root extract of E. japonica strongly inhibited butyryl cholinesterase (3.64 mg galantamine equivalent (GALAE)/g), whereas leaves, stems, seeds, and fruits showed comparable inhibition of both acetyl and butyryl cholinesterases.","['butyryl', 'galantamine']","['root extract', 'inhibition of both acetyl and butyryl cholinesterases']",True,butyryl,root extract,inhibited,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",butyryl,inhibit
1145,13555,33992354,"Furthermore, the root extract of E. japonica strongly inhibited butyryl cholinesterase (3.64 mg galantamine equivalent (GALAE)/g), whereas leaves, stems, seeds, and fruits showed comparable inhibition of both acetyl and butyryl cholinesterases.","['butyryl', 'galantamine']","['root extract', 'inhibition of both acetyl and butyryl cholinesterases']",True,butyryl,inhibition of both acetyl and butyryl cholinesterases,inhibited,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",butyryl,inhibit
1146,13555,33992354,"Furthermore, the root extract of E. japonica strongly inhibited butyryl cholinesterase (3.64 mg galantamine equivalent (GALAE)/g), whereas leaves, stems, seeds, and fruits showed comparable inhibition of both acetyl and butyryl cholinesterases.","['butyryl', 'galantamine']","['root extract', 'inhibition of both acetyl and butyryl cholinesterases']",True,galantamine,root extract,inhibited,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",galantamine,inhibit
1147,13555,33992354,"Furthermore, the root extract of E. japonica strongly inhibited butyryl cholinesterase (3.64 mg galantamine equivalent (GALAE)/g), whereas leaves, stems, seeds, and fruits showed comparable inhibition of both acetyl and butyryl cholinesterases.","['butyryl', 'galantamine']","['root extract', 'inhibition of both acetyl and butyryl cholinesterases']",True,galantamine,inhibition of both acetyl and butyryl cholinesterases,inhibited,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",galantamine,inhibit
1148,13564,33804376,"Further studies are ongoing to unravel the in vivo effect and cytotoxicity of this compound in fungi and human, that could be a novel drug to various diseases associated with hyperpigmentation by melanin.",['melanin'],['hyperpigmentation'],True,melanin,hyperpigmentation,associated,C0162834,Hyperpigmentation of the skin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melanin,associate
1149,13603,34594215,The effects of arbutin treatment on colitis were considerably inhibited by the JAK2 inhibitor AG490.,['arbutin'],['colitis'],True,arbutin,colitis,inhibited,C0009319,Colitis,440936,Arbutin,Arbutin,inhibit
1150,13676,33203185,"The aim of the study was to describe recent studies in the field of phytotherapy, focusing on compounds isolated from chosen plants of Centaureinae and the possibilities of using them to treat antifungal infections, inhibit serotonin and ease symptoms of seborrhea dermatitis and hyperpigmentation.",['serotonin'],"['antifungal infections', 'seborrhea dermatitis', 'hyperpigmentation']",True,serotonin,seborrhea dermatitis,inhibit,C0036508,Seborrheic eczema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,inhibit
1151,13676,33203185,"The aim of the study was to describe recent studies in the field of phytotherapy, focusing on compounds isolated from chosen plants of Centaureinae and the possibilities of using them to treat antifungal infections, inhibit serotonin and ease symptoms of seborrhea dermatitis and hyperpigmentation.",['serotonin'],"['antifungal infections', 'seborrhea dermatitis', 'hyperpigmentation']",True,serotonin,hyperpigmentation,inhibit,C0162834,Hyperpigmentation of the skin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,inhibit
1152,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,chenodeoxycholic acid,"alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase",increased,C0151904,Aspartate aminotransferase increased,10133,Chenodeoxycholic Acid,Chenodeoxycholic Acid,increase
1153,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,chenodeoxycholic acid,liver stiffness,increased,C1660792,Stiff toe,10133,Chenodeoxycholic Acid,Chenodeoxycholic Acid,increase
1154,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,deoxycholic acid,"alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase",increased,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",deoxycholic acid,increase
1155,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,deoxycholic acid,liver stiffness,increased,C1660792,Stiff toe,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",deoxycholic acid,increase
1156,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,glycocholic acid,"alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase",increased,C0151904,Aspartate aminotransferase increased,10140,Glycocholic Acid,Glycocholic Acid,increase
1157,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,glycocholic acid,liver stiffness,increased,C1660792,Stiff toe,10140,Glycocholic Acid,Glycocholic Acid,increase
1158,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,glycochenodeoxycholic acid,"alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase",increased,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycochenodeoxycholic acid,increase
1159,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,glycochenodeoxycholic acid,liver stiffness,increased,C1660792,Stiff toe,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycochenodeoxycholic acid,increase
1160,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,glycodeoxycholic acid,"alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase",increased,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycodeoxycholic acid,increase
1161,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,glycodeoxycholic acid,liver stiffness,increased,C1660792,Stiff toe,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycodeoxycholic acid,increase
1162,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,taurocholic acid,"alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase",increased,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurocholic acid,increase
1163,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,taurocholic acid,liver stiffness,increased,C1660792,Stiff toe,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurocholic acid,increase
1164,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,taurochenodeoxycholic acid,"alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase",increased,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurochenodeoxycholic acid,increase
1165,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,taurochenodeoxycholic acid,liver stiffness,increased,C1660792,Stiff toe,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurochenodeoxycholic acid,increase
1166,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,taurodeoxycholic acid,"alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase",increased,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurodeoxycholic acid,increase
1167,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,taurodeoxycholic acid,liver stiffness,increased,C1660792,Stiff toe,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurodeoxycholic acid,increase
1168,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,taurolithocholic acid,"alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase",increased,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurolithocholic acid,increase
1169,13809,35035690,"Results: (1) Prior to treatment, alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, FibroScan liver stiffness, total bile acid, chenodeoxycholic acid, deoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, and taurolithocholic acid increased with the severity of NAFLD (P<0.05).","['chenodeoxycholic acid', 'deoxycholic acid', 'glycocholic acid', 'glycochenodeoxycholic acid', 'glycodeoxycholic acid', 'taurocholic acid', 'taurochenodeoxycholic acid', 'taurodeoxycholic acid', 'taurolithocholic acid']","['alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase', 'liver stiffness', 'total bile acid']",True,taurolithocholic acid,liver stiffness,increased,C1660792,Stiff toe,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurolithocholic acid,increase
1170,13819,34979142,Both palmitate and GCDCA induced the expression of ER stress markers.,"['palmitate', 'GCDCA']",['expression of ER stress'],True,palmitate,expression of ER stress,induced,C0424448,Mask-like facies,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",palmitate,induce
1171,13819,34979142,Both palmitate and GCDCA induced the expression of ER stress markers.,"['palmitate', 'GCDCA']",['expression of ER stress'],True,GCDCA,expression of ER stress,induced,C0424448,Mask-like facies,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",GCDCA,induce
1172,13831,34718617,"Interestingly, glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), and GUDCA were positively associated with glucose and insulin serum levels, HOMA index, low-density lipoprotein cholesterol, tumor necrosis factor alpha, interleukin (IL)-2, and IL-8 levels, but negatively associated with high-density lipoprotein cholesterol, ApoA1, and adiponectin levels, yet these significant correlations partially disappeared after the inclusion of LBM as a confounder.","['glycocholic acid', 'glycochenodeoxycholic acid', 'insulin']","['GUDCA', 'tumor necrosis factor alpha', 'adiponectin levels']",True,glycocholic  ,adiponectin levels,associated,C4073126,Abnormal adiponectin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycocholic  ,associate
1173,13831,34718617,"Interestingly, glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), and GUDCA were positively associated with glucose and insulin serum levels, HOMA index, low-density lipoprotein cholesterol, tumor necrosis factor alpha, interleukin (IL)-2, and IL-8 levels, but negatively associated with high-density lipoprotein cholesterol, ApoA1, and adiponectin levels, yet these significant correlations partially disappeared after the inclusion of LBM as a confounder.","['glycocholic acid', 'glycochenodeoxycholic acid', 'insulin']","['GUDCA', 'tumor necrosis factor alpha', 'adiponectin levels']",True,glycochenodeoxycholic  ,adiponectin levels,associated,C4073126,Abnormal adiponectin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycochenodeoxycholic  ,associate
1174,13831,34718617,"Interestingly, glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), and GUDCA were positively associated with glucose and insulin serum levels, HOMA index, low-density lipoprotein cholesterol, tumor necrosis factor alpha, interleukin (IL)-2, and IL-8 levels, but negatively associated with high-density lipoprotein cholesterol, ApoA1, and adiponectin levels, yet these significant correlations partially disappeared after the inclusion of LBM as a confounder.","['glycocholic acid', 'glycochenodeoxycholic acid', 'insulin']","['GUDCA', 'tumor necrosis factor alpha', 'adiponectin levels']",True,insulin,adiponectin levels,associated,C4073126,Abnormal adiponectin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",insulin,associate
1175,13835,34493738,Serum levels of glycocholic acid and glycoursodeoxycholic acid clinically correlate with body mass index and airway hyperreactivity whereas murine levels of β-muricholic acid and tauro-β-muricholic acid were significantly increased and positively correlated with impaired lung function in obese mice with AAD.,"['glycocholic acid', 'glycoursodeoxycholic acid', 'β-muricholic acid']","['body mass index', 'airway hyperreactivity', 'impaired lung function']",True,β-muricholic acid,impaired lung function,increased,C0858943,Impaired lung function,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",β-muricholic acid,increase
1176,13844,34344785,"Linoleic acid and phenol significantly inhibited HCC proliferation, inferring their anti-HCC function as protective metabolites.","['Linoleic acid', 'phenol']",['HCC proliferation'],True,Linoleic acid,HCC proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Linoleic acid,inhibit
1177,13844,34344785,"Linoleic acid and phenol significantly inhibited HCC proliferation, inferring their anti-HCC function as protective metabolites.","['Linoleic acid', 'phenol']",['HCC proliferation'],True,phenol,HCC proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phenol,inhibit
1178,13865,33922434,"GCA and GUDCA protected RPE tight junctions against oxidative damage at concentrations of 100-500 µM, and GDCA protected tight junctions at 10-500 µM. Angiogenesis was induced with VEGF in RF/6A macaque CECs and evaluated with cell proliferation, cell migration, and tube formation assays.","['GUDCA', 'GDCA', 'VEGF']","['oxidative damage', 'cell proliferation']",True,VEGF,cell proliferation,induced,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",VEGF,induce
1179,13874,33458794," RESULTS: Several metabolites were selected as relevant, in particular:Glycocholic acid, Taurocholic acid, Phenylalanine, branched-chain amino-acids increased at the increase of the severity of the disease from steatosis to NASH, NASH-cirrhosis, while glutathione decreased (p < 0.001 for each).","['Glycocholic acid', 'Taurocholic acid', 'glutathione']","['increase of the severity of the disease', 'steatosis', 'NASH-cirrhosis']",True,Glycocholic acid,steatosis,increased,C2711227,Steatosis,10140,Glycocholic Acid,Glycocholic Acid,increase
1180,13874,33458794," RESULTS: Several metabolites were selected as relevant, in particular:Glycocholic acid, Taurocholic acid, Phenylalanine, branched-chain amino-acids increased at the increase of the severity of the disease from steatosis to NASH, NASH-cirrhosis, while glutathione decreased (p < 0.001 for each).","['Glycocholic acid', 'Taurocholic acid', 'glutathione']","['increase of the severity of the disease', 'steatosis', 'NASH-cirrhosis']",True,Glycocholic acid,NASH-cirrhosis,increased,C0023890,Cirrhosis,10140,Glycocholic Acid,Glycocholic Acid,increase
1181,13874,33458794," RESULTS: Several metabolites were selected as relevant, in particular:Glycocholic acid, Taurocholic acid, Phenylalanine, branched-chain amino-acids increased at the increase of the severity of the disease from steatosis to NASH, NASH-cirrhosis, while glutathione decreased (p < 0.001 for each).","['Glycocholic acid', 'Taurocholic acid', 'glutathione']","['increase of the severity of the disease', 'steatosis', 'NASH-cirrhosis']",True,Taurocholic acid,steatosis,increased,C2711227,Steatosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Taurocholic acid,increase
1182,13874,33458794," RESULTS: Several metabolites were selected as relevant, in particular:Glycocholic acid, Taurocholic acid, Phenylalanine, branched-chain amino-acids increased at the increase of the severity of the disease from steatosis to NASH, NASH-cirrhosis, while glutathione decreased (p < 0.001 for each).","['Glycocholic acid', 'Taurocholic acid', 'glutathione']","['increase of the severity of the disease', 'steatosis', 'NASH-cirrhosis']",True,Taurocholic acid,NASH-cirrhosis,increased,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Taurocholic acid,increase
1183,13888,32756004,  Glycochenodeoxycholic acid induces stemness and chemoresistance via the STAT3 signaling pathway in hepatocellular carcinoma cells.,['Glycochenodeoxycholic acid'],['hepatocellular carcinoma'],True,Glycochenodeoxycholic acid,hepatocellular carcinoma,induces,C2239176,Hepatocellular carcinoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Glycochenodeoxycholic acid,induce
1184,13891,32756004,"Furthermore, GCDC induced the EMT phenotype and stemness in HCC cells and activated the STAT3 signaling pathway.",['GCDC'],['activated the STAT3 signaling pathway'],True,GCDC,activated the STAT3 signaling pathway,induced,C2239176,Hepatocellular carcinoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",GCDC,induce
1185,13897,32634627,"Changes in levels of taurocholic acid (TCA), glycocholic acid, taurochenodeoxycholate, and glycochenodeoxycholate  associated with the increased levels of bilirubin and greater severity of DILI, and were also associated with CHB.","['taurocholic acid', 'glycocholic acid', 'taurochenodeoxycholate', 'glycochenodeoxycholate']","['increased levels of bilirubin', 'greater severity of DILI']",True,taurocholic acid,increased levels of bilirubin,associated,C0741494,High bili total,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurocholic acid,associate
1186,13897,32634627,"Changes in levels of taurocholic acid (TCA), glycocholic acid, taurochenodeoxycholate, and glycochenodeoxycholate  associated with the increased levels of bilirubin and greater severity of DILI, and were also associated with CHB.","['taurocholic acid', 'glycocholic acid', 'taurochenodeoxycholate', 'glycochenodeoxycholate']","['increased levels of bilirubin', 'greater severity of DILI']",True,glycocholic acid,increased levels of bilirubin,associated,C0741494,High bili total,10140,Glycocholic Acid,Glycocholic Acid,associate
1187,13897,32634627,"Changes in levels of taurocholic acid (TCA), glycocholic acid, taurochenodeoxycholate, and glycochenodeoxycholate  associated with the increased levels of bilirubin and greater severity of DILI, and were also associated with CHB.","['taurocholic acid', 'glycocholic acid', 'taurochenodeoxycholate', 'glycochenodeoxycholate']","['increased levels of bilirubin', 'greater severity of DILI']",True,taurochenodeoxycholate,increased levels of bilirubin,associated,C0741494,High bili total,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurochenodeoxycholate,associate
1188,13897,32634627,"Changes in levels of taurocholic acid (TCA), glycocholic acid, taurochenodeoxycholate, and glycochenodeoxycholate  associated with the increased levels of bilirubin and greater severity of DILI, and were also associated with CHB.","['taurocholic acid', 'glycocholic acid', 'taurochenodeoxycholate', 'glycochenodeoxycholate']","['increased levels of bilirubin', 'greater severity of DILI']",True,glycochenodeoxycholate,increased levels of bilirubin,associated,C0741494,High bili total,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycochenodeoxycholate,associate
1189,13919,32258950,"In contrast, deoxycholic acid and total unconjugated secondary bile acids were positively associated with steatosis, whereas relative glycoursodeoxycholic acid abundance was negatively associated.","['deoxycholic acid', 'glycoursodeoxycholic acid']",['steatosis'],True,deoxycholic acid,steatosis,associated,C2711227,Steatosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",deoxycholic acid,associate
1190,13919,32258950,"In contrast, deoxycholic acid and total unconjugated secondary bile acids were positively associated with steatosis, whereas relative glycoursodeoxycholic acid abundance was negatively associated.","['deoxycholic acid', 'glycoursodeoxycholic acid']",['steatosis'],True,glycoursodeoxycholic acid,steatosis,associated,C2711227,Steatosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycoursodeoxycholic acid,associate
1191,13925,32243703,"Specific gut bacteria link alterations in BA profiles and advanced fibrosis, and may be influenced by low-level alcohol consumption.",['alcohol'],"['Specific gut bacteria', 'fibrosis']",True,alcohol,fibrosis,link,C0151650,Renal fibrosis,702,Ethanol,Ethanol,link
1192,13947,29281030,"We found that the initial acquisition of motor learning induced a dopamine active transporter and D1 receptors mediated long-term potentiation, under a protocol of long-term depression in striatal medium spiny neurons.",['dopamine'],['depression'],True,dopamine,depression,induced,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dopamine,induce
1193,13953,28186690,"  Genetic variation in CACNA1C, which codes for the L-type calcium channel (LTCC) Cav 1.2, is associated with clinical diagnoses of bipolar disorder, depression and schizophrenia.",['calcium'],"['depression', 'schizophrenia']",True,calcium,depression,associated,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,associate
1194,13953,28186690,"  Genetic variation in CACNA1C, which codes for the L-type calcium channel (LTCC) Cav 1.2, is associated with clinical diagnoses of bipolar disorder, depression and schizophrenia.",['calcium'],"['depression', 'schizophrenia']",True,calcium,schizophrenia,associated,C0036341,Schizophrenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,associate
1195,13955,27890827,"These findings indicate that adolescent exposure to a dopamine transporter inhibitor results in loss of PV in GABAergic interneurons, elevations in markers of oxidative stress, and alterations in behavior in adulthood.",['dopamine'],"['loss of PV', 'elevations in markers of oxidative stress', 'alterations in behavior in adulthood']",True,dopamine,elevations in markers of oxidative stress,results,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dopamine,result
1196,13981,26073232,"GBR12909 caused hyperlocomotion at 2 and 24 h. Rearing behavior increased only at 2 h. GSH levels decreased in the hippocampus and striatum at the time points of 2, 4, 8 and 12 h. Increased lipid peroxidation was detected at the time-points of 2 and 12 h in all brain areas studied.",['GBR12909'],"['hyperlocomotion', 'Rearing behavior', 'Increased lipid peroxidation']",True,GBR12909,Rearing behavior,caused,C4021982,Abnormal eating behavior,3455,Vanoxerine,Vanoxerine,cause
1197,13985,25684233,"Although vanoxerine caused significant dose-dependent QTcF (QT correction by Fridericia) prolongation, monomorphic or polymorphic ventricular tachycardia did not occur.",['vanoxerine'],['ventricular tachycardia'],True,vanoxerine,ventricular tachycardia,caused,C0042514,Ventricular tachycardia,3455,Vanoxerine,Vanoxerine,cause
1198,14006,24832867,"However, misuse of MPH has been associated with an increased risk of aggression and psychosis.",['MPH'],"['increased risk of aggression', 'psychosis']",True,MPH,psychosis,associated,C0033975,Psychosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MPH,associate
1199,14052,21761147,"The dopaminergic reuptake inhibitor GBR-12909 increased impulsivity, whereas the nonselective DA and NA reuptake inhibitor methylphenidate had no significant effect on impulsive responses in HI and LI rats.",['methylphenidate'],"['dopaminergic reuptake', 'impulsivity']",True,methylphenidate,impulsivity,increased,C0021125,Impulsive,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methylphenidate,increase
1200,14075,20020109, RESULTS: Amphetamine produced hyperactivity and increased perseverative patterns  of locomotion as reflected in reduced spatial d values but reduced exploratory activity in contrast to the increased exploration observed in BD patients.,['Amphetamine'],"['hyperactivity', 'increased perseverative']",True,Amphetamine,hyperactivity,produced,C0424295,Hyperactivity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Amphetamine,produce
1201,14075,20020109, RESULTS: Amphetamine produced hyperactivity and increased perseverative patterns  of locomotion as reflected in reduced spatial d values but reduced exploratory activity in contrast to the increased exploration observed in BD patients.,['Amphetamine'],"['hyperactivity', 'increased perseverative']",True,Amphetamine,increased perseverative,produced,C0233651,Perseveration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Amphetamine,produce
1202,14093,19497322,"By contrast, the GABA(B) receptor agonist R-baclofen increased tremor at the lowest dose tested, but had no effects at higher doses.",['R-baclofen'],['tremor'],True,R-baclofen,tremor,increased,C0040822,Tremors,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",R-baclofen,increase
1203,14103,35238405,"Compared with steroids, tacrolimus did not increase the risk of elevated intraocular pressure (RR 0.07, 95% CI 0 to 1.13; 1 study; N = 80), while trifluridine conferred no additional risk compared to tear substitute (RR 5.50, 95% CI 0.31 to 96.49; 1 study; N = 97).","['tacrolimus', 'trifluridine']",['elevated intraocular pressure'],True,tacrolimus,elevated intraocular pressure,increase,C0234708,Raised IOP,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tacrolimus,increase
1204,14103,35238405,"Compared with steroids, tacrolimus did not increase the risk of elevated intraocular pressure (RR 0.07, 95% CI 0 to 1.13; 1 study; N = 80), while trifluridine conferred no additional risk compared to tear substitute (RR 5.50, 95% CI 0.31 to 96.49; 1 study; N = 97).","['tacrolimus', 'trifluridine']",['elevated intraocular pressure'],True,trifluridine,elevated intraocular pressure,increase,C0234708,Raised IOP,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trifluridine,increase
1205,14161,34327877,"Neomycin inhibits the biosynthesis of bacterial proteins by impairing their life functions, leading to death of cells.",['Neomycin'],['death'],True,Neomycin,death,inhibits,C1546180,Age of death,8378,Neomycin,Neomycin,inhibit
1206,14190,25100046," Thus, overcorrection of hyponatremia with urea resulted in significantly lower mortality and neurological impairment than the overcorrection caused by lixivaptan or hypertonic saline.",['lixivaptan'],"['overcorrection of hyponatremia', 'lower mortality', 'neurological impairment']",True,lixivaptan,neurological impairment,resulted,C0037822,Speech impairment,172997,Lixivaptan,Lixivaptan,result
1207,14232,21046526,The therapeutic benefits of lixivaptan are being evaluated in patients with conditions that are associated with water excess and hyponatremia.,"['lixivaptan', 'water']",['hyponatremia'],True,water,hyponatremia,associated,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,associate
1208,14251,19092365,"Because heart failure is associated with a state of water retention, several vasopressin antagonists have been evaluated for their potential aquaretic effect.",['water'],['heart failure'],True,water,heart failure,associated,C0018802,Heart failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,associate
1209,14255,18765079,"The addition of tolvaptan to standard therapy in hospitalized patients with heart failure has led to symptomatic improvement and decreased body weight,  but there is no long-term clinical benefit.",['tolvaptan'],"['heart failure', 'decreased body weight']",True,tolvaptan,heart failure,led,C0018802,Heart failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tolvaptan,lead
1210,14255,18765079,"The addition of tolvaptan to standard therapy in hospitalized patients with heart failure has led to symptomatic improvement and decreased body weight,  but there is no long-term clinical benefit.",['tolvaptan'],"['heart failure', 'decreased body weight']",True,tolvaptan,decreased body weight,led,C1262477,Weight loss,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tolvaptan,lead
1211,14269,18232127,"Elevated vasopressin levels in heart failure cause myocardial fibrosis,  hypertrophy and vasoconstriction by activating the V1a receptors, as well as water retention and hyponatremia by activating V2 receptors.",['water'],"['Elevated vasopressin levels in heart failure', 'myocardial fibrosis', 'hypertrophy', 'vasoconstriction', 'hyponatremia']",True,water,myocardial fibrosis,cause,C0151654,Myocardial fibrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
1212,14269,18232127,"Elevated vasopressin levels in heart failure cause myocardial fibrosis,  hypertrophy and vasoconstriction by activating the V1a receptors, as well as water retention and hyponatremia by activating V2 receptors.",['water'],"['Elevated vasopressin levels in heart failure', 'myocardial fibrosis', 'hypertrophy', 'vasoconstriction', 'hyponatremia']",True,water,hypertrophy,cause,C0020492,Bone Hypertrophy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
1213,14269,18232127,"Elevated vasopressin levels in heart failure cause myocardial fibrosis,  hypertrophy and vasoconstriction by activating the V1a receptors, as well as water retention and hyponatremia by activating V2 receptors.",['water'],"['Elevated vasopressin levels in heart failure', 'myocardial fibrosis', 'hypertrophy', 'vasoconstriction', 'hyponatremia']",True,water,hyponatremia,cause,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
1214,14271,18018383,"It is usually caused by dysregulation of arginine vasopressin (AVP) homeostasis which accompanies disorders associated with water retention such as congestive heart failure and cirrhosis, or follows euvolemic states such as syndrome of inapprioprate secretion of antidiuretic hormone.",['water'],"['dysregulation of arginine vasopressin', 'homeostasis', 'congestive heart failure', 'cirrhosis', 'inapprioprate secretion of antidiuretic hormone']",True,water,congestive heart failure,caused,C0018802,Heart failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
1215,14271,18018383,"It is usually caused by dysregulation of arginine vasopressin (AVP) homeostasis which accompanies disorders associated with water retention such as congestive heart failure and cirrhosis, or follows euvolemic states such as syndrome of inapprioprate secretion of antidiuretic hormone.",['water'],"['dysregulation of arginine vasopressin', 'homeostasis', 'congestive heart failure', 'cirrhosis', 'inapprioprate secretion of antidiuretic hormone']",True,water,cirrhosis,caused,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
1216,14271,18018383,"It is usually caused by dysregulation of arginine vasopressin (AVP) homeostasis which accompanies disorders associated with water retention such as congestive heart failure and cirrhosis, or follows euvolemic states such as syndrome of inapprioprate secretion of antidiuretic hormone.",['water'],"['dysregulation of arginine vasopressin', 'homeostasis', 'congestive heart failure', 'cirrhosis', 'inapprioprate secretion of antidiuretic hormone']",True,water,inapprioprate secretion,caused,C0021141,Inappropriate antidiuretic hormone secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,cause
1217,14271,18018383,"It is usually caused by dysregulation of arginine vasopressin (AVP) homeostasis which accompanies disorders associated with water retention such as congestive heart failure and cirrhosis, or follows euvolemic states such as syndrome of inapprioprate secretion of antidiuretic hormone.",['water'],"['dysregulation of arginine vasopressin', 'homeostasis', 'congestive heart failure', 'cirrhosis', 'inapprioprate secretion of antidiuretic hormone']",True,hormone,congestive heart failure,caused,C0018802,Heart failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hormone,cause
1218,14271,18018383,"It is usually caused by dysregulation of arginine vasopressin (AVP) homeostasis which accompanies disorders associated with water retention such as congestive heart failure and cirrhosis, or follows euvolemic states such as syndrome of inapprioprate secretion of antidiuretic hormone.",['water'],"['dysregulation of arginine vasopressin', 'homeostasis', 'congestive heart failure', 'cirrhosis', 'inapprioprate secretion of antidiuretic hormone']",True,hormone,cirrhosis,caused,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hormone,cause
1219,14271,18018383,"It is usually caused by dysregulation of arginine vasopressin (AVP) homeostasis which accompanies disorders associated with water retention such as congestive heart failure and cirrhosis, or follows euvolemic states such as syndrome of inapprioprate secretion of antidiuretic hormone.",['water'],"['dysregulation of arginine vasopressin', 'homeostasis', 'congestive heart failure', 'cirrhosis', 'inapprioprate secretion of antidiuretic hormone']",True,hormone,inapprioprate secretion,caused,C0021141,Inappropriate antidiuretic hormone secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hormone,cause
1220,14271,18018383,"It is usually caused by dysregulation of arginine vasopressin (AVP) homeostasis which accompanies disorders associated with water retention such as congestive heart failure and cirrhosis, or follows euvolemic states such as syndrome of inapprioprate secretion of antidiuretic hormone.",['water'],"['dysregulation of arginine vasopressin', 'homeostasis', 'congestive heart failure', 'cirrhosis', 'inapprioprate secretion of antidiuretic hormone']",True,water,congestive heart failure,associated,C0018802,Heart failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,associate
1221,14271,18018383,"It is usually caused by dysregulation of arginine vasopressin (AVP) homeostasis which accompanies disorders associated with water retention such as congestive heart failure and cirrhosis, or follows euvolemic states such as syndrome of inapprioprate secretion of antidiuretic hormone.",['water'],"['dysregulation of arginine vasopressin', 'homeostasis', 'congestive heart failure', 'cirrhosis', 'inapprioprate secretion of antidiuretic hormone']",True,water,cirrhosis,associated,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,associate
1222,14276,17970857,A thorough understanding of the physiology of water balance and the risk factors associated  with hyponatremia is essential for prompt and effective intervention.,['water'],['hyponatremia'],True,water,hyponatremia,associated,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,associate
1223,14282,17428103,"Several clinical conditions have been associated with inappropriately elevated levels of  AVP including heart failure, cirrhosis of the liver and the syndrome of inappropriate secretion of antidiuretic hormone.",['hormone'],"['heart failure', 'cirrhosis of the liver']",True,hormone,heart failure,associated,C0018802,Heart failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hormone,associate
1224,14282,17428103,"Several clinical conditions have been associated with inappropriately elevated levels of  AVP including heart failure, cirrhosis of the liver and the syndrome of inappropriate secretion of antidiuretic hormone.",['hormone'],"['heart failure', 'cirrhosis of the liver']",True,hormone,cirrhosis of the liver,associated,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hormone,associate
1225,14303,16970150,"Increased AVP secretion leads to decreased free water excretion with resulting water retention, and can cause dilutional hyponatremia.","['water', 'water']","['Increased AVP secretion', 'decreased free', 'dilutional hyponatremia']",True,water,dilutional hyponatremia,leads,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,lead
1226,14303,16970150,"Increased AVP secretion leads to decreased free water excretion with resulting water retention, and can cause dilutional hyponatremia.","['water', 'water']","['Increased AVP secretion', 'decreased free', 'dilutional hyponatremia']",True,water,dilutional hyponatremia,leads,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,lead
1227,14304,16970150,Numerous clinical trials show AVP antagonists to be effective at increasing free water excretion and serum sodium in patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion  or edema-forming states such as congestive heart failure and cirrhosis.,"['water', 'sodium']","['hyponatremia', 'congestive heart failure', 'cirrhosis']",True,water,hyponatremia,increasing,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,increase
1228,14304,16970150,Numerous clinical trials show AVP antagonists to be effective at increasing free water excretion and serum sodium in patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion  or edema-forming states such as congestive heart failure and cirrhosis.,"['water', 'sodium']","['hyponatremia', 'congestive heart failure', 'cirrhosis']",True,sodium,hyponatremia,increasing,C0020625,Hyponatremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium,increase
1229,14318,15847853,"However, the potent diuresis induced by agents such as furosemide results in loss of sodium and other essential electrolytes, which may exacerbate hyponatremia.",['furosemide'],"['loss of sodium', 'hyponatremia']",True,furosemide,hyponatremia,induced,C0020625,Hyponatremia,3440,Furosemide,Furosemide,induce
1230,14333,12436936,"Finally, further chemical developments in the oxindole family have led to the first specific and orally active V1b receptor antagonists (with SSR149415 as a representative), an awaited class of drugs with expected therapeutic interest mainly in ACTH-secreting tumors and various emotional diseases such as stress-related disorders, anxiety and depression.",['oxindole'],['depression'],True,oxindole,depression,led,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxindole,lead
1231,14334,12395330,"VPA produced a significant dose-related increase in daily urine output (1,454 +/- 858 mL to 4,568 +/- 4,385 mL with VPA 300 mg) and a dose-related decrease in urine osmolality.","['VPA', 'VPA']","['increase in daily urine output', 'decrease in urine osmolality']",True,VPA,increase in daily urine output,produced,C0032617,Polyuria,3121,2-propylpentanoic acid,2-propylpentanoic acid,produce
1232,14334,12395330,"VPA produced a significant dose-related increase in daily urine output (1,454 +/- 858 mL to 4,568 +/- 4,385 mL with VPA 300 mg) and a dose-related decrease in urine osmolality.","['VPA', 'VPA']","['increase in daily urine output', 'decrease in urine osmolality']",True,VPA,increase in daily urine output,produced,C0032617,Polyuria,3121,2-propylpentanoic acid,2-propylpentanoic acid,produce
1233,14335,12395330,"In conclusion, VPA induced a dose-related aquaretic response, suggesting a therapeutic potential in managing water retention in patients with liver cirrhosis with ascites.",['VPA'],"['liver cirrhosis', 'ascites']",True,VPA,liver cirrhosis,induced,C0023890,Cirrhosis,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
1234,14335,12395330,"In conclusion, VPA induced a dose-related aquaretic response, suggesting a therapeutic potential in managing water retention in patients with liver cirrhosis with ascites.",['VPA'],"['liver cirrhosis', 'ascites']",True,VPA,ascites,induced,C0003962,Ascites,3121,2-propylpentanoic acid,2-propylpentanoic acid,induce
1235,14345,35286963,Type 2 diabetes mellitus (T2DM) was induced in diabetic group by intraperitoneal administration of nicotinamide (110 mg/kg) and streptozotocin (55 mg/kg).,['nicotinamide'],"['diabetes mellitus', 'diabetic']",True,nicotinamide,diabetes mellitus,induced,C0011849,Diabetes mellitus,936,pyridine-3-carboxamide,pyridine-3-carboxamide,induce
1236,14345,35286963,Type 2 diabetes mellitus (T2DM) was induced in diabetic group by intraperitoneal administration of nicotinamide (110 mg/kg) and streptozotocin (55 mg/kg).,['nicotinamide'],"['diabetes mellitus', 'diabetic']",True,nicotinamide,diabetic,induced,C0011880,Diabetic ketosis,936,pyridine-3-carboxamide,pyridine-3-carboxamide,induce
1237,14351,35116186, CONCLUSIONS: Sacubitril/valsartan in patients with STEMI and cardiogenic shock may be associated with improved clinical outcome at 6 months compared with ramipril.,['ramipril'],['STEMI'],True,ramipril,STEMI,associated,C0011880,Diabetic ketosis,5362129,Ramipril,Ramipril,associate
1238,14376,34758252, CONCLUSIONS: Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction.,['ramipril'],"['lower incidence of death', 'heart failure', 'acute myocardial infarction']",True,Sacubitril-valsartan,heart failure,associated,C0018802,Heart failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Sacubitril-valsartan,associate
1239,14376,34758252, CONCLUSIONS: Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction.,['ramipril'],"['lower incidence of death', 'heart failure', 'acute myocardial infarction']",True,Sacubitril-valsartan,acute myocardial infarction,associated,C0027051,Heart attack,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Sacubitril-valsartan,associate
1240,14376,34758252, CONCLUSIONS: Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction.,['ramipril'],"['lower incidence of death', 'heart failure', 'acute myocardial infarction']",True,ramipril,heart failure,associated,C0018802,Heart failure,5362129,Ramipril,Ramipril,associate
1241,14376,34758252, CONCLUSIONS: Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction.,['ramipril'],"['lower incidence of death', 'heart failure', 'acute myocardial infarction']",True,ramipril,acute myocardial infarction,associated,C0027051,Heart attack,5362129,Ramipril,Ramipril,associate
1242,14391,34650309,"As rapid atrial arrhythmia could lead to inappropriate ICD shocks, amiodarone was added to prevent the recurrence of atrial tachycardia, and also control ventricular arrhythmia.",['amiodarone'],['ventricular arrhythmia'],True,amiodarone,ventricular arrhythmia,lead,C0085612,Ventricular arrhythmias,2157,Amiodarone,Amiodarone,lead
1243,14410,34363382,"The systolic, diastolic and mean arterial blood pressure of ovariectomised rats increased significantly (p<0.05),  but the alteration was significantly reduced by the administration of ramipril alone or in combination with vitamin E. Significant decrease (p<0.05) was observed in the serum level of nitric oxide in OVX group compared with Sham.","['ramipril', 'vitamin E.', 'OVX']","['systolic, diastolic and mean arterial blood pressure', 'decrease (p<0.05)']",True,ramipril,"systolic, diastolic and mean arterial blood pressure",increased,C0277890,Decreased diastolic blood pressure,5362129,Ramipril,Ramipril,increase
1244,14410,34363382,"The systolic, diastolic and mean arterial blood pressure of ovariectomised rats increased significantly (p<0.05),  but the alteration was significantly reduced by the administration of ramipril alone or in combination with vitamin E. Significant decrease (p<0.05) was observed in the serum level of nitric oxide in OVX group compared with Sham.","['ramipril', 'vitamin E.', 'OVX']","['systolic, diastolic and mean arterial blood pressure', 'decrease (p<0.05)']",True,vitamin E.,"systolic, diastolic and mean arterial blood pressure",increased,C0277890,Decreased diastolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",vitamin E.,increase
1245,14410,34363382,"The systolic, diastolic and mean arterial blood pressure of ovariectomised rats increased significantly (p<0.05),  but the alteration was significantly reduced by the administration of ramipril alone or in combination with vitamin E. Significant decrease (p<0.05) was observed in the serum level of nitric oxide in OVX group compared with Sham.","['ramipril', 'vitamin E.', 'OVX']","['systolic, diastolic and mean arterial blood pressure', 'decrease (p<0.05)']",True,OVX,"systolic, diastolic and mean arterial blood pressure",increased,C0277890,Decreased diastolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",OVX,increase
1246,14463,33452123," CONCLUSION: For patients with clinically defined heart failure following AMI, ramipril results in a sustained survival benefit, and is associated with an extension of life of up to 14.5 months for, on average, 13 months treatment duration.",['ramipril'],['heart failure'],True,ramipril,heart failure,results,C0018802,Heart failure,5362129,Ramipril,Ramipril,result
1247,14473,33186492," CONCLUSIONS: Combined treatment with a polypill plus aspirin led to a lower incidence of cardiovascular events than did placebo among participants without cardiovascular disease who were at intermediate cardiovascular risk. (Funded by the Wellcome Trust and others; TIPS-3 ClinicalTrials.gov number, NCT01646437.).",['aspirin'],"['lower incidence of cardiovascular events', 'cardiovascular disease']",True,aspirin,cardiovascular disease,led,C0007222,Cardiovascular disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aspirin,lead
1248,14481,33432057,"In conclusion, oral timolol and infusion of propranolol were associated with a significantly higher risk of developing an  asthma attack in patients, especially in those with a baseline asthma history, and should be avoided in patients who present a risk of asthma.",['propranolol'],"['higher risk of', 'asthma', 'asthma', 'asthma']",True,propranolol,asthma,associated,C0004096,Asthma,4946,propanolol,propanolol,associate
1249,14481,33432057,"In conclusion, oral timolol and infusion of propranolol were associated with a significantly higher risk of developing an  asthma attack in patients, especially in those with a baseline asthma history, and should be avoided in patients who present a risk of asthma.",['propranolol'],"['higher risk of', 'asthma', 'asthma', 'asthma']",True,propranolol,asthma,associated,C0004096,Asthma,4946,propanolol,propanolol,associate
1250,14481,33432057,"In conclusion, oral timolol and infusion of propranolol were associated with a significantly higher risk of developing an  asthma attack in patients, especially in those with a baseline asthma history, and should be avoided in patients who present a risk of asthma.",['propranolol'],"['higher risk of', 'asthma', 'asthma', 'asthma']",True,propranolol,asthma,associated,C0004096,Asthma,4946,propanolol,propanolol,associate
1251,14483,24296842,"A small number of published studies  suggest that celiac disease may be associated with altered drug absorption, resulting in higher serum concentrations of propranolol, lower peak concentrations of acetaminophen and practolol, higher dosing requirements with levothyroxine, impaired or delayed absorption of certain antibiotics, and other pharmacokinetic effects with a potential impact on medication efficacy and toxicity.","['propranolol', 'acetaminophen', 'practolol', 'levothyroxine']",['impaired or delayed absorption'],True,propranolol,impaired or delayed absorption,associated,C3714745,Intestinal malabsorption,4946,propanolol,propanolol,associate
1252,14483,24296842,"A small number of published studies  suggest that celiac disease may be associated with altered drug absorption, resulting in higher serum concentrations of propranolol, lower peak concentrations of acetaminophen and practolol, higher dosing requirements with levothyroxine, impaired or delayed absorption of certain antibiotics, and other pharmacokinetic effects with a potential impact on medication efficacy and toxicity.","['propranolol', 'acetaminophen', 'practolol', 'levothyroxine']",['impaired or delayed absorption'],True,acetaminophen,impaired or delayed absorption,associated,C3714745,Intestinal malabsorption,1983,Acetaminophen,Acetaminophen,associate
1253,14483,24296842,"A small number of published studies  suggest that celiac disease may be associated with altered drug absorption, resulting in higher serum concentrations of propranolol, lower peak concentrations of acetaminophen and practolol, higher dosing requirements with levothyroxine, impaired or delayed absorption of certain antibiotics, and other pharmacokinetic effects with a potential impact on medication efficacy and toxicity.","['propranolol', 'acetaminophen', 'practolol', 'levothyroxine']",['impaired or delayed absorption'],True,practolol,impaired or delayed absorption,associated,C3714745,Intestinal malabsorption,4883,Practolol,Practolol,associate
1254,14483,24296842,"A small number of published studies  suggest that celiac disease may be associated with altered drug absorption, resulting in higher serum concentrations of propranolol, lower peak concentrations of acetaminophen and practolol, higher dosing requirements with levothyroxine, impaired or delayed absorption of certain antibiotics, and other pharmacokinetic effects with a potential impact on medication efficacy and toxicity.","['propranolol', 'acetaminophen', 'practolol', 'levothyroxine']",['impaired or delayed absorption'],True,levothyroxine,impaired or delayed absorption,associated,C3714745,Intestinal malabsorption,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",levothyroxine,associate
1255,14497,12389072,"In the known examples that served as test cases, beta-blocking agents other than practolol are not associated with sclerosing peritonitis, but all angiotensin-converting enzyme inhibitors are associated with coughing, as are antihistamines with heart-rhythm  disorders and antipsychotics with myocarditis.",['practolol'],"['sclerosing peritonitis', 'heart-rhythm  disorders', 'myocarditis']",True,practolol,sclerosing peritonitis,associated,C0031154,Peritonitis,4883,Practolol,Practolol,associate
1256,14497,12389072,"In the known examples that served as test cases, beta-blocking agents other than practolol are not associated with sclerosing peritonitis, but all angiotensin-converting enzyme inhibitors are associated with coughing, as are antihistamines with heart-rhythm  disorders and antipsychotics with myocarditis.",['practolol'],"['sclerosing peritonitis', 'heart-rhythm  disorders', 'myocarditis']",True,practolol,heart-rhythm  disorders,associated,C0031154,Peritonitis,4883,Practolol,Practolol,associate
1257,14497,12389072,"In the known examples that served as test cases, beta-blocking agents other than practolol are not associated with sclerosing peritonitis, but all angiotensin-converting enzyme inhibitors are associated with coughing, as are antihistamines with heart-rhythm  disorders and antipsychotics with myocarditis.",['practolol'],"['sclerosing peritonitis', 'heart-rhythm  disorders', 'myocarditis']",True,practolol,myocarditis,associated,C0027059,Inflammation of heart muscle,4883,Practolol,Practolol,associate
1258,14498,12147535,"Constrictions to NE (2 of 39 vessels) were inhibited by prazosin (10(-6) mol/L, an alpha1-receptor blocker).",['prazosin'],['Constrictions to NE'],True,prazosin,Constrictions to NE,inhibited,C0027059,Inflammation of heart muscle,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",prazosin,inhibit
1259,14510,8824681,"ADVERSE REACTIONS TO ANTIHYPERTENSIVE AGENTS: Examples of type B adverse reactions to antihypertensives are the cutaneous and ocular reactions to practolol, and angioneurotic oedema associated  with angiotensin converting enzyme inhibitors.",['practolol'],['angioneurotic oedema'],True,practolol,angioneurotic oedema,associated,C0002994,Quincke edema,4883,Practolol,Practolol,associate
1260,14515,7564908,"The injection  of 2.10(-9) to 16.10(-9) M of isoproterenol, through a cannula permanently implanted into the SA produced a significant dose-dependent decrease in urinary Na+ and K+ excretion and urinary flow.",['isoproterenol'],['decrease in urinary Na+'],True,isoproterenol,decrease in urinary Na+,produced,C0878640,Decreased urinary K,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",isoproterenol,produce
1261,14553,1350351,"The combined treatment of indorenate and methiotepin resulted in an impairment of motor coordination and ambulatory behaviour in both species studied, thereby suggesting that the lack of effect of such combination was mediated by altering the motor behaviour.","['indorenate', 'methiotepin']",['impairment of motor coordination'],True,indorenate,impairment of motor coordination,resulted,C1867864,Poor fine motor coordination,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",indorenate,result
1262,14553,1350351,"The combined treatment of indorenate and methiotepin resulted in an impairment of motor coordination and ambulatory behaviour in both species studied, thereby suggesting that the lack of effect of such combination was mediated by altering the motor behaviour.","['indorenate', 'methiotepin']",['impairment of motor coordination'],True,methiotepin,impairment of motor coordination,resulted,C1867864,Poor fine motor coordination,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methiotepin,result
1263,14555,1687118,"Seven other studies reported favourable long-term effects of beta-blockers in 120 patients with other forms of dilated cardiomyopathy, e.g. caused by coronary artery disease, adriamycin, diabetes, or  valvular heart disease.",['adriamycin'],"['cardiomyopathy', 'coronary artery disease', 'diabetes', 'valvular heart disease']",True,adriamycin,coronary artery disease,caused,C1956346,Coronary disease,31703,Doxorubicin,Doxorubicin,cause
1264,14555,1687118,"Seven other studies reported favourable long-term effects of beta-blockers in 120 patients with other forms of dilated cardiomyopathy, e.g. caused by coronary artery disease, adriamycin, diabetes, or  valvular heart disease.",['adriamycin'],"['cardiomyopathy', 'coronary artery disease', 'diabetes', 'valvular heart disease']",True,adriamycin,diabetes,caused,C0085207,Maternal diabetes,31703,Doxorubicin,Doxorubicin,cause
1265,14555,1687118,"Seven other studies reported favourable long-term effects of beta-blockers in 120 patients with other forms of dilated cardiomyopathy, e.g. caused by coronary artery disease, adriamycin, diabetes, or  valvular heart disease.",['adriamycin'],"['cardiomyopathy', 'coronary artery disease', 'diabetes', 'valvular heart disease']",True,adriamycin,valvular heart disease,caused,C0018824,Valvular heart disease,31703,Doxorubicin,Doxorubicin,cause
1266,14576,34974400,"Acute UC was induced in mice by 3% dextran sulfate sodium (DSS), and (R)-, (S) and (RS)-BMB were orally administered.",['dextran sulfate sodium'],['Acute UC'],True,dextran sulfate sodium,Acute UC,induced,C0205178,Acute onset,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dextran sulfate sodium,induce
1267,14584,28467859,"Because hypoxemia causes vascular dysregulation that further restricts oxygen availability to tissue, it can be pharmacologically addressed.",['oxygen'],"['hypoxemia', 'vascular dysregulation']",True,oxygen,hypoxemia,causes,C0700292,Low blood oxygen level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,cause
1268,14604,20641640,"On  the other hand, some variants result in increased activity, such as the C5+ variant (combination of BChE with an unidentified protein), the Cynthiana variant (increased amount of BChE than normal level), and the Johannesburg variant (increased BChE activity with normal enzyme level).",['BChE'],['increased amount of BChE'],True,BChE,increased amount of BChE,result,C4025868,Increased facial adipose tissue,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BChE,result
1269,14605,20641589,"On  the other hand, some variants result in increased activity, such as the C5+ variant (combination of BChE with an unidentified protein), the Cynthiana variant (increased amount of BChE than normal level), and the Johannesburg variant (increased BChE activity with normal enzyme level).",['BChE'],['increased amount of BChE'],True,BChE,increased amount of BChE,result,C4025868,Increased facial adipose tissue,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BChE,result
1270,14617,17212694,"Infusion of a selective AChE inhibitor (BW284c51) caused a dose-dependent, up to 16-fold increase of extracellular ACh levels in AChE+/+ mice but did not change ACh levels in AChE-/- mice.",['BW284c51'],['increase of extracellular ACh levels'],True,BW284c51,increase of extracellular ACh levels,caused,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BW284c51,cause
1271,14620,15652380,"In wild-type mice acute reduction of AChE by Huperzine A (1 mg/kg) to the level found in asymptomatic heterozygotes, induced tremors but no respiratory depression, whereas the same dose of Huperzine in heterozygote animals further reduced AChE activity, increased tidal volume (V(T)) and decreased breathing frequency (f(R)).",['Huperzine'],"['acute reduction', 'tremors', 'respiratory depression', 'increased tidal volume', 'decreased breathing frequency']",True,Huperzine,acute reduction,induced,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Huperzine,induce
1272,14620,15652380,"In wild-type mice acute reduction of AChE by Huperzine A (1 mg/kg) to the level found in asymptomatic heterozygotes, induced tremors but no respiratory depression, whereas the same dose of Huperzine in heterozygote animals further reduced AChE activity, increased tidal volume (V(T)) and decreased breathing frequency (f(R)).",['Huperzine'],"['acute reduction', 'tremors', 'respiratory depression', 'increased tidal volume', 'decreased breathing frequency']",True,Huperzine,tremors,induced,C0040822,Tremors,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Huperzine,induce
1273,14620,15652380,"In wild-type mice acute reduction of AChE by Huperzine A (1 mg/kg) to the level found in asymptomatic heterozygotes, induced tremors but no respiratory depression, whereas the same dose of Huperzine in heterozygote animals further reduced AChE activity, increased tidal volume (V(T)) and decreased breathing frequency (f(R)).",['Huperzine'],"['acute reduction', 'tremors', 'respiratory depression', 'increased tidal volume', 'decreased breathing frequency']",True,Huperzine,respiratory depression,induced,C0235063,Decreased lung function,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Huperzine,induce
1274,14620,15652380,"In wild-type mice acute reduction of AChE by Huperzine A (1 mg/kg) to the level found in asymptomatic heterozygotes, induced tremors but no respiratory depression, whereas the same dose of Huperzine in heterozygote animals further reduced AChE activity, increased tidal volume (V(T)) and decreased breathing frequency (f(R)).",['Huperzine'],"['acute reduction', 'tremors', 'respiratory depression', 'increased tidal volume', 'decreased breathing frequency']",True,Huperzine,increased tidal volume,induced,C1836543,Full lips,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Huperzine,induce
1275,14620,15652380,"In wild-type mice acute reduction of AChE by Huperzine A (1 mg/kg) to the level found in asymptomatic heterozygotes, induced tremors but no respiratory depression, whereas the same dose of Huperzine in heterozygote animals further reduced AChE activity, increased tidal volume (V(T)) and decreased breathing frequency (f(R)).",['Huperzine'],"['acute reduction', 'tremors', 'respiratory depression', 'increased tidal volume', 'decreased breathing frequency']",True,Huperzine,decreased breathing frequency,induced,C4321352,Frequency,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Huperzine,induce
1276,14679,31389274,"While maintaining low estrogen levels, the combination therapy with letrozole and gonadotropin produce similar oocyte and embryo yield to the conventional IVF protocol in women with endometriosis.",['letrozole'],['endometriosis'],True,letrozole,endometriosis,produce,C0014175,Endometriosis,3902,"4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile","4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile",produce
1277,14686,31151754,"Under in vivo conditions, the administration of PGF2α or gonadotropin-releasing hormone antagonist; cetrorelix (CET) caused luteolysis as well as an increase in the protein level of Ddx5 (foldchange:1.9 ± 0.27 and 1.4 ± 0.09 viz.; p < 0.05) in CL of adult rats.",['cetrorelix (CET'],"['luteolysis', 'increase in the protein level of Ddx5']",True,cetrorelix,increase in the protein level of Ddx5,caused,C1806780,Increased CSF protein,25074887,Cetrorelix,Cetrorelix,cause
1278,14811,34599614,  Profit-driven games with the availability and prices of chenodeoxycholic acid led to the discontinuation of proper treatment for this cerebrotendinous xanthomatosis patient with disastrous consequences to his health.,['chenodeoxycholic acid'],['cerebrotendinous xanthomatosis'],True,chenodeoxycholic acid,cerebrotendinous xanthomatosis,led,C0043325,Xanthomatosis,10133,Chenodeoxycholic Acid,Chenodeoxycholic Acid,lead
1279,14837,34485606,"Disruption of  the bile acid biosynthesis pathway and accumulation of toxic precursors such as cholestanol cause chronic diarrhea, bilateral juvenile cataracts, tissue deposition of cholestanol and cholesterol (xanthomas), and progressive motor/neuropsychiatric alterations.","['cholestanol', 'cholesterol']","['bile acid biosynthesis pathway', 'accumulation of toxic precursors', 'cholestanol', 'chronic diarrhea', 'bilateral juvenile cataracts', 'tissue deposition', 'progressive motor/neuropsychiatric alterations']",True,cholestanol,chronic diarrhea,cause,C0401151,"Diarrhea, recurrent",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholestanol,cause
1280,14837,34485606,"Disruption of  the bile acid biosynthesis pathway and accumulation of toxic precursors such as cholestanol cause chronic diarrhea, bilateral juvenile cataracts, tissue deposition of cholestanol and cholesterol (xanthomas), and progressive motor/neuropsychiatric alterations.","['cholestanol', 'cholesterol']","['bile acid biosynthesis pathway', 'accumulation of toxic precursors', 'cholestanol', 'chronic diarrhea', 'bilateral juvenile cataracts', 'tissue deposition', 'progressive motor/neuropsychiatric alterations']",True,cholestanol,bilateral juvenile cataracts,cause,C0302254,Juvenile cataract,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholestanol,cause
1281,14837,34485606,"Disruption of  the bile acid biosynthesis pathway and accumulation of toxic precursors such as cholestanol cause chronic diarrhea, bilateral juvenile cataracts, tissue deposition of cholestanol and cholesterol (xanthomas), and progressive motor/neuropsychiatric alterations.","['cholestanol', 'cholesterol']","['bile acid biosynthesis pathway', 'accumulation of toxic precursors', 'cholestanol', 'chronic diarrhea', 'bilateral juvenile cataracts', 'tissue deposition', 'progressive motor/neuropsychiatric alterations']",True,cholestanol,tissue deposition,cause,C0302254,Juvenile cataract,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholestanol,cause
1282,14837,34485606,"Disruption of  the bile acid biosynthesis pathway and accumulation of toxic precursors such as cholestanol cause chronic diarrhea, bilateral juvenile cataracts, tissue deposition of cholestanol and cholesterol (xanthomas), and progressive motor/neuropsychiatric alterations.","['cholestanol', 'cholesterol']","['bile acid biosynthesis pathway', 'accumulation of toxic precursors', 'cholestanol', 'chronic diarrhea', 'bilateral juvenile cataracts', 'tissue deposition', 'progressive motor/neuropsychiatric alterations']",True,cholesterol,chronic diarrhea,cause,C0401151,"Diarrhea, recurrent",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholesterol,cause
1283,14837,34485606,"Disruption of  the bile acid biosynthesis pathway and accumulation of toxic precursors such as cholestanol cause chronic diarrhea, bilateral juvenile cataracts, tissue deposition of cholestanol and cholesterol (xanthomas), and progressive motor/neuropsychiatric alterations.","['cholestanol', 'cholesterol']","['bile acid biosynthesis pathway', 'accumulation of toxic precursors', 'cholestanol', 'chronic diarrhea', 'bilateral juvenile cataracts', 'tissue deposition', 'progressive motor/neuropsychiatric alterations']",True,cholesterol,bilateral juvenile cataracts,cause,C0302254,Juvenile cataract,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholesterol,cause
1284,14837,34485606,"Disruption of  the bile acid biosynthesis pathway and accumulation of toxic precursors such as cholestanol cause chronic diarrhea, bilateral juvenile cataracts, tissue deposition of cholestanol and cholesterol (xanthomas), and progressive motor/neuropsychiatric alterations.","['cholestanol', 'cholesterol']","['bile acid biosynthesis pathway', 'accumulation of toxic precursors', 'cholestanol', 'chronic diarrhea', 'bilateral juvenile cataracts', 'tissue deposition', 'progressive motor/neuropsychiatric alterations']",True,cholesterol,tissue deposition,cause,C0302254,Juvenile cataract,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholesterol,cause
1285,14942,34800920,"Although fluconazole and amphotericin B are the first-line treatments for cryptococcosis, the rate of  fluconazole resistance has increased significantly due to long-term use.","['fluconazole', 'amphotericin', 'fluconazole']",['cryptococcosis'],True,fluconazole,fluconazole resistance,increased,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluconazole,increase
1286,14942,34800920,"Although fluconazole and amphotericin B are the first-line treatments for cryptococcosis, the rate of  fluconazole resistance has increased significantly due to long-term use.","['fluconazole', 'amphotericin', 'fluconazole']",['cryptococcosis'],True,amphotericin,fluconazole resistance,increased,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amphotericin,increase
1287,14951,34778103,"Strains with high MIC values for azoles showed common ERG11 mutations, namely, F126L/K143R. In addition, L139R mutations may be  linked to high MICs of fluconazole.","['azoles', 'fluconazole']",['L139R mutations'],True,azoles,L139R mutations,linked,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azoles,link
1288,14951,34778103,"Strains with high MIC values for azoles showed common ERG11 mutations, namely, F126L/K143R. In addition, L139R mutations may be  linked to high MICs of fluconazole.","['azoles', 'fluconazole']",['L139R mutations'],True,fluconazole,L139R mutations,linked,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluconazole,link
1289,14989,35278057,"Although they had been used for a long time, recent studies have reported neuropsychiatric adverse drug reactions are associated with montelukast.",['montelukast'],['neuropsychiatric adverse drug reactions'],True,montelukast,neuropsychiatric adverse drug reactions,associated,C0041755,Adverse drug response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",montelukast,associate
1290,15049,34920651,"Our results showed that  the OVA challenge caused a marked elevation in AR symptoms like nasal rubbing, sneezing, and discharge which were remarkably diminished using pinitol (10 and 20 mg/kg) and the results were comparable with montelukast.","['pinitol', 'montelukast']","['nasal rubbing', 'sneezing', 'discharge']",True,pinitol,discharge,caused,C1260880,Nasal Discharge,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pinitol,cause
1291,15068,34715090,"Furthermore, MTK treatment resulted in a decreased activation of Iba1+ microglial cells in the retina and ON, and in a significantly increased RGC survival in OHT eyes.",['MTK'],"['decreased activation of Iba1+ microglial cells', 'increased RGC survival']",True,MTK,decreased activation of Iba1+ microglial cells,resulted,C1855752,Abnormal T cell morphology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MTK,result
1292,15096,34613593," METHODS: Data were derived from a retrospective questionnaire-based analysis of 2‒14-year-old children with mild persistent asthma, who received either 500 µg of BIS (n = 153) or 4‒5 mg of montelukast (n = 240) once daily.",['montelukast'],['asthma'],True,montelukast,asthma,derived,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",montelukast,derive
1293,15137,34382102,We tested whether exposure to montelukast plus  nonsteroidal antiinflammatory drugs (NSAIDs) elicits better control of paw inflammation in the rat formalin test and improves associated gastric damage.,['montelukast'],"['paw inflammation', 'gastric damage']",True,montelukast,paw inflammation,elicits,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",montelukast,elicit
1294,15157,34171261,Bifidobacterium adolescentis and bifidocin LHA treatment together induced substantial elevation of IL10 and IL-12  concentrations (P < 0.01) that helped to prevent damage caused by the inflammatory response.,['bifidocin'],"['damage', 'inflammatory response']",True,bifidocin,inflammatory response,induced,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bifidocin,induce
1295,15208,29262558,"These changes were associated with markedly reduced microglial/macrophage activation, neutrophil infiltration, matrix metalloproteinase-9 activity, inflammatory mediator expression at 1 and 4 day(s), and epoxyeicosatrienoic acid (EET) degradation at 1 and 4 day(s).",['epoxyeicosatrienoic acid'],"['reduced microglial/macrophage activation', 'neutrophil infiltration', 'matrix metalloproteinase-9 activity']",True,epoxyeicosatrienoic acid,neutrophil infiltration,associated,C4531258,Neutrophilic infiltration of the skin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",epoxyeicosatrienoic acid,associate
1296,15208,29262558,"These changes were associated with markedly reduced microglial/macrophage activation, neutrophil infiltration, matrix metalloproteinase-9 activity, inflammatory mediator expression at 1 and 4 day(s), and epoxyeicosatrienoic acid (EET) degradation at 1 and 4 day(s).",['epoxyeicosatrienoic acid'],"['reduced microglial/macrophage activation', 'neutrophil infiltration', 'matrix metalloproteinase-9 activity']",True,epoxyeicosatrienoic acid,matrix metalloproteinase-9 activity,associated,C4531258,Neutrophilic infiltration of the skin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",epoxyeicosatrienoic acid,associate
1297,15230,28694203,"In vitro, AUDA significantly inhibited TGF-β1-induced epithelial cells and fibroblast proliferation, reduced sEH expression and α-SMA expression, and increased epoxyeicosatrienoic acid (EET) levels and E-cadherin expression in epithelial cells.",['AUDA'],"['fibroblast proliferation', 'reduced sEH expression', 'increased epoxyeicosatrienoic acid', 'E-cadherin expression in epithelial cells']",True,AUDA,reduced sEH expression,inhibited,C4531163,Reduced T cell CD40 expression,10069117,AUDA,AUDA,inhibit
1298,15263,24780744,"Verapamil induced nuclear translocation of doxorubicin, G2-phase growth arrest and synergistically induced  100% cytotoxicity in 4T1-R cells in culture.","['Verapamil', 'doxorubicin']",['growth arrest'],True,Verapamil,growth arrest,induced,C1399128,Growth arrest lines,2520,VERAPAMIL,VERAPAMIL,induce
1299,15263,24780744,"Verapamil induced nuclear translocation of doxorubicin, G2-phase growth arrest and synergistically induced  100% cytotoxicity in 4T1-R cells in culture.","['Verapamil', 'doxorubicin']",['growth arrest'],True,doxorubicin,growth arrest,induced,C1399128,Growth arrest lines,31703,Doxorubicin,Doxorubicin,induce
1300,15272,24311719," We show that TCDD increased all four EETs (5,6-, 8,9-, 11,12-, and 14,15-), their corresponding DHETs, and 18- and 20-HETE in liver in vivo and increased 5,6-EET,  the four DHETs, and 18-HETE in heart, in a chick embryo model.",['TCDD'],"['increased 5,6-EET']",True,TCDD,"increased 5,6-EET",increased,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TCDD,increase
1301,15283,29888801,"Interestingly, TCPOBOP treatment caused transient decline in hepatocyte nuclear factor 4 alpha expression concomitant to proliferative response; this was not seen in [MET KO + EGFRi] mice.","['TCPOBOP', 'EGFRi']",['transient decline in hepatocyte nuclear factor 4 alpha expression'],True,TCPOBOP,transient decline in hepatocyte nuclear factor 4 alpha expression,caused,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TCPOBOP,cause
1302,15283,29888801,"Interestingly, TCPOBOP treatment caused transient decline in hepatocyte nuclear factor 4 alpha expression concomitant to proliferative response; this was not seen in [MET KO + EGFRi] mice.","['TCPOBOP', 'EGFRi']",['transient decline in hepatocyte nuclear factor 4 alpha expression'],True,EGFRi,transient decline in hepatocyte nuclear factor 4 alpha expression,caused,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",EGFRi,cause
1303,15306,26953171,"Shifting to serum/EGF-deficient medium also enhanced TCDD-mediated induction of cytochrome P450 (CYP)1A1 Treatment of cells cultured in complete medium with the EGFR inhibitors gefitinib (Iressa), AG1478, and CI-1033 resulted in concentration-dependent reductions of active EGFR and ERKs, and increased CYP1A1  mRNA content ∼3- to 18-fold above basal level.",['AG1478'],"['reductions of active EGFR and ERKs', 'increased CYP1A1']",True,AG1478,increased CYP1A1,resulted,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",AG1478,result
1304,15348,20564646,"Whereas EGFR inhibition with erlotinib and pan-ERBB inhibition with CI-1033 inhibited EGF-induced phosphorylation of EGFR, AKT, and ERK1/2, only CI-1033 induced growth inhibition and dose-dependent apoptosis in vitro.",['erlotinib'],"['EGFR inhibition', 'induced growth inhibition', 'apoptosis']",True,erlotinib,EGFR inhibition,inhibited,C0424296,Disinhibition,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",erlotinib,inhibit
1305,15349,20564646,"Both CI-1033 and erlotinib treatment of neuroblastoma xenograft tumors resulted in decreased tumor growth in vivo, although CI-1033 was more effective.",['erlotinib'],"['CI-1033', 'decreased tumor growth']",True,erlotinib,CI-1033,resulted,C0424296,Disinhibition,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",erlotinib,result
1306,15425,35292873, RESULTS: We confirmed that the growth of A. fumigatus was directly inhibited by thymol.,['thymol'],['growth'],True,thymol,growth,inhibited,C0456070,Growth delay,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thymol,inhibit
1307,15479,35164218,The use of the more polar solvent resulted in excellent conversion of the triglycerides to FAME esters with all three-catalyst media.,['FAME esters'],['triglycerides'],True,FAME esters,triglycerides,resulted,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",FAME esters,result
1308,15492,35111996,This study investigated if piperlongumine could inhibit such inflammation.,['piperlongumine'],['inflammation'],True,piperlongumine,inflammation,inhibit,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",piperlongumine,inhibit
1309,15493,35111996, Results: Piperlongumine inhibited inflammatory mediators and adherence of lymphocyte function-associated antigen 1 to MH-S cells following TDM activation.,['Piperlongumine'],"['inflammatory mediators', 'TDM activation']",True,Piperlongumine,inflammatory mediators,inhibited,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Piperlongumine,inhibit
1310,15516,35307918,  Toxic metals cause neurodegeneration via formation of toxic complexes with the cellular compounds and production of highly reactive oxygen species.,['oxygen'],"['neurodegeneration', 'formation of toxic complexes']",True,oxygen,neurodegeneration,cause,C0027746,Neurodegeneration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,cause
1311,15550,34848222,"While sodium arsenite, sodium arsenate, and lead acetate generate oxidative stress by an imbalance between ROS production and scavenging, cadmium chloride causes an increase in the pH level of the luminal fluid (from 6.5 to 7.37) that diminishes sperm viability.","['sodium arsenite', 'sodium arsenate', 'cadmium chloride']","['oxidative stress', 'increase in the pH level of the luminal fluid', 'diminishes sperm viability']",True,sodium arsenite,oxidative stress,generate,C0242606,Oxidative stress,443495,sodium;oxoarsinite,sodium;oxoarsinite,generate
1312,15550,34848222,"While sodium arsenite, sodium arsenate, and lead acetate generate oxidative stress by an imbalance between ROS production and scavenging, cadmium chloride causes an increase in the pH level of the luminal fluid (from 6.5 to 7.37) that diminishes sperm viability.","['sodium arsenite', 'sodium arsenate', 'cadmium chloride']","['oxidative stress', 'increase in the pH level of the luminal fluid', 'diminishes sperm viability']",True,sodium arsenate,oxidative stress,generate,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium arsenate,generate
1313,15550,34848222,"While sodium arsenite, sodium arsenate, and lead acetate generate oxidative stress by an imbalance between ROS production and scavenging, cadmium chloride causes an increase in the pH level of the luminal fluid (from 6.5 to 7.37) that diminishes sperm viability.","['sodium arsenite', 'sodium arsenate', 'cadmium chloride']","['oxidative stress', 'increase in the pH level of the luminal fluid', 'diminishes sperm viability']",True,sodium arsenite,oxidative stress,causes,C0242606,Oxidative stress,443495,sodium;oxoarsinite,sodium;oxoarsinite,cause
1314,15550,34848222,"While sodium arsenite, sodium arsenate, and lead acetate generate oxidative stress by an imbalance between ROS production and scavenging, cadmium chloride causes an increase in the pH level of the luminal fluid (from 6.5 to 7.37) that diminishes sperm viability.","['sodium arsenite', 'sodium arsenate', 'cadmium chloride']","['oxidative stress', 'increase in the pH level of the luminal fluid', 'diminishes sperm viability']",True,sodium arsenate,oxidative stress,causes,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium arsenate,cause
1315,15550,34848222,"While sodium arsenite, sodium arsenate, and lead acetate generate oxidative stress by an imbalance between ROS production and scavenging, cadmium chloride causes an increase in the pH level of the luminal fluid (from 6.5 to 7.37) that diminishes sperm viability.","['sodium arsenite', 'sodium arsenate', 'cadmium chloride']","['oxidative stress', 'increase in the pH level of the luminal fluid', 'diminishes sperm viability']",True,cadmium chloride,oxidative stress,causes,C0242606,Oxidative stress,24947,dichlorocadmium,dichlorocadmium,cause
1316,15605,34006163,"Sodium arsenite led rise in serum creatinine, urea, uric acid,  electrolytes (potassium, fractional excretion of sodium), microproteinuria, and decreased creatinine clearance (p < 0.001) indicated renal dysfunction in rats.","['Sodium arsenite', 'microproteinuria']","['rise in serum creatinine', 'fractional excretion of sodium)', 'decreased creatinine clearance', 'renal dysfunction']",True,Sodium arsenite,rise in serum creatinine,led,C0700225,High blood creatinine level,443495,sodium;oxoarsinite,sodium;oxoarsinite,lead
1317,15605,34006163,"Sodium arsenite led rise in serum creatinine, urea, uric acid,  electrolytes (potassium, fractional excretion of sodium), microproteinuria, and decreased creatinine clearance (p < 0.001) indicated renal dysfunction in rats.","['Sodium arsenite', 'microproteinuria']","['rise in serum creatinine', 'fractional excretion of sodium)', 'decreased creatinine clearance', 'renal dysfunction']",True,Sodium arsenite,decreased creatinine clearance,led,C0853068,Decreased glomerular filtration rate,443495,sodium;oxoarsinite,sodium;oxoarsinite,lead
1318,15605,34006163,"Sodium arsenite led rise in serum creatinine, urea, uric acid,  electrolytes (potassium, fractional excretion of sodium), microproteinuria, and decreased creatinine clearance (p < 0.001) indicated renal dysfunction in rats.","['Sodium arsenite', 'microproteinuria']","['rise in serum creatinine', 'fractional excretion of sodium)', 'decreased creatinine clearance', 'renal dysfunction']",True,Sodium arsenite,renal dysfunction,led,C0151747,Renal tubular disease,443495,sodium;oxoarsinite,sodium;oxoarsinite,lead
1319,15605,34006163,"Sodium arsenite led rise in serum creatinine, urea, uric acid,  electrolytes (potassium, fractional excretion of sodium), microproteinuria, and decreased creatinine clearance (p < 0.001) indicated renal dysfunction in rats.","['Sodium arsenite', 'microproteinuria']","['rise in serum creatinine', 'fractional excretion of sodium)', 'decreased creatinine clearance', 'renal dysfunction']",True,microproteinuria,rise in serum creatinine,led,C0700225,High blood creatinine level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",microproteinuria,lead
1320,15605,34006163,"Sodium arsenite led rise in serum creatinine, urea, uric acid,  electrolytes (potassium, fractional excretion of sodium), microproteinuria, and decreased creatinine clearance (p < 0.001) indicated renal dysfunction in rats.","['Sodium arsenite', 'microproteinuria']","['rise in serum creatinine', 'fractional excretion of sodium)', 'decreased creatinine clearance', 'renal dysfunction']",True,microproteinuria,decreased creatinine clearance,led,C0853068,Decreased glomerular filtration rate,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",microproteinuria,lead
1321,15605,34006163,"Sodium arsenite led rise in serum creatinine, urea, uric acid,  electrolytes (potassium, fractional excretion of sodium), microproteinuria, and decreased creatinine clearance (p < 0.001) indicated renal dysfunction in rats.","['Sodium arsenite', 'microproteinuria']","['rise in serum creatinine', 'fractional excretion of sodium)', 'decreased creatinine clearance', 'renal dysfunction']",True,microproteinuria,renal dysfunction,led,C0151747,Renal tubular disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",microproteinuria,lead
1322,15612,33884178, 1. Toxicol Res (Camb). 2021 Feb 17;10(2):277-283. doi: 10.1093/toxres/tfab007. eCollection 2021 Mar.  Sodium arsenite induces spatial learning and memory impairment associated with oxidative stress and activates the Nrf2/PPARγ pathway against oxidative injury in mice hippocampus.,['Sodium arsenite'],"['oxidative stress', 'oxidative injury']",True,Sodium arsenite,oxidative stress,induces,C0242606,Oxidative stress,443495,sodium;oxoarsinite,sodium;oxoarsinite,induce
1323,15624,33781819,"Arsenite increased Gln consumption of SV-HUC-1 cells, and Gln starvation inhibited cell proliferation in long-term arsenite-treated cells.",['Arsenite'],"['increased Gln consumption of SV-HUC-1 cells', 'cell proliferation']",True,Arsenite,cell proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Arsenite,inhibit
1324,15632,33635931,"By immunofluorescence analysis, we observed that IBV infection not only did not trigger SGs formation in approximately 80% of the infected cells, but also impaired the formation of SGs triggered by heat shock, sodium arsenite, or NaCl stimuli.","['sodium arsenite', 'NaCl']","['infected', 'formation of SGs', 'heat shock']",True,sodium arsenite,heat shock,triggered,C4531170,Abnormal cell proliferation,443495,sodium;oxoarsinite,sodium;oxoarsinite,trigger
1325,15632,33635931,"By immunofluorescence analysis, we observed that IBV infection not only did not trigger SGs formation in approximately 80% of the infected cells, but also impaired the formation of SGs triggered by heat shock, sodium arsenite, or NaCl stimuli.","['sodium arsenite', 'NaCl']","['infected', 'formation of SGs', 'heat shock']",True,NaCl,heat shock,triggered,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",NaCl,trigger
1326,15665,33268822,"We demonstrate that targeting telomeres by KML001 induces mitochondrial dysfunction, as evidenced by increased mitochondrial swelling and decreased mitochondrial membrane potential, oxidative phosphorylation, mitochondrial DNA content, mitochondrial respiration, oxygen consumption, glycolysis, and ATP energy production.","['oxygen', 'ATP']","['increased mitochondrial swelling', 'decreased mitochondrial membrane', 'oxidative phosphorylation']",True,oxygen,increased mitochondrial swelling,induces,C0026244,Mitochondrial swelling,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,induce
1327,15665,33268822,"We demonstrate that targeting telomeres by KML001 induces mitochondrial dysfunction, as evidenced by increased mitochondrial swelling and decreased mitochondrial membrane potential, oxidative phosphorylation, mitochondrial DNA content, mitochondrial respiration, oxygen consumption, glycolysis, and ATP energy production.","['oxygen', 'ATP']","['increased mitochondrial swelling', 'decreased mitochondrial membrane', 'oxidative phosphorylation']",True,oxygen,decreased mitochondrial membrane,induces,C0887941,Mitochondrial inheritance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,induce
1328,15665,33268822,"We demonstrate that targeting telomeres by KML001 induces mitochondrial dysfunction, as evidenced by increased mitochondrial swelling and decreased mitochondrial membrane potential, oxidative phosphorylation, mitochondrial DNA content, mitochondrial respiration, oxygen consumption, glycolysis, and ATP energy production.","['oxygen', 'ATP']","['increased mitochondrial swelling', 'decreased mitochondrial membrane', 'oxidative phosphorylation']",True,ATP,increased mitochondrial swelling,induces,C0026244,Mitochondrial swelling,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ATP,induce
1329,15665,33268822,"We demonstrate that targeting telomeres by KML001 induces mitochondrial dysfunction, as evidenced by increased mitochondrial swelling and decreased mitochondrial membrane potential, oxidative phosphorylation, mitochondrial DNA content, mitochondrial respiration, oxygen consumption, glycolysis, and ATP energy production.","['oxygen', 'ATP']","['increased mitochondrial swelling', 'decreased mitochondrial membrane', 'oxidative phosphorylation']",True,ATP,decreased mitochondrial membrane,induces,C0887941,Mitochondrial inheritance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ATP,induce
1330,15671,33171135," Taken together, our results show that prenatal arsenic exposure provoked reproductive disorders in prepubertal male rats, probably due to reproductive reprograming and oxidative stress induced by this pollutant.",['arsenic exposure'],['oxidative stress'],True,arsenic exposure,oxidative stress,provoked,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",arsenic exposure,provoke
1331,15699,12704432,The incidences of hepatocellular adenomas were increased in male and female mice given 50 mg/kg N-methylolacrylamide (male: 8/50; 4/50; 19/50; female: 3/50; 4/50; 17/49).,['N-methylolacrylamide'],['hepatocellular adenomas'],True,N-methylolacrylamide,hepatocellular adenomas,increased,C0206669,Hepatic adenoma,13543,N-Methylolacrylamide,N-Methylolacrylamide,increase
1332,15733,30960098,"The results showed that introduction of small amount of pectin (up to  6.7 wt %) to poly(acrylic acid) hydrogel increase the swelling capacity, while further increasing of pectin ratio cause decrease of swelling.","['pectin', 'poly(acrylic acid']",['decrease of swelling'],True,pectin,decrease of swelling,increase,C0239598,Swollen finger,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pectin,increase
1333,15733,30960098,"The results showed that introduction of small amount of pectin (up to  6.7 wt %) to poly(acrylic acid) hydrogel increase the swelling capacity, while further increasing of pectin ratio cause decrease of swelling.","['pectin', 'poly(acrylic acid']",['decrease of swelling'],True,poly(acrylic acid,decrease of swelling,increase,C0239598,Swollen finger,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",poly(acrylic acid,increase
1334,15740,27506246,The results showed that an increasing AAc composition led to more efficient inhibition of the hemolytic activity of melittin.,['melittin'],['hemolytic activity'],True,melittin,hemolytic activity,led,C4476774,Reduced hemolytic complement activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melittin,lead
1335,15757,35292247," IMPy, MDA, DETP, and 1-N were significantly associated with decreased serum BDNF  levels, while MDA, 3-PBA, and ETU were associated with higher DNA methylation percentages at several CpGs.","['DETP', 'ETU']","['decreased serum BDNF  levels', 'higher DNA methylation']",True,DETP,decreased serum BDNF  levels,associated,C4021093,Decreased serum complement C9,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DETP,associate
1336,15757,35292247," IMPy, MDA, DETP, and 1-N were significantly associated with decreased serum BDNF  levels, while MDA, 3-PBA, and ETU were associated with higher DNA methylation percentages at several CpGs.","['DETP', 'ETU']","['decreased serum BDNF  levels', 'higher DNA methylation']",True,ETU,decreased serum BDNF  levels,associated,C4021093,Decreased serum complement C9,2723650,imidazolidine-2-thione,imidazolidine-2-thione,associate
1337,15765,34174256,"Among boys in the TDID cohort, 2,4-D was associated with smaller head circumference in the second (b = -1.57; 95%CI: -2.74, -0.39) and third (b = -1.74, 95%CI: -2.98, -0.49) concentration categories compared to the first.","['2,4-D']",['smaller head circumference'],True,"2,4-D",smaller head circumference,associated,C4551563,Abnormally small skull,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","2,4-D",associate
1338,15790,31924582,Our results suggest that exposure to elevated concentrations of diazinon (the parent compound of IMPY) and chlorpyrifos and chlorpyrifos-methyl (parent compounds of TCPY) may be associated with endometriosis.,"['diazinon', 'IMPY', 'chlorpyrifos', 'chlorpyrifos-methyl', 'TCPY']",['endometriosis'],True,diazinon,endometriosis,associated,C0014175,Endometriosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",diazinon,associate
1339,15790,31924582,Our results suggest that exposure to elevated concentrations of diazinon (the parent compound of IMPY) and chlorpyrifos and chlorpyrifos-methyl (parent compounds of TCPY) may be associated with endometriosis.,"['diazinon', 'IMPY', 'chlorpyrifos', 'chlorpyrifos-methyl', 'TCPY']",['endometriosis'],True,IMPY,endometriosis,associated,C0014175,Endometriosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",IMPY,associate
1340,15790,31924582,Our results suggest that exposure to elevated concentrations of diazinon (the parent compound of IMPY) and chlorpyrifos and chlorpyrifos-methyl (parent compounds of TCPY) may be associated with endometriosis.,"['diazinon', 'IMPY', 'chlorpyrifos', 'chlorpyrifos-methyl', 'TCPY']",['endometriosis'],True,chlorpyrifos,endometriosis,associated,C0014175,Endometriosis,2730,Chlorpyrifos,Chlorpyrifos,associate
1341,15790,31924582,Our results suggest that exposure to elevated concentrations of diazinon (the parent compound of IMPY) and chlorpyrifos and chlorpyrifos-methyl (parent compounds of TCPY) may be associated with endometriosis.,"['diazinon', 'IMPY', 'chlorpyrifos', 'chlorpyrifos-methyl', 'TCPY']",['endometriosis'],True,chlorpyrifos-methyl,endometriosis,associated,C0014175,Endometriosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chlorpyrifos-methyl,associate
1342,15790,31924582,Our results suggest that exposure to elevated concentrations of diazinon (the parent compound of IMPY) and chlorpyrifos and chlorpyrifos-methyl (parent compounds of TCPY) may be associated with endometriosis.,"['diazinon', 'IMPY', 'chlorpyrifos', 'chlorpyrifos-methyl', 'TCPY']",['endometriosis'],True,TCPY,endometriosis,associated,C0014175,Endometriosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TCPY,associate
1343,15809,30815923,"Results from several epidemiological studies suggest that exposure to CPF can result in reproductive disorders, including infertility in male and female.",['CPF'],['infertility'],True,CPF,infertility,result,C0021359,Infertility,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CPF,result
1344,15823,35167857,  Epoxiconazole caused oxidative stress related DNA damage and apoptosis in PC12 rat Pheochromocytoma.,['Epoxiconazole'],"['oxidative stress', 'DNA damage', 'apoptosis']",True,Epoxiconazole,oxidative stress,caused,C0242606,Oxidative stress,3317081,epiconazole,epiconazole,cause
1345,15978,34451677,"In the field and pot studies, isoxaflutole 75 g ai ha-1 caused crop injury, and in the field experiment, it reduced mungbean yield by 61% compared with the best treatment (pyroxasulfone 100 g ai ha-1).","['isoxaflutole', 'pyroxasulfone']",['injury'],True,isoxaflutole,injury,caused,C0424366,Self injury,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",isoxaflutole,cause
1346,15978,34451677,"In the field and pot studies, isoxaflutole 75 g ai ha-1 caused crop injury, and in the field experiment, it reduced mungbean yield by 61% compared with the best treatment (pyroxasulfone 100 g ai ha-1).","['isoxaflutole', 'pyroxasulfone']",['injury'],True,pyroxasulfone,injury,caused,C0424366,Self injury,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pyroxasulfone,cause
1347,16031,35262227,"The safener furilazole caused a significant decrease in cell size, while benoxacor and AD-67 had no observed effect on algae cell size.","['furilazole', 'benoxacor']",['decrease in cell size'],True,safener,decrease in cell size,caused,C4024159,Aplasia/Hypoplasia involving the nose,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",safener,cause
1348,16031,35262227,"The safener furilazole caused a significant decrease in cell size, while benoxacor and AD-67 had no observed effect on algae cell size.","['furilazole', 'benoxacor']",['decrease in cell size'],True,benoxacor,decrease in cell size,caused,C4024159,Aplasia/Hypoplasia involving the nose,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",benoxacor,cause
1349,16102,33063577," Epinephrine was associated with QTca and JTpca shortening, which could be related to undercorrection in the presence of tachycardia, while minimal effects were observed for Tpeca.",['Tpeca'],['tachycardia'],True,Epinephrine,tachycardia,associated,C0039231,Heart racing,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Epinephrine,associate
1350,16102,33063577," Epinephrine was associated with QTca and JTpca shortening, which could be related to undercorrection in the presence of tachycardia, while minimal effects were observed for Tpeca.",['Tpeca'],['tachycardia'],True,Epinephrine,Tpeca,associated,C0039231,Heart racing,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Epinephrine,associate
1351,16112,32508659,"Dofetilide, but none of the KCa2 channel inhibitors increased Tp-Te during hypokalemia.",['Dofetilide'],['hypokalemia'],True,Dofetilide,hypokalemia,increased,C0020621,Hypokalemia,71329,Dofetilide,Dofetilide,increase
1352,16114,32508659," Conclusion: Hypokalemia was associated with an increased incidence of VF, an effect that also seen in the presence of dofetilide.",['dofetilide'],"['Hypokalemia', 'increased incidence of VF']",True,dofetilide,Hypokalemia,associated,C0020621,Hypokalemia,71329,Dofetilide,Dofetilide,associate
1353,16124,32175633," ABSTRACT: Antiarrhythmic drugs used to treat atrial fibrillation can occasionally induce ventricular tachyarrhythmia, which is typically precipitated by a premature ectopic beat through a mechanism related, in part, to the shortening of the excitation wavelength (EW).",['fibrillation'],"['ventricular tachyarrhythmia', 'premature ectopic beat']",True,fibrillation,ventricular tachyarrhythmia,induce,C0085612,Ventricular arrhythmias,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fibrillation,induce
1354,16127,31945853,The administration of dofetilide may cause ventricular arrhythmias and torsade de pointes.,['dofetilide'],['torsade de pointes'],True,dofetilide,torsade de pointes,cause,C0040479,Torsade de pointes,71329,Dofetilide,Dofetilide,cause
1355,16176,35012353,"  Acinetobacter baumannii causes high mortality in ventilator-associated pneumonia  patients, and antibiotic treatment is compromised by multidrug-resistant strains  resistant to β-lactams, carbapenems, cephalosporins, polymyxins, and tetracyclines.","['Acinetobacter baumannii', 'cephalosporins', 'polymyxins', 'tetracyclines']","['high mortality', 'pneumonia']",True,Acinetobacter baumannii,pneumonia,causes,C0032285,Pneumonia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Acinetobacter baumannii,cause
1356,16176,35012353,"  Acinetobacter baumannii causes high mortality in ventilator-associated pneumonia  patients, and antibiotic treatment is compromised by multidrug-resistant strains  resistant to β-lactams, carbapenems, cephalosporins, polymyxins, and tetracyclines.","['Acinetobacter baumannii', 'cephalosporins', 'polymyxins', 'tetracyclines']","['high mortality', 'pneumonia']",True,cephalosporins,pneumonia,causes,C0032285,Pneumonia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cephalosporins,cause
1357,16176,35012353,"  Acinetobacter baumannii causes high mortality in ventilator-associated pneumonia  patients, and antibiotic treatment is compromised by multidrug-resistant strains  resistant to β-lactams, carbapenems, cephalosporins, polymyxins, and tetracyclines.","['Acinetobacter baumannii', 'cephalosporins', 'polymyxins', 'tetracyclines']","['high mortality', 'pneumonia']",True,polymyxins,pneumonia,causes,C0032285,Pneumonia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",polymyxins,cause
1358,16176,35012353,"  Acinetobacter baumannii causes high mortality in ventilator-associated pneumonia  patients, and antibiotic treatment is compromised by multidrug-resistant strains  resistant to β-lactams, carbapenems, cephalosporins, polymyxins, and tetracyclines.","['Acinetobacter baumannii', 'cephalosporins', 'polymyxins', 'tetracyclines']","['high mortality', 'pneumonia']",True,tetracyclines,pneumonia,causes,C0032285,Pneumonia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tetracyclines,cause
1359,16208,34259502,"At 1× MIC, PBT2 alone induced a 3.75-fold increase in intracellular Zn, whereas PBT2-Zn challenge induced a 19-fold accumulation of intracellular Zn after 2 h. A corresponding 2.1-fold loss of Fe was observed at 1× MIC.","['Zn', 'PBT2-Zn', 'Zn', 'Fe']",['increase in intracellular'],True,Zn,increase in intracellular,induced,C4025593,Increased intracellular sodium,23994,zinc,zinc,induce
1360,16208,34259502,"At 1× MIC, PBT2 alone induced a 3.75-fold increase in intracellular Zn, whereas PBT2-Zn challenge induced a 19-fold accumulation of intracellular Zn after 2 h. A corresponding 2.1-fold loss of Fe was observed at 1× MIC.","['Zn', 'PBT2-Zn', 'Zn', 'Fe']",['increase in intracellular'],True,PBT2-Zn,increase in intracellular,induced,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PBT2-Zn,induce
1361,16208,34259502,"At 1× MIC, PBT2 alone induced a 3.75-fold increase in intracellular Zn, whereas PBT2-Zn challenge induced a 19-fold accumulation of intracellular Zn after 2 h. A corresponding 2.1-fold loss of Fe was observed at 1× MIC.","['Zn', 'PBT2-Zn', 'Zn', 'Fe']",['increase in intracellular'],True,Zn,increase in intracellular,induced,C4025593,Increased intracellular sodium,23994,zinc,zinc,induce
1362,16208,34259502,"At 1× MIC, PBT2 alone induced a 3.75-fold increase in intracellular Zn, whereas PBT2-Zn challenge induced a 19-fold accumulation of intracellular Zn after 2 h. A corresponding 2.1-fold loss of Fe was observed at 1× MIC.","['Zn', 'PBT2-Zn', 'Zn', 'Fe']",['increase in intracellular'],True,Fe,increase in intracellular,induced,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Fe,induce
1363,16217,33861690,"Furthermore, CQ inhibited the activation of fibroblasts, including proliferation, fibrotic differentiation, proinflammatory cytokine secretion, and migration.",['CQ'],"['activation of fibroblasts', 'proliferation', 'fibrotic differentiation']",True,CQ,activation of fibroblasts,inhibited,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CQ,inhibit
1364,16217,33861690,"Furthermore, CQ inhibited the activation of fibroblasts, including proliferation, fibrotic differentiation, proinflammatory cytokine secretion, and migration.",['CQ'],"['activation of fibroblasts', 'proliferation', 'fibrotic differentiation']",True,CQ,proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CQ,inhibit
1365,16228,33580904,Dyshomeostasis of copper levels  can lead to increased oxidative stress and neuronal loss.,['copper'],"['increased oxidative stress', 'neuronal loss']",True,copper,increased oxidative stress,lead,C0242606,Oxidative stress,23978,copper,copper,lead
1366,16228,33580904,Dyshomeostasis of copper levels  can lead to increased oxidative stress and neuronal loss.,['copper'],"['increased oxidative stress', 'neuronal loss']",True,copper,neuronal loss,lead,C0242606,Oxidative stress,23978,copper,copper,lead
1367,16231,34226497,"In  CR-infected Rag1-/- mice, higher levels of DCLK1 in the colonic crypts were inhibited when mice received DBZ for 10 days coincident with significant dysbiosis, barrier disruption, and colitis.",['DBZ'],"['higher levels of DCLK1 in the colonic crypts', 'dysbiosis', 'colitis']",True,DBZ,colitis,inhibited,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DBZ,inhibit
1368,16288,27307737," In Phase III studies, adjunctive therapy with ESL 800 or 1,200 mg/day leads to a  significant decrease in the seizure frequency in adults with refractory partial onset epilepsy.","['ESL 800 or 1,200 mg/day']",['decrease in the seizure frequency'],True,"ESL 800 or 1,200 mg/day",decrease in the seizure frequency,leads,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","ESL 800 or 1,200 mg/day",lead
1369,16292,26933171,"Combined inhibition of Notch1 and  Notch2 in adult mice led to decreased epithelial cell proliferation, including reduced proliferation of LGR5 stem cells, and increased apoptosis, similar to the response to global Notch inhibition with DBZ.",['DBZ'],"['decreased epithelial cell proliferation', 'reduced proliferation of LGR5 stem cells', 'increased apoptosis']",True,DBZ,increased apoptosis,led,C4280724,Increased lymphocyte apoptosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DBZ,lead
1370,16320,28962375,"TPT caused a transient decrease of weight gain at 3.75 mg/kg bw/d, and deaths and body weight deficits at higher doses.",['TPT'],"['transient decrease of weight gain', 'deaths', 'body weight deficits']",True,TPT,transient decrease of weight gain,caused,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TPT,cause
1371,16320,28962375,"TPT caused a transient decrease of weight gain at 3.75 mg/kg bw/d, and deaths and body weight deficits at higher doses.",['TPT'],"['transient decrease of weight gain', 'deaths', 'body weight deficits']",True,TPT,deaths,caused,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TPT,cause
1372,16335,17619067, TPTH also caused a dose-related increase of fetal skeleton variations (e.g. poorly ossified skull bones) and malformations (misshapened Axis and skull bones).,['TPTH'],"['increase of fetal skeleton variations', 'ossified skull bones', 'malformations', 'misshapened Axis and skull bones']",True,TPTH,ossified skull bones,caused,C0432073,Hypoossification of skull,6327657,Triphenyltin Hydroxide,Triphenyltin Hydroxide,cause
1373,16335,17619067, TPTH also caused a dose-related increase of fetal skeleton variations (e.g. poorly ossified skull bones) and malformations (misshapened Axis and skull bones).,['TPTH'],"['increase of fetal skeleton variations', 'ossified skull bones', 'malformations', 'misshapened Axis and skull bones']",True,TPTH,malformations,caused,C0040427,Abnormality of dental shape,6327657,Triphenyltin Hydroxide,Triphenyltin Hydroxide,cause
1374,16343,10477351,Both pesticides induced a dose-dependent increase but only TPTH induced a significant increase in MN at the highest dose (150 ng/ml) tested in CHO cells.,['TPTH'],['increase in MN'],True,TPTH,increase in MN,induced,C0853225,Reduced factor II activity,6327657,Triphenyltin Hydroxide,Triphenyltin Hydroxide,induce
1375,16343,10477351,Both pesticides induced a dose-dependent increase but only TPTH induced a significant increase in MN at the highest dose (150 ng/ml) tested in CHO cells.,['TPTH'],['increase in MN'],True,TPTH,increase in MN,induced,C0853225,Reduced factor II activity,6327657,Triphenyltin Hydroxide,Triphenyltin Hydroxide,induce
1376,16356,12799653,"In female rats no significant accelerated mortality, retardation of growth, or other signs of toxicity were associated with the dietary administration of triphenyltin hydroxide.",['triphenyltin hydroxide'],"['mortality', 'retardation of growth']",True,triphenyltin hydroxide,retardation of growth,associated,C0151686,Growth retardation,6327657,Triphenyltin Hydroxide,Triphenyltin Hydroxide,associate
1377,16358,310751,The intravenous administration of 25 mg/kg of Vancide KS to New Zealand strain albino rabbits induced death preceded by topic convulsions.,['Vancide'],"['death', 'convulsions']",True,Vancide,death,induced,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Vancide,induce
1378,16358,310751,The intravenous administration of 25 mg/kg of Vancide KS to New Zealand strain albino rabbits induced death preceded by topic convulsions.,['Vancide'],"['death', 'convulsions']",True,Vancide,convulsions,induced,C1527366,Epileptic spasms,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Vancide,induce
1379,16391,34577561,"Biological analyses looking for efficient neuroprotective effects in suitable phenotypic assays led us to identify MC903 as a new small quinolylnitrone for the potential dual therapy of stroke and AD, showing strong neuroprotection on (i) primary cortical neurons under oxygen-glucose deprivation/normoglycemic reoxygenation as an experimental ischemia model; (ii),  neuronal line cells treated with rotenone/oligomycin A, okadaic acid or β-amyloid peptide Aβ25-35, modeling toxic insults found among the effects of AD.","['MC903', 'oxygen-glucose', 'rotenone/oligomycin', 'okadaic acid']",['ischemia'],True,MC903,ischemia,led,C0007786,Brain ischemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MC903,lead
1380,16391,34577561,"Biological analyses looking for efficient neuroprotective effects in suitable phenotypic assays led us to identify MC903 as a new small quinolylnitrone for the potential dual therapy of stroke and AD, showing strong neuroprotection on (i) primary cortical neurons under oxygen-glucose deprivation/normoglycemic reoxygenation as an experimental ischemia model; (ii),  neuronal line cells treated with rotenone/oligomycin A, okadaic acid or β-amyloid peptide Aβ25-35, modeling toxic insults found among the effects of AD.","['MC903', 'oxygen-glucose', 'rotenone/oligomycin', 'okadaic acid']",['ischemia'],True,oxygen-glucose,ischemia,led,C0007786,Brain ischemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen-glucose,lead
1381,16391,34577561,"Biological analyses looking for efficient neuroprotective effects in suitable phenotypic assays led us to identify MC903 as a new small quinolylnitrone for the potential dual therapy of stroke and AD, showing strong neuroprotection on (i) primary cortical neurons under oxygen-glucose deprivation/normoglycemic reoxygenation as an experimental ischemia model; (ii),  neuronal line cells treated with rotenone/oligomycin A, okadaic acid or β-amyloid peptide Aβ25-35, modeling toxic insults found among the effects of AD.","['MC903', 'oxygen-glucose', 'rotenone/oligomycin', 'okadaic acid']",['ischemia'],True,rotenone/oligomycin,ischemia,led,C0007786,Brain ischemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rotenone/oligomycin,lead
1382,16391,34577561,"Biological analyses looking for efficient neuroprotective effects in suitable phenotypic assays led us to identify MC903 as a new small quinolylnitrone for the potential dual therapy of stroke and AD, showing strong neuroprotection on (i) primary cortical neurons under oxygen-glucose deprivation/normoglycemic reoxygenation as an experimental ischemia model; (ii),  neuronal line cells treated with rotenone/oligomycin A, okadaic acid or β-amyloid peptide Aβ25-35, modeling toxic insults found among the effects of AD.","['MC903', 'oxygen-glucose', 'rotenone/oligomycin', 'okadaic acid']",['ischemia'],True,okadaic acid,ischemia,led,C0007786,Brain ischemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",okadaic acid,lead
1383,16417,34148100,"  The consumption of contaminated shellfish with okadaic acid (OA) group of toxins  leads to diarrhoeic shellfish poisoning (DSP) characterized by a set of symptoms  including nausea, vomiting and diarrhoea.",['okadaic acid'],"['nausea', 'vomiting', 'diarrhoea']",True,okadaic acid,nausea,leads,C0027497,Nausea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",okadaic acid,lead
1384,16417,34148100,"  The consumption of contaminated shellfish with okadaic acid (OA) group of toxins  leads to diarrhoeic shellfish poisoning (DSP) characterized by a set of symptoms  including nausea, vomiting and diarrhoea.",['okadaic acid'],"['nausea', 'vomiting', 'diarrhoea']",True,okadaic acid,vomiting,leads,C0042963,Throwing up,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",okadaic acid,lead
1385,16417,34148100,"  The consumption of contaminated shellfish with okadaic acid (OA) group of toxins  leads to diarrhoeic shellfish poisoning (DSP) characterized by a set of symptoms  including nausea, vomiting and diarrhoea.",['okadaic acid'],"['nausea', 'vomiting', 'diarrhoea']",True,okadaic acid,diarrhoea,leads,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",okadaic acid,lead
1386,16445,33342257,"Further, Melatonin has increased the cellular  Nrf2 level and its nuclear translocation as an oxidative stress response in Tauopathy.",['Melatonin'],['oxidative stress response'],True,Melatonin,oxidative stress response,increased,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Melatonin,increase
1387,16455,34107429,"The results suggest that pyridaben exposure induced elevated oxidative stress through the WNT signaling pathway, which in turn led to apoptosis in the heart and cardiotoxicity.",['pyridaben'],"['oxidative stress', 'apoptosis', 'cardiotoxicity']",True,pyridaben,oxidative stress,induced,C0242606,Oxidative stress,91754,Pyridaben,Pyridaben,induce
1388,16541,34726659,"Acute colitis was induced with 5 days of dextran sodium sulfate (DSS, 3%) in the drinking water.","['dextran', 'water']",['Acute colitis'],True,dextran,Acute colitis,induced,C2118460,Acute colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dextran,induce
1389,16541,34726659,"Acute colitis was induced with 5 days of dextran sodium sulfate (DSS, 3%) in the drinking water.","['dextran', 'water']",['Acute colitis'],True,water,Acute colitis,induced,C2118460,Acute colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,induce
1390,16558,34361022,"In addition, α-MSH-induced hyperpigmentation in zebrafish larvae was inhibited from 246.3% ± 5.4% to 116.3%  ± 3.1% at 40 mM GABA, displaying no apparent cardiotoxicity.",['GABA'],"['hyperpigmentation', 'cardiotoxicity']",True,GABA,hyperpigmentation,inhibited,C0162834,Hyperpigmentation of the skin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",GABA,inhibit
1391,16564,34284029,"To address this issue, maternal hypothyroidism was induced by adding methimazole (MMI; 0.02% w/v) to the drinking water of pregnant dams from conception to postpartum day 4 (P4).",['methimazole'],['maternal hypothyroidism'],True,methimazole,maternal hypothyroidism,induced,C0020676,Underactive thyroid,1349907,Methimazole,Methimazole,induce
1392,16568,34210323," RESULTS: The administration of crude extract, fractions and subfractions produced analgesic responses in acetic acid, formalin, tail immersion, and hot plate model for pain similar to those obtained with the standard.","['acetic acid', 'formalin']",['pain'],True,acetic acid,pain,produced,C0030193,Pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",acetic acid,produce
1393,16568,34210323," RESULTS: The administration of crude extract, fractions and subfractions produced analgesic responses in acetic acid, formalin, tail immersion, and hot plate model for pain similar to those obtained with the standard.","['acetic acid', 'formalin']",['pain'],True,formalin,pain,produced,C0030193,Pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",formalin,produce
1394,16571,34181036, (#)Contributed equally  RATIONALE AND OBJECTIVE: This study was undertaken to assess the modulating effects of (1) pre-exposure to repeated social disruption and (2) group testing on writhing associated with visceral pain induced by intraperitoneal administration of acetic acid.,['acetic acid'],"['social disruption', 'visceral pain']",True,acetic acid,visceral pain,associated,C0030193,Pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",acetic acid,associate
1395,16577,34135897,"Mechanistically, topiramate increased the number of Ly6Clow macrophages in the heart during POH and circulating Ly6Chigh classic monocyte infiltration in late-phase POH.",['topiramate'],"['number of Ly6Clow macrophages in the heart', 'Ly6Chigh classic monocyte infiltration']",True,topiramate,number of Ly6Clow macrophages in the heart,increased,C0030193,Pain,5284627,"[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate","[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate",increase
1396,16579,34125084,"In animal models of both rodents and non-human primates, local application of GABAA antagonists, such as bicuculline and picrotoxin, into the motor parts of the striatum induces local disinhibition  resulting in the expression of motor tics.","['bicuculline', 'picrotoxin']","['local disinhibition', 'expression of motor tics']",True,bicuculline,expression of motor tics,induces,C0751900,Motor tics,10237,(+)-Bicuculline,(+)-Bicuculline,induce
1397,16579,34125084,"In animal models of both rodents and non-human primates, local application of GABAA antagonists, such as bicuculline and picrotoxin, into the motor parts of the striatum induces local disinhibition  resulting in the expression of motor tics.","['bicuculline', 'picrotoxin']","['local disinhibition', 'expression of motor tics']",True,picrotoxin,expression of motor tics,induces,C0751900,Motor tics,6473767,"(1R,3R,5S,8S,13R,14S)-1-hydroxy-14-(2-hydroxypropan-2-yl)-13-methyl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione;(1R,5S,8S,13R,14R)-1-hydroxy-13-methyl-14-prop-1-en-2-yl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione","(1R,3R,5S,8S,13R,14S)-1-hydroxy-14-(2-hydroxypropan-2-yl)-13-methyl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione;(1R,5S,8S,13R,14R)-1-hydroxy-13-methyl-14-prop-1-en-2-yl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione",induce
1398,16580,34125084,"In the acute model, bicuculline microinjections through a cannula implanted in the dorsal striatum elicit the expression of tics  lasting for short time periods of up to an hour.",['bicuculline microinjections'],['expression of tics'],True,bicuculline microinjections,expression of tics,elicit,C0751900,Motor tics,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bicuculline microinjections,elicit
1399,16587,34004209,"These findings suggest that diazepam induces the anxiety-like behavior under inflammation conditions, and may cause the GABAA receptor dysfunction associated with the chloride plasticity mediated by NKCC1, which contributes to benzodiazepine-induced delirium after surgery.",['diazepam'],"['inflammation', 'chloride plasticity mediated']",True,diazepam,inflammation,induces,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",diazepam,induce
1400,16605,33745922,"In contrast, hyper-aggressive behavior in socially isolated mice was inhibited following bicuculline microinfusion without  affecting anxiety.",['bicuculline microinfusion'],"['hyper-aggressive', 'anxiety']",True,bicuculline microinfusion,anxiety,inhibited,C0003467,Anxiousness,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bicuculline microinfusion,inhibit
1401,16619,33711021,"The ability of mecamylamine to decrease hippocampal network synchronization might be associated  with its therapeutic effects in a wide variety of CNS disorders including addiction, depression and anxiety.",['mecamylamine'],"['depression', 'anxiety']",True,mecamylamine,depression,associated,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mecamylamine,associate
1402,16619,33711021,"The ability of mecamylamine to decrease hippocampal network synchronization might be associated  with its therapeutic effects in a wide variety of CNS disorders including addiction, depression and anxiety.",['mecamylamine'],"['depression', 'anxiety']",True,mecamylamine,anxiety,associated,C0003467,Anxiousness,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mecamylamine,associate
1403,16638,33347288,"Moreover, two drugs which increase neuronal activity, 4-aminopyridine (4-AP) and bicuculline methochloride, induced  high-frequency synchronized network bursting to a similar extent in both organoids.",['bicuculline methochloride'],['increase neuronal activity'],True,bicuculline methochloride,increase neuronal activity,induced,C4025637,Increased phosphoribosylpyrophosphate synthetase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bicuculline methochloride,induce
1404,16652,33117274,The initial results indicate that add-on therapy with ganaxolone resulted in reduced seizure frequency with adverse effect being mainly mild to moderate.,['ganaxolone'],['reduced seizure frequency'],True,ganaxolone,reduced seizure frequency,resulted,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ganaxolone,result
1405,16701,35261621,  Post-treatment with propofol inhibits inflammatory response in LPS-induced alveolar type II epithelial cells.,['propofol'],['inflammatory response'],True,propofol,inflammatory response,inhibits,C4022805,Abnormal inflammatory response,4943,Propofol,Propofol,inhibit
1406,16711,35253651,  Propofol may cause an increase in reactive oxygen species in the body.,['oxygen'],['increase in reactive'],True,oxygen,increase in reactive,cause,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,cause
1407,16726,35239284,"The latter may cause  ROS and bradykinin release, resulting in pain.",['bradykinin'],['pain'],True,bradykinin,pain,cause,C0030193,Pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bradykinin,cause
1408,16766,35306208,"In ApoE-/- mice, intraperitoneal administration of apelin-13 induced the expression of MCU, Drp1, PINK1, Parkin, and α-SMA and increased atherosclerotic plaque lesions.",['apelin-13'],['increased atherosclerotic plaque lesions'],True,apelin-13,increased atherosclerotic plaque lesions,induced,C4703473,Atherosclerotic lesion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",apelin-13,induce
1409,16772,35129032,NLRP3 inflammasome and mitochondrial ROS (mtROS)  have been implicated in ALI but its role in injury caused through two hit i.e. Hydrochloric acid (HCl) + Lipopolysaccharide (LPS) is not known.,"['Hydrochloric acid', 'Lipopolysaccharide']",['injury'],True,Hydrochloric acid,injury,caused,C0424366,Self injury,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Hydrochloric acid,cause
1410,16772,35129032,NLRP3 inflammasome and mitochondrial ROS (mtROS)  have been implicated in ALI but its role in injury caused through two hit i.e. Hydrochloric acid (HCl) + Lipopolysaccharide (LPS) is not known.,"['Hydrochloric acid', 'Lipopolysaccharide']",['injury'],True,Lipopolysaccharide,injury,caused,C0424366,Self injury,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Lipopolysaccharide,cause
1411,16788,34929351,"Here, we reported that BPA inhibited the cell viability of MLO-Y4 cells, and increased apoptosis in a dose-dependent manner.",['BPA'],['increased apoptosis'],True,BPA,increased apoptosis,inhibited,C4280724,Increased lymphocyte apoptosis,6623,Bisphenol A,Bisphenol A,inhibit
1412,16794,34895324,"However, mito-TEMPO significantly inhibited production of cytokines and decreased expression of proteins in NF-κB and NLRP3 inflammasome pathways in bMECs infected with either P. bovis or P. ciferrii.",['mito-TEMPO'],['decreased expression of proteins'],True,mito-TEMPO,decreased expression of proteins,inhibited,C5209293,Decreased expression of GPI-anchored proteins on the cell surface,134828258,Mito-TEMPO,Mito-TEMPO,inhibit
1413,16802,34710564," CONCLUSION: By increasing oxidative stress in the lung, cisplatin induces lung cell damage, disruption of cilia, and release of disrupted cilia into the BALF.",['cisplatin'],"['increasing oxidative stress in the lung', 'lung cell damage', 'disruption of cilia', 'release of disrupted cilia into the BALF']",True,cisplatin,increasing oxidative stress in the lung,induces,C0242606,Oxidative stress,5702198,azane;dichloroplatinum,azane;dichloroplatinum,induce
1414,16838,33855696,  Ethanol (ET) causes cerebrovascular dysfunction by altering homocysteine (Hcy) metabolism and by causing oxidative stress.,['Ethanol'],"['cerebrovascular dysfunction', 'oxidative stress']",True,Ethanol,oxidative stress,causes,C0242606,Oxidative stress,702,Ethanol,Ethanol,cause
1415,16865,33050213,"  An overdose of acetaminophen (APAP), the most common cause of acute liver injury, induces oxidative stress that subsequently causes mitochondrial impairment and hepatic necroptosis.",['acetaminophen'],"['acute liver injury', 'oxidative stress']",True,acetaminophen,oxidative stress,induces,C0242606,Oxidative stress,1983,Acetaminophen,Acetaminophen,induce
1416,16871,32968209,Hyperglycemia was induced in the transgenic mice by injections of STZ.,['STZ'],['Hyperglycemia'],True,STZ,Hyperglycemia,induced,C0020456,High blood sugar,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",STZ,induce
1417,16876,32658869,"Bupivacaine, a local anesthetic commonly used in clinic, could induce neurotoxic injury via oxidative stress.",['Bupivacaine'],"['neurotoxic injury', 'oxidative stress']",True,Bupivacaine,oxidative stress,induce,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Bupivacaine,induce
1418,16888,32413425,"As a ROS (reactive oxygen species) scavenger, luteolin unexpectedly induced ROS; but co-treatment with antioxidants NAC or mito-TEMPO did not rescue cell growth inhibition, although the levels of ROS levels were reduced.","['oxygen', 'scavenger', 'luteolin', 'NAC', 'mito-TEMPO']","['cell growth inhibition', 'levels of ROS levels were reduced']",True,oxygen,levels of ROS levels were reduced,induced,C4021545,Decreased circulating IgG2 level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,induce
1419,16888,32413425,"As a ROS (reactive oxygen species) scavenger, luteolin unexpectedly induced ROS; but co-treatment with antioxidants NAC or mito-TEMPO did not rescue cell growth inhibition, although the levels of ROS levels were reduced.","['oxygen', 'scavenger', 'luteolin', 'NAC', 'mito-TEMPO']","['cell growth inhibition', 'levels of ROS levels were reduced']",True,scavenger,levels of ROS levels were reduced,induced,C4021545,Decreased circulating IgG2 level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",scavenger,induce
1420,16888,32413425,"As a ROS (reactive oxygen species) scavenger, luteolin unexpectedly induced ROS; but co-treatment with antioxidants NAC or mito-TEMPO did not rescue cell growth inhibition, although the levels of ROS levels were reduced.","['oxygen', 'scavenger', 'luteolin', 'NAC', 'mito-TEMPO']","['cell growth inhibition', 'levels of ROS levels were reduced']",True,luteolin,levels of ROS levels were reduced,induced,C4021545,Decreased circulating IgG2 level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",luteolin,induce
1421,16888,32413425,"As a ROS (reactive oxygen species) scavenger, luteolin unexpectedly induced ROS; but co-treatment with antioxidants NAC or mito-TEMPO did not rescue cell growth inhibition, although the levels of ROS levels were reduced.","['oxygen', 'scavenger', 'luteolin', 'NAC', 'mito-TEMPO']","['cell growth inhibition', 'levels of ROS levels were reduced']",True,NAC,levels of ROS levels were reduced,induced,C4021545,Decreased circulating IgG2 level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",NAC,induce
1422,16888,32413425,"As a ROS (reactive oxygen species) scavenger, luteolin unexpectedly induced ROS; but co-treatment with antioxidants NAC or mito-TEMPO did not rescue cell growth inhibition, although the levels of ROS levels were reduced.","['oxygen', 'scavenger', 'luteolin', 'NAC', 'mito-TEMPO']","['cell growth inhibition', 'levels of ROS levels were reduced']",True,mito-TEMPO,levels of ROS levels were reduced,induced,C4021545,Decreased circulating IgG2 level,134828258,Mito-TEMPO,Mito-TEMPO,induce
1423,16914,31953914,  TL1A/TNFR2-mediated mitochondrial dysfunction of fibroblast-like synoviocytes increases inflammatory response in patients with rheumatoid arthritis via reactive oxygen species generation.,['oxygen'],"['inflammatory response', 'rheumatoid arthritis']",True,oxygen,inflammatory response,increases,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,increase
1424,16914,31953914,  TL1A/TNFR2-mediated mitochondrial dysfunction of fibroblast-like synoviocytes increases inflammatory response in patients with rheumatoid arthritis via reactive oxygen species generation.,['oxygen'],"['inflammatory response', 'rheumatoid arthritis']",True,oxygen,rheumatoid arthritis,increases,C0003873,RA,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,increase
1425,16943,31184306, Kidney dysfunction was triggered by hypercholesterolemia.,['hypercholesterolemia'],['Kidney dysfunction'],True,hypercholesterolemia,Kidney dysfunction,triggered,C0151746,Kidney function issue,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hypercholesterolemia,trigger
1426,16970,35255785,"Similarly, both EAE and wedelolactone produced inhibitory effects against migration but the effective doses that significantly inhibited migration were lower than those affecting proliferation.",['wedelolactone'],['proliferation'],True,wedelolactone,proliferation,produced,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",wedelolactone,produce
1427,16971,35255785,Wedelolactone  below 12.5 μg/ml inhibited the epithelial-to-mesenchymal transition (EMT) with increased expression of E-cadherin and decreased expression of vimentin in SCC-4  and CU110-1 cells.,['Wedelolactone'],"['increased expression of E-cadherin', 'decreased expression of vimentin']",True,Wedelolactone,decreased expression of vimentin,inhibited,C1862474,Decreased facial expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Wedelolactone,inhibit
1428,16972,35255785,Further analysis showed wedelolactone inhibited the expression of AhR and its downstream target molecules CYP1A1 and CYP1B1 in both squamous carcinoma cells at the same doses inhibiting cell migration.,['wedelolactone'],['cell migration'],True,wedelolactone,cell migration,inhibited,C1862474,Decreased facial expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",wedelolactone,inhibit
1429,16976,35230387,"Our study showed that as B[a]P could induce the accumulation of MDSCs in lung tissues and enhance the immunosuppressive effect regulated by cytokines and metabolites, thereby promoting the formation of immunosuppressive microenvironment, where effector T cells were exhausted, NK cells were dysfunctional, regulatory T (Treg) cells were expanded, polarized alveolar macrophages were transformed from M1 to M2.",['B[a]P'],"['immunosuppressive effect', 'polarized alveolar macrophages']",True,B[a]P,immunosuppressive effect,induce,C1862474,Decreased facial expression,2336,Benzo[A]Pyrene,Benzo[A]Pyrene,induce
1430,16994,35151731,These cellular responses indicate that B[a]P will cause serious cellular damage to esophageal cells and increase the carcinogenic risk even as a result of short-term exposure.,['B[a]P'],['serious cellular damage'],True,B[a]P,serious cellular damage,cause,C1862474,Decreased facial expression,2336,Benzo[A]Pyrene,Benzo[A]Pyrene,cause
1431,17030,34953351,We found that the in vitro maturation (IVM) rate was significantly increased (P < 0.05) in the 0.1 μM Pae and BaP (co-treatment) group compared with BaP group due to reduced ROS levels and increased mitochondrial membrane potential (ΔΨ) and ATP content.,['ATP'],['reduced ROS levels'],True,ATP,reduced ROS levels,increased,C4021545,Decreased circulating IgG2 level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ATP,increase
1432,17034,34947813," Interestingly, the knockout of CXCL13 inhibits benzo(a)pyrene-induced lung cancer and azoxymethane/dextran sodium sulfate-induced colorectal cancer in mice.",['azoxymethane/dextran'],"['cancer', 'cancer']",True,azoxymethane/dextran,cancer,inhibits,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azoxymethane/dextran,inhibit
1433,17034,34947813," Interestingly, the knockout of CXCL13 inhibits benzo(a)pyrene-induced lung cancer and azoxymethane/dextran sodium sulfate-induced colorectal cancer in mice.",['azoxymethane/dextran'],"['cancer', 'cancer']",True,azoxymethane/dextran,cancer,inhibits,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azoxymethane/dextran,inhibit
1434,17108,32247816,"Following intravenous (i.v.) administration, EG-018 (56 mg/kg) produced hypomotility, catalepsy, and hypothermia, but only catalepsy was blocked by the selective CB1 antagonist rimonabant (3 mg/kg, i.v.).",['3\xa0mg/kg'],"['hypomotility', 'catalepsy', 'hypothermia']",True,3 mg/kg,hypothermia,produced,C0020672,Hypothermia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",3 mg/kg,produce
1435,17111,32120072,The aim of this article review is to survey recent works linking pyrazole structures to anticancer activities corresponding to 9 different type of cancer.,['pyrazole'],['cancer'],True,pyrazole,cancer,linking,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pyrazole,link
1436,17120,32289526,"In the present study, treatment with haloxyfop-P-methyl for 48 h induced developmental deficiencies in the eyes and bodies of the zebrafish embryos as a whole and was also linked to increases in the incidence of pericardial edema.",['haloxyfop-P-methyl'],"['developmental deficiencies in the eyes and bodies', 'increases in the incidence of pericardial edema']",True,haloxyfop-P-methyl,developmental deficiencies in the eyes and bodies,induced,C0006826,Cancer,13363033,Haloxyfop-P-Methyl,Haloxyfop-P-Methyl,induce
1437,17122,32289526,"Moreover, haloxyfop-P-methyl hampered vasculogenesis in the embryos through down-regulation of functional genes, and disruption of vessel formation caused neurodegeneration  in the olig2-positive notochord.",['haloxyfop-P-methyl'],"['vasculogenesis', 'disruption of vessel formation', 'neurodegeneration  ']",True,haloxyfop-P-methyl,neurodegeneration,caused,C0027746,Neurodegeneration,13363033,Haloxyfop-P-Methyl,Haloxyfop-P-Methyl,cause
1438,17125,30242651," The animals were subjected to the open field and elevated plus-maze tests; results showed that the HPME did not lead to anxiolytic or anxiety behavior, or to locomotive changes in the tested animals, fact that was confirmed through the  Basso Mouse Scale for locomotion scores.",['HPME'],['anxiety behavior'],True,HPME,anxiety behavior,lead,C4018849,Abnormal fear/anxiety-related behavior,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",HPME,lead
1439,17144,31533262,"In addition, the oxygen consumption rate (OCR) linked to basal respiration, ATP production, and maximal respiration and spare respiratory capacity (representing mitochondrial function) was increased in matured iPSC-CMs.","['oxygen', 'ATP']","['basal respiration', 'spare respiratory capacity']",True,ATP,basal respiration,linked,C1260922,Abnormal respiration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ATP,link
1440,17144,31533262,"In addition, the oxygen consumption rate (OCR) linked to basal respiration, ATP production, and maximal respiration and spare respiratory capacity (representing mitochondrial function) was increased in matured iPSC-CMs.","['oxygen', 'ATP']","['basal respiration', 'spare respiratory capacity']",True,oxygen,basal respiration,increased,C1260922,Abnormal respiration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,increase
1441,17144,31533262,"In addition, the oxygen consumption rate (OCR) linked to basal respiration, ATP production, and maximal respiration and spare respiratory capacity (representing mitochondrial function) was increased in matured iPSC-CMs.","['oxygen', 'ATP']","['basal respiration', 'spare respiratory capacity']",True,ATP,basal respiration,increased,C1260922,Abnormal respiration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ATP,increase
1442,17148,21036624,  Sodium 2-{6-(4-chlorophenoxy)hexyl}oxirane-2-carboxylate (Etomoxir) inhibits transport of fatty acids via the carnitine shuttle into mitochondria of muscle cells and prevents long chain fatty acids from providing energy through β-oxidation especially for muscle contraction.,['Etomoxir'],['long chain fatty acids'],True,Etomoxir,long chain fatty acids,inhibits,C1859241,Elevated circulating long chain fatty acid concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Etomoxir,inhibit
1443,17149,18713797,"Palmitate also reduced insulin-stimulated IR and IRS-2 tyrosine phosphorylation, IRS-2-associated PI 3-kinase activity, and phosphorylation of Akt, p70 S6 kinase, GSK-3 and FOXO1A. Palmitate also inhibited insulin action in hepatocytes derived  from wild-type IR (+/+) mice, but was ineffective in IR-deficient (-/-) cells.",['insulin'],"['phosphorylation of Akt, p70 S6 kinase']",True,insulin,"phosphorylation of Akt, p70 S6 kinase",inhibited,C1859241,Elevated circulating long chain fatty acid concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",insulin,inhibit
1444,17150,12619873,  A number of data are consistent with the hypothesis that increases in intracellular Na+ concentration (Na+i) during ischemia and early reperfusion lead to calcium overload and exacerbation of myocardial injury.,['calcium'],"['increases in intracellular Na+ concentration', 'ischemia', 'early reperfusion', 'exacerbation of myocardial injury']",True,calcium,increases in intracellular Na+ concentration,lead,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,lead
1445,17150,12619873,  A number of data are consistent with the hypothesis that increases in intracellular Na+ concentration (Na+i) during ischemia and early reperfusion lead to calcium overload and exacerbation of myocardial injury.,['calcium'],"['increases in intracellular Na+ concentration', 'ischemia', 'early reperfusion', 'exacerbation of myocardial injury']",True,calcium,ischemia,lead,C0007786,Brain ischemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,lead
1446,17150,12619873,  A number of data are consistent with the hypothesis that increases in intracellular Na+ concentration (Na+i) during ischemia and early reperfusion lead to calcium overload and exacerbation of myocardial injury.,['calcium'],"['increases in intracellular Na+ concentration', 'ischemia', 'early reperfusion', 'exacerbation of myocardial injury']",True,calcium,early reperfusion,lead,C0007786,Brain ischemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,lead
1447,17162,10066690," Furthermore, Bmax (per g heart wt) for both low-affinity and high-affinity binding sites in control and diabetic animals was increased by etomoxir treatment.",['etomoxir'],['diabetic'],True,etomoxir,diabetic,increased,C0011880,Diabetic ketosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",etomoxir,increase
1448,17163,10066690,Etomoxir treatment also increased the depressed left ventricular weight of diabetic rats and appeared to increase the density of the sarcolemma and transverse tubular system to normalize Na+-K+-ATPase activity.,['Etomoxir'],['depressed left ventricular weight of'],True,Etomoxir,depressed left ventricular weight of,increased,C0011880,Diabetic ketosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Etomoxir,increase
1449,17182,35314418,Acute inflammation was induced by carrageenan (1%) in vivo tests and there were several groups tested.,['carrageenan'],['Acute inflammation'],True,carrageenan,Acute inflammation,induced,C0267797,Acute hepatitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carrageenan,induce
1450,17225,35296577,Pan-histone deacetylase (HDAC) inhibitors inhibit cell proliferation and ACTH production in AtT-20 corticotroph tumor cells.,['ACTH'],['cell proliferation'],True,ACTH,cell proliferation,inhibit,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ACTH,inhibit
1451,17243,35285201,The allergic asthma model was induced in rats by intraperitoneal injection of ovalbumin(OVA) and aluminum hydroxide gel adjuvant(sensitization) and atomization of OVA solution(excitation).,['aluminum hydroxide'],['asthma'],True,aluminum hydroxide,asthma,induced,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aluminum hydroxide,induce
1452,17278,35274077,The development of eosinophilic myocarditis after administration of lenalidomide has been described and bortezomib has been associated with the development of cardiomyopathies and atherosclerosis.,"['lenalidomide', 'bortezomib']",['atherosclerosis'],True,bortezomib,atherosclerosis,associated,C0004153,Narrowing and hardening of arteries,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bortezomib,associate
1453,17309,35016149,TBT inhibited autophagy without affecting autophagosome-lysosome fusion before it caused cell death.,['TBT'],['death'],True,TBT,death,inhibited,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TBT,inhibit
1454,17324,34829518,"Thus, our findings suggested that there might be some mechanistic links between the behavioral abnormality induced by TBT exposure and oxidative stress in the eyes and brains of medaka.",['TBT'],['oxidative stress in the eyes and brains'],True,TBT,oxidative stress in the eyes and brains,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TBT,induce
1455,17357,34102259,"  Exposure to the obesogen tributyltin (TBT) alone or high carbohydrate diet (HCD)  alone leads to obesity and reproductive complications, such as premature ovary failure (POF) features.","['obesogen tributyltin', 'TBT']","['obesity', 'premature ovary failure']",True,tributyltin,obesity,leads,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tributyltin,lead
1456,17357,34102259,"  Exposure to the obesogen tributyltin (TBT) alone or high carbohydrate diet (HCD)  alone leads to obesity and reproductive complications, such as premature ovary failure (POF) features.","['obesogen tributyltin', 'TBT']","['obesity', 'premature ovary failure']",True,tributyltin,premature ovary failure,leads,C0025322,Climacterium praecox,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tributyltin,lead
1457,17364,34020283,"In addition, TBT increased interferon γ (IFNγ) and Mpeg1 levels to induce inflammation, accompanied by decreased 7-ketoLCA, tauro-alpha-muricholic acid (T-alpha-MCA) and alpha-muricholic acid (alpha-MCA) levels, which were negatively related to Coriobacteriaceae_UCG-002 and Bifidobacterium.",['TBT'],['inflammation'],True,TBT,inflammation,increased,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TBT,increase
1458,17402,33143349," Moreover, as a consequence of ROS production, TBT-F increased the levels of glucose regulated protein 78 (Grp78) and C/EBP homologous protein (CHOP), two ER  stress markers.",['TBT-F'],"['ROS production', 'levels of glucose regulated protein 78']",True,TBT-F,ROS production,increased,C4476796,Increased reactive oxygen species production,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TBT-F,increase
1459,17412,32888589,"Accordingly, TBT sharply elevated the cortisol levels in plasma in a concentration-dependent manner, suggesting that the elevated cortisol level might be involved in the enhanced anxiety.",['TBT'],"['elevated cortisol level', 'enhanced anxiety']",True,TBT,elevated cortisol level,elevated,C4023101,Elevated circulating luteinizing hormone level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TBT,elevated
1460,17412,32888589,"Accordingly, TBT sharply elevated the cortisol levels in plasma in a concentration-dependent manner, suggesting that the elevated cortisol level might be involved in the enhanced anxiety.",['TBT'],"['elevated cortisol level', 'enhanced anxiety']",True,TBT,enhanced anxiety,elevated,C0003467,Anxiousness,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TBT,elevated
1461,17415,32835916,"  Gut microbiome alterations induced by tributyltin exposure are associated with increased body weight, impaired glucose and insulin homeostasis and endocrine disruption in mice.",['tributyltin'],"['increased body weight', 'impaired glucose and insulin homeostasis', 'endocrine disruption']",True,tributyltin,increased body weight,associated,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tributyltin,associate
1462,17455,31516039,  Silver(I) complexes containing diclofenac and niflumic acid induce apoptosis in human-derived cancer cell lines.,"['diclofenac', 'niflumic acid']","['apoptosis', 'cancer']",True,diclofenac,cancer,induce,C0006826,Cancer,3033,Diclofenac,Diclofenac,induce
1463,17455,31516039,  Silver(I) complexes containing diclofenac and niflumic acid induce apoptosis in human-derived cancer cell lines.,"['diclofenac', 'niflumic acid']","['apoptosis', 'cancer']",True,niflumic acid,cancer,induce,C0006826,Cancer,4488,Niflumic Acid,Niflumic Acid,induce
1464,17487,30132504,"The inhibition of Cx43 with niflumic acid, flufenamic acid and 18‑α‑glycyrrhetinic acid in cultured human umbilical vein endothelial cells resulted in decreased phosphorylation of extracellular signal‑regulated kinase (ERK)1/2 and increased expression of Cav‑1, as shown by western blot analysis.","['niflumic acid', 'flufenamic acid']","['inhibition of Cx43', 'decreased phosphorylation of extracellular signal‑regulated kinase', 'increased expression']",True,niflumic acid,inhibition of Cx43,resulted,C0424296,Disinhibition,4488,Niflumic Acid,Niflumic Acid,result
1465,17487,30132504,"The inhibition of Cx43 with niflumic acid, flufenamic acid and 18‑α‑glycyrrhetinic acid in cultured human umbilical vein endothelial cells resulted in decreased phosphorylation of extracellular signal‑regulated kinase (ERK)1/2 and increased expression of Cav‑1, as shown by western blot analysis.","['niflumic acid', 'flufenamic acid']","['inhibition of Cx43', 'decreased phosphorylation of extracellular signal‑regulated kinase', 'increased expression']",True,flufenamic acid,inhibition of Cx43,resulted,C0424296,Disinhibition,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",flufenamic acid,result
1466,17536,35249660,"Chlorpyrifos (CPF), a broad-spectrum organophosphate insecticide, has resulted in oxidative stress, mitochondrial dysfunction, and apoptosis in zebrafish.","['Chlorpyrifos', 'CPF']","['oxidative stress', 'apoptosis']",True,Chlorpyrifos,oxidative stress,resulted,C0242606,Oxidative stress,2730,Chlorpyrifos,Chlorpyrifos,result
1467,17578,34985812,"According to our result, administration of CPF caused a significant increase in malondialdehid level and catalase activity while a significant decrease in superoxide dismutase activity in all tissues.",['CPF'],"['increase in malondialdehid level', 'decrease in superoxide dismutase activity']",True,CPF,decrease in superoxide dismutase activity,caused,C4703567,Decreased superoxide dismutase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CPF,cause
1468,17603,33480323,"Exposure to CPF causes a marked reduction in sperm counts with lowering in serum testosterone level, which suggests possible molecular interaction of CPF with AR.","['CPF', 'CPF']","['reduction in sperm counts', 'lowering in serum testosterone level']",True,CPF,lowering in serum testosterone level,causes,C0580454,Abnormal serum testosterone level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CPF,cause
1469,17603,33480323,"Exposure to CPF causes a marked reduction in sperm counts with lowering in serum testosterone level, which suggests possible molecular interaction of CPF with AR.","['CPF', 'CPF']","['reduction in sperm counts', 'lowering in serum testosterone level']",True,CPF,lowering in serum testosterone level,causes,C0580454,Abnormal serum testosterone level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CPF,cause
1470,17607,32730898,"For substances with unknown neuroactive MoA, 3 substances did not provoke any effect on the STC (pyraclostrobin, diuron and daunorubicin-hydrochloride) while 4 other substances provoked an increased STC (hexaconazole, aniline, dimethyl-sulfoxide and 3,4-dichloroaniline).","['pyraclostrobin', 'diuron', 'daunorubicin-hydrochloride', 'hexaconazole', 'aniline', 'dimethyl-sulfoxide']",['increased STC ('],True,pyraclostrobin,increased STC (,provoke,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pyraclostrobin,provoke
1471,17607,32730898,"For substances with unknown neuroactive MoA, 3 substances did not provoke any effect on the STC (pyraclostrobin, diuron and daunorubicin-hydrochloride) while 4 other substances provoked an increased STC (hexaconazole, aniline, dimethyl-sulfoxide and 3,4-dichloroaniline).","['pyraclostrobin', 'diuron', 'daunorubicin-hydrochloride', 'hexaconazole', 'aniline', 'dimethyl-sulfoxide']",['increased STC ('],True,diuron,increased STC (,provoke,C0302845,Increased mean corpuscular volume,3120,Diuron,Diuron,provoke
1472,17607,32730898,"For substances with unknown neuroactive MoA, 3 substances did not provoke any effect on the STC (pyraclostrobin, diuron and daunorubicin-hydrochloride) while 4 other substances provoked an increased STC (hexaconazole, aniline, dimethyl-sulfoxide and 3,4-dichloroaniline).","['pyraclostrobin', 'diuron', 'daunorubicin-hydrochloride', 'hexaconazole', 'aniline', 'dimethyl-sulfoxide']",['increased STC ('],True,daunorubicin-hydrochloride,increased STC (,provoke,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",daunorubicin-hydrochloride,provoke
1473,17607,32730898,"For substances with unknown neuroactive MoA, 3 substances did not provoke any effect on the STC (pyraclostrobin, diuron and daunorubicin-hydrochloride) while 4 other substances provoked an increased STC (hexaconazole, aniline, dimethyl-sulfoxide and 3,4-dichloroaniline).","['pyraclostrobin', 'diuron', 'daunorubicin-hydrochloride', 'hexaconazole', 'aniline', 'dimethyl-sulfoxide']",['increased STC ('],True,hexaconazole,increased STC (,provoke,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hexaconazole,provoke
1474,17607,32730898,"For substances with unknown neuroactive MoA, 3 substances did not provoke any effect on the STC (pyraclostrobin, diuron and daunorubicin-hydrochloride) while 4 other substances provoked an increased STC (hexaconazole, aniline, dimethyl-sulfoxide and 3,4-dichloroaniline).","['pyraclostrobin', 'diuron', 'daunorubicin-hydrochloride', 'hexaconazole', 'aniline', 'dimethyl-sulfoxide']",['increased STC ('],True,aniline,increased STC (,provoke,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aniline,provoke
1475,17607,32730898,"For substances with unknown neuroactive MoA, 3 substances did not provoke any effect on the STC (pyraclostrobin, diuron and daunorubicin-hydrochloride) while 4 other substances provoked an increased STC (hexaconazole, aniline, dimethyl-sulfoxide and 3,4-dichloroaniline).","['pyraclostrobin', 'diuron', 'daunorubicin-hydrochloride', 'hexaconazole', 'aniline', 'dimethyl-sulfoxide']",['increased STC ('],True,dimethyl-sulfoxide,increased STC (,provoke,C0302845,Increased mean corpuscular volume,679,Dimethyl Sulfoxide,Dimethyl Sulfoxide,provoke
1476,17607,32730898,"For substances with unknown neuroactive MoA, 3 substances did not provoke any effect on the STC (pyraclostrobin, diuron and daunorubicin-hydrochloride) while 4 other substances provoked an increased STC (hexaconazole, aniline, dimethyl-sulfoxide and 3,4-dichloroaniline).","['pyraclostrobin', 'diuron', 'daunorubicin-hydrochloride', 'hexaconazole', 'aniline', 'dimethyl-sulfoxide']",['increased STC ('],True,hexaconazole,increased STC (,provoked,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hexaconazole,provoke
1477,17607,32730898,"For substances with unknown neuroactive MoA, 3 substances did not provoke any effect on the STC (pyraclostrobin, diuron and daunorubicin-hydrochloride) while 4 other substances provoked an increased STC (hexaconazole, aniline, dimethyl-sulfoxide and 3,4-dichloroaniline).","['pyraclostrobin', 'diuron', 'daunorubicin-hydrochloride', 'hexaconazole', 'aniline', 'dimethyl-sulfoxide']",['increased STC ('],True,aniline,increased STC (,provoked,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aniline,provoke
1478,17607,32730898,"For substances with unknown neuroactive MoA, 3 substances did not provoke any effect on the STC (pyraclostrobin, diuron and daunorubicin-hydrochloride) while 4 other substances provoked an increased STC (hexaconazole, aniline, dimethyl-sulfoxide and 3,4-dichloroaniline).","['pyraclostrobin', 'diuron', 'daunorubicin-hydrochloride', 'hexaconazole', 'aniline', 'dimethyl-sulfoxide']",['increased STC ('],True,dimethyl-sulfoxide,increased STC (,provoked,C0302845,Increased mean corpuscular volume,679,Dimethyl Sulfoxide,Dimethyl Sulfoxide,provoke
1479,17608,32651842,"CPF metabolism generates chlorpyrifos-oxon (CPF-O), which possesses higher anticholinesterase activity and, consequently, plays a major role in the cholinergic syndrome observed after CPF poisoning.",['chlorpyrifos-oxon'],"['CPF metabolism', 'higher anticholinesterase activity']",True,chlorpyrifos-oxon,CPF metabolism,generates,C5139220,Abnormal metabolism,21804,Chlorpyrifos Oxon,Chlorpyrifos Oxon,generate
1480,17612,32651842," Pretreatment with N-acetylcysteine (NAC, a GSH precursor) protected against the cytotoxicity induced by both CPF and CPF-O. The present study indicates that GSH  depletion is a non-cholinergic event involved in CPF and CPF-O toxicities.","['N-acetylcysteine', 'CPF-O.', 'CPF', 'CPF-O']",['CPF'],True,CPF-O.,CPF,induced,C0007789,Cerebral palsy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CPF-O.,induce
1481,17638,27720795,"Chronic 14-day exposure to methylmercury, chlorpyrifos and α-cypermethrin inhibited MSR, all with a lowest-observed effect concentration (LOEC) of 0.1μM, while exposure to endosulfan increased MSR [LOEC: 1μM].","['methylmercury', 'chlorpyrifos', 'α-cypermethrin', 'endosulfan']",['Chronic 14-day'],True,methylmercury,Chronic 14-day,inhibited,C0205191,Chronic,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methylmercury,inhibit
1482,17638,27720795,"Chronic 14-day exposure to methylmercury, chlorpyrifos and α-cypermethrin inhibited MSR, all with a lowest-observed effect concentration (LOEC) of 0.1μM, while exposure to endosulfan increased MSR [LOEC: 1μM].","['methylmercury', 'chlorpyrifos', 'α-cypermethrin', 'endosulfan']",['Chronic 14-day'],True,chlorpyrifos,Chronic 14-day,inhibited,C0205191,Chronic,2730,Chlorpyrifos,Chlorpyrifos,inhibit
1483,17638,27720795,"Chronic 14-day exposure to methylmercury, chlorpyrifos and α-cypermethrin inhibited MSR, all with a lowest-observed effect concentration (LOEC) of 0.1μM, while exposure to endosulfan increased MSR [LOEC: 1μM].","['methylmercury', 'chlorpyrifos', 'α-cypermethrin', 'endosulfan']",['Chronic 14-day'],True,α-cypermethrin,Chronic 14-day,inhibited,C0205191,Chronic,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",α-cypermethrin,inhibit
1484,17638,27720795,"Chronic 14-day exposure to methylmercury, chlorpyrifos and α-cypermethrin inhibited MSR, all with a lowest-observed effect concentration (LOEC) of 0.1μM, while exposure to endosulfan increased MSR [LOEC: 1μM].","['methylmercury', 'chlorpyrifos', 'α-cypermethrin', 'endosulfan']",['Chronic 14-day'],True,endosulfan,Chronic 14-day,inhibited,C0205191,Chronic,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",endosulfan,inhibit
1485,17639,27720795,"Similar to the observations in the chronic 14-day exposure studies, MSR was inhibited by acute 30-min exposure to methylmercury, chlorpyrifos, and α-cypermethrin [LOECs: 1μM, 10μM, and 1μM, respectively], whereas endosulfan increased MSR [LOEC: 0.3μM].","['methylmercury', 'chlorpyrifos', 'α-cypermethrin', 'endosulfan']",['increased MSR [LOEC'],True,methylmercury,increased MSR [LOEC,inhibited,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methylmercury,inhibit
1486,17639,27720795,"Similar to the observations in the chronic 14-day exposure studies, MSR was inhibited by acute 30-min exposure to methylmercury, chlorpyrifos, and α-cypermethrin [LOECs: 1μM, 10μM, and 1μM, respectively], whereas endosulfan increased MSR [LOEC: 0.3μM].","['methylmercury', 'chlorpyrifos', 'α-cypermethrin', 'endosulfan']",['increased MSR [LOEC'],True,chlorpyrifos,increased MSR [LOEC,inhibited,C0302845,Increased mean corpuscular volume,2730,Chlorpyrifos,Chlorpyrifos,inhibit
1487,17639,27720795,"Similar to the observations in the chronic 14-day exposure studies, MSR was inhibited by acute 30-min exposure to methylmercury, chlorpyrifos, and α-cypermethrin [LOECs: 1μM, 10μM, and 1μM, respectively], whereas endosulfan increased MSR [LOEC: 0.3μM].","['methylmercury', 'chlorpyrifos', 'α-cypermethrin', 'endosulfan']",['increased MSR [LOEC'],True,α-cypermethrin,increased MSR [LOEC,inhibited,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",α-cypermethrin,inhibit
1488,17639,27720795,"Similar to the observations in the chronic 14-day exposure studies, MSR was inhibited by acute 30-min exposure to methylmercury, chlorpyrifos, and α-cypermethrin [LOECs: 1μM, 10μM, and 1μM, respectively], whereas endosulfan increased MSR [LOEC: 0.3μM].","['methylmercury', 'chlorpyrifos', 'α-cypermethrin', 'endosulfan']",['increased MSR [LOEC'],True,endosulfan,increased MSR [LOEC,inhibited,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",endosulfan,inhibit
1489,17713,33208024,"Moreover, administration of normal- or nano-calcium hydroxide particles suspension elevated the level of malondialdehyde and decreased both the glutathione peroxidase activity and the reduced glutathione level, as well as caused tissue injuries (e.g. renal tube degeneration, congested blood vessels, atrophied lymphoid follicles, interstitial inflammatory reaction,  and hyalinosis of myocardial muscles).",['malondialdehyde'],"['decreased both the glutathione peroxidase activity', 'reduced glutathione level', 'tissue injuries', 'renal tube degeneration', 'congested blood vessels', 'atrophied lymphoid follicles', 'interstitial inflammatory reaction', 'hyalinosis of myocardial muscles']",True,malondialdehyde,congested blood vessels,elevated,C0241657,Abnormality of the vasculature,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",malondialdehyde,elevated
1490,17722,32713795,"In Nf1null spines, MEKi increased bone volume (+194%, P < 0.001) whereas ZA increased bone density (+10%, P < 0.002) versus BMP-2 alone.",['ZA'],['increased bone density'],True,ZA,increased bone density,increased,C0029464,Increased bone density,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ZA,increase
1491,17725,32659402,"Conventional stabilizers, such as aromatic amines like diphenylamine (DPA) and urea, can produce carcinogenic/toxic substances during propellants shelf life.",['diphenylamine'],['carcinogenic/toxic'],True,diphenylamine,carcinogenic/toxic,produce,C0029464,Increased bone density,11487,Diphenylamine,Diphenylamine,produce
1492,17777,34070527,"DON simultaneously inhibited FBS- or PDGF-stimulated glycolysis and glutaminolysis as well as mammalian target of rapamycin complex I activity in growth factor-stimulated VSMCs, and thereby suppressed their proliferation and migration.",['DON'],"['glutaminolysis', 'proliferation']",True,DON,proliferation,inhibited,C4531170,Abnormal cell proliferation,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,inhibit
1493,17782,33915326,"Furthermore, inhibition of O-GlcNAcylation via 6-diazo-5-oxo-l-norleucine (DON) apparently increased insulin-induced Akt phosphorylation and restored its cardioprotective response against reperfusion injury in palmitate-induced insulin-resistant H9c2 cells.",['6-diazo-5-oxo-l-norleucine'],"['inhibition of O-GlcNAcylation', 'restored its cardioprotective response', 'reperfusion injury']",True,6-diazo-5-oxo-l-norleucine,inhibition of O-GlcNAcylation,increased,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",6-diazo-5-oxo-l-norleucine,increase
1494,17786,33712838, JHU395 treatment caused decreased growth and increased apoptosis in multiple human high-MYC medulloblastoma cell lines at lower concentrations than DON.,['DON'],"['decreased growth', 'increased apoptosis']",True,DON,decreased growth,caused,C0241240,Tall stature,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,cause
1495,17786,33712838, JHU395 treatment caused decreased growth and increased apoptosis in multiple human high-MYC medulloblastoma cell lines at lower concentrations than DON.,['DON'],"['decreased growth', 'increased apoptosis']",True,DON,increased apoptosis,caused,C4280724,Increased lymphocyte apoptosis,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,cause
1496,17797,32020477,DON also inhibited the proliferation of these cell lines in a dose-dependent manner.,['DON'],['proliferation of these'],True,DON,proliferation of these,inhibited,C4531170,Abnormal cell proliferation,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,inhibit
1497,17812,31011190,"While DON inhibited the differentiation of dendritic cells  and macrophages and facilitated that of Ly6G+ granulocytic (G)-MDSCs more strongly than did rapamycin, G-MDSCs treated with rapamycin but not DON suppressed CD4+ T cell proliferation in vitro.","['DON', 'rapamycin', 'rapamycin', 'DON']",['Ly6G+ granulocytic'],True,DON,Ly6G+ granulocytic,inhibited,C1534864,Granulocytic hypoplasia,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,inhibit
1498,17812,31011190,"While DON inhibited the differentiation of dendritic cells  and macrophages and facilitated that of Ly6G+ granulocytic (G)-MDSCs more strongly than did rapamycin, G-MDSCs treated with rapamycin but not DON suppressed CD4+ T cell proliferation in vitro.","['DON', 'rapamycin', 'rapamycin', 'DON']",['Ly6G+ granulocytic'],True,rapamycin,Ly6G+ granulocytic,inhibited,C1534864,Granulocytic hypoplasia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rapamycin,inhibit
1499,17812,31011190,"While DON inhibited the differentiation of dendritic cells  and macrophages and facilitated that of Ly6G+ granulocytic (G)-MDSCs more strongly than did rapamycin, G-MDSCs treated with rapamycin but not DON suppressed CD4+ T cell proliferation in vitro.","['DON', 'rapamycin', 'rapamycin', 'DON']",['Ly6G+ granulocytic'],True,rapamycin,Ly6G+ granulocytic,inhibited,C1534864,Granulocytic hypoplasia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rapamycin,inhibit
1500,17812,31011190,"While DON inhibited the differentiation of dendritic cells  and macrophages and facilitated that of Ly6G+ granulocytic (G)-MDSCs more strongly than did rapamycin, G-MDSCs treated with rapamycin but not DON suppressed CD4+ T cell proliferation in vitro.","['DON', 'rapamycin', 'rapamycin', 'DON']",['Ly6G+ granulocytic'],True,DON,Ly6G+ granulocytic,inhibited,C1534864,Granulocytic hypoplasia,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,inhibit
1501,17819,30821123,"Treatment with DON led to less lung injury, fewer lung neutrophils, lung inflammatory and interstitial macrophages, and lower levels of proinflammatory cytokines and chemokines at 5 and/or 7 days after injury.",['DON'],"['less lung injury', 'fewer lung neutrophils', 'injury']",True,DON,injury,led,C0424366,Self injury,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,lead
1502,17820,30821123,"Additionally, DON led to earlier expression of the growth factor amphiregulin and more rapid recovery of LPS-induced weight loss.",['DON'],['weight loss'],True,DON,weight loss,led,C1262477,Weight loss,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,lead
1503,17847,27489275,In vitro studies showed that DON inhibited stimulus-induced proliferation of lymphocytes.,['DON'],['proliferation of lymphocytes'],True,DON,proliferation of lymphocytes,inhibited,C4531169,Abnormal lymphocyte proliferation,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,inhibit
1504,17901,19212100,"Especially, glutamate released by activated microglia induces excito-neurotoxicity and may contribute to neurodegeneration in MS.",['glutamate'],['neurodegeneration'],True,glutamate,neurodegeneration,induces,C0027746,Neurodegeneration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutamate,induce
1505,17922,16517020,"Additionally, acute increase in intracellular levels of glutamine by treatment with the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (DON) after ammonia exposure also did not result in swelling.","['glutamine', '6-diazo-5-oxo-L-norleucine', 'ammonia']","['acute increase in intracellular levels of', 'swelling']",True,glutamine,acute increase in intracellular levels of,result,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutamine,result
1506,17922,16517020,"Additionally, acute increase in intracellular levels of glutamine by treatment with the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (DON) after ammonia exposure also did not result in swelling.","['glutamine', '6-diazo-5-oxo-L-norleucine', 'ammonia']","['acute increase in intracellular levels of', 'swelling']",True,glutamine,swelling,result,C0239598,Swollen finger,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutamine,result
1507,17922,16517020,"Additionally, acute increase in intracellular levels of glutamine by treatment with the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (DON) after ammonia exposure also did not result in swelling.","['glutamine', '6-diazo-5-oxo-L-norleucine', 'ammonia']","['acute increase in intracellular levels of', 'swelling']",True,6-diazo-5-oxo-L-norleucine,acute increase in intracellular levels of,result,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",6-diazo-5-oxo-L-norleucine,result
1508,17922,16517020,"Additionally, acute increase in intracellular levels of glutamine by treatment with the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (DON) after ammonia exposure also did not result in swelling.","['glutamine', '6-diazo-5-oxo-L-norleucine', 'ammonia']","['acute increase in intracellular levels of', 'swelling']",True,6-diazo-5-oxo-L-norleucine,swelling,result,C0239598,Swollen finger,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",6-diazo-5-oxo-L-norleucine,result
1509,17922,16517020,"Additionally, acute increase in intracellular levels of glutamine by treatment with the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (DON) after ammonia exposure also did not result in swelling.","['glutamine', '6-diazo-5-oxo-L-norleucine', 'ammonia']","['acute increase in intracellular levels of', 'swelling']",True,ammonia,acute increase in intracellular levels of,result,C4025593,Increased intracellular sodium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ammonia,result
1510,17922,16517020,"Additionally, acute increase in intracellular levels of glutamine by treatment with the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (DON) after ammonia exposure also did not result in swelling.","['glutamine', '6-diazo-5-oxo-L-norleucine', 'ammonia']","['acute increase in intracellular levels of', 'swelling']",True,ammonia,swelling,result,C0239598,Swollen finger,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ammonia,result
1511,17963,35051466,"Moreover, the overexpression of intracellular reactive oxygen species (ROS), free Ca2+ and cellular apoptosis suggested that exposure to OPFRs can lead to apoptosis related to oxidative stress.","['oxygen', 'OPFRs']","['apoptosis', 'oxidative stress']",True,OPFRs,oxidative stress,lead,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",OPFRs,lead
1512,17973,33049558,"The  results of the correlation analysis showed that EHDPP concentration was associated with the risk of breast cancer (p < 0.05), while tri-n-butyl phosphate (TNBP), tris (methylphenyl) phosphate (TMPP), triphenyl phosphate (TPHP), and EHDPP concentrations were associated with the risk of cervical cancer (p < 0.05 or p < 0.01).","['EHDPP', 'tris', 'phosphate', 'triphenyl phosphate', 'EHDPP']",['breast cancer'],True,EHDPP,breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",EHDPP,associate
1513,17973,33049558,"The  results of the correlation analysis showed that EHDPP concentration was associated with the risk of breast cancer (p < 0.05), while tri-n-butyl phosphate (TNBP), tris (methylphenyl) phosphate (TMPP), triphenyl phosphate (TPHP), and EHDPP concentrations were associated with the risk of cervical cancer (p < 0.05 or p < 0.01).","['EHDPP', 'tris', 'phosphate', 'triphenyl phosphate', 'EHDPP']",['breast cancer'],True,tris,breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tris,associate
1514,17973,33049558,"The  results of the correlation analysis showed that EHDPP concentration was associated with the risk of breast cancer (p < 0.05), while tri-n-butyl phosphate (TNBP), tris (methylphenyl) phosphate (TMPP), triphenyl phosphate (TPHP), and EHDPP concentrations were associated with the risk of cervical cancer (p < 0.05 or p < 0.01).","['EHDPP', 'tris', 'phosphate', 'triphenyl phosphate', 'EHDPP']",['breast cancer'],True,triphenyl,breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",triphenyl,associate
1515,17973,33049558,"The  results of the correlation analysis showed that EHDPP concentration was associated with the risk of breast cancer (p < 0.05), while tri-n-butyl phosphate (TNBP), tris (methylphenyl) phosphate (TMPP), triphenyl phosphate (TPHP), and EHDPP concentrations were associated with the risk of cervical cancer (p < 0.05 or p < 0.01).","['EHDPP', 'tris', 'phosphate', 'triphenyl phosphate', 'EHDPP']",['breast cancer'],True,EHDPP,breast cancer,associated,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",EHDPP,associate
1516,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,triphenyl,gastric cancer,associated,C0024623,Gastric cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",triphenyl,associate
1517,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,triphenyl,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",triphenyl,associate
1518,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,TMPP,gastric cancer,associated,C0024623,Gastric cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TMPP,associate
1519,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,TMPP,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TMPP,associate
1520,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,tris(2-ethylhexyl,gastric cancer,associated,C0024623,Gastric cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tris(2-ethylhexyl,associate
1521,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,tris(2-ethylhexyl,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tris(2-ethylhexyl,associate
1522,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,2-ethylhexyl diphenyl,gastric cancer,associated,C0024623,Gastric cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-ethylhexyl diphenyl,associate
1523,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,2-ethylhexyl diphenyl,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-ethylhexyl diphenyl,associate
1524,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,TMPP,gastric cancer,associated,C0024623,Gastric cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TMPP,associate
1525,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,TMPP,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TMPP,associate
1526,17980,32278140,"Correlation analysis found that concentrations of TEP, tris(2-chloroisopropyl) phosphate (TCIPP), triphenyl phosphate (TPHP), TMPP, tris(2-ethylhexyl) phosphate (TEHP), and 2-ethylhexyl diphenyl phosphate (EHDPP)  were associated with gastric cancer (p < 0.01), and concentrations of TEP, TCIPP, TPHP, TMPP and TEHP were associated with colorectal cancer (p < 0.01).","['phosphate', 'triphenyl phosphate', 'TMPP', 'tris(2-ethylhexyl) phosphate', '2-ethylhexyl diphenyl phosphate', 'EHDPP', 'TCIPP', 'TMPP', 'TEHP']","['gastric cancer', 'cancer']",True,TMPP,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TMPP,associate
1527,17984,31884710,The squamous epithelial hyperplasia and hyperkeratosis observed in the non-glandular forestomach of rats  exposed to the middle and high DEHPA doses were most likely caused by the slightly corrosive nature of this chemical.,['DEHPA'],"['squamous epithelial hyperplasia', 'hyperkeratosis']",True,DEHPA,hyperkeratosis,caused,C0870082,Hyperkeratosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DEHPA,cause
1528,17990,30312655,"Finally, alterations in heart rate and rhythmicity were assessed to determine cardiotoxicity in 48 hpf embryos exposed to compounds for 3 h. Results  suggest that several OPFRs (BPDP, EHDP; IPP, TMPP; TPHP and TDCIPP) produced adverse effects in multiple target organs at concentrations comparable to the two BFRs.","['OPFRs', 'BPDP', 'EHDP']","['cardiotoxicity', 'adverse effects']",True,OPFRs,adverse effects,produced,C0870082,Hyperkeratosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",OPFRs,produce
1529,17990,30312655,"Finally, alterations in heart rate and rhythmicity were assessed to determine cardiotoxicity in 48 hpf embryos exposed to compounds for 3 h. Results  suggest that several OPFRs (BPDP, EHDP; IPP, TMPP; TPHP and TDCIPP) produced adverse effects in multiple target organs at concentrations comparable to the two BFRs.","['OPFRs', 'BPDP', 'EHDP']","['cardiotoxicity', 'adverse effects']",True,BPDP,adverse effects,produced,C0870082,Hyperkeratosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",BPDP,produce
1530,17990,30312655,"Finally, alterations in heart rate and rhythmicity were assessed to determine cardiotoxicity in 48 hpf embryos exposed to compounds for 3 h. Results  suggest that several OPFRs (BPDP, EHDP; IPP, TMPP; TPHP and TDCIPP) produced adverse effects in multiple target organs at concentrations comparable to the two BFRs.","['OPFRs', 'BPDP', 'EHDP']","['cardiotoxicity', 'adverse effects']",True,EHDP,adverse effects,produced,C0870082,Hyperkeratosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",EHDP,produce
1531,18038,25078074,Gradual decline in mitochondrial function during ageing and concomitant increase in production of reactive oxygen species (ROS) leads to oxidative damage of macromolecules and impairment of ATP synthesis.,"['oxygen', 'ATP']",['increase in production of reactive'],True,oxygen,increase in production of reactive,leads,C4476796,Increased reactive oxygen species production,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,lead
1532,18038,25078074,Gradual decline in mitochondrial function during ageing and concomitant increase in production of reactive oxygen species (ROS) leads to oxidative damage of macromolecules and impairment of ATP synthesis.,"['oxygen', 'ATP']",['increase in production of reactive'],True,ATP,increase in production of reactive,leads,C4476796,Increased reactive oxygen species production,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ATP,lead
1533,18041,22743356,"These results demonstrate that tebufenpyrad, bixafen, fenpyroximat and tolfenpyrad induce DNA damage in human cell lines, very likely by a mode of action that involves oxidative stress.","['tebufenpyrad', 'bixafen', 'fenpyroximat', 'tolfenpyrad']","['DNA damage', 'oxidative stress']",True,tebufenpyrad,fenpyroximat,induce,C4476796,Increased reactive oxygen species production,86354,Tebufenpyrad,Tebufenpyrad,induce
1534,18041,22743356,"These results demonstrate that tebufenpyrad, bixafen, fenpyroximat and tolfenpyrad induce DNA damage in human cell lines, very likely by a mode of action that involves oxidative stress.","['tebufenpyrad', 'bixafen', 'fenpyroximat', 'tolfenpyrad']","['DNA damage', 'oxidative stress']",True,tebufenpyrad,oxidative stress,induce,C0242606,Oxidative stress,86354,Tebufenpyrad,Tebufenpyrad,induce
1535,18041,22743356,"These results demonstrate that tebufenpyrad, bixafen, fenpyroximat and tolfenpyrad induce DNA damage in human cell lines, very likely by a mode of action that involves oxidative stress.","['tebufenpyrad', 'bixafen', 'fenpyroximat', 'tolfenpyrad']","['DNA damage', 'oxidative stress']",True,bixafen,fenpyroximat,induce,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bixafen,induce
1536,18041,22743356,"These results demonstrate that tebufenpyrad, bixafen, fenpyroximat and tolfenpyrad induce DNA damage in human cell lines, very likely by a mode of action that involves oxidative stress.","['tebufenpyrad', 'bixafen', 'fenpyroximat', 'tolfenpyrad']","['DNA damage', 'oxidative stress']",True,bixafen,oxidative stress,induce,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bixafen,induce
1537,18041,22743356,"These results demonstrate that tebufenpyrad, bixafen, fenpyroximat and tolfenpyrad induce DNA damage in human cell lines, very likely by a mode of action that involves oxidative stress.","['tebufenpyrad', 'bixafen', 'fenpyroximat', 'tolfenpyrad']","['DNA damage', 'oxidative stress']",True,tolfenpyrad,fenpyroximat,induce,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tolfenpyrad,induce
1538,18041,22743356,"These results demonstrate that tebufenpyrad, bixafen, fenpyroximat and tolfenpyrad induce DNA damage in human cell lines, very likely by a mode of action that involves oxidative stress.","['tebufenpyrad', 'bixafen', 'fenpyroximat', 'tolfenpyrad']","['DNA damage', 'oxidative stress']",True,tolfenpyrad,oxidative stress,induce,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tolfenpyrad,induce
1539,18049,18180861,"This shows that macroinvertebrate drift can be induced even by short-term pulse exposures to neurotoxic insecticides, at field-relevant concentrations.",['macroinvertebrate'],['pulse exposures'],True,macroinvertebrate,pulse exposures,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",macroinvertebrate,induce
1540,18109,32865324,"In conclusion, these data suggested that palmatine inhibits inflammatory response in LPS-induced EpH4-Ev cells via down-regulating Akt/ NF-кB, ERK1/2 and P38 signalling pathways.",['palmatine'],['inflammatory response'],True,palmatine,inflammatory response,inhibits,C4022805,Abnormal inflammatory response,19009,Palmatine,Palmatine,inhibit
1541,18114,32848725,"KD treatment increased the proportion of Alloprevotella, Treponema, Prevotellaceae, and Prevotella, and reduced the proportion of Escherichia_Shigella and Desulfovibrio in gut microbiota.",['Prevotella'],['reduced the proportion of Escherichia_Shigella and Desulfovibrio in gut microbiota'],True,Prevotella,reduced the proportion of Escherichia_Shigella and Desulfovibrio in gut microbiota,increased,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Prevotella,increase
1542,18119,32658562," MATERIALS AND METHODS: We used proteomics to analyse differentially expressed proteins (DEPs) in goat endometrial epithelial cells (EECs) stimulated by lipopolysaccharide (LPS, 5 μg/mL, the dosage can induce inflammatory response, according to our previous study) for 12 h and then treated with palmatine (80 μg/mL) for 8 h; the dosage was selected based on MTT assay.",['palmatine'],['inflammatory response'],True,palmatine,inflammatory response,induce,C4022805,Abnormal inflammatory response,19009,Palmatine,Palmatine,induce
1543,18149,35219377,"Factor XII (FXII) is a key initiator of the kallikrein-kinin system, which produces bradykinin, a central mediator of angioedema.",['bradykinin'],['angioedema'],True,bradykinin,angioedema,produces,C0002994,Quincke edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bradykinin,produce
1544,18167,35178453,Our study found that rhein significantly inhibits the proliferation and migration of lung cancer cells.,['rhein'],['migration of lung cancer cells'],True,rhein,migration of lung cancer cells,inhibits,C1855752,Abnormal T cell morphology,10168,Rhein,Rhein,inhibit
1545,18190,35152432,"Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins.",['rifamycins'],"['narrow therapeutic indices', 'thrombosis', 'bleeding']",True,rifamycins,thrombosis,leading,C4025731,Abnormal thrombosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rifamycins,lead
1546,18190,35152432,"Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins.",['rifamycins'],"['narrow therapeutic indices', 'thrombosis', 'bleeding']",True,rifamycins,bleeding,leading,C1458140,Abnormal bleeding,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rifamycins,lead
1547,18195,34380979,"Although active TB can be prevented by treating latent TB infection (LTBI), individual factors, such as high prevalence of depression and anxiety, drug and alcohol use, and unstable housing, lead to poor  LTBI treatment adherence and completion among homeless adults.",['alcohol'],"['depression', 'anxiety']",True,alcohol,depression,lead,C0011581,Depression,702,Ethanol,Ethanol,lead
1548,18195,34380979,"Although active TB can be prevented by treating latent TB infection (LTBI), individual factors, such as high prevalence of depression and anxiety, drug and alcohol use, and unstable housing, lead to poor  LTBI treatment adherence and completion among homeless adults.",['alcohol'],"['depression', 'anxiety']",True,alcohol,anxiety,lead,C0003467,Anxiousness,702,Ethanol,Ethanol,lead
1549,18210,33677558,"Age, DM duration, chronic kidney disease stage ≥3, and dipeptidyl peptidase-4 inhibitor use, not using metformin, were associated with QFT-positivity.",['metformin'],['chronic kidney disease'],True,metformin,chronic kidney disease,associated,C1561643,Loss of renal function,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",metformin,associate
1550,18214,33361292,"Similarly, the independent predictors of ≥grade 2 ADE were use of 3HP regimen, presence of DM, and use of PD, whereas ≥grade 3 ADE were associated with eosinophil counts of >700/mm3 after 2 weeks of LTBI treatment even after adjustment for age and gender.",['LTBI'],['eosinophil counts'],True,LTBI,eosinophil counts,associated,C0853644,Abnormal eosinophil count,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",LTBI,associate
1551,18241,35150797,  Perfluorooctane sulfonate induces suppression of testosterone biosynthesis via Sertoli cell-derived exosomal/miR-9-3p downregulating StAR expression in Leydig cells.,['Perfluorooctane sulfonate'],['suppression of testosterone biosynthesis'],True,Perfluorooctane sulfonate,suppression of testosterone biosynthesis,induces,C0853644,Abnormal eosinophil count,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",induce
1552,18243,35150797,"Our results demonstrated that PFOS dose-dependently induced a decrease in sperm count, low levels of testosterone, and damage in testicular interstitium morphology.",['PFOS'],"['decrease in sperm count', 'damage in testicular interstitium morphology']",True,PFOS,decrease in sperm count,induced,C0028960,Oligospermia,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",induce
1553,18263,34915281," CONCLUSIONS: Great Lakes Basin fish consumption was associated with an increase in blood concentrations of some PFAS, and especially of PFOS, among licensed anglers and Burmese refugees and immigrants in western New York State.",['PFOS'],['increase in blood concentrations'],True,PFOS,increase in blood concentrations,associated,C4732893,Hyperserinemia,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",associate
1554,18266,34894504,"PFOS induced more severe oxidative stress in the liver than F-53B and OBS, and these three PFAS induced similar anti-inflammatory effects by repressing the expression of pro-inflammatory cytokines.",['PFOS'],"['oxidative stress in the liver', 'repressing the expression of pro-inflammatory cytokines']",True,PFOS,oxidative stress in the liver,induced,C0242606,Oxidative stress,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",induce
1555,18269,34890990,"Exposure to perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) has been linked to poorer kidney function in general population, but the related studies in individuals with diabetes were very limited.","['perfluorooctanoic acid', 'perfluorooctane sulfonate', 'PFOS']","['poorer kidney function', 'diabetes']",True,perfluorooctanoic acid,poorer kidney function,linked,C0151746,Kidney function issue,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",link
1556,18269,34890990,"Exposure to perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) has been linked to poorer kidney function in general population, but the related studies in individuals with diabetes were very limited.","['perfluorooctanoic acid', 'perfluorooctane sulfonate', 'PFOS']","['poorer kidney function', 'diabetes']",True,perfluorooctanoic acid,diabetes,linked,C0085207,Maternal diabetes,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",link
1557,18269,34890990,"Exposure to perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) has been linked to poorer kidney function in general population, but the related studies in individuals with diabetes were very limited.","['perfluorooctanoic acid', 'perfluorooctane sulfonate', 'PFOS']","['poorer kidney function', 'diabetes']",True,perfluorooctane sulfonate,poorer kidney function,linked,C0151746,Kidney function issue,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",link
1558,18269,34890990,"Exposure to perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) has been linked to poorer kidney function in general population, but the related studies in individuals with diabetes were very limited.","['perfluorooctanoic acid', 'perfluorooctane sulfonate', 'PFOS']","['poorer kidney function', 'diabetes']",True,perfluorooctane sulfonate,diabetes,linked,C0085207,Maternal diabetes,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",link
1559,18272,34890990,"PFOS exposure was negatively associated with CKD incidence in patients with diabetes, especially in those with baseline eGFR levels < 70 mL/min/1.73 m2.",['PFOS'],['diabetes'],True,PFOS,diabetes,associated,C0085207,Maternal diabetes,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",associate
1560,18285,34800587,"In  humans, PFOS exposure has been associated with a number of adverse health outcomes, including reduced birth weight.",['PFOS'],['reduced birth weight'],True,PFOS,reduced birth weight,associated,C0024032,Low birth weight,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",associate
1561,18295,34735953," RESULTS: Each log2-unit increase in serum PFNA concentration was significantly associated with higher odds of SGA birth (OR = 1.32, 95% CI 1.07, 1.63); similar  but borderline significant associations were found in PFOA (OR = 1.20, 95% CI 0.94, 1.49) with SGA.","['PFNA', 'PFOA']",['increase in serum'],True,PFNA,increase in serum,associated,C4021843,Increased circulating free T3,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",associate
1562,18295,34735953," RESULTS: Each log2-unit increase in serum PFNA concentration was significantly associated with higher odds of SGA birth (OR = 1.32, 95% CI 1.07, 1.63); similar  but borderline significant associations were found in PFOA (OR = 1.20, 95% CI 0.94, 1.49) with SGA.","['PFNA', 'PFOA']",['increase in serum'],True,PFOA,increase in serum,associated,C4021843,Increased circulating free T3,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
1563,18296,34735953,"Among 25,516 metabolic features extracted from the serum samples, we successfully annotated and confirmed 10 overlapping metabolites associated with both PFAS and fetal growth endpoints, including glycine, taurine, uric acid, ferulic acid, 2-hexyl-3-phenyl-2-propenal, unsaturated fatty acid C18:1, androgenic hormone conjugate, parent bile acid, and bile acid-glycine conjugate.","['glycine', 'taurine', 'uric acid', 'ferulic acid', '2-hexyl-3-phenyl-2-propenal']","['fetal growth endpoints', 'unsaturated fatty acid C18:1']",True,glycine,unsaturated fatty acid C18:1,associated,C5139059,Abnormal circulating unsaturated fatty acid concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycine,associate
1564,18296,34735953,"Among 25,516 metabolic features extracted from the serum samples, we successfully annotated and confirmed 10 overlapping metabolites associated with both PFAS and fetal growth endpoints, including glycine, taurine, uric acid, ferulic acid, 2-hexyl-3-phenyl-2-propenal, unsaturated fatty acid C18:1, androgenic hormone conjugate, parent bile acid, and bile acid-glycine conjugate.","['glycine', 'taurine', 'uric acid', 'ferulic acid', '2-hexyl-3-phenyl-2-propenal']","['fetal growth endpoints', 'unsaturated fatty acid C18:1']",True,taurine,unsaturated fatty acid C18:1,associated,C5139059,Abnormal circulating unsaturated fatty acid concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",taurine,associate
1565,18296,34735953,"Among 25,516 metabolic features extracted from the serum samples, we successfully annotated and confirmed 10 overlapping metabolites associated with both PFAS and fetal growth endpoints, including glycine, taurine, uric acid, ferulic acid, 2-hexyl-3-phenyl-2-propenal, unsaturated fatty acid C18:1, androgenic hormone conjugate, parent bile acid, and bile acid-glycine conjugate.","['glycine', 'taurine', 'uric acid', 'ferulic acid', '2-hexyl-3-phenyl-2-propenal']","['fetal growth endpoints', 'unsaturated fatty acid C18:1']",True,uric acid,unsaturated fatty acid C18:1,associated,C5139059,Abnormal circulating unsaturated fatty acid concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",uric acid,associate
1566,18296,34735953,"Among 25,516 metabolic features extracted from the serum samples, we successfully annotated and confirmed 10 overlapping metabolites associated with both PFAS and fetal growth endpoints, including glycine, taurine, uric acid, ferulic acid, 2-hexyl-3-phenyl-2-propenal, unsaturated fatty acid C18:1, androgenic hormone conjugate, parent bile acid, and bile acid-glycine conjugate.","['glycine', 'taurine', 'uric acid', 'ferulic acid', '2-hexyl-3-phenyl-2-propenal']","['fetal growth endpoints', 'unsaturated fatty acid C18:1']",True,ferulic acid,unsaturated fatty acid C18:1,associated,C5139059,Abnormal circulating unsaturated fatty acid concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ferulic acid,associate
1567,18303,34611219,We investigated whether umbilical cord blood concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) are associated with children's risk trajectory for obesity.,"['perfluorooctane sulfonate', 'perfluorooctanoic acid']","['umbilical cord blood concentrations', 'obesity']",True,perfluorooctane sulfonate,obesity,associated,C0028754,Obesity,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",associate
1568,18303,34611219,We investigated whether umbilical cord blood concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) are associated with children's risk trajectory for obesity.,"['perfluorooctane sulfonate', 'perfluorooctanoic acid']","['umbilical cord blood concentrations', 'obesity']",True,perfluorooctanoic acid,obesity,associated,C0028754,Obesity,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
1569,18318,34384190,"Comparing with the control group, PFOS exposure caused significantly decreased levels of C18:0 while significantly increased levels of C18:3n6.",['PFOS'],['decreased levels of C18:0 while significantly increased levels of C18:3n6'],True,PFOS,decreased levels of C18:0 while significantly increased levels of C18:3n6,caused,C4073162,Elevated hemoglobin A1c,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",cause
1570,18319,34363875,"  Perfluorooctane sulfonate and bisphenol A induce a similar level of mast cell activation via a common signaling pathway, Fyn-Lyn-Syk activation.","['Perfluorooctane sulfonate', 'bisphenol']",['mast cell activation'],True,Perfluorooctane sulfonate,mast cell activation,induce,C4531032,Abnormal T cell activation,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",induce
1571,18319,34363875,"  Perfluorooctane sulfonate and bisphenol A induce a similar level of mast cell activation via a common signaling pathway, Fyn-Lyn-Syk activation.","['Perfluorooctane sulfonate', 'bisphenol']",['mast cell activation'],True,bisphenol,mast cell activation,induce,C4531032,Abnormal T cell activation,6623,Bisphenol A,Bisphenol A,induce
1572,18322,34358914,"In a concentration-dependent manner, exposure to PFOS provoked hyperactivity and hypoactivity under light and dark conditions, respectively.",['PFOS'],"['hyperactivity', 'hypoactivity']",True,PFOS,hyperactivity,provoked,C0424295,Hyperactivity,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",provoke
1573,18322,34358914,"In a concentration-dependent manner, exposure to PFOS provoked hyperactivity and hypoactivity under light and dark conditions, respectively.",['PFOS'],"['hyperactivity', 'hypoactivity']",True,PFOS,hypoactivity,provoked,C0424295,Hyperactivity,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",provoke
1574,18324,34343554,"Each 1 ng/mL increase in serum concentrations of perfluorohexane sulfonic acid (PFHxS) and perfluorooctane sulfonic acid (PFOS) was associated with decreases of 78 % (95 % CI: 25-94 %) and 9 % (95 % CI: 2-16 %), respectively, in diphtheria antibody concentrations.","['perfluorohexane sulfonic acid', 'perfluorooctane sulfonic acid']",['increase in serum concentrations'],True,perfluorohexane sulfonic,increase in serum concentrations,associated,C4023004,Increased serum bile acid concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",perfluorohexane sulfonic,associate
1575,18324,34343554,"Each 1 ng/mL increase in serum concentrations of perfluorohexane sulfonic acid (PFHxS) and perfluorooctane sulfonic acid (PFOS) was associated with decreases of 78 % (95 % CI: 25-94 %) and 9 % (95 % CI: 2-16 %), respectively, in diphtheria antibody concentrations.","['perfluorohexane sulfonic acid', 'perfluorooctane sulfonic acid']",['increase in serum concentrations'],True,perfluorooctane sulfonic,increase in serum concentrations,associated,C4023004,Increased serum bile acid concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",perfluorooctane sulfonic,associate
1576,18354,34979306,doi: 10.1016/j.ecoenv.2021.113140. [Epub ahead of print]  Oxyfluorfen induces hepatotoxicity through lipo-sugar accumulation and inflammation in zebrafish (Danio rerio).,"['Oxyfluorfen', 'lipo-sugar']","['hepatotoxicity', 'inflammation']",True,Oxyfluorfen,inflammation,induces,C3875321,Skin inflammation,39327,Oxyfluorfen,Oxyfluorfen,induce
1577,18354,34979306,doi: 10.1016/j.ecoenv.2021.113140. [Epub ahead of print]  Oxyfluorfen induces hepatotoxicity through lipo-sugar accumulation and inflammation in zebrafish (Danio rerio).,"['Oxyfluorfen', 'lipo-sugar']","['hepatotoxicity', 'inflammation']",True,lipo-sugar,inflammation,induces,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lipo-sugar,induce
1578,18356,34979306,"OXY also caused inflammation by upregulating the inflammatory factors IL-6, IL-8, and TNF-α, and  activated the apoptotic pathway to inhibit hepatocyte proliferation, resulting in zebrafish liver toxicity.",['OXY'],"['inflammation', 'hepatocyte proliferation', 'liver toxicity']",True,OXY,inflammation,caused,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",OXY,cause
1579,18376,31648108,"Conclusively, the herbicides oxyfluorfen could induce multiple negative impacts on C. gariepinus with oxidative stress as a probable underlying mechanism.",['oxyfluorfen'],['oxidative stress'],True,oxyfluorfen,oxidative stress,induce,C0242606,Oxidative stress,39327,Oxyfluorfen,Oxyfluorfen,induce
1580,18387,30506409,"The herbicide concentrations were 0.125, 0.25, and 0.5 mg/L. The results showed that  oxyfluorfen induced significant frequencies of micronuclei, binucleated cells, and apoptosis in hemocytes of mollusks when compared to the control group.",['oxyfluorfen'],"['frequencies of micronuclei', 'binucleated cells, and', 'apoptosis']",True,oxyfluorfen,"binucleated cells, and",induced,C1855752,Abnormal T cell morphology,39327,Oxyfluorfen,Oxyfluorfen,induce
1581,18411,26197316,Both OF- and MV-treated plants resulted in not only down-regulation of most genes involved in porphyrin biosynthesis but also disappearance of Mg-porphyrins during the late stage of photooxidative stress.,"['porphyrin', 'Mg-porphyrins']",['photooxidative stress'],True,porphyrin,photooxidative stress,resulted,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",porphyrin,result
1582,18411,26197316,Both OF- and MV-treated plants resulted in not only down-regulation of most genes involved in porphyrin biosynthesis but also disappearance of Mg-porphyrins during the late stage of photooxidative stress.,"['porphyrin', 'Mg-porphyrins']",['photooxidative stress'],True,Mg-porphyrins,photooxidative stress,resulted,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Mg-porphyrins,result
1583,18442,35274092,  Background: Retrospective studies suggest that for patients with ulcerative colitis (UC) combination therapy with low-dose azathioprine and allopurinol (L-AZA/ALLO) may result in higher remission rates than monotherapy with azathioprine (AZA).,"['azathioprine', 'allopurinol', 'L-AZA/ALLO', 'azathioprine', 'AZA']","['ulcerative colitis', 'higher remission rates']",True,azathioprine,ulcerative colitis,result,C0009324,Ulcerative colitis,2265,Azathioprine,Azathioprine,result
1584,18442,35274092,  Background: Retrospective studies suggest that for patients with ulcerative colitis (UC) combination therapy with low-dose azathioprine and allopurinol (L-AZA/ALLO) may result in higher remission rates than monotherapy with azathioprine (AZA).,"['azathioprine', 'allopurinol', 'L-AZA/ALLO', 'azathioprine', 'AZA']","['ulcerative colitis', 'higher remission rates']",True,allopurinol,ulcerative colitis,result,C0009324,Ulcerative colitis,135401907,Allopurinol,Allopurinol,result
1585,18442,35274092,  Background: Retrospective studies suggest that for patients with ulcerative colitis (UC) combination therapy with low-dose azathioprine and allopurinol (L-AZA/ALLO) may result in higher remission rates than monotherapy with azathioprine (AZA).,"['azathioprine', 'allopurinol', 'L-AZA/ALLO', 'azathioprine', 'AZA']","['ulcerative colitis', 'higher remission rates']",True,azathioprine,ulcerative colitis,result,C0009324,Ulcerative colitis,2265,Azathioprine,Azathioprine,result
1586,18482,35120281,  The immunosuppressant drug azathioprine is associated with a 4% risk of acute pancreatitis in patients with inflammatory bowel disease (IBD).,['azathioprine'],"['acute pancreatitis', 'inflammatory bowel disease']",True,azathioprine,acute pancreatitis,associated,C0001339,Acute pancreatitis,2265,Azathioprine,Azathioprine,associate
1587,18482,35120281,  The immunosuppressant drug azathioprine is associated with a 4% risk of acute pancreatitis in patients with inflammatory bowel disease (IBD).,['azathioprine'],"['acute pancreatitis', 'inflammatory bowel disease']",True,azathioprine,inflammatory bowel disease,associated,C0021390,Inflammatory bowel disease,2265,Azathioprine,Azathioprine,associate
1588,18515,35032047,  BACKGROUND: NUDT15 polymorphisms are associated with leukopenia during treatment  with thiopurines.,['thiopurines'],['leukopenia'],True,thiopurines,leukopenia,associated,C0023530,Decreased blood leukocyte number,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiopurines,associate
1589,18533,34506219,"These metabolic adaptations were associated with reduced inflammation and triglyceride content but enhanced phosphoinositide 3-kinase (PI3K)-AKT/protein kinase B signaling and insulin action, the latter of which was abolished by exogenous oxidative stress.",['insulin'],"['reduced inflammation', 'triglyceride content', 'exogenous oxidative stress']",True,insulin,reduced inflammation,associated,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",insulin,associate
1590,18533,34506219,"These metabolic adaptations were associated with reduced inflammation and triglyceride content but enhanced phosphoinositide 3-kinase (PI3K)-AKT/protein kinase B signaling and insulin action, the latter of which was abolished by exogenous oxidative stress.",['insulin'],"['reduced inflammation', 'triglyceride content', 'exogenous oxidative stress']",True,insulin,triglyceride content,associated,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",insulin,associate
1591,18533,34506219,"These metabolic adaptations were associated with reduced inflammation and triglyceride content but enhanced phosphoinositide 3-kinase (PI3K)-AKT/protein kinase B signaling and insulin action, the latter of which was abolished by exogenous oxidative stress.",['insulin'],"['reduced inflammation', 'triglyceride content', 'exogenous oxidative stress']",True,insulin,exogenous oxidative stress,associated,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",insulin,associate
1592,18590,27736868,"A single dose  (65 mg/kg; i.p.) streptozotocin injection to rats resulted in hyperglycemia with  blood glucose levels of 443 ± 9 mg/dl versus 121 ± 7 mg/dl in control animals, p<0.0001, N = 7-11.",['streptozotocin'],['hyperglycemia'],True,streptozotocin,hyperglycemia,resulted,C0020456,High blood sugar,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",streptozotocin,result
1593,18599,27155576,Its destabilization was associated with reduced CoQ10 levels and mitochondrial energy deficiency in human cells treated with FCCP or exhibiting MERRF mutation.,['FCCP'],"['reduced CoQ10 levels', 'MERRF mutation']",True,FCCP,reduced CoQ10 levels,associated,C4021545,Decreased circulating IgG2 level,3330,Carbonyl Cyanide P-Trifluoromethoxyphenylhydrazone,Carbonyl Cyanide P-Trifluoromethoxyphenylhydrazone,associate
1594,18641,35127876,"Niclosamide, an FDA-improved anthelmintic drug, markedly inhibited calcification along with reduced alkaline phosphatase activity and CROT mRNA expression.",['Niclosamide'],"['calcification', 'reduced alkaline phosphatase activity']",True,Niclosamide,calcification,inhibited,C0263625,Skin calcification,4477,Niclosamide,Niclosamide,inhibit
1595,18641,35127876,"Niclosamide, an FDA-improved anthelmintic drug, markedly inhibited calcification along with reduced alkaline phosphatase activity and CROT mRNA expression.",['Niclosamide'],"['calcification', 'reduced alkaline phosphatase activity']",True,Niclosamide,reduced alkaline phosphatase activity,inhibited,C4025328,Abnormality of alkaline phosphatase activity,4477,Niclosamide,Niclosamide,inhibit
1596,18647,35115509,"  The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.",['niclosamide'],['pancreatic cancer'],True,niclosamide,pancreatic cancer,induces,C0346647,Cancer of the pancreas,4477,Niclosamide,Niclosamide,induce
1597,18648,35115509,"In this study, niclosamide inhibited proliferation of pancreatic cancer cells (PCCs), induced apoptosis via the mitochondrial-mediated  pathway, and suppressed cell migration and invasion by antagonizing epithelial-to-mesenchymal transition.",['niclosamide'],"['proliferation of pancreatic cancer', 'apoptosis', 'suppressed cell migration', 'invasion']",True,niclosamide,proliferation of pancreatic cancer cells,inhibited,C1855752,Abnormal T cell morphology,4477,Niclosamide,Niclosamide,inhibit
1598,18649,35115509,"Also, niclosamide inhibited tumor growth and metastasis in pancreatic cancer xenograft mouse models.",['niclosamide'],"['tumor growth', 'metastasis in pancreatic cancer']",True,niclosamide,metastasis in pancreatic cancer,inhibited,C0346647,Cancer of the pancreas,4477,Niclosamide,Niclosamide,inhibit
1599,18651,35115509,"Thus, our study indicated that niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability, and suppress pancreatic cancer progression.",['niclosamide'],['pancreatic cancer'],True,niclosamide,pancreatic cancer,induces,C0346647,Cancer of the pancreas,4477,Niclosamide,Niclosamide,induce
1600,18699,34572856,The treatment of niclosamide and pyrvinium inhibits the migration of osteosarcoma cells at nanomolar concentrations.,"['niclosamide', 'pyrvinium']",['migration of osteosarcoma cells'],True,niclosamide,migration of osteosarcoma cells,inhibits,C0029463,Osteogenic sarcoma,4477,Niclosamide,Niclosamide,inhibit
1601,18699,34572856,The treatment of niclosamide and pyrvinium inhibits the migration of osteosarcoma cells at nanomolar concentrations.,"['niclosamide', 'pyrvinium']",['migration of osteosarcoma cells'],True,pyrvinium,migration of osteosarcoma cells,inhibits,C0029463,Osteogenic sarcoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pyrvinium,inhibit
1602,18710,34386088,  Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer.,['Anthelminthic niclosamide'],"['tumor growth', 'invasion', 'epidermal growth factor', 'breast cancer']",True,Anthelminthic niclosamide,breast cancer,inhibits,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Anthelminthic niclosamide,inhibit
1603,18713,34386088,"The present study aimed to determine whether niclosamide can inhibit cell proliferation, invasion and epithelial-to-mesenchymal transition, as well as the  stem-like phenotype in cisplatin-resistant HER2-positive breast cancer.",['niclosamide'],"['cell proliferation', 'invasion', 'breast cancer']",True,niclosamide,cell proliferation,inhibit,C4531170,Abnormal cell proliferation,4477,Niclosamide,Niclosamide,inhibit
1604,18713,34386088,"The present study aimed to determine whether niclosamide can inhibit cell proliferation, invasion and epithelial-to-mesenchymal transition, as well as the  stem-like phenotype in cisplatin-resistant HER2-positive breast cancer.",['niclosamide'],"['cell proliferation', 'invasion', 'breast cancer']",True,niclosamide,breast cancer,inhibit,C0678222,Breast cancer,4477,Niclosamide,Niclosamide,inhibit
1605,18714,34386088,The results from the present study demonstrated that niclosamide inhibited the resistance of HER2-positive breast cancer to cisplatin both in vitro and in vivo.,"['niclosamide', 'cisplatin']",['breast cancer'],True,niclosamide,breast cancer,inhibited,C0678222,Breast cancer,4477,Niclosamide,Niclosamide,inhibit
1606,18714,34386088,The results from the present study demonstrated that niclosamide inhibited the resistance of HER2-positive breast cancer to cisplatin both in vitro and in vivo.,"['niclosamide', 'cisplatin']",['breast cancer'],True,cisplatin,breast cancer,inhibited,C0678222,Breast cancer,5702198,azane;dichloroplatinum,azane;dichloroplatinum,inhibit
1607,18715,34386088,"Furthermore, niclosamide combined with cisplatin could inhibit breast cancer cell invasion, epithelial-mesenchymal transition and cell stemness.","['niclosamide', 'cisplatin']",['breast cancer'],True,niclosamide,breast cancer,inhibit,C0678222,Breast cancer,4477,Niclosamide,Niclosamide,inhibit
1608,18715,34386088,"Furthermore, niclosamide combined with cisplatin could inhibit breast cancer cell invasion, epithelial-mesenchymal transition and cell stemness.","['niclosamide', 'cisplatin']",['breast cancer'],True,cisplatin,breast cancer,inhibit,C0678222,Breast cancer,5702198,azane;dichloroplatinum,azane;dichloroplatinum,inhibit
1609,18719,34360618,"Treatment of airway epithelial cells with niclosamide strongly inhibited expression of the essential transcription factor of Th2-dependent inflammation and goblet cell differentiation, SAM pointed domain-containing ETS-like factor (SPDEF).",['niclosamide'],"['inflammation', 'goblet cell differentiation']",True,niclosamide,inflammation,inhibited,C3875321,Skin inflammation,4477,Niclosamide,Niclosamide,inhibit
1610,18760,33860549,"Niclosamide also inhibits aberrant inflammation in the PF, ELL, pelvic organs (uterus and vagina) and dorsal root ganglion (DRG), as well as MΦ infiltration, vascularization and innervation in the ELL.",['Niclosamide'],"['inflammation', 'dorsal root ganglion', 'vascularization and innervation in the ELL']",True,Niclosamide,inflammation,inhibits,C3875321,Skin inflammation,4477,Niclosamide,Niclosamide,inhibit
1611,18837,33103467,Treatment of the breast cancer cells with TDZ (1-50 μmol/L) caused more stressful environment and induced a significant increase in active caspase-positive cells.,['TDZ'],"['breast cancer', 'increase in active caspase-positive']",True,TDZ,breast cancer,caused,C0678222,Breast cancer,40087,THIDIAZURON,THIDIAZURON,cause
1612,18935,35096073,"The 2,4-DCP concentration among girls increased by 0.007 and 0.01 units with a one-unit increase in Diastolic Blood Pressure (DBP) and FBS, respectively.","['2,4-DCP']",['increase in Diastolic Blood'],True,"2,4-DCP",increase in Diastolic Blood,increased,C0277890,Decreased diastolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","2,4-DCP",increase
1613,18983,34182386,"Atrazine induced oxidative stress in A. paniculata was also ameliorated by CIMAP-A7 by reducing stress enzymes, proline,  and malondialdehyde accumulation under contaminated soil conditions than un-inoculated treatments.","['Atrazine', 'proline']","['oxidative stress', 'malondialdehyde accumulation']",True,Atrazine,oxidative stress,induced,C0242606,Oxidative stress,2256,"6-chloro-4-N-ethyl-2-N-propan-2-yl-1,3,5-triazine-2,4-diamine","6-chloro-4-N-ethyl-2-N-propan-2-yl-1,3,5-triazine-2,4-diamine",induce
1614,18983,34182386,"Atrazine induced oxidative stress in A. paniculata was also ameliorated by CIMAP-A7 by reducing stress enzymes, proline,  and malondialdehyde accumulation under contaminated soil conditions than un-inoculated treatments.","['Atrazine', 'proline']","['oxidative stress', 'malondialdehyde accumulation']",True,proline,oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",proline,induce
1615,19013,20727709,"These results indicate that a short, late prenatal exposure to mixture of chlorotriazine metabolites can cause chronic prostatitis in male LE rats.",['chlorotriazine metabolites'],['chronic prostatitis'],True,chlorotriazine metabolites,chronic prostatitis,cause,C0033581,Inflammation of the prostate,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chlorotriazine metabolites,cause
1616,19056,35313046,"Physiologically, acetaminophen (APAP, an effective antipyretic and analgesic)-caused Sam50 reduction or Sam50 liver-specific knockout induces mtDNA release, leading to activation of the cGAS-STING pathway and liver inflammation in mice.",['acetaminophen'],"['mtDNA release', 'inflammation']",True,acetaminophen,inflammation,induces,C3875321,Skin inflammation,1983,Acetaminophen,Acetaminophen,induce
1617,19059,35312061,  A growing body of evidence links prenatal and early postnatal acetaminophen (APAP) exposure to atypical development of brain and behavior.,['acetaminophen'],['atypical development of brain and behavior'],True,acetaminophen,atypical development of brain and behavior,links,C0424323,Violent behavior,1983,Acetaminophen,Acetaminophen,link
1618,19104,35271621,"As compared to untreated patients, dipyrone only led to a marginal additional decrease in body temperature of only -0.1°C.",['dipyrone'],['decrease in body temperature'],True,dipyrone,decrease in body temperature,led,C0005904,Body temperature changes,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dipyrone,lead
1619,19107,35265717,"  Acetaminophen (APAP) can cause acute liver failure, but treatment options are still limited.",['Acetaminophen'],['acute liver failure'],True,Acetaminophen,acute liver failure,cause,C0162557,Acute liver failure,1983,Acetaminophen,Acetaminophen,cause
1620,19118,35259588,Acetaminophen (APAP) resulted in drug-induced liver injury is the main cause of acute liver failure (ALI) worldwide and only N-acetylcysteine is the accepted detoxification drug.,"['Acetaminophen', 'N-acetylcysteine']","['liver injury', 'acute liver failure']",True,Acetaminophen,acute liver failure,resulted,C0162557,Acute liver failure,1983,Acetaminophen,Acetaminophen,result
1621,19118,35259588,Acetaminophen (APAP) resulted in drug-induced liver injury is the main cause of acute liver failure (ALI) worldwide and only N-acetylcysteine is the accepted detoxification drug.,"['Acetaminophen', 'N-acetylcysteine']","['liver injury', 'acute liver failure']",True,N-acetylcysteine,acute liver failure,resulted,C0162557,Acute liver failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",N-acetylcysteine,result
1622,19139,35246743,"Anxiety, depression, alcohol use, and prior abdominal surgery were not associated with increased need for post-operative narcotics.",['alcohol'],['depression'],True,alcohol,depression,associated,C0011581,Depression,702,Ethanol,Ethanol,associate
1623,19166,35203104,Paracetamol resulted in significantly reduced risk of oliguria and a tendency towards less gastrointestinal bleeding.,['Paracetamol'],"['oliguria', 'less gastrointestinal bleeding']",True,Paracetamol,oliguria,resulted,C0028961,Oliguria,1983,Acetaminophen,Acetaminophen,result
1624,19166,35203104,Paracetamol resulted in significantly reduced risk of oliguria and a tendency towards less gastrointestinal bleeding.,['Paracetamol'],"['oliguria', 'less gastrointestinal bleeding']",True,Paracetamol,less gastrointestinal bleeding,resulted,C0017181,Gastrointestinal hemorrhage,1983,Acetaminophen,Acetaminophen,result
1625,19172,35201347, CONCLUSION: The initiation of sodium-containing acetaminophen was associated with increased risks of CVD and all-cause mortality among individuals with or without  hypertension.,['acetaminophen'],"['increased risks of CVD', 'mortality', 'hypertension']",True,acetaminophen,hypertension,associated,C0020538,Systemic hypertension,1983,Acetaminophen,Acetaminophen,associate
1626,19173,35201347, KEY FINDING: Sodium-containing acetaminophen was associated with a statistically  significant higher risk of incident cardiovascular disease and all-cause mortality than the non-sodium-containing acetaminophen initiation among individuals with and without hypertension.,"['acetaminophen', 'acetaminophen']","['cardiovascular disease', 'mortality', 'hypertension']",True,acetaminophen,cardiovascular disease,associated,C0007222,Cardiovascular disease,1983,Acetaminophen,Acetaminophen,associate
1627,19173,35201347, KEY FINDING: Sodium-containing acetaminophen was associated with a statistically  significant higher risk of incident cardiovascular disease and all-cause mortality than the non-sodium-containing acetaminophen initiation among individuals with and without hypertension.,"['acetaminophen', 'acetaminophen']","['cardiovascular disease', 'mortality', 'hypertension']",True,acetaminophen,hypertension,associated,C0020538,Systemic hypertension,1983,Acetaminophen,Acetaminophen,associate
1628,19173,35201347, KEY FINDING: Sodium-containing acetaminophen was associated with a statistically  significant higher risk of incident cardiovascular disease and all-cause mortality than the non-sodium-containing acetaminophen initiation among individuals with and without hypertension.,"['acetaminophen', 'acetaminophen']","['cardiovascular disease', 'mortality', 'hypertension']",True,acetaminophen,cardiovascular disease,associated,C0007222,Cardiovascular disease,1983,Acetaminophen,Acetaminophen,associate
1629,19173,35201347, KEY FINDING: Sodium-containing acetaminophen was associated with a statistically  significant higher risk of incident cardiovascular disease and all-cause mortality than the non-sodium-containing acetaminophen initiation among individuals with and without hypertension.,"['acetaminophen', 'acetaminophen']","['cardiovascular disease', 'mortality', 'hypertension']",True,acetaminophen,hypertension,associated,C0020538,Systemic hypertension,1983,Acetaminophen,Acetaminophen,associate
1630,19189,35219418,"Furthermore, organic materials increased the total porosity, total pore volume and average pore diameter, and reduced the micropore  content according to nitrogen gas adsorption (NA) and mercury intrusion porosimetry (MIP) analysis, whilst enhancing water retention of the residues based on water characteristic curves.","['mercury', 'water']","['reduced the micropore  content', 'enhancing water retention']",True,mercury,reduced the micropore  content,increased,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mercury,increase
1631,19196,35164284,"Contrarily, NaCl addition (from 0.3 to 1.7 g/100 g of flour) significantly increased (p < 0.05) the HMF formation (from 1236 µg/kg to 4239 µg/kg, respectively), probably through the dehydration of carbohydrates during the Maillard reaction.",['NaCl'],['dehydration of carbohydrates'],True,NaCl,dehydration of carbohydrates,increased,C0011175,Dehydration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",NaCl,increase
1632,19214,35079972,"The present results provide epidemiological evidence that exposure to AA, mainly its metabolite glycidamide,  is positively associated with the prevalence of hypertension or increased SBP in  adolescent females.",['glycidamide'],"['hypertension', 'increased SBP']",True,glycidamide,hypertension,associated,C0020538,Systemic hypertension,91550,oxirane-2-carboxamide,oxirane-2-carboxamide,associate
1633,19214,35079972,"The present results provide epidemiological evidence that exposure to AA, mainly its metabolite glycidamide,  is positively associated with the prevalence of hypertension or increased SBP in  adolescent females.",['glycidamide'],"['hypertension', 'increased SBP']",True,glycidamide,increased SBP,associated,C0302845,Increased mean corpuscular volume,91550,oxirane-2-carboxamide,oxirane-2-carboxamide,associate
1634,19244,35280551,"Exposure to thiamethoxam causes acute malady such as tumour development, cell apoptosis, liver damage and neurotoxicity.",['thiamethoxam'],"['acute malady', 'tumour development', 'cell apoptosis', 'liver damage', 'neurotoxicity']",True,thiamethoxam,tumour development,causes,C0027651,Neoplasm,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiamethoxam,cause
1635,19297,35235278,"Additionally, withaferin A triggered the production of ROS in human myeloma cells indicative of ROS mediated apoptosis in  human myeloma cells.",['withaferin'],"['production of ROS', 'apoptosis']",True,withaferin,production of ROS,triggered,C4476796,Increased reactive oxygen species production,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",withaferin,trigger
1636,19303,35226462,"Fe3O4-rGO-SA nanoparticles are nontoxic to erythrocytes, i.e., human peripheral blood mononuclear cells, but surpassingly inhibit the growth of three cancer cell lines, HeLa, HepG2, and HT29, with respect to pristine salicylic acid molecules.",['salicylic acid'],['cancer'],True,salicylic acid,cancer,inhibit,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",salicylic acid,inhibit
1637,19311,35004358," Results: Nitric oxide donors inhibited induction of the SOS response by classical inducers such as mitomycin C, ciprofloxacin, and zidovudine, as measured by assays for E. coli RecA. Nitric oxide donors also inhibited Stx toxin protein production as well as stx2 RNA in vitro and in vivo.","['ciprofloxacin', 'zidovudine']",['induction of the SOS response'],True,ciprofloxacin,induction of the SOS response,inhibited,C0006826,Cancer,2764,Ciprofloxacin,Ciprofloxacin,inhibit
1638,19311,35004358," Results: Nitric oxide donors inhibited induction of the SOS response by classical inducers such as mitomycin C, ciprofloxacin, and zidovudine, as measured by assays for E. coli RecA. Nitric oxide donors also inhibited Stx toxin protein production as well as stx2 RNA in vitro and in vivo.","['ciprofloxacin', 'zidovudine']",['induction of the SOS response'],True,zidovudine,induction of the SOS response,inhibited,C0006826,Cancer,35370,Zidovudine,Zidovudine,inhibit
1639,19327,34723625,"In this study, we analyzed reverse transcriptase (RT) variants based on sequences derived from an individual who had low-level rebound viremia while undergoing therapy with abacavir, azidothymidine (AZT) (zidovudine), and (-)-l-2',3'-dideoxy-3'-thiacytidine (3TC) (lamivudine).","['abacavir', 'azidothymidine', 'zidovudine', 'lamivudine']",['viremia'],True,abacavir,viremia,derived,C0042749,Viremia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",abacavir,derive
1640,19327,34723625,"In this study, we analyzed reverse transcriptase (RT) variants based on sequences derived from an individual who had low-level rebound viremia while undergoing therapy with abacavir, azidothymidine (AZT) (zidovudine), and (-)-l-2',3'-dideoxy-3'-thiacytidine (3TC) (lamivudine).","['abacavir', 'azidothymidine', 'zidovudine', 'lamivudine']",['viremia'],True,azidothymidine,viremia,derived,C0042749,Viremia,35370,Zidovudine,Zidovudine,derive
1641,19327,34723625,"In this study, we analyzed reverse transcriptase (RT) variants based on sequences derived from an individual who had low-level rebound viremia while undergoing therapy with abacavir, azidothymidine (AZT) (zidovudine), and (-)-l-2',3'-dideoxy-3'-thiacytidine (3TC) (lamivudine).","['abacavir', 'azidothymidine', 'zidovudine', 'lamivudine']",['viremia'],True,zidovudine,viremia,derived,C0042749,Viremia,35370,Zidovudine,Zidovudine,derive
1642,19335,34583644," Zidovudine (AZT), which is one of the nucleoside reverse transcriptase inhibitor  drug families of the first line antiretroviral therapy regimen for HIV/AIDS patients, causes anemia due to early long-term of higher-dose therapy.",['Zidovudine'],['anemia'],True,Zidovudine,anemia,causes,C0002871,Anaemia,35370,Zidovudine,Zidovudine,cause
1643,19368,35314078,"In utero exposure to BPA was associated with higher odds of current asthma (OR = 1.13, 95% CI = 1.01, 1.27) and wheeze (OR = 1.14, 95% CI = 1.01, 1.30) (p-interaction sex = 0.01) among girls, but not with wheezing patterns nor  lung function neither in overall nor among boys.",['BPA'],"['asthma', 'wheeze', 'wheezing']",True,BPA,asthma,associated,C0004096,Asthma,6623,Bisphenol A,Bisphenol A,associate
1644,19368,35314078,"In utero exposure to BPA was associated with higher odds of current asthma (OR = 1.13, 95% CI = 1.01, 1.27) and wheeze (OR = 1.14, 95% CI = 1.01, 1.30) (p-interaction sex = 0.01) among girls, but not with wheezing patterns nor  lung function neither in overall nor among boys.",['BPA'],"['asthma', 'wheeze', 'wheezing']",True,BPA,wheeze,associated,C0004096,Asthma,6623,Bisphenol A,Bisphenol A,associate
1645,19368,35314078,"In utero exposure to BPA was associated with higher odds of current asthma (OR = 1.13, 95% CI = 1.01, 1.27) and wheeze (OR = 1.14, 95% CI = 1.01, 1.30) (p-interaction sex = 0.01) among girls, but not with wheezing patterns nor  lung function neither in overall nor among boys.",['BPA'],"['asthma', 'wheeze', 'wheezing']",True,BPA,wheezing,associated,C0043144,Wheezing,6623,Bisphenol A,Bisphenol A,associate
1646,19370,35314078, CONCLUSION: This study suggests that in utero BPA exposure may be associated with higher odds of asthma and wheeze among school-age girls.,['BPA'],"['asthma', 'wheeze']",True,BPA,asthma,associated,C0004096,Asthma,6623,Bisphenol A,Bisphenol A,associate
1647,19370,35314078, CONCLUSION: This study suggests that in utero BPA exposure may be associated with higher odds of asthma and wheeze among school-age girls.,['BPA'],"['asthma', 'wheeze']",True,BPA,wheeze,associated,C0004096,Asthma,6623,Bisphenol A,Bisphenol A,associate
1648,19389,35292335,"Herein, we found that BPA induced ferroptosis in kidney and renal tubular epithelial cells, as showed by increased  intracellular iron accumulation, lipid peroxidation and cells death upon BPA exposure.","['BPA', 'iron', 'BPA']","['ferroptosis', 'lipid peroxidation', 'death']",True,BPA,death,induced,C1546180,Age of death,6623,Bisphenol A,Bisphenol A,induce
1649,19389,35292335,"Herein, we found that BPA induced ferroptosis in kidney and renal tubular epithelial cells, as showed by increased  intracellular iron accumulation, lipid peroxidation and cells death upon BPA exposure.","['BPA', 'iron', 'BPA']","['ferroptosis', 'lipid peroxidation', 'death']",True,iron,death,induced,C1546180,Age of death,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,induce
1650,19389,35292335,"Herein, we found that BPA induced ferroptosis in kidney and renal tubular epithelial cells, as showed by increased  intracellular iron accumulation, lipid peroxidation and cells death upon BPA exposure.","['BPA', 'iron', 'BPA']","['ferroptosis', 'lipid peroxidation', 'death']",True,BPA,death,induced,C1546180,Age of death,6623,Bisphenol A,Bisphenol A,induce
1651,19393,35292335,"In conclusion, renal dysfunction and renal tubular epithelial damage induced by BPA  are linked to ferroptosis, which depends on the activation of ferritinophagy through AMPK-mTOR-ULK1 axis.",['BPA'],"['renal dysfunction', 'renal tubular epithelial damage', 'ferroptosis']",True,BPA,renal dysfunction,linked,C0151747,Renal tubular disease,6623,Bisphenol A,Bisphenol A,link
1652,19399,35280594,  Tangeretin ameliorates bisphenol induced hepatocyte injury by inhibiting inflammation and oxidative stress.,"['Tangeretin ameliorates', 'bisphenol']","['hepatocyte injury', 'inflammation', 'oxidative stress']",True,bisphenol,inflammation,induced,C3875321,Skin inflammation,6623,Bisphenol A,Bisphenol A,induce
1653,19399,35280594,  Tangeretin ameliorates bisphenol induced hepatocyte injury by inhibiting inflammation and oxidative stress.,"['Tangeretin ameliorates', 'bisphenol']","['hepatocyte injury', 'inflammation', 'oxidative stress']",True,bisphenol,oxidative stress,induced,C0242606,Oxidative stress,6623,Bisphenol A,Bisphenol A,induce
1654,19403,35280563,The results indicated that BPA was associated with a reduction in the body weight of the pregnant mice from around 2-3 days after administration until the end of gestation.,['BPA'],['reduction in the body weight'],True,BPA,reduction in the body weight,associated,C0043094,Weight gain,6623,Bisphenol A,Bisphenol A,associate
1655,19404,35280563,"Furthermore, doses of BPA induced a reduction in implantation sites, lower foetal body weight and increased mortality rates.",['BPA'],"['lower foetal body weight', 'increased mortality']",True,BPA,lower foetal body weight,induced,C0043094,Weight gain,6623,Bisphenol A,Bisphenol A,induce
1656,19417,35269666,"Bisphenol A (BPA) is a pollutant, classified as an endocrine-disrupting chemical compound with estrogenic properties, their exposure in the early stages of neonatal life leads to an increase in the size and weight  of breast tumors and induces cellular changes in the tumoral immune microenvironment where cytokines play a key role.","['Bisphenol A', 'BPA']","['increase in the size', 'breast tumors']",True,Bisphenol A,increase in the size,leads,C1857501,Facial hyperostosis,6623,Bisphenol A,Bisphenol A,lead
1657,19417,35269666,"Bisphenol A (BPA) is a pollutant, classified as an endocrine-disrupting chemical compound with estrogenic properties, their exposure in the early stages of neonatal life leads to an increase in the size and weight  of breast tumors and induces cellular changes in the tumoral immune microenvironment where cytokines play a key role.","['Bisphenol A', 'BPA']","['increase in the size', 'breast tumors']",True,Bisphenol A,breast tumors,leads,C1458155,Breast tumor,6623,Bisphenol A,Bisphenol A,lead
1658,19422,35263230,"  Bisphenol A replacement chemicals, BPF and BPS, induce protumorigenic changes in  human mammary gland organoid morphology and proteome.",['BPF'],['BPS'],True,BPF,BPS,induce,C4477086,Cotton wool plaques,12111,"4,4'-Methylenediphenol","4,4'-Methylenediphenol",induce
1659,19442,35238458,"In addition, BPA caused autophagy flux impairment, which was confirmed by the increased of LC3-II and p62 levels, whereas melatonin treatment effectively reduced p62 levels under BPA treatment, and reversed apoptosis-related protein expression patterns caused by BPA.","['BPA', 'melatonin', 'BPA', 'BPA']",['reduced p62 levels'],True,BPA,reduced p62 levels,caused,C4021545,Decreased circulating IgG2 level,6623,Bisphenol A,Bisphenol A,cause
1660,19442,35238458,"In addition, BPA caused autophagy flux impairment, which was confirmed by the increased of LC3-II and p62 levels, whereas melatonin treatment effectively reduced p62 levels under BPA treatment, and reversed apoptosis-related protein expression patterns caused by BPA.","['BPA', 'melatonin', 'BPA', 'BPA']",['reduced p62 levels'],True,melatonin,reduced p62 levels,caused,C4021545,Decreased circulating IgG2 level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",melatonin,cause
1661,19442,35238458,"In addition, BPA caused autophagy flux impairment, which was confirmed by the increased of LC3-II and p62 levels, whereas melatonin treatment effectively reduced p62 levels under BPA treatment, and reversed apoptosis-related protein expression patterns caused by BPA.","['BPA', 'melatonin', 'BPA', 'BPA']",['reduced p62 levels'],True,BPA,reduced p62 levels,caused,C4021545,Decreased circulating IgG2 level,6623,Bisphenol A,Bisphenol A,cause
1662,19442,35238458,"In addition, BPA caused autophagy flux impairment, which was confirmed by the increased of LC3-II and p62 levels, whereas melatonin treatment effectively reduced p62 levels under BPA treatment, and reversed apoptosis-related protein expression patterns caused by BPA.","['BPA', 'melatonin', 'BPA', 'BPA']",['reduced p62 levels'],True,BPA,reduced p62 levels,caused,C4021545,Decreased circulating IgG2 level,6623,Bisphenol A,Bisphenol A,cause
1663,19461,35218298,"Concurrently, BPF resulted in severe oxidative stress and DNA damage, which triggered the early apoptosis in mouse oocytes.",['BPF'],"['oxidative stress', 'DNA damage', 'early apoptosis']",True,BPF,oxidative stress,resulted,C0242606,Oxidative stress,12111,"4,4'-Methylenediphenol","4,4'-Methylenediphenol",result
1664,19467,35204295," At the molecular level, bisphenol A (BPA) causes an increased production of ROS and hence a change in the redox balance, mitochondrial dysfunction, and modulation of cell signaling pathways.","['bisphenol A', 'BPA']",['increased production of ROS'],True,bisphenol A,increased production of ROS,causes,C4476796,Increased reactive oxygen species production,6623,Bisphenol A,Bisphenol A,cause
1665,19469,35199549,"Until now, several negative effects of bisphenol A were associated with reduced weight testes, histological alterations, impairment spermatogenesis, and steroidogenesis as well as with testes or prostate cancer.",['bisphenol A'],"['reduced weight testes', 'impairment spermatogenesis', 'steroidogenesis', 'cancer']",True,bisphenol A,impairment spermatogenesis,associated,C0520933,Abnormal spermatogenesis,6623,Bisphenol A,Bisphenol A,associate
1666,19469,35199549,"Until now, several negative effects of bisphenol A were associated with reduced weight testes, histological alterations, impairment spermatogenesis, and steroidogenesis as well as with testes or prostate cancer.",['bisphenol A'],"['reduced weight testes', 'impairment spermatogenesis', 'steroidogenesis', 'cancer']",True,bisphenol A,cancer,associated,C0006826,Cancer,6623,Bisphenol A,Bisphenol A,associate
1667,19511,31629899,  Benzyl butyl phthalate (BBP) triggers the malignancy of acute myeloid leukemia cells via upregulation of PDK4.,['Benzyl butyl phthalate'],"['malignancy of acute myeloid leukemia cells', 'upregulation of PDK4']",True,Benzyl butyl phthalate,malignancy of acute myeloid leukemia cells,triggers,C0023467,Acute myelogenous leukemia,2347,Benzyl Butyl Phthalate,Benzyl Butyl Phthalate,trigger
1668,19511,31629899,  Benzyl butyl phthalate (BBP) triggers the malignancy of acute myeloid leukemia cells via upregulation of PDK4.,['Benzyl butyl phthalate'],"['malignancy of acute myeloid leukemia cells', 'upregulation of PDK4']",True,Benzyl butyl phthalate,upregulation of PDK4,triggers,C4531237,Abnormal CD69 upregulation upon TCR activation,2347,Benzyl Butyl Phthalate,Benzyl Butyl Phthalate,trigger
1669,19572,35218575,"The ectopic expression of the human ALDH1A1 gene caused increase in hepatocyte proliferation and decrease in hepatic necrosis, oxidative stress, ECM remodeling, and inflammation  during ethanol/CCl4 -induced liver damage.",['ethanol/CCl4'],"['increase in hepatocyte proliferation', 'decrease in hepatic necrosis', 'oxidative stress', 'inflammation']",True,ethanol/CCl4,decrease in hepatic necrosis,caused,C0151798,Hepatic necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethanol/CCl4,cause
1670,19572,35218575,"The ectopic expression of the human ALDH1A1 gene caused increase in hepatocyte proliferation and decrease in hepatic necrosis, oxidative stress, ECM remodeling, and inflammation  during ethanol/CCl4 -induced liver damage.",['ethanol/CCl4'],"['increase in hepatocyte proliferation', 'decrease in hepatic necrosis', 'oxidative stress', 'inflammation']",True,ethanol/CCl4,oxidative stress,caused,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethanol/CCl4,cause
1671,19572,35218575,"The ectopic expression of the human ALDH1A1 gene caused increase in hepatocyte proliferation and decrease in hepatic necrosis, oxidative stress, ECM remodeling, and inflammation  during ethanol/CCl4 -induced liver damage.",['ethanol/CCl4'],"['increase in hepatocyte proliferation', 'decrease in hepatic necrosis', 'oxidative stress', 'inflammation']",True,ethanol/CCl4,inflammation,caused,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ethanol/CCl4,cause
1672,19575,35215494,"In addition, naringenin increased the expression of the antiapoptoic cell marker, Bcl-2.",['naringenin'],['expression of the antiapoptoic cell marker'],True,naringenin,expression of the antiapoptoic cell marker,increased,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",naringenin,increase
1673,19580,35202708,"  Previously we found that acute liver injury (ALI) with inflammation caused by carbon tetrachloride (CCl4) was associated with the activation of the 5-HT degradation system (5DS), which includes monoamine oxidase A (MAO-A), the 5-HT2A  receptor, and 5-HT synthases in hepatocytes.","['carbon tetrachloride', 'CCl4)']","['acute liver injury', 'inflammation', 'monoamine oxidase A']",True,carbon tetrachloride,inflammation,associated,C3875321,Skin inflammation,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,associate
1674,19580,35202708,"  Previously we found that acute liver injury (ALI) with inflammation caused by carbon tetrachloride (CCl4) was associated with the activation of the 5-HT degradation system (5DS), which includes monoamine oxidase A (MAO-A), the 5-HT2A  receptor, and 5-HT synthases in hepatocytes.","['carbon tetrachloride', 'CCl4)']","['acute liver injury', 'inflammation', 'monoamine oxidase A']",True,CCl4),inflammation,associated,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CCl4),associate
1675,19613,35107114,"LDFP can inhibit the activity of ALT, AST, TC, TG, tumor necrosis factor (TNF-α), and interleukin-6 (IL-6) in serum; significantly improve the inflammatory state of the liver; increase the activity of superoxide dismutase (SOD) and the glutathione (GSH) content; decrease the malondialdehyde (MDA) content; alleviate the toxicity caused by reactive oxygen species; and alleviate  liver injury.","['LDFP', 'glutathione', 'oxygen']","['tumor necrosis factor', 'inflammatory state of the liver', 'increase the activity of superoxide dismutase (SOD)', 'decrease the malondialdehyde (MDA) content']",True,glutathione,tumor necrosis factor,inhibit,C4023529,Abnormality of tumor necrosis factor secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione,inhibit
1676,19613,35107114,"LDFP can inhibit the activity of ALT, AST, TC, TG, tumor necrosis factor (TNF-α), and interleukin-6 (IL-6) in serum; significantly improve the inflammatory state of the liver; increase the activity of superoxide dismutase (SOD) and the glutathione (GSH) content; decrease the malondialdehyde (MDA) content; alleviate the toxicity caused by reactive oxygen species; and alleviate  liver injury.","['LDFP', 'glutathione', 'oxygen']","['tumor necrosis factor', 'inflammatory state of the liver', 'increase the activity of superoxide dismutase (SOD)', 'decrease the malondialdehyde (MDA) content']",True,glutathione,inflammatory state of the liver,inhibit,C4023529,Abnormality of tumor necrosis factor secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione,inhibit
1677,19613,35107114,"LDFP can inhibit the activity of ALT, AST, TC, TG, tumor necrosis factor (TNF-α), and interleukin-6 (IL-6) in serum; significantly improve the inflammatory state of the liver; increase the activity of superoxide dismutase (SOD) and the glutathione (GSH) content; decrease the malondialdehyde (MDA) content; alleviate the toxicity caused by reactive oxygen species; and alleviate  liver injury.","['LDFP', 'glutathione', 'oxygen']","['tumor necrosis factor', 'inflammatory state of the liver', 'increase the activity of superoxide dismutase (SOD)', 'decrease the malondialdehyde (MDA) content']",True,glutathione,increase the activity of superoxide dismutase,inhibit,C4023529,Abnormality of tumor necrosis factor secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione,inhibit
1678,19613,35107114,"LDFP can inhibit the activity of ALT, AST, TC, TG, tumor necrosis factor (TNF-α), and interleukin-6 (IL-6) in serum; significantly improve the inflammatory state of the liver; increase the activity of superoxide dismutase (SOD) and the glutathione (GSH) content; decrease the malondialdehyde (MDA) content; alleviate the toxicity caused by reactive oxygen species; and alleviate  liver injury.","['LDFP', 'glutathione', 'oxygen']","['tumor necrosis factor', 'inflammatory state of the liver', 'increase the activity of superoxide dismutase (SOD)', 'decrease the malondialdehyde (MDA) content']",True,glutathione,decrease the malondialdehyde,inhibit,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione,inhibit
1679,19613,35107114,"LDFP can inhibit the activity of ALT, AST, TC, TG, tumor necrosis factor (TNF-α), and interleukin-6 (IL-6) in serum; significantly improve the inflammatory state of the liver; increase the activity of superoxide dismutase (SOD) and the glutathione (GSH) content; decrease the malondialdehyde (MDA) content; alleviate the toxicity caused by reactive oxygen species; and alleviate  liver injury.","['LDFP', 'glutathione', 'oxygen']","['tumor necrosis factor', 'inflammatory state of the liver', 'increase the activity of superoxide dismutase (SOD)', 'decrease the malondialdehyde (MDA) content']",True,oxygen,tumor necrosis factor,inhibit,C4023529,Abnormality of tumor necrosis factor secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,inhibit
1680,19613,35107114,"LDFP can inhibit the activity of ALT, AST, TC, TG, tumor necrosis factor (TNF-α), and interleukin-6 (IL-6) in serum; significantly improve the inflammatory state of the liver; increase the activity of superoxide dismutase (SOD) and the glutathione (GSH) content; decrease the malondialdehyde (MDA) content; alleviate the toxicity caused by reactive oxygen species; and alleviate  liver injury.","['LDFP', 'glutathione', 'oxygen']","['tumor necrosis factor', 'inflammatory state of the liver', 'increase the activity of superoxide dismutase (SOD)', 'decrease the malondialdehyde (MDA) content']",True,oxygen,inflammatory state of the liver,inhibit,C4023529,Abnormality of tumor necrosis factor secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,inhibit
1681,19613,35107114,"LDFP can inhibit the activity of ALT, AST, TC, TG, tumor necrosis factor (TNF-α), and interleukin-6 (IL-6) in serum; significantly improve the inflammatory state of the liver; increase the activity of superoxide dismutase (SOD) and the glutathione (GSH) content; decrease the malondialdehyde (MDA) content; alleviate the toxicity caused by reactive oxygen species; and alleviate  liver injury.","['LDFP', 'glutathione', 'oxygen']","['tumor necrosis factor', 'inflammatory state of the liver', 'increase the activity of superoxide dismutase (SOD)', 'decrease the malondialdehyde (MDA) content']",True,oxygen,increase the activity of superoxide dismutase,inhibit,C4023529,Abnormality of tumor necrosis factor secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,inhibit
1682,19613,35107114,"LDFP can inhibit the activity of ALT, AST, TC, TG, tumor necrosis factor (TNF-α), and interleukin-6 (IL-6) in serum; significantly improve the inflammatory state of the liver; increase the activity of superoxide dismutase (SOD) and the glutathione (GSH) content; decrease the malondialdehyde (MDA) content; alleviate the toxicity caused by reactive oxygen species; and alleviate  liver injury.","['LDFP', 'glutathione', 'oxygen']","['tumor necrosis factor', 'inflammatory state of the liver', 'increase the activity of superoxide dismutase (SOD)', 'decrease the malondialdehyde (MDA) content']",True,oxygen,decrease the malondialdehyde,inhibit,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,inhibit
1683,19677,34964416," RESULTS: The application of CCl4 led to tubular necrosis, inflammation, vascular  congestion, and increased Serum BUN and creatinine values.",['CCl4'],"['tubular necrosis', 'inflammation', 'vascular  congestion', 'increased Serum BUN and creatinine values']",True,CCl4,tubular necrosis,led,C0022672,Acute tubular necrosis,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,lead
1684,19677,34964416," RESULTS: The application of CCl4 led to tubular necrosis, inflammation, vascular  congestion, and increased Serum BUN and creatinine values.",['CCl4'],"['tubular necrosis', 'inflammation', 'vascular  congestion', 'increased Serum BUN and creatinine values']",True,CCl4,inflammation,led,C3875321,Skin inflammation,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,lead
1685,19677,34964416," RESULTS: The application of CCl4 led to tubular necrosis, inflammation, vascular  congestion, and increased Serum BUN and creatinine values.",['CCl4'],"['tubular necrosis', 'inflammation', 'vascular  congestion', 'increased Serum BUN and creatinine values']",True,CCl4,vascular  congestion,led,C1761613,Conjunctival vascular congestion,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,lead
1686,19677,34964416," RESULTS: The application of CCl4 led to tubular necrosis, inflammation, vascular  congestion, and increased Serum BUN and creatinine values.",['CCl4'],"['tubular necrosis', 'inflammation', 'vascular  congestion', 'increased Serum BUN and creatinine values']",True,CCl4,increased Serum BUN and creatinine values,led,C0700225,High blood creatinine level,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,lead
1687,19682,34946608,"  Carbon tetrachloride (CCL4) induces oxidative stress by free radical toxicities,  inflammation, and neurotoxicity.",['Carbon tetrachloride'],"['oxidative stress', 'inflammation', 'neurotoxicity']",True,Carbon tetrachloride,oxidative stress,induces,C0242606,Oxidative stress,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,induce
1688,19682,34946608,"  Carbon tetrachloride (CCL4) induces oxidative stress by free radical toxicities,  inflammation, and neurotoxicity.",['Carbon tetrachloride'],"['oxidative stress', 'inflammation', 'neurotoxicity']",True,Carbon tetrachloride,inflammation,induces,C3875321,Skin inflammation,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,induce
1689,19736,35261172,"  Reactive oxygen species (ROS) exposure triggers granulosa cells' (GCs) senescence, which is an important causal factor for premature ovarian failure (POF).",['oxygen'],['premature ovarian failure'],True,oxygen,premature ovarian failure,triggers,C0025322,Climacterium praecox,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,trigger
1690,19757,35241369,  PURPOSE: The primary objective of this study was to investigate the potential protective effect of Vitamin D (Vit D) on DOX induced cardio toxicity (DIC) in early breast cancer patients receiving adjuvant DOX based chemotherapy (AC).,"['DOX', 'DOX']",['cancer'],True,DOX,cancer,induced,C0006826,Cancer,31703,Doxorubicin,Doxorubicin,induce
1691,19764,35237692, Methods: Spermatogenesis disorder was induced in male mice with CPA (cyclophosphamide).,"['CPA', 'cyclophosphamide']",['Spermatogenesis disorder'],True,CPA,Spermatogenesis disorder,induced,C0520933,Abnormal spermatogenesis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CPA,induce
1692,19764,35237692, Methods: Spermatogenesis disorder was induced in male mice with CPA (cyclophosphamide).,"['CPA', 'cyclophosphamide']",['Spermatogenesis disorder'],True,cyclophosphamide,Spermatogenesis disorder,induced,C0520933,Abnormal spermatogenesis,2907,Cyclophosphamide,Cyclophosphamide,induce
1693,19768,35237305,"High doses of PEG-asparaginase are associated with side effects such as hepatotoxicity, pancreatitis, venous thrombosis, hypersensitivity reactions against the drug and severe hypertriglyceridemia.",['PEG-asparaginase'],"['hepatotoxicity', 'pancreatitis', 'venous thrombosis', 'hypersensitivity reactions', 'hypertriglyceridemia']",True,PEG-asparaginase,pancreatitis,associated,C0030305,Pancreatitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PEG-asparaginase,associate
1694,19768,35237305,"High doses of PEG-asparaginase are associated with side effects such as hepatotoxicity, pancreatitis, venous thrombosis, hypersensitivity reactions against the drug and severe hypertriglyceridemia.",['PEG-asparaginase'],"['hepatotoxicity', 'pancreatitis', 'venous thrombosis', 'hypersensitivity reactions', 'hypertriglyceridemia']",True,PEG-asparaginase,venous thrombosis,associated,C0042487,Venous thrombosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PEG-asparaginase,associate
1695,19768,35237305,"High doses of PEG-asparaginase are associated with side effects such as hepatotoxicity, pancreatitis, venous thrombosis, hypersensitivity reactions against the drug and severe hypertriglyceridemia.",['PEG-asparaginase'],"['hepatotoxicity', 'pancreatitis', 'venous thrombosis', 'hypersensitivity reactions', 'hypertriglyceridemia']",True,PEG-asparaginase,hypersensitivity reactions,associated,C0042487,Venous thrombosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PEG-asparaginase,associate
1696,19768,35237305,"High doses of PEG-asparaginase are associated with side effects such as hepatotoxicity, pancreatitis, venous thrombosis, hypersensitivity reactions against the drug and severe hypertriglyceridemia.",['PEG-asparaginase'],"['hepatotoxicity', 'pancreatitis', 'venous thrombosis', 'hypersensitivity reactions', 'hypertriglyceridemia']",True,PEG-asparaginase,hypertriglyceridemia,associated,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PEG-asparaginase,associate
1697,19815,34856006,"After exclusion of olmesartan (to minimize a notoriety bias), two ARBs  were significantly associated with diarrhea: eprosartan (ROR = 1.93 (1.32-2.72) and telmisartan (ROR = 1.41 (1.23-1.62) but not the six others.","['olmesartan', 'eprosartan', 'telmisartan']",['diarrhea'],True,olmesartan,diarrhea,associated,C0011991,Diarrhoea,158781,5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid,5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid,associate
1698,19815,34856006,"After exclusion of olmesartan (to minimize a notoriety bias), two ARBs  were significantly associated with diarrhea: eprosartan (ROR = 1.93 (1.32-2.72) and telmisartan (ROR = 1.41 (1.23-1.62) but not the six others.","['olmesartan', 'eprosartan', 'telmisartan']",['diarrhea'],True,eprosartan,diarrhea,associated,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",eprosartan,associate
1699,19815,34856006,"After exclusion of olmesartan (to minimize a notoriety bias), two ARBs  were significantly associated with diarrhea: eprosartan (ROR = 1.93 (1.32-2.72) and telmisartan (ROR = 1.41 (1.23-1.62) but not the six others.","['olmesartan', 'eprosartan', 'telmisartan']",['diarrhea'],True,telmisartan,diarrhea,associated,C0011991,Diarrhoea,65999,Telmisartan,Telmisartan,associate
1700,19820,34834171,"By releasing 20% of the loaded telmisartan in 30 days, these hybrid biodegradable/stent telmisartan-loaded nanofibers increased the migration of endothelial progenitor cells in vitro, promoted endothelialization, and reduced intimal hyperplasia.",['telmisartan'],"['migration of endothelial progenitor cells', 'promoted endothelialization', 'reduced intimal hyperplasia']",True,telmisartan,migration of endothelial progenitor cells,increased,C0011991,Diarrhoea,65999,Telmisartan,Telmisartan,increase
1701,19820,34834171,"By releasing 20% of the loaded telmisartan in 30 days, these hybrid biodegradable/stent telmisartan-loaded nanofibers increased the migration of endothelial progenitor cells in vitro, promoted endothelialization, and reduced intimal hyperplasia.",['telmisartan'],"['migration of endothelial progenitor cells', 'promoted endothelialization', 'reduced intimal hyperplasia']",True,telmisartan,promoted endothelialization,increased,C0011991,Diarrhoea,65999,Telmisartan,Telmisartan,increase
1702,19839,34594226,Acute exposure of db/db mice to a telmisartan dose equivalent to therapeutic doses in humans resulted in lower blood glucose and increased plasma insulin concentration in OGTT.,['telmisartan'],"['lower blood glucose', 'increased plasma insulin concentration']",True,telmisartan,lower blood glucose,resulted,C0020456,High blood sugar,65999,Telmisartan,Telmisartan,result
1703,19847,34522111,"Multivariate analysis showed that the consumption of ACE-I or ARB was not associated with a decrease/constant  of UACR or increase potassium level, even after adjusting by confounding variables.",['ARB'],['increase potassium level'],True,ARB,increase potassium level,associated,C1846351,Increased urinary potassium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ARB,associate
1704,19872,34343694,"Compared to amlodipine monotherapy, the addition of moderate-intensity statin resulted in a significantly greater percentage reduction of systolic blood pressure (-2.22%, 95% confidence intervals: [-3.82 to -0.62]).",['amlodipine'],['systolic blood pressure'],True,amlodipine,systolic blood pressure,resulted,C0277885,Decreased systolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amlodipine,result
1705,19873,34343694,"Combined high-intensity statin and amlodipine lead to significant increase of high-density lipoprotein cholesterol (8.34%, 95% confidence intervals: [0.73 to 15.95]), while effective triglyceride reduction was achieved by adding amlodipine and telmisartan to high-intensity statin (-14.68%, 95% confidence intervals: [-28.48  to -0.89]).","['amlodipine', 'amlodipine', 'telmisartan']","['increase of high-density lipoprotein cholesterol', 'effective triglyceride reduction']",True,amlodipine,increase of high-density lipoprotein cholesterol,lead,C0151691,Decreased HDL cholesterol concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amlodipine,lead
1706,19873,34343694,"Combined high-intensity statin and amlodipine lead to significant increase of high-density lipoprotein cholesterol (8.34%, 95% confidence intervals: [0.73 to 15.95]), while effective triglyceride reduction was achieved by adding amlodipine and telmisartan to high-intensity statin (-14.68%, 95% confidence intervals: [-28.48  to -0.89]).","['amlodipine', 'amlodipine', 'telmisartan']","['increase of high-density lipoprotein cholesterol', 'effective triglyceride reduction']",True,amlodipine,effective triglyceride reduction,lead,C0151691,Decreased HDL cholesterol concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amlodipine,lead
1707,19873,34343694,"Combined high-intensity statin and amlodipine lead to significant increase of high-density lipoprotein cholesterol (8.34%, 95% confidence intervals: [0.73 to 15.95]), while effective triglyceride reduction was achieved by adding amlodipine and telmisartan to high-intensity statin (-14.68%, 95% confidence intervals: [-28.48  to -0.89]).","['amlodipine', 'amlodipine', 'telmisartan']","['increase of high-density lipoprotein cholesterol', 'effective triglyceride reduction']",True,amlodipine,increase of high-density lipoprotein cholesterol,lead,C0151691,Decreased HDL cholesterol concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amlodipine,lead
1708,19873,34343694,"Combined high-intensity statin and amlodipine lead to significant increase of high-density lipoprotein cholesterol (8.34%, 95% confidence intervals: [0.73 to 15.95]), while effective triglyceride reduction was achieved by adding amlodipine and telmisartan to high-intensity statin (-14.68%, 95% confidence intervals: [-28.48  to -0.89]).","['amlodipine', 'amlodipine', 'telmisartan']","['increase of high-density lipoprotein cholesterol', 'effective triglyceride reduction']",True,amlodipine,effective triglyceride reduction,lead,C0151691,Decreased HDL cholesterol concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amlodipine,lead
1709,19873,34343694,"Combined high-intensity statin and amlodipine lead to significant increase of high-density lipoprotein cholesterol (8.34%, 95% confidence intervals: [0.73 to 15.95]), while effective triglyceride reduction was achieved by adding amlodipine and telmisartan to high-intensity statin (-14.68%, 95% confidence intervals: [-28.48  to -0.89]).","['amlodipine', 'amlodipine', 'telmisartan']","['increase of high-density lipoprotein cholesterol', 'effective triglyceride reduction']",True,telmisartan,increase of high-density lipoprotein cholesterol,lead,C0151691,Decreased HDL cholesterol concentration,65999,Telmisartan,Telmisartan,lead
1710,19873,34343694,"Combined high-intensity statin and amlodipine lead to significant increase of high-density lipoprotein cholesterol (8.34%, 95% confidence intervals: [0.73 to 15.95]), while effective triglyceride reduction was achieved by adding amlodipine and telmisartan to high-intensity statin (-14.68%, 95% confidence intervals: [-28.48  to -0.89]).","['amlodipine', 'amlodipine', 'telmisartan']","['increase of high-density lipoprotein cholesterol', 'effective triglyceride reduction']",True,telmisartan,effective triglyceride reduction,lead,C0151691,Decreased HDL cholesterol concentration,65999,Telmisartan,Telmisartan,lead
1711,19890,34280191, CONCLUSIONS: The current study suggests that telmisartan use in hypertensive T2DM patients may be associated with a lower risk of dementia and any IS events in an  East-Asian population.,['telmisartan'],['dementia'],True,telmisartan,dementia,associated,C0497327,"Dementia, progressive",65999,Telmisartan,Telmisartan,associate
1712,19913,15629863,"Upregulation of GSH  is primarily caused by oxidative stress in the form of hydrogen peroxide generation, and both GSH upregulation and the rate of H(2)O(2) generation correlate well with the cytotoxicity.",['hydrogen peroxide'],['oxidative stress'],True,hydrogen peroxide,oxidative stress,caused,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydrogen peroxide,cause
1713,20116,22495295,"This successfully rescued the phenotype of the knockout mice including reduced birth rates, tissue iron overload, splenomegaly, anemia, leukocytosis, dendritic cell abnormalities, and survival after acute kidney injury induced by rhabdomyolysis or cisplatin nephrotoxicity.",['cisplatin'],"['reduced birth rates', 'splenomegaly', 'anemia', 'leukocytosis', 'dendritic cell abnormalities', 'survival', 'acute kidney injury', 'rhabdomyolysis']",True,cisplatin,rhabdomyolysis,induced,C0035410,Breakdown of skeletal muscle,5702198,azane;dichloroplatinum,azane;dichloroplatinum,induce
1714,20176,34820970,"On the other hand, individual treatment with probiotic exhibited highest serum levels of IL-10 and IgM, while diclazuril alone increased the blood concentrations of IL-10 and decreased the levels of IFN-γ compared to control positive group; however, there  was no significant effect of Prob on IFN-γ, Dic on IgM and all groups on interleukin-17.",['diclazuril alone'],['decreased the levels of IFN-γ'],True,diclazuril alone,decreased the levels of IFN-γ,increased,C4280714,Decreased level of tissue plasminogen activator,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",diclazuril alone,increase
1715,20242,35285362,"Besides, the micelle could increase the retention and release of EMO in colonic ulcers through multi-stage targeting, improve oral bioavailability, regulate the expression of inflammatory  factors and repair damaged tissues, which helped us to achieve the design goal of integrated diagnosis and treatment of UC.",['EMO'],"['colonic ulcers', 'expression of inflammatory  factors']",True,EMO,colonic ulcers,increase,C0267491,Colon ulcer,3220,Emodin,Emodin,increase
1716,20242,35285362,"Besides, the micelle could increase the retention and release of EMO in colonic ulcers through multi-stage targeting, improve oral bioavailability, regulate the expression of inflammatory  factors and repair damaged tissues, which helped us to achieve the design goal of integrated diagnosis and treatment of UC.",['EMO'],"['colonic ulcers', 'expression of inflammatory  factors']",True,EMO,expression of inflammatory  factors and repair damaged tissues,increase,C0267491,Colon ulcer,3220,Emodin,Emodin,increase
1717,20279,35002735," Compared with control rats, the levels of creatinine, urea, uric acid, total cholesterol, triglyceride, and low-density lipoprotein cholesterol in serum were  significantly increased in the adenine-induced CRF rats.",['cholesterol'],['levels of creatinine'],True,cholesterol,levels of creatinine,increased,C4021101,Abnormal circulating creatinine level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholesterol,increase
1718,20280,35002735,"This study first demonstrated that SKI and its major components protected against renal fibrosis by inhibiting  oxidative stress and inflammation via simultaneous targeting IƙB/NF-ƙB and Keap1/Nrf2 signaling pathways, which illuminated the potential molecular mechanism of anti-oxidative and anti-inflammatory effects of SKI.",['SKI'],"['renal fibrosis', 'inflammation']",True,SKI,renal fibrosis,inhibiting,C0151650,Renal fibrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",SKI,inhibit
1719,20280,35002735,"This study first demonstrated that SKI and its major components protected against renal fibrosis by inhibiting  oxidative stress and inflammation via simultaneous targeting IƙB/NF-ƙB and Keap1/Nrf2 signaling pathways, which illuminated the potential molecular mechanism of anti-oxidative and anti-inflammatory effects of SKI.",['SKI'],"['renal fibrosis', 'inflammation']",True,SKI,oxidative stress,inhibiting,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",SKI,inhibit
1720,20280,35002735,"This study first demonstrated that SKI and its major components protected against renal fibrosis by inhibiting  oxidative stress and inflammation via simultaneous targeting IƙB/NF-ƙB and Keap1/Nrf2 signaling pathways, which illuminated the potential molecular mechanism of anti-oxidative and anti-inflammatory effects of SKI.",['SKI'],"['renal fibrosis', 'inflammation']",True,SKI,inflammation,inhibiting,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",SKI,inhibit
1721,20294,34974127,"The addition of ascorbate to Fe(III)-Dp44mT substantially increased the peroxidation of micelles and bicelles, with the Fe(III)-Dp44mT complex being reduced by ascorbate to the Fe(II) state, explaining the increased reactivity.",['ascorbate'],"['peroxidation', 'increased reactivity']",True,ascorbate,increased reactivity,increased,C4025637,Increased phosphoribosylpyrophosphate synthetase activity,54670067,Ascorbic Acid,Ascorbic Acid,increase
1722,20320,34891117,Examination of the antiobesity effects of HAQs in 3T3-L1 adipocytes and high-fat diet (HFD)-induced obese rats showed that these anthraquinone compounds inhibited lipid accumulation in 3T3-L1 cells before and after differentiation.,['anthraquinone'],['lipid accumulation'],True,anthraquinone,lipid accumulation,inhibited,C1837262,Increased muscle lipid content,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",anthraquinone,inhibit
1723,20378,3764920,"These results show that a near-lethal dose of TET produced a reversible syndrome of hypoactivity, aphagia, and weight loss similar  to that seen after acute TMT; in the absence of the above signs, diurnal patterns of behavior revealed effects of TET at doses as low as 1.5 mg/kg; the magnitude of the effect depended on the time of day at which the response was measured; and TET did not produce the same effects on ingestive behaviors (polydipsia and reduced feeding efficiency) that were previously observed after acute TMT.",['TET'],"['aphagia', 'weight loss', 'reduced feeding efficiency']",True,TET,weight loss,produced,C1262477,Weight loss,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",TET,produce
1724,20405,1092646,"However, since a depression of mitochondrial function by catabolite repression did not result in sensitization to antimycin, alteration of the mitochondrial membrane does not appear to be responsible for resistance to mitochondrial inhibition.",['antimycin'],['depression'],True,antimycin,depression,result,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",antimycin,result
1725,20408,35304324,"  Cyclosporin A (CsA) induced nephrotoxicity i.e., renal fibrosis is a critical clinical problem in renal transplant patients, in which chronic inflammatory response is the major cause.",['Cyclosporin'],"['induced nephrotoxicity i.e.,', 'renal fibrosis', 'inflammatory response']",True,Cyclosporin,renal fibrosis,induced,C0151650,Renal fibrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Cyclosporin,induce
1726,20408,35304324,"  Cyclosporin A (CsA) induced nephrotoxicity i.e., renal fibrosis is a critical clinical problem in renal transplant patients, in which chronic inflammatory response is the major cause.",['Cyclosporin'],"['induced nephrotoxicity i.e.,', 'renal fibrosis', 'inflammatory response']",True,Cyclosporin,inflammatory response,induced,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Cyclosporin,induce
1727,20419,35216981,"Ecological risk analysis suggested that DDTs and HCHs  in soils would not lead to an adverse effect on soil ecological environment as well as agricultural production, and OCP residues in sediments also would not pose a threat to the sediment-dwelling organisms.",['HCHs  '],['OCP residues'],True,HCHs,OCP residues,lead,C0028768,Obsessive compulsive disorder,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",HCHs,lead
1728,20452,34759603," Results: Three OC pesticides and one organophosphate pesticide were strongly associated with increasing blood sugar levels after adjusting for age, sex, and body mass index - lindane (OR 4.95, 95% CI 1.03-23.73), DDT o, p' (OR 3.50, 95% CI 1.04-11.73), dimethoate (OR 19.31, 95% CI 4.22-88.37), and dichlorvas (OR 6.33, 95% CI 1.28-31.18).","['DDT', 'dimethoate']","['increasing blood sugar levels', 'body mass index - lindane']",True,DDT,increasing blood sugar levels,associated,C0020615,Hypoglycaemia,3036,Clofenotane,Clofenotane,associate
1729,20452,34759603," Results: Three OC pesticides and one organophosphate pesticide were strongly associated with increasing blood sugar levels after adjusting for age, sex, and body mass index - lindane (OR 4.95, 95% CI 1.03-23.73), DDT o, p' (OR 3.50, 95% CI 1.04-11.73), dimethoate (OR 19.31, 95% CI 4.22-88.37), and dichlorvas (OR 6.33, 95% CI 1.28-31.18).","['DDT', 'dimethoate']","['increasing blood sugar levels', 'body mass index - lindane']",True,DDT,body mass index - lindane,associated,C0020615,Hypoglycaemia,3036,Clofenotane,Clofenotane,associate
1730,20452,34759603," Results: Three OC pesticides and one organophosphate pesticide were strongly associated with increasing blood sugar levels after adjusting for age, sex, and body mass index - lindane (OR 4.95, 95% CI 1.03-23.73), DDT o, p' (OR 3.50, 95% CI 1.04-11.73), dimethoate (OR 19.31, 95% CI 4.22-88.37), and dichlorvas (OR 6.33, 95% CI 1.28-31.18).","['DDT', 'dimethoate']","['increasing blood sugar levels', 'body mass index - lindane']",True,dimethoate,increasing blood sugar levels,associated,C0020615,Hypoglycaemia,3082,2-dimethoxyphosphinothioylsulfanyl-N-methylacetamide,2-dimethoxyphosphinothioylsulfanyl-N-methylacetamide,associate
1731,20452,34759603," Results: Three OC pesticides and one organophosphate pesticide were strongly associated with increasing blood sugar levels after adjusting for age, sex, and body mass index - lindane (OR 4.95, 95% CI 1.03-23.73), DDT o, p' (OR 3.50, 95% CI 1.04-11.73), dimethoate (OR 19.31, 95% CI 4.22-88.37), and dichlorvas (OR 6.33, 95% CI 1.28-31.18).","['DDT', 'dimethoate']","['increasing blood sugar levels', 'body mass index - lindane']",True,dimethoate,body mass index - lindane,associated,C0020615,Hypoglycaemia,3082,2-dimethoxyphosphinothioylsulfanyl-N-methylacetamide,2-dimethoxyphosphinothioylsulfanyl-N-methylacetamide,associate
1732,20455,34700204,"Dose-response meta-analysis suggested a non-linear relation between p,p'-DDE and T2D. Exposure to p,p'-DDE was not associated with gestational diabetes (pooled OR = 1.01; 95%CI: 0.94, 1.09); similarly, p,p'-DDT was not associated with T2D (pooled OR = 1.03; 95%CI: 0.79, 1.35).","[""p'-DDE""]","['T2D.', 'gestational diabetes']",True,p'-DDE,gestational diabetes,associated,C0085207,Maternal diabetes,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",p'-DDE,associate
1733,20467,35247140,"Concretely, SY elevated the content of Se and increased GPX4 level in DLM-treated quail cerebrum.",['Se'],['increased GPX4 level'],True,Se,increased GPX4 level,elevated,C4477024,Increased NT-proBNP level,6326970,selenium,selenium,elevated
1734,20506,34782935,"As a  result, both P450 induction and constitutive overexpression were associated with  deltamethrin resistance.",['deltamethrin'],['constitutive overexpression'],True,deltamethrin,resistance,associated,C0021655,Insulin resistance,40585,Deltamethrin,Deltamethrin,associate
1735,20512,34668745,"Our findings  revealed significant alterations of Anopheles coluzzii microbiota associated with deltamethrin resistance, highlighting the potential for identification of novel microbial markers for insecticide resistance surveillance.",['deltamethrin'],['resistance'],True,deltamethrin,resistance,associated,C0021655,Insulin resistance,40585,Deltamethrin,Deltamethrin,associate
1736,20514,34668745,"Our results revealed significant alterations of Anopheles coluzzii microbiota associated with deltamethrin resistance, highlighting the potential for identification of novel microbial markers for surveillance and opportunities for designing innovative control techniques to prevent the further evolution and spread of insecticide resistance.",['deltamethrin'],['resistance'],True,deltamethrin,resistance,associated,C0021655,Insulin resistance,40585,Deltamethrin,Deltamethrin,associate
1737,20520,34608487,"In addition, the formulations azadirachtin did not reduce the parasitism and the emergence rate of the F0 generation, the same pesticides added to chlorantraniliprole, azadirachtin A+B (Agroneem 850 EC), and lufenuron did not cause reduction in parasitism and emergence rate of the F1 generation of D. longicaudata.","['azadirachtin', 'chlorantraniliprole', 'azadirachtin', 'lufenuron']","['emergence rate', 'emergence rate']",True,lufenuron,emergence rate,cause,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lufenuron,cause
1738,20521,34608487,"While pesticides chlorantraniliprole, azadirachtin formulations, bordeaux mixture, lufenuron, lime sulphur, and mancozeb do not cause lethal and sublethal effects for D. longicaudata adults.","['chlorantraniliprole', 'azadirachtin', 'lufenuron', 'lime', 'mancozeb']",['bordeaux'],True,chlorantraniliprole,bordeaux,cause,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chlorantraniliprole,cause
1739,20521,34608487,"While pesticides chlorantraniliprole, azadirachtin formulations, bordeaux mixture, lufenuron, lime sulphur, and mancozeb do not cause lethal and sublethal effects for D. longicaudata adults.","['chlorantraniliprole', 'azadirachtin', 'lufenuron', 'lime', 'mancozeb']",['bordeaux'],True,azadirachtin,bordeaux,cause,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azadirachtin,cause
1740,20521,34608487,"While pesticides chlorantraniliprole, azadirachtin formulations, bordeaux mixture, lufenuron, lime sulphur, and mancozeb do not cause lethal and sublethal effects for D. longicaudata adults.","['chlorantraniliprole', 'azadirachtin', 'lufenuron', 'lime', 'mancozeb']",['bordeaux'],True,lufenuron,bordeaux,cause,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lufenuron,cause
1741,20521,34608487,"While pesticides chlorantraniliprole, azadirachtin formulations, bordeaux mixture, lufenuron, lime sulphur, and mancozeb do not cause lethal and sublethal effects for D. longicaudata adults.","['chlorantraniliprole', 'azadirachtin', 'lufenuron', 'lime', 'mancozeb']",['bordeaux'],True,lime,bordeaux,cause,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lime,cause
1742,20521,34608487,"While pesticides chlorantraniliprole, azadirachtin formulations, bordeaux mixture, lufenuron, lime sulphur, and mancozeb do not cause lethal and sublethal effects for D. longicaudata adults.","['chlorantraniliprole', 'azadirachtin', 'lufenuron', 'lime', 'mancozeb']",['bordeaux'],True,mancozeb,bordeaux,cause,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mancozeb,cause
1743,20539,9191431," RESULTS: Intraperitoneal administration of L-ethionine caused liver steatosis, as established by liver triglyceride analysis, leading to a significant decrease in  the liver attenuation, from 69.2 +/- 2.4 to 27.8 +/- 12.0 HU.",['L-ethionine'],['liver steatosis'],True,L-ethionine,liver steatosis,caused,C2711227,Steatosis,25674,L-Ethionine,L-Ethionine,cause
1744,20551,8061431,"Mn-DPDP and Gd-BOPTA/dimeg increased the tumor-fatty liver C/N from -5.4 +/- 1.6 to -11.0 +/- 1.9 and -9.8 +/- 3.4, respectively (P < .001).",['Gd-BOPTA/dimeg'],['tumor-fatty liver C/N'],True,Gd-BOPTA/dimeg,tumor-fatty liver C/N,increased,C2711227,Steatosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Gd-BOPTA/dimeg,increase
1745,20576,3444119,"In both female and male mice, a single dose or three injections of DL- or L-ethionine caused increases in liver/body weight ratio, A/G ratio, GOT and GPT levels, and BSP retention.",['L-ethionine'],['increases in liver/body weight ratio'],True,L-ethionine,increases in liver/body weight ratio,caused,C0043094,Weight gain,25674,L-Ethionine,L-Ethionine,cause
1746,20595,3741696,Applying ethionine together with phenylalanine resulted in hyperphenylalaninemia and phenylketonuria.,['ethionine'],"['hyperphenylalaninemia', 'phenylketonuria']",True,ethionine,hyperphenylalaninemia,resulted,C0751435,Hyperphenylalaninemia,25674,L-Ethionine,L-Ethionine,result
1747,20596,3741696,"Ethionine only had a minimal effect  on body weight gain; however, the hyperphenylalaninemic condition induced by application of the high dosage of ethionine and phenylalanine induced severe loss of body weight.","['Ethionine', 'ethionine']","['body weight gain', 'loss of body weight']",True,ethionine,loss of body weight,induced,C1262477,Weight loss,25674,L-Ethionine,L-Ethionine,induce
1748,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,L-ethionine,acute steatosis,induce,C4025020,Acute hepatic steatosis,25674,L-Ethionine,L-Ethionine,induce
1749,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,L-ethionine,necrosis,induce,C0151798,Hepatic necrosis,25674,L-Ethionine,L-Ethionine,induce
1750,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,L-ethionine,steatosis,induce,C2711227,Steatosis,25674,L-Ethionine,L-Ethionine,induce
1751,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,L-ethionine,hepatic necrosis,induce,C0151798,Hepatic necrosis,25674,L-Ethionine,L-Ethionine,induce
1752,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,azaserine,acute steatosis,induce,C4025020,Acute hepatic steatosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azaserine,induce
1753,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,azaserine,necrosis,induce,C0151798,Hepatic necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azaserine,induce
1754,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,azaserine,steatosis,induce,C2711227,Steatosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azaserine,induce
1755,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,azaserine,hepatic necrosis,induce,C0151798,Hepatic necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",azaserine,induce
1756,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,carbon tetrachloride,acute steatosis,induce,C4025020,Acute hepatic steatosis,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,induce
1757,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,carbon tetrachloride,necrosis,induce,C0151798,Hepatic necrosis,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,induce
1758,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,carbon tetrachloride,steatosis,induce,C2711227,Steatosis,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,induce
1759,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,carbon tetrachloride,hepatic necrosis,induce,C0151798,Hepatic necrosis,5943,CARBON TETRACHLORIDE,CARBON TETRACHLORIDE,induce
1760,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,D-galactosamine,acute steatosis,induce,C4025020,Acute hepatic steatosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",D-galactosamine,induce
1761,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,D-galactosamine,necrosis,induce,C0151798,Hepatic necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",D-galactosamine,induce
1762,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,D-galactosamine,steatosis,induce,C2711227,Steatosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",D-galactosamine,induce
1763,20598,3526944," Ethanol and L-ethionine induce acute steatosis without necrosis, whereas azaserine, carbon tetrachloride, and D-galactosamine are known to produce steatosis with varying degrees of hepatic necrosis.","['L-ethionine', 'azaserine', 'carbon tetrachloride', 'D-galactosamine']","['acute steatosis', 'necrosis', 'steatosis', 'hepatic necrosis']",True,D-galactosamine,hepatic necrosis,induce,C0151798,Hepatic necrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",D-galactosamine,induce
1764,20625,6825206,"After a total of 20 weeks in culture, cells treated with 0.375 mM L-ethionine and cells treated with  0.2 mM L-AdoEt produced tumors following their injection into animals.",['L-ethionine'],['tumors'],True,L-ethionine,tumors,produced,C0022665,Renal neoplasia,25674,L-Ethionine,L-Ethionine,produce
1765,20632,6171338,Ethionine causes hepatic carcinoma in rats after prolonged feeding but is not a mutagen in the Ames test.,"['Ethionine', 'mutagen']",['hepatic carcinoma'],True,Ethionine,hepatic carcinoma,causes,C0007097,Carcinoma,25674,L-Ethionine,L-Ethionine,cause
1766,20632,6171338,Ethionine causes hepatic carcinoma in rats after prolonged feeding but is not a mutagen in the Ames test.,"['Ethionine', 'mutagen']",['hepatic carcinoma'],True,mutagen,hepatic carcinoma,causes,C0007097,Carcinoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mutagen,cause
1767,20671,35308525,"In addition to hepatic cell apoptosis and liver inflammation caused by oxidative stress during alcohol metabolism, intestinal microbiota disorders are also involved in the onset and development of ALD.",['alcohol'],"['hepatic cell apoptosis', 'liver inflammation', 'oxidative stress', 'intestinal microbiota disorders']",True,alcohol,oxidative stress,caused,C0242606,Oxidative stress,702,Ethanol,Ethanol,cause
1768,20750,33223173,  Postnatal exposure to DINP was associated with greater alterations of lipidomic markers for hepatic steatosis than DEHP in postweaning mice.,['DINP'],['hepatic steatosis'],True,DINP,hepatic steatosis,associated,C2711227,Steatosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DINP,associate
1769,20755,32759552,"In addition, the essential  oils produced significant reduction in acetylcholinesterase activity and induced  oxidative stress in the flies as evidenced by an increase in reactive oxygen species, thiol and thiobarbituric reactive substance levels, as well as catalase  activity.","['oxygen', 'thiol']","['reduction in acetylcholinesterase activity', 'increase in reactive']",True,oxygen,reduction in acetylcholinesterase activity,produced,C5209258,Reduced cholinesterase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,produce
1770,20755,32759552,"In addition, the essential  oils produced significant reduction in acetylcholinesterase activity and induced  oxidative stress in the flies as evidenced by an increase in reactive oxygen species, thiol and thiobarbituric reactive substance levels, as well as catalase  activity.","['oxygen', 'thiol']","['reduction in acetylcholinesterase activity', 'increase in reactive']",True,oxygen,oxidative stress,produced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,produce
1771,20755,32759552,"In addition, the essential  oils produced significant reduction in acetylcholinesterase activity and induced  oxidative stress in the flies as evidenced by an increase in reactive oxygen species, thiol and thiobarbituric reactive substance levels, as well as catalase  activity.","['oxygen', 'thiol']","['reduction in acetylcholinesterase activity', 'increase in reactive']",True,oxygen,increase in reactive,produced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,produce
1772,20755,32759552,"In addition, the essential  oils produced significant reduction in acetylcholinesterase activity and induced  oxidative stress in the flies as evidenced by an increase in reactive oxygen species, thiol and thiobarbituric reactive substance levels, as well as catalase  activity.","['oxygen', 'thiol']","['reduction in acetylcholinesterase activity', 'increase in reactive']",True,thiol,reduction in acetylcholinesterase activity,produced,C5209258,Reduced cholinesterase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiol,produce
1773,20755,32759552,"In addition, the essential  oils produced significant reduction in acetylcholinesterase activity and induced  oxidative stress in the flies as evidenced by an increase in reactive oxygen species, thiol and thiobarbituric reactive substance levels, as well as catalase  activity.","['oxygen', 'thiol']","['reduction in acetylcholinesterase activity', 'increase in reactive']",True,thiol,oxidative stress,produced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiol,produce
1774,20755,32759552,"In addition, the essential  oils produced significant reduction in acetylcholinesterase activity and induced  oxidative stress in the flies as evidenced by an increase in reactive oxygen species, thiol and thiobarbituric reactive substance levels, as well as catalase  activity.","['oxygen', 'thiol']","['reduction in acetylcholinesterase activity', 'increase in reactive']",True,thiol,increase in reactive,produced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiol,produce
1775,20755,32759552,"In addition, the essential  oils produced significant reduction in acetylcholinesterase activity and induced  oxidative stress in the flies as evidenced by an increase in reactive oxygen species, thiol and thiobarbituric reactive substance levels, as well as catalase  activity.","['oxygen', 'thiol']","['reduction in acetylcholinesterase activity', 'increase in reactive']",True,oxygen,oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,induce
1776,20755,32759552,"In addition, the essential  oils produced significant reduction in acetylcholinesterase activity and induced  oxidative stress in the flies as evidenced by an increase in reactive oxygen species, thiol and thiobarbituric reactive substance levels, as well as catalase  activity.","['oxygen', 'thiol']","['reduction in acetylcholinesterase activity', 'increase in reactive']",True,oxygen,increase in reactive,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,induce
1777,20755,32759552,"In addition, the essential  oils produced significant reduction in acetylcholinesterase activity and induced  oxidative stress in the flies as evidenced by an increase in reactive oxygen species, thiol and thiobarbituric reactive substance levels, as well as catalase  activity.","['oxygen', 'thiol']","['reduction in acetylcholinesterase activity', 'increase in reactive']",True,thiol,oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiol,induce
1778,20755,32759552,"In addition, the essential  oils produced significant reduction in acetylcholinesterase activity and induced  oxidative stress in the flies as evidenced by an increase in reactive oxygen species, thiol and thiobarbituric reactive substance levels, as well as catalase  activity.","['oxygen', 'thiol']","['reduction in acetylcholinesterase activity', 'increase in reactive']",True,thiol,increase in reactive,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiol,induce
1779,20778,34439561,"  It has been proven by several studies that Fusarium mycotoxins induce oxidative stress in animals, consequently inducing lipid peroxidation, which the glutathione system can neutralize.",['glutathione'],"['oxidative stress', 'lipid peroxidation']",True,glutathione,oxidative stress,induce,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione,induce
1780,20859,35080742,"Compared to therapy with furosemide alone, combination therapy resulted in significant reduction in body weight from 26.9 ± 10.3 kg to 24.8 ± 9.7 kg (p < 0.001).",['furosemide'],['reduction in body weight'],True,furosemide,reduction in body weight,resulted,C0043094,Weight gain,3440,Furosemide,Furosemide,result
1781,20864,35078204,Hypocalcemia likely produces corrected QT interval prolongation primarily through a calcium-dependent inactivation (CDI) mechanism on the L-type calcium channel (LTCC).,['calcium'],['Hypocalcemia'],True,calcium,Hypocalcemia,produces,C0020598,Hypocalcaemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,produce
1782,20868,35053747,"Hearing loss was induced by administration of kanamycin/furosemide and two BDNF treatments were performed: (1) by gelatin sponge (BDNF-GS) with acute cochlear implantation (CI), and (2) through a mini-osmotic pump (BDNF-OP) with chronic CI.",['kanamycin/furosemide'],"['Hearing loss', 'acute cochlear implantation']",True,kanamycin/furosemide,Hearing loss,induced,C1384666,Hearing loss,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",kanamycin/furosemide,induce
1783,20885,35022312,"  BACKGROUND: Treatment with the aminoglycoside antibiotic gentamicin can be associated with severe adverse effects, including renal Ca2+ wasting.","['aminoglycoside', 'gentamicin']",['wasting'],True,aminoglycoside,wasting,associated,C1846348,Renal potassium wasting,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aminoglycoside,associate
1784,20885,35022312,"  BACKGROUND: Treatment with the aminoglycoside antibiotic gentamicin can be associated with severe adverse effects, including renal Ca2+ wasting.","['aminoglycoside', 'gentamicin']",['wasting'],True,gentamicin,wasting,associated,C1846348,Renal potassium wasting,3467,Gentamicin,Gentamicin,associate
1785,20911,34930794,"Extreme premature neonates, supratherapeutic vancomycin trough levels, hypotension and furosemide use are associated with an increased incidence of vancomycin-induced nephrotoxicity.",['furosemide'],"['premature neonates', 'supratherapeutic vancomycin trough levels', 'hypotension', 'increased incidence of vancomycin-induced nephrotoxicity']",True,furosemide,hypotension,associated,C0020649,Hypotension,3440,Furosemide,Furosemide,associate
1786,20929,34852633,"Intravenous and oral nalfurafine produced a marked diuresis, antinatriuresis, antikaliuresis, and a decrease in mean arterial pressure.",['nalfurafine'],"['diuresis', 'antinatriuresis', 'antikaliuresis', 'decrease in mean arterial pressure']",True,nalfurafine,antikaliuresis,produced,C1846351,Increased urinary potassium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",nalfurafine,produce
1787,20929,34852633,"Intravenous and oral nalfurafine produced a marked diuresis, antinatriuresis, antikaliuresis, and a decrease in mean arterial pressure.",['nalfurafine'],"['diuresis', 'antinatriuresis', 'antikaliuresis', 'decrease in mean arterial pressure']",True,nalfurafine,decrease in mean arterial pressure,produced,C1840376,Elevated mean arterial pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",nalfurafine,produce
1788,20943,34850530,Different incidents associated with upper airway obstruction can produce an episode of NPPE.,['NPPE'],['upper airway obstruction'],True,NPPE,upper airway obstruction,produce,C0740852,Upper airway obstruction,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",NPPE,produce
1789,20944,34829321,"This condition is believed to be associated with oral iron intake,  antihypertensive drugs containing a sulfur moiety (i.e., hydralazine, furosemide), and several chronic diseases (i.e., hypertension, end-stage renal disease, diabetes).","['hydralazine', 'furosemide']","['hypertension', 'renal disease', 'diabetes']",True,hydralazine,hypertension,associated,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydralazine,associate
1790,20944,34829321,"This condition is believed to be associated with oral iron intake,  antihypertensive drugs containing a sulfur moiety (i.e., hydralazine, furosemide), and several chronic diseases (i.e., hypertension, end-stage renal disease, diabetes).","['hydralazine', 'furosemide']","['hypertension', 'renal disease', 'diabetes']",True,hydralazine,renal disease,associated,C0151747,Renal tubular disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydralazine,associate
1791,20944,34829321,"This condition is believed to be associated with oral iron intake,  antihypertensive drugs containing a sulfur moiety (i.e., hydralazine, furosemide), and several chronic diseases (i.e., hypertension, end-stage renal disease, diabetes).","['hydralazine', 'furosemide']","['hypertension', 'renal disease', 'diabetes']",True,hydralazine,diabetes,associated,C0085207,Maternal diabetes,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydralazine,associate
1792,20944,34829321,"This condition is believed to be associated with oral iron intake,  antihypertensive drugs containing a sulfur moiety (i.e., hydralazine, furosemide), and several chronic diseases (i.e., hypertension, end-stage renal disease, diabetes).","['hydralazine', 'furosemide']","['hypertension', 'renal disease', 'diabetes']",True,furosemide,hypertension,associated,C0020538,Systemic hypertension,3440,Furosemide,Furosemide,associate
1793,20944,34829321,"This condition is believed to be associated with oral iron intake,  antihypertensive drugs containing a sulfur moiety (i.e., hydralazine, furosemide), and several chronic diseases (i.e., hypertension, end-stage renal disease, diabetes).","['hydralazine', 'furosemide']","['hypertension', 'renal disease', 'diabetes']",True,furosemide,renal disease,associated,C0151747,Renal tubular disease,3440,Furosemide,Furosemide,associate
1794,20944,34829321,"This condition is believed to be associated with oral iron intake,  antihypertensive drugs containing a sulfur moiety (i.e., hydralazine, furosemide), and several chronic diseases (i.e., hypertension, end-stage renal disease, diabetes).","['hydralazine', 'furosemide']","['hypertension', 'renal disease', 'diabetes']",True,furosemide,diabetes,associated,C0085207,Maternal diabetes,3440,Furosemide,Furosemide,associate
1795,20946,34823036,"Furosemide, a common diuretic prescribed to treat hypertension and edema-associated conditions, induces systemic dehydration.",['Furosemide'],"['diuretic', 'hypertension']",True,Furosemide,hypertension,induces,C0020538,Systemic hypertension,3440,Furosemide,Furosemide,induce
1796,20956,34774248,"Conversely, denosumab, compared with zoledronic acid, is associated with a lower risk of HCM, both first episode  and recurrence, in patients with breast cancer and multiple myeloma.",['zoledronic acid'],['breast cancer'],True,zoledronic acid,breast cancer,associated,C0678222,Breast cancer,68740,(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid,(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid,associate
1797,20957,34768805,"SRBC-pulsed macrophages from mice treated with captopril combined with diuretics increased the secretion of antigen-specific antibodies by recipient B cells, while macrophages of mice treated with hydrochlorothiazide or  furosemide with captopril increased the number of antigen-specific B cells.","['captopril', 'hydrochlorothiazide', 'captopril']",['secretion of antigen-specific antibodies'],True,captopril,secretion of antigen-specific antibodies,increased,C0678222,Breast cancer,44093,(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid,(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid,increase
1798,20957,34768805,"SRBC-pulsed macrophages from mice treated with captopril combined with diuretics increased the secretion of antigen-specific antibodies by recipient B cells, while macrophages of mice treated with hydrochlorothiazide or  furosemide with captopril increased the number of antigen-specific B cells.","['captopril', 'hydrochlorothiazide', 'captopril']",['secretion of antigen-specific antibodies'],True,hydrochlorothiazide,secretion of antigen-specific antibodies,increased,C0678222,Breast cancer,3639,Hydrochlorothiazide,Hydrochlorothiazide,increase
1799,20957,34768805,"SRBC-pulsed macrophages from mice treated with captopril combined with diuretics increased the secretion of antigen-specific antibodies by recipient B cells, while macrophages of mice treated with hydrochlorothiazide or  furosemide with captopril increased the number of antigen-specific B cells.","['captopril', 'hydrochlorothiazide', 'captopril']",['secretion of antigen-specific antibodies'],True,captopril,secretion of antigen-specific antibodies,increased,C0678222,Breast cancer,44093,(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid,(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid,increase
1800,20985,27521834,"We conclude  that benserazide inhibits CBS activity and suppresses colon cancer cell proliferation and bioenergetics in vitro, and tumor growth in vivo.",['benserazide'],"['cancer cell proliferation', 'tumor growth']",True,benserazide,cancer cell proliferation,inhibits,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",benserazide,inhibit
1801,21016,19531491,"Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of  GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate.","['epigallocatechin gallate', 'gallate']",['hyperinsulinemia/hyperammonemia forms'],True,epigallocatechin gallate,hyperinsulinemia/hyperammonemia forms,inhibited,C0020459,Hyperinsulinemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",epigallocatechin gallate,inhibit
1802,21016,19531491,"Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of  GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate.","['epigallocatechin gallate', 'gallate']",['hyperinsulinemia/hyperammonemia forms'],True,gallate,hyperinsulinemia/hyperammonemia forms,inhibited,C0020459,Hyperinsulinemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",gallate,inhibit
1803,21018,18172196,"The FASII inhibitor hexachlorophene and the antibiotics, tetracycline and rifampicin, that  target the apicoplast inhibited LS development, identifying FASII and other pathways localized in the apicoplast as potential drug targets to prevent malaria infection.","['tetracycline', 'rifampicin']",['LS development'],True,tetracycline,LS development,inhibited,C0557874,Psychomotor developmental delay,54675776,Tetracycline,Tetracycline,inhibit
1804,21018,18172196,"The FASII inhibitor hexachlorophene and the antibiotics, tetracycline and rifampicin, that  target the apicoplast inhibited LS development, identifying FASII and other pathways localized in the apicoplast as potential drug targets to prevent malaria infection.","['tetracycline', 'rifampicin']",['LS development'],True,rifampicin,LS development,inhibited,C0557874,Psychomotor developmental delay,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rifampicin,inhibit
1805,21019,16797711,"On the other hand, conventional biochemical analyses have revealed that ethylene oxide, methyl bromide, and acrylamide inhibit creatine kinase (CK; an enzyme catalyzing the reaction: ATP+creatine<-->ADP+phosphocreatine) activities in the brain of animals.",['oxide'],['creatine kinase'],True,oxide,creatine kinase,inhibit,C0241005,Elevated serum creatine phosphokinase,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxide,inhibit
1806,21020,16076531,"Results for female HW indicated that some compounds caused spastic paralysis of contractile activity and inhibition of motility in culture (bephenium, DL-tetramisole, and pyrantel); some caused only spastic paralysis of contractile activity (methyridine and disophenol); and some  caused only inhibition of motility in culture (chlorpromazine, dithiazanine, 1-ethoxycarbonylmethyl-1-methylpyrrolidinium, and 4-methyltropolone).","['bephenium', 'DL-tetramisole', 'pyrantel', 'methyridine', 'disophenol', 'chlorpromazine', 'dithiazanine', '1-ethoxycarbonylmethyl-1-methylpyrrolidinium', '4-methyltropolone']","['spastic paralysis', 'inhibition of motility in', 'spastic paralysis', 'inhibition of motility in']",True,bephenium,spastic paralysis,caused,C0522224,Inability to move,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bephenium,cause
1807,21020,16076531,"Results for female HW indicated that some compounds caused spastic paralysis of contractile activity and inhibition of motility in culture (bephenium, DL-tetramisole, and pyrantel); some caused only spastic paralysis of contractile activity (methyridine and disophenol); and some  caused only inhibition of motility in culture (chlorpromazine, dithiazanine, 1-ethoxycarbonylmethyl-1-methylpyrrolidinium, and 4-methyltropolone).","['bephenium', 'DL-tetramisole', 'pyrantel', 'methyridine', 'disophenol', 'chlorpromazine', 'dithiazanine', '1-ethoxycarbonylmethyl-1-methylpyrrolidinium', '4-methyltropolone']","['spastic paralysis', 'inhibition of motility in', 'spastic paralysis', 'inhibition of motility in']",True,DL-tetramisole,spastic paralysis,caused,C0522224,Inability to move,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DL-tetramisole,cause
1808,21020,16076531,"Results for female HW indicated that some compounds caused spastic paralysis of contractile activity and inhibition of motility in culture (bephenium, DL-tetramisole, and pyrantel); some caused only spastic paralysis of contractile activity (methyridine and disophenol); and some  caused only inhibition of motility in culture (chlorpromazine, dithiazanine, 1-ethoxycarbonylmethyl-1-methylpyrrolidinium, and 4-methyltropolone).","['bephenium', 'DL-tetramisole', 'pyrantel', 'methyridine', 'disophenol', 'chlorpromazine', 'dithiazanine', '1-ethoxycarbonylmethyl-1-methylpyrrolidinium', '4-methyltropolone']","['spastic paralysis', 'inhibition of motility in', 'spastic paralysis', 'inhibition of motility in']",True,pyrantel,spastic paralysis,caused,C0522224,Inability to move,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pyrantel,cause
1809,21020,16076531,"Results for female HW indicated that some compounds caused spastic paralysis of contractile activity and inhibition of motility in culture (bephenium, DL-tetramisole, and pyrantel); some caused only spastic paralysis of contractile activity (methyridine and disophenol); and some  caused only inhibition of motility in culture (chlorpromazine, dithiazanine, 1-ethoxycarbonylmethyl-1-methylpyrrolidinium, and 4-methyltropolone).","['bephenium', 'DL-tetramisole', 'pyrantel', 'methyridine', 'disophenol', 'chlorpromazine', 'dithiazanine', '1-ethoxycarbonylmethyl-1-methylpyrrolidinium', '4-methyltropolone']","['spastic paralysis', 'inhibition of motility in', 'spastic paralysis', 'inhibition of motility in']",True,methyridine,spastic paralysis,caused,C0522224,Inability to move,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methyridine,cause
1810,21020,16076531,"Results for female HW indicated that some compounds caused spastic paralysis of contractile activity and inhibition of motility in culture (bephenium, DL-tetramisole, and pyrantel); some caused only spastic paralysis of contractile activity (methyridine and disophenol); and some  caused only inhibition of motility in culture (chlorpromazine, dithiazanine, 1-ethoxycarbonylmethyl-1-methylpyrrolidinium, and 4-methyltropolone).","['bephenium', 'DL-tetramisole', 'pyrantel', 'methyridine', 'disophenol', 'chlorpromazine', 'dithiazanine', '1-ethoxycarbonylmethyl-1-methylpyrrolidinium', '4-methyltropolone']","['spastic paralysis', 'inhibition of motility in', 'spastic paralysis', 'inhibition of motility in']",True,disophenol,spastic paralysis,caused,C0522224,Inability to move,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",disophenol,cause
1811,21020,16076531,"Results for female HW indicated that some compounds caused spastic paralysis of contractile activity and inhibition of motility in culture (bephenium, DL-tetramisole, and pyrantel); some caused only spastic paralysis of contractile activity (methyridine and disophenol); and some  caused only inhibition of motility in culture (chlorpromazine, dithiazanine, 1-ethoxycarbonylmethyl-1-methylpyrrolidinium, and 4-methyltropolone).","['bephenium', 'DL-tetramisole', 'pyrantel', 'methyridine', 'disophenol', 'chlorpromazine', 'dithiazanine', '1-ethoxycarbonylmethyl-1-methylpyrrolidinium', '4-methyltropolone']","['spastic paralysis', 'inhibition of motility in', 'spastic paralysis', 'inhibition of motility in']",True,chlorpromazine,spastic paralysis,caused,C0522224,Inability to move,2726,Chlorpromazine,Chlorpromazine,cause
1812,21020,16076531,"Results for female HW indicated that some compounds caused spastic paralysis of contractile activity and inhibition of motility in culture (bephenium, DL-tetramisole, and pyrantel); some caused only spastic paralysis of contractile activity (methyridine and disophenol); and some  caused only inhibition of motility in culture (chlorpromazine, dithiazanine, 1-ethoxycarbonylmethyl-1-methylpyrrolidinium, and 4-methyltropolone).","['bephenium', 'DL-tetramisole', 'pyrantel', 'methyridine', 'disophenol', 'chlorpromazine', 'dithiazanine', '1-ethoxycarbonylmethyl-1-methylpyrrolidinium', '4-methyltropolone']","['spastic paralysis', 'inhibition of motility in', 'spastic paralysis', 'inhibition of motility in']",True,dithiazanine,spastic paralysis,caused,C0522224,Inability to move,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dithiazanine,cause
1813,21020,16076531,"Results for female HW indicated that some compounds caused spastic paralysis of contractile activity and inhibition of motility in culture (bephenium, DL-tetramisole, and pyrantel); some caused only spastic paralysis of contractile activity (methyridine and disophenol); and some  caused only inhibition of motility in culture (chlorpromazine, dithiazanine, 1-ethoxycarbonylmethyl-1-methylpyrrolidinium, and 4-methyltropolone).","['bephenium', 'DL-tetramisole', 'pyrantel', 'methyridine', 'disophenol', 'chlorpromazine', 'dithiazanine', '1-ethoxycarbonylmethyl-1-methylpyrrolidinium', '4-methyltropolone']","['spastic paralysis', 'inhibition of motility in', 'spastic paralysis', 'inhibition of motility in']",True,1-ethoxycarbonylmethyl-1-methylpyrrolidinium,spastic paralysis,caused,C0522224,Inability to move,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",1-ethoxycarbonylmethyl-1-methylpyrrolidinium,cause
1814,21023,15081572,"These chemicals were also observed to inhibit the transcriptional activity of 17beta-estradiol in a reporter gene assay system using MCF-7 cells, estrogen receptor-positive breast cancer cells, and to  bind directly to estrogen receptor alpha in a competitive binding assay system, although the order of the activity was slightly different among the 3 assays.",['17beta-estradiol'],['breast cancer'],True,17beta-estradiol,breast cancer,inhibit,C0678222,Breast cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",17beta-estradiol,inhibit
1815,21031,35314480,"Tolvaptan also causes polyuria, limiting tolerability.",['Tolvaptan'],['polyuria'],True,Tolvaptan,polyuria,causes,C0032617,Polyuria,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Tolvaptan,cause
1816,21038,35278085,"Some drugs, i.e. thiazides and thiazide-like-diuretics, were associated with an increased risk of  non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma).","['thiazides', 'thiazide-like-diuretics']","['increased risk of  non-melanoma skin cancers', 'basal cell carcinoma', 'squamous cell carcinoma']",True,thiazides,increased risk of  non-melanoma skin cancers,associated,C0699893,Skin cancer (non-melanoma),NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazides,associate
1817,21038,35278085,"Some drugs, i.e. thiazides and thiazide-like-diuretics, were associated with an increased risk of  non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma).","['thiazides', 'thiazide-like-diuretics']","['increased risk of  non-melanoma skin cancers', 'basal cell carcinoma', 'squamous cell carcinoma']",True,thiazides,basal cell carcinoma,associated,C4721806,Basal cell carcinoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazides,associate
1818,21038,35278085,"Some drugs, i.e. thiazides and thiazide-like-diuretics, were associated with an increased risk of  non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma).","['thiazides', 'thiazide-like-diuretics']","['increased risk of  non-melanoma skin cancers', 'basal cell carcinoma', 'squamous cell carcinoma']",True,thiazides,squamous cell carcinoma,associated,C0007137,Squamous cell carcinoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazides,associate
1819,21038,35278085,"Some drugs, i.e. thiazides and thiazide-like-diuretics, were associated with an increased risk of  non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma).","['thiazides', 'thiazide-like-diuretics']","['increased risk of  non-melanoma skin cancers', 'basal cell carcinoma', 'squamous cell carcinoma']",True,thiazide-like-diuretics,increased risk of  non-melanoma skin cancers,associated,C0699893,Skin cancer (non-melanoma),NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazide-like-diuretics,associate
1820,21038,35278085,"Some drugs, i.e. thiazides and thiazide-like-diuretics, were associated with an increased risk of  non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma).","['thiazides', 'thiazide-like-diuretics']","['increased risk of  non-melanoma skin cancers', 'basal cell carcinoma', 'squamous cell carcinoma']",True,thiazide-like-diuretics,basal cell carcinoma,associated,C4721806,Basal cell carcinoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazide-like-diuretics,associate
1821,21038,35278085,"Some drugs, i.e. thiazides and thiazide-like-diuretics, were associated with an increased risk of  non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma).","['thiazides', 'thiazide-like-diuretics']","['increased risk of  non-melanoma skin cancers', 'basal cell carcinoma', 'squamous cell carcinoma']",True,thiazide-like-diuretics,squamous cell carcinoma,associated,C0007137,Squamous cell carcinoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazide-like-diuretics,associate
1822,21056,35069250,"  Aberrant activation of with-no-lysine kinase (WNK)-STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) kinase signaling in the distal convoluted tubule (DCT) causes unbridled activation of the thiazide-sensitive sodium chloride cotransporter (NCC), leading to familial hyperkalemic hypertension (FHHt) in humans.",['sodium chloride cotransporter'],"['activation of the thiazide-sensitive', 'familial hyperkalemic hypertension']",True,sodium chloride cotransporter,familial hyperkalemic hypertension,causes,C0020461,Elevated serum potassium levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium chloride cotransporter,cause
1823,21104,34556798,"After a typical follow-up of 8 weeks, fixed-dose combinations of ARB with a high dose (25 mg) of HCTZ were associated with a higher hypokalemia risk difference (RD) from placebo (e.g.,Valsartan + HCTZ: 2.52%[95%CIs:1.17, 4.38%]).","['ARB', 'HCTZ', 'HCTZ']",['higher hypokalemia risk'],True,ARB,higher hypokalemia risk,associated,C0020621,Hypokalemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ARB,associate
1824,21104,34556798,"After a typical follow-up of 8 weeks, fixed-dose combinations of ARB with a high dose (25 mg) of HCTZ were associated with a higher hypokalemia risk difference (RD) from placebo (e.g.,Valsartan + HCTZ: 2.52%[95%CIs:1.17, 4.38%]).","['ARB', 'HCTZ', 'HCTZ']",['higher hypokalemia risk'],True,HCTZ,higher hypokalemia risk,associated,C0020621,Hypokalemia,3639,Hydrochlorothiazide,Hydrochlorothiazide,associate
1825,21104,34556798,"After a typical follow-up of 8 weeks, fixed-dose combinations of ARB with a high dose (25 mg) of HCTZ were associated with a higher hypokalemia risk difference (RD) from placebo (e.g.,Valsartan + HCTZ: 2.52%[95%CIs:1.17, 4.38%]).","['ARB', 'HCTZ', 'HCTZ']",['higher hypokalemia risk'],True,HCTZ,higher hypokalemia risk,associated,C0020621,Hypokalemia,3639,Hydrochlorothiazide,Hydrochlorothiazide,associate
1826,21112,34524440,"Chlorthalidone use was also associated with a higher risk of hypokalemia compared with hydrochlorothiazide use, which was more pronounced among those with higher eGFR (eGFR ≥60 mL/min/1.73 m2: HR, 1.86 [95% CI, 1.67-2.08]; eGFR 45-59 mL/min/1.73 m2: HR, 1.57 [95% CI, 1.25-1.96]; eGFR <45 mL/min/1.73 m2: HR, 1.10 [95% CI, 0.84-1.45]; P for interaction = .001).","['Chlorthalidone', 'hydrochlorothiazide']",['hypokalemia'],True,Chlorthalidone,hypokalemia,associated,C0020621,Hypokalemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Chlorthalidone,associate
1827,21112,34524440,"Chlorthalidone use was also associated with a higher risk of hypokalemia compared with hydrochlorothiazide use, which was more pronounced among those with higher eGFR (eGFR ≥60 mL/min/1.73 m2: HR, 1.86 [95% CI, 1.67-2.08]; eGFR 45-59 mL/min/1.73 m2: HR, 1.57 [95% CI, 1.25-1.96]; eGFR <45 mL/min/1.73 m2: HR, 1.10 [95% CI, 0.84-1.45]; P for interaction = .001).","['Chlorthalidone', 'hydrochlorothiazide']",['hypokalemia'],True,hydrochlorothiazide,hypokalemia,associated,C0020621,Hypokalemia,3639,Hydrochlorothiazide,Hydrochlorothiazide,associate
1828,21114,34524440," Conclusions and Relevance: This cohort study found that among older adults, chlorthalidone use was associated with a higher risk of eGFR decline, cardiovascular events, and hypokalemia compared with hydrochlorothiazide use.","['chlorthalidone', 'hydrochlorothiazide']","['cardiovascular events', 'hypokalemia']",True,chlorthalidone,cardiovascular events,associated,C0020621,Hypokalemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chlorthalidone,associate
1829,21121,34493493,"  BACKGROUND: Because of continuous hyperglycemia and hyperinsulinemia and the use  of photosensitizing drug, hydrochlorothiazide (HCTZ), the risk of cutaneous squamous cell carcinoma (cSCC) might be increased among patients with diabetes.","['photosensitizing', 'hydrochlorothiazide', 'HCTZ']","['hyperglycemia', 'hyperinsulinemia', 'cutaneous squamous cell carcinoma', 'diabetes']",True,photosensitizing,hyperglycemia,increased,C0020456,High blood sugar,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",photosensitizing,increase
1830,21121,34493493,"  BACKGROUND: Because of continuous hyperglycemia and hyperinsulinemia and the use  of photosensitizing drug, hydrochlorothiazide (HCTZ), the risk of cutaneous squamous cell carcinoma (cSCC) might be increased among patients with diabetes.","['photosensitizing', 'hydrochlorothiazide', 'HCTZ']","['hyperglycemia', 'hyperinsulinemia', 'cutaneous squamous cell carcinoma', 'diabetes']",True,photosensitizing,hyperinsulinemia,increased,C0020459,Hyperinsulinemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",photosensitizing,increase
1831,21121,34493493,"  BACKGROUND: Because of continuous hyperglycemia and hyperinsulinemia and the use  of photosensitizing drug, hydrochlorothiazide (HCTZ), the risk of cutaneous squamous cell carcinoma (cSCC) might be increased among patients with diabetes.","['photosensitizing', 'hydrochlorothiazide', 'HCTZ']","['hyperglycemia', 'hyperinsulinemia', 'cutaneous squamous cell carcinoma', 'diabetes']",True,photosensitizing,cutaneous squamous cell carcinoma,increased,C0007137,Squamous cell carcinoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",photosensitizing,increase
1832,21121,34493493,"  BACKGROUND: Because of continuous hyperglycemia and hyperinsulinemia and the use  of photosensitizing drug, hydrochlorothiazide (HCTZ), the risk of cutaneous squamous cell carcinoma (cSCC) might be increased among patients with diabetes.","['photosensitizing', 'hydrochlorothiazide', 'HCTZ']","['hyperglycemia', 'hyperinsulinemia', 'cutaneous squamous cell carcinoma', 'diabetes']",True,photosensitizing,diabetes,increased,C0085207,Maternal diabetes,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",photosensitizing,increase
1833,21121,34493493,"  BACKGROUND: Because of continuous hyperglycemia and hyperinsulinemia and the use  of photosensitizing drug, hydrochlorothiazide (HCTZ), the risk of cutaneous squamous cell carcinoma (cSCC) might be increased among patients with diabetes.","['photosensitizing', 'hydrochlorothiazide', 'HCTZ']","['hyperglycemia', 'hyperinsulinemia', 'cutaneous squamous cell carcinoma', 'diabetes']",True,hydrochlorothiazide,hyperglycemia,increased,C0020456,High blood sugar,3639,Hydrochlorothiazide,Hydrochlorothiazide,increase
1834,21121,34493493,"  BACKGROUND: Because of continuous hyperglycemia and hyperinsulinemia and the use  of photosensitizing drug, hydrochlorothiazide (HCTZ), the risk of cutaneous squamous cell carcinoma (cSCC) might be increased among patients with diabetes.","['photosensitizing', 'hydrochlorothiazide', 'HCTZ']","['hyperglycemia', 'hyperinsulinemia', 'cutaneous squamous cell carcinoma', 'diabetes']",True,hydrochlorothiazide,hyperinsulinemia,increased,C0020459,Hyperinsulinemia,3639,Hydrochlorothiazide,Hydrochlorothiazide,increase
1835,21121,34493493,"  BACKGROUND: Because of continuous hyperglycemia and hyperinsulinemia and the use  of photosensitizing drug, hydrochlorothiazide (HCTZ), the risk of cutaneous squamous cell carcinoma (cSCC) might be increased among patients with diabetes.","['photosensitizing', 'hydrochlorothiazide', 'HCTZ']","['hyperglycemia', 'hyperinsulinemia', 'cutaneous squamous cell carcinoma', 'diabetes']",True,hydrochlorothiazide,cutaneous squamous cell carcinoma,increased,C0007137,Squamous cell carcinoma,3639,Hydrochlorothiazide,Hydrochlorothiazide,increase
1836,21121,34493493,"  BACKGROUND: Because of continuous hyperglycemia and hyperinsulinemia and the use  of photosensitizing drug, hydrochlorothiazide (HCTZ), the risk of cutaneous squamous cell carcinoma (cSCC) might be increased among patients with diabetes.","['photosensitizing', 'hydrochlorothiazide', 'HCTZ']","['hyperglycemia', 'hyperinsulinemia', 'cutaneous squamous cell carcinoma', 'diabetes']",True,hydrochlorothiazide,diabetes,increased,C0085207,Maternal diabetes,3639,Hydrochlorothiazide,Hydrochlorothiazide,increase
1837,21122,34493493," CONCLUSIONS: In patients with diabetes, exposure to HCTZ for >2 years is associated with an increased risk of cSCC, whereas no increased risk associated with thiazide-like diuretics was observed.",['HCTZ'],"['diabetes', 'increased risk of cSCC', 'increased risk associated']",True,HCTZ,diabetes,associated,C0085207,Maternal diabetes,3639,Hydrochlorothiazide,Hydrochlorothiazide,associate
1838,21218,35135381,Discontinuation of ibuprofen resulted in a resolution of hypokalemia  and acidosis within days in 47 cases.,['ibuprofen'],"['hypokalemia', 'acidosis']",True,ibuprofen,hypokalemia,resulted,C0020621,Hypokalemia,3672,Ibuprofen,Ibuprofen,result
1839,21218,35135381,Discontinuation of ibuprofen resulted in a resolution of hypokalemia  and acidosis within days in 47 cases.,['ibuprofen'],"['hypokalemia', 'acidosis']",True,ibuprofen,acidosis,resulted,C0001122,Acidosis,3672,Ibuprofen,Ibuprofen,result
1840,21269,34848483, CONCLUSION: Combination of DXR and IFM for STS induces skeletal muscle loss and sleep disruption.,['DXR'],['skeletal muscle loss'],True,DXR,skeletal muscle loss,induces,C0541794,Muscle wasting,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DXR,induce
1841,21284,34681807,"Our data highlight that, in ES cells, CHIR99021 induces cell cycle arrest, mitotic catastrophe (MC) and autophagic response, resulting in reduced cell proliferation.",['CHIR99021'],"['mitotic catastrophe', 'reduced cell proliferation']",True,CHIR99021,reduced cell proliferation,induces,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CHIR99021,induce
1842,21292,33814411,"The antioxidant effect of loading with water with saturation with molecular hydrogen leads to a decrease in the loss of sodium ions due to an  improvement in its reabsorption and β2-microglobulin in the proximal tubule, a decrease in lipid peroxidation in the renal cortex was noted, the degree of its damage by an increase in the K+/Na+ ratio and a decrease in degree of edema.",['water'],"['loss of sodium ions', 'decrease in lipid peroxidation', 'damage', 'increase in the K+/Na+ ratio', 'edema']",True,water,increase in the K+/Na+ ratio,leads,C4022846,Increased T3/T4 ratio,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,lead
1843,21292,33814411,"The antioxidant effect of loading with water with saturation with molecular hydrogen leads to a decrease in the loss of sodium ions due to an  improvement in its reabsorption and β2-microglobulin in the proximal tubule, a decrease in lipid peroxidation in the renal cortex was noted, the degree of its damage by an increase in the K+/Na+ ratio and a decrease in degree of edema.",['water'],"['loss of sodium ions', 'decrease in lipid peroxidation', 'damage', 'increase in the K+/Na+ ratio', 'edema']",True,water,edema,leads,C0013604,Edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,lead
1844,21303,12621522,The widespread use of mercury has resulted in increased levels of mercury in rivers and lakes.,"['mercury', 'mercury']",['increased levels'],True,mercury,increased levels,resulted,C0013604,Edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mercury,result
1845,21303,12621522,The widespread use of mercury has resulted in increased levels of mercury in rivers and lakes.,"['mercury', 'mercury']",['increased levels'],True,mercury,increased levels,resulted,C0013604,Edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mercury,result
1846,21347,35129917,"Propylthiouracil has been linked to hepatotoxicity and vasculitis and is therefore less commonly used first line, whereas carbimazole is associated with an increased risk of teratogenicity and pancreatitis.","['Propylthiouracil', 'carbimazole']","['hepatotoxicity', 'vasculitis', 'increased risk of teratogenicity', 'pancreatitis']",True,Propylthiouracil,vasculitis,linked,C0042384,Vasculitis,657298,Propylthiouracil,Propylthiouracil,link
1847,21347,35129917,"Propylthiouracil has been linked to hepatotoxicity and vasculitis and is therefore less commonly used first line, whereas carbimazole is associated with an increased risk of teratogenicity and pancreatitis.","['Propylthiouracil', 'carbimazole']","['hepatotoxicity', 'vasculitis', 'increased risk of teratogenicity', 'pancreatitis']",True,Propylthiouracil,pancreatitis,linked,C0030305,Pancreatitis,657298,Propylthiouracil,Propylthiouracil,link
1848,21347,35129917,"Propylthiouracil has been linked to hepatotoxicity and vasculitis and is therefore less commonly used first line, whereas carbimazole is associated with an increased risk of teratogenicity and pancreatitis.","['Propylthiouracil', 'carbimazole']","['hepatotoxicity', 'vasculitis', 'increased risk of teratogenicity', 'pancreatitis']",True,carbimazole,vasculitis,linked,C0042384,Vasculitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carbimazole,link
1849,21347,35129917,"Propylthiouracil has been linked to hepatotoxicity and vasculitis and is therefore less commonly used first line, whereas carbimazole is associated with an increased risk of teratogenicity and pancreatitis.","['Propylthiouracil', 'carbimazole']","['hepatotoxicity', 'vasculitis', 'increased risk of teratogenicity', 'pancreatitis']",True,carbimazole,pancreatitis,linked,C0030305,Pancreatitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carbimazole,link
1850,21347,35129917,"Propylthiouracil has been linked to hepatotoxicity and vasculitis and is therefore less commonly used first line, whereas carbimazole is associated with an increased risk of teratogenicity and pancreatitis.","['Propylthiouracil', 'carbimazole']","['hepatotoxicity', 'vasculitis', 'increased risk of teratogenicity', 'pancreatitis']",True,carbimazole,pancreatitis,associated,C0030305,Pancreatitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carbimazole,associate
1851,21353,35082799,"Furthermore, further mechanistic exploration showed that the addition of berberine resulted in a significant upregulation of the synthesis of enterobactin, which may have increased iron functioning and thus restored thyroid function.","['berberine', 'enterobactin', 'iron']","['upregulation of the synthesis', 'restored thyroid function']",True,berberine,restored thyroid function,resulted,C0857576,Abnormality of thyroid physiology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",berberine,result
1852,21353,35082799,"Furthermore, further mechanistic exploration showed that the addition of berberine resulted in a significant upregulation of the synthesis of enterobactin, which may have increased iron functioning and thus restored thyroid function.","['berberine', 'enterobactin', 'iron']","['upregulation of the synthesis', 'restored thyroid function']",True,enterobactin,restored thyroid function,resulted,C0857576,Abnormality of thyroid physiology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enterobactin,result
1853,21353,35082799,"Furthermore, further mechanistic exploration showed that the addition of berberine resulted in a significant upregulation of the synthesis of enterobactin, which may have increased iron functioning and thus restored thyroid function.","['berberine', 'enterobactin', 'iron']","['upregulation of the synthesis', 'restored thyroid function']",True,iron,restored thyroid function,resulted,C0857576,Abnormality of thyroid physiology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,result
1854,21353,35082799,"Furthermore, further mechanistic exploration showed that the addition of berberine resulted in a significant upregulation of the synthesis of enterobactin, which may have increased iron functioning and thus restored thyroid function.","['berberine', 'enterobactin', 'iron']","['upregulation of the synthesis', 'restored thyroid function']",True,iron,restored thyroid function,increased,C0857576,Abnormality of thyroid physiology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,increase
1855,21369,34845757,"Compared  to nondisease controls, adjusted risk ratio (RR) and 95% confidence intervals (95% CIs) for congenital anomalies was increased for CMZ/MMI (RR, 1.28; 95% CI, 1.06-1.54) and PTU (RR, 1.16; 95% CI, 1.08-1.25).","['CMZ/MMI', 'PTU']",['congenital anomalies'],True,CMZ/MMI,congenital anomalies,increased,C0857576,Abnormality of thyroid physiology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CMZ/MMI,increase
1856,21369,34845757,"Compared  to nondisease controls, adjusted risk ratio (RR) and 95% confidence intervals (95% CIs) for congenital anomalies was increased for CMZ/MMI (RR, 1.28; 95% CI, 1.06-1.54) and PTU (RR, 1.16; 95% CI, 1.08-1.25).","['CMZ/MMI', 'PTU']",['congenital anomalies'],True,PTU,congenital anomalies,increased,C0857576,Abnormality of thyroid physiology,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PTU,increase
1857,21376,34791119,"Hypothyroidism was induced in female Sprague-Dawley rats by adding methimazole (MMI) to drinking water at moderate (MOD, MMI at 0.005% w/v) and severe (SEV, MMI at 0.02% w/v) doses from 1 week before pregnancy and throughout gestation.","['methimazole', 'water']",['Hypothyroidism'],True,methimazole,Hypothyroidism,induced,C0020676,Underactive thyroid,1349907,Methimazole,Methimazole,induce
1858,21376,34791119,"Hypothyroidism was induced in female Sprague-Dawley rats by adding methimazole (MMI) to drinking water at moderate (MOD, MMI at 0.005% w/v) and severe (SEV, MMI at 0.02% w/v) doses from 1 week before pregnancy and throughout gestation.","['methimazole', 'water']",['Hypothyroidism'],True,water,Hypothyroidism,induced,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,induce
1859,21381,34700210,Hypothyroidism was induced by continuous exposure to 0.1% methimazole (MTZ) in drinking water for 31 days.,"['methimazole', 'MTZ']",['Hypothyroidism'],True,methimazole,Hypothyroidism,induced,C0020676,Underactive thyroid,1349907,Methimazole,Methimazole,induce
1860,21397,34628889,"Serum Ca2+, free triiodothyronine (FT3), free thyroxine (FT4), and thyrotropin hormone receptor antibody (TRAb) levels increased in patients with hypercalcemia.",['triiodothyronine'],['hypercalcemia'],True,triiodothyronine,hypercalcemia,increased,C0020437,Increased calcium in blood,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",triiodothyronine,increase
1861,21402,34588587,"MMI led to shell growth retardation in a concentration-dependent manner in juveniles of M. coruscus after 4 weeks of exposure, whereas PTU had no effect on juvenile growth.",['PTU'],"['shell growth retardation', 'juvenile growth']",True,PTU,shell growth retardation,led,C0151686,Growth retardation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PTU,lead
1862,21402,34588587,"MMI led to shell growth retardation in a concentration-dependent manner in juveniles of M. coruscus after 4 weeks of exposure, whereas PTU had no effect on juvenile growth.",['PTU'],"['shell growth retardation', 'juvenile growth']",True,PTU,juvenile growth,led,C3714757,Juvenile idiopathic arthritis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PTU,lead
1863,21412,34479513,"  BACKGROUND: Rash and cholestatic liver injury caused by methimazole (MMI) in patients with Turner syndrome (TS) and Graves's disease (GD) are rarely reported, and there is a paucity of reports on the management of this condition.",['methimazole'],"['Rash', 'cholestatic liver injury', 'Turner syndrome']",True,methimazole,Turner syndrome,caused,C3714757,Juvenile idiopathic arthritis,1349907,Methimazole,Methimazole,cause
1864,21424,34351027,"  BACKGROUND: Radioiodine (131 I) is the treatment of choice for hyperthyroidism in cats, but current 131 I-dosing protocols can induce iatrogenic hypothyroidism and expose azotemia.",['Radioiodine'],"['hyperthyroidism', 'iatrogenic hypothyroidism', 'azotemia']",True,Radioiodine,hyperthyroidism,induce,C0020550,Overactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Radioiodine,induce
1865,21424,34351027,"  BACKGROUND: Radioiodine (131 I) is the treatment of choice for hyperthyroidism in cats, but current 131 I-dosing protocols can induce iatrogenic hypothyroidism and expose azotemia.",['Radioiodine'],"['hyperthyroidism', 'iatrogenic hypothyroidism', 'azotemia']",True,Radioiodine,iatrogenic hypothyroidism,induce,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Radioiodine,induce
1866,21424,34351027,"  BACKGROUND: Radioiodine (131 I) is the treatment of choice for hyperthyroidism in cats, but current 131 I-dosing protocols can induce iatrogenic hypothyroidism and expose azotemia.",['Radioiodine'],"['hyperthyroidism', 'iatrogenic hypothyroidism', 'azotemia']",True,Radioiodine,azotemia,induce,C0242528,Azotaemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Radioiodine,induce
1867,21428,34336407,"In this case, chronic alcohol abuse may have increased the patient's tolerance to the profound hypokalemia such that it did not immediately show critical symptoms.",['alcohol'],['hypokalemia'],True,alcohol,hypokalemia,increased,C0020621,Hypokalemia,702,Ethanol,Ethanol,increase
1868,21449,34216800,Methimazole was prone to causing a more serious agranulocytosis than propylthiouracil.,"['Methimazole', 'propylthiouracil']",['agranulocytosis'],True,propylthiouracil,agranulocytosis,causing,C0001824,Agranulocytosis,657298,Propylthiouracil,Propylthiouracil,cause
1869,21509,35284067,"Result: A total of 34 RA patients were followed and the MTX was well tolerated in which no increase of serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and glomerular filtration rate (GFR) were observed.",['RA'],"['increase of serum glutamic oxaloacetic transaminase', 'glutamic pyruvic transaminase', 'glomerular filtration']",True,RA,increase of serum glutamic oxaloacetic transaminase,Result,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",RA,result
1870,21509,35284067,"Result: A total of 34 RA patients were followed and the MTX was well tolerated in which no increase of serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and glomerular filtration rate (GFR) were observed.",['RA'],"['increase of serum glutamic oxaloacetic transaminase', 'glutamic pyruvic transaminase', 'glomerular filtration']",True,RA,glomerular filtration,Result,C0854050,Abnormal glomerular filtration rate,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",RA,result
1871,21524,35266893, RECENT FINDINGS: Intravitreal vancomycin can cause hemorrhagic occlusive retinal  vasculitis resulting in severe vision loss.,['vancomycin'],"['hemorrhagic occlusive retinal', 'severe vision loss']",True,vancomycin,severe vision loss,cause,C1301509,Severely reduced visual acuity,14969,"(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid","(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid",cause
1872,21526,35266525,doi: 10.1093/rheumatology/keac154. [Epub ahead of print]  Tapering subcutaneous methotrexate causes more disease flares compared to tapering oral administration in established rheumatoid arthritis patients.,['methotrexate'],['rheumatoid arthritis'],True,methotrexate,rheumatoid arthritis,causes,C0003873,RA,126941,Methotrexate,Methotrexate,cause
1873,21538,35261195,"Among the 1781 SARS-CoV-2-positive patients with cancer, BCR/ABL-negative myeloproliferative neoplasms (RR 2.15, 95% CI: 1.25-3.41, p = 0.007), venetoclax (RR 2.96, 95% CI: 1.14-5.66, p = 0.028), and methotrexate (RR 2.72, 95% CI: 1.10-5.19, p = 0.032) were associated with greater hospitalization risk.",['methotrexate'],"['cancer', 'BCR/ABL-negative myeloproliferative neoplasms', 'greater hospitalization risk']",True,methotrexate,cancer,associated,C0006826,Cancer,126941,Methotrexate,Methotrexate,associate
1874,21538,35261195,"Among the 1781 SARS-CoV-2-positive patients with cancer, BCR/ABL-negative myeloproliferative neoplasms (RR 2.15, 95% CI: 1.25-3.41, p = 0.007), venetoclax (RR 2.96, 95% CI: 1.14-5.66, p = 0.028), and methotrexate (RR 2.72, 95% CI: 1.10-5.19, p = 0.032) were associated with greater hospitalization risk.",['methotrexate'],"['cancer', 'BCR/ABL-negative myeloproliferative neoplasms', 'greater hospitalization risk']",True,methotrexate,BCR/ABL-negative myeloproliferative neoplasms,associated,C0006826,Cancer,126941,Methotrexate,Methotrexate,associate
1875,21575,35020261,"Irrespective of other mycotoxin exposure and presence of EED, AFB1 was negatively associated with length, weight, head circumference, LAZ and WAZ, and with increased odds of stunting and underweight, UFB1 was associated with increased odds of underweight, and DON was negatively associated with head circumference.",['DON'],"['weight', 'head circumference', 'increased odds of stunting', 'increased odds of underweight']",True,DON,weight,associated,C1262477,Weight loss,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,associate
1876,21575,35020261,"Irrespective of other mycotoxin exposure and presence of EED, AFB1 was negatively associated with length, weight, head circumference, LAZ and WAZ, and with increased odds of stunting and underweight, UFB1 was associated with increased odds of underweight, and DON was negatively associated with head circumference.",['DON'],"['weight', 'head circumference', 'increased odds of stunting', 'increased odds of underweight']",True,DON,head circumference,associated,C1262477,Weight loss,164,6-Diazo-5-Oxo-Norleucine,6-Diazo-5-Oxo-Norleucine,associate
1877,21585,34921099,"OTA systemic exposure in NASH mice increased modestly from 5.65 {plus minus} 1.10 to  7.95 {plus minus} 0.61 mg*h/mL/kg BW, renal excretion increased robustly from 5.55 {plus minus} 0.37% to 13.11 {plus minus} 3.10%, relative to healthy mice.",['OTA'],['renal excretion increased'],True,OTA,renal excretion increased,increased,C4023579,Abnormality of renal excretion,442530,OCHRATOXIN A,OCHRATOXIN A,increase
1878,21590,34822586,"Therefore, OTA induces hepatic steatosis via PPARγ-CD36 axis, suggesting that OTA has an impact on liver lipid metabolism and may contribute to the development of metabolic diseases.","['OTA', 'OTA']",['hepatic steatosis'],True,OTA,hepatic steatosis,induces,C2711227,Steatosis,442530,OCHRATOXIN A,OCHRATOXIN A,induce
1879,21590,34822586,"Therefore, OTA induces hepatic steatosis via PPARγ-CD36 axis, suggesting that OTA has an impact on liver lipid metabolism and may contribute to the development of metabolic diseases.","['OTA', 'OTA']",['hepatic steatosis'],True,OTA,hepatic steatosis,induces,C2711227,Steatosis,442530,OCHRATOXIN A,OCHRATOXIN A,induce
1880,21605,35290563,"In Wistar rats, gastric ulcers were induced using one oral dose of 70% ethanol (5 ml/kg b. w.) Cinnamon oil at doses  of 2.5 ml/kg body weight and omeprazole (a reference drug) at a dose of 20 mg/kg  body weight were orally administrated daily for 7 days before ulcer induction.","['ethanol', 'omeprazole']","['gastric ulcers', 'ulcer induction']",True,ethanol,gastric ulcers,induced,C0038358,Stomach ulcer,702,Ethanol,Ethanol,induce
1881,21605,35290563,"In Wistar rats, gastric ulcers were induced using one oral dose of 70% ethanol (5 ml/kg b. w.) Cinnamon oil at doses  of 2.5 ml/kg body weight and omeprazole (a reference drug) at a dose of 20 mg/kg  body weight were orally administrated daily for 7 days before ulcer induction.","['ethanol', 'omeprazole']","['gastric ulcers', 'ulcer induction']",True,omeprazole,gastric ulcers,induced,C0038358,Stomach ulcer,4594,Omeprazole,Omeprazole,induce
1882,21631,35218765,"Melatonin also inhibits the downregulation of HSP-70 and activates p38 dephosphorylation and thereby, it rescues gastric mucosal cells from stress-induced ulceration.",['Melatonin'],"['p38 dephosphorylation', 'ulceration']",True,Melatonin,ulceration,inhibits,C4732740,Acral ulceration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Melatonin,inhibit
1883,21648,35091806,doi: 10.1007/s00441-022-03587-z. [Epub ahead of print]  Esomeprazole inhibits hypoxia/endothelial dysfunction-induced autophagy in preeclampsia.,['Esomeprazole'],"['hypoxia/endothelial dysfunction-induced autophagy', 'preeclampsia']",True,Esomeprazole,preeclampsia,inhibits,C0032914,Preeclampsia,4594,Omeprazole,Omeprazole,inhibit
1884,21658,35062043,"It can cause some health complications, such as GIT ulcers, so it should be co-administered with proton-pump inhibitors, such as esomeprazole, to prevent the risk of ulcers.",['esomeprazole'],"['GIT ulcers', 'ulcers']",True,esomeprazole,GIT ulcers,cause,C0032914,Preeclampsia,4594,Omeprazole,Omeprazole,cause
1885,21658,35062043,"It can cause some health complications, such as GIT ulcers, so it should be co-administered with proton-pump inhibitors, such as esomeprazole, to prevent the risk of ulcers.",['esomeprazole'],"['GIT ulcers', 'ulcers']",True,esomeprazole,ulcers,cause,C0149745,Mouth ulcer,4594,Omeprazole,Omeprazole,cause
1886,21696,34923545,"Necrosis and apoptosis were inhibited by OMZ in GaIN/LPS rats, but OMZ had no effects on necrosis in PH/LPS rats.",['OMZ'],"['Necrosis', 'apoptosis', 'necrosis']",True,OMZ,Necrosis,inhibited,C0151798,Hepatic necrosis,4594,Omeprazole,Omeprazole,inhibit
1887,21696,34923545,"Necrosis and apoptosis were inhibited by OMZ in GaIN/LPS rats, but OMZ had no effects on necrosis in PH/LPS rats.",['OMZ'],"['Necrosis', 'apoptosis', 'necrosis']",True,OMZ,necrosis,inhibited,C0151798,Hepatic necrosis,4594,Omeprazole,Omeprazole,inhibit
1888,21704,34868331,SJZPs could inhibit the metabolism of omeprazole and increase the concentration of omeprazole in beagle dogs.,"['omeprazole', 'omeprazole']",['increase the concentration'],True,omeprazole,increase the concentration,inhibit,C0151798,Hepatic necrosis,4594,Omeprazole,Omeprazole,inhibit
1889,21704,34868331,SJZPs could inhibit the metabolism of omeprazole and increase the concentration of omeprazole in beagle dogs.,"['omeprazole', 'omeprazole']",['increase the concentration'],True,omeprazole,increase the concentration,inhibit,C0151798,Hepatic necrosis,4594,Omeprazole,Omeprazole,inhibit
1890,21710,34816630,"It is confirmed that PPIs (including omeprazole) do inhibit endosomal TLR signaling and inflammatory responses in macrophages and human peripheral blood mononuclear cells, and exhibits anti-inflammatory activity in an LPS-induced ALI mouse model.",['omeprazole'],['inflammatory responses in macrophages'],True,omeprazole,inflammatory responses in macrophages,inhibit,C4022805,Abnormal inflammatory response,4594,Omeprazole,Omeprazole,inhibit
1891,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,sugars,height,increased,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sugars,increase
1892,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,sugars,chlorophyll fluorescence,increased,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sugars,increase
1893,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,potassium,height,increased,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",potassium,increase
1894,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,potassium,chlorophyll fluorescence,increased,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",potassium,increase
1895,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,anthocyanin,height,increased,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",anthocyanin,increase
1896,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,anthocyanin,chlorophyll fluorescence,increased,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",anthocyanin,increase
1897,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,proline,height,increased,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",proline,increase
1898,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,proline,chlorophyll fluorescence,increased,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",proline,increase
1899,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,sugars,height,increased,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sugars,increase
1900,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,sugars,chlorophyll fluorescence,increased,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sugars,increase
1901,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,proline,height,resulted,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",proline,result
1902,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,proline,chlorophyll fluorescence,resulted,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",proline,result
1903,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,sugars,height,resulted,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sugars,result
1904,21725,35214829,"Ae at 0.5% increased the values of total soluble sugars, total free amino acids, potassium, anthocyanin, a single-photon avalanche diode,  stem diameter, fruit number, and fresh weight, whereas 1% of Ae resulted in the highest plant height, chlorophyll fluorescence (Fv/Fm), performance index, relative water content, membrane stability index, proline, total soluble sugars,  and acidity.","['sugars', 'potassium', 'anthocyanin', 'proline', 'sugars']","['height', 'chlorophyll fluorescence']",True,sugars,chlorophyll fluorescence,resulted,C1836047,Increased length of face,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sugars,result
1905,21770,35162599," Salicylic acid increased NaSF, ClSF, and MgSF and decreased KSF and CaSF, meaning less Na+, Cl-, and Mg2+ and more K+ and Ca2+ transferred to shoots in SA-treated  plants.",['Salicylic acid'],['decreased KSF'],True,Salicylic acid,decreased KSF,increased,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Salicylic acid,increase
1906,21778,35144692,"Most commonly, this condition is caused by an autosomal dominant calcium channel mutation, and patients typically have an established family medical history of hypokalemic periodic paralysis.",['calcium'],['hypokalemic periodic paralysis'],True,calcium,hypokalemic periodic paralysis,caused,C0238357,Hyperkalemic periodic paralysis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,cause
1907,21783,35135630,"  BACKGROUND: The use of thiazide (T) diuretics for the treatment of hypertension may be associated with adverse metabolic effects, which can be minimized by combining thiazides with potassium-sparing (PS) diuretics.",['thiazide'],['hypertension'],True,thiazide,hypertension,associated,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thiazide,associate
1908,21788,35089471,"Higher serum UA is associated with male, alcohol use, multiple serum and urine electrolytes (e.g. potassium, chloride, calcium, phosphorus), and lower estimated glomerular filtration rate.","['alcohol', 'potassium', 'chloride', 'calcium']","['Higher serum UA', 'glomerular filtration']",True,alcohol,glomerular filtration,associated,C0854050,Abnormal glomerular filtration rate,702,Ethanol,Ethanol,associate
1909,21788,35089471,"Higher serum UA is associated with male, alcohol use, multiple serum and urine electrolytes (e.g. potassium, chloride, calcium, phosphorus), and lower estimated glomerular filtration rate.","['alcohol', 'potassium', 'chloride', 'calcium']","['Higher serum UA', 'glomerular filtration']",True,potassium,glomerular filtration,associated,C0854050,Abnormal glomerular filtration rate,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",potassium,associate
1910,21788,35089471,"Higher serum UA is associated with male, alcohol use, multiple serum and urine electrolytes (e.g. potassium, chloride, calcium, phosphorus), and lower estimated glomerular filtration rate.","['alcohol', 'potassium', 'chloride', 'calcium']","['Higher serum UA', 'glomerular filtration']",True,chloride,glomerular filtration,associated,C0854050,Abnormal glomerular filtration rate,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chloride,associate
1911,21788,35089471,"Higher serum UA is associated with male, alcohol use, multiple serum and urine electrolytes (e.g. potassium, chloride, calcium, phosphorus), and lower estimated glomerular filtration rate.","['alcohol', 'potassium', 'chloride', 'calcium']","['Higher serum UA', 'glomerular filtration']",True,calcium,glomerular filtration,associated,C0854050,Abnormal glomerular filtration rate,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,associate
1912,21792,35063401," In Caco-2 cells, which only contain Na,K-ATPase α1 isoform, the FeCl3 increased the intracellular storage of iron, catalase activity, the production of H2O2 and  the expression levels of the α1 isoform.",['iron'],['production of H2O2'],True,iron,production of H2O2,increased,C4021801,Lacrimation abnormality,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,increase
1913,21826,35129911,In addition antithyroid drugs (e.g. carbimazole and propylthiouracil) are associated with rare and idiosyncratic side effects such as agranulocytosis and liver failure which need to be taken into consideration when monitoring during treatment.,"['carbimazole', 'propylthiouracil']","['agranulocytosis', 'liver failure']",True,carbimazole,agranulocytosis,associated,C0001824,Agranulocytosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carbimazole,associate
1914,21826,35129911,In addition antithyroid drugs (e.g. carbimazole and propylthiouracil) are associated with rare and idiosyncratic side effects such as agranulocytosis and liver failure which need to be taken into consideration when monitoring during treatment.,"['carbimazole', 'propylthiouracil']","['agranulocytosis', 'liver failure']",True,carbimazole,liver failure,associated,C0001824,Agranulocytosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carbimazole,associate
1915,21826,35129911,In addition antithyroid drugs (e.g. carbimazole and propylthiouracil) are associated with rare and idiosyncratic side effects such as agranulocytosis and liver failure which need to be taken into consideration when monitoring during treatment.,"['carbimazole', 'propylthiouracil']","['agranulocytosis', 'liver failure']",True,propylthiouracil,agranulocytosis,associated,C0001824,Agranulocytosis,657298,Propylthiouracil,Propylthiouracil,associate
1916,21826,35129911,In addition antithyroid drugs (e.g. carbimazole and propylthiouracil) are associated with rare and idiosyncratic side effects such as agranulocytosis and liver failure which need to be taken into consideration when monitoring during treatment.,"['carbimazole', 'propylthiouracil']","['agranulocytosis', 'liver failure']",True,propylthiouracil,liver failure,associated,C0001824,Agranulocytosis,657298,Propylthiouracil,Propylthiouracil,associate
1917,21836,34672293,Hypothyroidism was induced in immature Wistar rats by administration of propylthiouracil in drinking water.,"['propylthiouracil', 'water']",['Hypothyroidism'],True,propylthiouracil,Hypothyroidism,induced,C0020676,Underactive thyroid,657298,Propylthiouracil,Propylthiouracil,induce
1918,21836,34672293,Hypothyroidism was induced in immature Wistar rats by administration of propylthiouracil in drinking water.,"['propylthiouracil', 'water']",['Hypothyroidism'],True,water,Hypothyroidism,induced,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,induce
1919,21837,34672293,Treatment of hypothyroid rats with both doses of Rosi increased BDNF levels and decreased NO metabolites and malondialdehyde concentrations.,['Rosi'],"['BDNF levels', 'decreased NO metabolites']",True,Rosi,BDNF levels,increased,C0020676,Underactive thyroid,77999,"5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione","5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione",increase
1920,21873,34106297,"In this study, (hypothyroidism group; HP group) adult  male Sprague Dawley (SD) rats were induced to hypothyroidism after 5 weeks of exposure to 0.05% propylthiouracil (PTU) in potable water, control animals (CON group) were given the same amount of water.","['propylthiouracil', 'water', 'water']","['hypothyroidism', 'hypothyroidism']",True,propylthiouracil,hypothyroidism,induced,C0020676,Underactive thyroid,657298,Propylthiouracil,Propylthiouracil,induce
1921,21873,34106297,"In this study, (hypothyroidism group; HP group) adult  male Sprague Dawley (SD) rats were induced to hypothyroidism after 5 weeks of exposure to 0.05% propylthiouracil (PTU) in potable water, control animals (CON group) were given the same amount of water.","['propylthiouracil', 'water', 'water']","['hypothyroidism', 'hypothyroidism']",True,propylthiouracil,hypothyroidism,induced,C0020676,Underactive thyroid,657298,Propylthiouracil,Propylthiouracil,induce
1922,21873,34106297,"In this study, (hypothyroidism group; HP group) adult  male Sprague Dawley (SD) rats were induced to hypothyroidism after 5 weeks of exposure to 0.05% propylthiouracil (PTU) in potable water, control animals (CON group) were given the same amount of water.","['propylthiouracil', 'water', 'water']","['hypothyroidism', 'hypothyroidism']",True,water,hypothyroidism,induced,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,induce
1923,21873,34106297,"In this study, (hypothyroidism group; HP group) adult  male Sprague Dawley (SD) rats were induced to hypothyroidism after 5 weeks of exposure to 0.05% propylthiouracil (PTU) in potable water, control animals (CON group) were given the same amount of water.","['propylthiouracil', 'water', 'water']","['hypothyroidism', 'hypothyroidism']",True,water,hypothyroidism,induced,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,induce
1924,21873,34106297,"In this study, (hypothyroidism group; HP group) adult  male Sprague Dawley (SD) rats were induced to hypothyroidism after 5 weeks of exposure to 0.05% propylthiouracil (PTU) in potable water, control animals (CON group) were given the same amount of water.","['propylthiouracil', 'water', 'water']","['hypothyroidism', 'hypothyroidism']",True,water,hypothyroidism,induced,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,induce
1925,21873,34106297,"In this study, (hypothyroidism group; HP group) adult  male Sprague Dawley (SD) rats were induced to hypothyroidism after 5 weeks of exposure to 0.05% propylthiouracil (PTU) in potable water, control animals (CON group) were given the same amount of water.","['propylthiouracil', 'water', 'water']","['hypothyroidism', 'hypothyroidism']",True,water,hypothyroidism,induced,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,induce
1926,21874,34106297,"Besides, 5 weeks of PTU administration was associated with significantly decreased expression levels of 5-HT[Formula: see text] receptor and 5-HT[Formula: see text] receptor proteins compared with control group, which were significantly negatively correlated with immobility time in FST and TST.",['PTU administration'],['decreased expression levels'],True,PTU administration,decreased expression levels,associated,C1862474,Decreased facial expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PTU administration,associate
1927,21875,34106297,"In conclusion, our results suggest that hypothyroidism induces depressive behaviors through the influence of the serotonin system, and the decreased expression of the 5-HT[Formula: see text] receptor is an important cause of the depressive behaviors in hypothyroidism.",['serotonin'],"['depressive behaviors', 'decreased expression', 'hypothyroidism']",True,serotonin,depressive behaviors,induces,C1862474,Decreased facial expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,induce
1928,21896,33846035,"PTU can also induce ANCA-free or lupus vasculitis, maculopapular rashes or urticaria.",['PTU'],"['lupus vasculitis', 'maculopapular rashes', 'urticaria']",True,PTU,lupus vasculitis,induce,C0042384,Vasculitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PTU,induce
1929,21896,33846035,"PTU can also induce ANCA-free or lupus vasculitis, maculopapular rashes or urticaria.",['PTU'],"['lupus vasculitis', 'maculopapular rashes', 'urticaria']",True,PTU,urticaria,induce,C0042109,Urticaria,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PTU,induce
1930,21897,33845696,Hypothyroidism was induced using propylthiouracil  and hyperthyroidism was induced using L-thyroxine.,['propylthiouracil'],"['Hypothyroidism', 'hyperthyroidism']",True,propylthiouracil,Hypothyroidism,induced,C0020676,Underactive thyroid,657298,Propylthiouracil,Propylthiouracil,induce
1931,21897,33845696,Hypothyroidism was induced using propylthiouracil  and hyperthyroidism was induced using L-thyroxine.,['propylthiouracil'],"['Hypothyroidism', 'hyperthyroidism']",True,propylthiouracil,hyperthyroidism,induced,C0020550,Overactive thyroid,657298,Propylthiouracil,Propylthiouracil,induce
1932,21901,33781005,"Experiment groups were designed as follows. 1-Control, 2-Hypothyroidism; To induce hypothyroidism PTU was applied by intraperitoneal as 10 mg/kg/day for 2 weeks.",['PTU'],"['2-Hypothyroidism', 'hypothyroidism']",True,PTU,hypothyroidism,induce,C0020676,Underactive thyroid,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PTU,induce
1933,21903,33779553,"  OBJECTIVE: Thionamides (methimazole and propylthiouracil) have been associated with common side effects, such as rash and pruritus, and rare but serious adverse effects, such as agranulocytosis and hepatotoxicity.","['methimazole', 'propylthiouracil']","['rash', 'pruritus', 'agranulocytosis', 'hepatotoxicity']",True,methimazole,rash,associated,C0015230,Rash,1349907,Methimazole,Methimazole,associate
1934,21903,33779553,"  OBJECTIVE: Thionamides (methimazole and propylthiouracil) have been associated with common side effects, such as rash and pruritus, and rare but serious adverse effects, such as agranulocytosis and hepatotoxicity.","['methimazole', 'propylthiouracil']","['rash', 'pruritus', 'agranulocytosis', 'hepatotoxicity']",True,methimazole,pruritus,associated,C0033774,Skin itching,1349907,Methimazole,Methimazole,associate
1935,21903,33779553,"  OBJECTIVE: Thionamides (methimazole and propylthiouracil) have been associated with common side effects, such as rash and pruritus, and rare but serious adverse effects, such as agranulocytosis and hepatotoxicity.","['methimazole', 'propylthiouracil']","['rash', 'pruritus', 'agranulocytosis', 'hepatotoxicity']",True,propylthiouracil,rash,associated,C0015230,Rash,657298,Propylthiouracil,Propylthiouracil,associate
1936,21903,33779553,"  OBJECTIVE: Thionamides (methimazole and propylthiouracil) have been associated with common side effects, such as rash and pruritus, and rare but serious adverse effects, such as agranulocytosis and hepatotoxicity.","['methimazole', 'propylthiouracil']","['rash', 'pruritus', 'agranulocytosis', 'hepatotoxicity']",True,propylthiouracil,pruritus,associated,C0033774,Skin itching,657298,Propylthiouracil,Propylthiouracil,associate
1937,21910,35306950,"  INTRODUCTION: Mycobacterium simiae (M.simiae), a rare non-tuberculous mycobacterium (NTM), causes infection including localized pulmonary to disseminated disease in immunocompromised patients.",['mycobacterium'],['infection including localized pulmonary to disseminated disease'],True,mycobacterium,infection including localized pulmonary to disseminated disease,causes,C0033774,Skin itching,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mycobacterium,cause
1938,22001,35279796,"Selenium and copper are related to insulin resistance, and their increasing levels are associated with increased levels of markers of oxidative stress and inflammatory cytokines (p < 0.05).Increased levels of copper and selenium are associated with T2DM and this increase is also  associated with increased levels of TNF-α, IL-6, and oxidative stress in T2DM.","['Selenium', 'copper', 'copper', 'selenium']","['oxidative stress', 'increased levels of TNF-α', 'oxidative stress']",True,copper,oxidative stress,associated,C0242606,Oxidative stress,23978,copper,copper,associate
1939,22001,35279796,"Selenium and copper are related to insulin resistance, and their increasing levels are associated with increased levels of markers of oxidative stress and inflammatory cytokines (p < 0.05).Increased levels of copper and selenium are associated with T2DM and this increase is also  associated with increased levels of TNF-α, IL-6, and oxidative stress in T2DM.","['Selenium', 'copper', 'copper', 'selenium']","['oxidative stress', 'increased levels of TNF-α', 'oxidative stress']",True,copper,increased levels of TNF-α,associated,C4073162,Elevated hemoglobin A1c,23978,copper,copper,associate
1940,22001,35279796,"Selenium and copper are related to insulin resistance, and their increasing levels are associated with increased levels of markers of oxidative stress and inflammatory cytokines (p < 0.05).Increased levels of copper and selenium are associated with T2DM and this increase is also  associated with increased levels of TNF-α, IL-6, and oxidative stress in T2DM.","['Selenium', 'copper', 'copper', 'selenium']","['oxidative stress', 'increased levels of TNF-α', 'oxidative stress']",True,copper,oxidative stress,associated,C0242606,Oxidative stress,23978,copper,copper,associate
1941,22001,35279796,"Selenium and copper are related to insulin resistance, and their increasing levels are associated with increased levels of markers of oxidative stress and inflammatory cytokines (p < 0.05).Increased levels of copper and selenium are associated with T2DM and this increase is also  associated with increased levels of TNF-α, IL-6, and oxidative stress in T2DM.","['Selenium', 'copper', 'copper', 'selenium']","['oxidative stress', 'increased levels of TNF-α', 'oxidative stress']",True,selenium,oxidative stress,associated,C0242606,Oxidative stress,6326970,selenium,selenium,associate
1942,22001,35279796,"Selenium and copper are related to insulin resistance, and their increasing levels are associated with increased levels of markers of oxidative stress and inflammatory cytokines (p < 0.05).Increased levels of copper and selenium are associated with T2DM and this increase is also  associated with increased levels of TNF-α, IL-6, and oxidative stress in T2DM.","['Selenium', 'copper', 'copper', 'selenium']","['oxidative stress', 'increased levels of TNF-α', 'oxidative stress']",True,selenium,increased levels of TNF-α,associated,C4073162,Elevated hemoglobin A1c,6326970,selenium,selenium,associate
1943,22001,35279796,"Selenium and copper are related to insulin resistance, and their increasing levels are associated with increased levels of markers of oxidative stress and inflammatory cytokines (p < 0.05).Increased levels of copper and selenium are associated with T2DM and this increase is also  associated with increased levels of TNF-α, IL-6, and oxidative stress in T2DM.","['Selenium', 'copper', 'copper', 'selenium']","['oxidative stress', 'increased levels of TNF-α', 'oxidative stress']",True,selenium,oxidative stress,associated,C0242606,Oxidative stress,6326970,selenium,selenium,associate
1944,22007,35277041,"Evidence of inflammation (C-reactive protein, &gt;5 mg/L) was associated with a lower Se concentration and higher Cu concentration.",['Cu'],['inflammation'],True,Cu,inflammation,associated,C3875321,Skin inflammation,23978,copper,copper,associate
1945,22033,35267927," CONCLUSION: Our meta-analysis suggested that both body selenium status and selenium intake were negatively associated with hepatitis, cirrhosis, and liver cancer.","['selenium', 'selenium']","['hepatitis', 'cirrhosis', 'liver cancer']",True,selenium,hepatitis,associated,C0019158,Liver inflammation,6326970,selenium,selenium,associate
1946,22033,35267927," CONCLUSION: Our meta-analysis suggested that both body selenium status and selenium intake were negatively associated with hepatitis, cirrhosis, and liver cancer.","['selenium', 'selenium']","['hepatitis', 'cirrhosis', 'liver cancer']",True,selenium,cirrhosis,associated,C0023890,Cirrhosis,6326970,selenium,selenium,associate
1947,22033,35267927," CONCLUSION: Our meta-analysis suggested that both body selenium status and selenium intake were negatively associated with hepatitis, cirrhosis, and liver cancer.","['selenium', 'selenium']","['hepatitis', 'cirrhosis', 'liver cancer']",True,selenium,liver cancer,associated,C0345904,Liver cancer,6326970,selenium,selenium,associate
1948,22033,35267927," CONCLUSION: Our meta-analysis suggested that both body selenium status and selenium intake were negatively associated with hepatitis, cirrhosis, and liver cancer.","['selenium', 'selenium']","['hepatitis', 'cirrhosis', 'liver cancer']",True,selenium,hepatitis,associated,C0019158,Liver inflammation,6326970,selenium,selenium,associate
1949,22033,35267927," CONCLUSION: Our meta-analysis suggested that both body selenium status and selenium intake were negatively associated with hepatitis, cirrhosis, and liver cancer.","['selenium', 'selenium']","['hepatitis', 'cirrhosis', 'liver cancer']",True,selenium,cirrhosis,associated,C0023890,Cirrhosis,6326970,selenium,selenium,associate
1950,22033,35267927," CONCLUSION: Our meta-analysis suggested that both body selenium status and selenium intake were negatively associated with hepatitis, cirrhosis, and liver cancer.","['selenium', 'selenium']","['hepatitis', 'cirrhosis', 'liver cancer']",True,selenium,liver cancer,associated,C0345904,Liver cancer,6326970,selenium,selenium,associate
1951,22039,35263859,Ischemic stroke is associated with the generation of oxygen free radicals resulting in a condition of oxidative stress.,['oxygen'],"['Ischemic stroke', 'oxidative stress']",True,oxygen,Ischemic stroke,associated,C0948008,Ischemic stroke,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,associate
1952,22039,35263859,Ischemic stroke is associated with the generation of oxygen free radicals resulting in a condition of oxidative stress.,['oxygen'],"['Ischemic stroke', 'oxidative stress']",True,oxygen,oxidative stress,associated,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,associate
1953,22055,35247670,Phytomedicine. 2022 Feb 26;99:154014. doi: 10.1016/j.phymed.2022.154014. [Epub ahead of print]  Biosynthesis and cytotoxic effect of silymarin-functionalized selenium nanoparticles induced autophagy mediated cellular apoptosis via downregulation of PI3K/Akt/mTOR pathway in gastric cancer.,['selenium'],"['downregulation of PI3K/Akt/mTOR pathway in', 'gastric cancer']",True,selenium,gastric cancer,induced,C0024623,Gastric cancer,6326970,selenium,selenium,induce
1954,22074,34944156,"  Macrolide drugs are the treatment of choice for Rhodococcus equi infections, despite severe side-effects temporary anhidrosis as a. To better understand the molecular biology leading to macrolide induced anhidrosis, we performed skin biopsies and Quantitative Intradermal Terbutaline Sweat Tests (QITSTs) in six healthy pony-cross foals for three different timepoints during erythromycin administration-pre-treatment (baseline), during anhidrosis and post-recovery.","['macrolide', 'erythromycin']","['temporary anhidrosis', 'anhidrosis', 'anhidrosis']",True,macrolide,anhidrosis,leading,C0003028,Sudomotor dysfunction,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",macrolide,lead
1955,22082,34768291,"Antenatal terbutaline was not associated with RDS or BPD but was significantly associated with a reduction in grade III-IV IVH  (aOR 0.11, CI 0.01-0.98; p = 0.048), in infants with the GA of <32 weeks.",['terbutaline'],"['BPD', 'reduction in grade III-IV IVH']",True,terbutaline,BPD,associated,C0003028,Sudomotor dysfunction,5403,Terbutaline,Terbutaline,associate
1956,22086,34739146,Our in vitro results showed that terbutaline can directly inhibit osteogenesis by impairing osteogenic differentiation and mineralization.,['terbutaline'],"['osteogenesis', 'osteogenic differentiation', 'mineralization']",True,terbutaline,mineralization,inhibit,C1857074,Absent sternal ossification,5403,Terbutaline,Terbutaline,inhibit
1957,22119,33347508,"Terbutaline (100 nmol-100 M), forskolin (30 nM-100 M) or 8-Br-cAMP (100 nM- 10 μM), administered in the arterial perfusate produced significant reductions in AHF.","['Terbutaline', 'forskolin']",['reductions in AHF'],True,Terbutaline,reductions in AHF,produced,C1857074,Absent sternal ossification,5403,Terbutaline,Terbutaline,produce
1958,22119,33347508,"Terbutaline (100 nmol-100 M), forskolin (30 nM-100 M) or 8-Br-cAMP (100 nM- 10 μM), administered in the arterial perfusate produced significant reductions in AHF.","['Terbutaline', 'forskolin']",['reductions in AHF'],True,forskolin,reductions in AHF,produced,C1857074,Absent sternal ossification,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",forskolin,produce
1959,22126,33136831, CONCLUSIONS: Terbutaline administration given to pediatric patients experiencing  a severe asthma exacerbation was not associated with decreased PICU or general hospital floor admission.,['Terbutaline'],"['asthma', 'decreased PICU', 'general hospital floor admission']",True,Terbutaline,asthma,associated,C0004096,Asthma,5403,Terbutaline,Terbutaline,associate
1960,22126,33136831, CONCLUSIONS: Terbutaline administration given to pediatric patients experiencing  a severe asthma exacerbation was not associated with decreased PICU or general hospital floor admission.,['Terbutaline'],"['asthma', 'decreased PICU', 'general hospital floor admission']",True,Terbutaline,decreased PICU,associated,C0427437,Decreased mean corpuscular haemoglobin,5403,Terbutaline,Terbutaline,associate
1961,22198,33870020,"  Environmental pollutants have been associated with hypertensive disorders in pregnancy including gestational hypertension, preeclampsia, and eclampsia, though few have focused on drinking water contamination.",['water'],"['hypertensive disorders in pregnancy including gestational hypertension', 'preeclampsia', 'eclampsia']",True,water,hypertensive disorders in pregnancy including gestational hypertension,associated,C4551893,Toxemia of pregnancy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,associate
1962,22198,33870020,"  Environmental pollutants have been associated with hypertensive disorders in pregnancy including gestational hypertension, preeclampsia, and eclampsia, though few have focused on drinking water contamination.",['water'],"['hypertensive disorders in pregnancy including gestational hypertension', 'preeclampsia', 'eclampsia']",True,water,preeclampsia,associated,C0032914,Preeclampsia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,associate
1963,22198,33870020,"  Environmental pollutants have been associated with hypertensive disorders in pregnancy including gestational hypertension, preeclampsia, and eclampsia, though few have focused on drinking water contamination.",['water'],"['hypertensive disorders in pregnancy including gestational hypertension', 'preeclampsia', 'eclampsia']",True,water,eclampsia,associated,C0013537,Eclampsia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,associate
1964,22199,33870020,Methods: We linked water quality data on 13 contaminants and two violations from the California Communities Environmental Health Screening Tool to birth records from vital statistics and hospital discharge records (2007-2012) to examine the relationship between drinking water contamination and hypertensive disorders in pregnancy.,['water'],['hypertensive disorders in pregnancy'],True,water,hypertensive disorders in pregnancy,linked,C4551893,Toxemia of pregnancy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",water,link
1965,22202,33870020," In multipollutant models, cadmium was consistent, lead and trihalomethane were stronger, and additional contaminants were associated with hypertensive disorders in pregnancy including trichloroethylene, 1,2-Dibromo-3-chloropropane, nitrate, and tetrachloroethylene.","['cadmium', 'trichloroethylene', 'tetrachloroethylene']",['hypertensive disorders in pregnancy'],True,trichloroethylene,hypertensive disorders in pregnancy,associated,C4551893,Toxemia of pregnancy,6575,"1,1,2-trichloroethene","1,1,2-trichloroethene",associate
1966,22202,33870020," In multipollutant models, cadmium was consistent, lead and trihalomethane were stronger, and additional contaminants were associated with hypertensive disorders in pregnancy including trichloroethylene, 1,2-Dibromo-3-chloropropane, nitrate, and tetrachloroethylene.","['cadmium', 'trichloroethylene', 'tetrachloroethylene']",['hypertensive disorders in pregnancy'],True,tetrachloroethylene,hypertensive disorders in pregnancy,associated,C4551893,Toxemia of pregnancy,31373,TETRACHLOROETHYLENE,TETRACHLOROETHYLENE,associate
1967,22248,35186174,"  Background: Toluene diisocyanate (TDI) causes occupational asthma by generating oxidative stress, leading to tissue injury and inflammation.",['Toluene diisocyanate'],"['asthma', 'tissue injury', 'inflammation']",True,Toluene diisocyanate,asthma,causes,C0004096,Asthma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Toluene diisocyanate,cause
1968,22248,35186174,"  Background: Toluene diisocyanate (TDI) causes occupational asthma by generating oxidative stress, leading to tissue injury and inflammation.",['Toluene diisocyanate'],"['asthma', 'tissue injury', 'inflammation']",True,Toluene diisocyanate,inflammation,causes,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Toluene diisocyanate,cause
1969,22303,31789848,  PURPOSE OF REVIEW: Proteinuria in nephrotic syndrome is associated with sodium retention and edema.,['sodium retention'],"['Proteinuria in nephrotic syndrome', 'edema']",True,sodium retention,Proteinuria in nephrotic syndrome,associated,C0027726,Nephrotic syndrome,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium retention,associate
1970,22303,31789848,  PURPOSE OF REVIEW: Proteinuria in nephrotic syndrome is associated with sodium retention and edema.,['sodium retention'],"['Proteinuria in nephrotic syndrome', 'edema']",True,sodium retention,edema,associated,C0013604,Edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium retention,associate
1971,22312,31644115,"Common side effects are those that are caused by the diuresis and mineral loss such as weakness, dizziness, electrolyte imbalance, low sodium and potassium.",['potassium'],"['diuresis', 'mineral loss', 'weakness', 'dizziness', 'electrolyte imbalance']",True,potassium,dizziness,caused,C0012833,Dizziness,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",potassium,cause
1972,22312,31644115,"Common side effects are those that are caused by the diuresis and mineral loss such as weakness, dizziness, electrolyte imbalance, low sodium and potassium.",['potassium'],"['diuresis', 'mineral loss', 'weakness', 'dizziness', 'electrolyte imbalance']",True,potassium,electrolyte imbalance,caused,C0012833,Dizziness,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",potassium,cause
1973,22330,30867489," Furthermore, inhibition of the TGR5 receptor with triamterene or of deiodinase II downstream of the TGR5 receptor with iopanoic acid also resulted in the attenuation of MDMA-induced hyperthermia.","['triamterene', 'iopanoic acid']",['inhibition of the TGR5 receptor'],True,triamterene,inhibition of the TGR5 receptor,resulted,C0012833,Dizziness,5546,Triamterene,Triamterene,result
1974,22330,30867489," Furthermore, inhibition of the TGR5 receptor with triamterene or of deiodinase II downstream of the TGR5 receptor with iopanoic acid also resulted in the attenuation of MDMA-induced hyperthermia.","['triamterene', 'iopanoic acid']",['inhibition of the TGR5 receptor'],True,iopanoic acid,inhibition of the TGR5 receptor,resulted,C0012833,Dizziness,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iopanoic acid,result
1975,22339,20301512," DIAGNOSIS/TESTING: The diagnosis of hypoPP is established in a proband who meets  the consensus diagnostic criteria based on a history of attacks of muscle weakness associated with documented serum potassium <3.5 mmol/L during attacks and/or the identification of a heterozygous pathogenic variant in CACNA1S or SCN4A. Of all individuals meeting diagnostic criteria for hypoPP, approximately 30% do not have a pathogenic variant identified in either of these known genes.",['potassium'],"['attacks of muscle weakness', 'attacks']",True,potassium,attacks,associated,C0270846,drop seizures,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",potassium,associate
1976,22344,29792170,"Treatment with triamterene together with a steroid for nephrotic syndrome resulted in rapid and  remarkable effective on improvements of hypertension, hypokalemia, and edema of the lower extremities.",['triamterene'],"['hypertension', 'hypokalemia', 'edema of the lower extremities']",True,triamterene,hypertension,resulted,C0020538,Systemic hypertension,5546,Triamterene,Triamterene,result
1977,22344,29792170,"Treatment with triamterene together with a steroid for nephrotic syndrome resulted in rapid and  remarkable effective on improvements of hypertension, hypokalemia, and edema of the lower extremities.",['triamterene'],"['hypertension', 'hypokalemia', 'edema of the lower extremities']",True,triamterene,hypokalemia,resulted,C0020621,Hypokalemia,5546,Triamterene,Triamterene,result
1978,22344,29792170,"Treatment with triamterene together with a steroid for nephrotic syndrome resulted in rapid and  remarkable effective on improvements of hypertension, hypokalemia, and edema of the lower extremities.",['triamterene'],"['hypertension', 'hypokalemia', 'edema of the lower extremities']",True,triamterene,edema of the lower extremities,resulted,C0013604,Edema,5546,Triamterene,Triamterene,result
1979,22370,26908119,"Antihypertensive drugs (particularly alpha blockers) can result in stress incontinence, whereas selective serotonin reuptake inhibitors (SSRI) can cause urge incontinence and estrogen promotes both forms.",['serotonin'],"['stress incontinence', 'incontinence']",True,serotonin,incontinence,result,C0015732,Loss of bowel control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,result
1980,22370,26908119,"Antihypertensive drugs (particularly alpha blockers) can result in stress incontinence, whereas selective serotonin reuptake inhibitors (SSRI) can cause urge incontinence and estrogen promotes both forms.",['serotonin'],"['stress incontinence', 'incontinence']",True,serotonin,incontinence,cause,C0015732,Loss of bowel control,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",serotonin,cause
1981,22373,26855365,"Triamterene (10, 20 and 40 mg/kg) treatment also increased the latency of clonic seizure and decreased its frequency in intraperitoneal PTZ model.",['Triamterene'],['latency of clonic seizure'],True,Triamterene,latency of clonic seizure,increased,C0015732,Loss of bowel control,5546,Triamterene,Triamterene,increase
1982,22377,26556568," Spironolactone caused greater hyperkalemia than amiloride across their dose ranges: 0.14, P = 0.043.","['Spironolactone', 'amiloride']",['greater hyperkalemia'],True,Spironolactone,greater hyperkalemia,caused,C0020461,Elevated serum potassium levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Spironolactone,cause
1983,22377,26556568," Spironolactone caused greater hyperkalemia than amiloride across their dose ranges: 0.14, P = 0.043.","['Spironolactone', 'amiloride']",['greater hyperkalemia'],True,amiloride,greater hyperkalemia,caused,C0020461,Elevated serum potassium levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amiloride,cause
1984,22394,25325125,"Thiazide diuretics can provoke hyperglycaemia and diabetes, although this does not reduce their efficacy in the prevention of cardiovascular events.",['Thiazide'],"['hyperglycaemia', 'diabetes']",True,Thiazide,hyperglycaemia,provoke,C0020615,Hypoglycaemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Thiazide,provoke
1985,22394,25325125,"Thiazide diuretics can provoke hyperglycaemia and diabetes, although this does not reduce their efficacy in the prevention of cardiovascular events.",['Thiazide'],"['hyperglycaemia', 'diabetes']",True,Thiazide,diabetes,provoke,C0085207,Maternal diabetes,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Thiazide,provoke
1986,22398,35316152,"In vitro cell function experiments verified that silencing MT1X inhibited the proliferation of AML cells, sensitized cells to doxorubicin, and increased their apoptosis.",['doxorubicin'],"['proliferation of AML cells', 'increased their apoptosis']",True,doxorubicin,proliferation of AML cells,inhibited,C1855752,Abnormal T cell morphology,31703,Doxorubicin,Doxorubicin,inhibit
1987,22479,35278676,"Importantly, we identified  the approved drug tadalafil as a novel PRMT5 inhibitor that could decrease RNA m6A methylation and increase doxorubicin sensitivity in breast cancer.","['tadalafil', 'doxorubicin']","['methylation', 'breast cancer']",True,doxorubicin,breast cancer,increase,C0678222,Breast cancer,31703,Doxorubicin,Doxorubicin,increase
1988,22489,35276382,  Plasma-activated medium inhibits cancer stem cell-like properties and exhibits a  synergistic effect in combination with cisplatin in ovarian cancer.,['cisplatin'],"['cancer stem', 'cancer']",True,cisplatin,cancer stem,inhibits,C0006826,Cancer,5702198,azane;dichloroplatinum,azane;dichloroplatinum,inhibit
1989,22489,35276382,  Plasma-activated medium inhibits cancer stem cell-like properties and exhibits a  synergistic effect in combination with cisplatin in ovarian cancer.,['cisplatin'],"['cancer stem', 'cancer']",True,cisplatin,cancer,inhibits,C0006826,Cancer,5702198,azane;dichloroplatinum,azane;dichloroplatinum,inhibit
1990,22520,35265195,"Conclusions: Collectively, targeted tumor delivery of anti-PD-L1 peptide and DOX via PD-NPs efficiently inhibit tumor progression with minimal side effects.",['DOX'],"['tumor delivery', 'tumor progression']",True,DOX,tumor delivery,inhibit,C0023903,Liver tumor,31703,Doxorubicin,Doxorubicin,inhibit
1991,22520,35265195,"Conclusions: Collectively, targeted tumor delivery of anti-PD-L1 peptide and DOX via PD-NPs efficiently inhibit tumor progression with minimal side effects.",['DOX'],"['tumor delivery', 'tumor progression']",True,DOX,tumor progression,inhibit,C0027651,Neoplasm,31703,Doxorubicin,Doxorubicin,inhibit
1992,22526,35260914,ACT-iPSC CM generated from individuals with CD20+ B-cell lymphoma who had received high doses of DOX and suffered cardiac dysfunction were studied  and compared to control-iPSC CM from cancer survivors without cardiac symptoms.,['DOX'],"['suffered cardiac dysfunction', 'cancer']",True,DOX,suffered cardiac dysfunction,generated,C0543968,Congenital stationary cone dysfunction,31703,Doxorubicin,Doxorubicin,generate
1993,22535,35259354,"Furthermore, siRNA can be used to suppress the activity of P-glycoprotein as a cell membrane transporter of drugs, leading to enhanced accumulation of DOX.",['DOX'],['enhanced accumulation'],True,DOX,enhanced accumulation,leading,C0543968,Congenital stationary cone dysfunction,31703,Doxorubicin,Doxorubicin,lead
1994,22564,35283069,"This analytical method  has been successfully applied for the determination of plasma aescinate A and aescinate B concentrations in patients with cerebral infarction, and the results  showed that the incidence and grade of phlebitis were not associated with the in  vivo exposure of aescinate A and aescinate B.  Copyright © 2022.","['aescinate', 'aescinate A', 'aescinate B.']","['cerebral infarction', 'phlebitis']",True,aescinate A,phlebitis,associated,C3550150,Recurrent thrombophlebitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aescinate A,associate
1995,22581,35169665, Conclusions: We did not observe evidence that urinary BPA or BPS concentrations during childhood were associated with greater child adiposity at ages 8 and 12 years in this cohort.,['BPA'],"['childhood', 'greater child adiposity']",True,BPA,childhood,associated,C1837352,Childhood onset,6623,Bisphenol A,Bisphenol A,associate
1996,22582,35149449,"We aimed to explore whether individual or mixtures of BPA, BPS and BPF assessed in repeated urinary measurements were associated with semen quality among 984 Chinese men from an infertility clinic.","['BPA', 'BPF']","['BPS', 'infertility']",True,BPA,BPS,associated,C4477086,Cotton wool plaques,6623,Bisphenol A,Bisphenol A,associate
1997,22582,35149449,"We aimed to explore whether individual or mixtures of BPA, BPS and BPF assessed in repeated urinary measurements were associated with semen quality among 984 Chinese men from an infertility clinic.","['BPA', 'BPF']","['BPS', 'infertility']",True,BPA,infertility,associated,C0021359,Infertility,6623,Bisphenol A,Bisphenol A,associate
1998,22582,35149449,"We aimed to explore whether individual or mixtures of BPA, BPS and BPF assessed in repeated urinary measurements were associated with semen quality among 984 Chinese men from an infertility clinic.","['BPA', 'BPF']","['BPS', 'infertility']",True,BPF,BPS,associated,C4477086,Cotton wool plaques,12111,"4,4'-Methylenediphenol","4,4'-Methylenediphenol",associate
1999,22582,35149449,"We aimed to explore whether individual or mixtures of BPA, BPS and BPF assessed in repeated urinary measurements were associated with semen quality among 984 Chinese men from an infertility clinic.","['BPA', 'BPF']","['BPS', 'infertility']",True,BPF,infertility,associated,C0021359,Infertility,12111,"4,4'-Methylenediphenol","4,4'-Methylenediphenol",associate
2000,22583,35149449,"We found that higher BPA exposure was associated with increased odds ratios (ORs) of having below-reference sperm concentration, total sperm count, progressive motility and total motility (all P  for trends < 0.05).",['BPA'],"['increased odds ratios (ORs)', 'total sperm count', 'progressive motility', 'total motility']",True,BPA,increased odds ratios,associated,C0021359,Infertility,6623,Bisphenol A,Bisphenol A,associate
2001,22583,35149449,"We found that higher BPA exposure was associated with increased odds ratios (ORs) of having below-reference sperm concentration, total sperm count, progressive motility and total motility (all P  for trends < 0.05).",['BPA'],"['increased odds ratios (ORs)', 'total sperm count', 'progressive motility', 'total motility']",True,BPA,total sperm count,associated,C0028960,Oligospermia,6623,Bisphenol A,Bisphenol A,associate
2002,22583,35149449,"We found that higher BPA exposure was associated with increased odds ratios (ORs) of having below-reference sperm concentration, total sperm count, progressive motility and total motility (all P  for trends < 0.05).",['BPA'],"['increased odds ratios (ORs)', 'total sperm count', 'progressive motility', 'total motility']",True,BPA,progressive motility,associated,C0205329,Worsens with time,6623,Bisphenol A,Bisphenol A,associate
2003,22584,35143014,"BPA  inhibits key cardiac ion channels, impairs cardiac excitability, and acts as a more potent inhibitor as compared to BPF and BPS.","['BPA', 'BPF']","['impairs cardiac excitability', 'BPS']",True,BPA,BPS,inhibits,C4477086,Cotton wool plaques,6623,Bisphenol A,Bisphenol A,inhibit
2004,22584,35143014,"BPA  inhibits key cardiac ion channels, impairs cardiac excitability, and acts as a more potent inhibitor as compared to BPF and BPS.","['BPA', 'BPF']","['impairs cardiac excitability', 'BPS']",True,BPF,BPS,inhibits,C4477086,Cotton wool plaques,12111,"4,4'-Methylenediphenol","4,4'-Methylenediphenol",inhibit
2005,22601,35045766,All bisphenol derivatives caused increases in intracellular ROS  production.,['bisphenol'],['increases in intracellular ROS  production'],True,bisphenol,increases in intracellular ROS  production,caused,C4476796,Increased reactive oxygen species production,6623,Bisphenol A,Bisphenol A,cause
2006,22607,34990787,"Furthermore, BPS challenge triggered oxidative stress manifested by compromised activities of superoxide dismutase and catalase with exaggerated formation of reactive oxygen species.",['oxygen'],['oxidative stress'],True,oxygen,oxidative stress,triggered,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,trigger
2007,22617,34942454,"Furthermore, zebrafish embryo-larvae were exposed to BPS (0, 1, 10 and 100 μg/L) for 15 days (d) and the characteristic symptoms of ASCVD including an inflammatory response, macrophage recruitment around blood vessels,  and accumulation of oxLDL on vascular endothelium, were induced in 15-d larvae.",['oxLDL'],"['ASCVD', 'inflammatory response', 'macrophage recruitment around blood vessels', 'vascular endothelium']",True,oxLDL,inflammatory response,induced,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxLDL,induce
2008,22617,34942454,"Furthermore, zebrafish embryo-larvae were exposed to BPS (0, 1, 10 and 100 μg/L) for 15 days (d) and the characteristic symptoms of ASCVD including an inflammatory response, macrophage recruitment around blood vessels,  and accumulation of oxLDL on vascular endothelium, were induced in 15-d larvae.",['oxLDL'],"['ASCVD', 'inflammatory response', 'macrophage recruitment around blood vessels', 'vascular endothelium']",True,oxLDL,macrophage recruitment around blood vessels,induced,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxLDL,induce
2009,22620,34915096,"BPA levels were associated with decreased HDL-C levels (Q3: β = -0.053,  p = 0.08 (US); Q2: β = -0.030, p-0.03), increased TG levels (Q3: β = 0.121, p = 0.029 (US); Q3: β = 0.089, p = 0.021, and higher odds for obesity (Q3: OR = 1.58, 95% CI: 1.06, 2.35 (US); Q3: OR = 1.41, 95% CI: 1.11, 1.78).",['BPA'],"['decreased HDL-C levels', 'increased TG levels', 'obesity']",True,BPA,increased TG levels,associated,C4073162,Elevated hemoglobin A1c,6623,Bisphenol A,Bisphenol A,associate
2010,22620,34915096,"BPA levels were associated with decreased HDL-C levels (Q3: β = -0.053,  p = 0.08 (US); Q2: β = -0.030, p-0.03), increased TG levels (Q3: β = 0.121, p = 0.029 (US); Q3: β = 0.089, p = 0.021, and higher odds for obesity (Q3: OR = 1.58, 95% CI: 1.06, 2.35 (US); Q3: OR = 1.41, 95% CI: 1.11, 1.78).",['BPA'],"['decreased HDL-C levels', 'increased TG levels', 'obesity']",True,BPA,obesity,associated,C0028754,Obesity,6623,Bisphenol A,Bisphenol A,associate
2011,22622,34915096,"The findings of our study indicate that BPA and its analogues, BPS and BPF, are associated with lipid metabolism disorders in addition to obesity in adults.","['BPA', 'BPF']","['lipid metabolism disorders', 'obesity']",True,BPA,obesity,associated,C0028754,Obesity,6623,Bisphenol A,Bisphenol A,associate
2012,22622,34915096,"The findings of our study indicate that BPA and its analogues, BPS and BPF, are associated with lipid metabolism disorders in addition to obesity in adults.","['BPA', 'BPF']","['lipid metabolism disorders', 'obesity']",True,BPF,obesity,associated,C0028754,Obesity,12111,"4,4'-Methylenediphenol","4,4'-Methylenediphenol",associate
2013,22651,34820485,"Maternal EX led to a significant decrease in body fat percentage and bone stiffness, independent of EDC exposure.",['EDC'],['decrease in body fat percentage and bone stiffness'],True,EDC,decrease in body fat percentage and bone stiffness,led,C4476824,Increased body fat percentage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",EDC,lead
2014,22661,34781130,"Results indicate that prenatal exposure to bisphenol mixtures might increase the risk of PTB, which might be primarily driven by BPA, BPF and BPS.","['bisphenol', 'BPA', 'BPF']",['BPS'],True,bisphenol,BPS,increase,C4477086,Cotton wool plaques,6623,Bisphenol A,Bisphenol A,increase
2015,22661,34781130,"Results indicate that prenatal exposure to bisphenol mixtures might increase the risk of PTB, which might be primarily driven by BPA, BPF and BPS.","['bisphenol', 'BPA', 'BPF']",['BPS'],True,BPA,BPS,increase,C4477086,Cotton wool plaques,6623,Bisphenol A,Bisphenol A,increase
2016,22661,34781130,"Results indicate that prenatal exposure to bisphenol mixtures might increase the risk of PTB, which might be primarily driven by BPA, BPF and BPS.","['bisphenol', 'BPA', 'BPF']",['BPS'],True,BPF,BPS,increase,C4477086,Cotton wool plaques,12111,"4,4'-Methylenediphenol","4,4'-Methylenediphenol",increase
2017,22666,34624477,"The interference in amino acid metabolism by bisphenol S could trigger Alzheimer's disease, while its disturbance of glucose metabolism was associated with type II diabetes.",['bisphenol S'],"['amino acid metabolism', 'disturbance of glucose metabolism']",True,bisphenol S,amino acid metabolism,trigger,C1328440,Abnormality of amino acid metabolism,6626,Bisphenol S,Bisphenol S,trigger
2018,22667,34624477,Disturbed glycolipid metabolism  and vitamin metabolism could induce Alzheimer's disease and diabetes.,['vitamin metabolism'],['diabetes'],True,vitamin metabolism,diabetes,induce,C0085207,Maternal diabetes,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",vitamin metabolism,induce
2019,22678,34474391,"Taken together, these findings imply that BPA and BPS cause behavioral impairments in juvenile mice by disrupting local neuronal activation in the BLA.",['BPA'],"['BPS', 'local neuronal activation']",True,BPA,BPS,cause,C4477086,Cotton wool plaques,6623,Bisphenol A,Bisphenol A,cause
2020,22682,34474090, BPA increased ATP levels and decreased ROS but did not affect mitochondrial permeability transition pores (mPTP).,['BPA'],['decreased ROS'],True,BPA,decreased ROS,increased,C0427437,Decreased mean corpuscular haemoglobin,6623,Bisphenol A,Bisphenol A,increase
2021,22685,34438265,"  While bisphenol A (BPA) exposure was inconsistently associated with hypertension  risk, little is known about whether its alternatives bisphenol S and F (BPS and BPF) have similar hypertensive effects.","['bisphenol A', 'BPA', 'BPF']",['hypertension  risk'],True,bisphenol A,hypertension  risk,associated,C0020538,Systemic hypertension,6623,Bisphenol A,Bisphenol A,associate
2022,22689,34382084,"Temephos inhibits acetylcholinesterase (AChE) and is metabolized in different tissues, probably by mixed-function oxidases; one of its metabolites is bisphenol S (BPS), which is considered an endocrine disruptor.","['Temephos', 'bisphenol S']",['endocrine disruptor'],True,Temephos,endocrine disruptor,inhibits,C0020538,Systemic hypertension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Temephos,inhibit
2023,22689,34382084,"Temephos inhibits acetylcholinesterase (AChE) and is metabolized in different tissues, probably by mixed-function oxidases; one of its metabolites is bisphenol S (BPS), which is considered an endocrine disruptor.","['Temephos', 'bisphenol S']",['endocrine disruptor'],True,bisphenol S,endocrine disruptor,inhibits,C0020538,Systemic hypertension,6626,Bisphenol S,Bisphenol S,inhibit
2024,22713,34238571," Second trimester BPA concentrations were associated with preterm birth (Risk Ratio [RR] 1.24; 95%CI: 0.92, 1.69), which was primarily driven by female (RR 1.40; 95%CI: 1.04, 1.89) and not male (RR 0.85; 95%CI 0.50, 1.46) infants.",['BPA'],['preterm birth'],True,BPA,preterm birth,associated,C0020538,Systemic hypertension,6623,Bisphenol A,Bisphenol A,associate
2025,22790,34749916,Acetazolamide use is associated with mild metabolic acidosis.,['Acetazolamide'],['metabolic acidosis'],True,Acetazolamide,metabolic acidosis,associated,C0220981,Metabolic acidosis,1986,Acetazolamide,Acetazolamide,associate
2026,22816,34628431,"Significant IOP elevation in fellow eyes was associated with tube shunt surgery (P<0.008 at all-time points), a diagnosis of glaucoma following cataract  surgery, IOP ≤5 mm Hg on the first postoperative day (P=0.002) and use of preoperative acetazolamide.",['acetazolamide'],['glaucoma'],True,acetazolamide,glaucoma,associated,C0017601,Glaucoma,1986,Acetazolamide,Acetazolamide,associate
2027,22852,34888886,[Epub ahead of print]  Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.,['nivolumab'],"['pustular psoriasiform', 'metastatic esophageal adenocarcinoma']",True,nivolumab,metastatic esophageal adenocarcinoma,associated,C0152018,Esophageal carcinoma,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",nivolumab,associate
2028,22857,34884474,"In vitro, these expressions were synergistically induced by the triple combination of tumor necrosis factor (TNF)-α, IL-17A, and interferon (IFN)-γ, and suppressed by dexamethasone, vitamin D3, and acitretin.","['interferon', 'dexamethasone', 'vitamin', 'acitretin']",['tumor necrosis factor'],True,dexamethasone,tumor necrosis factor,induced,C4023529,Abnormality of tumor necrosis factor secretion,5743,Dexamethasone,Dexamethasone,induce
2029,22857,34884474,"In vitro, these expressions were synergistically induced by the triple combination of tumor necrosis factor (TNF)-α, IL-17A, and interferon (IFN)-γ, and suppressed by dexamethasone, vitamin D3, and acitretin.","['interferon', 'dexamethasone', 'vitamin', 'acitretin']",['tumor necrosis factor'],True,vitamin,tumor necrosis factor,induced,C4023529,Abnormality of tumor necrosis factor secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",vitamin,induce
2030,22857,34884474,"In vitro, these expressions were synergistically induced by the triple combination of tumor necrosis factor (TNF)-α, IL-17A, and interferon (IFN)-γ, and suppressed by dexamethasone, vitamin D3, and acitretin.","['interferon', 'dexamethasone', 'vitamin', 'acitretin']",['tumor necrosis factor'],True,acitretin,tumor necrosis factor,induced,C4023529,Abnormality of tumor necrosis factor secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",acitretin,induce
2031,22868,34661345,"Ablative surgical interventions such as dermabrasion and CO2 laser surgery can lead to long-term remissions in intertriginous Hailey-Hailey disease, while temporary relief may also be achieved by intralesional injections  of botulinum toxin.",['botulinum'],['remissions in intertriginous Hailey-Hailey disease'],True,botulinum,remissions in intertriginous Hailey-Hailey disease,lead,C4023529,Abnormality of tumor necrosis factor secretion,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",botulinum,lead
2032,22894,34315969,"As an unintended side effect, acitretin could result in hyperlipidemia.",['acitretin'],['hyperlipidemia'],True,acitretin,hyperlipidemia,result,C0020473,Elevated lipids in blood,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",acitretin,result
2033,22902,34172768,Exposure to acitretin  and NB-UVB irradiation alone or in combination led to reduction of cell proliferation and MMP13 expression in HaCaT cells.,['acitretin'],['reduction of cell proliferation'],True,acitretin,reduction of cell proliferation,led,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",acitretin,lead
2034,22917,34068890," CONCLUSIONS: In patients with nail psoriasis, acitretin treatment resulted in a rapid decrease in the thickness of the nail bed and matrix, but it did not affect the thickness of the nail plate after six months.",['acitretin'],"['nail psoriasis', 'thickness of the nail plate']",True,acitretin,nail psoriasis,resulted,C0033860,Psoriasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",acitretin,result
2035,22934,34011542,IMPORTANCE Acitretin selectively inhibits BKPyV replication in primary human cell culture models of nephropathy and hemorrhagic cystitis.,['Acitretin'],"['BKPyV replication', 'hemorrhagic cystitis']",True,Acitretin,hemorrhagic cystitis,inhibits,C0473311,Hemorrhagic ovarian cyst,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Acitretin,inhibit
2036,22951,33871811,"Retinoids have evolved from first-generation agents, such as tretinoin, through chemical modifications resulting in a second generation (etretinate and acitretin for psoriasis), a third generation (adapalene and tazarotene) and, most recently, a fourth (trifarotene).","['tretinoin', 'etretinate', 'acitretin', 'adapalene', 'tazarotene', 'trifarotene']",['psoriasis'],True,etretinate,psoriasis,resulting,C0033860,Psoriasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",etretinate,result
2037,22951,33871811,"Retinoids have evolved from first-generation agents, such as tretinoin, through chemical modifications resulting in a second generation (etretinate and acitretin for psoriasis), a third generation (adapalene and tazarotene) and, most recently, a fourth (trifarotene).","['tretinoin', 'etretinate', 'acitretin', 'adapalene', 'tazarotene', 'trifarotene']",['psoriasis'],True,acitretin,psoriasis,resulting,C0033860,Psoriasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",acitretin,result
2038,22970,35226683,"Despite lower serum urate levels, febuxostat was significantly more associated with a 30% decline in eGFR (hazard ratio 1.26; 95% CI 1.03-1.54) and end-stage renal disease (hazard ratio 1.91, 95% CI 1.42-2.58) than allopurinol.","['febuxostat', 'allopurinol']",['renal disease'],True,febuxostat,renal disease,associated,C0151747,Renal tubular disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",febuxostat,associate
2039,22970,35226683,"Despite lower serum urate levels, febuxostat was significantly more associated with a 30% decline in eGFR (hazard ratio 1.26; 95% CI 1.03-1.54) and end-stage renal disease (hazard ratio 1.91, 95% CI 1.42-2.58) than allopurinol.","['febuxostat', 'allopurinol']",['renal disease'],True,allopurinol,renal disease,associated,C0151747,Renal tubular disease,135401907,Allopurinol,Allopurinol,associate
2040,22995,35171306,"  Status epilepticus (SE) can result in an overproduction of hydrogen peroxide (H2O2), which contributes to oxidative stress and brain injury during different phases of epileptogenesis and seizures.",['hydrogen peroxide'],"['oxidative stress', 'brain injury', 'epileptogenesis', 'seizures']",True,hydrogen peroxide,oxidative stress,result,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydrogen peroxide,result
2041,22995,35171306,"  Status epilepticus (SE) can result in an overproduction of hydrogen peroxide (H2O2), which contributes to oxidative stress and brain injury during different phases of epileptogenesis and seizures.",['hydrogen peroxide'],"['oxidative stress', 'brain injury', 'epileptogenesis', 'seizures']",True,hydrogen peroxide,seizures,result,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydrogen peroxide,result
2042,23007,35139160," CONCLUSION: Colchicine use is associated with a lower risk of adverse kidney outcomes in CKD patients with hyperuricemia, or chronic gout.",['Colchicine'],"['adverse kidney outcomes', 'hyperuricemia', 'chronic gout']",True,Colchicine,hyperuricemia,associated,C0740394,Hyperuricemia,6167,"N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide","N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide",associate
2043,23007,35139160," CONCLUSION: Colchicine use is associated with a lower risk of adverse kidney outcomes in CKD patients with hyperuricemia, or chronic gout.",['Colchicine'],"['adverse kidney outcomes', 'hyperuricemia', 'chronic gout']",True,Colchicine,chronic gout,associated,C0205191,Chronic,6167,"N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide","N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide",associate
2044,23037,35073156," CONCLUSION: In this population-based data, neither allopurinol initiation, nor achieving target SU level with allopurinol, nor allopurinol dose escalation was associated with increased mortality in patients with gout and concurrent CKD.","['allopurinol', 'allopurinol', 'allopurinol']","['increased mortality', 'gout']",True,allopurinol,gout,associated,C0018099,Gout,135401907,Allopurinol,Allopurinol,associate
2045,23037,35073156," CONCLUSION: In this population-based data, neither allopurinol initiation, nor achieving target SU level with allopurinol, nor allopurinol dose escalation was associated with increased mortality in patients with gout and concurrent CKD.","['allopurinol', 'allopurinol', 'allopurinol']","['increased mortality', 'gout']",True,allopurinol,gout,associated,C0018099,Gout,135401907,Allopurinol,Allopurinol,associate
2046,23037,35073156," CONCLUSION: In this population-based data, neither allopurinol initiation, nor achieving target SU level with allopurinol, nor allopurinol dose escalation was associated with increased mortality in patients with gout and concurrent CKD.","['allopurinol', 'allopurinol', 'allopurinol']","['increased mortality', 'gout']",True,allopurinol,gout,associated,C0018099,Gout,135401907,Allopurinol,Allopurinol,associate
2047,23043,35055099,"Special attention must be paid to cardiovascular morbidities associated with urolithiasis in order to take advantage of pleiotropic effects of statins, angiotensin receptor blockers and allopurinol.",['allopurinol'],['urolithiasis'],True,allopurinol,urolithiasis,associated,C0403719,Uric acid urolithiasis,135401907,Allopurinol,Allopurinol,associate
2048,23087,34855873,"Of the 15 observational studies with sufficient quality, allopurinol was associated with reduced cardiovascular mortality in 1 out of 3 studies that reported this outcome, myocardial infarction in 6 out of 8, stroke in 4 out of 7, and combined  end-point in 2 out of 2.",['allopurinol'],"['reduced cardiovascular mortality', 'myocardial infarction']",True,allopurinol,reduced cardiovascular mortality,associated,C0243050,Cardiac anomaly,135401907,Allopurinol,Allopurinol,associate
2049,23087,34855873,"Of the 15 observational studies with sufficient quality, allopurinol was associated with reduced cardiovascular mortality in 1 out of 3 studies that reported this outcome, myocardial infarction in 6 out of 8, stroke in 4 out of 7, and combined  end-point in 2 out of 2.",['allopurinol'],"['reduced cardiovascular mortality', 'myocardial infarction']",True,allopurinol,myocardial infarction,associated,C0027051,Heart attack,135401907,Allopurinol,Allopurinol,associate
2050,23119,35221126,"Recent research suggests that amiodarone exposure leads to activation of fibroblasts, a cell type that synthesizes stroma in the lung, associated with acute respiratory distress syndrome and CLAD.",['amiodarone'],"['stroma in the lung', 'acute respiratory distress syndrome']",True,amiodarone,acute respiratory distress syndrome,leads,C0476273,Respiratory distress,2157,Amiodarone,Amiodarone,lead
2051,23159,35050451,  PURPOSE: To investigate whether co-administration of antiarrhythmic dronedarone and anticoagulant rivaroxaban would increase the risks of hemorrhage after atrial fibrillation (AF) ablation.,['dronedarone'],['hemorrhage'],True,dronedarone,hemorrhage,increase,C0029163,Oral bleeding,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dronedarone,increase
2052,23162,35047663,Amiodarone discontinuation was associated with recurrence of arrhythmia in 6 CF-LVAD patients.,['Amiodarone'],['arrhythmia'],True,Amiodarone,arrhythmia,associated,C0003811,Cardiac arrhythmia,2157,Amiodarone,Amiodarone,associate
2053,23204,34800024,"AHs/MHs can be associated with hypoacusis, psychiatric or neurological  diseases, intoxication and adverse reactions of different medications (e.g., propranolol, amantadine, voriconazole).A CASE REPORT: The authors present a case  of a 77-year-old male with advanced heart failure, recurrent episodes of atrial fibrillations and moderate hypoacusis, who mistakenly overdosed oral amiodarone (6 pills 200 mg each daily within 3 days).","['propranolol', 'amantadine', 'overdosed oral amiodarone']","['hypoacusis', 'intoxication', 'advanced heart failure', 'atrial fibrillations', 'moderate hypoacusis']",True,propranolol,hypoacusis,associated,C0018772,Hypoacusis,4946,propanolol,propanolol,associate
2054,23204,34800024,"AHs/MHs can be associated with hypoacusis, psychiatric or neurological  diseases, intoxication and adverse reactions of different medications (e.g., propranolol, amantadine, voriconazole).A CASE REPORT: The authors present a case  of a 77-year-old male with advanced heart failure, recurrent episodes of atrial fibrillations and moderate hypoacusis, who mistakenly overdosed oral amiodarone (6 pills 200 mg each daily within 3 days).","['propranolol', 'amantadine', 'overdosed oral amiodarone']","['hypoacusis', 'intoxication', 'advanced heart failure', 'atrial fibrillations', 'moderate hypoacusis']",True,propranolol,atrial fibrillations,associated,C0004238,Atrial fibrillation,4946,propanolol,propanolol,associate
2055,23204,34800024,"AHs/MHs can be associated with hypoacusis, psychiatric or neurological  diseases, intoxication and adverse reactions of different medications (e.g., propranolol, amantadine, voriconazole).A CASE REPORT: The authors present a case  of a 77-year-old male with advanced heart failure, recurrent episodes of atrial fibrillations and moderate hypoacusis, who mistakenly overdosed oral amiodarone (6 pills 200 mg each daily within 3 days).","['propranolol', 'amantadine', 'overdosed oral amiodarone']","['hypoacusis', 'intoxication', 'advanced heart failure', 'atrial fibrillations', 'moderate hypoacusis']",True,propranolol,moderate hypoacusis,associated,C0018772,Hypoacusis,4946,propanolol,propanolol,associate
2056,23204,34800024,"AHs/MHs can be associated with hypoacusis, psychiatric or neurological  diseases, intoxication and adverse reactions of different medications (e.g., propranolol, amantadine, voriconazole).A CASE REPORT: The authors present a case  of a 77-year-old male with advanced heart failure, recurrent episodes of atrial fibrillations and moderate hypoacusis, who mistakenly overdosed oral amiodarone (6 pills 200 mg each daily within 3 days).","['propranolol', 'amantadine', 'overdosed oral amiodarone']","['hypoacusis', 'intoxication', 'advanced heart failure', 'atrial fibrillations', 'moderate hypoacusis']",True,amantadine,hypoacusis,associated,C0018772,Hypoacusis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amantadine,associate
2057,23204,34800024,"AHs/MHs can be associated with hypoacusis, psychiatric or neurological  diseases, intoxication and adverse reactions of different medications (e.g., propranolol, amantadine, voriconazole).A CASE REPORT: The authors present a case  of a 77-year-old male with advanced heart failure, recurrent episodes of atrial fibrillations and moderate hypoacusis, who mistakenly overdosed oral amiodarone (6 pills 200 mg each daily within 3 days).","['propranolol', 'amantadine', 'overdosed oral amiodarone']","['hypoacusis', 'intoxication', 'advanced heart failure', 'atrial fibrillations', 'moderate hypoacusis']",True,amantadine,atrial fibrillations,associated,C0004238,Atrial fibrillation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amantadine,associate
2058,23204,34800024,"AHs/MHs can be associated with hypoacusis, psychiatric or neurological  diseases, intoxication and adverse reactions of different medications (e.g., propranolol, amantadine, voriconazole).A CASE REPORT: The authors present a case  of a 77-year-old male with advanced heart failure, recurrent episodes of atrial fibrillations and moderate hypoacusis, who mistakenly overdosed oral amiodarone (6 pills 200 mg each daily within 3 days).","['propranolol', 'amantadine', 'overdosed oral amiodarone']","['hypoacusis', 'intoxication', 'advanced heart failure', 'atrial fibrillations', 'moderate hypoacusis']",True,amantadine,moderate hypoacusis,associated,C0018772,Hypoacusis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amantadine,associate
2059,23204,34800024,"AHs/MHs can be associated with hypoacusis, psychiatric or neurological  diseases, intoxication and adverse reactions of different medications (e.g., propranolol, amantadine, voriconazole).A CASE REPORT: The authors present a case  of a 77-year-old male with advanced heart failure, recurrent episodes of atrial fibrillations and moderate hypoacusis, who mistakenly overdosed oral amiodarone (6 pills 200 mg each daily within 3 days).","['propranolol', 'amantadine', 'overdosed oral amiodarone']","['hypoacusis', 'intoxication', 'advanced heart failure', 'atrial fibrillations', 'moderate hypoacusis']",True,overdosed oral amiodarone,hypoacusis,associated,C0018772,Hypoacusis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",overdosed oral amiodarone,associate
2060,23204,34800024,"AHs/MHs can be associated with hypoacusis, psychiatric or neurological  diseases, intoxication and adverse reactions of different medications (e.g., propranolol, amantadine, voriconazole).A CASE REPORT: The authors present a case  of a 77-year-old male with advanced heart failure, recurrent episodes of atrial fibrillations and moderate hypoacusis, who mistakenly overdosed oral amiodarone (6 pills 200 mg each daily within 3 days).","['propranolol', 'amantadine', 'overdosed oral amiodarone']","['hypoacusis', 'intoxication', 'advanced heart failure', 'atrial fibrillations', 'moderate hypoacusis']",True,overdosed oral amiodarone,atrial fibrillations,associated,C0004238,Atrial fibrillation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",overdosed oral amiodarone,associate
2061,23204,34800024,"AHs/MHs can be associated with hypoacusis, psychiatric or neurological  diseases, intoxication and adverse reactions of different medications (e.g., propranolol, amantadine, voriconazole).A CASE REPORT: The authors present a case  of a 77-year-old male with advanced heart failure, recurrent episodes of atrial fibrillations and moderate hypoacusis, who mistakenly overdosed oral amiodarone (6 pills 200 mg each daily within 3 days).","['propranolol', 'amantadine', 'overdosed oral amiodarone']","['hypoacusis', 'intoxication', 'advanced heart failure', 'atrial fibrillations', 'moderate hypoacusis']",True,overdosed oral amiodarone,moderate hypoacusis,associated,C0018772,Hypoacusis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",overdosed oral amiodarone,associate
2062,23210,34796981,"The anticonvulsive effect of amiodarone was prominent, it diminished (p < 0.001) the severity of seizures and hence, deaths and reduced serum noradrenaline levels.",['amiodarone'],"['deaths', 'reduced serum noradrenaline levels']",True,amiodarone,deaths,diminished,C1546180,Age of death,2157,Amiodarone,Amiodarone,diminish
2063,23216,34794979,"Long-term minocycline use is associated with scleral and skin hyperpigmentation, with no apparent adverse effect on ocular structure or function.",['minocycline'],['skin hyperpigmentation'],True,minocycline,skin hyperpigmentation,associated,C0162834,Hyperpigmentation of the skin,54675783,"(4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide","(4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide",associate
2064,23218,34794979,"Amiodarone may also cause skin hyperpigmentation, but scleral pigmentation is not a known association.",['Amiodarone'],"['skin hyperpigmentation', 'scleral pigmentation']",True,Amiodarone,skin hyperpigmentation,cause,C0162834,Hyperpigmentation of the skin,2157,Amiodarone,Amiodarone,cause
2065,23218,34794979,"Amiodarone may also cause skin hyperpigmentation, but scleral pigmentation is not a known association.",['Amiodarone'],"['skin hyperpigmentation', 'scleral pigmentation']",True,Amiodarone,scleral pigmentation,cause,C0162834,Hyperpigmentation of the skin,2157,Amiodarone,Amiodarone,cause
2066,23316,8287508,"Methotrexate can cause hepatic fibrosis during chronic use, but the liver injury is poorly reflected by plasma transaminase concentrations; it is difficult to formulate monitoring recommendations when this agent is used in rheumatic disease.",['Methotrexate'],"['hepatic fibrosis', 'liver injury']",True,Methotrexate,hepatic fibrosis,cause,C0239946,Hepatic fibrosis,126941,Methotrexate,Methotrexate,cause
2067,23343,2782221,"In contrast, pretreatment of endothelium with 5.0 and 50.0 micrograms/ml benoxaprofen for at least 6 h resulted in a mean 35% and 31% inhibition of polymorphonuclear cell (PMN) adhesion in 6/11 experiments.",['benoxaprofen'],"['endothelium', 'inhibition of polymorphonuclear cell']",True,benoxaprofen,endothelium,resulted,C4023332,Abnormal corneal endothelium morphology,39941,Benoxaprofen,Benoxaprofen,result
2068,23353,2916245,"In contrast, the relative volume percent values of other progressively more damaged cell types (i.e. Types II, III, and IV cells) increased with elevation of indomethacin levels.",['indomethacin'],['damaged'],True,indomethacin,damaged,increased,C3887709,Optic neuropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",indomethacin,increase
2069,23374,3312930,"Agranulocytosis has been particularly associated with the pyrazolone compounds, although it has been reported with most others.",['pyrazolone'],['Agranulocytosis'],True,pyrazolone,Agranulocytosis,associated,C0001824,Agranulocytosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pyrazolone,associate
2070,23381,3553833," Other agents (alpha-naphthylisothiocyanate, methylenedianiline, contaminated rapeseed oil, paraquat) lead to ductal injury resulting in cholestasis.","['alpha-naphthylisothiocyanate', 'paraquat']","['ductal injury resulting', 'cholestasis']",True,alpha-naphthylisothiocyanate,cholestasis,lead,C0008370,Cholestasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",alpha-naphthylisothiocyanate,lead
2071,23381,3553833," Other agents (alpha-naphthylisothiocyanate, methylenedianiline, contaminated rapeseed oil, paraquat) lead to ductal injury resulting in cholestasis.","['alpha-naphthylisothiocyanate', 'paraquat']","['ductal injury resulting', 'cholestasis']",True,paraquat,cholestasis,lead,C0008370,Cholestasis,15939,1-methyl-4-(1-methylpyridin-1-ium-4-yl)pyridin-1-ium,1-methyl-4-(1-methylpyridin-1-ium-4-yl)pyridin-1-ium,lead
2072,23405,31525093," Transient Fanconi syndrome without azotemia was associated with firocoxib, cefadroxil, tramadol, and famotidine treatment.","['firocoxib', 'cefadroxil', 'tramadol', 'famotidine']","['Transient Fanconi syndrome', 'azotemia']",True,firocoxib,Transient Fanconi syndrome,associated,C0341703,Renal tubular fanconi syndrome,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",firocoxib,associate
2073,23405,31525093," Transient Fanconi syndrome without azotemia was associated with firocoxib, cefadroxil, tramadol, and famotidine treatment.","['firocoxib', 'cefadroxil', 'tramadol', 'famotidine']","['Transient Fanconi syndrome', 'azotemia']",True,firocoxib,azotemia,associated,C0242528,Azotaemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",firocoxib,associate
2074,23405,31525093," Transient Fanconi syndrome without azotemia was associated with firocoxib, cefadroxil, tramadol, and famotidine treatment.","['firocoxib', 'cefadroxil', 'tramadol', 'famotidine']","['Transient Fanconi syndrome', 'azotemia']",True,cefadroxil,Transient Fanconi syndrome,associated,C0341703,Renal tubular fanconi syndrome,47965,Cefadroxil,Cefadroxil,associate
2075,23405,31525093," Transient Fanconi syndrome without azotemia was associated with firocoxib, cefadroxil, tramadol, and famotidine treatment.","['firocoxib', 'cefadroxil', 'tramadol', 'famotidine']","['Transient Fanconi syndrome', 'azotemia']",True,cefadroxil,azotemia,associated,C0242528,Azotaemia,47965,Cefadroxil,Cefadroxil,associate
2076,23405,31525093," Transient Fanconi syndrome without azotemia was associated with firocoxib, cefadroxil, tramadol, and famotidine treatment.","['firocoxib', 'cefadroxil', 'tramadol', 'famotidine']","['Transient Fanconi syndrome', 'azotemia']",True,tramadol,Transient Fanconi syndrome,associated,C0341703,Renal tubular fanconi syndrome,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tramadol,associate
2077,23405,31525093," Transient Fanconi syndrome without azotemia was associated with firocoxib, cefadroxil, tramadol, and famotidine treatment.","['firocoxib', 'cefadroxil', 'tramadol', 'famotidine']","['Transient Fanconi syndrome', 'azotemia']",True,tramadol,azotemia,associated,C0242528,Azotaemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tramadol,associate
2078,23405,31525093," Transient Fanconi syndrome without azotemia was associated with firocoxib, cefadroxil, tramadol, and famotidine treatment.","['firocoxib', 'cefadroxil', 'tramadol', 'famotidine']","['Transient Fanconi syndrome', 'azotemia']",True,famotidine,Transient Fanconi syndrome,associated,C0341703,Renal tubular fanconi syndrome,3325,"3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide","3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide",associate
2079,23405,31525093," Transient Fanconi syndrome without azotemia was associated with firocoxib, cefadroxil, tramadol, and famotidine treatment.","['firocoxib', 'cefadroxil', 'tramadol', 'famotidine']","['Transient Fanconi syndrome', 'azotemia']",True,famotidine,azotemia,associated,C0242528,Azotaemia,3325,"3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide","3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide",associate
2080,23434,26776155,"In conclusion, these results demonstrate that a novel eEF2K inhibitor (cefatrizine) induces ER stress in breast cancer cells by integrating bioinformatics prediction, proteomics analyses and experimental validation, which would provide a clue for exploring more mechanisms of eEF2K and its targeted inhibitors in cancer therapy.",['cefatrizine'],"['ER stress in', 'cancer']",True,cefatrizine,cancer,induces,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cefatrizine,induce
2081,23471,34902109,"The majority of non-purulent, uncomplicated cases of cellulitis are caused by β-hemolytic streptococci or methicillin-sensitive Staphylococcus aureus, and appropriate targeted coverage of this pathogen with oral antibiotics such as penicillin, amoxicillin, and cephalexin is sufficient.","['penicillin', 'amoxicillin', 'cephalexin']",['cellulitis'],True,penicillin,cellulitis,caused,C0007642,Cellulitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",penicillin,cause
2082,23471,34902109,"The majority of non-purulent, uncomplicated cases of cellulitis are caused by β-hemolytic streptococci or methicillin-sensitive Staphylococcus aureus, and appropriate targeted coverage of this pathogen with oral antibiotics such as penicillin, amoxicillin, and cephalexin is sufficient.","['penicillin', 'amoxicillin', 'cephalexin']",['cellulitis'],True,amoxicillin,cellulitis,caused,C0007642,Cellulitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amoxicillin,cause
2083,23471,34902109,"The majority of non-purulent, uncomplicated cases of cellulitis are caused by β-hemolytic streptococci or methicillin-sensitive Staphylococcus aureus, and appropriate targeted coverage of this pathogen with oral antibiotics such as penicillin, amoxicillin, and cephalexin is sufficient.","['penicillin', 'amoxicillin', 'cephalexin']",['cellulitis'],True,cephalexin,cellulitis,caused,C0007642,Cellulitis,27447,Cephalexin,Cephalexin,cause
2084,23519,35280179," Conclusion: Antipsychotics, especially clozapine, risperidone, chlorpromazine, and perphenazine, increased the T2DM risk among NBPHSP enrollees with schizophrenia.","['clozapine', 'risperidone', 'chlorpromazine', 'perphenazine']",['schizophrenia'],True,clozapine,schizophrenia,increased,C0036341,Schizophrenia,135398737,Clozapine,Clozapine,increase
2085,23519,35280179," Conclusion: Antipsychotics, especially clozapine, risperidone, chlorpromazine, and perphenazine, increased the T2DM risk among NBPHSP enrollees with schizophrenia.","['clozapine', 'risperidone', 'chlorpromazine', 'perphenazine']",['schizophrenia'],True,risperidone,schizophrenia,increased,C0036341,Schizophrenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",risperidone,increase
2086,23519,35280179," Conclusion: Antipsychotics, especially clozapine, risperidone, chlorpromazine, and perphenazine, increased the T2DM risk among NBPHSP enrollees with schizophrenia.","['clozapine', 'risperidone', 'chlorpromazine', 'perphenazine']",['schizophrenia'],True,chlorpromazine,schizophrenia,increased,C0036341,Schizophrenia,2726,Chlorpromazine,Chlorpromazine,increase
2087,23519,35280179," Conclusion: Antipsychotics, especially clozapine, risperidone, chlorpromazine, and perphenazine, increased the T2DM risk among NBPHSP enrollees with schizophrenia.","['clozapine', 'risperidone', 'chlorpromazine', 'perphenazine']",['schizophrenia'],True,perphenazine,schizophrenia,increased,C0036341,Schizophrenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",perphenazine,increase
2088,23528,35236263," CONCLUSION: Long-term CPZ and CLZ prescriptions were associated with similar profiles for the development of MetS, as well as similar factors associated with  developing schizophrenia.","['CPZ', 'CLZ']",['schizophrenia'],True,CPZ,schizophrenia,associated,C0036341,Schizophrenia,2726,Chlorpromazine,Chlorpromazine,associate
2089,23528,35236263," CONCLUSION: Long-term CPZ and CLZ prescriptions were associated with similar profiles for the development of MetS, as well as similar factors associated with  developing schizophrenia.","['CPZ', 'CLZ']",['schizophrenia'],True,CLZ,schizophrenia,associated,C0036341,Schizophrenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",CLZ,associate
2090,23620,34194969,"In vitro and in vivo experiments showed that CPZ inhibited the growth and survival of the patient-derived AML cells, implying potent efficacy of CPZ in AML with KIT-D816V.  © 2021 The Authors.","['CPZ', 'CPZ']","['survival', 'AML', 'AML']",True,CPZ,AML,inhibited,C0023465,Acute monocytic leukemia,2726,Chlorpromazine,Chlorpromazine,inhibit
2091,23620,34194969,"In vitro and in vivo experiments showed that CPZ inhibited the growth and survival of the patient-derived AML cells, implying potent efficacy of CPZ in AML with KIT-D816V.  © 2021 The Authors.","['CPZ', 'CPZ']","['survival', 'AML', 'AML']",True,CPZ,AML,inhibited,C0023465,Acute monocytic leukemia,2726,Chlorpromazine,Chlorpromazine,inhibit
2092,23620,34194969,"In vitro and in vivo experiments showed that CPZ inhibited the growth and survival of the patient-derived AML cells, implying potent efficacy of CPZ in AML with KIT-D816V.  © 2021 The Authors.","['CPZ', 'CPZ']","['survival', 'AML', 'AML']",True,CPZ,AML,inhibited,C0023465,Acute monocytic leukemia,2726,Chlorpromazine,Chlorpromazine,inhibit
2093,23620,34194969,"In vitro and in vivo experiments showed that CPZ inhibited the growth and survival of the patient-derived AML cells, implying potent efficacy of CPZ in AML with KIT-D816V.  © 2021 The Authors.","['CPZ', 'CPZ']","['survival', 'AML', 'AML']",True,CPZ,AML,inhibited,C0023465,Acute monocytic leukemia,2726,Chlorpromazine,Chlorpromazine,inhibit
2094,23753,35046674,"NTM-PD is associated with airway lesions such as bronchiectasis, which is  frequently seen in RA patients.",['RA'],"['airway lesions', 'bronchiectasis']",True,RA,bronchiectasis,associated,C0006267,Bronchiectasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",RA,associate
2095,23803,35039083," Discovery of diffuse intravascular calcification on computed tomography, in addition to a markedly elevated calcium-phosphate product immediately prior to the onset of his ulcers, led to the diagnosis of calciphylaxis.",['calcium-phosphate'],"['intravascular calcification', 'calciphylaxis']",True,calcium-phosphate,intravascular calcification,led,C0342649,Vascular calcification,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium-phosphate,lead
2096,23853,35273789," Conclusion: In the present study, we could not confirm that clozapine treatment was associated with neutropenia.",['clozapine'],['neutropenia'],True,clozapine,neutropenia,associated,C0853697,Low neutrophil count,135398737,Clozapine,Clozapine,associate
2097,23869,35240428,"The male-dependent increase in TG levels was associated with leptin, insulin, cortisol and TSH levels.",['insulin'],['increase in TG levels'],True,insulin,increase in TG levels,associated,C4073162,Elevated hemoglobin A1c,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",insulin,associate
2098,23874,35238829,"  BACKGROUND: Clozapine, an antipsychotic medication used to treat treatment-refractory schizophrenia, has been associated with various dangerous side effects, including myocarditis.",['Clozapine'],['myocarditis'],True,Clozapine,myocarditis,associated,C0027059,Inflammation of heart muscle,135398737,Clozapine,Clozapine,associate
2099,23886,35228573,"Furthermore, olanzapine concentration was associated with changes in weight, BMI, and LDL levels in the drug-naive group and glucose, triglyceride and LDL levels in chronic patients who have not used olanzapine/clozapine previously.","['olanzapine', 'LDL', 'olanzapine/clozapine']","['glucose, triglyceride and LDL levels']",True,olanzapine,"glucose, triglyceride and LDL levels",associated,C0853085,Decreased LDL,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",olanzapine,associate
2100,23886,35228573,"Furthermore, olanzapine concentration was associated with changes in weight, BMI, and LDL levels in the drug-naive group and glucose, triglyceride and LDL levels in chronic patients who have not used olanzapine/clozapine previously.","['olanzapine', 'LDL', 'olanzapine/clozapine']","['glucose, triglyceride and LDL levels']",True,LDL,"glucose, triglyceride and LDL levels",associated,C0853085,Decreased LDL,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",LDL,associate
2101,23886,35228573,"Furthermore, olanzapine concentration was associated with changes in weight, BMI, and LDL levels in the drug-naive group and glucose, triglyceride and LDL levels in chronic patients who have not used olanzapine/clozapine previously.","['olanzapine', 'LDL', 'olanzapine/clozapine']","['glucose, triglyceride and LDL levels']",True,olanzapine/clozapine,"glucose, triglyceride and LDL levels",associated,C0853085,Decreased LDL,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",olanzapine/clozapine,associate
2102,23891,35220525," CONCLUSIONS: Olanzapine, clozapine and quetiapine used during pregnancy were associated with increased risks for gestational diabetes and the infant being large for gestational age.","['Olanzapine', 'clozapine', 'quetiapine']",['increased risks for gestational diabetes'],True,Olanzapine,increased risks for gestational diabetes,associated,C0085207,Maternal diabetes,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Olanzapine,associate
2103,23891,35220525," CONCLUSIONS: Olanzapine, clozapine and quetiapine used during pregnancy were associated with increased risks for gestational diabetes and the infant being large for gestational age.","['Olanzapine', 'clozapine', 'quetiapine']",['increased risks for gestational diabetes'],True,clozapine,increased risks for gestational diabetes,associated,C0085207,Maternal diabetes,135398737,Clozapine,Clozapine,associate
2104,23891,35220525," CONCLUSIONS: Olanzapine, clozapine and quetiapine used during pregnancy were associated with increased risks for gestational diabetes and the infant being large for gestational age.","['Olanzapine', 'clozapine', 'quetiapine']",['increased risks for gestational diabetes'],True,quetiapine,increased risks for gestational diabetes,associated,C0085207,Maternal diabetes,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",quetiapine,associate
2105,23896,35219120,"Furthermore, inhibitory effects of subchronic lurasidone administration on ERK and AMPK activities (without affecting AKT activity) induced by downregulation of 5-HT7R could result in clinical advantages of lurasidone, lower risk of weight gain.","['subchronic lurasidone', 'lurasidone']",['lower risk of weight gain'],True,subchronic lurasidone,lower risk of weight gain,result,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",subchronic lurasidone,result
2106,23896,35219120,"Furthermore, inhibitory effects of subchronic lurasidone administration on ERK and AMPK activities (without affecting AKT activity) induced by downregulation of 5-HT7R could result in clinical advantages of lurasidone, lower risk of weight gain.","['subchronic lurasidone', 'lurasidone']",['lower risk of weight gain'],True,lurasidone,lower risk of weight gain,result,C0043094,Weight gain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",lurasidone,result
2107,23923,35163764,"A better understanding of the roles of OS, mitochondrial dysfunction, and inflammation in the pathogenesis of bipolar disorder, along with a stronger elucidation of the therapeutic functions of antioxidants, antipsychotics, anti-inflammatory agents, lithium therapy, and light therapies, may lead to improved strategies for the treatment and prevention of bipolar disorder.",['lithium'],['inflammation'],True,lithium,inflammation,lead,C3875321,Skin inflammation,3028194,lithium,lithium,lead
2108,23927,35152873,"  Clozapine, a superior treatment for otherwise treatment-resistant schizophrenia can produce a potentially life-threatening myocarditis and dilated cardiomyopathy.",['Clozapine'],"['schizophrenia', 'dilated cardiomyopathy']",True,Clozapine,schizophrenia,produce,C0036341,Schizophrenia,135398737,Clozapine,Clozapine,produce
2109,23927,35152873,"  Clozapine, a superior treatment for otherwise treatment-resistant schizophrenia can produce a potentially life-threatening myocarditis and dilated cardiomyopathy.",['Clozapine'],"['schizophrenia', 'dilated cardiomyopathy']",True,Clozapine,dilated cardiomyopathy,produce,C0007193,"Cardiomyopathy, dilated",135398737,Clozapine,Clozapine,produce
2110,23963,35080634," RESULTS: We found that chronic clozapine treatment in patients with schizophrenia resulted in the abnormal expression of serum cytokines, such as IL-2, IL-6, IL-17, and TNF-α, compared with the healthy controls.",['clozapine'],['schizophrenia'],True,clozapine,schizophrenia,resulted,C0036341,Schizophrenia,135398737,Clozapine,Clozapine,result
2111,23967,35078963,"Among those, clozapine induced rhabdomyolysis can compromise clozapine treatment.","['clozapine', 'clozapine']",['rhabdomyolysis'],True,clozapine,rhabdomyolysis,induced,C0035410,Breakdown of skeletal muscle,135398737,Clozapine,Clozapine,induce
2112,23967,35078963,"Among those, clozapine induced rhabdomyolysis can compromise clozapine treatment.","['clozapine', 'clozapine']",['rhabdomyolysis'],True,clozapine,rhabdomyolysis,induced,C0035410,Breakdown of skeletal muscle,135398737,Clozapine,Clozapine,induce
2113,23973,35077502,"Activation  of bladder VEGF signaling causes sensory neural plasticity and visceral hypersensitivity in mice, confirming its role of an UCPPS biomarker as identified by the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) research studies.",['VEGF'],"['sensory neural plasticity', 'visceral hypersensitivity', 'Chronic Pelvic Pain']",True,VEGF,sensory neural plasticity,causes,C0035410,Breakdown of skeletal muscle,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",VEGF,cause
2114,23973,35077502,"Activation  of bladder VEGF signaling causes sensory neural plasticity and visceral hypersensitivity in mice, confirming its role of an UCPPS biomarker as identified by the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) research studies.",['VEGF'],"['sensory neural plasticity', 'visceral hypersensitivity', 'Chronic Pelvic Pain']",True,VEGF,visceral hypersensitivity,causes,C0035410,Breakdown of skeletal muscle,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",VEGF,cause
2115,23973,35077502,"Activation  of bladder VEGF signaling causes sensory neural plasticity and visceral hypersensitivity in mice, confirming its role of an UCPPS biomarker as identified by the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) research studies.",['VEGF'],"['sensory neural plasticity', 'visceral hypersensitivity', 'Chronic Pelvic Pain']",True,VEGF,Chronic Pelvic Pain,causes,C0150055,Chronic pain,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",VEGF,cause
2116,23977,35067911,"No other factors, including genetic risk, sex, ethnicity, smoking, alcohol, substance abuse or cardiometabolic disease, were associated with greater odds of myocarditis.",['alcohol'],"['smoking', 'myocarditis']",True,alcohol,smoking,associated,C0150055,Chronic pain,702,Ethanol,Ethanol,associate
2117,23977,35067911,"No other factors, including genetic risk, sex, ethnicity, smoking, alcohol, substance abuse or cardiometabolic disease, were associated with greater odds of myocarditis.",['alcohol'],"['smoking', 'myocarditis']",True,alcohol,myocarditis,associated,C0027059,Inflammation of heart muscle,702,Ethanol,Ethanol,associate
2118,23981,35062840,  INTRODUCTION: Pharmacovigilance studies have definitely established that clozapine can cause myocarditis.,['clozapine'],['myocarditis'],True,clozapine,myocarditis,cause,C0027059,Inflammation of heart muscle,135398737,Clozapine,Clozapine,cause
2119,23992,35048875,  BACKGROUND: Clozapine is associated with increased risk of myocarditis.,['Clozapine'],['increased risk of myocarditis'],True,Clozapine,increased risk of myocarditis,associated,C0027059,Inflammation of heart muscle,135398737,Clozapine,Clozapine,associate
2120,23996,35048875, CONCLUSIONS: Suspicion of myocarditis can lead to unnecessary discontinuation of  clozapine.,['clozapine'],['myocarditis'],True,clozapine,myocarditis,lead,C0027059,Inflammation of heart muscle,135398737,Clozapine,Clozapine,lead
2121,24004,34610820,doi: 10.1186/s12879-021-06736-x.  Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis.,['delafloxacin'],['skin structure infections'],True,delafloxacin,skin structure infections,results,C1853193,"Skin infections, recurrent",NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",delafloxacin,result
2122,24027,30089175,Selected strains were whole-genome sequenced to find mutations causing thioridazine resistance.,['thioridazine'],['resistance'],True,thioridazine,resistance,causing,C0021655,Insulin resistance,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thioridazine,cause
2123,24060,27648882,We investigated whether removing gentamicin from our antibiotic protocol would cause fewer and less severe cases of renal impairment.,['gentamicin'],['renal impairment'],True,gentamicin,renal impairment,cause,C4021047,Impaired visually enhanced vestibulo-ocular reflex,3467,Gentamicin,Gentamicin,cause
2124,24073,25978794,"Similarly, obesity was associated with filled prescriptions of antimicrobials overall (women: HR = 1.22, 95% CI = 1.14, 1.30; men: HR = 1.23, 95% CI: 1.15, 1.33) and particularly with phenoxymethylpenicillin, macrolides, dicloxacillin and flucloxacillin, and broad-spectrum penicillins.","['phenoxymethylpenicillin', 'macrolides', 'dicloxacillin', 'flucloxacillin', 'penicillins']",['obesity'],True,phenoxymethylpenicillin,obesity,associated,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phenoxymethylpenicillin,associate
2125,24073,25978794,"Similarly, obesity was associated with filled prescriptions of antimicrobials overall (women: HR = 1.22, 95% CI = 1.14, 1.30; men: HR = 1.23, 95% CI: 1.15, 1.33) and particularly with phenoxymethylpenicillin, macrolides, dicloxacillin and flucloxacillin, and broad-spectrum penicillins.","['phenoxymethylpenicillin', 'macrolides', 'dicloxacillin', 'flucloxacillin', 'penicillins']",['obesity'],True,macrolides,obesity,associated,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",macrolides,associate
2126,24073,25978794,"Similarly, obesity was associated with filled prescriptions of antimicrobials overall (women: HR = 1.22, 95% CI = 1.14, 1.30; men: HR = 1.23, 95% CI: 1.15, 1.33) and particularly with phenoxymethylpenicillin, macrolides, dicloxacillin and flucloxacillin, and broad-spectrum penicillins.","['phenoxymethylpenicillin', 'macrolides', 'dicloxacillin', 'flucloxacillin', 'penicillins']",['obesity'],True,dicloxacillin,obesity,associated,C0028754,Obesity,18381,Dicloxacillin,Dicloxacillin,associate
2127,24073,25978794,"Similarly, obesity was associated with filled prescriptions of antimicrobials overall (women: HR = 1.22, 95% CI = 1.14, 1.30; men: HR = 1.23, 95% CI: 1.15, 1.33) and particularly with phenoxymethylpenicillin, macrolides, dicloxacillin and flucloxacillin, and broad-spectrum penicillins.","['phenoxymethylpenicillin', 'macrolides', 'dicloxacillin', 'flucloxacillin', 'penicillins']",['obesity'],True,flucloxacillin,obesity,associated,C0028754,Obesity,21319,Flucloxacillin,Flucloxacillin,associate
2128,24073,25978794,"Similarly, obesity was associated with filled prescriptions of antimicrobials overall (women: HR = 1.22, 95% CI = 1.14, 1.30; men: HR = 1.23, 95% CI: 1.15, 1.33) and particularly with phenoxymethylpenicillin, macrolides, dicloxacillin and flucloxacillin, and broad-spectrum penicillins.","['phenoxymethylpenicillin', 'macrolides', 'dicloxacillin', 'flucloxacillin', 'penicillins']",['obesity'],True,penicillins,obesity,associated,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",penicillins,associate
2129,24089,35260150,"Furthermore, GlucoMedix® produced a dose-dependent decrease in systolic  and diastolic arterial blood pressure in L-NAME-induced hypertensive rats at 28 days.",['L-NAME-induced'],['decrease in systolic  and diastolic arterial blood pressure'],True,L-NAME-induced,systolic  and diastolic arterial blood pressure,produced,C0277890,Decreased diastolic blood pressure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",L-NAME-induced,produce
2130,24118,34982964,"Furthermore, javamide-I ester could inhibit ATF-2 phosphorylation better than javamide-I in the cells, suggesting that the ester could be transported inside the cells better than javamide-I. Similarly, javamide-I/-II esters were found to be transported and biotransformed in PBMCs involved in inflammation processes.",['ester'],"['ATF-2 phosphorylation', 'inflammation']",True,ester,inflammation,inhibit,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ester,inhibit
2131,24132,34884209, Both inhibitors inhibited the degradation of substance P and bradykinin and were  thus expected to cause angioedema.,['bradykinin'],['angioedema'],True,bradykinin,angioedema,inhibited,C0002994,Quincke edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bradykinin,inhibit
2132,24286,33633747,"Flucloxacillin (FLX), a β-lactam antibiotic for narrow-spectrum gram-positive bacterial infections, has been associated with severe immune-mediated drug-induced liver injury caused by an influx of T-lymphocytes targeting liver cells potentially recognizing drug-haptenated peptides in the context of HLA-B*57:01.",['Flucloxacillin'],"['bacterial infections', 'liver injury']",True,Flucloxacillin,bacterial infections,associated,C0162627,Bacterial infection of skin,21319,Flucloxacillin,Flucloxacillin,associate
2133,24314,32665925, Long-lasting concomitant use of flucloxacillin and acetaminophen can lead to 5-oxoproline accumulation and severe high anion gap metabolic acidosis.,"['flucloxacillin', 'acetaminophen']",['severe high anion gap metabolic acidosis'],True,flucloxacillin,severe high anion gap metabolic acidosis,lead,C0220981,Metabolic acidosis,21319,Flucloxacillin,Flucloxacillin,lead
2134,24314,32665925, Long-lasting concomitant use of flucloxacillin and acetaminophen can lead to 5-oxoproline accumulation and severe high anion gap metabolic acidosis.,"['flucloxacillin', 'acetaminophen']",['severe high anion gap metabolic acidosis'],True,acetaminophen,severe high anion gap metabolic acidosis,lead,C0220981,Metabolic acidosis,1983,Acetaminophen,Acetaminophen,lead
2135,24315,32665925,"Females and patients with sepsis, impaired kidney and/or liver function, malnutrition, advanced age, congenital 5-oxoprolinase deficiency and supratherapeutic acetaminophen and flucloxacillin dosage are associated with increased risk.","['acetaminophen', 'flucloxacillin']","['sepsis', 'impaired kidney and/or liver function', 'malnutrition', 'increased risk']",True,acetaminophen,sepsis,associated,C0036690,Infection in blood stream,1983,Acetaminophen,Acetaminophen,associate
2136,24315,32665925,"Females and patients with sepsis, impaired kidney and/or liver function, malnutrition, advanced age, congenital 5-oxoprolinase deficiency and supratherapeutic acetaminophen and flucloxacillin dosage are associated with increased risk.","['acetaminophen', 'flucloxacillin']","['sepsis', 'impaired kidney and/or liver function', 'malnutrition', 'increased risk']",True,flucloxacillin,sepsis,associated,C0036690,Infection in blood stream,21319,Flucloxacillin,Flucloxacillin,associate
2137,24434,34818122,Succinic acid was also found to inhibit the activity of CYP2C9 with the IC50 value of 13.87 μM. DISCUSSION AND CONCLUSIONS: Succinic acid increased the system exposure of irbesartan via inhibiting CYP2C9.,"['Succinic acid', 'Succinic acid', 'irbesartan']",['inhibiting CYP2C9'],True,Succinic acid,inhibiting CYP2C9,increased,C0424296,Disinhibition,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Succinic acid,increase
2138,24434,34818122,Succinic acid was also found to inhibit the activity of CYP2C9 with the IC50 value of 13.87 μM. DISCUSSION AND CONCLUSIONS: Succinic acid increased the system exposure of irbesartan via inhibiting CYP2C9.,"['Succinic acid', 'Succinic acid', 'irbesartan']",['inhibiting CYP2C9'],True,irbesartan,inhibiting CYP2C9,increased,C0424296,Disinhibition,3749,Irbesartan,Irbesartan,increase
2139,24555,35080463,"Finally, the combination treatment with ABL/PI5P and amikacin, to specifically target intracellular and extracellular bacilli, resulted in a further significant reduction of both pulmonary mycobacterial burden and inflammatory response in comparison with the single treatments.",['amikacin'],['inflammatory response'],True,amikacin,inflammatory response,resulted,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amikacin,result
2140,24564,34997203,Zn5002 complexes in combination with amikacin at  different concentrations completely inhibited growth of the tested strains.,['amikacin'],['growth'],True,amikacin,growth,inhibited,C0456070,Growth delay,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",amikacin,inhibit
2141,24599,35302210, High-dose remifentanil with 1 mg/kg ketamine was associated with more severe chest wall rigidity and lower mean blood pressure and heart rate than was low-dose remifentanil with 2 mg/kg ketamine.,"['remifentanil', 'remifentanil', 'ketamine']","['lower mean blood pressure', 'heart rate than was low-dose']",True,remifentanil,lower mean blood pressure,associated,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",remifentanil,associate
2142,24599,35302210, High-dose remifentanil with 1 mg/kg ketamine was associated with more severe chest wall rigidity and lower mean blood pressure and heart rate than was low-dose remifentanil with 2 mg/kg ketamine.,"['remifentanil', 'remifentanil', 'ketamine']","['lower mean blood pressure', 'heart rate than was low-dose']",True,remifentanil,heart rate than was low-dose,associated,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",remifentanil,associate
2143,24599,35302210, High-dose remifentanil with 1 mg/kg ketamine was associated with more severe chest wall rigidity and lower mean blood pressure and heart rate than was low-dose remifentanil with 2 mg/kg ketamine.,"['remifentanil', 'remifentanil', 'ketamine']","['lower mean blood pressure', 'heart rate than was low-dose']",True,remifentanil,lower mean blood pressure,associated,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",remifentanil,associate
2144,24599,35302210, High-dose remifentanil with 1 mg/kg ketamine was associated with more severe chest wall rigidity and lower mean blood pressure and heart rate than was low-dose remifentanil with 2 mg/kg ketamine.,"['remifentanil', 'remifentanil', 'ketamine']","['lower mean blood pressure', 'heart rate than was low-dose']",True,remifentanil,heart rate than was low-dose,associated,C0020649,Hypotension,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",remifentanil,associate
2145,24599,35302210, High-dose remifentanil with 1 mg/kg ketamine was associated with more severe chest wall rigidity and lower mean blood pressure and heart rate than was low-dose remifentanil with 2 mg/kg ketamine.,"['remifentanil', 'remifentanil', 'ketamine']","['lower mean blood pressure', 'heart rate than was low-dose']",True,ketamine,lower mean blood pressure,associated,C0020649,Hypotension,3821,Ketamine,Ketamine,associate
2146,24599,35302210, High-dose remifentanil with 1 mg/kg ketamine was associated with more severe chest wall rigidity and lower mean blood pressure and heart rate than was low-dose remifentanil with 2 mg/kg ketamine.,"['remifentanil', 'remifentanil', 'ketamine']","['lower mean blood pressure', 'heart rate than was low-dose']",True,ketamine,heart rate than was low-dose,associated,C0020649,Hypotension,3821,Ketamine,Ketamine,associate
2147,24602,35295154,This is the first study to show that administration  of allylnitrile can cause a complete loss of hearing function in mice.,['allylnitrile'],['loss of hearing function'],True,allylnitrile,loss of hearing function,cause,C1384666,Hearing loss,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",allylnitrile,cause
2148,24607,35278826,"By meta-regression, we observed that: (1) Age and BMI are negatively associated with mood response to ketamine.",['ketamine'],['mood'],True,ketamine,mood,associated,C0085633,Emotional instability,3821,Ketamine,Ketamine,associate
2149,24626,35231204,"Treatment with any form of ketamine was associated with improved response (RR=2.14; 95% CI, 1.72-2.66; I2=65%), remission (RR=1.64; 95% CI, 1.33-2.02; I2=39%), and depression severity (d=-0.63; 95% CI, -0.80 to -0.45; I2=78%) against placebo.",['ketamine'],['depression'],True,ketamine,depression,associated,C0011581,Depression,3821,Ketamine,Ketamine,associate
2150,24644,35202796,"In summary, we developed a ketamine-induced schizophrenia-like behavior mouse model and found that ketamine  inhibited the levels of miR-15a-3p, miR-15b-3p, miR-16-1-3p and increased DRD1 expression in mice.",['ketamine'],"['schizophrenia-like', 'increased DRD1 expression']",True,ketamine,increased DRD1 expression,inhibited,C1862474,Decreased facial expression,3821,Ketamine,Ketamine,inhibit
2151,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,nausea,linked,C0027497,Nausea,126941,Methotrexate,Methotrexate,link
2152,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,emesis,linked,C0042963,Throwing up,126941,Methotrexate,Methotrexate,link
2153,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,lethargy,linked,C0023380,Lethargy,126941,Methotrexate,Methotrexate,link
2154,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,blurred vision,linked,C0344232,Blurred vision,126941,Methotrexate,Methotrexate,link
2155,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,aphasia,linked,C0003537,Losing words,126941,Methotrexate,Methotrexate,link
2156,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,hemiparesis,linked,C0018989,Weakness of one side of body,126941,Methotrexate,Methotrexate,link
2157,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,paresis,linked,C0427065,Weakness of outermost muscles,126941,Methotrexate,Methotrexate,link
2158,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,convulsions,linked,C1527366,Epileptic spasms,126941,Methotrexate,Methotrexate,link
2159,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,leukoencephalopathy,linked,C0270612,Leukoencephalopathy,126941,Methotrexate,Methotrexate,link
2160,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,nausea,linked,C0027497,Nausea,126941,Methotrexate,Methotrexate,link
2161,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,emesis,linked,C0042963,Throwing up,126941,Methotrexate,Methotrexate,link
2162,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,lethargy,linked,C0023380,Lethargy,126941,Methotrexate,Methotrexate,link
2163,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,blurred vision,linked,C0344232,Blurred vision,126941,Methotrexate,Methotrexate,link
2164,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,aphasia,linked,C0003537,Losing words,126941,Methotrexate,Methotrexate,link
2165,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,hemiparesis,linked,C0018989,Weakness of one side of body,126941,Methotrexate,Methotrexate,link
2166,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,paresis,linked,C0427065,Weakness of outermost muscles,126941,Methotrexate,Methotrexate,link
2167,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,convulsions,linked,C1527366,Epileptic spasms,126941,Methotrexate,Methotrexate,link
2168,24646,35200225,"MTX has been linked with side effects of varying severity; headaches, nausea, emesis, lethargy, blurred vision, aphasia, hemiparesis, paresis, convulsions, leukoencephalopathy,  and arachnoiditis are symptoms of MTX toxicity.","['MTX', 'MTX']","['nausea', 'emesis', 'lethargy', 'blurred vision', 'aphasia', 'hemiparesis', 'paresis', 'convulsions', 'leukoencephalopathy', 'arachnoiditis']",True,MTX,leukoencephalopathy,linked,C0270612,Leukoencephalopathy,126941,Methotrexate,Methotrexate,link
2169,24650,35199228,"In contrast, K/X/A given 1-2 h prior to ozone increased lung and  systemic inflammation.",['ozone'],['inflammation'],True,ozone,inflammation,increased,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ozone,increase
2170,24662,35056399,Pretreatment with lansoprazole and different concentrations of garlic oil extracts increased prostaglandin E2 and glutathione concentrations in the cell culture model of peptic ulcer disease (p < 0.001).,"['lansoprazole', 'glutathione']",['peptic ulcer disease'],True,lansoprazole,peptic ulcer disease,increased,C0030920,Peptic ulcer,3883,Lansoprazole,Lansoprazole,increase
2171,24662,35056399,Pretreatment with lansoprazole and different concentrations of garlic oil extracts increased prostaglandin E2 and glutathione concentrations in the cell culture model of peptic ulcer disease (p < 0.001).,"['lansoprazole', 'glutathione']",['peptic ulcer disease'],True,glutathione,peptic ulcer disease,increased,C0030920,Peptic ulcer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione,increase
2172,24721,33728619,"On the 11th day of the study, colitis was induced by intrarectal instillation of 2, 4-Dinitrobenzene sulfonic acid (DNBS), and treatment was continued for the next 7 days.","['intrarectal instillation', 'DNBS']",['colitis'],True,intrarectal instillation,colitis,induced,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",intrarectal instillation,induce
2173,24724,33728619,"On the 11th day of the study, colitis was induced by intrarectal instillation of 2, 4-Dinitrobenzene sulfonic acid (DNBS), and treatment was continued for the next 7 days.","['intrarectal instillation', 'DNBS']",['colitis'],True,intrarectal instillation,colitis,induced,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",intrarectal instillation,induce
2174,24728,33641315," Results: Glucose, HbA1c, triglyceride, low density cholesterol (LDL), leptin, and Homeostatic Model Assessment for insulin resistance (HOMA-IR) levels increased and insulin and HOMA-β levels decreased in the diabetic rats compared to the healthy control group.","['low density cholesterol', 'LDL']",['triglyceride'],True,low density cholesterol,triglyceride,increased,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",low density cholesterol,increase
2175,24733,33605079,The results showed that LPZ significantly aggravated the tubular damage and further increased the elevated levels of serum creatinine and blood urea nitrogen induced by cisplatin.,['cisplatin'],"['aggravated the tubular damage', 'elevated levels of serum creatinine']",True,cisplatin,elevated levels of serum creatinine,increased,C0700225,High blood creatinine level,5702198,azane;dichloroplatinum,azane;dichloroplatinum,increase
2176,24734,33605079,"Notably, LPZ increased the number of necrotic renal tubular cells compared to that by cisplatin treatment alone, which was further confirmed by the elevated necroptosis-associated protein expression of RIPK1, p-RIPK3 and p-MLKL.",['cisplatin'],['necrotic renal tubular cells'],True,cisplatin,necrotic renal tubular cells,increased,C0022672,Acute tubular necrosis,5702198,azane;dichloroplatinum,azane;dichloroplatinum,increase
2177,24746,33532070,It is always  recommended to associate lansoprazole 30 mg to prevent gastric hemorrhages and potassium and magnesium supplements.,"['lansoprazole', 'potassium', 'magnesium']",['gastric hemorrhages'],True,lansoprazole,gastric hemorrhages,associate,C0017181,Gastrointestinal hemorrhage,3883,Lansoprazole,Lansoprazole,associate
2178,24746,33532070,It is always  recommended to associate lansoprazole 30 mg to prevent gastric hemorrhages and potassium and magnesium supplements.,"['lansoprazole', 'potassium', 'magnesium']",['gastric hemorrhages'],True,potassium,gastric hemorrhages,associate,C0017181,Gastrointestinal hemorrhage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",potassium,associate
2179,24746,33532070,It is always  recommended to associate lansoprazole 30 mg to prevent gastric hemorrhages and potassium and magnesium supplements.,"['lansoprazole', 'potassium', 'magnesium']",['gastric hemorrhages'],True,magnesium,gastric hemorrhages,associate,C0017181,Gastrointestinal hemorrhage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",magnesium,associate
2180,24767,33368499," CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact.","['omeprazole', 'esomeprazole', 'lansoprazole', 'pantoprazole', 'rabeprazole']","['cirrhosis', 'microsomal activity']",True,omeprazole,cirrhosis,inhibit,C0023890,Cirrhosis,4594,Omeprazole,Omeprazole,inhibit
2181,24767,33368499," CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact.","['omeprazole', 'esomeprazole', 'lansoprazole', 'pantoprazole', 'rabeprazole']","['cirrhosis', 'microsomal activity']",True,omeprazole,microsomal activity,inhibit,C0023890,Cirrhosis,4594,Omeprazole,Omeprazole,inhibit
2182,24767,33368499," CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact.","['omeprazole', 'esomeprazole', 'lansoprazole', 'pantoprazole', 'rabeprazole']","['cirrhosis', 'microsomal activity']",True,esomeprazole,cirrhosis,inhibit,C0023890,Cirrhosis,4594,Omeprazole,Omeprazole,inhibit
2183,24767,33368499," CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact.","['omeprazole', 'esomeprazole', 'lansoprazole', 'pantoprazole', 'rabeprazole']","['cirrhosis', 'microsomal activity']",True,esomeprazole,microsomal activity,inhibit,C0023890,Cirrhosis,4594,Omeprazole,Omeprazole,inhibit
2184,24767,33368499," CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact.","['omeprazole', 'esomeprazole', 'lansoprazole', 'pantoprazole', 'rabeprazole']","['cirrhosis', 'microsomal activity']",True,lansoprazole,cirrhosis,inhibit,C0023890,Cirrhosis,3883,Lansoprazole,Lansoprazole,inhibit
2185,24767,33368499," CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact.","['omeprazole', 'esomeprazole', 'lansoprazole', 'pantoprazole', 'rabeprazole']","['cirrhosis', 'microsomal activity']",True,lansoprazole,microsomal activity,inhibit,C0023890,Cirrhosis,3883,Lansoprazole,Lansoprazole,inhibit
2186,24767,33368499," CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact.","['omeprazole', 'esomeprazole', 'lansoprazole', 'pantoprazole', 'rabeprazole']","['cirrhosis', 'microsomal activity']",True,pantoprazole,cirrhosis,inhibit,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pantoprazole,inhibit
2187,24767,33368499," CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact.","['omeprazole', 'esomeprazole', 'lansoprazole', 'pantoprazole', 'rabeprazole']","['cirrhosis', 'microsomal activity']",True,pantoprazole,microsomal activity,inhibit,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",pantoprazole,inhibit
2188,24767,33368499," CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact.","['omeprazole', 'esomeprazole', 'lansoprazole', 'pantoprazole', 'rabeprazole']","['cirrhosis', 'microsomal activity']",True,rabeprazole,cirrhosis,inhibit,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rabeprazole,inhibit
2189,24767,33368499," CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact.","['omeprazole', 'esomeprazole', 'lansoprazole', 'pantoprazole', 'rabeprazole']","['cirrhosis', 'microsomal activity']",True,rabeprazole,microsomal activity,inhibit,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rabeprazole,inhibit
2190,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sulfonamides,diarrhea,cause,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sulfonamides,cause
2191,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sulfonamides,colitis,cause,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sulfonamides,cause
2192,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sulfonamides,dysrhythmia,cause,C0003811,Cardiac arrhythmia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sulfonamides,cause
2193,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sulfonamides,arthropathy,cause,C0022408,Arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sulfonamides,cause
2194,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sulfonamides,ataxia,cause,C0007758,Cerebellar ataxia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sulfonamides,cause
2195,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sulfonamides,anorexia,cause,C0003123,Anorexia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sulfonamides,cause
2196,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sulfonamides,seizures,cause,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sulfonamides,cause
2197,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sulfonamides,peripheral neuropathy,cause,C0031117,Peripheral nerve damage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sulfonamides,cause
2198,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,trimethoprim/sulfonamide,diarrhea,cause,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trimethoprim/sulfonamide,cause
2199,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,trimethoprim/sulfonamide,colitis,cause,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trimethoprim/sulfonamide,cause
2200,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,trimethoprim/sulfonamide,dysrhythmia,cause,C0003811,Cardiac arrhythmia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trimethoprim/sulfonamide,cause
2201,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,trimethoprim/sulfonamide,arthropathy,cause,C0022408,Arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trimethoprim/sulfonamide,cause
2202,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,trimethoprim/sulfonamide,ataxia,cause,C0007758,Cerebellar ataxia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trimethoprim/sulfonamide,cause
2203,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,trimethoprim/sulfonamide,anorexia,cause,C0003123,Anorexia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trimethoprim/sulfonamide,cause
2204,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,trimethoprim/sulfonamide,seizures,cause,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trimethoprim/sulfonamide,cause
2205,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,trimethoprim/sulfonamide,peripheral neuropathy,cause,C0031117,Peripheral nerve damage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",trimethoprim/sulfonamide,cause
2206,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,benzylpenicillin,diarrhea,cause,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",benzylpenicillin,cause
2207,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,benzylpenicillin,colitis,cause,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",benzylpenicillin,cause
2208,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,benzylpenicillin,dysrhythmia,cause,C0003811,Cardiac arrhythmia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",benzylpenicillin,cause
2209,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,benzylpenicillin,arthropathy,cause,C0022408,Arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",benzylpenicillin,cause
2210,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,benzylpenicillin,ataxia,cause,C0007758,Cerebellar ataxia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",benzylpenicillin,cause
2211,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,benzylpenicillin,anorexia,cause,C0003123,Anorexia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",benzylpenicillin,cause
2212,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,benzylpenicillin,seizures,cause,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",benzylpenicillin,cause
2213,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,benzylpenicillin,peripheral neuropathy,cause,C0031117,Peripheral nerve damage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",benzylpenicillin,cause
2214,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,cefquinome,diarrhea,cause,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cefquinome,cause
2215,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,cefquinome,colitis,cause,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cefquinome,cause
2216,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,cefquinome,dysrhythmia,cause,C0003811,Cardiac arrhythmia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cefquinome,cause
2217,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,cefquinome,arthropathy,cause,C0022408,Arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cefquinome,cause
2218,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,cefquinome,ataxia,cause,C0007758,Cerebellar ataxia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cefquinome,cause
2219,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,cefquinome,anorexia,cause,C0003123,Anorexia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cefquinome,cause
2220,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,cefquinome,seizures,cause,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cefquinome,cause
2221,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,cefquinome,peripheral neuropathy,cause,C0031117,Peripheral nerve damage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cefquinome,cause
2222,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,fluphenazine,diarrhea,cause,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluphenazine,cause
2223,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,fluphenazine,colitis,cause,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluphenazine,cause
2224,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,fluphenazine,dysrhythmia,cause,C0003811,Cardiac arrhythmia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluphenazine,cause
2225,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,fluphenazine,arthropathy,cause,C0022408,Arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluphenazine,cause
2226,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,fluphenazine,ataxia,cause,C0007758,Cerebellar ataxia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluphenazine,cause
2227,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,fluphenazine,anorexia,cause,C0003123,Anorexia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluphenazine,cause
2228,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,fluphenazine,seizures,cause,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluphenazine,cause
2229,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,fluphenazine,peripheral neuropathy,cause,C0031117,Peripheral nerve damage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fluphenazine,cause
2230,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,enrofloxacin,diarrhea,cause,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enrofloxacin,cause
2231,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,enrofloxacin,colitis,cause,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enrofloxacin,cause
2232,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,enrofloxacin,dysrhythmia,cause,C0003811,Cardiac arrhythmia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enrofloxacin,cause
2233,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,enrofloxacin,arthropathy,cause,C0022408,Arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enrofloxacin,cause
2234,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,enrofloxacin,ataxia,cause,C0007758,Cerebellar ataxia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enrofloxacin,cause
2235,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,enrofloxacin,anorexia,cause,C0003123,Anorexia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enrofloxacin,cause
2236,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,enrofloxacin,seizures,cause,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enrofloxacin,cause
2237,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,enrofloxacin,peripheral neuropathy,cause,C0031117,Peripheral nerve damage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",enrofloxacin,cause
2238,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sodium ceftriaxone,diarrhea,cause,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium ceftriaxone,cause
2239,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sodium ceftriaxone,colitis,cause,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium ceftriaxone,cause
2240,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sodium ceftriaxone,dysrhythmia,cause,C0003811,Cardiac arrhythmia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium ceftriaxone,cause
2241,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sodium ceftriaxone,arthropathy,cause,C0022408,Arthropathy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium ceftriaxone,cause
2242,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sodium ceftriaxone,ataxia,cause,C0007758,Cerebellar ataxia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium ceftriaxone,cause
2243,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sodium ceftriaxone,anorexia,cause,C0003123,Anorexia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium ceftriaxone,cause
2244,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sodium ceftriaxone,seizures,cause,C0036572,Seizure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium ceftriaxone,cause
2245,24801,33478757,"Surprisingly, antibiotics such as sulfonamides or trimethoprim/sulfonamide combinations, benzylpenicillin, cefquinome, fluphenazine, enrofloxacin, and sodium ceftriaxone cause detrimental effects on horses' health, namely, diarrhea, colitis, nephrotoxicity, ototoxicity, dysrhythmia, arthropathy, ataxia, anorexia, seizures, peripheral neuropathy, and  certain neurologic abnormalities.","['sulfonamides', 'trimethoprim/sulfonamide', 'benzylpenicillin', 'cefquinome', 'fluphenazine', 'enrofloxacin', 'sodium ceftriaxone']","['diarrhea', 'colitis', 'nephrotoxicity', 'ototoxicity', 'dysrhythmia', 'arthropathy', 'ataxia', 'anorexia', 'seizures', 'peripheral neuropathy']",True,sodium ceftriaxone,peripheral neuropathy,cause,C0031117,Peripheral nerve damage,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium ceftriaxone,cause
2246,24828,35219693,"  The antimalarial drug chloroquine (CQ) induces retinopathy, a disorder characterized by lysosomotropic alteration.",['chloroquine'],['retinopathy'],True,chloroquine,retinopathy,induces,C0035309,Retinal disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chloroquine,induce
2247,24839,33859795,A scaffold-hop to the corresponding imidazole resulted in increased biochemical potency.,['imidazole'],['increased biochemical potency'],True,imidazole,increased biochemical potency,resulted,C0035309,Retinal disease,795,1H-imidazole,1H-imidazole,result
2248,24875,35298964," Therefore, the purpose of this study was to investigate whether NaAsO2 might induce mitochondrial damage and apoptosis of cervical cancer cells through NF-κB/ miR-21 /GCLC induced oxidative stress, and play the anti-tumor role of arsenic as a potential drug for the treatment of cervical cancer.","['NaAsO2', 'arsenic']","['apoptosis', 'cervical cancer', 'oxidative stress', 'cervical cancer']",True,NaAsO2,cervical cancer,induce,C4048328,Cervix cancer,443495,sodium;oxoarsinite,sodium;oxoarsinite,induce
2249,24875,35298964," Therefore, the purpose of this study was to investigate whether NaAsO2 might induce mitochondrial damage and apoptosis of cervical cancer cells through NF-κB/ miR-21 /GCLC induced oxidative stress, and play the anti-tumor role of arsenic as a potential drug for the treatment of cervical cancer.","['NaAsO2', 'arsenic']","['apoptosis', 'cervical cancer', 'oxidative stress', 'cervical cancer']",True,arsenic,oxidative stress,induced,C0242606,Oxidative stress,5359596,arsenic,arsenic,induce
2250,24875,35298964," Therefore, the purpose of this study was to investigate whether NaAsO2 might induce mitochondrial damage and apoptosis of cervical cancer cells through NF-κB/ miR-21 /GCLC induced oxidative stress, and play the anti-tumor role of arsenic as a potential drug for the treatment of cervical cancer.","['NaAsO2', 'arsenic']","['apoptosis', 'cervical cancer', 'oxidative stress', 'cervical cancer']",True,arsenic,cervical cancer,induced,C4048328,Cervix cancer,5359596,arsenic,arsenic,induce
2251,24876,35298964," RESULTS: Compared with the control group, with the gradual increasing dose of NaAsO2, cell viability was considerable reduced, and increased rate of apoptosis, intracellular GSH level was decreased significantly, ROS was increased, mitochondrial structure was damaged, mitochondrial membrane potential ΔΨm and Bcl2/BAX lowered, the expression of Caspase3 and cleaved-caspase3 were significantly increased, resulting in mitochondrial apoptosis.",['NaAsO2'],"['viability', 'increased rate of apoptosis', 'damaged', 'expression of Caspase3 and cleaved-caspase3 were significantly increased']",True,NaAsO2,damaged,increased,C3887709,Optic neuropathy,443495,sodium;oxoarsinite,sodium;oxoarsinite,increase
2252,24894,35276128, [Epub ahead of print]  Arsenic trioxide inhibits the functions of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.,['Arsenic trioxide'],['idiopathic pulmonary fibrosis'],True,Arsenic trioxide,idiopathic pulmonary fibrosis,inhibits,C0034069,Pulmonary fibrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Arsenic trioxide,inhibit
2253,24906,35272572,"There was a positive dose-response relationship between arsenic and p-GSK-3β when the dose of arsenic was less than  8 μmol/L. The expression of Mcl-1 and pro-caspase-3 were decreased, while the loss of mitochondrial membrane potential and cleaved-caspase-3 increased significantly when arsenic stimulated GSK-3β (Ser9) (P < 0.05).",['arsenic'],['loss of mitochondrial membrane'],True,arsenic,loss of mitochondrial membrane,increased,C0034069,Pulmonary fibrosis,5359596,arsenic,arsenic,increase
2254,24914,35262446,"The risk assessment indicated that high cancer risks are associated with exposure to As, Cd, Cr, and Ni, while lower risks are associated with Pb.","['Cd, Cr', 'Ni', 'Pb']",['cancer'],True,"Cd, Cr",cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","Cd, Cr",associate
2255,24914,35262446,"The risk assessment indicated that high cancer risks are associated with exposure to As, Cd, Cr, and Ni, while lower risks are associated with Pb.","['Cd, Cr', 'Ni', 'Pb']",['cancer'],True,Ni,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Ni,associate
2256,24914,35262446,"The risk assessment indicated that high cancer risks are associated with exposure to As, Cd, Cr, and Ni, while lower risks are associated with Pb.","['Cd, Cr', 'Ni', 'Pb']",['cancer'],True,Pb,cancer,associated,C0006826,Cancer,5352425,lead,lead,associate
2257,24917,35262446,"A high risk of developing cancer is associated with exposure to As,  Cd, Cr, and Ni, while a lower risk is associated with exposure to Pb.","['Cd, Cr', 'Ni', 'Pb']",['cancer'],True,"Cd,",cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate","Cd,",associate
2258,24917,35262446,"A high risk of developing cancer is associated with exposure to As,  Cd, Cr, and Ni, while a lower risk is associated with exposure to Pb.","['Cd, Cr', 'Ni', 'Pb']",['cancer'],True,Cr,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Cr,associate
2259,24917,35262446,"A high risk of developing cancer is associated with exposure to As,  Cd, Cr, and Ni, while a lower risk is associated with exposure to Pb.","['Cd, Cr', 'Ni', 'Pb']",['cancer'],True,Ni,cancer,associated,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Ni,associate
2260,24917,35262446,"A high risk of developing cancer is associated with exposure to As,  Cd, Cr, and Ni, while a lower risk is associated with exposure to Pb.","['Cd, Cr', 'Ni', 'Pb']",['cancer'],True,Pb,cancer,associated,C0006826,Cancer,5352425,lead,lead,associate
2261,24949,35314935,"doi: 10.1007/s11356-022-19250-7. [Epub ahead of print]  Environmental exposures to lead, cadmium, and mercury and pterygium in Korean adults.","['cadmium', 'mercury']",['pterygium'],True,cadmium,pterygium,lead,C0033999,Pterygium,23973,cadmium,cadmium,lead
2262,24949,35314935,"doi: 10.1007/s11356-022-19250-7. [Epub ahead of print]  Environmental exposures to lead, cadmium, and mercury and pterygium in Korean adults.","['cadmium', 'mercury']",['pterygium'],True,mercury,pterygium,lead,C0033999,Pterygium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mercury,lead
2263,24959,35307496,"In addition, the defensive plant hormones, i.e. salicylic acid in the roots, increased significantly by 338%.",['salicylic acid'],['defensive plant'],True,salicylic acid,defensive plant,increased,C0033999,Pterygium,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",salicylic acid,increase
2264,24966,35301059,"Moreover, we found that cadmium exposure induces the pro-inflammatory state of the adipocytes by enhancing the expression of genes such as IL-6, IL-1B  and CCL2, cytokines also induced in obesity.",['cadmium'],"['enhancing the expression of genes', 'obesity']",True,cadmium,obesity,induces,C0028754,Obesity,23973,cadmium,cadmium,induce
2265,24970,35298719,"The results revealed that Cd toxicity increased the levels of hydrogen peroxide (H2O2), methylglyoxal (MG) and malondialdehyde (MDA), resulting in oxidative stress and the induction of electrolyte leakage (EL).","['Cd toxicity', 'hydrogen peroxide']","['oxidative stress', 'induction of electrolyte leakage']",True,Cd toxicity,oxidative stress,increased,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Cd toxicity,increase
2266,24970,35298719,"The results revealed that Cd toxicity increased the levels of hydrogen peroxide (H2O2), methylglyoxal (MG) and malondialdehyde (MDA), resulting in oxidative stress and the induction of electrolyte leakage (EL).","['Cd toxicity', 'hydrogen peroxide']","['oxidative stress', 'induction of electrolyte leakage']",True,hydrogen peroxide,oxidative stress,increased,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",hydrogen peroxide,increase
2267,24978,35288159, DISCUSSION AND CONCLUSIONS: The results suggest that even low levels of Cd in the kidney can induce a mild degree of tubular atrophy.,['Cd in the kidney'],['tubular atrophy'],True,Cd in the kidney,tubular atrophy,induce,C1858395,Renal tubular cell atrophy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Cd in the kidney,induce
2268,25023,35272187,"Exposure to 5 ppm Cd caused iron accumulation, increased levels of malondialdehyde (MDA) and nitro tyrosine (3-NT), and decreased expression of Nrf2, HO-1 and SOD2.","['Cd', 'iron']","['increased levels of malondialdehyde (MDA) and nitro tyrosine', 'decreased expression of Nrf2']",True,Cd,decreased expression of Nrf2,caused,C1862474,Decreased facial expression,23973,cadmium,cadmium,cause
2269,25023,35272187,"Exposure to 5 ppm Cd caused iron accumulation, increased levels of malondialdehyde (MDA) and nitro tyrosine (3-NT), and decreased expression of Nrf2, HO-1 and SOD2.","['Cd', 'iron']","['increased levels of malondialdehyde (MDA) and nitro tyrosine', 'decreased expression of Nrf2']",True,iron,decreased expression of Nrf2,caused,C1862474,Decreased facial expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",iron,cause
2270,25023,35272187,"Exposure to 5 ppm Cd caused iron accumulation, increased levels of malondialdehyde (MDA) and nitro tyrosine (3-NT), and decreased expression of Nrf2, HO-1 and SOD2.","['Cd', 'iron']","['increased levels of malondialdehyde (MDA) and nitro tyrosine', 'decreased expression of Nrf2']",True,nitro,decreased expression of Nrf2,caused,C1862474,Decreased facial expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",nitro,cause
2271,25037,35260619,"The co-existence of PHE and Cd caused the change of the structure of soil and rhamnolipid micelle, which lead to different  removal rate of PHE and Cd from co-contaminated soil compared with single contaminated soil.","['Cd', 'rhamnolipid micelle', 'Cd']",['change of the structure'],True,Cd,change of the structure,caused,C1862474,Decreased facial expression,23973,cadmium,cadmium,cause
2272,25037,35260619,"The co-existence of PHE and Cd caused the change of the structure of soil and rhamnolipid micelle, which lead to different  removal rate of PHE and Cd from co-contaminated soil compared with single contaminated soil.","['Cd', 'rhamnolipid micelle', 'Cd']",['change of the structure'],True,rhamnolipid micelle,change of the structure,caused,C1862474,Decreased facial expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",rhamnolipid micelle,cause
2273,25037,35260619,"The co-existence of PHE and Cd caused the change of the structure of soil and rhamnolipid micelle, which lead to different  removal rate of PHE and Cd from co-contaminated soil compared with single contaminated soil.","['Cd', 'rhamnolipid micelle', 'Cd']",['change of the structure'],True,Cd,change of the structure,caused,C1862474,Decreased facial expression,23973,cadmium,cadmium,cause
2274,25096,35293731,"  Patients having experienced the ischemia-reperfusion process are particularly vulnerable to subsequent heart attacks because this process can induce myocardial fibrosis, hallmarked by the release of reactive oxygen species and some proteases, such as cathepsin G, into the circulating blood.",['oxygen'],"['ischemia-reperfusion', 'heart attacks', 'myocardial fibrosis']",True,oxygen,myocardial fibrosis,induce,C0151654,Myocardial fibrosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,induce
2275,25116,35316733,"Results of experiments in vitro demonstrated that treatment with serum withdrawal or tunicamycin inhibited cell proliferation and promoted cell apoptosis in SWFs, and the adverse effects of tunicamycin on SWFs manifested a dose-dependent increase.","['tunicamycin', 'tunicamycin']","['cell proliferation', 'promoted cell apoptosis']",True,tunicamycin,cell proliferation,inhibited,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tunicamycin,inhibit
2276,25148,35306571," MTX also caused diminished ATP synthase β expression, increased autophagic protein LC3 II and tended to decrease p62 expression.",['ATP'],"['increased autophagic protein LC3 II', 'decrease p62 expression']",True,ATP,decrease p62 expression,caused,C1862474,Decreased facial expression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ATP,cause
2277,25156,35299945,"In cultured human brain microvascular endothelial cells, tert-butyl hydroperoxide induced oxidative stress and a decrease in manganese superoxide dismutase (MnSOD) mRNA and protein expression that were blocked by the antioxidant drugs.","['tert-butyl hydroperoxide', 'manganese']",['oxidative stress'],True,tert-butyl hydroperoxide,oxidative stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tert-butyl hydroperoxide,induce
2278,25156,35299945,"In cultured human brain microvascular endothelial cells, tert-butyl hydroperoxide induced oxidative stress and a decrease in manganese superoxide dismutase (MnSOD) mRNA and protein expression that were blocked by the antioxidant drugs.","['tert-butyl hydroperoxide', 'manganese']",['oxidative stress'],True,manganese,oxidative stress,induced,C0242606,Oxidative stress,23930,manganese,manganese,induce
2279,25193,35270089,"In addition, it has been reported that E. coli MnSOD activity is inhibited by Fe and that MTM1-mutated yeast cells exhibit elevated Fe content and decreased MnSOD activity, which can be restored by the Fe2+-specific chelator, bathophenanthroline disulfonate (BPS).","['Fe', 'Fe', 'bathophenanthroline disulfonate']",['decreased MnSOD activity'],True,Fe,decreased MnSOD activity,inhibited,C0235659,Decreased movement in utero,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Fe,inhibit
2280,25193,35270089,"In addition, it has been reported that E. coli MnSOD activity is inhibited by Fe and that MTM1-mutated yeast cells exhibit elevated Fe content and decreased MnSOD activity, which can be restored by the Fe2+-specific chelator, bathophenanthroline disulfonate (BPS).","['Fe', 'Fe', 'bathophenanthroline disulfonate']",['decreased MnSOD activity'],True,Fe,decreased MnSOD activity,inhibited,C0235659,Decreased movement in utero,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Fe,inhibit
2281,25193,35270089,"In addition, it has been reported that E. coli MnSOD activity is inhibited by Fe and that MTM1-mutated yeast cells exhibit elevated Fe content and decreased MnSOD activity, which can be restored by the Fe2+-specific chelator, bathophenanthroline disulfonate (BPS).","['Fe', 'Fe', 'bathophenanthroline disulfonate']",['decreased MnSOD activity'],True,bathophenanthroline disulfonate,decreased MnSOD activity,inhibited,C0235659,Decreased movement in utero,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",bathophenanthroline disulfonate,inhibit
2282,25263,34915094,The presence of nTiO2 led to a substantial decrease of the THg in D. magna when exposed to IHg/MeHg via algal food.,['IHg/MeHg'],['decrease of the THg'],True,IHg/MeHg,decrease of the THg,led,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",IHg/MeHg,lead
2283,25267,34905692,"We have previously shown that MeHg causes lipid dysregulation in Caenorhabditis elegans (C. elegans), leading to altered gene expression, increased triglyceride levels and lipid storage, and altered feeding behaviors.",['MeHg'],"['lipid dysregulation', 'altered gene expression', 'increased triglyceride levels']",True,MeHg,increased triglyceride levels,causes,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MeHg,cause
2284,25286,34822840,"The study revealed that: (1) cadmium cytotoxicity in vascular endothelial cells was potentiated by the overexpression  of ZIP8, and the intracellular accumulation of cadmium in the cells was increased; (2) cadmium highly induced the expression of ZIP8, but not other ZIPs; (3) lead and methylmercury moderately induced ZIP8 expression, but the other tested metals did not; (4) the induction of ZIP8 expression by cadmium was mediated by both NF-κB and JNK signaling, and the accumulation of NF-κB in the nucleus was regulated by JNK signaling.","['cadmium', 'cadmium', 'cadmium', 'methylmercury', 'cadmium']","['ZIP8 expression', 'induction of ZIP8 expression', 'accumulation of NF-κB in the nucleus']",True,methylmercury,ZIP8 expression,induced,C0424448,Mask-like facies,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",methylmercury,induce
2285,25292,34678407,"Treatment of wild-type (WT) MEFs were treated with  MeHg (1 μM) increased mRNA levels of Chop encoding C/EBP homologous protein, Trib3 encoding Tribbles homolog 3, and Dnajb9 encoding DnaJ heat-shock protein family (Hsp40) member B9 increased, suggesting that ER stress is elicited by MeHg stress.","['MeHg', 'MeHg']","['increased mRNA levels of Chop encoding C/EBP homologous protein', 'ER stress']",True,MeHg,ER stress,elicited,C0424448,Mask-like facies,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",MeHg,elicit
2286,25346,34418744," CONCLUSIONS: Total blood mercury and blood methylmercury concentrations were inversely associated with diabetes in adults, and the associations were modified  by selenium.",['selenium'],"['Total blood mercury', 'diabetes']",True,selenium,diabetes,associated,C0085207,Maternal diabetes,6326970,selenium,selenium,associate
2287,25356,35316142,"Here, we explored whether oxidation metabolites produced by the host during inflammation, sodium nitrate and trimethylamine oxide, impact the composition of a human stool bacterial population in a gut simulator.",['sodium nitrate'],['inflammation'],True,sodium nitrate,inflammation,produced,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",sodium nitrate,produce
2288,25399,35242376," Conclusions: ICOS could inhibit the lipid phagocytosis of HASMCs by down-regulating the expression of CD36, suggesting a potential anti-atherosclerosis (anti-AS) mechanism of ICOS, and preventing ox-LDL-induced formation of myogenic foam cells.",['ox-LDL-'],['lipid phagocytosis'],True,ox-LDL-,lipid phagocytosis,inhibit,C5139054,Abnormal phagocytosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ox-LDL-,inhibit
2289,25456,35189193,"The representative antioxidant enzyme activities indicated that MPs induced severer oxidative stress to earthworms than NPs, especially at the concentration of 100 mg/kg, thus leading to increased accumulation of pyrene by earthworms at the initial stage.",['pyrene'],"['severer oxidative stress', 'increased accumulation']",True,pyrene,severer oxidative stress,induced,C0242606,Oxidative stress,31423,pyrene,pyrene,induce
2290,25471,35310945,This protein inhibits F4+ ETEC adhesion to porcine epithelial cells ex vivo and decreases F4+ ETEC proliferation when administrated as a feed additive to weaned F4+ ETEC challenged piglets.,['ETEC'],"['decreases F4', 'proliferation']",True,ETEC,proliferation,inhibits,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ETEC,inhibit
2291,25482,35302712,"  The aberrant activation of the Gli family of zinc finger transcription factors (ZFTFs) is associated with several types of human cancer, including medulloblastoma and basal cell carcinoma.",['zinc'],"['cancer', 'basal cell carcinoma']",True,zinc,cancer,associated,C0006826,Cancer,23994,zinc,zinc,associate
2292,25482,35302712,"  The aberrant activation of the Gli family of zinc finger transcription factors (ZFTFs) is associated with several types of human cancer, including medulloblastoma and basal cell carcinoma.",['zinc'],"['cancer', 'basal cell carcinoma']",True,zinc,basal cell carcinoma,associated,C4721806,Basal cell carcinoma,23994,zinc,zinc,associate
2293,25492,35298549,"Post weaning diarrhea causes significant losses for the producers, most  commonly it is prevented by feeding high doses of zinc oxide (ZnO).",['zinc oxide'],['diarrhea'],True,zinc oxide,diarrhea,causes,C0011991,Diarrhoea,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",zinc oxide,cause
2294,25578,31812418,"Exposure to EHDPP for 10 days extensively induced adipogenesis in 3T3-L1 preadipocytes as assessed by lipid accumulation and gene expression of adipogenic markers of fatty acid binding protein 4 (FABP4), lipoprotein lipase (Lpl), adiponectin (Adip), and fatty acid synthase (Fasn).",['EHDPP'],"['lipid accumulation', 'adiponectin (Adip), and fatty acid synthase']",True,EHDPP,lipid accumulation,induced,C1837262,Increased muscle lipid content,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",EHDPP,induce
2295,25578,31812418,"Exposure to EHDPP for 10 days extensively induced adipogenesis in 3T3-L1 preadipocytes as assessed by lipid accumulation and gene expression of adipogenic markers of fatty acid binding protein 4 (FABP4), lipoprotein lipase (Lpl), adiponectin (Adip), and fatty acid synthase (Fasn).",['EHDPP'],"['lipid accumulation', 'adiponectin (Adip), and fatty acid synthase']",True,EHDPP,adiponectin,induced,C4073126,Abnormal adiponectin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",EHDPP,induce
2296,25578,31812418,"Exposure to EHDPP for 10 days extensively induced adipogenesis in 3T3-L1 preadipocytes as assessed by lipid accumulation and gene expression of adipogenic markers of fatty acid binding protein 4 (FABP4), lipoprotein lipase (Lpl), adiponectin (Adip), and fatty acid synthase (Fasn).",['EHDPP'],"['lipid accumulation', 'adiponectin (Adip), and fatty acid synthase']",True,EHDPP,fatty acid synthase,induced,C4073126,Abnormal adiponectin level,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",EHDPP,induce
2297,25582,31310930," We found that the non-chlorinated PFR metabolites, 2-ethylhexyl phenyl phosphate  (EHPHP), bis(2-butoxyethyl) phosphate (BBOEP), and diphenyl phosphate (DPHP) were associated with increased levels of oxidative stress biomarkers.","['2-ethylhexyl phenyl phosphate', 'bis(2-butoxyethyl) phosphate', 'diphenyl phosphate']",['increased levels of oxidative stress'],True,2-ethylhexyl phenyl,increased levels of oxidative stress,associated,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-ethylhexyl phenyl,associate
2298,25582,31310930," We found that the non-chlorinated PFR metabolites, 2-ethylhexyl phenyl phosphate  (EHPHP), bis(2-butoxyethyl) phosphate (BBOEP), and diphenyl phosphate (DPHP) were associated with increased levels of oxidative stress biomarkers.","['2-ethylhexyl phenyl phosphate', 'bis(2-butoxyethyl) phosphate', 'diphenyl phosphate']",['increased levels of oxidative stress'],True,diphenyl,increased levels of oxidative stress,associated,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",diphenyl,associate
2299,25584,31268531,House dust extracts (100 µg/ml) also caused significant reductions (up to 33%) in imidapril activation.,['imidapril'],['reductions (up to 33%)'],True,imidapril,reductions (up to 33%),caused,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",imidapril,cause
2300,25588,29604578,The urinary DNBP concentration was significantly associated with self-reported symptoms of allergy.,['DNBP'],['allergy'],True,DNBP,allergy,associated,C0020517,Allergy,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DNBP,associate
2301,25667,34314170,"PFHxS was associated with an increase in TSH (% change in outcome  [95% CI] per 2-fold PFAS increase = 6.09 [-0.71, 13.4]), and PFOA and PFNA were associated with a decrease in TT3 (-7.17 [-13.5, -0.39] and -6.28 [-12.3, 0.12],  respectively).","['PFHxS', 'PFOA', 'PFNA']","['increase in TSH', 'decrease in TT3']",True,PFHxS,increase in TSH,associated,C0853225,Reduced factor II activity,67734,"1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid",associate
2302,25667,34314170,"PFHxS was associated with an increase in TSH (% change in outcome  [95% CI] per 2-fold PFAS increase = 6.09 [-0.71, 13.4]), and PFOA and PFNA were associated with a decrease in TT3 (-7.17 [-13.5, -0.39] and -6.28 [-12.3, 0.12],  respectively).","['PFHxS', 'PFOA', 'PFNA']","['increase in TSH', 'decrease in TT3']",True,PFHxS,decrease in TT3,associated,C0580413,Decreased prothrombin time,67734,"1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid",associate
2303,25667,34314170,"PFHxS was associated with an increase in TSH (% change in outcome  [95% CI] per 2-fold PFAS increase = 6.09 [-0.71, 13.4]), and PFOA and PFNA were associated with a decrease in TT3 (-7.17 [-13.5, -0.39] and -6.28 [-12.3, 0.12],  respectively).","['PFHxS', 'PFOA', 'PFNA']","['increase in TSH', 'decrease in TT3']",True,PFOA,increase in TSH,associated,C0853225,Reduced factor II activity,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
2304,25667,34314170,"PFHxS was associated with an increase in TSH (% change in outcome  [95% CI] per 2-fold PFAS increase = 6.09 [-0.71, 13.4]), and PFOA and PFNA were associated with a decrease in TT3 (-7.17 [-13.5, -0.39] and -6.28 [-12.3, 0.12],  respectively).","['PFHxS', 'PFOA', 'PFNA']","['increase in TSH', 'decrease in TT3']",True,PFOA,decrease in TT3,associated,C0580413,Decreased prothrombin time,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
2305,25667,34314170,"PFHxS was associated with an increase in TSH (% change in outcome  [95% CI] per 2-fold PFAS increase = 6.09 [-0.71, 13.4]), and PFOA and PFNA were associated with a decrease in TT3 (-7.17 [-13.5, -0.39] and -6.28 [-12.3, 0.12],  respectively).","['PFHxS', 'PFOA', 'PFNA']","['increase in TSH', 'decrease in TT3']",True,PFNA,increase in TSH,associated,C0853225,Reduced factor II activity,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",associate
2306,25667,34314170,"PFHxS was associated with an increase in TSH (% change in outcome  [95% CI] per 2-fold PFAS increase = 6.09 [-0.71, 13.4]), and PFOA and PFNA were associated with a decrease in TT3 (-7.17 [-13.5, -0.39] and -6.28 [-12.3, 0.12],  respectively).","['PFHxS', 'PFOA', 'PFNA']","['increase in TSH', 'decrease in TT3']",True,PFNA,decrease in TT3,associated,C0580413,Decreased prothrombin time,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",associate
2307,25667,34314170,"PFHxS was associated with an increase in TSH (% change in outcome  [95% CI] per 2-fold PFAS increase = 6.09 [-0.71, 13.4]), and PFOA and PFNA were associated with a decrease in TT3 (-7.17 [-13.5, -0.39] and -6.28 [-12.3, 0.12],  respectively).","['PFHxS', 'PFOA', 'PFNA']","['increase in TSH', 'decrease in TT3']",True,PFOA,decrease in TT3,associated,C0580413,Decreased prothrombin time,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
2308,25667,34314170,"PFHxS was associated with an increase in TSH (% change in outcome  [95% CI] per 2-fold PFAS increase = 6.09 [-0.71, 13.4]), and PFOA and PFNA were associated with a decrease in TT3 (-7.17 [-13.5, -0.39] and -6.28 [-12.3, 0.12],  respectively).","['PFHxS', 'PFOA', 'PFNA']","['increase in TSH', 'decrease in TT3']",True,PFNA,decrease in TT3,associated,C0580413,Decreased prothrombin time,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",associate
2309,25681,33208860,"PFOS and PFHxS were not associated with alterations in BMI trajectories, but were monotonically associated with lower BMI across infancy, childhood, and adolescence.","['PFOS', 'PFHxS']",['childhood'],True,PFOS,childhood,associated,C1837352,Childhood onset,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",associate
2310,25681,33208860,"PFOS and PFHxS were not associated with alterations in BMI trajectories, but were monotonically associated with lower BMI across infancy, childhood, and adolescence.","['PFOS', 'PFHxS']",['childhood'],True,PFHxS,childhood,associated,C1837352,Childhood onset,67734,"1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid",associate
2311,25684,33091773,Our study shows that total PFCs and PFHS were associated with an increased risk of kidney stones.,['PFHS'],['increased risk of kidney stones'],True,PFHS,increased risk of kidney stones,associated,C0392525,Renal calculi,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PFHS,associate
2312,25706,32271623," RESULTS: PFHxS or PFOS exposure caused failed swim bladder inflation, abnormal ventroflexion of the tail, and hyperactivity at nonteratogenic concentrations.","['PFHxS', 'PFOS']","['failed swim bladder inflation', 'abnormal ventroflexion of the tail', 'hyperactivity']",True,PFHxS,hyperactivity,caused,C0424295,Hyperactivity,67734,"1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid",cause
2313,25706,32271623," RESULTS: PFHxS or PFOS exposure caused failed swim bladder inflation, abnormal ventroflexion of the tail, and hyperactivity at nonteratogenic concentrations.","['PFHxS', 'PFOS']","['failed swim bladder inflation', 'abnormal ventroflexion of the tail', 'hyperactivity']",True,PFOS,hyperactivity,caused,C0424295,Hyperactivity,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",cause
2314,25707,32271623,"Exposure to PFPeS, PFHxS,  PFHpS, or PFOS resulted in a shared toxicity phenotype characterized by body axis and swim bladder defects and hyperactivity.",['PFOS'],"['body axis and swim bladder defects', 'hyperactivity']",True,PFOS,body axis and swim bladder defects,resulted,C0424295,Hyperactivity,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",result
2315,25707,32271623,"Exposure to PFPeS, PFHxS,  PFHpS, or PFOS resulted in a shared toxicity phenotype characterized by body axis and swim bladder defects and hyperactivity.",['PFOS'],"['body axis and swim bladder defects', 'hyperactivity']",True,PFOS,hyperactivity,resulted,C0424295,Hyperactivity,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",result
2316,25709,32222633,"Using BKMR  and multivariable models, we found that among children born to mothers with higher thyroid peroxidase antibody (TPOAb), perfluorooctanoic acid (PFOA), PFOS,  and perfluorohexanesulfonic acid (PFHxS) were associated with decreased cord FT4  suggesting modification by maternal TPOAb status.","['higher thyroid peroxidase', 'perfluorooctanoic acid', 'PFOS']",['decreased cord FT4'],True,higher thyroid peroxidase,decreased cord FT4,associated,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",higher thyroid peroxidase,associate
2317,25709,32222633,"Using BKMR  and multivariable models, we found that among children born to mothers with higher thyroid peroxidase antibody (TPOAb), perfluorooctanoic acid (PFOA), PFOS,  and perfluorohexanesulfonic acid (PFHxS) were associated with decreased cord FT4  suggesting modification by maternal TPOAb status.","['higher thyroid peroxidase', 'perfluorooctanoic acid', 'PFOS']",['decreased cord FT4'],True,perfluorooctanoic acid,decreased cord FT4,associated,C0427437,Decreased mean corpuscular haemoglobin,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
2318,25709,32222633,"Using BKMR  and multivariable models, we found that among children born to mothers with higher thyroid peroxidase antibody (TPOAb), perfluorooctanoic acid (PFOA), PFOS,  and perfluorohexanesulfonic acid (PFHxS) were associated with decreased cord FT4  suggesting modification by maternal TPOAb status.","['higher thyroid peroxidase', 'perfluorooctanoic acid', 'PFOS']",['decreased cord FT4'],True,PFOS,decreased cord FT4,associated,C0427437,Decreased mean corpuscular haemoglobin,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",associate
2319,25710,32169067, RESULTS: Drinking water contamination caused high serum levels of PFOS (median 157 ng/ml) and PFHxS (median 136 ng/ml) and PFOA (median 8.6 ng/ml).,"['PFOS', 'PFHxS', 'PFOA']",['high serum levels of'],True,PFOS,high serum levels of,caused,C4072885,Increased serum testosterone level,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",cause
2320,25710,32169067, RESULTS: Drinking water contamination caused high serum levels of PFOS (median 157 ng/ml) and PFHxS (median 136 ng/ml) and PFOA (median 8.6 ng/ml).,"['PFOS', 'PFHxS', 'PFOA']",['high serum levels of'],True,PFHxS,high serum levels of,caused,C4072885,Increased serum testosterone level,67734,"1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfonic acid",cause
2321,25710,32169067, RESULTS: Drinking water contamination caused high serum levels of PFOS (median 157 ng/ml) and PFHxS (median 136 ng/ml) and PFOA (median 8.6 ng/ml).,"['PFOS', 'PFHxS', 'PFOA']",['high serum levels of'],True,PFOA,high serum levels of,caused,C4072885,Increased serum testosterone level,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",cause
2322,25714,31931806," RESULTS: For lipids and apolipoproteins in total plasma at baseline, elevated plasma PFAS concentrations were significantly associated with higher apoB and apoC-III concentrations, but not with total cholesterol or triglycerides.",['cholesterol'],['triglycerides'],True,cholesterol,triglycerides,associated,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholesterol,associate
2323,25724,31536623,"In fully adjusted models, several PFAS were associated with higher lipid levels, including evidence of a strong linear trend between triglycerides and both PFOA and PFHxS. CONCLUSIONS: Findings support previous evidence of an association between PFAS exposure and altered lipid profiles and add novel information on this relationship in cord blood, as well as for an understudied PFAS, PFDS (J Clin Endocrinol Metab XX: 0-0, 2019).","['PFOA', 'PFDS']","['higher lipid levels', 'triglycerides']",True,PFDS,triglycerides,associated,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PFDS,associate
2324,25730,31227916,"  INTRODUCTION: Exposure to perfluoroalkyl substances (PFAS), synthetic and persistent chemicals used in commercial and industrial processes, are associated  with cardiometabolic dysfunction and related risk factors including reduced birth weight, excess adiposity, and dyslipidemia.",['perfluoroalkyl substances'],"['reduced birth weight', 'excess adiposity', 'dyslipidemia']",True,perfluoroalkyl substances,reduced birth weight,associated,C0024032,Low birth weight,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",perfluoroalkyl substances,associate
2325,25730,31227916,"  INTRODUCTION: Exposure to perfluoroalkyl substances (PFAS), synthetic and persistent chemicals used in commercial and industrial processes, are associated  with cardiometabolic dysfunction and related risk factors including reduced birth weight, excess adiposity, and dyslipidemia.",['perfluoroalkyl substances'],"['reduced birth weight', 'excess adiposity', 'dyslipidemia']",True,perfluoroalkyl substances,dyslipidemia,associated,C0242339,Dyslipidemia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",perfluoroalkyl substances,associate
2326,25743,30055518,"For the overall cohort, perfluorooctanoic acid was negatively associated with birth length per SD increase in concentration (β = -0.23 cm; 95% CI -0.35, -0.10), while perfluorohexanesulfonic acid was negatively associated with umbilical circumference (β = -0.26 cm; 95% CI -0.40, -0.13), perfluorodecanoic acid with arm length (-0.09 cm; 95% CI -0.14, -0.04), and PCBs congeners 118/106 (-0.12 cm; 95% CI -0.20, -0.04) and 146/161 (-0.14 cm; 95% CI -0.23, -0.05) with thigh length, as were 7 other poly-and-perfluorinated alkyl substances (PFASs).","['perfluorooctanoic acid', 'perfluorodecanoic acid']","['birth length', 'thigh length']",True,perfluorooctanoic acid,thigh length,associated,C0743924,Short fetal femur length,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
2327,25743,30055518,"For the overall cohort, perfluorooctanoic acid was negatively associated with birth length per SD increase in concentration (β = -0.23 cm; 95% CI -0.35, -0.10), while perfluorohexanesulfonic acid was negatively associated with umbilical circumference (β = -0.26 cm; 95% CI -0.40, -0.13), perfluorodecanoic acid with arm length (-0.09 cm; 95% CI -0.14, -0.04), and PCBs congeners 118/106 (-0.12 cm; 95% CI -0.20, -0.04) and 146/161 (-0.14 cm; 95% CI -0.23, -0.05) with thigh length, as were 7 other poly-and-perfluorinated alkyl substances (PFASs).","['perfluorooctanoic acid', 'perfluorodecanoic acid']","['birth length', 'thigh length']",True,perfluorodecanoic acid,thigh length,associated,C0743924,Short fetal femur length,9555,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-nonadecafluorodecanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-nonadecafluorodecanoic acid",associate
2328,25744,29986037,"Exposure to PFOS and PFOA was associated with elevation of prolactin (PFOS: adjusted β, 0.17; 95% CI, 0.06 to 0.29; PFOA: adjusted β, 0.16; 95% CI, 0.01 to 0.30) or with a decrease of free triiodothyronine (PFOS: adjusted β, -0.88; 95% CI, -1.64 to -0.09; PFOA: adjusted β, -0.90; 95% CI, -1.88 to 0.09) and thyroxine (PFOS: adjusted β, -2.99; 95% CI, -4.52 to -1.46; PFOA: adjusted β, -3.42; 95% CI, -5.39 to -1.46).","['PFOS', 'PFOA', 'thyroxine']","['elevation of', 'decrease of free triiodothyronine']",True,PFOS,elevation of,associated,C0743924,Short fetal femur length,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",associate
2329,25744,29986037,"Exposure to PFOS and PFOA was associated with elevation of prolactin (PFOS: adjusted β, 0.17; 95% CI, 0.06 to 0.29; PFOA: adjusted β, 0.16; 95% CI, 0.01 to 0.30) or with a decrease of free triiodothyronine (PFOS: adjusted β, -0.88; 95% CI, -1.64 to -0.09; PFOA: adjusted β, -0.90; 95% CI, -1.88 to 0.09) and thyroxine (PFOS: adjusted β, -2.99; 95% CI, -4.52 to -1.46; PFOA: adjusted β, -3.42; 95% CI, -5.39 to -1.46).","['PFOS', 'PFOA', 'thyroxine']","['elevation of', 'decrease of free triiodothyronine']",True,PFOS,decrease of free triiodothyronine,associated,C4021843,Increased circulating free T3,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",associate
2330,25744,29986037,"Exposure to PFOS and PFOA was associated with elevation of prolactin (PFOS: adjusted β, 0.17; 95% CI, 0.06 to 0.29; PFOA: adjusted β, 0.16; 95% CI, 0.01 to 0.30) or with a decrease of free triiodothyronine (PFOS: adjusted β, -0.88; 95% CI, -1.64 to -0.09; PFOA: adjusted β, -0.90; 95% CI, -1.88 to 0.09) and thyroxine (PFOS: adjusted β, -2.99; 95% CI, -4.52 to -1.46; PFOA: adjusted β, -3.42; 95% CI, -5.39 to -1.46).","['PFOS', 'PFOA', 'thyroxine']","['elevation of', 'decrease of free triiodothyronine']",True,PFOA,elevation of,associated,C4021843,Increased circulating free T3,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
2331,25744,29986037,"Exposure to PFOS and PFOA was associated with elevation of prolactin (PFOS: adjusted β, 0.17; 95% CI, 0.06 to 0.29; PFOA: adjusted β, 0.16; 95% CI, 0.01 to 0.30) or with a decrease of free triiodothyronine (PFOS: adjusted β, -0.88; 95% CI, -1.64 to -0.09; PFOA: adjusted β, -0.90; 95% CI, -1.88 to 0.09) and thyroxine (PFOS: adjusted β, -2.99; 95% CI, -4.52 to -1.46; PFOA: adjusted β, -3.42; 95% CI, -5.39 to -1.46).","['PFOS', 'PFOA', 'thyroxine']","['elevation of', 'decrease of free triiodothyronine']",True,PFOA,decrease of free triiodothyronine,associated,C4021843,Increased circulating free T3,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
2332,25744,29986037,"Exposure to PFOS and PFOA was associated with elevation of prolactin (PFOS: adjusted β, 0.17; 95% CI, 0.06 to 0.29; PFOA: adjusted β, 0.16; 95% CI, 0.01 to 0.30) or with a decrease of free triiodothyronine (PFOS: adjusted β, -0.88; 95% CI, -1.64 to -0.09; PFOA: adjusted β, -0.90; 95% CI, -1.88 to 0.09) and thyroxine (PFOS: adjusted β, -2.99; 95% CI, -4.52 to -1.46; PFOA: adjusted β, -3.42; 95% CI, -5.39 to -1.46).","['PFOS', 'PFOA', 'thyroxine']","['elevation of', 'decrease of free triiodothyronine']",True,thyroxine,elevation of,associated,C4021843,Increased circulating free T3,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thyroxine,associate
2333,25744,29986037,"Exposure to PFOS and PFOA was associated with elevation of prolactin (PFOS: adjusted β, 0.17; 95% CI, 0.06 to 0.29; PFOA: adjusted β, 0.16; 95% CI, 0.01 to 0.30) or with a decrease of free triiodothyronine (PFOS: adjusted β, -0.88; 95% CI, -1.64 to -0.09; PFOA: adjusted β, -0.90; 95% CI, -1.88 to 0.09) and thyroxine (PFOS: adjusted β, -2.99; 95% CI, -4.52 to -1.46; PFOA: adjusted β, -3.42; 95% CI, -5.39 to -1.46).","['PFOS', 'PFOA', 'thyroxine']","['elevation of', 'decrease of free triiodothyronine']",True,thyroxine,decrease of free triiodothyronine,associated,C4021843,Increased circulating free T3,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",thyroxine,associate
2334,25761,28890218,"Perfluorohexanesulfonic acid levels were associated with decreased insulin resistance (beta coefficient=-0.09, 95% CI: -0.18, -0.003, -8.6% change); PFOA and perfluorononanoic acid were associated with increased brachial artery distensibility.",['perfluorononanoic acid'],"['Perfluorohexanesulfonic acid levels', 'decreased insulin resistance', 'increased brachial artery distensibility']",True,perfluorononanoic acid,decreased insulin resistance,associated,C0021655,Insulin resistance,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",associate
2335,25794,35218824,"An increase in perfluorooctanoic acid (PFOA) equivalent to the  magnitude of its geometric mean (GM) of 2.0 μg/L was associated with percentage (95% CI) increases in serum enzymes reflecting liver function: aspartate aminotransferase (AST) 3.7 (1.1, 6.4), gamma-glutamyl transferase (GGT) 11.8 (2.5, 21.8), alanine aminotransferase (ALT) 3.2 (0.5, 5.9), and bilirubin 3.6 (2.7, 4.5).",['perfluorooctanoic acid'],"['increases in serum enzymes reflecting liver function', 'aspartate aminotransferase (AST)', 'alanine aminotransferase']",True,perfluorooctanoic acid,aspartate aminotransferase,associated,C0151904,Aspartate aminotransferase increased,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
2336,25794,35218824,"An increase in perfluorooctanoic acid (PFOA) equivalent to the  magnitude of its geometric mean (GM) of 2.0 μg/L was associated with percentage (95% CI) increases in serum enzymes reflecting liver function: aspartate aminotransferase (AST) 3.7 (1.1, 6.4), gamma-glutamyl transferase (GGT) 11.8 (2.5, 21.8), alanine aminotransferase (ALT) 3.2 (0.5, 5.9), and bilirubin 3.6 (2.7, 4.5).",['perfluorooctanoic acid'],"['increases in serum enzymes reflecting liver function', 'aspartate aminotransferase (AST)', 'alanine aminotransferase']",True,perfluorooctanoic acid,alanine aminotransferase,associated,C0151905,Elevated serum ALT,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",associate
2337,25795,35218824,"A GM increase in perfluorodecanoic acid (PFDA) of 0.2 μg/L was positively associated with percentage increases in GGT, triglycerides, low-density lipoprotein (LDL) cholesterol, total cholesterol, and calcium with respective increases of 15.5 (2.2, 30.4), 7.0 (1.0, 13.2), 10.7 (5.5, 16.1), 2.8  (0.2, 5.3), and 0.8 (0.3, 1.3).","['perfluorodecanoic acid', 'PFDA', 'LDL', 'cholesterol', 'cholesterol', 'calcium']","['increases in GGT', 'triglycerides']",True,perfluorodecanoic acid,increases in GGT,associated,C0853225,Reduced factor II activity,9555,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-nonadecafluorodecanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-nonadecafluorodecanoic acid",associate
2338,25795,35218824,"A GM increase in perfluorodecanoic acid (PFDA) of 0.2 μg/L was positively associated with percentage increases in GGT, triglycerides, low-density lipoprotein (LDL) cholesterol, total cholesterol, and calcium with respective increases of 15.5 (2.2, 30.4), 7.0 (1.0, 13.2), 10.7 (5.5, 16.1), 2.8  (0.2, 5.3), and 0.8 (0.3, 1.3).","['perfluorodecanoic acid', 'PFDA', 'LDL', 'cholesterol', 'cholesterol', 'calcium']","['increases in GGT', 'triglycerides']",True,perfluorodecanoic acid,triglycerides,associated,C0813230,Increased plasma Tg levels,9555,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-nonadecafluorodecanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-nonadecafluorodecanoic acid",associate
2339,25795,35218824,"A GM increase in perfluorodecanoic acid (PFDA) of 0.2 μg/L was positively associated with percentage increases in GGT, triglycerides, low-density lipoprotein (LDL) cholesterol, total cholesterol, and calcium with respective increases of 15.5 (2.2, 30.4), 7.0 (1.0, 13.2), 10.7 (5.5, 16.1), 2.8  (0.2, 5.3), and 0.8 (0.3, 1.3).","['perfluorodecanoic acid', 'PFDA', 'LDL', 'cholesterol', 'cholesterol', 'calcium']","['increases in GGT', 'triglycerides']",True,cholesterol,increases in GGT,associated,C0853225,Reduced factor II activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholesterol,associate
2340,25795,35218824,"A GM increase in perfluorodecanoic acid (PFDA) of 0.2 μg/L was positively associated with percentage increases in GGT, triglycerides, low-density lipoprotein (LDL) cholesterol, total cholesterol, and calcium with respective increases of 15.5 (2.2, 30.4), 7.0 (1.0, 13.2), 10.7 (5.5, 16.1), 2.8  (0.2, 5.3), and 0.8 (0.3, 1.3).","['perfluorodecanoic acid', 'PFDA', 'LDL', 'cholesterol', 'cholesterol', 'calcium']","['increases in GGT', 'triglycerides']",True,cholesterol,triglycerides,associated,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",cholesterol,associate
2341,25795,35218824,"A GM increase in perfluorodecanoic acid (PFDA) of 0.2 μg/L was positively associated with percentage increases in GGT, triglycerides, low-density lipoprotein (LDL) cholesterol, total cholesterol, and calcium with respective increases of 15.5 (2.2, 30.4), 7.0 (1.0, 13.2), 10.7 (5.5, 16.1), 2.8  (0.2, 5.3), and 0.8 (0.3, 1.3).","['perfluorodecanoic acid', 'PFDA', 'LDL', 'cholesterol', 'cholesterol', 'calcium']","['increases in GGT', 'triglycerides']",True,calcium,increases in GGT,associated,C0853225,Reduced factor II activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,associate
2342,25795,35218824,"A GM increase in perfluorodecanoic acid (PFDA) of 0.2 μg/L was positively associated with percentage increases in GGT, triglycerides, low-density lipoprotein (LDL) cholesterol, total cholesterol, and calcium with respective increases of 15.5 (2.2, 30.4), 7.0 (1.0, 13.2), 10.7 (5.5, 16.1), 2.8  (0.2, 5.3), and 0.8 (0.3, 1.3).","['perfluorodecanoic acid', 'PFDA', 'LDL', 'cholesterol', 'cholesterol', 'calcium']","['increases in GGT', 'triglycerides']",True,calcium,triglycerides,associated,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,associate
2343,25827,35123778,"On the other hand, the inclusion of NaHCO3 increased the pH daily average, independent of Mg source, which led to a reduced  time that pH was below 5.8 and decreased area under the curve.",['Mg'],['decreased area'],True,Mg,decreased area,increased,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Mg,increase
2344,25854,34246765,"Consequently, PFNA increased reactive oxygen species (ROS) levels, leading to oxidative stress, DNA damage, and eventually early-stage apoptosis in oocytes.","['PFNA', 'oxygen']","['oxidative stress', 'DNA damage', 'apoptosis']",True,PFNA,oxidative stress,increased,C0242606,Oxidative stress,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",increase
2345,25854,34246765,"Consequently, PFNA increased reactive oxygen species (ROS) levels, leading to oxidative stress, DNA damage, and eventually early-stage apoptosis in oocytes.","['PFNA', 'oxygen']","['oxidative stress', 'DNA damage', 'apoptosis']",True,oxygen,oxidative stress,increased,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,increase
2346,25889,30576894,"In conclusion, the results suggest that PFNA exposure to prepubertal male mice altered antioxidant enzymes activity and Nrf2-HO-1 signaling, leading to oxidative stress and a decrease in testosterone biosynthesis in the testis; these changes, in turn, caused increased apoptosis and decreased proliferation of germ  cells, thereby suppression of spermatogenesis.",['PFNA'],"['oxidative stress', 'decrease in testosterone biosynthesis', 'increased apoptosis', 'decreased proliferation of germ  cells', 'suppression of spermatogenesis']",True,PFNA,oxidative stress,caused,C0242606,Oxidative stress,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",cause
2347,25889,30576894,"In conclusion, the results suggest that PFNA exposure to prepubertal male mice altered antioxidant enzymes activity and Nrf2-HO-1 signaling, leading to oxidative stress and a decrease in testosterone biosynthesis in the testis; these changes, in turn, caused increased apoptosis and decreased proliferation of germ  cells, thereby suppression of spermatogenesis.",['PFNA'],"['oxidative stress', 'decrease in testosterone biosynthesis', 'increased apoptosis', 'decreased proliferation of germ  cells', 'suppression of spermatogenesis']",True,PFNA,increased apoptosis,caused,C4280724,Increased lymphocyte apoptosis,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",cause
2348,25907,29187073,"These results suggested that exposure to PFNA elevated the intracellular calcium level and activated the CaMKII signaling pathway, which may aggravate oxidative stress in PC12 cells and lead to cell damage or cell apoptosis.","['PFNA', 'calcium']","['activated the CaMKII signaling pathway', 'oxidative stress', 'cell damage', 'apoptosis']",True,PFNA,oxidative stress,elevated,C0242606,Oxidative stress,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",elevated
2349,25907,29187073,"These results suggested that exposure to PFNA elevated the intracellular calcium level and activated the CaMKII signaling pathway, which may aggravate oxidative stress in PC12 cells and lead to cell damage or cell apoptosis.","['PFNA', 'calcium']","['activated the CaMKII signaling pathway', 'oxidative stress', 'cell damage', 'apoptosis']",True,calcium,oxidative stress,elevated,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium,elevated
2350,25909,29112762,"PFNA caused cholestasis in the WT mice, indicated by increased serum alanine aminotransferase, hyperbilirubinemia, elevated BA concentrations in mouse serum, and appearance of  bile plugs in mouse liver.",['PFNA'],"['cholestasis', 'increased serum alanine aminotransferase', 'hyperbilirubinemia', 'elevated BA concentrations']",True,PFNA,cholestasis,caused,C0008370,Cholestasis,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",cause
2351,25909,29112762,"PFNA caused cholestasis in the WT mice, indicated by increased serum alanine aminotransferase, hyperbilirubinemia, elevated BA concentrations in mouse serum, and appearance of  bile plugs in mouse liver.",['PFNA'],"['cholestasis', 'increased serum alanine aminotransferase', 'hyperbilirubinemia', 'elevated BA concentrations']",True,PFNA,increased serum alanine aminotransferase,caused,C0151905,Elevated serum ALT,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",cause
2352,25909,29112762,"PFNA caused cholestasis in the WT mice, indicated by increased serum alanine aminotransferase, hyperbilirubinemia, elevated BA concentrations in mouse serum, and appearance of  bile plugs in mouse liver.",['PFNA'],"['cholestasis', 'increased serum alanine aminotransferase', 'hyperbilirubinemia', 'elevated BA concentrations']",True,PFNA,hyperbilirubinemia,caused,C0311468,Hyperbilirubinemia,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",cause
2353,25909,29112762,"PFNA caused cholestasis in the WT mice, indicated by increased serum alanine aminotransferase, hyperbilirubinemia, elevated BA concentrations in mouse serum, and appearance of  bile plugs in mouse liver.",['PFNA'],"['cholestasis', 'increased serum alanine aminotransferase', 'hyperbilirubinemia', 'elevated BA concentrations']",True,PFNA,elevated BA concentrations,caused,C4732838,Increased CSF urate concentration,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",cause
2354,25912,29112762,"In conclusion, PFNA produced cholestasis in mouse liver, and the activation of PPARα plays a central role in regulating BA and cholesterol metabolism and transport in mouse serum and liver.",['PFNA'],['cholestasis'],True,PFNA,cholestasis,produced,C0008370,Cholestasis,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",produce
2355,25930,26056853,"PFNA increased the activities of lipid synthetase, fatty acid synthease, glucose-6-phosphate dehydrogenase and decreased the activity of lipolytic enzyme, hepatic lipase, in the liver of diabetic rats.",['PFNA'],"['glucose-6-phosphate dehydrogenase', 'decreased the activity of lipolytic enzyme, hepatic lipase']",True,PFNA,glucose-6-phosphate dehydrogenase,increased,C4703662,Abnormal glucose-6-phosphate dehydrogenase level,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",increase
2356,25939,25543169,"Similar to PFOS and PFOA, PFNA at 5mg/kg or lower doses produced hepatomegaly in the pregnant dams, but did not affect the number of implantations, fetal viability, or fetal weight.","['PFOS', 'PFOA', 'PFNA']","['hepatomegaly', 'fetal viability', 'fetal weight']",True,PFOS,hepatomegaly,produced,C0019209,Enlarged liver,74483,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid","1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid",produce
2357,25939,25543169,"Similar to PFOS and PFOA, PFNA at 5mg/kg or lower doses produced hepatomegaly in the pregnant dams, but did not affect the number of implantations, fetal viability, or fetal weight.","['PFOS', 'PFOA', 'PFNA']","['hepatomegaly', 'fetal viability', 'fetal weight']",True,PFOA,hepatomegaly,produced,C0019209,Enlarged liver,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",produce
2358,25939,25543169,"Similar to PFOS and PFOA, PFNA at 5mg/kg or lower doses produced hepatomegaly in the pregnant dams, but did not affect the number of implantations, fetal viability, or fetal weight.","['PFOS', 'PFOA', 'PFNA']","['hepatomegaly', 'fetal viability', 'fetal weight']",True,PFNA,hepatomegaly,produced,C0019209,Enlarged liver,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",produce
2359,25946,25181679," Administration of perfluorononanoic acid (PFNA), a perfluorocarboxylic acid (PFCA) with a nine carbon backbone, resulted in dose-dependent hepatomegaly in mice (0, 0.2, 1, and 5 mg/kg body weight, once a day for 14 days) and an increase in hepatic triglycerides (TG) and total cholesterol (TCHO) in the median dose group as well as serum transaminases in the high dose group.","['perfluorononanoic acid', 'perfluorocarboxylic acid', 'cholesterol']","['increase in hepatic triglycerides', 'serum transaminases']",True,perfluorononanoic,increase in hepatic triglycerides,resulted,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",perfluorononanoic,result
2360,25946,25181679," Administration of perfluorononanoic acid (PFNA), a perfluorocarboxylic acid (PFCA) with a nine carbon backbone, resulted in dose-dependent hepatomegaly in mice (0, 0.2, 1, and 5 mg/kg body weight, once a day for 14 days) and an increase in hepatic triglycerides (TG) and total cholesterol (TCHO) in the median dose group as well as serum transaminases in the high dose group.","['perfluorononanoic acid', 'perfluorocarboxylic acid', 'cholesterol']","['increase in hepatic triglycerides', 'serum transaminases']",True,perfluorononanoic,serum transaminases,resulted,C0813230,Increased plasma Tg levels,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",perfluorononanoic,result
2361,25947,25181679,The mRNA analysis results further suggested that PFNA exposure not only resulted in a fatty acid oxidation effect but also activated mouse liver genes involved in fatty acid and cholesterol synthesis.,['PFNA'],['fatty acid'],True,PFNA,fatty acid,resulted,C0813230,Increased plasma Tg levels,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",result
2362,25950,25113910,Results  showed that both PFOA and PFNA induced DNA damage indicated by increased tail length (DNA migration).,"['PFOA', 'PFNA']","['DNA damage', 'increased tail length']",True,PFOA,increased tail length,induced,C3150613,Long toe,9554,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid",induce
2363,25950,25113910,Results  showed that both PFOA and PFNA induced DNA damage indicated by increased tail length (DNA migration).,"['PFOA', 'PFNA']","['DNA damage', 'increased tail length']",True,PFNA,increased tail length,induced,C3150613,Long toe,67821,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid","2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononanoic acid",induce
2364,26001,35289987,"No evidence was found on whether folic acid supplementation before and/or during pregnancy was associated with other included outcomes: movement and physical development, academic performance, ADD or ADHD, anxiety, or depression.",['folic acid'],"['anxiety', 'depression']",True,folic acid,anxiety,associated,C0003467,Anxiousness,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",folic acid,associate
2365,26001,35289987,"No evidence was found on whether folic acid supplementation before and/or during pregnancy was associated with other included outcomes: movement and physical development, academic performance, ADD or ADHD, anxiety, or depression.",['folic acid'],"['anxiety', 'depression']",True,folic acid,depression,associated,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",folic acid,associate
2366,26010,35273240,"The GABA content marginally increased over control in both the cultivars namely, A-157 (1.9%) and B-370 (9.5%).",['A-157'],['GABA content'],True,A-157,GABA content,increased,C0011581,Depression,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",A-157,increase
2367,26021,35257064, Conclusion: Triple immunosuppression with the addition of TAC to mycophenolate and PRED resulted in further proteinuria reduction and sustained disease quiescence in patients with LN whose proteinuria did not respond optimally to standard therapy.,"['mycophenolate', 'PRED']",['LN whose proteinuria'],True,mycophenolate,LN whose proteinuria,resulted,C0033687,Protein in urine,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",mycophenolate,result
2368,26021,35257064, Conclusion: Triple immunosuppression with the addition of TAC to mycophenolate and PRED resulted in further proteinuria reduction and sustained disease quiescence in patients with LN whose proteinuria did not respond optimally to standard therapy.,"['mycophenolate', 'PRED']",['LN whose proteinuria'],True,PRED,LN whose proteinuria,resulted,C0033687,Protein in urine,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",PRED,result
2369,26111,34939007," Conclusions: Serum ADMA levels increased as kidney function declined, and high serum ADMA level was associated with incident kidney failure.",['ADMA'],"['kidney function', 'kidney failure']",True,ADMA,kidney failure,increased,C0022660,Acute kidney failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ADMA,increase
2370,26111,34939007," Conclusions: Serum ADMA levels increased as kidney function declined, and high serum ADMA level was associated with incident kidney failure.",['ADMA'],"['kidney function', 'kidney failure']",True,ADMA,kidney failure,associated,C0022660,Acute kidney failure,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ADMA,associate
2371,26128,34721296,Mutations in SLC34A3 and SLC9A3R1 have been associated with phosphate wasting without hypercalcemia.,['phosphate'],['hypercalcemia'],True,phosphate,hypercalcemia,associated,C0020437,Increased calcium in blood,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phosphate,associate
2372,26145,34520829,Systemic and topical administration of Egb-761 and dexamethasone resulted in a significant reduction in carrageenan-induced rat paw edema.,['dexamethasone'],"['reduction in carrageenan-induced', 'edema']",True,dexamethasone,edema,resulted,C0013604,Edema,5743,Dexamethasone,Dexamethasone,result
2373,26165,35298477,"After controlling for sociodemographic factors, smoking status, other medications, other mental comorbidities, and physical comorbidities, lithium use was associated with a lower risk of dementia (hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.40 to 0.78), including AD (HR 0.55, 95% CI 0.37 to 0.82) and VD (HR 0.36, 95% CI 0.19 to 0.69).",['lithium'],['dementia'],True,lithium,dementia,associated,C0497327,"Dementia, progressive",3028194,lithium,lithium,associate
2374,26208,35287592, RESULTS: 2-napthol and 3-fluorene were significantly associated with decreased klotho.,"['2-napthol', '3-fluorene']",['decreased klotho'],True,2-napthol,decreased klotho,associated,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",2-napthol,associate
2375,26208,35287592, RESULTS: 2-napthol and 3-fluorene were significantly associated with decreased klotho.,"['2-napthol', '3-fluorene']",['decreased klotho'],True,3-fluorene,decreased klotho,associated,C0427437,Decreased mean corpuscular haemoglobin,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",3-fluorene,associate
2376,26257,35204245,"Pretreatment with T. foenum-graecum extract caused significant improvement in antioxidants such as superoxide dismutase (SOD), CAT (catalase), malondialdehyde (MDA), and myeloperoxidase (MPO) against oxidative stress induced by carrageenan.","['malondialdehyde', 'carrageenan']",['myeloperoxidase (MPO) against oxidative stress'],True,malondialdehyde,oxidative stress,caused,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",malondialdehyde,cause
2377,26257,35204245,"Pretreatment with T. foenum-graecum extract caused significant improvement in antioxidants such as superoxide dismutase (SOD), CAT (catalase), malondialdehyde (MDA), and myeloperoxidase (MPO) against oxidative stress induced by carrageenan.","['malondialdehyde', 'carrageenan']",['myeloperoxidase (MPO) against oxidative stress'],True,carrageenan,oxidative stress,caused,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carrageenan,cause
2378,26276,34959301,"LP aqueous extract inhibited the pancreatic α-amylase with an IC50 almost identical to acarbose (0.44 ± 0.05 mg/mL and 0.36 ± 0.02 mg/mL, respectively), as well as the intestinal α-glucosidase, (IC50 = 131 ± 20 µg/mL) and the intestinal glucose absorption (IC50 = 81.28 ± 4.01 µg/mL) in concentration-dependent manners.",['acarbose'],['intestinal glucose absorption'],True,acarbose,intestinal glucose absorption,inhibited,C3714745,Intestinal malabsorption,41774,"(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol","(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol",inhibit
2379,26287,34799857,"Diosgenin brought changes in treatment line of lung, breast, prostate, liver, and colon cancer.",['Diosgenin'],"['breast, prostate, liver', 'cancer']",True,Diosgenin,"breast, prostate, liver",brought,C0266009,Mammary gland aplasia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Diosgenin,bring
2380,26287,34799857,"Diosgenin brought changes in treatment line of lung, breast, prostate, liver, and colon cancer.",['Diosgenin'],"['breast, prostate, liver', 'cancer']",True,Diosgenin,cancer,brought,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Diosgenin,bring
2381,26294,34733302,Knockdown of TfSMT1 expression led to increased cholesterol level but caused a large reduction of diosgenin.,['diosgenin'],['increased cholesterol level'],True,diosgenin,increased cholesterol level,led,C1291155,Increased cholesterol esters,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",diosgenin,lead
2382,26322,34126406,"Nettle revealed apoptotic activity through activation of caspases  9 (P = 0.047), 8 (P = 0.022) and 3 (P = 0.004), whereas fenugreek increased (P = 0.042) follicular cell proliferation marked by PCNA protein abundance.","['Nettle', 'fenugreek']","['apoptotic activity', 'follicular cell proliferation']",True,fenugreek,follicular cell proliferation,increased,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",fenugreek,increase
2383,26360,34503491,"Elemental sulfur supplementation (P < 0.05) significantly increased the in vitro gas produced from an insoluble fraction (b), in vitro DM degradability and either neutral detergent fiber (NDF)  or acid detergent fiber (ADF) degradability and propionate (C3) concentration while decreased the ruminal HCN concentration.",['propionate'],['decreased the ruminal HCN concentration'],True,propionate,decreased the ruminal HCN concentration,increased,C4732833,Decreased serum bicarbonate concentration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",propionate,increase
2384,26381,35301132,"We identified that caspase activation and lipid peroxidation are common endpoints of glyphosate exposure, while vasopressin and polyol pathways are associated with heat stress and dehydration.","['glyphosate', 'polyol']","['caspase activation', 'lipid peroxidation', 'vasopressin', 'heat stress', 'dehydration']",True,polyol,dehydration,associated,C0011175,Dehydration,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",polyol,associate
2385,26399,35286942, CONCLUSION: It is concluded that fluoride intoxication leads to the development of oxidative stress and damaging the cellular metabolism resulting in the declined ability of free radical scavengers along with increased level of MDA and decreased expression level of antioxidant genes which helps to understand the possible mechanism of fluoride-induced toxicity at the molecular level.,['fluoride'],"['oxidative stress', 'declined ability', 'decreased expression level']",True,fluoride,oxidative stress,leads,C0242606,Oxidative stress,28179,fluoride,fluoride,lead
2386,26399,35286942, CONCLUSION: It is concluded that fluoride intoxication leads to the development of oxidative stress and damaging the cellular metabolism resulting in the declined ability of free radical scavengers along with increased level of MDA and decreased expression level of antioxidant genes which helps to understand the possible mechanism of fluoride-induced toxicity at the molecular level.,['fluoride'],"['oxidative stress', 'declined ability', 'decreased expression level']",True,fluoride,declined ability,leads,C0242606,Oxidative stress,28179,fluoride,fluoride,lead
2387,26400,35286933,doi: 10.1016/j.jhazmat.2022.128654. [Epub  ahead of print]  High concentration of sodium fluoride in drinking water induce hypertrophy versus atrophy in mouse skeletal muscle via modulation of sarcomeric proteins.,['sodium fluoride'],['hypertrophy versus atrophy'],True,sodium fluoride,hypertrophy versus atrophy,induce,C0151514,Atrophic skin,5235,sodium;fluoride,sodium;fluoride,induce
2388,26448,35111869,"Compared with foscarnet, ganciclovir was associated with lower incidences of thrombocytopenia (incidence rate ratio [IRR], 0.38; 95% CI, 0.15-0.97), electrolyte AEs (IRR, 0.42; 95% CI, 0.24-0.75), endocrine AEs (IRR, 0.52; 95% CI, 0.34-0.79), and renal AEs (IRR, 0.36; 95% CI, 0.19-0.65).",['foscarnet'],"['ganciclovir', 'thrombocytopenia', 'electrolyte AEs', 'endocrine AEs', 'renal AEs']",True,foscarnet,thrombocytopenia,associated,C0040034,Thrombocytopenia,3415,phosphonoformic acid,phosphonoformic acid,associate
2389,26448,35111869,"Compared with foscarnet, ganciclovir was associated with lower incidences of thrombocytopenia (incidence rate ratio [IRR], 0.38; 95% CI, 0.15-0.97), electrolyte AEs (IRR, 0.42; 95% CI, 0.24-0.75), endocrine AEs (IRR, 0.52; 95% CI, 0.34-0.79), and renal AEs (IRR, 0.36; 95% CI, 0.19-0.65).",['foscarnet'],"['ganciclovir', 'thrombocytopenia', 'electrolyte AEs', 'endocrine AEs', 'renal AEs']",True,foscarnet,electrolyte AEs,associated,C0040034,Thrombocytopenia,3415,phosphonoformic acid,phosphonoformic acid,associate
2390,26448,35111869,"Compared with foscarnet, ganciclovir was associated with lower incidences of thrombocytopenia (incidence rate ratio [IRR], 0.38; 95% CI, 0.15-0.97), electrolyte AEs (IRR, 0.42; 95% CI, 0.24-0.75), endocrine AEs (IRR, 0.52; 95% CI, 0.34-0.79), and renal AEs (IRR, 0.36; 95% CI, 0.19-0.65).",['foscarnet'],"['ganciclovir', 'thrombocytopenia', 'electrolyte AEs', 'endocrine AEs', 'renal AEs']",True,foscarnet,endocrine AEs,associated,C0014132,Neoplasm of the endocrine system,3415,phosphonoformic acid,phosphonoformic acid,associate
2391,26448,35111869,"Compared with foscarnet, ganciclovir was associated with lower incidences of thrombocytopenia (incidence rate ratio [IRR], 0.38; 95% CI, 0.15-0.97), electrolyte AEs (IRR, 0.42; 95% CI, 0.24-0.75), endocrine AEs (IRR, 0.52; 95% CI, 0.34-0.79), and renal AEs (IRR, 0.36; 95% CI, 0.19-0.65).",['foscarnet'],"['ganciclovir', 'thrombocytopenia', 'electrolyte AEs', 'endocrine AEs', 'renal AEs']",True,foscarnet,renal AEs,associated,C1319314,Renal urothelial carcinoma,3415,phosphonoformic acid,phosphonoformic acid,associate
2392,26457,34864943,Maribavir was associated with less acute kidney injury versus foscarnet (8.5% vs 21.3%) and neutropenia versus valganciclovir/ganciclovir (9.4% vs 33.9%).,['foscarnet'],"['less acute kidney injury', 'neutropenia']",True,foscarnet,less acute kidney injury,associated,C2609414,Acute kidney injury,3415,phosphonoformic acid,phosphonoformic acid,associate
2393,26457,34864943,Maribavir was associated with less acute kidney injury versus foscarnet (8.5% vs 21.3%) and neutropenia versus valganciclovir/ganciclovir (9.4% vs 33.9%).,['foscarnet'],"['less acute kidney injury', 'neutropenia']",True,foscarnet,neutropenia,associated,C0853697,Low neutrophil count,3415,phosphonoformic acid,phosphonoformic acid,associate
2394,26460,34688540,"Neither TNF-α alone nor supernatants of monocytes stimulated with HP promoted the expression of osteopontin and Runt-related transcription factor 2 (Runx2) or caused mineralization in human aortic smooth muscle cells, but combined with HP intervention, the calcification  effects were markedly increased in human aortic smooth muscle cells and ameliorated by phosphonoformic acid treatment.",['phosphonoformic acid'],['mineralization'],True,phosphonoformic acid,calcification,increased,C0263625,Skin calcification,3415,phosphonoformic acid,phosphonoformic acid,increase
2395,26461,34688540," CONCLUSION: Hyperphosphatemia directly increased the synthesis and secretion of TNF-α by monocytes may via PiT-1 pathway, resulting in elevated systemic inflammatory response, which may further aggravate VC induced by phosphate overload in MHD patients.",['phosphate'],"['Hyperphosphatemia', 'increased the synthesis and secretion of TNF-α by monocytes may via PiT-1 pathway', 'elevated systemic inflammatory response']",True,phosphate,elevated systemic inflammatory response,resulting,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",phosphate,result
2396,26462,34643504,"In the kidney, foscarnet-induced injury may be attributed to reversible tubulointerstitial lesions, but foscarnet crystals have also been observed within glomerular capillaries, suggesting that foscarnet can lead to glomerular lesions  such as crescentic glomerulonephritis.","['foscarnet', 'foscarnet']","['foscarnet-induced injury', 'tubulointerstitial lesions', 'glomerular capillaries', 'glomerular lesions', 'crescentic glomerulonephritis']",True,foscarnet,crescentic glomerulonephritis,lead,C0403416,Crescentic glomerulonephritis,3415,phosphonoformic acid,phosphonoformic acid,lead
2397,26529,32815746,High-dose intravenous aciclovir caused renal impairment and was suspended for two-days.,['aciclovir'],['renal impairment'],True,aciclovir,renal impairment,caused,C4021047,Impaired visually enhanced vestibulo-ocular reflex,135398513,Acyclovir,Acyclovir,cause
2398,26563,27173049,These results suggested that ANIT induced liver injury with cholestasis partly due to its ability to activate the ER stress pathway.,['ANIT'],"['liver injury', 'cholestasis']",True,ANIT,cholestasis,induced,C0008370,Cholestasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ANIT,induce
2399,26580,16015684,"DDC and ANIT caused cirrhosis within 4-12 and 12-24 wk, respectively.","['DDC', 'ANIT']",['cirrhosis'],True,DDC,cirrhosis,caused,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DDC,cause
2400,26580,16015684,"DDC and ANIT caused cirrhosis within 4-12 and 12-24 wk, respectively.","['DDC', 'ANIT']",['cirrhosis'],True,ANIT,cirrhosis,caused,C0023890,Cirrhosis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ANIT,cause
2401,26583,14623915,"In the bile duct-ligation and alpha-naphthylisothiocyanate models of cholestasis, GW4064 treatment resulted in  significant reductions in serum alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase, as well as other markers of liver damage.",['alpha-naphthylisothiocyanate models'],"['cholestasis', 'reductions in serum alanine aminotransferase', 'aspartate aminotransferase']",True,alpha-naphthylisothiocyanate models,cholestasis,resulted,C0008370,Cholestasis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",alpha-naphthylisothiocyanate models,result
2402,26583,14623915,"In the bile duct-ligation and alpha-naphthylisothiocyanate models of cholestasis, GW4064 treatment resulted in  significant reductions in serum alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase, as well as other markers of liver damage.",['alpha-naphthylisothiocyanate models'],"['cholestasis', 'reductions in serum alanine aminotransferase', 'aspartate aminotransferase']",True,alpha-naphthylisothiocyanate models,reductions in serum alanine aminotransferase,resulted,C0151905,Elevated serum ALT,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",alpha-naphthylisothiocyanate models,result
2403,26583,14623915,"In the bile duct-ligation and alpha-naphthylisothiocyanate models of cholestasis, GW4064 treatment resulted in  significant reductions in serum alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase, as well as other markers of liver damage.",['alpha-naphthylisothiocyanate models'],"['cholestasis', 'reductions in serum alanine aminotransferase', 'aspartate aminotransferase']",True,alpha-naphthylisothiocyanate models,aspartate aminotransferase,resulted,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",alpha-naphthylisothiocyanate models,result
2404,26611,34839860,"The number of apoptotic enterocytes were significantly increased in model group compared with Sham group  24 hours after operation (cells: 25.48±6.10 vs. 4.00±2.04, P < 0.05), and the number of apoptotic enterocytes was lower in curcumin group than that in model group at the same time (cells: 15.48±3.75 vs. 25.48±6.10), the difference was statistically significant (both P < 0.05).",['curcumin'],['number of apoptotic enterocytes'],True,curcumin,number of apoptotic enterocytes,increased,C0151904,Aspartate aminotransferase increased,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",curcumin,increase
2405,26619,34797737," FVC was positively associated with ozone at lag0 in the high n-3 group while the  association was null in the low n-3 group [for an IQR increase in ozone, 1.8%(95% CI:0.5-3.2) vs. 0.0%(95% CI:-1.4-1.5)]; however, the association shifted to negative at lag4 [-1.9%(95% CI:-3.2- -0.5) vs. 0.2%(95% CI:-1.2-1.5)] and lag5 [-1.2%(95% CI:-2.4-0.0) vs. 0.9%(-0.4-2.3)].","['ozone', 'ozone']",['IQR increase'],True,ozone,IQR increase,associated,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ozone,associate
2406,26619,34797737," FVC was positively associated with ozone at lag0 in the high n-3 group while the  association was null in the low n-3 group [for an IQR increase in ozone, 1.8%(95% CI:0.5-3.2) vs. 0.0%(95% CI:-1.4-1.5)]; however, the association shifted to negative at lag4 [-1.9%(95% CI:-3.2- -0.5) vs. 0.2%(95% CI:-1.2-1.5)] and lag5 [-1.2%(95% CI:-2.4-0.0) vs. 0.9%(-0.4-2.3)].","['ozone', 'ozone']",['IQR increase'],True,ozone,IQR increase,associated,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",ozone,associate
2407,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,nitrate,obesity,associated,C0028754,Obesity,943,nitrate,nitrate,associate
2408,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,nitrate,hypertensive,associated,C0020546,Hypertensive crisis,943,nitrate,nitrate,associate
2409,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,nitrate,IQR increases,associated,C0302845,Increased mean corpuscular volume,943,nitrate,nitrate,associate
2410,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,chloride,obesity,associated,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chloride,associate
2411,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,chloride,hypertensive,associated,C0020546,Hypertensive crisis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chloride,associate
2412,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,chloride,IQR increases,associated,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",chloride,associate
2413,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,copper,obesity,associated,C0028754,Obesity,23978,copper,copper,associate
2414,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,copper,hypertensive,associated,C0020546,Hypertensive crisis,23978,copper,copper,associate
2415,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,copper,IQR increases,associated,C0302845,Increased mean corpuscular volume,23978,copper,copper,associate
2416,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,zinc,obesity,associated,C0028754,Obesity,23994,zinc,zinc,associate
2417,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,zinc,hypertensive,associated,C0020546,Hypertensive crisis,23994,zinc,zinc,associate
2418,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,zinc,IQR increases,associated,C0302845,Increased mean corpuscular volume,23994,zinc,zinc,associate
2419,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,barium,obesity,associated,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",barium,associate
2420,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,barium,hypertensive,associated,C0020546,Hypertensive crisis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",barium,associate
2421,26630,34749965,"The magnitude of the association differed by age, sex,  prediabetic status, obesity, and hypertensive status, with a significantly greater increase in 20-HETE observed among those with fasting plasma glucose concentrations ≥ 6.1 mmol/L. In addition to the PM2.5 mass, the 20-HETE concentration was associated consistently with IQR increases in the 1-day lag exposure to organic carbon (5.7%), black carbon (9.5%), nitrate (3.9%), chloride  (2.9%), copper (5.5%), zinc (4.7%), barium (4.1%), and lead (6.2%).","['nitrate', 'chloride  ', 'copper', 'zinc', 'barium']","['obesity', 'hypertensive', 'IQR increases']",True,barium,IQR increases,associated,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",barium,associate
2422,26635,34749872," RESULTS: Compared with the control group, 40 μmol/L HgCl_2 could significantly reduce cell viability, the level was 0.52±0.03(P&lt;0.05), OA pretreatment could  significantly inhibit the decrease of cell viability induced by HgCl_2, the level was 0.86±0.05(P&lt;0.05).",['OA'],"['viability', 'decrease of']",True,OA,decrease of,inhibit,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",OA,inhibit
2423,26643,15036005,"Regarding the mechanisms of this action of norharman with aniline, a mutagenic compound, 9-(4'-aminophenyl)-9H-pyrido[3,4-b]indole[aminophenylnorharman (APNH)] is produced by their interaction, and converted to the hydroxyamino derivative which eventually forms the DNA adduct, dG-C8-APNH through possible ultimate reactive forms with esterification, and this induces mutations.","['norharman', 'aniline', 'APNH']",['dG-C8-APNH'],True,norharman,dG-C8-,produced,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",norharman,produce
2424,26643,15036005,"Regarding the mechanisms of this action of norharman with aniline, a mutagenic compound, 9-(4'-aminophenyl)-9H-pyrido[3,4-b]indole[aminophenylnorharman (APNH)] is produced by their interaction, and converted to the hydroxyamino derivative which eventually forms the DNA adduct, dG-C8-APNH through possible ultimate reactive forms with esterification, and this induces mutations.","['norharman', 'aniline', 'APNH']",['dG-C8-APNH'],True,aniline,dG-C8-,produced,C0302845,Increased mean corpuscular volume,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",aniline,produce
2425,26649,35301992,"Phthalate metabolites collected in summer and autumn were associated with an increase in 25(OH)D, while monobenzyl phthalate collected in winter and spring was inversely associated with 25(OH)D. Finally, high-molecular-weight phthalates  had lag associations with 25(OH)D with a 1-trimester lag period.",['monobenzyl phthalate'],['increase in 25(OH)D'],True,monobenzyl phthalate,increase in 25(OH)D,associated,C0853225,Reduced factor II activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",monobenzyl phthalate,associate
2426,26722,35183477," High thoracic aortic 18F-sodium fluoride activity was strongly associated with ischemic stroke (HR: 10.3 [3.1 to 34.8]; P = 0.00017), but not myocardial infarction (P = 0.40).",['18F-sodium fluoride'],"['High thoracic aortic', 'ischemic stroke', 'myocardial infarction']",True,18F-sodium fluoride,ischemic stroke,associated,C0948008,Ischemic stroke,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",18F-sodium fluoride,associate
2427,26722,35183477," High thoracic aortic 18F-sodium fluoride activity was strongly associated with ischemic stroke (HR: 10.3 [3.1 to 34.8]; P = 0.00017), but not myocardial infarction (P = 0.40).",['18F-sodium fluoride'],"['High thoracic aortic', 'ischemic stroke', 'myocardial infarction']",True,18F-sodium fluoride,myocardial infarction,associated,C0027051,Heart attack,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",18F-sodium fluoride,associate
2428,26723,35183477,"Conversely, high coronary 18F-sodium fluoride activity was associated with myocardial infarction (HR: 4.8 [1.9 to 12.2]; P = 0.00095) but not ischemic stroke (P = 0.39).",['18F-sodium fluoride'],['myocardial infarction'],True,18F-sodium fluoride,myocardial infarction,associated,C0027051,Heart attack,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",18F-sodium fluoride,associate
2429,26724,35183477,"In a multivariable Cox regression model including imaging and clinical risk factors, thoracic aortic 18F-sodium fluoride activity was the only variable associated with ischemic stroke (HR: 8.19 (2.33 to 28.7), P = 0.0010).",['18F-sodium fluoride'],['ischemic stroke'],True,18F-sodium fluoride,ischemic stroke,associated,C0948008,Ischemic stroke,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",18F-sodium fluoride,associate
2430,26725,35183477," CONCLUSIONS: In patients with established cardiovascular disease, thoracic aortic 18F-sodium fluoride activity is associated with the progression of atherosclerosis and future ischemic stroke.",['18F-sodium fluoride'],"['cardiovascular disease', 'atherosclerosis']",True,18F-sodium fluoride,cardiovascular disease,associated,C0007222,Cardiovascular disease,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",18F-sodium fluoride,associate
2431,26725,35183477," CONCLUSIONS: In patients with established cardiovascular disease, thoracic aortic 18F-sodium fluoride activity is associated with the progression of atherosclerosis and future ischemic stroke.",['18F-sodium fluoride'],"['cardiovascular disease', 'atherosclerosis']",True,18F-sodium fluoride,atherosclerosis,associated,C0004153,Narrowing and hardening of arteries,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",18F-sodium fluoride,associate
2432,26749,34959734,Oxidative stress in THP-1 cells was induced via sodium fluoride.,['sodium fluoride'],['Oxidative stress'],True,sodium fluoride,Oxidative stress,induced,C0242606,Oxidative stress,5235,sodium;fluoride,sodium;fluoride,induce
2433,26772,34824510,The study concludes that topical application of a 38% SDF solution can inhibit demineralization of enamel.,['SDF'],['demineralization of enamel'],True,SDF,demineralization of enamel,inhibit,C3665628,Mottled tooth enamel,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",SDF,inhibit
2434,26780,34815892,"This causes a pathogenic inflammatory response, resulting in calcium phosphate deposition in the form of microcalcifications, which causes plaque formation, ultimately becoming unstable with sequelae of complications.",['calcium phosphate'],"['inflammatory response', 'plaque formation']",True,calcium phosphate,inflammatory response,causes,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium phosphate,cause
2435,26780,34815892,"This causes a pathogenic inflammatory response, resulting in calcium phosphate deposition in the form of microcalcifications, which causes plaque formation, ultimately becoming unstable with sequelae of complications.",['calcium phosphate'],"['inflammatory response', 'plaque formation']",True,calcium phosphate,plaque formation,causes,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium phosphate,cause
2436,26780,34815892,"This causes a pathogenic inflammatory response, resulting in calcium phosphate deposition in the form of microcalcifications, which causes plaque formation, ultimately becoming unstable with sequelae of complications.",['calcium phosphate'],"['inflammatory response', 'plaque formation']",True,calcium phosphate,plaque formation,resulting,C4022805,Abnormal inflammatory response,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",calcium phosphate,result
2437,26795,22851017," Growth of Methylocystis strain SB2 on methane was inhibited in the presence of all compounds, while only 1,1-DCE and cis-DCE inhibited growth on ethanol.",['ethanol'],['growth'],True,ethanol,growth,inhibited,C0456070,Growth delay,702,Ethanol,Ethanol,inhibit
2438,26795,22851017," Growth of Methylocystis strain SB2 on methane was inhibited in the presence of all compounds, while only 1,1-DCE and cis-DCE inhibited growth on ethanol.",['ethanol'],['growth'],True,ethanol,growth,inhibited,C0456070,Growth delay,702,Ethanol,Ethanol,inhibit
2439,26802,20665324, About 66-93% of the cancer risk of the four processes was caused by trichloroethylene.,['trichloroethylene'],['cancer risk'],True,trichloroethylene,cancer risk,caused,C0006826,Cancer,6575,"1,1,2-trichloroethene","1,1,2-trichloroethene",cause
2440,26832,35294117,"Antipyretic, anti-inflammatory and anti-diabetic potential was evaluated using brewer's yeast induced pyrexia, carrageenan induced paw edema and streptozocin induced diabetes protocols respectively.","['carrageenan', 'streptozocin']","['pyrexia', 'paw edema']",True,carrageenan,paw edema,induced,C0013604,Edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",carrageenan,induce
2441,26832,35294117,"Antipyretic, anti-inflammatory and anti-diabetic potential was evaluated using brewer's yeast induced pyrexia, carrageenan induced paw edema and streptozocin induced diabetes protocols respectively.","['carrageenan', 'streptozocin']","['pyrexia', 'paw edema']",True,streptozocin,paw edema,induced,C0013604,Edema,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",streptozocin,induce
2442,26864,35312093,"However, when linezolid induces thrombocytopenia in adults, its side effects in VLBW infants are concerning.",['linezolid'],['thrombocytopenia'],True,linezolid,thrombocytopenia,induces,C0040034,Thrombocytopenia,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",linezolid,induce
2443,26877,35307916,"Among children with diabetes, four  covariates were independently associated with the primary outcome, living in the  poorest regions of the country (Northeast, HR, 2.17, 95% CI 1.18-4.01, and North, (HR 4.0, 95% CI 1.79-8.94), oxygen saturation < 95% at admission (HR 2.97, 95% CI 1.64-5.36), presence of kidney disorders (HR 3.39, 95% CI 1.42-8.09), and presence of obesity (HR 3.77, 95% CI 1.83-7.76).",['oxygen'],['obesity'],True,oxygen,obesity,associated,C0028754,Obesity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",oxygen,associate
2444,26891,35301838," CONCLUSIONS: Selumetinib can produce sustained shrinkage in the majority of patients with NF1 and symptomatic plexiform neurofibroma to provide clinically meaningful benefit in functional ability, with more robust evidence in children.",['Selumetinib'],['sustained shrinkage'],True,Selumetinib,sustained shrinkage,produce,C0028754,Obesity,10127622,6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide,6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide,produce
2445,26902,35302913,"Licoisoflavone A, glyasperin C, and glycycoumarin increased CYP3A4 activity while glabridin, glyasperin C, glycycoumarin, and formononetin increased CYP1A2 activity (>2-fold).","['Licoisoflavone A', 'glyasperin', 'glycycoumarin', 'glabridin', 'glyasperin', 'glycycoumarin', 'formononetin']",['increased CYP1A2 activity'],True,glyasperin,increased CYP1A2 activity,increased,C4025637,Increased phosphoribosylpyrophosphate synthetase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glyasperin,increase
2446,26902,35302913,"Licoisoflavone A, glyasperin C, and glycycoumarin increased CYP3A4 activity while glabridin, glyasperin C, glycycoumarin, and formononetin increased CYP1A2 activity (>2-fold).","['Licoisoflavone A', 'glyasperin', 'glycycoumarin', 'glabridin', 'glyasperin', 'glycycoumarin', 'formononetin']",['increased CYP1A2 activity'],True,glycycoumarin,increased CYP1A2 activity,increased,C4025637,Increased phosphoribosylpyrophosphate synthetase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycycoumarin,increase
2447,26902,35302913,"Licoisoflavone A, glyasperin C, and glycycoumarin increased CYP3A4 activity while glabridin, glyasperin C, glycycoumarin, and formononetin increased CYP1A2 activity (>2-fold).","['Licoisoflavone A', 'glyasperin', 'glycycoumarin', 'glabridin', 'glyasperin', 'glycycoumarin', 'formononetin']",['increased CYP1A2 activity'],True,glabridin,increased CYP1A2 activity,increased,C4025637,Increased phosphoribosylpyrophosphate synthetase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glabridin,increase
2448,26902,35302913,"Licoisoflavone A, glyasperin C, and glycycoumarin increased CYP3A4 activity while glabridin, glyasperin C, glycycoumarin, and formononetin increased CYP1A2 activity (>2-fold).","['Licoisoflavone A', 'glyasperin', 'glycycoumarin', 'glabridin', 'glyasperin', 'glycycoumarin', 'formononetin']",['increased CYP1A2 activity'],True,glyasperin,increased CYP1A2 activity,increased,C4025637,Increased phosphoribosylpyrophosphate synthetase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glyasperin,increase
2449,26902,35302913,"Licoisoflavone A, glyasperin C, and glycycoumarin increased CYP3A4 activity while glabridin, glyasperin C, glycycoumarin, and formononetin increased CYP1A2 activity (>2-fold).","['Licoisoflavone A', 'glyasperin', 'glycycoumarin', 'glabridin', 'glyasperin', 'glycycoumarin', 'formononetin']",['increased CYP1A2 activity'],True,glycycoumarin,increased CYP1A2 activity,increased,C4025637,Increased phosphoribosylpyrophosphate synthetase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glycycoumarin,increase
2450,26902,35302913,"Licoisoflavone A, glyasperin C, and glycycoumarin increased CYP3A4 activity while glabridin, glyasperin C, glycycoumarin, and formononetin increased CYP1A2 activity (>2-fold).","['Licoisoflavone A', 'glyasperin', 'glycycoumarin', 'glabridin', 'glyasperin', 'glycycoumarin', 'formononetin']",['increased CYP1A2 activity'],True,formononetin,increased CYP1A2 activity,increased,C4025637,Increased phosphoribosylpyrophosphate synthetase activity,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",formononetin,increase
2451,26957,35238128,"Collectively, DMF exposure caused mitochondrial damage, oxidative stress, spindle assembly and chromosome arrangement disorder, leading to oocyte maturation arrest and fertilization failure.",['DMF'],['oxidative stress'],True,DMF,oxidative stress,caused,C0242606,Oxidative stress,6228,"N,N-dimethylformamide","N,N-dimethylformamide",cause
2452,27003,35104576,"Colitis was induced by intrarectal instillation of 200 mg/kg of  DNBS dissolved vehicle, 50% ethanol.","['intrarectal instillation', 'ethanol']",['Colitis'],True,intrarectal instillation,Colitis,induced,C0009319,Colitis,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",intrarectal instillation,induce
2453,27003,35104576,"Colitis was induced by intrarectal instillation of 200 mg/kg of  DNBS dissolved vehicle, 50% ethanol.","['intrarectal instillation', 'ethanol']",['Colitis'],True,ethanol,Colitis,induced,C0009319,Colitis,702,Ethanol,Ethanol,induce
2454,27030,34973335,"DNFB has shown to more potently sensitize skin; however, how DNFB and DNCB cause skin inflammation at a  molecular level and why this difference in their sensitization ability is observed remain unknown.","['DNFB', 'DNFB', 'DNCB']",['skin inflammation'],True,DNFB,skin inflammation,cause,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DNFB,cause
2455,27030,34973335,"DNFB has shown to more potently sensitize skin; however, how DNFB and DNCB cause skin inflammation at a  molecular level and why this difference in their sensitization ability is observed remain unknown.","['DNFB', 'DNFB', 'DNCB']",['skin inflammation'],True,DNCB,skin inflammation,cause,C3875321,Skin inflammation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",DNCB,cause
2456,27033,34957533,"In conclusion, except for improving body weight in FF-treated birds, prophylactic administration of vitamin C is not associated with improvements in clinical outcome of antimicrobial therapy of broilers with SA, although it ameliorates oxidative stress and some histopathological changes.",['vitamin'],"['improving body weight', 'oxidative stress']",True,vitamin,oxidative stress,associated,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",vitamin,associate
2457,27103,10647871, There is increasing evidence relating exposure to trichloroethylene with autoimmunity.,['trichloroethylene'],['autoimmunity'],True,trichloroethylene,autoimmunity,relating,C0004368,Autoimmunity,6575,"1,1,2-trichloroethene","1,1,2-trichloroethene",relate
2458,27153,16448743,  Kaurene diterpenes from Laetia thamnia inhibit the growth of human cancer cells in vitro.,['Laetia'],['cancer'],True,Laetia,cancer,inhibit,C0006826,Cancer,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",Laetia,inhibit
2459,27160,15289792,"Pupil diameter was significantly decreased by LAAM after both placebo and ketoconazole pretreatment; ketoconazole  increased the tmax for miosis 2.92-fold (2.01-4.25, P <.001).","['LAAM', 'ketoconazole', 'ketoconazole']",['miosis'],True,ketoconazole,miosis,increased,C0026205,Pupillary constriction,456201,"1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone","1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone",increase
2460,27162,35272161,"Application of ICB could effectively result in increased populations of Dhc and RDase genes, which corresponded with improved dechlorination of cis-DCE and vinyl chloride.",['dechlorination'],['increased populations of Dhc and RDase genes'],True,dechlorination,increased populations of Dhc and RDase genes,result,C0026205,Pupillary constriction,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",dechlorination,result
2461,27172,34717031,"Our data suggest that even in the  absence of high fat diet, exposure to VC (0.8 ppm, 6 h/day, 5 day/week, for 12 weeks) induces glucose intolerance (1.0 g/kg, i.p.) in male C57BL/6 mice.",['VC'],"['high fat diet', 'glucose intolerance']",True,VC,glucose intolerance,induces,C0271650,Abnormal glucose tolerance,6338,chloroethene,chloroethene,induce
2462,27300,27251157,  Stimulation of cell proliferation by glutathione monoethyl ester in aged bone marrow stromal cells is associated with the assistance of TERT gene expression and telomerase activity.,['glutathione monoethyl'],['Stimulation of cell proliferation'],True,glutathione monoethyl,Stimulation of cell proliferation,associated,C4531170,Abnormal cell proliferation,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",glutathione monoethyl,associate
2463,27323,24035973,"In the present study, we have shown that oral administration of tributyltin, used as a model environmental chemical, induced oxidative-stress status in the bronchial lymph node, mesenteric lymph node and spleen, but not in the lung, where the initial step of allergic asthma pathogenesis takes place.",['tributyltin'],['oxidative-stress'],True,tributyltin,oxidative-stress,induced,C0242606,Oxidative stress,NA,"[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",tributyltin,induce
